Glioma O +
tumor O +
stem O +
- O +
like O +
cells O +
promote O +
tumor O +
angiogenesis O +
and O +
vasculogenesis O +
via O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
stromal O +
- O +
derived O +
factor O +
1 O +
. O +

Cancer O +
stem O +
cells O +
( O +
CSC O +
) O +
are O +
predicted O +
to O +
be O +
critical O +
drivers O +
of O +
tumor O +
progression O +
due O +
to O +
their O +
self O +
- O +
renewal O +
capacity O +
and O +
limitless O +
proliferative O +
potential O +
. O +

An O +
emerging O +
area O +
of O +
research O +
suggests O +
that O +
CSC O +
may O +
also O +
support O +
tumor O +
progression O +
by O +
promoting O +
tumor O +
angiogenesis O +
. O +

To O +
investigate O +
how O +
CSC O +
contribute O +
to O +
tumor O +
vascular O +
development O +
, O +
we O +
used O +
an O +
approach O +
comparing O +
tumor O +
xenografts O +
of O +
the O +
C6 B-CellLine +
glioma O +
cell O +
line O +
containing O +
either O +
a O +
low O +
or O +
a O +
high O +
fraction O +
of O +
CSC O +
. O +

Compared O +
with O +
CSC O +
- O +
low O +
tumors O +
, O +
CSC O +
- O +
high O +
tumors O +
exhibited O +
increased O +
microvessel O +
density O +
and O +
blood O +
perfusion O +
and O +
induced O +
increased O +
mobilization O +
and O +
tumor O +
recruitment O +
of O +
bone O +
marrow O +
- O +
derived O +
endothelial O +
progenitor O +
cells O +
( O +
EPC O +
) O +
. O +

CSC O +
- O +
high O +
C6 B-CellLine +
cell O +
cultures O +
also O +
induced O +
higher O +
levels O +
of O +
endothelial O +
cell O +
proliferation O +
and O +
tubule O +
organization O +
in O +
vitro O +
compared O +
with O +
CSC O +
- O +
low O +
cultures O +
. O +

CSC O +
- O +
high O +
cultures O +
and O +
tumors O +
expressed O +
increased O +
levels O +
of O +
the O +
proangiogenic O +
factors O +
vascular O +
endothelial O +
growth O +
factor O +
and O +
stromal O +
- O +
derived O +
factor O +
1 O +
, O +
and O +
when O +
signaling O +
by O +
either O +
factor O +
was O +
blocked O +
, O +
all O +
aspects O +
of O +
angiogenesis O +
observed O +
in O +
CSC O +
- O +
high O +
cultures O +
and O +
tumors O +
, O +
including O +
microvessel O +
density O +
, O +
perfusion O +
, O +
EPC O +
mobilization O +
/ O +
recruitment O +
, O +
and O +
stimulation O +
of O +
endothelial O +
cell O +
activity O +
, O +
were O +
reduced O +
to O +
levels O +
comparable O +
with O +
those O +
observed O +
in O +
CSC O +
- O +
low O +
cultures O +
/ O +
tumors O +
. O +

These O +
results O +
suggest O +
that O +
CSC O +
contribute O +
to O +
tumor O +
angiogenesis O +
by O +
promoting O +
both O +
local O +
endothelial O +
cell O +
activity O +
and O +
systemic O +
angiogenic O +
processes O +
involving O +
bone O +
marrow O +
- O +
derived O +
EPC O +
in O +
a O +
vascular O +
endothelial O +
growth O +
factor O +
- O +
dependent O +
and O +
stromal O +
- O +
derived O +
factor O +
1 O +
- O +
dependent O +
manner O +
. O +

Islet O +
endothelial O +
activation O +
and O +
oxidative O +
stress O +
gene O +
expression O +
is O +
reduced O +
by O +
IL O +
- O +
1Ra O +
treatment O +
in O +
the O +
type O +
2 O +
diabetic O +
GK O +
rat O +
. O +

BACKGROUND O +
: O +
Inflammation O +
followed O +
by O +
fibrosis O +
is O +
a O +
component O +
of O +
islet O +
dysfunction O +
in O +
both O +
rodent O +
and O +
human O +
type O +
2 O +
diabetes O +
. O +

Because O +
islet O +
inflammation O +
may O +
originate O +
from O +
endothelial O +
cells O +
, O +
we O +
assessed O +
the O +
expression O +
of O +
selected O +
genes O +
involved O +
in O +
endothelial O +
cell O +
activation O +
in O +
islets O +
from O +
a O +
spontaneous O +
model O +
of O +
type O +
2 O +
diabetes O +
, O +
the O +
Goto O +
- O +
Kakizaki O +
( O +
GK O +
) O +
rat O +
. O +

We O +
also O +
examined O +
islet O +
endotheliuml O +
/ O +
oxidative O +
stress O +
( O +
OS O +
) O +
/ O +
inflammation O +
- O +
related O +
gene O +
expression O +
, O +
islet O +
vascularization O +
and O +
fibrosis O +
after O +
treatment O +
with O +
the O +
interleukin O +
- O +
1 O +
( O +
IL O +
- O +
1 O +
) O +
receptor O +
antagonist O +
( O +
IL O +
- O +
1Ra O +
) O +
. O +

METHODOLOGY O +
/ O +
PRINCIPAL O +
FINDINGS O +
: O +
Gene O +
expression O +
was O +
analyzed O +
by O +
quantitative O +
RT O +
- O +
PCR O +
on O +
islets O +
isolated O +
from O +
10 O +
- O +
week O +
- O +
old O +
diabetic O +
GK O +
and O +
control O +
Wistar O +
rats O +
. O +

Furthermore O +
, O +
GK O +
rats O +
were O +
treated O +
s O +
. O +
c O +
twice O +
daily O +
with O +
IL O +
- O +
1Ra O +
( O +
Kineret O +
, O +
Amgen O +
, O +
100 O +
mg O +
/ O +
kg O +
/ O +
day O +
) O +
or O +
saline O +
, O +
from O +
4 O +
weeks O +
of O +
age O +
onwards O +
( O +
onset O +
of O +
diabetes O +
) O +
. O +

Four O +
weeks O +
later O +
, O +
islet O +
gene O +
analysis O +
and O +
pancreas O +
immunochemistry O +
were O +
performed O +
. O +

Thirty O +
- O +
two O +
genes O +
were O +
selected O +
encoding O +
molecules O +
involved O +
in O +
endothelial O +
cell O +
activation O +
, O +
particularly O +
fibrinolysis O +
, O +
vascular O +
tone O +
, O +
OS O +
, O +
angiogenesis O +
and O +
also O +
inflammation O +
. O +

All O +
genes O +
except O +
those O +
encoding O +
angiotensinogen O +
and O +
epoxide O +
hydrolase O +
( O +
that O +
were O +
decreased O +
) O +
, O +
and O +
12 O +
- O +
lipoxygenase O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
that O +
showed O +
no O +
change O +
) O +
, O +
were O +
significantly O +
up O +
- O +
regulated O +
in O +
GK O +
islets O +
. O +

After O +
IL O +
- O +
1Ra O +
treatment O +
of O +
GK O +
rats O +
in O +
vivo O +
, O +
most O +
selected O +
genes O +
implied O +
in O +
endothelium O +
/ O +
OS O +
/ O +
immune O +
cells O +
/ O +
fibrosis O +
were O +
significantly O +
down O +
- O +
regulated O +
. O +

IL O +
- O +
1Ra O +
also O +
improved O +
islet O +
vascularization O +
, O +
reduced O +
fibrosis O +
and O +
ameliorated O +
glycemia O +
. O +

CONCLUSIONS O +
/ O +
SIGNIFICANCE O +
: O +
GK O +
rat O +
islets O +
have O +
increased O +
mRNA O +
expression O +
of O +
markers O +
of O +
early O +
islet O +
endothelial O +
cell O +
activation O +
, O +
possibly O +
triggered O +
by O +
several O +
metabolic O +
factors O +
, O +
and O +
also O +
some O +
defense O +
mechanisms O +
. O +

The O +
beneficial O +
effect O +
of O +
IL O +
- O +
1Ra O +
on O +
most O +
islet O +
endothelial O +
/ O +
OS O +
/ O +
immune O +
cells O +
/ O +
fibrosis O +
parameters O +
analyzed O +
highlights O +
a O +
major O +
endothelial O +
- O +
related O +
role O +
for O +
IL O +
- O +
1 O +
in O +
GK O +
islet O +
alterations O +
. O +

Thus O +
, O +
metabolically O +
- O +
altered O +
islet O +
endothelium O +
might O +
affect O +
the O +
beta O +
- O +
cell O +
microenvironment O +
and O +
contribute O +
to O +
progressive O +
type O +
2 O +
diabetic O +
beta O +
- O +
cell O +
dysfunction O +
in O +
GK O +
rats O +
. O +

Counteracting O +
islet O +
endothelial O +
cell O +
inflammation O +
might O +
be O +
one O +
way O +
to O +
ameliorate O +
/ O +
prevent O +
beta O +
- O +
cell O +
dysfunction O +
in O +
type O +
2 O +
diabetes O +
. O +

Cognitive O +
function O +
and O +
number O +
of O +
teeth O +
in O +
a O +
community O +
- O +
dwelling O +
elderly O +
population O +
without O +
dementia O +
. O +

Although O +
the O +
number O +
of O +
sound O +
or O +
decayed O +
teeth O +
has O +
been O +
reported O +
to O +
be O +
associated O +
with O +
cognitive O +
function O +
in O +
elderly O +
populations O +
with O +
dementia O +
, O +
little O +
is O +
known O +
about O +
this O +
association O +
in O +
elderly O +
populations O +
without O +
dementia O +
. O +

We O +
evaluated O +
this O +
relationship O +
, O +
with O +
adjustment O +
for O +
confounding O +
factors O +
, O +
in O +
Japanese O +
populations O +
of O +
60 O +
- O +
year O +
- O +
old O +
( O +
n O +
= O +
270 O +
; O +
120 O +
males O +
and O +
150 O +
females O +
) O +
and O +
65 O +
- O +
year O +
- O +
old O +
( O +
n O +
= O +
123 O +
; O +
57 O +
males O +
and O +
66 O +
females O +
) O +
individuals O +
residing O +
in O +
Fukuoka O +
Prefecture O +
of O +
Japan O +
. O +

Dental O +
examinations O +
were O +
performed O +
in O +
all O +
subjects O +
, O +
along O +
with O +
the O +
Mini O +
- O +
mental O +
state O +
examination O +
( O +
MMSE O +
) O +
for O +
assessing O +
cognitive O +
function O +
. O +

Among O +
the O +
total O +
of O +
393 O +
subjects O +
, O +
the O +
mean O +
MMSE O +
score O +
was O +
27 O +
. O +
9 O +
+ O +
/ O +
- O +
1 O +
. O +
9 O +
, O +
and O +
391 O +
subjects O +
scored O +
24 O +
or O +
higher O +
. O +

The O +
mean O +
numbers O +
of O +
sound O +
and O +
decayed O +
teeth O +
were O +
12 O +
. O +
0 O +
+ O +
/ O +
- O +
6 O +
. O +
3 O +
and O +
0 O +
. O +
5 O +
+ O +
/ O +
- O +
1 O +
. O +
2 O +
, O +
respectively O +
. O +

Associations O +
were O +
found O +
between O +
the O +
numbers O +
of O +
sound O +
and O +
decayed O +
teeth O +
and O +
MMSE O +
in O +
total O +
subjects O +
and O +
males O +
, O +
but O +
not O +
in O +
females O +
, O +
by O +
multiple O +
regression O +
analysis O +
adjusted O +
for O +
gender O +
, O +
age O +
, O +
level O +
of O +
education O +
, O +
marital O +
status O +
, O +
smoking O +
, O +
alcohol O +
drinking O +
, O +
working O +
status O +
, O +
systolic O +
blood O +
pressure O +
and O +
blood O +
glucose O +
. O +

An O +
association O +
was O +
also O +
found O +
between O +
MMSE O +
and O +
the O +
number O +
of O +
sound O +
teeth O +
in O +
a O +
logistic O +
regression O +
analysis O +
. O +

In O +
conclusion O +
, O +
associations O +
were O +
found O +
between O +
normal O +
- O +
range O +
cognitive O +
function O +
and O +
the O +
numbers O +
of O +
sound O +
and O +
decayed O +
teeth O +
, O +
after O +
adjustment O +
for O +
various O +
confounding O +
factors O +
, O +
in O +
an O +
elderly O +
Japanese O +
population O +
. O +

Magnesium O +
for O +
treatment O +
of O +
asthma O +
in O +
children O +
. O +

QUESTION O +
: O +
Magnesium O +
is O +
considered O +
adjuvant O +
therapy O +
for O +
moderate O +
to O +
severe O +
asthma O +
exacerbations O +
in O +
adults O +
, O +
but O +
can O +
it O +
be O +
used O +
to O +
treat O +
children O +
? O +

ANSWER O +
: O +
Magnesium O +
seems O +
to O +
be O +
beneficial O +
in O +
the O +
treatment O +
of O +
moderate O +
to O +
severe O +
asthma O +
in O +
children O +
. O +

It O +
is O +
a O +
safe O +
drug O +
to O +
administer O +
, O +
but O +
there O +
have O +
been O +
minor O +
side O +
effects O +
reported O +
, O +
such O +
as O +
epigastric O +
or O +
facial O +
warmth O +
, O +
flushing O +
, O +
pain O +
and O +
numbness O +
at O +
the O +
infusion O +
site O +
, O +
dry O +
mouth O +
, O +
malaise O +
, O +
and O +
hypotension O +
. O +

Owing O +
to O +
its O +
bronchodilating O +
and O +
anti O +
- O +
inflammatory O +
effects O +
, O +
magnesium O +
is O +
an O +
encouraging O +
adjuvant O +
therapy O +
for O +
pediatric O +
patients O +
who O +
do O +
not O +
respond O +
to O +
conventional O +
treatment O +
in O +
acute O +
severe O +
exacerbations O +
. O +

Future O +
studies O +
should O +
focus O +
on O +
establishing O +
the O +
optimal O +
dosage O +
for O +
maximal O +
benefits O +
and O +
the O +
best O +
route O +
of O +
administration O +
. O +

Magnesium O +
should O +
also O +
be O +
considered O +
as O +
a O +
prophylactic O +
treatment O +
. O +

AVE8062 O +
: O +
a O +
new O +
combretastatin O +
derivative O +
vascular O +
disrupting O +
agent O +
. O +

Angiogenesis O +
has O +
an O +
essential O +
role O +
in O +
promoting O +
and O +
supporting O +
tumor O +
growth O +
and O +
it O +
is O +
an O +
important O +
therapeutic O +
target O +
. O +

The O +
tumor O +
vascular O +
network O +
is O +
the O +
result O +
of O +
pro O +
- O +
angiogenic O +
and O +
inhibitory O +
factors O +
as O +
well O +
as O +
of O +
the O +
interaction O +
between O +
endothelial O +
cells O +
and O +
extracellular O +
matrix O +
. O +

Different O +
antiangiogenic O +
therapeutics O +
have O +
been O +
developed O +
to O +
improve O +
tumor O +
control O +
through O +
vascular O +
- O +
targeting O +
agents O +
( O +
VTA O +
) O +
. O +

VTAs O +
can O +
be O +
divided O +
into O +
two O +
groups O +
: O +
antiangiogenic O +
agents O +
and O +
vascular O +
- O +
disrupting O +
agents O +
( O +
VDAs O +
) O +
. O +

VTAs O +
inhibit O +
specific O +
factors O +
required O +
to O +
induce O +
and O +
direct O +
the O +
angiogenic O +
process O +
, O +
with O +
major O +
activity O +
against O +
small O +
tumor O +
masses O +
and O +
at O +
the O +
tumor O +
periphery O +
, O +
encompassing O +
monoclonal O +
antibodies O +
and O +
small O +
molecules O +
inhibitors O +
of O +
the O +
tyrosine O +
kinase O +
domain O +
of O +
the O +
VEGF O +
receptor O +
. O +

VDAs O +
specifically O +
target O +
and O +
destroy O +
well O +
- O +
established O +
tumor O +
vessels O +
with O +
ischemia O +
and O +
destruction O +
of O +
large O +
masses O +
with O +
central O +
hemorrhagic O +
necrosis O +
and O +
survival O +
of O +
a O +
thin O +
peripheral O +
tumor O +
layer O +
. O +

VDAs O +
can O +
be O +
divided O +
into O +
biologics O +
, O +
such O +
as O +
ligand O +
- O +
based O +
, O +
and O +
small O +
- O +
molecule O +
agents O +
; O +
this O +
second O +
group O +
includes O +
small O +
- O +
molecule O +
VDAs O +
like O +
flavonoids O +
, O +
such O +
as O +
5 O +
, O +
6 O +
- O +
dimethylxanthenone O +
- O +
4 O +
- O +
acetic O +
acid O +
( O +
DMXAA O +
) O +
, O +
and O +
microtubule O +
- O +
destabilizing O +
agents O +
. O +

In O +
this O +
review O +
we O +
will O +
discuss O +
the O +
mechanism O +
of O +
action O +
, O +
as O +
well O +
as O +
the O +
preclinical O +
and O +
clinical O +
results O +
, O +
of O +
one O +
of O +
the O +
most O +
promising O +
antitubulin O +
agents O +
: O +
the O +
combretastatin O +
A4 O +
- O +
phosphate O +
derivative O +
, O +
AVE8062A O +
. O +

Targeting O +
TNF O +
for O +
Treatment O +
of O +
Cancer O +
and O +
Autoimmunity O +
. O +

Tumor O +
necrosis O +
factor O +
- O +
alpha O +
( O +
TNF O +
- O +
alpha O +
) O +
was O +
first O +
isolated O +
two O +
decades O +
ago O +
as O +
a O +
macrophageproduced O +
protein O +
that O +
can O +
effectively O +
kill O +
tumor O +
cells O +
. O +

TNF O +
- O +
alpha O +
is O +
also O +
an O +
essential O +
component O +
of O +
the O +
immune O +
system O +
and O +
is O +
required O +
for O +
hematopoiesis O +
, O +
for O +
protection O +
from O +
bacterial O +
infection O +
and O +
for O +
immune O +
cell O +
- O +
mediated O +
cytotoxicity O +
. O +

Extensive O +
research O +
, O +
however O +
, O +
has O +
revealed O +
that O +
TNF O +
- O +
alpha O +
is O +
one O +
of O +
the O +
major O +
players O +
in O +
tumor O +
initiation O +
, O +
proliferation O +
, O +
invasion O +
, O +
angiogenesis O +
and O +
metastasis O +
. O +

The O +
proinflammatory O +
activities O +
link O +
TNF O +
- O +
alpha O +
with O +
a O +
wide O +
variety O +
of O +
autoimmune O +
diseases O +
, O +
including O +
psoriasis O +
, O +
inflammatory O +
bowel O +
disease O +
, O +
rheumatoid O +
arthritis O +
, O +
systemic O +
sclerosis O +
, O +
systemic O +
lupus O +
erythematosus O +
, O +
multiple O +
sclerosis O +
, O +
diabetes O +
and O +
ankylosing O +
spondylitis O +
. O +

Systemic O +
inhibitors O +
of O +
TNF O +
such O +
as O +
etanercept O +
( O +
Enbrel O +
) O +
( O +
a O +
soluble O +
TNF O +
receptor O +
) O +
and O +
infliximab O +
( O +
Remicade O +
) O +
and O +
adalimumab O +
( O +
Humira O +
) O +
( O +
anti O +
- O +
TNF O +
antibodies O +
) O +
have O +
been O +
approved O +
for O +
the O +
treatment O +
inflammatory O +
bowel O +
disease O +
, O +
psoriasis O +
and O +
rheumatoid O +
arthritis O +
. O +

These O +
drugs O +
, O +
however O +
, O +
exhibit O +
severe O +
side O +
effects O +
and O +
are O +
expensive O +
. O +

Hence O +
orally O +
active O +
blockers O +
of O +
TNF O +
- O +
alpha O +
that O +
are O +
safe O +
, O +
efficacious O +
and O +
inexpensive O +
are O +
urgently O +
needed O +
. O +

Numerous O +
products O +
from O +
fruits O +
, O +
vegetable O +
and O +
traditional O +
medicinal O +
plants O +
have O +
been O +
described O +
which O +
can O +
suppress O +
TNF O +
expression O +
and O +
TNF O +
signaling O +
but O +
their O +
clinical O +
potential O +
is O +
yet O +
uncertain O +
. O +

[ O +
Prognostic O +
significance O +
of O +
cellular O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
expression O +
in O +
the O +
course O +
of O +
chronic O +
myeloid O +
leukaemia O +
] O +

INTRODUCTION O +
: O +
Increased O +
angiogenesis O +
in O +
bone O +
marrow O +
is O +
one O +
of O +
the O +
characteristics O +
of O +
chronic O +
myeloid O +
leukaemia O +
( O +
CML O +
) O +
, O +
a O +
clonal O +
myeloproliferative O +
disorder O +
that O +
expresses O +
a O +
chimeric O +
bcr O +
/ O +
abl O +
protein O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
is O +
one O +
of O +
the O +
most O +
potent O +
and O +
a O +
specific O +
regulator O +
of O +
angiogenesis O +
which O +
principally O +
targets O +
endothelial O +
cells O +
and O +
regulates O +
several O +
of O +
their O +
functions O +
, O +
including O +
mitogenesis O +
, O +
permeability O +
and O +
migration O +
. O +

The O +
impact O +
of O +
elevated O +
VEGF O +
expression O +
on O +
the O +
course O +
of O +
chronic O +
myeloid O +
leukaemia O +
is O +
unknown O +
. O +

OBJECTIVE O +
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
the O +
follow O +
- O +
up O +
of O +
VEGF O +
expression O +
during O +
the O +
course O +
of O +
CML O +
. O +

METHODS O +
: O +
We O +
studied O +
VEGF O +
expression O +
of O +
85 O +
CML O +
patients O +
( O +
median O +
age O +
50 O +
years O +
, O +
range O +
16 O +
- O +
75 O +
years O +
) O +
. O +

At O +
the O +
commencement O +
of O +
the O +
study O +
, O +
29 O +
patients O +
were O +
in O +
chronic O +
phase O +
( O +
CP O +
) O +
, O +
25 O +
in O +
an O +
accelerated O +
phase O +
( O +
AP O +
) O +
, O +
and O +
31 O +
in O +
the O +
blast O +
crisis O +
( O +
BC O +
) O +
. O +

The O +
temporal O +
expression O +
( O +
percentage O +
positivity O +
per O +
1000 O +
analysed O +
cells O +
) O +
VEGF O +
proteins O +
over O +
the O +
course O +
of O +
CML O +
were O +
studied O +
using O +
the O +
immunohistochemical O +
technique O +
utilizing O +
relevant O +
monoclonal O +
antibodies O +
. O +

It O +
was O +
correlated O +
with O +
the O +
laboratory O +
( O +
Hb O +
, O +
WBC O +
and O +
platelet O +
counts O +
, O +
and O +
the O +
percentage O +
of O +
blasts O +
) O +
and O +
clinical O +
parameters O +
( O +
organomegaly O +
, O +
duration O +
of O +
CP O +
, O +
AP O +
, O +
and O +
BC O +
) O +
of O +
disease O +
progression O +
. O +

RESULTS O +
: O +
The O +
expression O +
ofVEGF O +
protein O +
was O +
most O +
pronounced O +
in O +
AP O +
( O +
ANOVA O +
, O +
p O +
= O +
0 O +
. O +
033 O +
) O +
. O +

The O +
level O +
of O +
VEGF O +
expression O +
correlated O +
inversely O +
with O +
the O +
degree O +
of O +
splenomegaly O +
( O +
Pearson O +
, O +
r O +
= O +
- O +
0 O +
. O +
400 O +
, O +
p O +
= O +
0 O +
. O +
011 O +
) O +
. O +

High O +
expression O +
of O +
VEGF O +
correlated O +
with O +
a O +
shorter O +
overall O +
survival O +
( O +
log O +
rank O +
, O +
p O +
= O +
0 O +
. O +
042 O +
) O +
. O +

CONCLUSION O +
: O +
Immunohistochemically O +
confirmed O +
significance O +
of O +
the O +
expression O +
of O +
VEGF O +
in O +
dependence O +
of O +
the O +
CML O +
stage O +
could O +
be O +
of O +
clinical O +
importance O +
in O +
deciding O +
on O +
the O +
timing O +
therapy O +
. O +

These O +
data O +
suggest O +
that O +
VEGF O +
plays O +
a O +
role O +
in O +
the O +
biology O +
of O +
CML O +
and O +
that O +
VEGF O +
inhibitors O +
should O +
be O +
investigated O +
in O +
CML O +
. O +

Pbx1 O +
is O +
a O +
downstream O +
target O +
of O +
Evi O +
- O +
1 O +
in O +
hematopoietic O +
stem O +
/ O +
progenitors O +
and O +
leukemic O +
cells O +
. O +

Ecotropic O +
viral O +
integration O +
site O +
- O +
1 O +
( O +
Evi O +
- O +
1 O +
) O +
is O +
a O +
nuclear O +
transcription O +
factor O +
, O +
which O +
is O +
essential O +
for O +
the O +
proliferation O +
/ O +
maintenance O +
of O +
hematopoietic O +
stem O +
cells O +
( O +
HSCs O +
) O +
. O +

Aberrant O +
expression O +
of O +
Evi O +
- O +
1 O +
has O +
been O +
frequently O +
found O +
in O +
myeloid O +
leukemia O +
, O +
and O +
is O +
associated O +
with O +
a O +
poor O +
patient O +
survival O +
. O +

Recently O +
, O +
we O +
reported O +
candidate O +
target O +
genes O +
of O +
Evi O +
- O +
1 O +
shared O +
in O +
HSCs O +
and O +
leukemic O +
cells O +
using O +
gene O +
expression O +
profiling O +
analysis O +
. O +

In O +
this O +
study O +
, O +
we O +
identified O +
Pbx1 O +
, O +
a O +
proto O +
- O +
oncogene O +
in O +
hematopoietic O +
malignancy O +
, O +
as O +
a O +
target O +
gene O +
of O +
Evi O +
- O +
1 O +
. O +

Overexpression O +
of O +
Evi O +
- O +
1 O +
increased O +
Pbx1 O +
expression O +
in O +
hematopoietic O +
stem O +
/ O +
progenitor O +
cells O +
. O +

An O +
analysis O +
of O +
the O +
Pbx1 O +
promoter O +
region O +
revealed O +
that O +
Evi O +
- O +
1 O +
upregulates O +
Pbx1 O +
transcription O +
. O +

Furthermore O +
, O +
reduction O +
of O +
Pbx1 O +
levels O +
through O +
RNAi O +
- O +
mediated O +
knockdown O +
significantly O +
inhibited O +
Evi O +
- O +
1 O +
- O +
induced O +
transformation O +
. O +

In O +
contrast O +
, O +
knockdown O +
of O +
Pbx1 O +
did O +
not O +
impair O +
bone O +
marrow O +
transformation O +
by O +
E2A O +
/ O +
HLF O +
or O +
AML1 O +
/ O +
ETO O +
, O +
suggesting O +
that O +
Pbx1 O +
is O +
specifically O +
required O +
for O +
the O +
maintenance O +
of O +
bone O +
marrow O +
transformation O +
mediated O +
by O +
Evi O +
- O +
1 O +
. O +

These O +
results O +
indicate O +
that O +
Pbx1 O +
is O +
a O +
target O +
gene O +
of O +
Evi O +
- O +
1 O +
involved O +
in O +
Evi O +
- O +
1 O +
- O +
mediated O +
leukemogenesis O +
. O +

Inducible O +
nitric O +
oxide O +
synthase O +
modulates O +
angiogenesis O +
in O +
ischemic O +
hindlimb O +
of O +
rat O +
. O +

BACKGROUND O +
: O +
Angiogenesis O +
plays O +
an O +
important O +
role O +
in O +
maintaining O +
adequate O +
oxygen O +
delivery O +
, O +
and O +
nitric O +
oxide O +
( O +
NO O +
) O +
is O +
a O +
potential O +
regulator O +
of O +
angiogenesis O +
. O +

NO O +
is O +
synthesized O +
through O +
three O +
isoforms O +
of O +
NO O +
synthase O +
( O +
NOS O +
) O +
. O +

It O +
is O +
hypothesized O +
that O +
the O +
NO O +
derived O +
from O +
inducible O +
NOS O +
( O +
iNOS O +
) O +
may O +
promote O +
survival O +
of O +
ischemic O +
tissue O +
through O +
angiogenesis O +
. O +

To O +
test O +
this O +
hypothesis O +
, O +
we O +
investigated O +
the O +
effect O +
of O +
iNOS O +
deficiency O +
( O +
by O +
L O +
- O +
NIL O +
) O +
on O +
angiogenesis O +
in O +
a O +
hindlimb O +
ischemia O +
model O +
. O +

METHODS O +
: O +
Thirty O +
- O +
two O +
male O +
wistar O +
rats O +
randomly O +
divided O +
into O +
four O +
groups O +
. O +

In O +
groups O +
1 O +
& O +
2 O +
, O +
hindlimb O +
ischemia O +
was O +
induced O +
by O +
ligation O +
of O +
femoral O +
artery O +
and O +
they O +
received O +
L O +
- O +
NIL O +
and O +
saline O +
respectively O +
. O +

The O +
animals O +
in O +
groups O +
3 O +
and O +
4 O +
also O +
received O +
L O +
- O +
NIL O +
and O +
saline O +
respectively O +
without O +
surgical O +
procedure O +
. O +

After O +
21 O +
days O +
, O +
the O +
serum O +
concentration O +
of O +
nitrite O +
, O +
capillary O +
density O +
and O +
expression O +
of O +
HIF1alpha O +
were O +
determined O +
. O +

RESULTS O +
: O +
Serum O +
nitrite O +
levels O +
were O +
significantly O +
lower O +
in O +
L O +
- O +
NIL O +
groups O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

The O +
capillary O +
density O +
in O +
group O +
1 O +
( O +
ischemia O +
+ O +
L O +
- O +
NIL O +
) O +
was O +
significantly O +
different O +
from O +
group O +
2 O +
( O +
ischemia O +
+ O +
saline O +
) O +
; O +
group O +
1 O +
: O +
360 O +
. O +
33 O +
+ O +
/ O +
- O +
77 O +
. O +
02 O +
, O +
group O +
2 O +
: O +
549 O +
+ O +
/ O +
- O +
81 O +
. O +
85 O +
/ O +
mm2 O +
, O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +
In O +
addition O +
, O +
expression O +
of O +
HIF1alpha O +
was O +
significantly O +
increased O +
in O +
ischemic O +
groups O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

CONCLUSION O +
: O +
Selective O +
inhibition O +
of O +
iNOS O +
by O +
L O +
- O +
NIL O +
inhibits O +
angiogenesis O +
in O +
a O +
hindlimb O +
ischemic O +
rat O +
model O +
. O +

In O +
addition O +
, O +
ischemia O +
induces O +
expression O +
of O +
HIF1alpha O +
in O +
hypoxic O +
tissue O +
. O +

Tumor O +
Angiogenesis O +
: O +
Initiation O +
and O +
Targeting O +
- O +
Therapeutic O +
Targeting O +
of O +
an O +
FGF O +
- O +
Binding O +
Protein O +
, O +
an O +
Angiogenic O +
Switch O +
Molecule O +
, O +
and O +
Indicator O +
of O +
Early O +
Stages O +
of O +
Gastrointestinal O +
Adenocarcinomas O +
- O +
. O +

Tumor O +
angiogenesis O +
has O +
been O +
related O +
to O +
the O +
initiation O +
as O +
well O +
as O +
progression O +
toward O +
more O +
aggressive O +
behavior O +
of O +
human O +
tumors O +
. O +

In O +
particular O +
, O +
the O +
activity O +
of O +
angiogenic O +
factors O +
is O +
crucial O +
for O +
tumor O +
progression O +
. O +

We O +
previously O +
characterized O +
a O +
secreted O +
fibroblast O +
growth O +
factor O +
- O +
binding O +
protein O +
( O +
FGF O +
- O +
BP O +
) O +
as O +
a O +
chaperone O +
molecule O +
, O +
which O +
binds O +
to O +
various O +
FGFs O +
, O +
enhances O +
FGF O +
- O +
mediated O +
biochemical O +
and O +
biologic O +
events O +
and O +
importantly O +
is O +
a O +
crucial O +
rate O +
- O +
limiting O +
factor O +
for O +
tumor O +
- O +
dependent O +
angiogenesis O +
. O +

We O +
generated O +
monoclonal O +
antibodies O +
that O +
target O +
FGF O +
- O +
BP O +
protein O +
and O +
used O +
them O +
as O +
a O +
tool O +
to O +
evaluate O +
frequency O +
and O +
pattern O +
of O +
FGF O +
- O +
BP O +
expression O +
during O +
the O +
malignant O +
progression O +
of O +
pancreas O +
and O +
colorectal O +
carcinoma O +
in O +
archival O +
tissue O +
samples O +
. O +

We O +
found O +
that O +
FGF O +
- O +
BP O +
is O +
dramatically O +
upregulated O +
during O +
the O +
initiation O +
of O +
colorectal O +
and O +
pancreatic O +
adenocarcinoma O +
. O +

Crucial O +
genetic O +
events O +
underlying O +
the O +
initiation O +
and O +
progression O +
of O +
colorectal O +
and O +
pancreatic O +
adenocarcinoma O +
with O +
a O +
particular O +
focus O +
on O +
the O +
modulation O +
of O +
angiogenesis O +
and O +
antiangiogenic O +
therapies O +
are O +
discussed O +
. O +

We O +
propose O +
that O +
the O +
upregulation O +
of O +
the O +
secreted O +
FGF O +
- O +
BP O +
protein O +
during O +
early O +
phases O +
of O +
pancreas O +
and O +
colon O +
cancer O +
could O +
make O +
this O +
protein O +
a O +
possible O +
serum O +
marker O +
indicating O +
the O +
presence O +
of O +
high O +
- O +
risk O +
premalignant O +
lesions O +
. O +

Furthermore O +
, O +
the O +
biological O +
activity O +
of O +
FGF O +
- O +
BP O +
is O +
neutralized O +
by O +
monoclonal O +
antibodies O +
suggesting O +
the O +
potential O +
for O +
antibody O +
- O +
based O +
therapeutic O +
targeting O +
. O +

Range O +
of O +
motion O +
limitation O +
after O +
rotator O +
cuff O +
repair O +
. O +

HYPOTHESIS O +
: O +

This O +
study O +
was O +
conducted O +
to O +
identify O +
preoperative O +
factors O +
correlating O +
with O +
limited O +
motion O +
after O +
rotator O +
cuff O +
repair O +
( O +
RCR O +
) O +
and O +
to O +
evaluate O +
the O +
affect O +
of O +
loss O +
of O +
motion O +
on O +
outcome O +
. O +

We O +
hypothesized O +
that O +
patients O +
with O +
preoperative O +
ROM O +
loss O +
, O +
diabetes O +
, O +
and O +
workman O +
' O +
s O +
compensation O +
claims O +
would O +
exhibit O +
postoperative O +
ROM O +
loss O +
at O +
3 O +
months O +
. O +

MATERIAL O +
AND O +
METHODS O +
: O +

Preoperative O +
and O +
postoperative O +
evaluations O +
, O +
including O +
outcomes O +
assessment O +
and O +
physical O +
examination O +
parameters O +
, O +
were O +
reviewed O +
for O +
345 O +
patients O +
who O +
underwent O +
RCR O +
. O +

Correlations O +
between O +
demographic O +
, O +
physical O +
examination O +
, O +
and O +
surgical O +
variables O +
and O +
postoperative O +
limitation O +
of O +
motion O +
and O +
need O +
for O +
capsular O +
release O +
were O +
determined O +
. O +

RESULTS O +
: O +

At O +
3 O +
- O +
month O +
follow O +
- O +
up O +
, O +
mean O +
active O +
forward O +
elevation O +
( O +
AFE O +
) O +
, O +
active O +
external O +
rotation O +
( O +
AER O +
) O +
, O +
and O +
passive O +
internal O +
rotation O +
( O +
PIR O +
) O +
were O +
90 O +
% O +
, O +
78 O +
% O +
, O +
and O +
80 O +
% O +
of O +
the O +
contralateral O +
side O +
. O +

Limitation O +
of O +
preoperative O +
motion O +
correlated O +
with O +
limitation O +
of O +
postoperative O +
AFE O +
, O +
AER O +
, O +
and O +
PIR O +
( O +
P O +
< O +
. O +
001 O +
) O +
. O +

Forty O +
- O +
seven O +
patients O +
considered O +
clinically O +
stiff O +
were O +
followed O +
at O +
1 O +
year O +
postoperatively O +
. O +

Three O +
patients O +
required O +
arthroscopic O +
capsular O +
release O +
for O +
persistent O +
range O +
of O +
motion O +
loss O +
. O +

CONCLUSION O +
: O +

Early O +
postoperative O +
limitation O +
of O +
motion O +
after O +
RCR O +
is O +
associated O +
with O +
restricted O +
preoperative O +
motion O +
. O +

Other O +
factors O +
, O +
including O +
diabetes O +
mellitus O +
and O +
worker O +
' O +
s O +
compensation O +
claim O +
, O +
are O +
also O +
associated O +
with O +
range O +
of O +
motion O +
loss O +
. O +

Most O +
shoulders O +
with O +
early O +
motion O +
loss O +
recover O +
motion O +
and O +
rarely O +
require O +
capsular O +
release O +
. O +

[ O +
Effect O +
of O +
osteopontin O +
silencing O +
by O +
lentivirus O +
- O +
mediated O +
delivery O +
of O +
siRNA O +
on O +
glioma O +
cell O +
invasion O +
and O +
apoptosis O +
] O +
. O +

OBJECTIVE O +
: O +
To O +
investigate O +
the O +
effect O +
of O +
osteopontin O +
silencing O +
on O +
the O +
invasion O +
and O +
apoptosis O +
of O +
U251 B-CellLine +
cells O +
. O +

METHODS O +
: O +
The O +
invasion O +
, O +
apoptosis O +
and O +
levels O +
of O +
uPA O +
, O +
MMP O +
- O +
2 O +
and O +
MMP O +
- O +
9 O +
were O +
determined O +
by O +
invasion O +
assay O +
, O +
flow O +
cytometry O +
, O +
Western O +
blot O +
and O +
real O +
- O +
time O +
fluorescence O +
quantitative O +
PCR O +
respectively O +
. O +

RESULTS O +
: O +
Osteopontin O +
small O +
interference O +
RNA O +
( O +
siRNA O +
) O +
inhibited O +
osteopontin O +
expression O +
and O +
cell O +
invasion O +
, O +
promoted O +
apoptosis O +
in O +
U251 B-CellLine +
cells O +
. O +

In O +
addition O +
, O +
the O +
expression O +
of O +
Bcl O +
- O +
2 O +
, O +
uPA O +
, O +
MMP O +
- O +
2 O +
and O +
MMP O +
- O +
9 O +
was O +
decreased O +
, O +
while O +
Bax O +
level O +
was O +
elevated O +
. O +

CONCLUSION O +
: O +
Osteopontin O +
siRNA O +
can O +
inhibit O +
U251 B-CellLine +
cells O +
invasion O +
via O +
the O +
down O +
- O +
regulation O +
of O +
uPA O +
, O +
MMP O +
- O +
2 O +
and O +
MMP O +
- O +
9 O +
levels O +
, O +
and O +
promote O +
apoptosis O +
through O +
induction O +
of O +
Bax O +
expression O +
and O +
inhibition O +
of O +
Bcl O +
2 O +
level O +
. O +

It O +
suggests O +
that O +
osteopontin O +
plays O +
an O +
important O +
role O +
in O +
human O +
glioma O +
progression O +
. O +

The O +
role O +
of O +
hypoxia O +
in O +
2 O +
- O +
butoxyethanol O +
- O +
induced O +
hemangiosarcoma O +
. O +

To O +
understand O +
the O +
molecular O +
mechanisms O +
underlying O +
compound O +
- O +
induced O +
hemangiosarcomas O +
in O +
mice O +
, O +
and O +
therefore O +
, O +
their O +
human O +
relevance O +
, O +
a O +
systems O +
biology O +
approach O +
was O +
undertaken O +
using O +
transcriptomics O +
and O +
Causal O +
Network O +
Modeling O +
from O +
mice O +
treated O +
with O +
2 O +
- O +
butoxyethanol O +
( O +
2 O +
- O +
BE O +
) O +
. O +

2 O +
- O +
BE O +
is O +
a O +
hemolytic O +
agent O +
that O +
induces O +
hemangiosarcomas O +
in O +
mice O +
. O +

We O +
hypothesized O +
that O +
the O +
hemolysis O +
induced O +
by O +
2 O +
- O +
BE O +
would O +
result O +
in O +
local O +
tissue O +
hypoxia O +
, O +
a O +
well O +
- O +
documented O +
trigger O +
for O +
endothelial O +
cell O +
proliferation O +
leading O +
to O +
hemangiosarcoma O +
. O +

Gene O +
expression O +
data O +
from O +
bone O +
marrow O +
( O +
BM O +
) O +
, O +
liver O +
, O +
and O +
spleen O +
of O +
mice O +
exposed O +
to O +
a O +
single O +
dose O +
( O +
4 O +
h O +
) O +
or O +
seven O +
daily O +
doses O +
of O +
2 O +
- O +
BE O +
were O +
used O +
to O +
develop O +
a O +
mechanistic O +
model O +
of O +
hemangiosarcoma O +
. O +

The O +
resulting O +
mechanistic O +
model O +
confirms O +
previous O +
work O +
proposing O +
that O +
2 O +
- O +
BE O +
induces O +
macrophage O +
activation O +
and O +
inflammation O +
in O +
the O +
liver O +
. O +

In O +
addition O +
, O +
the O +
model O +
supports O +
local O +
tissue O +
hypoxia O +
in O +
the O +
liver O +
and O +
spleen O +
, O +
coupled O +
with O +
increased O +
erythropoeitin O +
signaling O +
and O +
erythropoiesis O +
in O +
the O +
spleen O +
and O +
BM O +
, O +
and O +
suppression O +
of O +
mechanisms O +
that O +
contribute O +
to O +
genomic O +
stability O +
, O +
events O +
that O +
could O +
be O +
contributing O +
factors O +
to O +
hemangiosarcoma O +
formation O +
. O +

Finally O +
, O +
an O +
immunohistochemistry O +
method O +
( O +
Hypoxyprobe O +
) O +
demonstrated O +
that O +
tissue O +
hypoxia O +
was O +
present O +
in O +
the O +
spleen O +
and O +
BM O +
. O +

Together O +
, O +
the O +
results O +
of O +
this O +
study O +
identify O +
molecular O +
mechanisms O +
that O +
initiate O +
hemangiosarcoma O +
, O +
a O +
key O +
step O +
in O +
understanding O +
safety O +
concerns O +
that O +
can O +
impact O +
drug O +
decision O +
processes O +
, O +
and O +
identified O +
hypoxia O +
as O +
a O +
possible O +
contributing O +
factor O +
for O +
2 O +
- O +
BE O +
- O +
induced O +
hemangiosarcoma O +
in O +
mice O +
. O +

Magnitude O +
of O +
malate O +
- O +
aspartate O +
reduced O +
nicotinamide O +
adenine O +
dinucleotide O +
shuttle O +
activity O +
in O +
intact O +
respiring O +
tumor O +
cells O +
. O +

Measurements O +
of O +
respiration O +
, O +
CO2 O +
and O +
lactate O +
production O +
, O +
and O +
changes O +
in O +
the O +
levels O +
of O +
various O +
key O +
metabolites O +
of O +
the O +
glycolytic O +
sequence O +
and O +
tricarboxylic O +
acid O +
cycle O +
were O +
made O +
on O +
five O +
lines O +
of O +
rodent O +
ascites O +
tumor O +
cells O +
( O +
two O +
strains O +
of O +
Ehrlich O +
ascites O +
tumor O +
cells O +
, O +
Krebs B-CellLine +
II I-CellLine +
carcinoma O +
, O +
AS B-CellLine +
- I-CellLine +
30D I-CellLine +
carcinoma O +
, O +
and O +
L1210 B-CellLine +
cells O +
) O +
incubated O +
aerobically O +
in O +
the O +
presence O +
of O +
uniformly O +
labeled O +
D O +
- O +
[ O +
14C O +
] O +
glucose O +
. O +

From O +
these O +
data O +
, O +
as O +
well O +
as O +
earlier O +
evidence O +
demonstrating O +
that O +
the O +
reduced O +
nicotinamide O +
adenine O +
dinucleotide O +
( O +
NADH O +
) O +
shuttle O +
in O +
these O +
cells O +
requires O +
a O +
transaminase O +
step O +
and O +
is O +
thus O +
identified O +
as O +
the O +
malate O +
- O +
aspartate O +
shuttle O +
( O +
W O +
. O +
V O +
. O +
V O +
. O +
Greenhouse O +
and O +
A O +
. O +
L O +
. O +
Lehninger O +
, O +
Cancer O +
Res O +
. O +
, O +
36 O +
: O +
1392 O +
- O +
1396 O +
, O +
1976 O +
) O +
, O +
metabolic O +
flux O +
diagrams O +
were O +
constructed O +
for O +
the O +
five O +
cell O +
lines O +
. O +

These O +
diagrams O +
show O +
the O +
relative O +
rates O +
of O +
glycolysis O +
, O +
the O +
tricarboxylic O +
acid O +
cycle O +
, O +
electron O +
transport O +
, O +
and O +
the O +
malate O +
- O +
aspartate O +
shuttle O +
in O +
these O +
tumors O +
. O +

Large O +
amounts O +
of O +
cytosolic O +
NADH O +
were O +
oxidized O +
by O +
the O +
mitochondrial O +
respiratory O +
chain O +
via O +
the O +
NADH O +
shuttle O +
, O +
comprising O +
anywhere O +
from O +
about O +
20 O +
to O +
80 O +
% O +
of O +
the O +
total O +
flow O +
of O +
reducing O +
equivalents O +
to O +
oxygen O +
in O +
these O +
tumors O +
. O +

Calculations O +
of O +
the O +
sources O +
of O +
energy O +
for O +
adenosine O +
triphosphate O +
synthesis O +
indicated O +
that O +
on O +
the O +
average O +
about O +
one O +
- O +
third O +
of O +
the O +
respiratory O +
adenosine O +
triphosphate O +
is O +
generated O +
by O +
electron O +
flow O +
originating O +
from O +
cytosolic O +
NADH O +
via O +
the O +
malate O +
- O +
aspartate O +
shuttle O +
. O +

AKT2 O +
is O +
a O +
downstream O +
target O +
of O +
metabotropic O +
glutamate O +
receptor O +
1 O +
( O +
Grm1 O +
) O +
. O +

We O +
reported O +
earlier O +
on O +
the O +
oncogenic O +
properties O +
of O +
Grm1 O +
by O +
demonstrating O +
that O +
stable O +
Grm1 O +
- O +
mouse O +
- O +
melanocytic O +
clones O +
proliferate O +
in O +
the O +
absence O +
of O +
growth O +
supplement O +
and O +
anchorage O +
in O +
vitro O +
. O +

In O +
addition O +
, O +
these O +
clones O +
also O +
exhibit O +
aggressive O +
tumorigenic O +
phenotypes O +
in O +
vivo O +
with O +
short O +
latency O +
in O +
tumor O +
formation O +
in O +
both O +
immunodeficient O +
and O +
syngeneic O +
mice O +
. O +

We O +
also O +
detected O +
strong O +
activation O +
of O +
AKT O +
in O +
allograft O +
tumors O +
specifically O +
AKT2 O +
as O +
the O +
predominant O +
isoform O +
involved O +
. O +

In O +
parallel O +
, O +
we O +
assessed O +
several O +
human O +
melanoma O +
biopsy O +
samples O +
and O +
found O +
again O +
that O +
AKT2 O +
was O +
the O +
predominantly O +
activated O +
AKT O +
in O +
these O +
human O +
melanoma O +
biopsies O +
. O +

In O +
cultured O +
stable O +
Grm1 O +
- O +
mouse O +
- O +
melanocytic O +
clones O +
, O +
as O +
well O +
as O +
an O +
metabotropic O +
glutamate O +
receptor O +
1 O +
( O +
Grm1 O +
) O +
expressing O +
human O +
melanoma O +
cell O +
line O +
, O +
C8161 B-CellLine +
, O +
stimulation O +
of O +
Grm1 O +
by O +
its O +
agonist O +
led O +
to O +
the O +
activation O +
of O +
AKT O +
, O +
while O +
preincubation O +
with O +
Grm1 O +
- O +
antagonist O +
abolished O +
Grm1 O +
- O +
agonist O +
- O +
induced O +
AKT O +
activation O +
. O +

In O +
addition O +
, O +
a O +
reduction O +
in O +
tumor O +
volume O +
of O +
Grm1 O +
- O +
mouse O +
- O +
melanocytic O +
- O +
allografts O +
was O +
detected O +
in O +
the O +
presence O +
of O +
small O +
interfering O +
AKT2 O +
RNA O +
( O +
siAKT2 O +
) O +
. O +

Taken O +
together O +
, O +
these O +
results O +
showed O +
that O +
, O +
in O +
addition O +
to O +
the O +
MAPK O +
pathway O +
previously O +
reported O +
being O +
a O +
downstream O +
target O +
of O +
stimulated O +
Grm1 O +
, O +
AKT2 O +
is O +
another O +
downstream O +
target O +
in O +
Grm1 O +
mediated O +
melanocyte O +
transformation O +
. O +

Pancreatic O +
endocrine O +
tumors O +
: O +
expression O +
profiling O +
evidences O +
a O +
role O +
for O +
AKT O +
- O +
mTOR O +
pathway O +
. O +

PURPOSE O +
: O +
We O +
investigated O +
the O +
global O +
gene O +
expression O +
in O +
a O +
large O +
panel O +
of O +
pancreatic O +
endocrine O +
tumors O +
( O +
PETs O +
) O +
aimed O +
at O +
identifying O +
new O +
potential O +
targets O +
for O +
therapy O +
and O +
biomarkers O +
to O +
predict O +
patient O +
outcome O +
. O +

PATIENTS O +
AND O +
METHODS O +
: O +
Using O +
a O +
custom O +
microarray O +
, O +
we O +
analyzed O +
72 O +
primary O +
PETs O +
, O +
seven O +
matched O +
metastases O +
, O +
and O +
10 O +
normal O +
pancreatic O +
samples O +
. O +

Relevant O +
differentially O +
expressed O +
genes O +
were O +
validated O +
by O +
either O +
quantitative O +
real O +
- O +
time O +
polymerase O +
chain O +
reaction O +
or O +
immunohistochemistry O +
on O +
tissue O +
microarrays O +
. O +

RESULTS O +
: O +
Our O +
data O +
showed O +
that O +
: O +
tuberous O +
sclerosis O +
2 O +
( O +
TSC2 O +
) O +
and O +
phosphatase O +
and O +
tensin O +
homolog O +
( O +
PTEN O +
) O +
were O +
downregulated O +
in O +
most O +
of O +
the O +
primary O +
tumors O +
, O +
and O +
their O +
low O +
expression O +
was O +
significantly O +
associated O +
with O +
shorter O +
disease O +
- O +
free O +
and O +
overall O +
survival O +
; O +
somatostatin O +
receptor O +
2 O +
( O +
SSTR2 O +
) O +
was O +
absent O +
or O +
very O +
low O +
in O +
insulinomas O +
compared O +
with O +
nonfunctioning O +
tumors O +
; O +
and O +
expression O +
of O +
fibroblast O +
growth O +
factor O +
13 O +
( O +
FGF13 O +
) O +
gene O +
was O +
significantly O +
associated O +
with O +
the O +
occurrence O +
of O +
liver O +
metastasis O +
and O +
shorter O +
disease O +
- O +
free O +
survival O +
. O +

TSC2 O +
and O +
PTEN O +
are O +
two O +
key O +
inhibitors O +
of O +
the O +
Akt O +
/ O +
mammalian O +
target O +
of O +
rapamycin O +
( O +
mTOR O +
) O +
pathway O +
and O +
the O +
specific O +
inhibition O +
of O +
mTOR O +
with O +
rapamycin O +
or O +
RAD001 O +
inhibited O +
cell O +
proliferation O +
of O +
PET O +
cell O +
lines O +
. O +

CONCLUSION O +
: O +
Our O +
results O +
strongly O +
support O +
a O +
role O +
for O +
PI3 O -
K O +
/ O +
Akt O +
/ O +
mTOR O +
pathway O +
in O +
PET O +
, O +
which O +
ties O +
in O +
with O +
the O +
fact O +
that O +
mTOR O +
inhibitors O +
have O +
reached O +
phase O +
III O +
trials O +
in O +
neuroendocrine O +
tumors O +
. O +

The O +
finding O +
of O +
differential O +
SSTR O +
expression O +
raises O +
the O +
potential O +
for O +
SSTR O +
expression O +
to O +
be O +
evaluated O +
as O +
a O +
marker O +
of O +
response O +
to O +
somatostatin O +
analogs O +
. O +

Finally O +
, O +
we O +
identified O +
FGF13 O +
as O +
a O +
new O +
prognostic O +
marker O +
that O +
predicted O +
poorer O +
outcome O +
in O +
patients O +
who O +
were O +
clinically O +
considered O +
free O +
from O +
disease O +
. O +

Neural O +
network O +
analysis O +
of O +
spectroscopic O +
data O +
of O +
lycopene O +
and O +
beta O +
- O +
carotene O +
content O +
in O +
food O +
samples O +
compared O +
to O +
HPLC O +
- O +
UV O +
- O +
vis O +
. O +

In O +
this O +
study O +
a O +
neural O +
network O +
( O +
NN O +
) O +
model O +
was O +
designed O +
to O +
predict O +
lycopene O +
and O +
beta O +
- O +
carotene O +
concentrations O +
in O +
food O +
samples O +
, O +
combined O +
with O +
a O +
simple O +
and O +
fast O +
technique O +
, O +
such O +
as O +
UV O +
- O +
vis O +
spectroscopy O +
. O +

The O +
measurement O +
of O +
the O +
absorbance O +
at O +
446 O +
and O +
502 O +
nm O +
of O +
different O +
beta O +
- O +
carotene O +
and O +
lycopene O +
standard O +
mixtures O +
was O +
used O +
to O +
optimize O +
a O +
neural O +
network O +
based O +
on O +
a O +
multilayer O +
perceptron O +
( O +
MLP O +
) O +
( O +
learning O +
and O +
verification O +
process O +
) O +
. O +

Then O +
, O +
for O +
validation O +
purposes O +
, O +
the O +
optimized O +
NN O +
has O +
been O +
applied O +
to O +
determine O +
the O +
concentration O +
of O +
both O +
compounds O +
in O +
food O +
samples O +
( O +
fresh O +
tomato O +
, O +
tomato O +
concentrate O +
, O +
tomato O +
sauce O +
, O +
ketchup O +
, O +
tomato O +
juice O +
, O +
watermelon O +
, O +
medlar O +
, O +
green O +
pepper O +
, O +
and O +
carrots O +
) O +
, O +
comparing O +
the O +
NN O +
results O +
with O +
the O +
known O +
values O +
of O +
these O +
compounds O +
obtained O +
by O +
analytical O +
techniques O +
( O +
UV O +
- O +
vis O +
and O +
HPLC O +
) O +
. O +

It O +
was O +
concluded O +
that O +
when O +
the O +
MLP O +
- O +
NN O +
is O +
used O +
within O +
the O +
range O +
studied O +
, O +
the O +
optimized O +
NN O +
is O +
able O +
to O +
estimate O +
the O +
beta O +
- O +
carotene O +
and O +
lycopene O +
concentrations O +
in O +
food O +
samples O +
with O +
an O +
adequate O +
accuracy O +
, O +
solving O +
the O +
UV O +
- O +
vis O +
interference O +
of O +
beta O +
- O +
carotene O +
and O +
lycopene O +
. O +

Effectiveness O +
of O +
different O +
approaches O +
for O +
establishing O +
cisplatin O +
- O +
induced O +
cochlear O +
lesions O +
in O +
mice O +
. O +

CONCLUSIONS O +
: O +

Mouse O +
cochleae O +
are O +
highly O +
resistant O +
to O +
systemically O +
administered O +
cisplatin O +
. O +

However O +
, O +
cochlear O +
lesions O +
can O +
be O +
produced O +
effectively O +
in O +
mice O +
when O +
cisplatin O +
is O +
applied O +
locally O +
through O +
the O +
round O +
window O +
niche O +
or O +
tympanum O +
. O +

OBJECTIVE O +
: O +

To O +
explore O +
the O +
optimal O +
approach O +
for O +
creating O +
cisplatin O +
- O +
induced O +
cochlear O +
lesions O +
in O +
mice O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +

Cisplatin O +
was O +
administered O +
to O +
adult O +
C57BL O +
/ O +
6J O +
mice O +
via O +
four O +
approaches O +
: O +
( O +
1 O +
) O +
transtympanic O +
injection O +
, O +
( O +
2 O +
) O +
round O +
window O +
niche O +
injection O +
, O +
( O +
3 O +
) O +
intraperitoneal O +
injection O +
( O +
i O +
. O +
p O +
. O +
) O +
at O +
4 O +
mg O +
/ O +
kg O +
/ O +
day O +
for O +
4 O +
consecutive O +
days O +
, O +
and O +
( O +
4 O +
) O +
one O +
15 O +
mg O +
/ O +
kg O +
dose O +
i O +
. O +
p O +
. O +

The O +
hearing O +
was O +
monitored O +
using O +
frequency O +
- O +
specific O +
auditory O +
brainstem O +
responses O +
( O +
ABRs O +
) O +
and O +
distortion O +
- O +
product O +
otoacoustic O +
emissions O +
( O +
DPOAEs O +
) O +
. O +

Cochlear O +
pathology O +
was O +
observed O +
in O +
cochleograms O +
with O +
Harris O +
' O +
hematoxylin O +
staining O +
. O +

RESULTS O +
: O +

Cisplatin O +
applied O +
systemically O +
did O +
not O +
cause O +
any O +
significant O +
ABR O +
threshold O +
elevation O +
across O +
the O +
frequencies O +
tested O +
( O +
2 O +
- O +
32 O +
kHz O +
) O +
, O +
whereas O +
local O +
application O +
of O +
cisplatin O +
through O +
the O +
round O +
window O +
niche O +
or O +
tympanum O +
resulted O +
in O +
significant O +
ABR O +
threshold O +
elevations O +
from O +
high O +
to O +
medium O +
frequencies O +
. O +

The O +
functional O +
changes O +
were O +
consistent O +
with O +
the O +
cochlear O +
pathology O +
across O +
groups O +
. O +

[ O +
Reconstruction O +
of O +
hepatic O +
artery O +
in O +
adult O +
to O +
adult O +
living O +
donor O +
liver O +
transplantation O +
in O +
104 O +
patients O +
] O +
. O +

OBJECTIVE O +
: O +

To O +
report O +
the O +
experience O +
of O +
hepatic O +
artery O +
reconstruction O +
with O +
adult O +
- O +
to O +
- O +
adult O +
living O +
donor O +
liver O +
transplantation O +
( O +
ALDLT O +
) O +
using O +
right O +
lobe O +
liver O +
grafts O +
. O +

METHODS O +
: O +

From O +
January O +
2002 O +
to O +
August O +
2007 O +
, O +
104 O +
patients O +
underwent O +
ALDLT O +
using O +
right O +
lobe O +
grafts O +
. O +

Hepatic O +
arteries O +
of O +
donors O +
and O +
recipients O +
were O +
assessed O +
carefully O +
with O +
spiral O +
CT O +
angiography O +
and O +
DSA O +
before O +
ALDLT O +
. O +

All O +
patients O +
underwent O +
reconstruction O +
of O +
hepatic O +
artery O +
between O +
right O +
lobe O +
liver O +
grafts O +
of O +
donor O +
and O +
recipient O +
which O +
included O +
the O +
anastomosis O +
between O +
right O +
hepatic O +
artery O +
of O +
donors O +
and O +
recipients O +
; O +
the O +
reconstruction O +
of O +
right O +
hepatic O +
artery O +
between O +
donor O +
grafts O +
and O +
left O +
hepatic O +
artery O +
of O +
recipients O +
; O +
interpositional O +
bypass O +
using O +
autogenous O +
saphenous O +
vein O +
and O +
cryopreserved O +
iliac O +
artery O +
between O +
right O +
hepatic O +
artery O +
of O +
donors O +
and O +
hepatic O +
artery O +
, O +
common O +
hepatic O +
artery O +
and O +
abdominal O +
aorta O +
of O +
recipients O +
. O +

The O +
microsurgical O +
technique O +
was O +
employed O +
under O +
the O +
magnification O +
of O +
3 O +
. O +
5 O +
times O +
and O +
operative O +
microscope O +
of O +
5 O +
- O +
10 O +
times O +
. O +

RESULTS O +
: O +

In O +
these O +
series O +
, O +
HAT O +
occurred O +
in O +
2 O +
recipients O +
at O +
Days O +
1 O +
and O +
7 O +
post O +
- O +
ALDLT O +
( O +
1 O +
. O +
9 O +
% O +
) O +
. O +

Both O +
were O +
revascularized O +
with O +
autogenous O +
saphenous O +
vein O +
between O +
right O +
hepatic O +
artery O +
of O +
donor O +
and O +
abdominal O +
aorta O +
of O +
recipient O +
. O +

HAT O +
occurred O +
in O +
1 O +
recipient O +
at O +
Days O +
90 O +
post O +
- O +
ALDLT O +
, O +
but O +
no O +
symptom O +
was O +
presented O +
. O +

There O +
was O +
no O +
severe O +
complication O +
and O +
mortality O +
related O +
to O +
hepatic O +
artery O +
reconstruction O +
in O +
recipients O +
. O +

No O +
HAT O +
, O +
hepatic O +
artery O +
stenosis O +
and O +
aneurysm O +
occurred O +
during O +
the O +
follow O +
- O +
up O +
period O +
of O +
2 O +
- O +
60 O +
months O +
. O +

The O +
1 O +
, O +
2 O +
and O +
3 O +
- O +
year O +
survival O +
rates O +
were O +
89 O +
. O +
3 O +
% O +
, O +
76 O +
. O +
0 O +
% O +
and O +
69 O +
. O +
3 O +
% O +
respectively O +
. O +

CONCLUSION O +
: O +

Careful O +
evaluation O +
of O +
hepatic O +
artery O +
condition O +
and O +
using O +
microsurgical O +
techniques O +
are O +
important O +
for O +
safer O +
arterial O +
reconstruction O +
and O +
a O +
long O +
- O +
term O +
patency O +
of O +
hepatic O +
artery O +
in O +
living O +
donor O +
liver O +
transplantation O +
in O +
adults O +
using O +
right O +
lobe O +
liver O +
grafts O +
. O +

ICAM O +
- O +
3 O +
enhances O +
the O +
migratory O +
and O +
invasive O +
potential O +
of O +
human O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
cells O +
by O +
inducing O +
MMP O +
- O +
2 O +
and O +
MMP O +
- O +
9 O +
via O +
Akt O +
and O +
CREB O +
. O +

We O +
have O +
previously O +
reported O +
that O +
intercellular O +
adhesion O +
molecule O +
- O +
3 O +
( O +
ICAM O +
- O +
3 O +
) O +
is O +
associated O +
with O +
an O +
increase O +
of O +
cellular O +
radio O +
- O +
resistance O +
and O +
cancer O +
cell O +
proliferation O +
. O +

In O +
this O +
study O +
, O +
we O +
hypothesized O +
that O +
ICAM O +
- O +
3 O +
has O +
an O +
additional O +
effect O +
on O +
cancer O +
cell O +
migration O +
and O +
invasion O +
because O +
molecules O +
induced O +
by O +
ICAM O +
- O +
3 O +
are O +
known O +
as O +
regulators O +
of O +
cell O +
migration O +
and O +
invasion O +
. O +

To O +
examine O +
this O +
hypothesis O +
, O +
we O +
used O +
NCI B-CellLine +
- I-CellLine +
H1299 I-CellLine +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
( O +
NSCLC O +
) O +
cell O +
line O +
( O +
p53 O +
and O +
PTEN O +
null O +
cell O +
) O +
and O +
constructed O +
an O +
ICAM O +
- O +
3 O +
- O +
over O +
- O +
expressing O +
stable O +
transfectant O +
, O +
which O +
exhibited O +
increased O +
cell O +
migration O +
and O +
invasion O +
. O +

The O +
increased O +
migration O +
and O +
invasion O +
resulted O +
from O +
up O +
- O +
regulation O +
of O +
expression O +
and O +
activities O +
of O +
MMP O +
- O +
2 O +
and O +
MMP O +
- O +
9 O +
. O +

ICAM O +
- O +
3 O +
also O +
increased O +
Akt O +
phosphorylation O +
, O +
which O +
caused O +
an O +
increase O +
in O +
cellular O +
migration O +
/ O +
invasion O +
and O +
MMP O +
activities O +
. O +

Activity O +
of O +
several O +
transcriptional O +
factors O +
located O +
downstream O +
in O +
the O +
Akt O +
pathway O +
was O +
also O +
tested O +
, O +
and O +
constitutive O +
activation O +
of O +
adenosine O +
3 O +
' O +
, O +
5 O +
' O +
- O +
monophosphate O +
response O +
element O +
- O +
binding O +
protein O +
( O +
CREB O +
) O +
by O +
ICAM O +
- O +
3 O +
was O +
detected O +
. O +

Blockage O +
of O +
the O +
Akt O +
pathway O +
attenuated O +
CREB O +
activation O +
, O +
and O +
a O +
decrease O +
in O +
CREB O +
expression O +
reduced O +
cellular O +
migration O +
/ O +
invasion O +
and O +
activity O +
of O +
MMPs O +
. O +

This O +
result O +
indicates O +
that O +
CREB O +
functions O +
in O +
the O +
signaling O +
pathway O +
between O +
Akt O +
and O +
MMP O +
. O +

We O +
also O +
showed O +
ICAM O +
- O +
3 O +
- O +
induced O +
cell O +
migration O +
and O +
invasion O +
in O +
NCI B-CellLine +
- I-CellLine +
H460 I-CellLine +
NSCLC O +
cells O +
( O +
wild O +
- O +
type O +
p53 O +
and O +
PTEN O +
cell O +
) O +
through O +
the O +
same O +
signaling O +
pathway O +
. O +

Taken O +
together O +
, O +
our O +
findings O +
suggest O +
that O +
ICAM O +
- O +
3 O +
stimulates O +
cancer O +
cell O +
migration O +
/ O +
invasion O +
via O +
ICAM O +
- O +
3 O +
/ O +
Akt O +
/ O +
CREB O +
/ O +
MMP O +
pathway O +
regardless O +
of O +
p53 O +
and O +
PTEN O +
status O +
, O +
and O +
this O +
reflects O +
the O +
possibility O +
that O +
ICAM O +
- O +
3 O +
could O +
be O +
considered O +
as O +
a O +
candidate O +
for O +
anti O +
- O +
cancer O +
drug O +
development O +
and O +
as O +
a O +
cancer O +
diagnostic O +
marker O +
. O +

Phenolic O +
fraction O +
of O +
tobacco O +
smoke O +
condensate O +
potentiates O +
benzo O +
[ O +
a O +
] O +
pyerene O +
diol O +
epoxide O +
- O +
induced O +
cell O +
transformation O +
: O +
role O +
of O +
protein O +
kinase O +
C O +
. O +

In O +
this O +
study O +
we O +
separated O +
weakly O +
acidic O +
phenolic O +
components O +
from O +
other O +
neutral O +
, O +
acidic O +
and O +
basic O +
components O +
of O +
tobacco O +
smoke O +
condensate O +
( O +
TSC O +
) O +
and O +
observed O +
that O +
phenolic O +
fraction O +
of O +
TSC O +
significantly O +
increased O +
the O +
number O +
of O +
colonies O +
of O +
promotion O +
- O +
sensitive O +
JB6 B-CellLine +
Cl41 I-CellLine +
cells O +
that O +
showed O +
anchorage O +
- O +
independent O +
growth O +
on O +
soft O +
agar O +
in O +
response O +
to O +
BPDE O +
( O +
an O +
ultimate O +
carcinogen O +
produced O +
by O +
metabolic O +
activation O +
of O +
the O +
PAH O +
benzo O +
[ O +
a O +
] O +
pyrene O +
) O +
. O +

Anchorage O +
- O +
independent O +
cell O +
growth O +
is O +
indicative O +
of O +
cell O +
transformation O +
resulting O +
in O +
acquisition O +
of O +
tumorigenic O +
potential O +
. O +

In O +
order O +
to O +
understand O +
the O +
underlying O +
mechanism O +
by O +
which O +
TSC O +
phenolic O +
fraction O +
potentiates O +
BPDE O +
- O +
induced O +
tumorigenicity O +
, O +
we O +
examined O +
its O +
effect O +
on O +
the O +
activation O +
of O +
two O +
transcription O +
factors O +
AP O +
- O +
1 O +
and O +
NF O +
- O +
kappaB O +
which O +
are O +
known O +
to O +
be O +
influenced O +
by O +
established O +
tumor O +
promoter O +
TPA O +
. O +

BPDE O +
treatment O +
caused O +
induction O +
of O +
both O +
AP O +
- O +
1 O +
and O +
NF O +
- O +
kappaB O +
activity O +
as O +
determined O +
by O +
luciferase O +
reporter O +
assay O +
and O +
only O +
NF O +
- O +
kappaB O +
induction O +
in O +
response O +
to O +
BPDE O +
was O +
significantly O +
attenuated O +
by O +
TSC O +
phenolic O +
fraction O +
whereas O +
AP O +
- O +
1 O +
induction O +
remains O +
unaltered O +
. O +

Attenuation O +
of O +
NF O +
- O +
kappaB O +
activation O +
by O +
TSC O +
phenolic O +
fraction O +
was O +
associated O +
with O +
significant O +
decrease O +
of O +
intracellular O +
PKC O +
substrate O +
phosphorylation O +
in O +
BPDE O +
treated O +
cells O +
. O +

Non O +
- O +
specific O +
PKC O +
inhibitors O +
staurosporine O +
and O +
bisindolylmaleimide O +
II O +
as O +
well O +
as O +
inhibitors O +
specific O +
to O +
conventional O +
PKCs O +
( O +
Go6976 O +
) O +
and O +
PKC O +
- O +
delta O +
( O +
rottlerin O +
) O +
attenuated O +
NF O +
- O +
kappaB O +
activation O +
in O +
BPDE O +
treated O +
cells O +
to O +
a O +
varying O +
degree O +
indicating O +
a O +
possible O +
link O +
between O +
PKC O +
down O +
- O +
regulation O +
and O +
the O +
attenuation O +
of O +
NF O +
- O +
kappaB O +
activity O +
by O +
TSC O +
phenolic O +
fraction O +
. O +

Treatment O +
of O +
cells O +
with O +
PKC O +
inhibitors O +
also O +
potentiated O +
anchorage O +
- O +
independent O +
growth O +
of O +
BPDE O +
treated O +
cells O +
on O +
soft O +
agar O +
. O +

Our O +
data O +
suggest O +
a O +
possible O +
role O +
of O +
PKC O +
down O +
- O +
regulation O +
in O +
potentiation O +
of O +
BPDE O +
- O +
induced O +
tumorogenicity O +
by O +
TSC O +
phenolic O +
fraction O +
. O +

Costs O +
of O +
hip O +
fracture O +
. O +

Rehabilitation O +
of O +
180 O +
patients O +
in O +
primary O +
health O +
care O +
. O +

Costs O +
related O +
to O +
functional O +
status O +
were O +
calculated O +
for O +
180 O +
consecutive O +
hip O +
fracture O +
patients O +
( O +
mean O +
age O +
78 O +
years O +
) O +
who O +
were O +
admitted O +
from O +
their O +
own O +
home O +
and O +
rehabilitated O +
in O +
primary O +
health O +
care O +
. O +

Within O +
4 O +
months O +
after O +
the O +
fracture O +
, O +
75 O +
percent O +
of O +
the O +
patients O +
had O +
been O +
discharged O +
to O +
their O +
own O +
home O +
, O +
9 O +
percent O +
were O +
dead O +
, O +
and O +
the O +
short O +
- O +
term O +
medical O +
treatment O +
costs O +
per O +
patient O +
were O +
SEK O +
43 O +
, O +
000 O +
, O +
whereas O +
the O +
total O +
costs O +
including O +
communal O +
help O +
and O +
costs O +
for O +
living O +
accommodations O +
after O +
discharge O +
were O +
twice O +
as O +
high O +
. O +

The O +
total O +
costs O +
per O +
patient O +
for O +
long O +
- O +
term O +
medical O +
treatment O +
( O +
from O +
4 O +
months O +
up O +
to O +
3 O +
years O +
after O +
fracture O +
) O +
were O +
7 O +
percent O +
of O +
the O +
short O +
- O +
term O +
medical O +
treatment O +
costs O +
. O +

Patients O +
with O +
a O +
cervical O +
fracture O +
discharged O +
to O +
their O +
own O +
home O +
and O +
with O +
good O +
functional O +
status O +
consumed O +
only O +
one O +
fifth O +
of O +
the O +
resources O +
that O +
patients O +
with O +
a O +
trochanteric O +
fracture O +
discharged O +
to O +
institutional O +
care O +
and O +
who O +
had O +
reduced O +
functional O +
status O +
consumed O +
. O +

A O +
substantial O +
part O +
of O +
the O +
costs O +
can O +
be O +
saved O +
by O +
improved O +
organization O +
of O +
rehabilitation O +
after O +
discharge O +
from O +
the O +
hospital O +
. O +

A O +
further O +
cost O +
reduction O +
would O +
require O +
a O +
combination O +
of O +
technologic O +
, O +
social O +
, O +
and O +
organizational O +
changes O +
aimed O +
at O +
early O +
discharge O +
and O +
continued O +
follow O +
- O +
up O +
in O +
primary O +
health O +
care O +
. O +

The O +
role O +
of O +
p53 O +
in O +
glucose O +
metabolism O +
. O +

The O +
p53 O +
protein O +
functions O +
to O +
prevent O +
tumour O +
development O +
by O +
inhibiting O +
the O +
outgrowth O +
of O +
stressed O +
or O +
damaged O +
cells O +
. O +

In O +
addition O +
to O +
well O +
established O +
functions O +
to O +
block O +
cell O +
proliferation O +
, O +
recent O +
studies O +
have O +
revealed O +
a O +
role O +
for O +
p53 O +
in O +
the O +
regulation O +
of O +
pathways O +
involved O +
in O +
glucose O +
metabolism O +
. O +

The O +
metabolic O +
functions O +
of O +
p53 O +
resist O +
the O +
shift O +
to O +
glycolysis O +
that O +
is O +
characteristically O +
seen O +
in O +
cancers O +
, O +
and O +
also O +
help O +
cells O +
adapt O +
to O +
and O +
survive O +
limited O +
periods O +
of O +
metabolic O +
stress O +
. O +

Such O +
activities O +
of O +
p53 O +
would O +
not O +
only O +
help O +
to O +
prevent O +
cancer O +
development O +
, O +
but O +
might O +
also O +
contribute O +
to O +
non O +
- O +
tumour O +
related O +
roles O +
for O +
p53 O +
, O +
such O +
as O +
in O +
the O +
regulation O +
of O +
longevity O +
. O +

These O +
new O +
functions O +
of O +
p53 O +
are O +
providing O +
interesting O +
possibilities O +
for O +
the O +
development O +
of O +
novel O +
therapies O +
. O +

14 O +
- O +
3 O +
- O +
3zeta O +
Overexpression O +
and O +
abnormal O +
beta O +
- O +
catenin O +
expression O +
are O +
associated O +
with O +
poor O +
differentiation O +
and O +
progression O +
in O +
stage O +
I O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
. O +

Recent O +
studies O +
have O +
shown O +
that O +
14 O +
- O +
3 O +
- O +
3zeta O +
interacted O +
with O +
other O +
key O +
cellular O +
proteins O +
involved O +
in O +
the O +
tumor O +
development O +
and O +
progression O +
. O +

Knowledge O +
of O +
14 O +
- O +
3 O +
- O +
3zeta O +
and O +
beta O +
- O +
catenin O +
expression O +
and O +
clinical O +
significance O +
in O +
the O +
same O +
tumor O +
tissues O +
is O +
limited O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
expression O +
and O +
significance O +
of O +
14 O +
- O +
3 O +
- O +
3zeta O +
and O +
beta O +
- O +
catenin O +
in O +
stage O +
I O +
non O +
- O +
small O +
- O +
cell O +
lung O +
cancer O +
( O +
NSCLC O +
) O +
. O +

Specimens O +
of O +
NSCLC O +
and O +
adjacent O +
normal O +
lung O +
tissues O +
were O +
collected O +
from O +
110 O +
patients O +
. O +

The O +
expressions O +
of O +
14 O +
- O +
3 O +
- O +
3zeta O +
and O +
beta O +
- O +
catenin O +
were O +
detected O +
by O +
western O +
blotting O +
, O +
double O +
labeling O +
immunofluorescence O +
, O +
confocal O +
laser O +
scanning O +
microscopy O +
and O +
immunohistochemistry O +
. O +

The O +
expression O +
of O +
14 O +
- O +
3 O +
- O +
3zeta O +
was O +
upregulated O +
in O +
stage O +
I O +
NSCLC O +
. O +

Further O +
, O +
the O +
overexpression O +
of O +
14 O +
- O +
3 O +
- O +
3zeta O +
correlated O +
with O +
histological O +
grades O +
, O +
lymph O +
node O +
metastasis O +
and O +
poor O +
clinical O +
outcome O +
. O +

Abnormal O +
expression O +
of O +
beta O +
- O +
catenin O +
was O +
significantly O +
correlated O +
with O +
poor O +
differentiation O +
and O +
lymph O +
node O +
metastasis O +
. O +

Abnormal O +
beta O +
- O +
catenin O +
expression O +
was O +
associated O +
significantly O +
with O +
positive O +
14 O +
- O +
3 O +
- O +
3zeta O +
expression O +
. O +

In O +
conclusion O +
, O +
14 O +
- O +
3 O +
- O +
3zeta O +
and O +
beta O +
- O +
catenin O +
might O +
have O +
an O +
important O +
role O +
in O +
development O +
, O +
progression O +
and O +
metastatic O +
process O +
of O +
NSCLC O +
. O +

14 O +
- O +
3 O +
- O +
3zeta O +
might O +
be O +
used O +
as O +
prognostic O +
biomarkers O +
for O +
NSCLC O +
. O +

A O +
randomized O +
pilot O +
study O +
of O +
the O +
Engaging O +
Moms O +
Program O +
for O +
family O +
drug O +
court O +
. O +

In O +
response O +
to O +
the O +
need O +
for O +
effective O +
drug O +
court O +
interventions O +
, O +
the O +
effectiveness O +
of O +
the O +
Engaging O +
Moms O +
Program O +
( O +
EMP O +
) O +
versus O +
Intensive O +
Case O +
Management O +
Services O +
( O +
ICMS O +
) O +
on O +
multiple O +
outcomes O +
for O +
mothers O +
enrolled O +
in O +
family O +
drug O +
court O +
was O +
investigated O +
. O +

In O +
this O +
intent O +
- O +
to O +
- O +
treat O +
study O +
, O +
mothers O +
( O +
N O +
= O +
62 O +
) O +
were O +
randomly O +
assigned O +
to O +
either O +
usual O +
drug O +
court O +
care O +
or O +
the O +
Engaging O +
Moms O +
drug O +
court O +
program O +
. O +

Mothers O +
were O +
assessed O +
at O +
intake O +
and O +
3 O +
, O +
6 O +
, O +
12 O +
, O +
and O +
18 O +
months O +
following O +
intake O +
. O +

Results O +
indicated O +
that O +
at O +
18 O +
months O +
post O +
drug O +
court O +
enrollment O +
, O +
77 O +
% O +
of O +
mothers O +
assigned O +
to O +
EMP O +
versus O +
55 O +
% O +
of O +
mothers O +
assigned O +
to O +
ICMS O +
had O +
positive O +
child O +
welfare O +
dispositions O +
. O +

There O +
were O +
statistically O +
significant O +
time O +
effects O +
for O +
both O +
intervention O +
groups O +
on O +
multiple O +
outcomes O +
including O +
substance O +
use O +
, O +
mental O +
health O +
, O +
parenting O +
practices O +
, O +
and O +
family O +
functioning O +
. O +

EMP O +
showed O +
equal O +
or O +
better O +
improvement O +
than O +
ICMS O +
on O +
all O +
outcomes O +
. O +

The O +
results O +
suggest O +
that O +
EMP O +
in O +
family O +
drug O +
court O +
is O +
a O +
viable O +
and O +
promising O +
intervention O +
approach O +
to O +
reduce O +
maternal O +
addiction O +
and O +
child O +
maltreatment O +
. O +

Hormonal O +
regulation O +
and O +
distinct O +
functions O +
of O +
semaphorin O +
- O +
3B O +
and O +
semaphorin O +
- O +
3F O +
in O +
ovarian O +
cancer O +
. O +

Semaphorins O +
comprise O +
a O +
family O +
of O +
molecules O +
that O +
influence O +
neuronal O +
growth O +
and O +
guidance O +
. O +

Class O +
- O +
3 O +
semaphorins O +
, O +
semaphorin O +
- O +
3B O +
( O +
SEMA3B O +
) O +
and O +
semaphorin O +
- O +
3F O +
( O +
SEMA3F O +
) O +
, O +
illustrate O +
their O +
effects O +
by O +
forming O +
a O +
complex O +
with O +
neuropilins O +
( O +
NP O +
- O +
1 O +
or O +
NP O +
- O +
2 O +
) O +
and O +
plexins O +
. O +

We O +
examined O +
the O +
status O +
and O +
regulation O +
of O +
semaphorins O +
and O +
their O +
receptors O +
in O +
human O +
ovarian O +
cancer O +
cells O +
. O +

A O +
significantly O +
reduced O +
expression O +
of O +
SEMA3B O +
( O +
83 O +
kDa O +
) O +
, O +
SEMA3F O +
( O +
90 O +
kDa O +
) O +
, O +
and O +
plexin O +
- O +
A3 O +
was O +
observed O +
in O +
ovarian O +
cancer O +
cell O +
lines O +
when O +
compared O +
with O +
normal O +
human O +
ovarian O +
surface O +
epithelial O +
cells O +
. O +

The O +
expression O +
of O +
NP O +
- O +
1 O +
, O +
NP O +
- O +
2 O +
, O +
and O +
plexin O +
- O +
A1 O +
was O +
not O +
altered O +
in O +
human O +
ovarian O +
surface O +
epithelial O +
and O +
ovarian O +
cancer O +
cells O +
. O +

The O +
decreased O +
expression O +
of O +
SEMA3B O +
, O +
SEMA3F O +
, O +
and O +
plexin O +
- O +
A3 O +
was O +
confirmed O +
in O +
stage O +
3 O +
ovarian O +
tumors O +
. O +

The O +
treatment O +
of O +
ovarian O +
cancer O +
cells O +
with O +
luteinizing O +
hormone O +
, O +
follicle O +
- O +
stimulating O +
hormone O +
, O +
and O +
estrogen O +
induced O +
a O +
significant O +
upregulation O +
of O +
SEMA3B O +
, O +
whereas O +
SEMA3F O +
was O +
upregulated O +
only O +
by O +
estrogen O +
. O +

Cotreatment O +
of O +
cell O +
lines O +
with O +
a O +
hormone O +
and O +
its O +
specific O +
antagonist O +
blocked O +
the O +
effect O +
of O +
the O +
hormone O +
. O +

Ectopic O +
expression O +
of O +
SEMA3B O +
or O +
SEMA3F O +
reduced O +
soft O +
- O +
agar O +
colony O +
formation O +
, O +
adhesion O +
, O +
and O +
cell O +
invasion O +
of O +
ovarian O +
cancer O +
cell O +
cultures O +
. O +

Forced O +
expression O +
of O +
SEMA3B O +
, O +
but O +
not O +
SEMA3F O +
, O +
inhibited O +
viability O +
of O +
ovarian O +
cancer O +
cells O +
. O +

Overexpression O +
of O +
SEMA3B O +
and O +
SEMA3F O +
reduced O +
focal O +
adhesion O +
kinase O +
phosphorylation O +
and O +
matrix O +
metalloproteinase O +
- O +
2 O +
and O +
matrix O +
metalloproteinase O +
- O +
9 O +
expression O +
in O +
ovarian O +
cancer O +
cells O +
. O +

Forced O +
expression O +
of O +
SEMA3F O +
, O +
but O +
not O +
SEMA3B O +
in O +
ovarian O +
cancer O +
cells O +
, O +
significantly O +
inhibited O +
endothelial O +
cell O +
tube O +
formation O +
. O +

Collectively O +
, O +
our O +
results O +
suggest O +
that O +
the O +
loss O +
of O +
SEMA3 O +
expression O +
could O +
be O +
a O +
hallmark O +
of O +
cancer O +
progression O +
. O +

Furthermore O +
, O +
gonadotropin O +
- O +
and O +
/ O +
or O +
estrogen O +
- O +
mediated O +
maintenance O +
of O +
SEMA3 O +
expression O +
could O +
control O +
ovarian O +
cancer O +
angiogenesis O +
and O +
metastasis O +
. O +

Tobacco O +
smoke O +
promotes O +
lung O +
tumorigenesis O +
by O +
triggering O +
IKKbeta O +
- O +
and O +
JNK1 O +
- O +
dependent O +
inflammation O +
. O +

Chronic O +
exposure O +
to O +
tobacco O +
smoke O +
, O +
which O +
contains O +
over O +
60 O +
tumor O +
- O +
initiating O +
carcinogens O +
, O +
is O +
the O +
major O +
risk O +
factor O +
for O +
development O +
of O +
lung O +
cancer O +
, O +
accounting O +
for O +
a O +
large O +
portion O +
of O +
cancer O +
- O +
related O +
deaths O +
worldwide O +
. O +

It O +
is O +
well O +
established O +
that O +
tobacco O +
smoke O +
is O +
a O +
tumor O +
initiator O +
, O +
but O +
we O +
asked O +
whether O +
it O +
also O +
acts O +
as O +
a O +
tumor O +
promoter O +
once O +
malignant O +
initiation O +
, O +
such O +
as O +
caused O +
by O +
K O +
- O +
ras O +
activation O +
, O +
has O +
taken O +
place O +
. O +

Here O +
we O +
demonstrate O +
that O +
repetitive O +
exposure O +
to O +
tobacco O +
smoke O +
promotes O +
tumor O +
development O +
both O +
in O +
carcinogen O +
- O +
treated O +
mice O +
and O +
in O +
transgenic O +
mice O +
undergoing O +
sporadic O +
K O +
- O +
ras O +
activation O +
in O +
lung O +
epithelial O +
cells O +
. O +

Tumor O +
promotion O +
is O +
due O +
to O +
induction O +
of O +
inflammation O +
that O +
results O +
in O +
enhanced O +
pneumocyte O +
proliferation O +
and O +
is O +
abrogated O +
by O +
IKKbeta O +
ablation O +
in O +
myeloid O +
cells O +
or O +
inactivation O +
of O +
JNK1 O +
. O +

Killing O +
tumor O +
cells O +
through O +
their O +
surface O +
beta O +
( O +
2 O +
) O +
- O +
microglobulin O +
or O +
major O +
histocompatibility O +
complex O +
class O +
I O +
molecules O +
. O +

Targeted O +
antibody O +
- O +
based O +
therapy O +
has O +
been O +
used O +
successfully O +
to O +
treat O +
cancers O +
. O +

Recent O +
studies O +
have O +
demonstrated O +
that O +
tumor O +
cells O +
treated O +
with O +
antibodies O +
specific O +
for O +
beta O +
( O +
2 O +
) O +
- O +
microglobulin O +
( O +
beta O +
( O +
2 O +
) O +
M O +
) O +
or O +
major O +
histocompatibility O +
complex O +
( O +
MHC O +
) O +
class O +
I O +
molecules O +
undergo O +
apoptosis O +
in O +
vitro O +
and O +
in O +
vivo O +
( O +
mouse O +
models O +
) O +
. O +

Antibodies O +
against O +
beta O +
( O +
2 O +
) O +
M O +
or O +
MHC O +
class O +
I O +
induce O +
tumor O +
cell O +
apoptosis O +
by O +
1 O +
) O +
recruiting O +
MHC O +
class O +
I O +
molecules O +
to O +
lipid O +
rafts O +
and O +
activating O +
LYN O +
kinase O +
and O +
the O +
signal O +
- O +
transducing O +
enzyme O +
phospholipase O +
C O +
- O +
gamma2 O +
- O +
dependent O +
c O +
- O +
Jun O +
N O +
- O +
terminal O +
kinase O +
signaling O +
pathway O +
and O +
2 O +
) O +
expelling O +
interleukin O +
6 O +
and O +
insulin O +
- O +
like O +
growth O +
factor O +
1 O +
receptors O +
out O +
of O +
lipid O +
rafts O +
and O +
inhibiting O +
the O +
growth O +
and O +
survival O +
factor O +
- O +
induced O +
activation O +
of O +
the O +
phosphatidylinositol O +
3 O +
- O +
kinase O +
/ O +
Akt O +
and O +
extracellular O +
signal O +
- O +
related O +
kinase O +
pathways O +
. O +

Consequently O +
, O +
mitochondrial O +
integrity O +
is O +
compromised O +
, O +
and O +
the O +
caspase O +
- O +
9 O +
- O +
dependent O +
cascade O +
is O +
activated O +
in O +
treated O +
tumor O +
cells O +
. O +

However O +
, O +
although O +
beta O +
( O +
2 O +
) O +
M O +
and O +
MHC O +
class O +
I O +
are O +
expressed O +
on O +
normal O +
hematopoietic O +
cells O +
, O +
which O +
is O +
a O +
potential O +
safety O +
concern O +
, O +
the O +
monoclonal O +
antibodies O +
were O +
selective O +
to O +
tumor O +
cells O +
and O +
did O +
not O +
damage O +
normal O +
cells O +
in O +
vitro O +
or O +
in O +
human O +
- O +
like O +
mouse O +
models O +
. O +

These O +
findings O +
suggest O +
that O +
targeting O +
beta O +
( O +
2 O +
) O +
M O +
or O +
MHC O +
class O +
I O +
by O +
using O +
antibodies O +
or O +
other O +
agents O +
offers O +
a O +
potential O +
therapeutic O +
approach O +
for O +
beta O +
( O +
2 O +
) O +
M O +
/ O +
MHC O +
class O +
I O +
- O +
expressing O +
malignancies O +
. O +

Cancer O +
2010 O +
. O +

( O +
c O +
) O +
2010 O +
American O +
Cancer O +
Society O +
. O +

Further O +
Characterization O +
of O +
Activin O +
A O +
- O +
induced O +
IgA O +
Response O +
in O +
Murine O +
B O +
Lymphocytes O +
. O +

We O +
have O +
recently O +
shown O +
that O +
activin O +
A O +
, O +
a O +
member O +
of O +
TGF O +
- O +
beta O +
superfamily O +
, O +
stimulates O +
mouse O +
B O +
cells O +
to O +
express O +
IgA O +
isotype O +
but O +
other O +
isotypes O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
further O +
characterized O +
effects O +
of O +
activin O +
A O +
on O +
B O +
cell O +
growth O +
and O +
IgA O +
expression O +
. O +

We O +
found O +
that O +
activin O +
A O +
did O +
not O +
have O +
effect O +
on O +
LPS O +
- O +
stimulated O +
cell O +
viability O +
. O +

In O +
parallel O +
, O +
CFSE O +
staining O +
analysis O +
revealed O +
that O +
activin O +
A O +
did O +
not O +
alter O +
cell O +
division O +
. O +

An O +
increase O +
of O +
IgA O +
secretion O +
by O +
activin O +
A O +
was O +
completely O +
abrogated O +
by O +
anti O +
- O +
activin O +
A O +
Ab O +
but O +
not O +
by O +
anti O +
- O +
TGFbeta1 O +
Ab O +
. O +

In O +
the O +
same O +
conditions O +
, O +
no O +
other O +
isotypes O +
are O +
significantly O +
affected O +
by O +
each O +
antibody O +
treatment O +
. O +

Finally O +
, O +
activin O +
A O +
, O +
as O +
similar O +
to O +
TGF O +
- O +
beta1 O +
, O +
increased O +
IgA O +
secretion O +
by O +
mesenteric O +
lymph O +
node O +
cells O +
. O +

These O +
results O +
suggest O +
that O +
activin O +
A O +
can O +
specifically O +
stimulate O +
IgA O +
response O +
, O +
independent O +
of O +
TGF O +
- O +
beta O +
in O +
the O +
gut O +
. O +

Posterior O +
stabilization O +
of O +
the O +
cervical O +
spine O +
with O +
hook O +
plates O +
. O +

Hook O +
- O +
plate O +
fixation O +
is O +
designed O +
for O +
posterior O +
cervical O +
stabilization O +
from O +
C2 O +
to O +
C7 O +
. O +

Indications O +
remain O +
the O +
same O +
as O +
for O +
standard O +
posterior O +
fixations O +
. O +

The O +
prime O +
indications O +
are O +
discoligamentous O +
injuries O +
. O +

The O +
plates O +
are O +
hooked O +
under O +
the O +
lower O +
laminas O +
and O +
attached O +
to O +
the O +
articular O +
masses O +
of O +
the O +
upper O +
vertebra O +
by O +
oblique O +
screws O +
. O +

An O +
H O +
- O +
graft O +
is O +
placed O +
between O +
the O +
spinous O +
processes O +
. O +

The O +
vertebrae O +
are O +
compressed O +
together O +
by O +
the O +
plates O +
at O +
three O +
points O +
, O +
the O +
facet O +
joints O +
, O +
and O +
graft O +
. O +

The O +
resulting O +
pre O +
- O +
stressed O +
system O +
is O +
stable O +
in O +
all O +
directions O +
. O +

A O +
protocol O +
for O +
safe O +
reduction O +
of O +
cervical O +
dislocations O +
is O +
observed O +
. O +

Of O +
70 O +
patients O +
treated O +
from O +
1979 O +
to O +
1986 O +
, O +
51 O +
were O +
examined O +
12 O +
- O +
54 O +
months O +
after O +
surgery O +
. O +

All O +
fusions O +
consolidated O +
. O +

Two O +
neurologic O +
complications O +
not O +
attributable O +
to O +
the O +
fixation O +
occurred O +
. O +

Other O +
major O +
complications O +
were O +
not O +
seen O +
. O +

Comment O +
on O +
" O +
Why O +
reduced O +
- O +
form O +
regression O +
models O +
of O +
health O +
effects O +
versus O +
exposures O +
should O +
not O +
replace O +
QRA O +
: O +
livestock O +
production O +
and O +
infant O +
mortality O +
as O +
an O +
example O +
, O +
" O +
by O +
Louis O +
Anthony O +
( O +
Tony O +
) O +
Cox O +
, O +
Jr O +
. O +
, O +
Risk O +
Analysis O +
2009 O +
, O +
Vol O +
. O +

29 O +
, O +
No O +
. O +
12 O +
. O +

While O +
a O +
recent O +
paper O +
by O +
Cox O +
in O +
this O +
journal O +
uses O +
as O +
its O +
motivating O +
factor O +
the O +
benefits O +
of O +
quantitative O +
risk O +
assessment O +
, O +
its O +
content O +
is O +
entirely O +
devoted O +
to O +
critiquing O +
Sneeringer O +
' O +
s O +
article O +
in O +
the O +
American O +
Journal O +
of O +
Agricultural O +
Economics O +
. O +

Cox O +
' O +
s O +
two O +
main O +
critiques O +
of O +
Sneeringer O +
are O +
fundamentally O +
flawed O +
and O +
misrepresent O +
the O +
original O +
article O +
. O +

Cox O +
posits O +
that O +
Sneeringer O +
did O +
A O +
and O +
B O +
, O +
and O +
then O +
argues O +
why O +
A O +
and O +
B O +
are O +
incorrect O +
. O +

However O +
, O +
Sneeringer O +
in O +
fact O +
did O +
C O +
and O +
D O +
; O +
thus O +
critiques O +
of O +
A O +
and O +
B O +
are O +
not O +
applicable O +
to O +
Sneeringer O +
' O +
s O +
analysis O +
. O +

Dose O +
- O +
and O +
time O +
- O +
dependent O +
effects O +
of O +
doxorubicin O +
on O +
cytotoxicity O +
, O +
cell O +
cycle O +
and O +
apoptotic O +
cell O +
death O +
in O +
human O +
colon O +
cancer O +
cells O +
. O +

The O +
cytostatic O +
drug O +
doxorubicin O +
is O +
a O +
well O +
- O +
known O +
chemotherapeutic O +
agent O +
which O +
is O +
used O +
in O +
treatment O +
of O +
a O +
wide O +
variety O +
of O +
cancers O +
. O +

A O +
key O +
factor O +
in O +
the O +
response O +
of O +
cancer O +
cells O +
to O +
chemotherapeutic O +
drugs O +
is O +
the O +
activation O +
of O +
the O +
apoptotic O +
pathway O +
, O +
a O +
pathway O +
that O +
is O +
often O +
impaired O +
in O +
chemoresistant O +
colon O +
cancer O +
cells O +
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
effects O +
of O +
doxorubicin O +
in O +
Hct B-CellLine +
- I-CellLine +
116 I-CellLine +
human O +
colon O +
carcinoma O +
cells O +
in O +
order O +
to O +
clarify O +
if O +
a O +
time O +
/ O +
concentration O +
range O +
for O +
optimal O +
doxorubicin O +
- O +
induced O +
apoptosis O +
exists O +
. O +

We O +
compared O +
a O +
treatment O +
schedule O +
were O +
cells O +
were O +
bolus O +
incubated O +
for O +
3h O +
with O +
doxorubicin O +
followed O +
by O +
24h O +
in O +
drug O +
- O +
free O +
medium O +
, O +
with O +
a O +
continuous O +
doxorubicin O +
treatment O +
schedule O +
for O +
24h O +
. O +

Bolus O +
incubation O +
was O +
carried O +
out O +
to O +
determine O +
effects O +
of O +
doxorubicin O +
accumulated O +
during O +
the O +
first O +
3h O +
, O +
whereas O +
continuous O +
incubation O +
allowed O +
further O +
( O +
continuous O +
) O +
exposure O +
to O +
doxorubicin O +
. O +

We O +
found O +
that O +
bolus O +
( O +
3h O +
) O +
treatment O +
with O +
doxorubicin O +
resulted O +
in O +
a O +
dose O +
- O +
dependent O +
decrease O +
of O +
viable O +
cells O +
and O +
concomitant O +
increase O +
of O +
apoptosis O +
. O +

Additionally O +
, O +
bolus O +
( O +
3h O +
) O +
doxorubicin O +
incubation O +
led O +
to O +
phosphorylation O +
of O +
p53 O +
at O +
serine O +
392 O +
, O +
induction O +
of O +
p21 O +
, O +
G2 O +
arrest O +
and O +
increase O +
of O +
proapoptotic O +
protein O +
Bax O +
. O +

In O +
contrast O +
, O +
continuous O +
( O +
24h O +
) O +
treatment O +
with O +
doxorubicin O +
reduced O +
the O +
number O +
of O +
living O +
cells O +
with O +
no O +
parallel O +
raise O +
in O +
the O +
amount O +
of O +
dead O +
cells O +
. O +

Continuous O +
( O +
24h O +
) O +
treatment O +
with O +
5 O +
microM O +
doxorubicin O +
resulted O +
in O +
cell O +
cycle O +
arrest O +
in O +
G0 O +
/ O +
G1 O +
phase O +
that O +
was O +
neither O +
accompanied O +
by O +
phosphorylation O +
and O +
activation O +
of O +
p53 O +
nor O +
enhanced O +
expression O +
of O +
p21 O +
. O +

These O +
results O +
suggest O +
that O +
doxorubicin O +
is O +
able O +
to O +
induce O +
cell O +
death O +
by O +
apoptosis O +
only O +
at O +
particular O +
dose O +
and O +
treatment O +
conditions O +
and O +
imply O +
a O +
completely O +
different O +
cellular O +
response O +
following O +
bolus O +
or O +
continuous O +
exposure O +
to O +
doxorubicin O +
. O +

p24 O +
family O +
type O +
1 O +
transmembrane O +
proteins O +
are O +
required O +
for O +
insulin O +
biosynthesis O +
and O +
secretion O +
in O +
pancreatic O +
beta O +
- O +
cells O +
. O +

The O +
p24 O +
protein O +
family O +
have O +
multiple O +
functions O +
in O +
protein O +
transport O +
in O +
the O +
early O +
secretory O +
pathway O +
. O +

In O +
this O +
study O +
we O +
examined O +
the O +
role O +
of O +
p24 O +
proteins O +
in O +
insulin O +
transport O +
. O +

Several O +
members O +
were O +
detected O +
in O +
insulinoma O +
cell O +
lines O +
and O +
rat O +
islets O +
and O +
expression O +
levels O +
positively O +
correlated O +
with O +
insulin O +
abundance O +
, O +
particularly O +
for O +
p24delta1 O +
and O +
p24beta1 O +
. O +

Knocking O +
down O +
p24delta1 O +
in O +
insulinoma O +
cell O +
lines O +
, O +
which O +
also O +
resulted O +
in O +
the O +
concomitant O +
knock O +
- O +
down O +
of O +
other O +
family O +
members O +
, O +
impaired O +
glucose O +
- O +
stimulated O +
insulin O +
secretion O +
, O +
decreased O +
total O +
cellular O +
insulin O +
content O +
and O +
reduced O +
proinsulin O +
biosynthesis O +
. O +

There O +
was O +
no O +
effect O +
on O +
overall O +
protein O +
biosynthesis O +
or O +
ER O +
stress O +
. O +

These O +
results O +
suggest O +
that O +
p24delta1 O +
and O +
possibly O +
other O +
p24 O +
family O +
proteins O +
are O +
required O +
for O +
normal O +
insulin O +
biosynthesis O +
and O +
subsequent O +
secretion O +
in O +
pancreatic O +
beta O +
- O +
cells O +
. O +

Absence O +
of O +
microbiota O +
( O +
germ O +
- O +
free O +
conditions O +
) O +
accelerates O +
the O +
atherosclerosis O +
in O +
ApoE O +
- O +
deficient O +
mice O +
fed O +
standard O +
low O +
cholesterol O +
diet O +
. O +

AIM O +
: O +

The O +
aim O +
of O +
our O +
work O +
was O +
to O +
determine O +
the O +
influence O +
of O +
intestinal O +
bacteria O +
on O +
the O +
development O +
of O +
atherosclerotic O +
lesions O +
using O +
apolipoprotein O +
E O +
( O +
ApoE O +
) O +
- O +
deficient O +
knockout O +
mice O +
. O +

METHODS O +
: O +

The O +
experiments O +
were O +
performed O +
on O +
ApoE O +
- O +
/ O +
- O +
- O +
deficient O +
mouse O +
strain O +
C57BL O +
/ O +
6 O +
, O +
bred O +
under O +
germ O +
- O +
free O +
( O +
GF O +
) O +
conditions O +
for O +
two O +
generations O +
or O +
under O +
conventional O +
conditions O +
with O +
defined O +
microflora O +
( O +
CV O +
) O +
. O +

The O +
mice O +
were O +
fed O +
a O +
standard O +
low O +
cholesterol O +
diet O +
or O +
cholesterol O +
- O +
rich O +
diet O +
for O +
3 O +
- O +
4 O +
months O +
. O +

We O +
studied O +
the O +
development O +
of O +
advanced O +
lesions O +
in O +
the O +
thoracic O +
and O +
abdominal O +
aorta O +
by O +
histological O +
, O +
morphometric O +
and O +
immunohistological O +
methods O +
. O +

RESULTS O +
: O +

Conventionally O +
reared O +
ApoE O +
- O +
/ O +
- O +
mice O +
( O +
containing O +
no O +
pathogenic O +
intestinal O +
microbiota O +
) O +
and O +
fed O +
a O +
standard O +
low O +
cholesterol O +
diet O +
in O +
contrast O +
to O +
a O +
high O +
cholesterol O +
diet O +
did O +
not O +
develop O +
atherosclerotic O +
aortic O +
plaques O +
. O +

In O +
contrast O +
, O +
ApoE O +
- O +
/ O +
- O +
mice O +
reared O +
under O +
germfree O +
conditions O +
for O +
2 O +
generations O +
and O +
fed O +
a O +
low O +
cholesterol O +
diet O +
exhibited O +
atherosclerotic O +
plaques O +
in O +
the O +
aorta O +
. O +

Characteristic O +
lipid O +
deposition O +
with O +
foam O +
cells O +
and O +
macrophages O +
was O +
found O +
in O +
their O +
arterial O +
walls O +
. O +

CONCLUSION O +
: O +

In O +
contrast O +
to O +
the O +
absence O +
of O +
atherosclerotic O +
plaques O +
in O +
conventionally O +
reared O +
ApoE O +
- O +
deficient O +
mice O +
, O +
germ O +
- O +
free O +
ApoE O +
- O +
/ O +
- O +
mice O +
consuming O +
the O +
same O +
low O +
cholesterol O +
standard O +
diet O +
developed O +
atherosclerotic O +
plaques O +
in O +
the O +
aorta O +
. O +

Differences O +
in O +
atherosclerotic O +
plaques O +
between O +
GF O +
and O +
CV O +
ApoE O +
- O +
/ O +
- O +
mice O +
are O +
not O +
so O +
apparent O +
when O +
mice O +
are O +
fed O +
a O +
high O +
cholesterol O +
diet O +
. O +

Our O +
findings O +
thus O +
document O +
the O +
protective O +
effect O +
of O +
microbiota O +
( O +
commensal O +
bacteria O +
) O +
on O +
atherosclerosis O +
development O +
. O +

Lactate O +
- O +
dehydrogenase O +
5 O +
is O +
overexpressed O +
in O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
and O +
correlates O +
with O +
the O +
expression O +
of O +
the O +
transketolase O +
- O +
like O +
protein O +
1 O +
. O +

AIMS O +
: O +
As O +
one O +
of O +
the O +
five O +
lactate O +
dehydrogenase O +
( O +
LDH O +
) O +
isoenzymes O +
, O +
LDH5 O +
has O +
the O +
highest O +
efficiency O +
to O +
catalyze O +
pyruvate O +
transformation O +
to O +
lactate O +
. O +

LDH5 O +
overexpression O +
in O +
cancer O +
cells O +
induces O +
an O +
upregulated O +
glycolytic O +
metabolism O +
and O +
reduced O +
dependence O +
on O +
the O +
presence O +
of O +
oxygen O +
. O +

Here O +
we O +
analyzed O +
LDH5 O +
protein O +
expression O +
in O +
a O +
well O +
characterized O +
large O +
cohort O +
of O +
primary O +
lung O +
cancers O +
in O +
correlation O +
to O +
clinico O +
- O +
pathological O +
data O +
and O +
its O +
possible O +
impact O +
on O +
patient O +
survival O +
. O +

METHODS O +
: O +
Primary O +
lung O +
cancers O +
( O +
n O +
= O +
269 O +
) O +
and O +
non O +
neoplastic O +
lung O +
tissue O +
( O +
n O +
= O +
35 O +
) O +
were O +
tested O +
for O +
LDH5 O +
expression O +
by O +
immunohistochemistry O +
using O +
a O +
polyclonal O +
LDH5 O +
antibody O +
( O +
ab53010 O +
) O +
. O +

The O +
results O +
of O +
LDH5 O +
expression O +
were O +
correlated O +
to O +
clinico O +
- O +
pathological O +
data O +
as O +
well O +
as O +
to O +
patient O +
' O +
s O +
survival O +
. O +

In O +
addition O +
, O +
the O +
results O +
of O +
the O +
previously O +
tested O +
transketolase O +
like O +
1 O +
protein O +
( O +
TKTL1 O +
) O +
expression O +
were O +
correlated O +
to O +
LDH5 O +
expression O +
. O +

RESULTS O +
: O +
89 O +
. O +
5 O +
% O +
( O +
n O +
= O +
238 O +
) O +
of O +
NSCLC O +
revealed O +
LDH5 O +
expression O +
whereas O +
LDH5 O +
expression O +
was O +
not O +
detected O +
in O +
non O +
neoplastic O +
lung O +
tissues O +
( O +
n O +
= O +
34 O +
) O +
( O +
p O +
< O +
0 O +
. O +
0001 O +
) O +
. O +

LDH5 O +
overexpression O +
was O +
associated O +
with O +
histological O +
type O +
( O +
adenocarcinoma O +
= O +
57 O +
% O +
, O +
squamous O +
cell O +
carcinoma O +
= O +
45 O +
% O +
, O +
large O +
cell O +
carcinoma O +
= O +
46 O +
% O +
, O +
p O +
= O +
0 O +
. O +
006 O +
) O +
. O +

No O +
significant O +
correlation O +
could O +
be O +
detected O +
with O +
regard O +
to O +
TNM O +
- O +
stage O +
, O +
grading O +
or O +
survival O +
. O +

A O +
two O +
sided O +
correlation O +
between O +
the O +
expression O +
of O +
TKTL1 O +
and O +
LDH5 O +
could O +
be O +
shown O +
( O +
p O +
= O +
0 O +
. O +
002 O +
) O +
within O +
the O +
overall O +
cohort O +
as O +
well O +
as O +
for O +
each O +
grading O +
and O +
pN O +
group O +
. O +

A O +
significant O +
correlation O +
between O +
LDH5 O +
and O +
TKTL1 O +
within O +
each O +
histologic O +
tumortype O +
could O +
not O +
be O +
revealed O +
. O +

CONCLUSIONS O +
: O +
LDH5 O +
is O +
overexpressed O +
in O +
NSCLC O +
and O +
could O +
hence O +
serve O +
as O +
an O +
additional O +
marker O +
for O +
malignancy O +
. O +

Furthermore O +
, O +
LDH5 O +
correlates O +
positively O +
with O +
the O +
prognostic O +
marker O +
TKTL1 O +
. O +

Our O +
results O +
confirm O +
a O +
close O +
link O +
between O +
the O +
two O +
metabolic O +
enzymes O +
and O +
indicate O +
an O +
alteration O +
in O +
the O +
glucose O +
metabolism O +
in O +
the O +
process O +
of O +
malignant O +
transformation O +
. O +

Expression O +
of O +
KISS1 O +
and O +
MMP O +
- O +
9 O +
in O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
and O +
their O +
relations O +
to O +
metastasis O +
and O +
survival O +
. O +

KISS1 O +
and O +
matrix O +
metalloproteinase O +
- O +
9 O +
( O +
MMP O +
- O +
9 O +
) O +
may O +
play O +
important O +
roles O +
as O +
metastasis O +
suppressor O +
and O +
metastasis O +
promoter O +
genes O +
, O +
respectively O +
, O +
in O +
a O +
variety O +
of O +
malignancies O +
. O +

However O +
, O +
there O +
is O +
little O +
information O +
about O +
their O +
possible O +
roles O +
in O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
( O +
NSCLC O +
) O +
. O +

The O +
goals O +
of O +
this O +
study O +
were O +
to O +
determine O +
the O +
mRNA O +
and O +
protein O +
expressions O +
of O +
KISS1 O +
and O +
MMP O +
- O +
9 O +
in O +
NSCLC O +
and O +
their O +
relations O +
to O +
metastasis O +
and O +
prognosis O +
. O +

The O +
mRNA O +
and O +
protein O +
expressions O +
of O +
KISS1 O +
and O +
of O +
MMP O +
- O +
9 O +
protein O +
were O +
detected O +
by O +
in O +
situ O +
hybridization O +
and O +
immunohistochemistry O +
respectively O +
in O +
85 O +
cases O +
of O +
NSCLC O +
, O +
and O +
their O +
matched O +
lymph O +
node O +
metastases O +
. O +

Expressions O +
of O +
KISS1 O +
mRNA O +
and O +
protein O +
were O +
significantly O +
higher O +
in O +
low O +
TNM O +
stages O +
of O +
NSCLC O +
( O +
I O +
- O +
II O +
) O +
compared O +
to O +
more O +
advanced O +
stages O +
( O +
III O +
- O +
IV O +
) O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

Moreover O +
, O +
in O +
advanced O +
TNM O +
stages O +
, O +
cases O +
without O +
metastasis O +
had O +
higher O +
KISS1 O +
gene O +
expression O +
compared O +
to O +
those O +
with O +
lymph O +
node O +
metastasis O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

In O +
contrast O +
, O +
MMP O +
- O +
9 O +
expression O +
was O +
higher O +
in O +
stage O +
III O +
- O +
IV O +
NSCLC O +
cases O +
compared O +
to O +
stage O +
I O +
- O +
II O +
tumors O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
and O +
higher O +
in O +
NSCLC O +
cases O +
with O +
metastasis O +
than O +
those O +
without O +
metastasis O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

There O +
was O +
negative O +
correction O +
between O +
KISS1 O +
and O +
MMP O +
- O +
9 O +
protein O +
expression O +
( O +
p O +
< O +
0 O +
. O +
01 O +
) O +
. O +

The O +
5 O +
- O +
year O +
survival O +
rate O +
in O +
cases O +
with O +
higher O +
KISS1 O +
protein O +
expression O +
was O +
significantly O +
higher O +
than O +
in O +
those O +
with O +
low O +
expression O +
( O +
20 O +
. O +
9 O +
vs O +
. O +
2 O +
. O +
4 O +
% O +
, O +
p O +
< O +
0 O +
. O +
01 O +
) O +
. O +

However O +
, O +
the O +
5 O +
- O +
year O +
survival O +
rate O +
of O +
patients O +
with O +
high O +
MMP O +
- O +
9 O +
protein O +
expression O +
were O +
lower O +
than O +
those O +
with O +
low O +
expression O +
( O +
19 O +
vs O +
. O +
4 O +
. O +
7 O +
% O +
, O +
p O +
< O +
0 O +
. O +
05 O +
) O +
. O +

Our O +
data O +
suggest O +
that O +
KISS1 O +
and O +
MMP O +
- O +
9 O +
may O +
serve O +
as O +
potential O +
prognostic O +
and O +
therapeutic O +
markers O +
in O +
lung O +
cancer O +
. O +

Is O +
the O +
elimination O +
of O +
HIV O +
infection O +
within O +
reach O +
in O +
the O +
United O +
States O +
? O +

Lessons O +
from O +
an O +
epidemiologic O +
transmission O +
model O +
. O +

Recent O +
estimates O +
show O +
that O +
the O +
transmission O +
rate O +
of O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
in O +
the O +
U O +
. O +
S O +
. O +
has O +
substantially O +
decreased O +
. O +

This O +
raises O +
the O +
question O +
, O +
is O +
elimination O +
of O +
HIV O +
infection O +
in O +
the O +
nation O +
feasible O +
in O +
the O +
foreseeable O +
future O +
? O +

We O +
demonstrate O +
that O +
if O +
the O +
HIV O +
transmission O +
rate O +
were O +
reduced O +
by O +
50 O +
% O +
, O +
then O +
the O +
reproductive O +
rate O +
of O +
HIV O +
infection O +
would O +
drop O +
below O +
unity O +
and O +
lead O +
to O +
eventual O +
elimination O +
of O +
infection O +
. O +

In O +
recent O +
congressional O +
testimony O +
, O +
the O +
director O +
of O +
the O +
Centers O +
for O +
Disease O +
Control O +
and O +
Prevention O +
and O +
others O +
asserted O +
that O +
the O +
HIV O +
transmission O +
rate O +
can O +
be O +
halved O +
by O +
2020 O +
, O +
if O +
not O +
earlier O +
, O +
provided O +
sufficient O +
investment O +
is O +
made O +
toward O +
achieving O +
this O +
goal O +
. O +

We O +
assert O +
that O +
if O +
adequate O +
investment O +
is O +
made O +
and O +
the O +
transmission O +
rate O +
is O +
in O +
fact O +
lowered O +
by O +
50 O +
% O +
, O +
then O +
the O +
HIV O +
reproductive O +
rate O +
would O +
fall O +
below O +
unity O +
, O +
setting O +
the O +
stage O +
for O +
eventual O +
elimination O +
of O +
HIV O +
infection O +
in O +
the O +
U O +
. O +
S O +
. O +

Loss O +
of O +
CDC4 O +
/ O +
FBXW7 O +
in O +
gastric O +
carcinoma O +
. O +

BACKGROUND O +
: O +
CDC4 O +
/ O +
FBXW7 O +
, O +
encoding O +
a O +
ubiquitin O +
ligase O +
, O +
maps O +
to O +
4q32 O +
and O +
has O +
been O +
implicated O +
as O +
a O +
tumor O +
suppressor O +
gene O +
and O +
therapeutic O +
target O +
in O +
many O +
tumor O +
types O +
. O +

Mutations O +
in O +
colonic O +
adenomas O +
, O +
and O +
the O +
frequent O +
losses O +
on O +
4q O +
described O +
in O +
gastric O +
cancer O +
prompt O +
speculation O +
about O +
the O +
role O +
of O +
CDC4 O +
/ O +
FBXW7 O +
in O +
gastric O +
carcinogenesis O +
. O +

METHODS O +
: O +
We O +
assessed O +
the O +
role O +
of O +
CDC4 O +
/ O +
FBXW7 O +
in O +
gastric O +
cancer O +
, O +
through O +
loss O +
of O +
heterozygosity O +
( O +
LOH O +
) O +
and O +
multiplex O +
ligation O +
- O +
dependent O +
probe O +
amplification O +
( O +
MLPA O +
) O +
on O +
47 O +
flow O +
- O +
sorted O +
gastric O +
carcinomas O +
including O +
early O +
- O +
onset O +
gastric O +
cancers O +
( O +
EOGC O +
) O +
and O +
xenografted O +
conventional O +
gastric O +
carcinomas O +
. O +

Ploidy O +
analysis O +
was O +
carried O +
out O +
on O +
39 O +
EOGCs O +
and O +
immunohistochemistry O +
of O +
CDC4 O +
/ O +
FBXW7 O +
and O +
its O +
substrates O +
c O +
- O +
myc O +
, O +
c O +
- O +
jun O +
, O +
Notch O +
and O +
cyclin O +
E O +
was O +
performed O +
on O +
204 O +
gastric O +
carcinomas O +
using O +
tissue O +
microarrays O +
( O +
TMAs O +
) O +
. O +

Sequence O +
analysis O +
of O +
CDC4 O +
/ O +
FBXW7 O +
was O +
carried O +
out O +
on O +
gastric O +
carcinoma O +
cell O +
lines O +
and O +
xenografts O +
. O +

RESULTS O +
: O +
Loss O +
of O +
heterozygosity O +
of O +
CDC4 O +
/ O +
FBXW7 O +
occurred O +
in O +
32 O +
% O +
of O +
EOGCs O +
, O +
and O +
correlated O +
with O +
loss O +
of O +
expression O +
in O +
26 O +
% O +
. O +

Loss O +
of O +
expression O +
was O +
frequent O +
in O +
both O +
EOGC O +
and O +
conventional O +
gastric O +
cancers O +
. O +

No O +
CDC4 O +
/ O +
FBXW7 O +
mutations O +
were O +
found O +
and O +
loss O +
of O +
CDC4 O +
/ O +
FBXW7 O +
did O +
not O +
correlate O +
with O +
ploidy O +
status O +
. O +

There O +
was O +
a O +
significant O +
correlation O +
between O +
loss O +
of O +
CDC4 O +
/ O +
FBXW7 O +
expression O +
and O +
upregulation O +
of O +
c O +
- O +
myc O +
. O +

CONCLUSION O +
: O +
Loss O +
of O +
CDC4 O +
/ O +
FBXW7 O +
appears O +
to O +
play O +
a O +
role O +
in O +
both O +
EOGC O +
and O +
conventional O +
gastric O +
carcinogenesis O +
, O +
and O +
c O +
- O +
myc O +
overexpression O +
is O +
likely O +
to O +
be O +
an O +
important O +
oncogenic O +
consequence O +
of O +
CDC4 O +
/ O +
FBXW7 O +
loss O +
. O +

Pain O +
assessment O +
by O +
continuous O +
EEG O +
: O +
association O +
between O +
subjective O +
perception O +
of O +
tonic O +
pain O +
and O +
peak O +
frequency O +
of O +
alpha O +
oscillations O +
during O +
stimulation O +
and O +
at O +
rest O +
. O +

Recordings O +
of O +
neurophysiological O +
brain O +
responses O +
to O +
noxious O +
stimuli O +
have O +
been O +
traditionally O +
based O +
on O +
short O +
stimuli O +
, O +
in O +
the O +
order O +
of O +
milliseconds O +
, O +
which O +
induce O +
distinct O +
event O +
- O +
related O +
potentials O +
( O +
ERPs O +
) O +
. O +

However O +
, O +
using O +
such O +
stimuli O +
in O +
the O +
experimental O +
setting O +
is O +
disadvantageous O +
as O +
they O +
are O +
too O +
brief O +
to O +
faithfully O +
simulate O +
clinical O +
pain O +
. O +

We O +
aimed O +
at O +
utilizing O +
continuous O +
EEG O +
to O +
investigate O +
the O +
properties O +
of O +
peak O +
alpha O +
frequency O +
( O +
PAF O +
) O +
as O +
an O +
objective O +
cortical O +
measure O +
associated O +
with O +
subjective O +
perception O +
of O +
tonic O +
pain O +
. O +

Five O +
minute O +
long O +
continuous O +
EEG O +
was O +
recorded O +
in O +
18 O +
healthy O +
volunteers O +
under O +
: O +
( O +
i O +
) O +
resting O +
- O +
state O +
; O +
( O +
ii O +
) O +
innocuous O +
temperature O +
; O +
and O +
( O +
iii O +
) O +
psychophysically O +
- O +
anchored O +
noxious O +
temperature O +
. O +

Numerical O +
pain O +
scores O +
( O +
NPSs O +
) O +
collected O +
during O +
the O +
application O +
of O +
tonic O +
noxious O +
stimuli O +
were O +
tested O +
for O +
correlation O +
with O +
peak O +
frequencies O +
of O +
alpha O +
power O +
- O +
curves O +
derived O +
from O +
central O +
, O +
temporal O +
and O +
frontal O +
electrodes O +
. O +

NPSs O +
and O +
PAFs O +
remained O +
stable O +
throughout O +
the O +
recording O +
conditions O +
( O +
RM O +
- O +
ANOVAs O +
; O +
Ps O +
> O +
0 O +
. O +
51 O +
) O +
. O +

In O +
the O +
noxious O +
condition O +
, O +
PAFs O +
obtained O +
at O +
the O +
bilateral O +
temporal O +
scalp O +
were O +
correlated O +
with O +
NPSs O +
( O +
Ps O +
< O +
0 O +
. O +
001 O +
) O +
. O +

Moreover O +
, O +
resting O +
- O +
state O +
PAFs O +
recorded O +
at O +
the O +
bilateral O +
temporal O +
scalp O +
were O +
correlated O +
with O +
NPSs O +
reported O +
during O +
the O +
noxious O +
condition O +
( O +
Ps O +
< O +
0 O +
. O +
01 O +
) O +
. O +

These O +
psychophysical O +
- O +
neurophysiological O +
relations O +
attest O +
to O +
the O +
properties O +
of O +
PAF O +
as O +
a O +
novel O +
cortical O +
objective O +
measure O +
of O +
subjective O +
perception O +
of O +
tonic O +
pain O +
. O +

Moreover O +
, O +
resting O +
- O +
state O +
PAFs O +
might O +
hold O +
inherent O +
pain O +
modulation O +
attributes O +
, O +
possibly O +
enabling O +
the O +
prediction O +
of O +
individual O +
responsiveness O +
to O +
prolonged O +
pain O +
. O +

The O +
relevance O +
of O +
PAF O +
to O +
the O +
neural O +
processing O +
of O +
tonic O +
pain O +
may O +
indicate O +
its O +
potential O +
to O +
advance O +
pain O +
research O +
as O +
well O +
as O +
clinical O +
pain O +
characterization O +
. O +

Acoustic O +
trauma O +
evokes O +
hyperactivity O +
and O +
changes O +
in O +
gene O +
expression O +
in O +
guinea O +
- O +
pig O +
auditory O +
brainstem O +
. O +

Hearing O +
loss O +
from O +
acoustic O +
trauma O +
is O +
a O +
risk O +
factor O +
for O +
tinnitus O +
. O +

Animal O +
models O +
using O +
acoustic O +
trauma O +
have O +
demonstrated O +
hyperactivity O +
in O +
central O +
auditory O +
pathways O +
, O +
which O +
has O +
been O +
suggested O +
as O +
a O +
substrate O +
for O +
tinnitus O +
. O +

We O +
used O +
a O +
guinea O +
- O +
pig O +
model O +
of O +
unilateral O +
acoustic O +
trauma O +
. O +

Within O +
the O +
same O +
animals O +
, O +
measurements O +
of O +
peripheral O +
hearing O +
loss O +
, O +
spontaneous O +
activity O +
of O +
single O +
neurons O +
in O +
the O +
inferior O +
colliculus O +
and O +
gene O +
expression O +
in O +
cochlear O +
nucleus O +
and O +
inferior O +
colliculus O +
were O +
combined O +
, O +
acutely O +
and O +
after O +
recovery O +
from O +
acoustic O +
trauma O +
. O +

Genes O +
investigated O +
related O +
to O +
inhibitory O +
( O +
GABA O +
- O +
A O +
receptor O +
subunit O +
alpha O +
1 O +
; O +
glycine O +
receptor O +
subunit O +
alpha O +
1 O +
) O +
and O +
excitatory O +
neurotransmission O +
( O +
glutamate O +
decarboxylase O +
1 O +
; O +
glutamate O +
receptor O +
AMPA O +
subunit O +
alpha O +
2 O +
; O +
glutamate O +
receptor O +
NMDA O +
subunit O +
1 O +
) O +
, O +
regulation O +
of O +
transmitter O +
release O +
( O +
member O +
of O +
RAB O +
family O +
of O +
small O +
GTPase O +
; O +
RAB3 O +
GTPase O +
activating O +
protein O +
subunit O +
1 O +
) O +
and O +
neuronal O +
excitability O +
( O +
potassium O +
channel O +
subfamily O +
K O +
member O +
15 O +
) O +
. O +

Acoustic O +
trauma O +
resulted O +
in O +
unilateral O +
hearing O +
loss O +
and O +
hyperactivity O +
bilaterally O +
in O +
inferior O +
colliculus O +
. O +

Changes O +
in O +
expression O +
of O +
different O +
mRNAs O +
were O +
observed O +
in O +
ipsilateral O +
cochlear O +
nucleus O +
and O +
in O +
ipsi O +
- O +
and O +
contralateral O +
inferior O +
colliculus O +
, O +
immediately O +
after O +
acoustic O +
trauma O +
, O +
and O +
after O +
2 O +
and O +
4 O +
weeks O +
' O +
recovery O +
. O +

Gene O +
expression O +
was O +
generally O +
reduced O +
immediately O +
after O +
trauma O +
, O +
followed O +
by O +
a O +
return O +
to O +
near O +
normal O +
levels O +
or O +
over O +
- O +
expression O +
as O +
recovery O +
time O +
increased O +
. O +

Different O +
mechanisms O +
appear O +
to O +
underlie O +
the O +
spontaneous O +
hyperactivity O +
observed O +
. O +

There O +
is O +
evidence O +
of O +
down O +
- O +
regulation O +
of O +
genes O +
associated O +
with O +
neuronal O +
inhibition O +
in O +
the O +
contralateral O +
inferior O +
colliculus O +
, O +
whereas O +
in O +
ipsilateral O +
cochlear O +
nucleus O +
, O +
competing O +
actions O +
of O +
inhibitory O +
and O +
excitatory O +
systems O +
seem O +
to O +
play O +
a O +
major O +
role O +
in O +
determining O +
overall O +
excitability O +
. O +

Telomere O +
/ O +
telomerase O +
interplay O +
in O +
virus O +
- O +
driven O +
and O +
virus O +
- O +
independent O +
lymphomagenesis O +
: O +
pathogenic O +
and O +
clinical O +
implications O +
. O +

Telomerase O +
is O +
a O +
ribonucleoprotein O +
complex O +
critically O +
involved O +
in O +
extending O +
and O +
maintaining O +
telomeres O +
. O +

Unlike O +
the O +
majority O +
of O +
somatic O +
cells O +
, O +
in O +
which O +
hTERT O +
and O +
telomerase O +
activity O +
are O +
generally O +
silent O +
, O +
normal O +
lymphocytes O +
show O +
transient O +
physiological O +
hTERT O +
expression O +
and O +
telomerase O +
activity O +
according O +
to O +
their O +
differentiation O +
/ O +
activation O +
status O +
. O +

During O +
lymphomagenesis O +
, O +
induction O +
of O +
persistent O +
telomerase O +
expression O +
and O +
activity O +
may O +
occur O +
before O +
or O +
after O +
telomere O +
shortening O +
, O +
as O +
a O +
consequence O +
of O +
the O +
different O +
mechanisms O +
through O +
which O +
transforming O +
factors O +
/ O +
agents O +
may O +
activate O +
telomerase O +
. O +

Available O +
data O +
indicate O +
that O +
the O +
timing O +
of O +
telomerase O +
activation O +
may O +
allow O +
the O +
distinction O +
of O +
two O +
different O +
lymphomagenetic O +
models O +
: O +
( O +
i O +
) O +
an O +
early O +
activation O +
of O +
telomerase O +
via O +
exogenous O +
regulators O +
of O +
hTERT O +
, O +
along O +
with O +
an O +
increased O +
lymphocyte O +
growth O +
and O +
a O +
subsequent O +
selection O +
of O +
cells O +
with O +
increased O +
transforming O +
potential O +
may O +
characterize O +
several O +
virus O +
- O +
related O +
lymphoid O +
malignancies O +
; O +
( O +
ii O +
) O +
a O +
progressive O +
shortening O +
of O +
telomeres O +
, O +
leading O +
to O +
genetic O +
instability O +
which O +
favors O +
a O +
subsequent O +
activation O +
of O +
telomerase O +
via O +
endogenous O +
regulators O +
may O +
occur O +
in O +
most O +
virus O +
- O +
unrelated O +
lymphoid O +
tumors O +
. O +

These O +
models O +
may O +
have O +
clinically O +
relevant O +
implications O +
, O +
particularly O +
for O +
the O +
tailoring O +
of O +
therapeutic O +
strategies O +
targeting O +
telomerase O +
. O +

Angiogenesis O +
inhibitors O +
: O +
current O +
strategies O +
and O +
future O +
prospects O +
. O +

Angiogenesis O +
has O +
become O +
an O +
attractive O +
target O +
for O +
drug O +
therapy O +
because O +
of O +
its O +
key O +
role O +
in O +
tumor O +
growth O +
. O +

An O +
extensive O +
array O +
of O +
compounds O +
is O +
currently O +
in O +
preclinical O +
development O +
, O +
with O +
many O +
now O +
entering O +
the O +
clinic O +
and O +
/ O +
or O +
achieving O +
approval O +
from O +
the O +
US O +
Food O +
and O +
Drug O +
Administration O +
. O +

Several O +
regulatory O +
and O +
signaling O +
molecules O +
governing O +
angiogenesis O +
are O +
of O +
interest O +
, O +
including O +
growth O +
factors O +
( O +
eg O +
, O +
vascular O +
endothelial O +
growth O +
factor O +
, O +
platelet O +
- O +
derived O +
growth O +
factor O +
, O +
fibroblast O +
growth O +
factor O +
, O +
and O +
epidermal O +
growth O +
factor O +
) O +
, O +
receptor O +
tyrosine O +
kinases O +
, O +
and O +
transcription O +
factors O +
such O +
as O +
hypoxia O +
inducible O +
factor O +
, O +
as O +
well O +
as O +
molecules O +
involved O +
in O +
mitogen O +
- O +
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
and O +
phosphoinositide O +
3 O +
- O +
kinase O +
( O +
PI3 O -
K O +
) O +
signaling O +
. O +

Pharmacologic O +
agents O +
have O +
been O +
identified O +
that O +
target O +
these O +
pathways O +
, O +
yet O +
for O +
some O +
agents O +
( O +
notably O +
thalidomide O +
) O +
, O +
an O +
understanding O +
of O +
the O +
specific O +
mechanisms O +
of O +
antitumor O +
action O +
has O +
proved O +
elusive O +
. O +

The O +
following O +
review O +
describes O +
key O +
molecular O +
mechanisms O +
and O +
novel O +
therapies O +
that O +
are O +
on O +
the O +
horizon O +
for O +
antiangiogenic O +
tumor O +
therapy O +
. O +

A O +
generative O +
model O +
for O +
image O +
segmentation O +
based O +
on O +
label O +
fusion O +
. O +

We O +
propose O +
a O +
nonparametric O +
, O +
probabilistic O +
model O +
for O +
the O +
automatic O +
segmentation O +
of O +
medical O +
images O +
, O +
given O +
a O +
training O +
set O +
of O +
images O +
and O +
corresponding O +
label O +
maps O +
. O +

The O +
resulting O +
inference O +
algorithms O +
rely O +
on O +
pairwise O +
registrations O +
between O +
the O +
test O +
image O +
and O +
individual O +
training O +
images O +
. O +

The O +
training O +
labels O +
are O +
then O +
transferred O +
to O +
the O +
test O +
image O +
and O +
fused O +
to O +
compute O +
the O +
final O +
segmentation O +
of O +
the O +
test O +
subject O +
. O +

Such O +
label O +
fusion O +
methods O +
have O +
been O +
shown O +
to O +
yield O +
accurate O +
segmentation O +
, O +
since O +
the O +
use O +
of O +
multiple O +
registrations O +
captures O +
greater O +
inter O +
- O +
subject O +
anatomical O +
variability O +
and O +
improves O +
robustness O +
against O +
occasional O +
registration O +
failures O +
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O +
, O +
this O +
manuscript O +
presents O +
the O +
first O +
comprehensive O +
probabilistic O +
framework O +
that O +
rigorously O +
motivates O +
label O +
fusion O +
as O +
a O +
segmentation O +
approach O +
. O +

The O +
proposed O +
framework O +
allows O +
us O +
to O +
compare O +
different O +
label O +
fusion O +
algorithms O +
theoretically O +
and O +
practically O +
. O +

In O +
particular O +
, O +
recent O +
label O +
fusion O +
or O +
multiatlas O +
segmentation O +
algorithms O +
are O +
interpreted O +
as O +
special O +
cases O +
of O +
our O +
framework O +
. O +

We O +
conduct O +
two O +
sets O +
of O +
experiments O +
to O +
validate O +
the O +
proposed O +
methods O +
. O +

In O +
the O +
first O +
set O +
of O +
experiments O +
, O +
we O +
use O +
39 O +
brain O +
MRI O +
scans O +
- O +
with O +
manually O +
segmented O +
white O +
matter O +
, O +
cerebral O +
cortex O +
, O +
ventricles O +
and O +
subcortical O +
structures O +
- O +
to O +
compare O +
different O +
label O +
fusion O +
algorithms O +
and O +
the O +
widely O +
- O +
used O +
FreeSurfer O +
whole O +
- O +
brain O +
segmentation O +
tool O +
. O +

Our O +
results O +
indicate O +
that O +
the O +
proposed O +
framework O +
yields O +
more O +
accurate O +
segmentation O +
than O +
FreeSurfer O +
and O +
previous O +
label O +
fusion O +
algorithms O +
. O +

In O +
a O +
second O +
experiment O +
, O +
we O +
use O +
brain O +
MRI O +
scans O +
of O +
282 O +
subjects O +
to O +
demonstrate O +
that O +
the O +
proposed O +
segmentation O +
tool O +
is O +
sufficiently O +
sensitive O +
to O +
robustly O +
detect O +
hippocampal O +
volume O +
changes O +
in O +
a O +
study O +
of O +
aging O +
and O +
Alzheimer O +
' O +
s O +
Disease O +
. O +

Yellow O +
- O +
green O +
52 O +
. O +
3W O +
laser O +
at O +
556 O -
nm O +
based O +
on O +
frequency O +
doubling O +
of O +
a O +
diode O +
side O +
- O +
pumped O +
Q O +
- O +
switched O +
Nd O +
: O +
YAG O +
laser O +
. O +

We O +
demonstrate O +
a O +
high O +
- O +
power O +
556 O -
nm O +
yellow O +
- O +
green O +
laser O +
generated O +
by O +
intracavity O +
frequency O +
doubling O +
of O +
a O +
diode O +
side O +
- O +
pumped O +
Nd O +
: O +
YAG O +
laser O +
at O +
1112 O -
nm O +
. O +

A O +
symmetrical O +
L O +
- O +
shaped O +
flat O +
- O +
flat O +
cavity O +
was O +
employed O +
to O +
implement O +
efficient O +
operation O +
of O +
the O +
low O +
- O +
gain O +
1112 O -
nm O +
transition O +
and O +
to O +
achieve O +
good O +
power O +
scalability O +
. O +

The O +
coatings O +
of O +
the O +
cavity O +
mirrors O +
were O +
carefully O +
designed O +
to O +
optimize O +
the O +
performance O +
of O +
the O +
laser O +
, O +
and O +
a O +
92W O +
continuous O +
wave O +
laser O +
output O +
at O +
1112 O -
nm O +
was O +
achieved O +
when O +
the O +
pumping O +
power O +
of O +
the O +
laser O +
diodes O +
reached O +
960W O +
. O +

By O +
intracavity O +
frequency O +
doubling O +
of O +
the O +
fundamental O +
laser O +
in O +
a O +
lithium O +
triborate O +
crystal O +
, O +
the O +
maximum O +
power O +
of O +
the O +
frequency O +
- O +
doubled O +
output O +
at O +
556 O -
nm O +
was O +
found O +
to O +
be O +
as O +
high O +
as O +
52 O +
. O +
3W O +
with O +
a O +
pulse O +
repetition O +
frequency O +
of O +
10kHz O +
. O +

This O +
corresponds O +
to O +
an O +
optical O +
- O +
to O +
- O +
optical O +
conversion O +
efficiency O +
of O +
about O +
5 O +
. O +
4 O +
% O +
. O +

Betulin O +
induces O +
mitochondrial O +
cytochrome O +
c O +
release O +
associated O +
apoptosis O +
in O +
human O +
cancer O +
cells O +
. O +

We O +
examined O +
whether O +
betulin O +
, O +
a O +
naturally O +
abundant O +
compound O +
, O +
has O +
anticancer O +
functions O +
in O +
human O +
cancer O +
cells O +
. O +

The O +
results O +
showed O +
that O +
betulin O +
significantly O +
inhibited O +
cell O +
viability O +
in O +
cervix O +
carcinoma O +
HeLa B-CellLine +
cells O +
, O +
hepatoma O +
HepG2 B-CellLine +
cells O +
, O +
lung O +
adenocarcinoma O +
A549 B-CellLine +
cells O +
, O +
and O +
breast O +
cancer O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
with O +
IC O +
( O +
50 O +
) O +
values O +
ranging O +
from O +
10 O +
to O +
15 O +
microg O +
/ O +
mL O +
. O +

While O +
betulin O +
exhibited O +
only O +
moderate O +
anticancer O +
activity O +
in O +
other O +
human O +
cancer O +
cells O +
such O +
as O +
hepatoma O +
SK B-CellLine +
- I-CellLine +
HEP I-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
, O +
prostate O +
carcinoma O +
PC B-CellLine +
- I-CellLine +
3 I-CellLine +
, O +
and O +
lung O +
carcinoma O +
NCI B-CellLine +
- I-CellLine +
H460 I-CellLine +
, O +
with O +
IC O +
( O +
50 O +
) O +
values O +
ranging O +
from O +
20 O +
to O +
60 O +
microg O +
/ O +
mL O +
, O +
it O +
showed O +
minor O +
growth O +
inhibition O +
in O +
human O +
erythroleukemia O +
K562 B-CellLine +
cells O +
( O +
IC O +
( O +
50 O +
) O +
> O +
100 O +
microg O +
/ O +
mL O +
) O +
. O +

We O +
further O +
investigated O +
the O +
mechanism O +
of O +
anticancer O +
activity O +
by O +
betulin O +
, O +
using O +
HeLa B-CellLine +
cells O +
as O +
an O +
experimental O +
model O +
. O +

Betulin O +
( O +
10 O +
microg O +
/ O +
mL O +
) O +
induces O +
apoptotic O +
cell O +
death O +
, O +
as O +
evidenced O +
by O +
morphological O +
characteristics O +
such O +
as O +
membrane O +
phosphatidylserine O +
translocation O +
, O +
nuclear O +
condensation O +
/ O +
fragmentation O +
, O +
and O +
apoptotic O +
body O +
formation O +
. O +

A O +
kinetics O +
analysis O +
showed O +
that O +
the O +
depolarization O +
of O +
mitochondrial O +
membrane O +
potential O +
and O +
the O +
release O +
of O +
mitochondrial O +
cytochrome O +
c O +
occurred O +
as O +
early O +
as O +
30 O +
min O +
after O +
treatment O +
with O +
betulin O +
. O +

Betulin O +
, O +
unlike O +
its O +
chemical O +
derivative O +
betulinic O +
acid O +
, O +
did O +
not O +
directly O +
trigger O +
mitochondrial O +
cytochrome O +
c O +
release O +
in O +
isolated O +
mitochondria O +
. O +

Importantly O +
, O +
Bax O +
and O +
Bak O +
were O +
rapidly O +
translocated O +
to O +
the O +
mitochondria O +
30 O +
min O +
after O +
betulin O +
treatment O +
. O +

The O +
sequential O +
activation O +
of O +
caspase O +
- O +
9 O +
and O +
caspase O +
- O +
3 O +
/ O +
- O +
7 O +
and O +
the O +
cleavage O +
of O +
poly O +
( O +
ADP O +
- O +
ribose O +
) O +
polymerase O +
( O +
PARP O +
) O +
were O +
observed O +
behind O +
those O +
mitochondrial O +
events O +
. O +

Furthermore O +
, O +
specific O +
downregulation O +
of O +
either O +
caspase O +
- O +
9 O +
, O +
Bax O +
, O +
or O +
Bak O +
by O +
siRNA O +
effectively O +
reduced O +
PARP O +
cleavage O +
and O +
caspase O +
- O +
3 O +
activation O +
. O +

Taken O +
together O +
, O +
the O +
lines O +
of O +
evidence O +
demonstrate O +
that O +
betulin O +
triggers O +
apoptosis O +
of O +
human O +
cancer O +
cells O +
through O +
the O +
intrinsic O +
apoptotic O +
pathway O +
. O +

Relationship O +
and O +
prognostic O +
significance O +
of O +
SPARC O +
and O +
VEGF O +
protein O +
expression O +
in O +
colon O +
cancer O +
. O +

BACKGROUND O +
: O +
SPARC O +
( O +
secreted O +
protein O +
, O +
acidic O +
and O +
rich O +
in O +
cysteine O +
) O +
is O +
closely O +
related O +
with O +
the O +
progress O +
, O +
invasion O +
and O +
metastasis O +
of O +
malignant O +
tumor O +
and O +
angiogenesis O +
. O +

METHODS O +
: O +
Using O +
human O +
colon O +
adenocarcinoma O +
tissues O +
( O +
hereinafter O +
referred O +
to O +
as O +
colon O +
cancer O +
) O +
and O +
their O +
corresponding O +
non O +
- O +
diseased O +
colon O +
from O +
114 O +
patients O +
' O +
biopsies O +
, O +
the O +
expression O +
of O +
SPARC O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
were O +
investigated O +
by O +
immunohistochemistry O +
staining O +
to O +
assessment O +
the O +
relationship O +
between O +
SPARC O +
and O +
VEGF O +
, O +
as O +
well O +
as O +
their O +
prognostic O +
significance O +
in O +
patients O +
. O +

Evaluation O +
of O +
VEGF O +
expression O +
level O +
with O +
the O +
same O +
tissues O +
was O +
used O +
to O +
establish O +
the O +
antigenic O +
profiles O +
, O +
and O +
the O +
marker O +
of O +
CD34 O +
staining O +
was O +
used O +
as O +
an O +
indicator O +
of O +
microvessel O +
density O +
( O +
MVD O +
) O +
. O +

RESULTS O +
: O +
SPARC O +
expression O +
was O +
mainly O +
in O +
the O +
stromal O +
cells O +
surrounding O +
the O +
colon O +
cancer O +
, O +
and O +
was O +
significant O +
difference O +
in O +
those O +
tissues O +
with O +
the O +
lymph O +
node O +
metastasis O +
and O +
differentiation O +
degree O +
of O +
tumor O +
. O +

Expression O +
of O +
SPARC O +
was O +
significantly O +
correlated O +
with O +
the O +
expression O +
of O +
VEGF O +
and O +
MVD O +
in O +
colon O +
cancer O +
tissues O +
. O +

Patients O +
with O +
low O +
or O +
absence O +
expressing O +
SPARC O +
had O +
significantly O +
worse O +
overall O +
survival O +
and O +
disease O +
- O +
free O +
survival O +
in O +
a O +
Single O +
Factor O +
Analysis O +
; O +
Cox O +
Regression O +
Analysis O +
, O +
SPARC O +
emerged O +
as O +
an O +
overall O +
survival O +
and O +
disease O +
- O +
free O +
survival O +
independent O +
prognostic O +
factor O +
for O +
colon O +
cancer O +
. O +

CONCLUSION O +
: O +
The O +
low O +
expression O +
or O +
absence O +
of O +
stromal O +
SPARC O +
was O +
an O +
independent O +
prognostic O +
factor O +
for O +
poor O +
prognosis O +
of O +
colon O +
cancer O +
. O +

SPARC O +
maybe O +
involved O +
in O +
the O +
regulation O +
of O +
anti O +
- O +
angiogenesis O +
by O +
which O +
it O +
may O +
serve O +
as O +
a O +
novel O +
target O +
for O +
colon O +
cancer O +
treatment O +
as O +
well O +
as O +
a O +
novel O +
distinctive O +
marker O +
. O +

Prognostic O +
significance O +
of O +
TRAIL O +
signaling O +
molecules O +
in O +
stage O +
II O +
and O +
III O +
colorectal O +
cancer O +
. O +

PURPOSE O +
: O +

We O +
previously O +
found O +
that O +
cellular O +
FLICE O +
- O +
inhibitory O +
protein O +
( O +
c O +
- O +
FLIP O +
) O +
, O +
caspase O +
8 O +
, O +
and O +
tumor O +
necrosis O +
factor O +
- O +
related O +
apoptosis O +
- O +
inducing O +
ligand O +
( O +
TRAIL O +
) O +
receptor O +
2 O +
( O +
DR5 O +
) O +
are O +
major O +
regulators O +
of O +
cell O +
viability O +
and O +
chemotherapy O +
- O +
induced O +
apoptosis O +
in O +
colorectal O +
cancer O +
. O +

In O +
this O +
study O +
, O +
we O +
determined O +
the O +
prognostic O +
significance O +
of O +
c O +
- O +
FLIP O +
, O +
caspase O +
8 O +
, O +
TRAIL O +
and O +
DR5 O +
expression O +
in O +
tissues O +
from O +
patients O +
with O +
stage O +
II O +
and O +
III O +
colorectal O +
cancer O +
. O +

EXPERIMENTAL O +
DESIGN O +
: O +

Tissue O +
microarrays O +
were O +
constructed O +
from O +
matched O +
normal O +
and O +
tumor O +
tissue O +
derived O +
from O +
patients O +
( O +
n O +
= O +
253 O +
) O +
enrolled O +
in O +
a O +
phase O +
III O +
trial O +
of O +
adjuvant O +
5 O +
- O +
fluorouracil O +
- O +
based O +
chemotherapy O +
versus O +
postoperative O +
observation O +
alone O +
. O +

TRAIL O +
, O +
DR5 O +
, O +
caspase O +
8 O +
, O +
and O +
c O +
- O +
FLIP O +
expression O +
levels O +
were O +
determined O +
by O +
immunohistochemistry O +
. O +

RESULTS O +
: O +

Colorectal O +
tumors O +
displayed O +
significantly O +
higher O +
expression O +
levels O +
of O +
c O +
- O +
FLIP O +
( O +
P O +
< O +
0 O +
. O +
001 O +
) O +
, O +
caspase O +
8 O +
( O +
P O +
= O +
0 O +
. O +
01 O +
) O +
, O +
and O +
DR5 O +
( O +
P O +
< O +
0 O +
. O +
001 O +
) O +
, O +
but O +
lower O +
levels O +
of O +
TRAIL O +
( O +
P O +
< O +
0 O +
. O +
001 O +
) O +
compared O +
with O +
matched O +
normal O +
tissue O +
. O +

In O +
univariate O +
analysis O +
, O +
higher O +
TRAIL O +
expression O +
in O +
the O +
tumor O +
was O +
associated O +
with O +
worse O +
overall O +
survival O +
( O +
P O +
= O +
0 O +
. O +
026 O +
) O +
, O +
with O +
a O +
trend O +
to O +
decreased O +
relapse O +
- O +
free O +
survival O +
( O +
RFS O +
; O +
P O +
= O +
0 O +
. O +
06 O +
) O +
, O +
and O +
higher O +
tumor O +
c O +
- O +
FLIP O +
expression O +
was O +
associated O +
with O +
a O +
significantly O +
decreased O +
RFS O +
( O +
P O +
= O +
0 O +
. O +
015 O +
) O +
. O +

Using O +
multivariate O +
predictive O +
modeling O +
for O +
RFS O +
in O +
all O +
patients O +
and O +
including O +
all O +
biomarkers O +
, O +
age O +
, O +
treatment O +
, O +
and O +
stage O +
, O +
we O +
found O +
that O +
the O +
model O +
was O +
significant O +
when O +
the O +
mean O +
tumor O +
c O +
- O +
FLIP O +
expression O +
score O +
and O +
disease O +
stage O +
were O +
included O +
( O +
P O +
< O +
0 O +
. O +
001 O +
) O +
. O +

As O +
regards O +
overall O +
survival O +
, O +
the O +
overall O +
model O +
was O +
predictive O +
when O +
both O +
TRAIL O +
expression O +
and O +
disease O +
stage O +
were O +
included O +
( O +
P O +
< O +
0 O +
. O +
001 O +
) O +
. O +

CONCLUSIONS O +
: O +

High O +
c O +
- O +
FLIP O +
and O +
TRAIL O +
expression O +
may O +
be O +
independent O +
adverse O +
prognostic O +
markers O +
in O +
stage O +
II O +
and O +
III O +
colorectal O +
cancer O +
and O +
might O +
identify O +
patients O +
most O +
at O +
risk O +
of O +
relapse O +
. O +

Overexpression O +
of O +
Bax O +
inhibitor O +
- O +
1 O +
( O +
BI O +
- O +
1 O +
) O +
induces O +
cell O +
transformation O +
in O +
NIH3T3 B-CellLine +
cells O +
. O +

BI O +
- O +
1 O +
( O +
Bax O +
inhibitor O +
- O +
1 O +
) O +
, O +
an O +
apoptosis O +
- O +
inhibiting O +
gene O +
belonging O +
to O +
the O +
Bcl O +
- O +
2 O +
protein O +
family O +
, O +
plays O +
an O +
important O +
role O +
in O +
mitochondrial O +
apoptosis O +
pathway O +
to O +
suppress O +
Bax O +
- O +
induced O +
apoptosis O +
. O +

To O +
investigate O +
the O +
potential O +
role O +
of O +
BI O +
- O +
1 O +
in O +
promoting O +
cell O +
growth O +
and O +
tumorigenesis O +
, O +
in O +
the O +
present O +
study O +
we O +
overexpressed O +
the O +
BI O +
- O +
1 O +
gene O +
in O +
NIH3T3 B-CellLine +
cells O +
using O +
the O +
lentivirus O +
- O +
mediated O +
gene O +
expression O +
system O +
. O +

Our O +
in O +
vitro O +
studies O +
showed O +
that O +
NIH3T3 B-CellLine +
cells O +
overexpressing O +
BI O +
- O +
1 O +
displayed O +
a O +
significantly O +
higher O +
growth O +
rate O +
and O +
formed O +
more O +
and O +
larger O +
colonies O +
than O +
the O +
control O +
cells O +
. O +

In O +
addition O +
, O +
our O +
in O +
vivo O +
studies O +
indicated O +
that O +
the O +
lenti O +
- O +
BI O +
- O +
1 O +
- O +
infected O +
cells O +
formed O +
obvious O +
tumours O +
, O +
while O +
no O +
tumours O +
were O +
formed O +
by O +
the O +
control O +
cells O +
after O +
subcutaneously O +
injected O +
into O +
nude O +
mice O +
. O +

These O +
results O +
strongly O +
suggested O +
that O +
the O +
BI O +
- O +
1 O +
gene O +
might O +
play O +
a O +
crucial O +
role O +
in O +
neoplastic O +
genesis O +
and O +
development O +
. O +

Structure O +
of O +
human O +
hemoglobin O +
messenger O +
RNA O +
and O +
its O +
relation O +
to O +
hemoglobinopathies O +
. O +

1 O +
. O +

One O +
- O +
fifth O +
to O +
1 O +
/ O +
4 O +
of O +
globin O +
mRNA O +
is O +
untranslated O +
sequence O +
other O +
than O +
polyadenylic O +
acid O +
. O +

2 O +
. O +

The O +
untranslated O +
sequences O +
of O +
mRNA O +
vary O +
markedly O +
in O +
their O +
sequence O +
and O +
in O +
their O +
length O +
. O +

3 O +
. O +

Globin O +
mRNAs O +
demonstrate O +
a O +
marked O +
bias O +
in O +
codon O +
selection O +
. O +

4 O +
. O +

Viral O +
mRNA O +
shows O +
a O +
quite O +
different O +
pattern O +
of O +
codon O +
selection O +
; O +
therefore O +
, O +
the O +
selection O +
of O +
codons O +
is O +
not O +
uniform O +
for O +
all O +
mRNAs O +
functioning O +
in O +
animal O +
cells O +
. O +

5 O +
. O +

Elongated O +
hemoglobin O +
chains O +
can O +
be O +
accounted O +
for O +
by O +
frame O +
- O +
shift O +
mutations O +
, O +
or O +
point O +
mutations O +
within O +
the O +
normal O +
termination O +
codon O +
. O +

The O +
additional O +
amino O +
acids O +
are O +
then O +
coded O +
for O +
by O +
sequences O +
that O +
are O +
normally O +
untranslated O +
. O +

6 O +
. O +

Certain O +
hemoglobin O +
deletion O +
mutants O +
occur O +
at O +
sites O +
where O +
there O +
are O +
partially O +
reiterated O +
sequences O +
within O +
the O +
heomoglobin O +
messenger O +
RNA O +
. O +

Anti O +
- O +
metastasis O +
effects O +
of O +
gallic O +
acid O +
on O +
gastric O +
cancer O +
cells O +
involves O +
inhibition O +
of O +
NF O +
- O +
kappaB O +
activity O +
and O +
downregulation O +
of O +
PI3 O -
K O +
/ O +
AKT O +
/ O +
small O +
GTPase O +
signals O +
. O +

Polyphenols O +
are O +
natural O +
antioxidants O +
that O +
are O +
thought O +
to O +
contribute O +
to O +
prevention O +
of O +
cardiovascular O +
disease O +
and O +
malignancy O +
. O +

Although O +
many O +
studies O +
have O +
been O +
carried O +
out O +
to O +
investigate O +
the O +
chemopreventive O +
role O +
of O +
flavonoids O +
, O +
less O +
attention O +
has O +
been O +
focused O +
on O +
phenolic O +
acids O +
. O +

In O +
this O +
study O +
, O +
the O +
aim O +
was O +
to O +
investigate O +
the O +
effect O +
of O +
phenolic O +
acids O +
found O +
abundantly O +
in O +
vegetables O +
, O +
i O +
. O +
e O +
. O +
gallic O +
acid O +
( O +
GA O +
) O +
, O +
caffeic O +
acid O +
( O +
CA O +
) O +
and O +
protocatechuic O +
acid O +
( O +
PCA O +
) O +
, O +
on O +
the O +
inhibition O +
of O +
gastric O +
adenocarcinoma O +
( O +
AGS O +
) O +
cell O +
metastasis O +
. O +

The O +
results O +
showed O +
0 O +
. O +
01 O +
mM O +
GA O +
induced O +
the O +
same O +
level O +
of O +
cell O +
toxicity O +
as O +
4 O +
. O +
0mM O +
PCA O +
. O +

Using O +
wound O +
- O +
healing O +
assay O +
and O +
Boyden O +
chamber O +
assay O +
, O +
GA O +
had O +
potent O +
inhibitory O +
effects O +
on O +
AGS O +
cell O +
migration O +
. O +

The O +
expression O +
of O +
MMP O +
- O +
2 O +
/ O +
9 O +
of O +
AGS O +
cells O +
was O +
inhibited O +
by O +
2 O +
. O +
0 O +
microM O +
of O +
GA O +
. O +

It O +
is O +
possible O +
that O +
the O +
suppressive O +
effect O +
of O +
GA O +
on O +
MMP O +
- O +
2 O +
/ O +
9 O +
might O +
involve O +
the O +
inhibition O +
of O +
NF O +
- O +
kappaB O +
activity O +
. O +

Multiple O +
proteins O +
involved O +
in O +
metastasis O +
and O +
the O +
cytoskeletal O +
reorganization O +
signal O +
pathway O +
, O +
including O +
Ras O +
, O +
Cdc42 O +
, O +
Rac1 O +
, O +
RhoA O +
, O +
RhoB O +
, O +
PI3 O -
K O +
and O +
p38MAPK O +
, O +
were O +
also O +
inhibited O +
by O +
GA O +
. O +

Furthermore O +
, O +
immunoreactivity O +
assay O +
of O +
cytoskeletal O +
F O +
- O +
actin O +
demonstrated O +
a O +
significant O +
inhibitory O +
effect O +
of O +
GA O +
treatment O +
. O +

In O +
conclusion O +
, O +
GA O +
may O +
have O +
the O +
potential O +
to O +
be O +
an O +
effective O +
agent O +
for O +
prevention O +
and O +
treatment O +
of O +
gastric O +
cancer O +
metastasis O +
. O +

1 O +
, O +
4 O +
- O +
phenylenebis O +
( O +
methylene O +
) O +
selenocyanate O +
, O +
but O +
not O +
selenomethionine O +
, O +
inhibits O +
androgen O +
receptor O +
and O +
Akt O +
signaling O +
in O +
human O +
prostate O +
cancer O +
cells O +
. O +

The O +
lack O +
of O +
treatment O +
for O +
worried O +
- O +
well O +
patients O +
with O +
high O +
- O +
grade O +
prostatic O +
intraepithelial O +
neoplasia O +
combined O +
with O +
issues O +
of O +
recurrence O +
and O +
hormone O +
resistance O +
in O +
prostate O +
cancer O +
survivors O +
remains O +
a O +
major O +
public O +
health O +
obstacle O +
. O +

The O +
long O +
latency O +
of O +
prostate O +
cancer O +
development O +
provides O +
an O +
opportunity O +
to O +
intervene O +
with O +
agents O +
of O +
known O +
mechanisms O +
at O +
various O +
stages O +
of O +
disease O +
progression O +
. O +

A O +
number O +
of O +
signaling O +
cascades O +
have O +
been O +
shown O +
to O +
play O +
important O +
roles O +
in O +
prostate O +
cancer O +
development O +
and O +
progression O +
, O +
including O +
the O +
androgen O +
receptor O +
( O +
AR O +
) O +
and O +
phosphatidylinositol O +
3 O +
- O +
kinase O +
/ O +
Akt O +
signaling O +
pathways O +
. O +

Crosstalk O +
between O +
these O +
two O +
pathways O +
is O +
also O +
thought O +
to O +
contribute O +
to O +
progression O +
and O +
hormone O +
- O +
refractory O +
prostate O +
disease O +
. O +

Our O +
initial O +
investigations O +
show O +
that O +
the O +
naturally O +
occurring O +
organoselenium O +
compound O +
selenomethionine O +
( O +
SM O +
) O +
and O +
the O +
synthetic O +
1 O +
, O +
4 O +
- O +
phenylenebis O +
( O +
methylene O +
) O +
selenocyanate O +
( O +
p O +
- O +
XSC O +
) O +
can O +
inhibit O +
human O +
prostate O +
cancer O +
cell O +
viability O +
; O +
however O +
, O +
in O +
contrast O +
to O +
SM O +
, O +
p O +
- O +
XSC O +
is O +
active O +
at O +
physiologically O +
relevant O +
doses O +
. O +

In O +
the O +
current O +
investigation O +
, O +
we O +
show O +
that O +
p O +
- O +
XSC O +
, O +
but O +
not O +
an O +
equivalent O +
dose O +
of O +
SM O +
, O +
alters O +
molecular O +
targets O +
and O +
induces O +
apoptosis O +
in O +
androgen O +
- O +
responsive O +
LNCaP B-CellLine +
and O +
androgen O +
- O +
independent O +
LNCaP B-CellLine +
C4 I-CellLine +
- I-CellLine +
2 I-CellLine +
human O +
prostate O +
cancer O +
cells O +
. O +

p O +
- O +
XSC O +
effectively O +
inhibits O +
AR O +
expression O +
and O +
transcriptional O +
activity O +
in O +
both O +
cell O +
lines O +
. O +

p O +
- O +
XSC O +
also O +
decreases O +
Akt O +
phosphorylation O +
as O +
well O +
as O +
Akt O +
- O +
specific O +
phosphorylation O +
of O +
the O +
AR O +
. O +

Inhibition O +
of O +
Akt O +
, O +
however O +
, O +
does O +
not O +
fully O +
attenuate O +
p O +
- O +
XSC O +
- O +
mediated O +
downregulation O +
of O +
AR O +
activity O +
, O +
suggesting O +
that O +
inhibition O +
of O +
AR O +
signaling O +
by O +
p O +
- O +
XSC O +
does O +
not O +
occur O +
solely O +
through O +
alterations O +
in O +
the O +
phosphatidylinositol O +
3 O +
- O +
kinase O +
/ O +
Akt O +
survival O +
pathway O +
. O +

Our O +
data O +
suggest O +
that O +
p O +
- O +
XSC O +
inhibits O +
multiple O +
signaling O +
pathways O +
in O +
prostate O +
cancer O +
, O +
likely O +
accounting O +
for O +
the O +
downstream O +
effects O +
on O +
proliferation O +
and O +
apoptosis O +
. O +

Listerine O +
: O +
past O +
, O +
present O +
and O +
future O +
- O +
- O +
a O +
test O +
of O +
thyme O +
. O +

Listerine O +
, O +
a O +
mouthrinse O +
composed O +
of O +
a O +
mixture O +
of O +
essential O +
oils O +
, O +
was O +
created O +
in O +
1879 O +
and O +
was O +
originally O +
formulated O +
as O +
a O +
surgical O +
antiseptic O +
. O +

In O +
spite O +
of O +
its O +
known O +
antimicrobial O +
properties O +
it O +
was O +
thought O +
of O +
as O +
a O +
product O +
in O +
search O +
of O +
a O +
use O +
and O +
promoted O +
as O +
a O +
deterrent O +
for O +
halitosis O +
and O +
as O +
a O +
floor O +
cleaner O +
. O +

In O +
the O +
last O +
several O +
years O +
Listerine O +
has O +
emerged O +
as O +
a O +
bona O +
fide O +
therapeutic O +
agent O +
for O +
reduction O +
of O +
plaque O +
induced O +
oral O +
diseases O +
. O +

In O +
contrast O +
to O +
the O +
inconsistent O +
history O +
of O +
Listerine O +
, O +
systemic O +
antibiotics O +
discovered O +
in O +
the O +
1940 O +
' O +
s O +
were O +
heralded O +
as O +
miracle O +
drugs O +
. O +

However O +
, O +
the O +
value O +
of O +
prophylactic O +
usage O +
of O +
antibiotics O +
has O +
come O +
under O +
scrutiny O +
as O +
a O +
result O +
of O +
increasing O +
resistance O +
and O +
adverse O +
reactions O +
. O +

Moreover O +
, O +
reports O +
by O +
both O +
American O +
and O +
British O +
professional O +
societies O +
have O +
led O +
to O +
a O +
re O +
- O +
evaluation O +
of O +
the O +
relative O +
risks O +
associated O +
with O +
plaque O +
induced O +
bacteremia O +
when O +
twice O +
- O +
yearly O +
visits O +
to O +
dental O +
professionals O +
are O +
compared O +
to O +
daily O +
activities O +
. O +

These O +
new O +
recommendations O +
and O +
revelations O +
open O +
the O +
door O +
for O +
local O +
antimicrobial O +
approaches O +
to O +
reduce O +
the O +
challenge O +
of O +
plaque O +
- O +
induced O +
bacteremias O +
. O +

These O +
issues O +
will O +
be O +
discussed O +
in O +
the O +
context O +
of O +
Listerine O +
, O +
its O +
intricate O +
and O +
complicated O +
past O +
, O +
and O +
its O +
connection O +
to O +
current O +
uses O +
in O +
oral O +
health O +
and O +
beyond O +
. O +

Ventral O +
and O +
dorsal O +
striatal O +
dopamine O +
efflux O +
and O +
behavior O +
in O +
rats O +
with O +
simple O +
vs O +
. O +
co O +
- O +
morbid O +
histories O +
of O +
cocaine O +
sensitization O +
and O +
neonatal O +
ventral O +
hippocampal O +
lesions O +
. O +

UNLABELLED O +
: O +

RATIONAL O +
: O +
Exposing O +
animal O +
models O +
of O +
mental O +
illness O +
to O +
addictive O +
drugs O +
provides O +
an O +
approach O +
to O +
understanding O +
the O +
neural O +
etiology O +
of O +
dual O +
diagnosis O +
disorders O +
. O +

Previous O +
studies O +
have O +
shown O +
that O +
neonatal O +
ventral O +
hippocampal O +
lesions O +
( O +
NVHL O +
) O +
in O +
rats O +
produce O +
features O +
of O +
both O +
schizophrenia O +
and O +
addiction O +
vulnerability O +
. O +

OBJECTIVE O +
: O +

This O +
study O +
investigated O +
ventral O +
and O +
dorsal O +
striatal O +
dopamine O +
( O +
DA O +
) O +
efflux O +
in O +
NVHL O +
rats O +
combined O +
with O +
behavioral O +
sensitization O +
to O +
cocaine O +
. O +

METHODS O +
: O +

Adult O +
NVHL O +
vs O +
. O +
SHAM O +
- O +
operated O +
rats O +
underwent O +
a O +
5 O +
- O +
day O +
injection O +
series O +
of O +
cocaine O +
( O +
15 O +
mg O +
/ O +
kg O +
/ O +
day O +
) O +
vs O +
. O +
saline O +
. O +

One O +
week O +
later O +
, O +
rats O +
were O +
cannulated O +
in O +
nucleus O +
accumbens O +
SHELL O +
, O +
CORE O +
, O +
or O +
caudate O +
- O +
putamen O +
. O +

Another O +
week O +
later O +
, O +
in O +
vivo O +
microdialysis O +
sampled O +
DA O +
during O +
locomotor O +
testing O +
in O +
which O +
a O +
single O +
cocaine O +
injection O +
( O +
15 O +
mg O +
/ O +
kg O +
) O +
was O +
delivered O +
. O +

RESULTS O +
: O +

NVHLs O +
and O +
cocaine O +
history O +
significantly O +
increased O +
behavioral O +
activation O +
approximately O +
2 O +
- O +
fold O +
over O +
SHAM O +
- O +
saline O +
history O +
rats O +
. O +

DA O +
efflux O +
curves O +
corresponded O +
time O +
dependently O +
with O +
the O +
cocaine O +
injection O +
and O +
locomotor O +
curves O +
and O +
varied O +
significantly O +
by O +
striatal O +
region O +
: O +
Baseline O +
DA O +
levels O +
increased O +
5 O +
- O +
fold O +
while O +
cocaine O +
- O +
stimulated O +
DA O +
efflux O +
decreased O +
by O +
half O +
across O +
a O +
ventral O +
to O +
dorsal O +
striatal O +
gradient O +
. O +

However O +
, O +
NVHLs O +
, O +
prior O +
cocaine O +
history O +
, O +
and O +
individual O +
differences O +
in O +
behavior O +
were O +
not O +
underpinned O +
by O +
differential O +
DA O +
efflux O +
overall O +
or O +
within O +
any O +
striatal O +
region O +
. O +

CONCLUSION O +
: O +

Differences O +
in O +
ventral O +
/ O +
dorsal O +
striatal O +
DA O +
efflux O +
are O +
not O +
present O +
in O +
and O +
are O +
not O +
required O +
for O +
producing O +
differential O +
levels O +
of O +
acute O +
cocaine O +
- O +
induced O +
behavioral O +
activation O +
in O +
NVHLs O +
with O +
and O +
without O +
a O +
behaviorally O +
sensitizing O +
cocaine O +
history O +
. O +

These O +
findings O +
suggest O +
other O +
neurotransmitter O +
systems O +
, O +
and O +
alterations O +
in O +
striatal O +
network O +
function O +
post O +
- O +
synaptic O +
to O +
DA O +
transmission O +
are O +
more O +
important O +
to O +
understanding O +
the O +
interactive O +
effects O +
of O +
addictive O +
drugs O +
and O +
mental O +
illness O +
. O +

Adenovirus O +
5 O +
E1A O +
enhances O +
histone O +
deacetylase O +
inhibitors O +
- O +
induced O +
apoptosis O +
through O +
Egr O +
- O +
1 O +
- O +
mediated O +
Bim O +
upregulation O +
. O +

Histone O +
deacetylase O +
inhibitors O +
( O +
HDACi O +
) O +
are O +
potent O +
anti O +
- O +
cancer O +
agents O +
for O +
variety O +
of O +
cancer O +
types O +
. O +

Suberoylanilide O +
hydroxamic O +
acid O +
( O +
SAHA O +
) O +
has O +
been O +
approved O +
as O +
a O +
drug O +
to O +
treat O +
cutaneous O +
T O +
cell O +
lymphoma O +
, O +
and O +
the O +
combination O +
of O +
HDACi O +
and O +
other O +
agents O +
have O +
been O +
actively O +
tested O +
in O +
many O +
clinical O +
trials O +
. O +

Adenovirus O +
5 O +
early O +
region O +
1A O +
( O +
E1A O +
) O +
has O +
been O +
shown O +
to O +
exhibit O +
high O +
tumor O +
suppressor O +
activity O +
, O +
and O +
gene O +
therapy O +
using O +
E1A O +
has O +
been O +
tested O +
in O +
clinical O +
trials O +
. O +

Here O +
, O +
we O +
showed O +
that O +
proapoptotic O +
activity O +
of O +
HDACi O +
was O +
robustly O +
enhanced O +
by O +
E1A O +
in O +
multiple O +
cancer O +
cells O +
, O +
but O +
not O +
in O +
normal O +
cells O +
. O +

Moreover O +
, O +
we O +
showed O +
that O +
combination O +
of O +
E1A O +
gene O +
therapy O +
and O +
SAHA O +
showed O +
high O +
therapeutic O +
efficacy O +
with O +
low O +
toxicity O +
in O +
vivo O +
ovarian O +
and O +
breast O +
xenograft O +
models O +
. O +

SAHA O +
downregulated O +
Bcl O +
- O +
XL O +
and O +
upregulated O +
proapoptotic O +
BH3 O +
- O +
only O +
protein O +
Bim O +
, O +
whose O +
expression O +
was O +
further O +
enhanced O +
by O +
E1A O +
in O +
cancer O +
cells O +
. O +

These O +
alterations O +
of O +
Bcl O +
- O +
2 O +
family O +
proteins O +
were O +
critical O +
for O +
apoptosis O +
induced O +
by O +
the O +
combination O +
in O +
cancer O +
cells O +
. O +

SAHA O +
enhanced O +
acetylation O +
of O +
histone O +
H3 O +
in O +
Bim O +
promoter O +
region O +
, O +
while O +
E1A O +
upregulated O +
Egr O +
- O +
1 O +
, O +
which O +
was O +
directly O +
involved O +
in O +
Bim O +
transactivation O +
. O +

Together O +
, O +
our O +
results O +
provide O +
not O +
only O +
a O +
novel O +
insight O +
into O +
the O +
mechanisms O +
underlying O +
anti O +
- O +
tumor O +
activity O +
of O +
E1A O +
, O +
but O +
also O +
a O +
rationale O +
for O +
the O +
combined O +
HDACi O +
and O +
E1A O +
gene O +
therapy O +
in O +
future O +
clinical O +
trials O +
. O +

Sanguinarine O +
induces O +
apoptosis O +
of O +
human O +
osteosarcoma O +
cells O +
through O +
the O +
extrinsic O +
and O +
intrinsic O +
pathways O +
. O +

The O +
quaternary O +
benzo O +
[ O +
c O +
] O +
phenanthridine O +
alkaloid O +
sanguinarine O +
inhibits O +
the O +
proliferation O +
of O +
cancerous O +
cells O +
from O +
different O +
origins O +
, O +
including O +
lung O +
, O +
breast O +
, O +
pancreatic O +
and O +
colon O +
, O +
but O +
nothing O +
is O +
known O +
of O +
its O +
effects O +
on O +
osteosarcoma O +
, O +
a O +
primary O +
malignant O +
bone O +
tumour O +
. O +

We O +
have O +
found O +
that O +
sanguinarine O +
alters O +
the O +
morphology O +
and O +
reduces O +
the O +
viability O +
of O +
MG B-CellLine +
- I-CellLine +
63 I-CellLine +
and O +
SaOS B-CellLine +
- I-CellLine +
2 I-CellLine +
human O +
osteosarcoma O +
cell O +
lines O +
in O +
concentration O +
- O +
and O +
time O +
- O +
dependent O +
manner O +
. O +

Incubation O +
with O +
1 O +
micromol O +
/ O +
L O +
sanguinarine O +
for O +
4 O +
and O +
24h O +
killed O +
more O +
efficiently O +
MG B-CellLine +
- I-CellLine +
63 I-CellLine +
cells O +
than O +
SaOS B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
, O +
while O +
incubation O +
with O +
5 O +
micromol O +
/ O +
L O +
sanguinarine O +
killed O +
almost O +
100 O +
% O +
of O +
both O +
cell O +
populations O +
within O +
24h O +
. O +

This O +
treatment O +
also O +
changed O +
the O +
mitochondrial O +
membrane O +
potential O +
in O +
both O +
MG B-CellLine +
- I-CellLine +
63 I-CellLine +
and O +
SaOS B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
within O +
1h O +
, O +
caused O +
chromatin O +
condensation O +
and O +
the O +
formation O +
of O +
apoptotic O +
bodies O +
. O +

It O +
activated O +
multicaspases O +
, O +
and O +
increased O +
the O +
activities O +
of O +
caspase O +
- O +
8 O +
and O +
caspase O +
- O +
9 O +
in O +
both O +
MG B-CellLine +
- I-CellLine +
63 I-CellLine +
and O +
SaOS B-CellLine +
- I-CellLine +
2 I-CellLine +
cells O +
. O +

These O +
data O +
highlight O +
sanguinarine O +
as O +
a O +
novel O +
potential O +
agent O +
for O +
bone O +
cancer O +
therapy O +
. O +

Using O +
a O +
web O +
- O +
based O +
orthopaedic O +
clinic O +
in O +
the O +
curricular O +
teaching O +
of O +
a O +
German O +
university O +
hospital O +
: O +
analysis O +
of O +
learning O +
effect O +
, O +
student O +
usage O +
and O +
reception O +
. O +

PURPOSE O +
: O +

Modern O +
teaching O +
concepts O +
for O +
undergraduate O +
medical O +
students O +
in O +
Germany O +
include O +
problem O +
based O +
learning O +
as O +
a O +
major O +
component O +
of O +
the O +
new O +
licensing O +
regulations O +
for O +
physicians O +
. O +

Here O +
we O +
describe O +
the O +
usage O +
of O +
a O +
web O +
- O +
based O +
virtual O +
outpatient O +
clinic O +
in O +
the O +
teaching O +
curriculum O +
of O +
undergraduate O +
medical O +
students O +
, O +
its O +
effect O +
on O +
learning O +
success O +
, O +
and O +
student O +
reception O +
. O +

METHODS O +
: O +

Fifth O +
year O +
medial O +
students O +
were O +
requested O +
to O +
examine O +
7 O +
virtual O +
orthopaedic O +
patients O +
which O +
had O +
been O +
created O +
by O +
the O +
authors O +
using O +
the O +
Inmedea O +
- O +
Simulator O +
. O +

They O +
also O +
had O +
to O +
take O +
a O +
multiple O +
- O +
choice O +
examination O +
on O +
two O +
different O +
occasions O +
and O +
their O +
utilisation O +
of O +
the O +
simulator O +
was O +
analysed O +
subjectively O +
and O +
objectively O +
. O +

RESULTS O +
: O +

One O +
hundred O +
and O +
sixty O +
students O +
took O +
part O +
in O +
the O +
study O +
. O +

The O +
average O +
age O +
was O +
24 O +
. O +
9 O +
years O +
, O +
60 O +
% O +
were O +
female O +
. O +

Most O +
of O +
the O +
participants O +
studied O +
on O +
their O +
own O +
using O +
their O +
private O +
computer O +
with O +
a O +
fast O +
internet O +
- O +
connection O +
at O +
home O +
. O +

The O +
average O +
usage O +
time O +
was O +
263 O +
min O +
, O +
most O +
of O +
the O +
students O +
worked O +
with O +
the O +
system O +
in O +
the O +
afternoon O +
, O +
although O +
a O +
considerable O +
number O +
used O +
it O +
late O +
in O +
the O +
night O +
. O +

Regarding O +
learning O +
success O +
, O +
we O +
found O +
that O +
the O +
examination O +
results O +
were O +
significantly O +
better O +
after O +
using O +
the O +
system O +
( O +
7 O +
. O +
66 O +
versus O +
8 O +
. O +
37 O +
, O +
p O +
< O +
0 O +
. O +
0001 O +
) O +
. O +

Eighty O +
percent O +
of O +
the O +
students O +
enjoyed O +
dealing O +
with O +
the O +
virtual O +
patients O +
emphasizing O +
the O +
completeness O +
of O +
patient O +
cases O +
, O +
the O +
artistic O +
graphic O +
design O +
and O +
the O +
expert O +
comments O +
available O +
, O +
as O +
well O +
as O +
the O +
good O +
applicability O +
to O +
real O +
cases O +
. O +

Eighty O +
- O +
seven O +
percent O +
of O +
the O +
students O +
graded O +
the O +
virtual O +
orthopaedic O +
clinic O +
as O +
appropriate O +
to O +
teach O +
orthopaedic O +
content O +
. O +

CONCLUSION O +
: O +

Using O +
the O +
Inmedea O +
- O +
Simulator O +
is O +
an O +
effective O +
method O +
to O +
enhance O +
students O +
' O +
learning O +
efficacy O +
. O +

The O +
way O +
the O +
system O +
was O +
used O +
by O +
the O +
students O +
emphasises O +
the O +
advantages O +
of O +
the O +
internet O +
- O +
like O +
free O +
time O +
management O +
and O +
the O +
implementation O +
of O +
multimedia O +
- O +
based O +
content O +
. O +

Constitutively O +
nuclear O +
FOXO3a O +
localization O +
predicts O +
poor O +
survival O +
and O +
promotes O +
Akt O +
phosphorylation O +
in O +
breast O +
cancer O +
. O +

BACKGROUND O +
: O +
The O +
PI3 O -
K O +
- O +
Akt O +
signal O +
pathway O +
plays O +
a O +
key O +
role O +
in O +
tumorigenesis O +
and O +
the O +
development O +
of O +
drug O +
- O +
resistance O +
. O +

Cytotoxic O +
chemotherapy O +
resistance O +
is O +
linked O +
to O +
limited O +
therapeutic O +
options O +
and O +
poor O +
prognosis O +
. O +

METHODOLOGY O +
/ O +
PRINCIPAL O +
FINDINGS O +
: O +
Examination O +
of O +
FOXO3a O +
and O +
phosphorylated O +
- O +
Akt O +
( O +
P O +
- O +
Akt O +
) O +
expression O +
in O +
breast O +
cancer O +
tissue O +
microarrays O +
showed O +
nuclear O +
FOXO3a O +
was O +
associated O +
with O +
lymph O +
node O +
positivity O +
( O +
p O +
= O +
0 O +
. O +
052 O +
) O +
, O +
poor O +
prognosis O +
( O +
p O +
= O +
0 O +
. O +
014 O +
) O +
, O +
and O +
P O +
- O +
Akt O +
expression O +
in O +
invasive O +
ductal O +
carcinoma O +
. O +

Using O +
tamoxifen O +
and O +
doxorubicin O +
- O +
sensitive O +
and O +
- O +
resistant O +
breast O +
cancer O +
cell O +
lines O +
as O +
models O +
, O +
we O +
found O +
that O +
doxorubicin O +
- O +
but O +
not O +
tamoxifen O +
- O +
resistance O +
is O +
associated O +
with O +
nuclear O +
accumulation O +
of O +
FOXO3a O +
, O +
consistent O +
with O +
the O +
finding O +
that O +
sustained O +
nuclear O +
FOXO3a O +
is O +
associated O +
with O +
poor O +
prognosis O +
. O +

We O +
also O +
established O +
that O +
doxorubicin O +
treatment O +
induces O +
proliferation O +
arrest O +
and O +
FOXO3a O +
nuclear O +
relocation O +
in O +
sensitive O +
breast O +
cancer O +
cells O +
. O +

Induction O +
of O +
FOXO3a O +
activity O +
in O +
doxorubicin O +
- O +
sensitive O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
was O +
sufficient O +
to O +
promote O +
Akt O +
phosphorylation O +
and O +
arrest O +
cell O +
proliferation O +
. O +

Conversely O +
, O +
knockdown O +
of O +
endogenous O +
FOXO3a O +
expression O +
reduced O +
PI3 O -
K O +
/ O +
Akt O +
activity O +
. O +

Using O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
231 I-CellLine +
cells O +
, O +
in O +
which O +
FOXO3a O +
activity O +
can O +
be O +
induced O +
by O +
4 O +
- O +
hydroxytamoxifen O +
, O +
we O +
showed O +
that O +
FOXO3a O +
induction O +
up O +
- O +
regulates O +
PI3 O -
K O +
- O +
Akt O +
activity O +
and O +
enhanced O +
doxorubicin O +
resistance O +
. O +

However O +
FOXO3a O +
induction O +
has O +
little O +
effect O +
on O +
cell O +
proliferation O +
, O +
indicating O +
that O +
FOXO3a O +
or O +
its O +
downstream O +
activity O +
is O +
deregulated O +
in O +
the O +
cytotoxic O +
drug O +
resistant O +
breast O +
cancer O +
cells O +
. O +

Thus O +
, O +
our O +
results O +
suggest O +
that O +
sustained O +
FOXO3a O +
activation O +
can O +
enhance O +
hyperactivation O +
of O +
the O +
PI3 O -
K O +
/ O +
Akt O +
pathway O +
. O +

CONCLUSIONS O +
/ O +
SIGNIFICANCE O +
: O +
Together O +
these O +
data O +
suggest O +
that O +
lymph O +
node O +
metastasis O +
and O +
poor O +
survival O +
in O +
invasive O +
ductal O +
breast O +
carcinoma O +
are O +
linked O +
to O +
an O +
uncoupling O +
of O +
the O +
Akt O +
- O +
FOXO3a O +
signaling O +
axis O +
. O +

In O +
these O +
breast O +
cancers O +
activated O +
Akt O +
fails O +
to O +
inactivate O +
and O +
re O +
- O +
localize O +
FOXO3a O +
to O +
the O +
cytoplasm O +
, O +
and O +
nuclear O +
- O +
targeted O +
FOXO3a O +
does O +
not O +
induce O +
cell O +
death O +
or O +
cell O +
cycle O +
arrest O +
. O +

As O +
such O +
, O +
sustained O +
nuclear O +
FOXO3a O +
expression O +
in O +
breast O +
cancer O +
may O +
culminate O +
in O +
cancer O +
progression O +
and O +
the O +
development O +
of O +
an O +
aggressive O +
phenotype O +
similar O +
to O +
that O +
observed O +
in O +
cytotoxic O +
chemotherapy O +
resistant O +
breast O +
cancer O +
cell O +
models O +
. O +

The O +
neural O +
stem O +
cell O +
fate O +
determinant O +
TLX O +
promotes O +
tumorigenesis O +
and O +
genesis O +
of O +
cells O +
resembling O +
glioma O +
stem O +
cells O +
. O +

A O +
growing O +
body O +
of O +
evidence O +
indicates O +
that O +
deregulation O +
of O +
stem O +
cell O +
fate O +
determinants O +
is O +
a O +
hallmark O +
of O +
many O +
types O +
of O +
malignancies O +
. O +

The O +
neural O +
stem O +
cell O +
fate O +
determinant O +
TLX O +
plays O +
a O +
pivotal O +
role O +
in O +
neurogenesis O +
in O +
the O +
adult O +
brain O +
by O +
maintaining O +
neural O +
stem O +
cells O +
. O +

Here O +
, O +
we O +
report O +
a O +
tumorigenic O +
role O +
of O +
TLX O +
in O +
brain O +
tumor O +
initiation O +
and O +
progression O +
. O +

Increased O +
TLX O +
expression O +
was O +
observed O +
in O +
a O +
number O +
of O +
glioma O +
cells O +
and O +
glioma O +
stem O +
cells O +
, O +
and O +
correlated O +
with O +
poor O +
survival O +
of O +
patients O +
with O +
gliomas O +
. O +

Ectopic O +
expression O +
of O +
TLX O +
in O +
the O +
U87MG B-CellLine +
glioma O +
cell O +
line O +
and O +
Ink4a O +
/ O +
Arf O +
- O +
deficient O +
mouse O +
astrocytes O +
( O +
Ink4a O +
/ O +
Arf O +
( O +
- O +
/ O +
- O +
) O +
astrocytes O +
) O +
induced O +
cell O +
proliferation O +
with O +
a O +
concomitant O +
increase O +
in O +
cyclin O +
D O +
expression O +
, O +
and O +
accelerated O +
foci O +
formation O +
in O +
soft O +
agar O +
and O +
tumor O +
formation O +
in O +
in O +
vivo O +
transplantation O +
assays O +
. O +

Furthermore O +
, O +
overexpression O +
of O +
TLX O +
in O +
Ink4a O +
/ O +
Arf O +
( O +
- O +
/ O +
- O +
) O +
astrocytes O +
inhibited O +
cell O +
migration O +
and O +
invasion O +
and O +
promoted O +
neurosphere O +
formation O +
and O +
Nestin O +
expression O +
, O +
which O +
are O +
hallmark O +
characteristics O +
of O +
glioma O +
stem O +
cells O +
, O +
under O +
stem O +
cell O +
culture O +
conditions O +
. O +

Our O +
results O +
indicate O +
that O +
TLX O +
is O +
involved O +
in O +
glioma O +
stem O +
cell O +
genesis O +
and O +
represents O +
a O +
potential O +
therapeutic O +
target O +
for O +
this O +
type O +
of O +
malignancy O +
. O +

Actin O +
- O +
sequestering O +
protein O +
, O +
thymosin O +
beta O +
- O +
4 O +
, O +
is O +
a O +
novel O +
hypoxia O +
responsive O +
regulator O +
. O +

Angiogenesis O +
is O +
induced O +
by O +
soluble O +
factors O +
such O +
as O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
released O +
from O +
tumor O +
cells O +
in O +
hypoxia O +
. O +

It O +
enhances O +
solid O +
tumor O +
growth O +
and O +
provides O +
an O +
ability O +
to O +
establish O +
metastasis O +
at O +
peripheral O +
sites O +
by O +
tumor O +
cell O +
migration O +
. O +

Thymosin O +
beta O +
- O +
4 O +
( O +
TB4 O +
) O +
is O +
an O +
actin O +
- O +
sequestering O +
protein O +
to O +
control O +
cytoskeletal O +
reorganization O +
. O +

Here O +
, O +
we O +
investigated O +
whether O +
angiogenesis O +
and O +
tumor O +
metastasis O +
are O +
dependent O +
on O +
hypoxia O +
conditioning O +
- O +
induced O +
TB4 O +
expression O +
in O +
B16F10 B-CellLine +
melanoma O +
cells O +
. O +

TB4 O +
expression O +
in O +
B16F10 B-CellLine +
cells O +
was O +
increased O +
by O +
hypoxia O +
conditioning O +
in O +
a O +
time O +
- O +
dependent O +
manner O +
. O +

In O +
addition O +
, O +
we O +
found O +
an O +
increase O +
of O +
angiogenesis O +
and O +
HIF O +
- O +
1alpha O +
expression O +
in O +
TB4 O +
- O +
transgenic O +
( O +
Tg O +
) O +
mice O +
as O +
compared O +
to O +
wildtype O +
mice O +
. O +

When O +
wound O +
healing O +
assay O +
was O +
used O +
to O +
assess O +
in O +
vitro O +
tumor O +
cell O +
migration O +
, O +
hypoxia O +
conditioning O +
for O +
1 O +
h O +
enhanced O +
B16F10 B-CellLine +
cell O +
migration O +
. O +

When O +
TB4 O +
expression O +
in O +
B16F10 B-CellLine +
cells O +
was O +
inhibited O +
by O +
the O +
infection O +
with O +
small O +
hairpin O +
( O +
sh O +
) O +
RNA O +
of O +
TB4 O +
cloned O +
in O +
lentiviral O +
vector O +
, O +
tumor O +
cell O +
migration O +
was O +
retarded O +
. O +

In O +
addition O +
, O +
hypoxia O +
conditioning O +
- O +
induced O +
tumor O +
cell O +
migration O +
was O +
reduced O +
by O +
the O +
infection O +
of O +
lentiviral O +
shRNA O +
of O +
TB4 O +
. O +

HIF O +
- O +
1alpha O +
stabilization O +
and O +
the O +
expression O +
of O +
VEGF O +
isoform O +
165 O +
and O +
121 O +
in O +
hypoxia O +
were O +
also O +
reduced O +
by O +
the O +
infection O +
of O +
lentiviral O +
shRNA O +
of O +
TB4 O +
in O +
B16F10 B-CellLine +
cells O +
. O +

We O +
also O +
found O +
an O +
increase O +
of O +
tumor O +
growth O +
and O +
lung O +
metastasis O +
count O +
in O +
TB4 O +
- O +
Tg O +
mice O +
as O +
compared O +
to O +
wildtype O +
mice O +
. O +

Collectively O +
, O +
hypoxia O +
conditioning O +
induced O +
tumor O +
cell O +
migration O +
by O +
TB4 O +
expression O +
- O +
dependent O +
HIF O +
- O +
1alpha O +
stabilization O +
. O +

It O +
suggests O +
that O +
TB4 O +
could O +
be O +
a O +
hypoxia O +
responsive O +
regulator O +
to O +
control O +
tumor O +
cell O +
migration O +
in O +
angiogenesis O +
and O +
tumor O +
metastasis O +
. O +

Acute O +
ablation O +
of O +
Langerhans O +
cells O +
enhances O +
skin O +
immune O +
responses O +
. O +

Understanding O +
the O +
function O +
of O +
Langerhans O +
cells O +
( O +
LCs O +
) O +
in O +
vivo O +
has O +
been O +
complicated O +
by O +
conflicting O +
results O +
from O +
LC O +
- O +
deficient O +
mice O +
. O +

Human O +
Langerin O +
- O +
DTA O +
mice O +
constitutively O +
lack O +
LCs O +
and O +
develop O +
exaggerated O +
contact O +
hypersensitivity O +
( O +
CHS O +
) O +
responses O +
. O +

Murine O +
Langerin O +
- O +
diphtheria O +
toxin O +
receptor O +
( O +
DTR O +
) O +
mice O +
allow O +
for O +
the O +
inducible O +
elimination O +
of O +
LCs O +
and O +
Langerin O +
( O +
+ O +
) O +
dermal O +
dendritic O +
cells O +
( O +
dDCs O +
) O +
after O +
administration O +
of O +
diphtheria O +
toxin O +
, O +
which O +
results O +
in O +
reduced O +
CHS O +
. O +

When O +
Langerin O +
( O +
+ O +
) O +
dDCs O +
have O +
partially O +
repopulated O +
the O +
skin O +
but O +
LCs O +
are O +
still O +
absent O +
, O +
CHS O +
returns O +
to O +
normal O +
. O +

Thus O +
, O +
LCs O +
appear O +
to O +
be O +
suppressive O +
in O +
human O +
Langerin O +
- O +
DTA O +
mice O +
and O +
redundant O +
in O +
murine O +
Langerin O +
- O +
DTR O +
mice O +
. O +

To O +
determine O +
whether O +
inducible O +
versus O +
constitutive O +
LC O +
ablation O +
explains O +
these O +
results O +
, O +
we O +
engineered O +
human O +
Langerin O +
- O +
DTR O +
mice O +
in O +
which O +
diphtheria O +
toxin O +
ablates O +
LCs O +
without O +
affecting O +
Langerin O +
( O +
+ O +
) O +
dDCs O +
. O +

The O +
inducible O +
ablation O +
of O +
LCs O +
in O +
human O +
Langerin O +
- O +
DTR O +
mice O +
resulted O +
in O +
increased O +
CHS O +
. O +

Thus O +
, O +
LC O +
- O +
mediated O +
suppression O +
does O +
not O +
require O +
their O +
absence O +
during O +
ontogeny O +
or O +
during O +
the O +
steady O +
- O +
state O +
and O +
is O +
consistent O +
with O +
a O +
model O +
in O +
which O +
LCs O +
actively O +
suppress O +
Ag O +
- O +
specific O +
CHS O +
responses O +
. O +

Skin O +
deep O +
and O +
deeper O +
: O +
multiple O +
pathways O +
in O +
basal O +
cell O +
carcinogenesis O +
. O +

This O +
perspective O +
places O +
the O +
report O +
by O +
Villani O +
et O +
al O +
. O +
that O +
appears O +
in O +
this O +
issue O +
of O +
the O +
journal O +
( O +
beginning O +
on O +
page O +
1222 O +
) O +
in O +
the O +
context O +
of O +
recent O +
work O +
showing O +
an O +
intersection O +
between O +
two O +
important O +
developmental O +
pathways O +
implicated O +
in O +
oncogenesis O +
: O +
the O +
hedgehog O +
and O +
insulin O +
- O +
like O +
growth O +
factor O +
( O +
IGF O +
) O +
pathways O +
. O +

Villani O +
et O +
al O +
. O +
define O +
a O +
key O +
role O +
for O +
the O +
IGF O +
regulatory O +
protein O +
Igfbp2 O +
in O +
a O +
genetic O +
model O +
of O +
basal O +
cell O +
carcinogenesis O +
driven O +
by O +
targeted O +
constitutive O +
activation O +
of O +
hedgehog O +
signaling O +
. O +

Placed O +
in O +
the O +
framework O +
of O +
other O +
recently O +
published O +
work O +
, O +
the O +
observations O +
of O +
Villani O +
et O +
al O +
. O +
both O +
raise O +
questions O +
about O +
the O +
cell O +
of O +
origin O +
for O +
basal O +
cell O +
cancers O +
and O +
define O +
additional O +
putative O +
therapeutic O +
and O +
preventive O +
targets O +
for O +
this O +
disease O +
. O +

Brick1 O +
is O +
an O +
essential O +
regulator O +
of O +
actin O +
cytoskeleton O +
required O +
for O +
embryonic O +
development O +
and O +
cell O +
transformation O +
. O +

Brick1 O +
( O +
Brk1 O +
) O +
is O +
the O +
less O +
- O +
studied O +
component O +
of O +
the O +
Wave O +
/ O +
Scar O +
pathway O +
involved O +
in O +
the O +
branched O +
nucleation O +
of O +
actin O +
fibers O +
. O +

The O +
clinical O +
relevance O +
of O +
Brk1 O +
is O +
emphasized O +
by O +
correlative O +
data O +
showing O +
that O +
Von O +
Hippel O +
- O +
Lindau O +
( O +
VHL O +
) O +
patients O +
that O +
also O +
lose O +
the O +
BRK1 O +
gene O +
are O +
protected O +
against O +
the O +
development O +
of O +
tumors O +
. O +

This O +
contrasts O +
with O +
recent O +
evidence O +
suggesting O +
that O +
the O +
Wave O +
complex O +
may O +
function O +
as O +
an O +
invasion O +
suppressor O +
in O +
epithelial O +
cancers O +
. O +

Here O +
, O +
we O +
show O +
that O +
the O +
downregulation O +
of O +
Brk1 O +
results O +
in O +
abnormal O +
actin O +
stress O +
fiber O +
formation O +
and O +
vinculin O +
distribution O +
and O +
loss O +
of O +
Arp2 O +
/ O +
3 O +
and O +
Wave O +
proteins O +
at O +
the O +
cellular O +
protrusions O +
. O +

Brk1 O +
is O +
required O +
for O +
cell O +
proliferation O +
and O +
cell O +
transformation O +
by O +
oncogenes O +
. O +

In O +
addition O +
, O +
Brk1 O +
downregulation O +
results O +
in O +
defective O +
directional O +
migration O +
and O +
invasive O +
growth O +
in O +
renal O +
cell O +
carcinoma O +
cells O +
as O +
well O +
as O +
in O +
other O +
tumor O +
cell O +
types O +
. O +

Finally O +
, O +
genetic O +
ablation O +
of O +
Brk1 O +
results O +
in O +
dramatic O +
defects O +
in O +
embryo O +
compaction O +
and O +
development O +
, O +
suggesting O +
an O +
essential O +
role O +
for O +
this O +
protein O +
in O +
actin O +
dynamics O +
. O +

Thus O +
, O +
genetic O +
loss O +
or O +
inhibition O +
of O +
BRK1 O +
is O +
likely O +
to O +
be O +
protective O +
against O +
tumor O +
development O +
due O +
to O +
proliferation O +
and O +
motility O +
defects O +
in O +
affected O +
cells O +
. O +

The O +
proenkephalin O +
- O +
A O +
- O +
derivative O +
Met O +
- O +
enkephalin O +
- O +
Arg O +
- O +
Gly O +
- O +
Leu O +
is O +
not O +
present O +
in O +
the O +
feline O +
species O +
. O +

No O +
opioid O +
octapeptide O +
Met O +
- O +
enkephalin O +
- O +
Arg O +
- O +
Gly O +
- O +
Leu O +
was O +
detected O +
either O +
in O +
the O +
brain O +
or O +
in O +
the O +
adrenal O +
gland O +
of O +
the O +
cat O +
using O +
a O +
specific O +
radioimmunoassay O +
. O +

Whereas O +
it O +
was O +
possible O +
to O +
determine O +
the O +
Met O +
- O +
enkephalin O +
and O +
Leu O +
- O +
enkephalin O +
contents O +
. O +

The O +
Met O +
- O +
enkephalin O +
versus O +
Leu O +
- O +
enkephalin O +
concentration O +
ratio O +
was O +
around O +
five O +
in O +
each O +
area O +
of O +
the O +
brain O +
assayed O +
. O +

The O +
presence O +
of O +
authentic O +
Met O +
- O +
enkephalin O +
and O +
Leu O +
- O +
enkephalin O +
was O +
confirmed O +
by O +
high O +
performance O +
liquid O +
chromatography O +
analysis O +
. O +

All O +
in O +
all O +
, O +
these O +
data O +
seem O +
to O +
indicate O +
that O +
the O +
cat O +
proenkephalin O +
is O +
partly O +
different O +
from O +
that O +
previously O +
analysed O +
in O +
mammalian O +
species O +
including O +
humans O +
, O +
rats O +
and O +
cows O +
. O +

Ras O +
- O +
association O +
domain O +
family O +
1C O +
protein O +
promotes O +
breast O +
cancer O +
cell O +
migration O +
and O +
attenuates O +
apoptosis O +
. O +

BACKGROUND O +
: O +
The O +
Ras O +
association O +
domain O +
family O +
1 O +
( O +
RASSF1 O +
) O +
gene O +
is O +
a O +
Ras O +
effector O +
encoding O +
two O +
major O +
mRNA O +
forms O +
, O +
RASSF1A O +
and O +
RASSF1C O +
, O +
derived O +
by O +
alternative O +
promoter O +
selection O +
and O +
alternative O +
mRNA O +
splicing O +
. O +

RASSF1A O +
is O +
a O +
tumor O +
suppressor O +
gene O +
. O +

However O +
, O +
very O +
little O +
is O +
known O +
about O +
the O +
function O +
of O +
RASSF1C O +
both O +
in O +
normal O +
and O +
transformed O +
cells O +
. O +

METHODS O +
: O +
Gene O +
silencing O +
and O +
over O +
- O +
expression O +
techniques O +
were O +
used O +
to O +
modulate O +
RASSF1C O +
expression O +
in O +
human O +
breast O +
cancer O +
cells O +
. O +

Affymetrix O +
- O +
microarray O +
analysis O +
was O +
performed O +
using O +
T47D B-CellLine +
cells O +
over O +
- O +
expressing O +
RASSF1C O +
to O +
identify O +
RASSF1C O +
target O +
genes O +
. O +

RT O +
- O +
PCR O +
and O +
western O +
blot O +
techniques O +
were O +
used O +
to O +
validate O +
target O +
gene O +
expression O +
. O +

Cell O +
invasion O +
and O +
apoptosis O +
assays O +
were O +
also O +
performed O +
. O +

RESULTS O +
: O +
In O +
this O +
article O +
, O +
we O +
report O +
the O +
effects O +
of O +
altering O +
RASSF1C O +
expression O +
in O +
human O +
breast O +
cancer O +
cells O +
. O +

We O +
found O +
that O +
silencing O +
RASSF1C O +
mRNA O +
in O +
breast O +
cancer O +
cell O +
lines O +
( O +
MDA B-CellLine +
- I-CellLine +
MB231 I-CellLine +
and O +
T47D B-CellLine +
) O +
caused O +
a O +
small O +
but O +
significant O +
decrease O +
in O +
cell O +
proliferation O +
. O +

Conversely O +
, O +
inducible O +
over O +
- O +
expression O +
of O +
RASSF1C O +
in O +
breast O +
cancer O +
cells O +
( O +
MDA B-CellLine +
- I-CellLine +
MB231 I-CellLine +
and O +
T47D B-CellLine +
) O +
resulted O +
in O +
a O +
small O +
increase O +
in O +
cell O +
proliferation O +
. O +

We O +
also O +
report O +
on O +
the O +
identification O +
of O +
novel O +
RASSF1C O +
target O +
genes O +
. O +

RASSF1C O +
down O +
- O +
regulates O +
several O +
pro O +
- O +
apoptotic O +
and O +
tumor O +
suppressor O +
genes O +
and O +
up O +
- O +
regulates O +
several O +
growth O +
promoting O +
genes O +
in O +
breast O +
cancer O +
cells O +
. O +

We O +
further O +
show O +
that O +
down O +
- O +
regulation O +
of O +
caspase O +
3 O +
via O +
overexpression O +
of O +
RASSF1C O +
reduces O +
breast O +
cancer O +
cells O +
' O +
sensitivity O +
to O +
the O +
apoptosis O +
inducing O +
agent O +
, O +
etoposide O +
. O +

Furthermore O +
, O +
we O +
found O +
that O +
RASSF1C O +
over O +
- O +
expression O +
enhances O +
T47D B-CellLine +
cell O +
invasion O +
/ O +
migration O +
in O +
vitro O +
. O +

CONCLUSION O +
: O +
Together O +
, O +
our O +
findings O +
suggest O +
that O +
RASSF1C O +
, O +
unlike O +
RASSF1A O +
, O +
is O +
not O +
a O +
tumor O +
suppressor O +
, O +
but O +
instead O +
may O +
play O +
a O +
role O +
in O +
stimulating O +
metastasis O +
and O +
survival O +
in O +
breast O +
cancer O +
cells O +
. O +

Androgen O +
stimulates O +
glycolysis O +
for O +
de O +
novo O +
lipid O +
synthesis O +
by O +
increasing O +
the O +
activities O +
of O +
hexokinase O +
2 O +
and O +
6 O +
- O +
phosphofructo O +
- O +
2 O +
- O +
kinase O +
/ O +
fructose O +
- O +
2 O +
, O +
6 O +
- O +
bisphosphatase O +
2 O +
in O +
prostate O +
cancer O +
cells O +
. O +

Up O +
- O +
regulation O +
of O +
lipogenesis O +
by O +
androgen O +
is O +
one O +
of O +
the O +
most O +
characteristic O +
metabolic O +
features O +
of O +
LNCaP B-CellLine +
prostate O +
cancer O +
cells O +
. O +

The O +
present O +
study O +
revealed O +
that O +
androgen O +
increases O +
glucose O +
utilization O +
for O +
de O +
novo O +
lipogenesis O +
in O +
LNCaP B-CellLine +
cells O +
through O +
the O +
activation O +
of O +
HK2 O +
( O +
hexokinase O +
2 O +
) O +
and O +
activation O +
of O +
the O +
cardiac O +
isoform O +
of O +
PFKFB2 O +
( O +
6 O +
- O +
phosphofructo O +
- O +
2 O +
- O +
kinase O +
/ O +
fructose O +
- O +
2 O +
, O +
6 O +
- O +
bisphosphatase O +
) O +
. O +

Activation O +
of O +
PKA O +
( O +
cAMP O +
- O +
dependent O +
protein O +
kinase O +
) O +
by O +
androgen O +
increased O +
phosphorylation O +
of O +
CREB O +
[ O +
CRE O +
( O +
cAMP O +
- O +
response O +
element O +
) O +
- O +
binding O +
protein O +
] O +
, O +
which O +
in O +
turn O +
bound O +
to O +
CRE O +
on O +
the O +
promoter O +
of O +
the O +
HK2 O +
gene O +
resulting O +
in O +
transcriptional O +
activation O +
of O +
the O +
HK2 O +
gene O +
. O +

Up O +
- O +
regulation O +
of O +
PFKFB2 O +
expression O +
was O +
mediated O +
by O +
the O +
direct O +
binding O +
of O +
ligand O +
- O +
activated O +
androgen O +
receptor O +
to O +
the O +
PFKFB2 O +
promoter O +
. O +

The O +
activated O +
PI3 O -
K O +
( O +
phosphoinositide O +
3 O +
- O +
kinase O +
) O +
/ O +
Akt O +
signalling O +
pathway O +
in O +
LNCaP B-CellLine +
cells O +
contributes O +
to O +
the O +
phosphorylation O +
of O +
PFKFB2 O +
at O +
Ser466 O +
and O +
Ser483 O +
, O +
resulting O +
in O +
the O +
constitutive O +
activation O +
of O +
PFK O +
- O +
2 O +
( O +
6 O +
- O +
phosphofructo O +
- O +
2 O +
- O +
kinase O +
) O +
activity O +
. O +

Glucose O +
uptake O +
and O +
lipogenesis O +
were O +
severely O +
blocked O +
by O +
knocking O +
- O +
down O +
of O +
PFKFB2 O +
using O +
siRNA O +
( O +
small O +
interfering O +
RNA O +
) O +
or O +
by O +
inhibition O +
of O +
PFK O +
- O +
2 O +
activity O +
with O +
LY294002 O +
treatment O +
. O +

Taken O +
together O +
, O +
our O +
results O +
suggest O +
that O +
the O +
induction O +
of O +
de O +
novo O +
lipid O +
synthesis O +
by O +
androgen O +
requires O +
the O +
transcriptional O +
up O +
- O +
regulation O +
of O +
HK2 O +
and O +
PFKFB2 O +
, O +
and O +
phosphorylation O +
of O +
PFKFB2 O +
generated O +
by O +
the O +
PI3 O -
K O +
/ O +
Akt O +
signalling O +
pathway O +
to O +
supply O +
the O +
source O +
for O +
lipogenesis O +
from O +
glucose O +
in O +
prostate O +
cancer O +
cells O +
. O +

Expression O +
profiling O +
in O +
progressive O +
stages O +
of O +
fumarate O +
- O +
hydratase O +
deficiency O +
: O +
the O +
contribution O +
of O +
metabolic O +
changes O +
to O +
tumorigenesis O +
. O +

Hereditary O +
leiomyomatosis O +
and O +
renal O +
cell O +
carcinoma O +
( O +
HLRCC O +
) O +
is O +
caused O +
by O +
mutations O +
in O +
the O +
Krebs O +
cycle O +
enzyme O +
fumarate O +
hydratase O +
( O +
FH O +
) O +
. O +

It O +
has O +
been O +
proposed O +
that O +
" O +
pseudohypoxic O +
" O +
stabilization O +
of O +
hypoxia O +
- O +
inducible O +
factor O +
- O +
alpha O +
( O +
HIF O +
- O +
alpha O +
) O +
by O +
fumarate O +
accumulation O +
contributes O +
to O +
tumorigenesis O +
in O +
HLRCC O +
. O +

We O +
hypothesized O +
that O +
an O +
additional O +
direct O +
consequence O +
of O +
FH O +
deficiency O +
is O +
the O +
establishment O +
of O +
a O +
biosynthetic O +
milieu O +
. O +

To O +
investigate O +
this O +
hypothesis O +
, O +
we O +
isolated O +
primary O +
mouse O +
embryonic O +
fibroblast O +
( O +
MEF O +
) O +
lines O +
from O +
Fh1 O +
- O +
deficient O +
mice O +
. O +

As O +
predicted O +
, O +
these O +
MEFs O +
upregulated O +
Hif O +
- O +
1alpha O +
and O +
HIF O +
target O +
genes O +
directly O +
as O +
a O +
result O +
of O +
FH O +
deficiency O +
. O +

In O +
addition O +
, O +
detailed O +
metabolic O +
assessment O +
of O +
these O +
MEFs O +
confirmed O +
their O +
dependence O +
on O +
glycolysis O +
, O +
and O +
an O +
elevated O +
rate O +
of O +
lactate O +
efflux O +
, O +
associated O +
with O +
the O +
upregulation O +
of O +
glycolytic O +
enzymes O +
known O +
to O +
be O +
associated O +
with O +
tumorigenesis O +
. O +

Correspondingly O +
, O +
Fh1 O +
- O +
deficient O +
benign O +
murine O +
renal O +
cysts O +
and O +
an O +
advanced O +
human O +
HLRCC O +
- O +
related O +
renal O +
cell O +
carcinoma O +
manifested O +
a O +
prominent O +
and O +
progressive O +
increase O +
in O +
the O +
expression O +
of O +
HIF O +
- O +
alpha O +
target O +
genes O +
and O +
in O +
genes O +
known O +
to O +
be O +
relevant O +
to O +
tumorigenesis O +
and O +
metastasis O +
. O +

In O +
accord O +
with O +
our O +
hypothesis O +
, O +
in O +
a O +
variety O +
of O +
different O +
FH O +
- O +
deficient O +
tissues O +
, O +
including O +
a O +
novel O +
murine O +
model O +
of O +
Fh1 O +
- O +
deficient O +
smooth O +
muscle O +
, O +
we O +
show O +
a O +
striking O +
and O +
progressive O +
upregulation O +
of O +
a O +
tumorigenic O +
metabolic O +
profile O +
, O +
as O +
manifested O +
by O +
increased O +
PKM2 O +
and O +
LDHA O +
protein O +
. O +

Based O +
on O +
the O +
models O +
assessed O +
herein O +
, O +
we O +
infer O +
that O +
that O +
FH O +
deficiency O +
compels O +
cells O +
to O +
adopt O +
an O +
early O +
, O +
reversible O +
, O +
and O +
progressive O +
protumorigenic O +
metabolic O +
milieu O +
that O +
is O +
reminiscent O +
of O +
that O +
driving O +
the O +
Warburg O +
effect O +
. O +

Targets O +
identified O +
in O +
these O +
novel O +
and O +
diverse O +
FH O +
- O +
deficient O +
models O +
represent O +
excellent O +
potential O +
candidates O +
for O +
further O +
mechanistic O +
investigation O +
and O +
therapeutic O +
metabolic O +
manipulation O +
in O +
tumors O +
. O +

Role O +
of O +
stromal O +
myofibroblasts O +
in O +
invasive O +
breast O +
cancer O +
: O +
stromal O +
expression O +
of O +
alpha O +
- O +
smooth O +
muscle O +
actin O +
correlates O +
with O +
worse O +
clinical O +
outcome O +
. O +

BACKGROUND O +
: O +
Recently O +
, O +
the O +
desmoplastic O +
reaction O +
has O +
been O +
implicated O +
as O +
having O +
an O +
important O +
function O +
in O +
epithelial O +
solid O +
tumor O +
biology O +
. O +

There O +
have O +
been O +
no O +
reports O +
showing O +
the O +
relativity O +
of O +
invasive O +
breast O +
cancer O +
and O +
the O +
desmoplastic O +
reaction O +
by O +
a O +
quantitative O +
analysis O +
of O +
the O +
myofibroblasts O +
that O +
were O +
an O +
important O +
player O +
in O +
the O +
desmoplastic O +
reaction O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
immunohistochemically O +
investigate O +
the O +
correlation O +
between O +
the O +
desmoplastic O +
reaction O +
and O +
the O +
clinicopathology O +
of O +
invasive O +
breast O +
cancer O +
. O +

METHODS O +
: O +
The O +
study O +
included O +
60 O +
patients O +
with O +
a O +
known O +
prognosis O +
of O +
invasive O +
breast O +
cancer O +
. O +

We O +
quantified O +
the O +
expression O +
of O +
alpha O +
- O +
SMA O +
as O +
a O +
marker O +
of O +
myofibroblasts O +
in O +
the O +
invasive O +
breast O +
cancer O +
. O +

After O +
staining O +
samples O +
for O +
alpha O +
- O +
SMA O +
, O +
their O +
expression O +
was O +
extracted O +
and O +
quantified O +
as O +
a O +
relative O +
percentage O +
by O +
computer O +
- O +
assisted O +
image O +
analysis O +
. O +

RESULTS O +
: O +
There O +
was O +
relatively O +
wide O +
variation O +
in O +
the O +
expression O +
of O +
alpha O +
- O +
SMA O +
with O +
the O +
percentage O +
of O +
the O +
area O +
from O +
0 O +
. O +
68 O +
to O +
28 O +
. O +
15 O +
% O +
( O +
mean O +
8 O +
. O +
48 O +
+ O +
/ O +
- O +
5 O +
. O +
40 O +
% O +
) O +
. O +

The O +
metastasis O +
group O +
showed O +
significantly O +
higher O +
alpha O +
- O +
SMA O +
expression O +
compared O +
with O +
the O +
no O +
metastasis O +
group O +
( O +
p O +
< O +
0 O +
. O +
001 O +
) O +
. O +

When O +
the O +
patients O +
were O +
divided O +
into O +
two O +
groups O +
according O +
to O +
their O +
alpha O +
- O +
SMA O +
expression O +
using O +
a O +
cutoff O +
point O +
at O +
the O +
mean O +
value O +
of O +
8 O +
. O +
48 O +
% O +
, O +
the O +
high O +
alpha O +
- O +
SMA O +
group O +
had O +
a O +
significantly O +
poorer O +
overall O +
survival O +
rate O +
( O +
p O +
< O +
0 O +
. O +
001 O +
) O +
. O +

Multivariate O +
analysis O +
demonstrated O +
that O +
alpha O +
- O +
SMA O +
and O +
lymph O +
node O +
metastasis O +
were O +
identified O +
as O +
independent O +
predictive O +
factors O +
of O +
metastasis O +
. O +

CONCLUSION O +
: O +
Myofibroblasts O +
represent O +
an O +
important O +
prognostic O +
factor O +
for O +
invasive O +
growth O +
that O +
is O +
translated O +
into O +
a O +
poor O +
clinical O +
prognosis O +
for O +
patients O +
with O +
invasive O +
breast O +
cancer O +
. O +

A O +
STAT3 O +
- O +
mediated O +
metabolic O +
switch O +
is O +
involved O +
in O +
tumour O +
transformation O +
and O +
STAT3 O +
addiction O +
. O +

The O +
pro O +
- O +
oncogenic O +
transcription O +
factor O +
STAT3 O +
is O +
constitutively O +
activated O +
in O +
a O +
wide O +
variety O +
of O +
tumours O +
that O +
often O +
become O +
addicted O +
to O +
its O +
activity O +
, O +
but O +
no O +
unifying O +
view O +
of O +
a O +
core O +
function O +
determining O +
this O +
widespread O +
STAT3 O +
- O +
dependence O +
has O +
yet O +
emerged O +
. O +

We O +
show O +
here O +
that O +
constitutively O +
active O +
STAT3 O +
acts O +
as O +
a O +
master O +
regulator O +
of O +
cell O +
metabolism O +
, O +
inducing O +
aerobic O +
glycolysis O +
and O +
down O +
- O +
regulating O +
mitochondrial O +
activity O +
both O +
in O +
primary O +
fibroblasts O +
and O +
in O +
STAT3 O +
- O +
dependent O +
tumour O +
cell O +
lines O +
. O +

As O +
a O +
result O +
, O +
cells O +
are O +
protected O +
from O +
apoptosis O +
and O +
senescence O +
while O +
becoming O +
highly O +
sensitive O +
to O +
glucose O +
deprivation O +
. O +

We O +
show O +
that O +
enhanced O +
glycolysis O +
is O +
dependent O +
on O +
HIF O +
- O +
1alpha O +
up O +
- O +
regulation O +
, O +
while O +
reduced O +
mitochondrial O +
activity O +
is O +
HIF O +
- O +
1alpha O +
- O +
independent O +
and O +
likely O +
caused O +
by O +
STAT3 O +
- O +
mediated O +
down O +
- O +
regulation O +
of O +
mitochondrial O +
proteins O +
. O +

The O +
induction O +
of O +
aerobic O +
glycolysis O +
is O +
an O +
important O +
component O +
of O +
STAT3 O +
pro O +
- O +
oncogenic O +
activities O +
, O +
since O +
inhibition O +
of O +
STAT3 O +
tyrosine O +
phosphorylation O +
in O +
the O +
tumour O +
cell O +
lines O +
down O +
- O +
regulates O +
glycolysis O +
prior O +
to O +
leading O +
to O +
growth O +
arrest O +
and O +
cell O +
death O +
, O +
both O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

We O +
propose O +
that O +
this O +
novel O +
, O +
central O +
metabolic O +
role O +
is O +
at O +
the O +
core O +
of O +
the O +
addiction O +
for O +
STAT3 O +
shown O +
by O +
so O +
many O +
biologically O +
different O +
tumours O +
. O +

The O +
disintegrin O +
- O +
like O +
and O +
cysteine O +
- O +
rich O +
domains O +
of O +
ADAM O +
- O +
9 O +
mediate O +
interactions O +
between O +
melanoma O +
cells O +
and O +
fibroblasts O +
. O +

A O +
characteristic O +
of O +
malignant O +
cells O +
is O +
their O +
capacity O +
to O +
invade O +
their O +
surrounding O +
and O +
to O +
metastasize O +
to O +
distant O +
organs O +
. O +

During O +
these O +
processes O +
, O +
proteolytic O +
activities O +
of O +
tumor O +
and O +
stromal O +
cells O +
modify O +
the O +
extracellular O +
matrix O +
to O +
produce O +
a O +
microenvironment O +
suitable O +
for O +
their O +
growth O +
and O +
migration O +
. O +

In O +
recent O +
years O +
the O +
family O +
of O +
ADAM O +
proteases O +
has O +
been O +
ascribed O +
important O +
roles O +
in O +
these O +
processes O +
. O +

ADAM O +
- O +
9 O +
is O +
expressed O +
in O +
human O +
melanoma O +
at O +
the O +
tumor O +
- O +
stroma O +
border O +
where O +
direct O +
or O +
indirect O +
interactions O +
between O +
tumor O +
cells O +
and O +
fibroblasts O +
occur O +
. O +

To O +
analyze O +
the O +
role O +
of O +
ADAM O +
- O +
9 O +
for O +
the O +
interaction O +
between O +
melanoma O +
cells O +
and O +
stromal O +
fibroblasts O +
, O +
we O +
produced O +
the O +
recombinant O +
disintegrin O +
- O +
like O +
and O +
cysteine O +
- O +
rich O +
domain O +
of O +
ADAM O +
- O +
9 O +
( O +
DC O +
- O +
9 O +
) O +
. O +

Melanoma O +
cells O +
and O +
human O +
fibroblasts O +
adhered O +
to O +
immobilized O +
DC O +
- O +
9 O +
in O +
a O +
Mn O +
( O +
2 O +
+ O +
) O +
- O +
dependent O +
fashion O +
suggesting O +
an O +
integrin O +
- O +
mediated O +
process O +
. O +

Inhibition O +
studies O +
showed O +
that O +
adhesion O +
of O +
fibroblasts O +
was O +
mediated O +
by O +
several O +
beta1 O +
integrin O +
receptors O +
independent O +
of O +
the O +
RGD O +
and O +
ECD O +
recognition O +
motif O +
. O +

Furthermore O +
, O +
interaction O +
of O +
fibroblasts O +
and O +
high O +
invasive O +
melanoma O +
cells O +
with O +
soluble O +
recombinant O +
DC O +
- O +
9 O +
resulted O +
in O +
enhanced O +
expression O +
of O +
MMP O +
- O +
1 O +
and O +
MMP O +
- O +
2 O +
. O +

Silencing O +
of O +
ADAM O +
- O +
9 O +
in O +
melanoma O +
cells O +
significantly O +
reduced O +
cell O +
adhesion O +
to O +
fibroblasts O +
. O +

Ablation O +
of O +
ADAM O +
- O +
9 O +
in O +
fibroblasts O +
almost O +
completely O +
abolished O +
these O +
cellular O +
interactions O +
and O +
melanoma O +
cell O +
invasion O +
in O +
vitro O +
. O +

In O +
summary O +
, O +
these O +
results O +
suggest O +
that O +
ADAM O +
- O +
9 O +
expression O +
plays O +
an O +
important O +
role O +
in O +
mediating O +
cell O +
- O +
cell O +
contacts O +
between O +
fibroblasts O +
and O +
melanoma O +
cells O +
and O +
that O +
these O +
interactions O +
contribute O +
to O +
proteolytic O +
activities O +
required O +
during O +
invasion O +
of O +
melanoma O +
cells O +
. O +

Influences O +
on O +
the O +
pharmacokinetics O +
of O +
oxycodone O +
: O +
a O +
multicentre O +
cross O +
- O +
sectional O +
study O +
in O +
439 O +
adult O +
cancer O +
patients O +
. O +

OBJECTIVE O +
: O +

Oxycodone O +
is O +
widely O +
used O +
for O +
the O +
treatment O +
of O +
cancer O +
pain O +
, O +
but O +
little O +
is O +
known O +
of O +
its O +
pharmacokinetics O +
in O +
cancer O +
pain O +
patients O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
explore O +
the O +
relationships O +
between O +
ordinary O +
patient O +
characteristics O +
and O +
serum O +
concentrations O +
of O +
oxycodone O +
and O +
the O +
ratios O +
noroxycodone O +
or O +
oxymorphone O +
/ O +
oxycodone O +
in O +
cancer O +
patients O +
. O +

METHODS O +
: O +

Four O +
hundred O +
and O +
thirty O +
- O +
nine O +
patients O +
using O +
oral O +
oxycodone O +
for O +
cancer O +
pain O +
were O +
included O +
. O +

The O +
patients O +
' O +
characteristics O +
( O +
sex O +
, O +
age O +
, O +
body O +
mass O +
index O +
[ O +
BMI O +
] O +
, O +
Karnofsky O +
performance O +
status O +
, O +
" O +
time O +
since O +
starting O +
opioids O +
" O +
, O +
" O +
oxycodone O +
total O +
daily O +
dose O +
" O +
, O +
" O +
time O +
from O +
last O +
oxycodone O +
dose O +
" O +
, O +
use O +
of O +
CYP3A4 O +
inducer O +
/ O +
inhibitor O +
, O +
" O +
use O +
of O +
systemic O +
steroids O +
" O +
, O +
" O +
number O +
of O +
medications O +
taken O +
in O +
the O +
last O +
24 O +
h O +
" O +
, O +
glomerular O +
filtration O +
rate O +
( O +
GFR O +
) O +
and O +
albumin O +
serum O +
concentrations O +
) O +
influence O +
on O +
oxycodone O +
serum O +
concentrations O +
or O +
metabolite O +
/ O +
oxycodone O +
ratios O +
were O +
explored O +
by O +
multiple O +
regression O +
analyses O +
. O +

RESULTS O +
: O +

Sex O +
, O +
CYP3A4 O +
inducers O +
/ O +
inhibitors O +
, O +
total O +
daily O +
dose O +
, O +
and O +
" O +
time O +
from O +
last O +
oxycodone O +
dose O +
" O +
predicted O +
oxycodone O +
concentrations O +
. O +

CYP3A4 O +
inducers O +
, O +
total O +
daily O +
dose O +
, O +
and O +
" O +
number O +
of O +
medications O +
taken O +
in O +
the O +
last O +
24 O +
h O +
" O +
predicted O +
the O +
oxymorphone O +
/ O +
oxycodone O +
ratio O +
. O +

Total O +
daily O +
dose O +
, O +
" O +
time O +
from O +
last O +
dose O +
to O +
blood O +
sample O +
" O +
, O +
albumin O +
, O +
sex O +
, O +
CYP3A4 O +
inducers O +
/ O +
inhibitors O +
, O +
steroids O +
, O +
BMI O +
and O +
GFR O +
predicted O +
the O +
noroxycodone O +
/ O +
oxycodone O +
ratio O +
. O +

CONCLUSION O +
: O +

Women O +
had O +
lower O +
oxycodone O +
serum O +
concentrations O +
than O +
men O +
. O +

CYP3A4 O +
inducers O +
/ O +
inhibitors O +
should O +
be O +
used O +
with O +
caution O +
as O +
these O +
are O +
predicted O +
to O +
have O +
a O +
significant O +
impact O +
on O +
oxycodone O +
pharmacokinetics O +
. O +

Other O +
characteristics O +
explained O +
only O +
minor O +
parts O +
of O +
the O +
variability O +
of O +
the O +
outcomes O +
. O +

Emerging O +
metabolic O +
targets O +
in O +
cancer O +
therapy O +
. O +

Cancer O +
cells O +
are O +
different O +
from O +
normal O +
cells O +
in O +
their O +
metabolic O +
properties O +
. O +

Normal O +
cells O +
mostly O +
rely O +
on O +
mitochondrial O +
oxidative O +
phosphorylation O +
to O +
produce O +
energy O +
. O +

In O +
contrast O +
, O +
cancer O +
cells O +
depend O +
mostly O +
on O +
glycolysis O +
, O +
the O +
aerobic O +
breakdown O +
of O +
glucose O +
into O +
ATP O +
. O +

This O +
altered O +
energy O +
dependency O +
is O +
known O +
as O +
the O +
" O +
Warburg O +
effect O +
" O +
and O +
is O +
a O +
hallmark O +
of O +
cancer O +
cells O +
. O +

In O +
recent O +
years O +
, O +
investigating O +
the O +
metabolic O +
changes O +
within O +
cancer O +
cells O +
has O +
been O +
a O +
rapidly O +
growing O +
area O +
. O +

Emerging O +
evidence O +
shows O +
that O +
oncogenes O +
that O +
drive O +
the O +
cancer O +
- O +
promoting O +
signals O +
also O +
drive O +
the O +
altered O +
metabolism O +
. O +

Although O +
the O +
exact O +
mechanisms O +
underlying O +
the O +
Warburg O +
effect O +
are O +
unclear O +
, O +
the O +
existing O +
evidence O +
suggests O +
that O +
increased O +
glycolysis O +
plays O +
an O +
important O +
role O +
in O +
support O +
malignant O +
behavior O +
of O +
cancer O +
cells O +
. O +

A O +
thorough O +
understanding O +
of O +
the O +
unique O +
metabolism O +
of O +
cancer O +
cells O +
will O +
help O +
to O +
design O +
of O +
more O +
effective O +
drugs O +
targeting O +
metabolic O +
pathways O +
, O +
which O +
will O +
greatly O +
impact O +
the O +
capacity O +
to O +
effectively O +
treat O +
cancer O +
patients O +
. O +

Here O +
we O +
provide O +
an O +
overview O +
of O +
the O +
current O +
understanding O +
of O +
the O +
Warburg O +
effect O +
upon O +
tumor O +
cell O +
growth O +
and O +
survival O +
, O +
and O +
discussion O +
on O +
the O +
potential O +
metabolic O +
targets O +
for O +
cancer O +
therapy O +
. O +

MTSS1 O +
: O +
a O +
multifunctional O +
protein O +
and O +
its O +
role O +
in O +
cancer O +
invasion O +
and O +
metastasis O +
. O +

MTSS1 O +
( O +
metastasis O +
suppressor O +
- O +
1 O +
) O +
was O +
first O +
identified O +
as O +
a O +
metastasis O +
suppressor O +
missing O +
in O +
metastatic O +
bladder O +
carcinoma O +
cell O +
lines O +
. O +

The O +
down O +
- O +
regulation O +
of O +
MTSS1 O +
that O +
may O +
be O +
caused O +
by O +
DNA O +
methylation O +
was O +
also O +
observed O +
in O +
many O +
other O +
types O +
of O +
cancer O +
. O +

While O +
accumlating O +
evidence O +
for O +
the O +
function O +
of O +
MTSS1 O +
support O +
the O +
concept O +
that O +
it O +
is O +
unlikely O +
to O +
be O +
a O +
metastasis O +
suppressor O +
, O +
but O +
actually O +
acts O +
as O +
a O +
scaffold O +
protein O +
that O +
interacts O +
with O +
multiple O +
partners O +
to O +
regulate O +
actin O +
dynamics O +
. O +

It O +
has O +
also O +
been O +
demonstrated O +
that O +
MTSS1 O +
is O +
involved O +
in O +
the O +
Shh O +
signaling O +
pathway O +
in O +
the O +
developing O +
hair O +
follicle O +
and O +
in O +
basal O +
cell O +
carcinomas O +
of O +
the O +
skin O +
. O +

Such O +
evidence O +
indicates O +
that O +
MTSS1 O +
as O +
a O +
multiple O +
functional O +
molecular O +
player O +
and O +
has O +
an O +
important O +
role O +
in O +
development O +
, O +
carcinogenesis O +
and O +
metastasis O +
. O +

However O +
, O +
the O +
biochemical O +
mechanisms O +
by O +
which O +
MTSS1 O +
functions O +
in O +
cells O +
and O +
the O +
physiological O +
role O +
of O +
this O +
protein O +
in O +
animals O +
remain O +
largely O +
unknown O +
. O +

In O +
this O +
review O +
, O +
we O +
will O +
discuss O +
the O +
current O +
knowledge O +
of O +
MTSS1 O +
' O +
s O +
role O +
in O +
cancer O +
metastasis O +
, O +
carcinogenesis O +
, O +
and O +
development O +
. O +

The O +
clinical O +
significance O +
of O +
MTSS1 O +
will O +
also O +
be O +
discussed O +
. O +

Geometric O +
correlations O +
and O +
breakdown O +
of O +
mesoscopic O +
universality O +
in O +
spin O +
transport O +
. O +

We O +
construct O +
a O +
unified O +
semiclassical O +
theory O +
of O +
charge O +
and O +
spin O +
transport O +
in O +
chaotic O +
ballistic O +
and O +
disordered O +
diffusive O +
mesoscopic O +
systems O +
with O +
spin O +
- O +
orbit O +
interaction O +
. O +

Neglecting O +
dynamic O +
effects O +
of O +
spin O +
- O +
orbit O +
interaction O +
, O +
we O +
reproduce O +
the O +
random O +
matrix O +
theory O +
results O +
that O +
the O +
spin O +
conductance O +
fluctuates O +
universally O +
around O +
zero O +
average O +
. O +

Incorporating O +
these O +
effects O +
into O +
the O +
theory O +
, O +
we O +
show O +
that O +
geometric O +
correlations O +
generate O +
finite O +
average O +
spin O +
conductances O +
, O +
but O +
that O +
they O +
do O +
not O +
affect O +
the O +
charge O +
conductance O +
to O +
leading O +
order O +
. O +

The O +
theory O +
, O +
which O +
is O +
confirmed O +
by O +
numerical O +
transport O +
calculations O +
, O +
allows O +
us O +
to O +
investigate O +
the O +
entire O +
range O +
from O +
the O +
weak O +
to O +
the O +
previously O +
unexplored O +
strong O +
spin O +
- O +
orbit O +
regime O +
, O +
where O +
the O +
spin O +
rotation O +
time O +
is O +
shorter O +
than O +
the O +
momentum O +
relaxation O +
time O +
. O +

Development O +
and O +
validation O +
of O +
an O +
approach O +
to O +
produce O +
large O +
- O +
scale O +
quantities O +
of O +
CpG O +
- O +
methylated O +
plasmid O +
DNA O +
. O +

The O +
prokaryotic O +
CpG O +
- O +
specific O +
DNA O +
methylase O +
from O +
Spiroplasma O +
, O +
SssI O +
methylase O +
, O +
has O +
been O +
extensively O +
used O +
to O +
methylate O +
plasmid O +
DNA O +
in O +
vitro O +
to O +
investigate O +
the O +
effects O +
of O +
methylation O +
in O +
vertebrate O +
systems O +
. O +

Currently O +
available O +
methods O +
to O +
produce O +
CpG O +
- O +
methylated O +
plasmid O +
DNA O +
have O +
certain O +
limitations O +
and O +
can O -
not O +
generate O +
large O +
quantities O +
of O +
methylated O +
DNA O +
without O +
cost O +
or O +
problems O +
of O +
purity O +
. O +

Here O +
we O +
describe O +
an O +
approach O +
in O +
which O +
the O +
SssI O +
methylase O +
gene O +
has O +
been O +
introduced O +
into O +
the O +
Escherichia O +
coli O +
bacterial O +
genome O +
under O +
the O +
control O +
of O +
an O +
inducible O +
promoter O +
. O +

Plasmid O +
DNA O +
propagated O +
in O +
this O +
bacterium O +
under O +
conditions O +
which O +
induce O +
the O +
methylase O +
gene O +
result O +
in O +
significant O +
( O +
> O +
90 O +
% O +
) O +
CpG O +
methylation O +
. O +

Methylated O +
DNA O +
produced O +
by O +
this O +
approach O +
behaves O +
similarly O +
to O +
methylated O +
DNA O +
produced O +
in O +
vitro O +
using O +
the O +
purified O +
methylase O +
. O +

The O +
approach O +
is O +
scalable O +
allowing O +
for O +
the O +
production O +
of O +
milligram O +
quantities O +
of O +
methylated O +
plasmid O +
DNA O +
. O +

Dissecting O +
genetic O +
networks O +
underlying O +
complex O +
phenotypes O +
: O +
the O +
theoretical O +
framework O +
. O +

Great O +
progress O +
has O +
been O +
made O +
in O +
genetic O +
dissection O +
of O +
quantitative O +
trait O +
variation O +
during O +
the O +
past O +
two O +
decades O +
, O +
but O +
many O +
studies O +
still O +
reveal O +
only O +
a O +
small O +
fraction O +
of O +
quantitative O +
trait O +
loci O +
( O +
QTLs O +
) O +
, O +
and O +
epistasis O +
remains O +
elusive O +
. O +

We O +
integrate O +
contemporary O +
knowledge O +
of O +
signal O +
transduction O +
pathways O +
with O +
principles O +
of O +
quantitative O +
and O +
population O +
genetics O +
to O +
characterize O +
genetic O +
networks O +
underlying O +
complex O +
traits O +
, O +
using O +
a O +
model O +
founded O +
upon O +
one O +
- O +
way O +
functional O +
dependency O +
of O +
downstream O +
genes O +
on O +
upstream O +
regulators O +
( O +
the O +
principle O +
of O +
hierarchy O +
) O +
and O +
mutual O +
functional O +
dependency O +
among O +
related O +
genes O +
( O +
functional O +
genetic O +
units O +
, O +
FGU O +
) O +
. O +

Both O +
simulated O +
and O +
real O +
data O +
suggest O +
that O +
complementary O +
epistasis O +
contributes O +
greatly O +
to O +
quantitative O +
trait O +
variation O +
, O +
and O +
obscures O +
the O +
phenotypic O +
effects O +
of O +
many O +
' O +
downstream O +
' O +
loci O +
in O +
pathways O +
. O +

The O +
mathematical O +
relationships O +
between O +
the O +
main O +
effects O +
and O +
epistatic O +
effects O +
of O +
genes O +
acting O +
at O +
different O +
levels O +
of O +
signaling O +
pathways O +
were O +
established O +
using O +
the O +
quantitative O +
and O +
population O +
genetic O +
parameters O +
. O +

Both O +
loss O +
of O +
function O +
and O +
" O +
co O +
- O +
adapted O +
" O +
gene O +
complexes O +
formed O +
by O +
multiple O +
alleles O +
with O +
differentiated O +
functions O +
( O +
effects O +
) O +
are O +
predicted O +
to O +
be O +
frequent O +
types O +
of O +
allelic O +
diversity O +
at O +
loci O +
that O +
contribute O +
to O +
the O +
genetic O +
variation O +
of O +
complex O +
traits O +
in O +
populations O +
. O +

Downstream O +
FGUs O +
appear O +
to O +
be O +
more O +
vulnerable O +
to O +
loss O +
of O +
function O +
than O +
their O +
upstream O +
regulators O +
, O +
but O +
this O +
vulnerability O +
is O +
apparently O +
compensated O +
by O +
different O +
FGUs O +
of O +
similar O +
functions O +
. O +

Other O +
predictions O +
from O +
the O +
model O +
may O +
account O +
for O +
puzzling O +
results O +
regarding O +
responses O +
to O +
selection O +
, O +
genotype O +
by O +
environment O +
interaction O +
, O +
and O +
the O +
genetic O +
basis O +
of O +
heterosis O +
. O +

Ras O +
p21 O +
onco O +
- O +
protein O +
in O +
the O +
sera O +
of O +
mice O +
carrying O +
an O +
experimentally O +
induced O +
tumor O +
and O +
in O +
human O +
cancer O +
patients O +
. O +

We O +
have O +
established O +
a O +
model O +
system O +
to O +
detect O +
the O +
presence O +
of O +
ras O +
p21 O +
in O +
the O +
sera O +
of O +
Balb O +
/ O +
c O +
mice O +
carrying O +
tumors O +
induced O +
by O +
a O +
mouse O +
cell O +
line O +
transformed O +
with O +
the O +
Harvey O +
murine O +
sarcoma O +
virus O +
in O +
the O +
presence O +
of O +
a O +
helper O +
Friend O +
murine O +
leukemia O +
virus O +
. O +

As O +
determined O +
by O +
ELISA O +
and O +
immunoblot O +
assays O +
, O +
ras O +
p21 O +
in O +
the O +
serum O +
increased O +
with O +
increased O +
tumor O +
growth O +
. O +

Since O +
ras O +
genes O +
have O +
been O +
found O +
to O +
be O +
frequently O +
activated O +
in O +
human O +
tumours O +
, O +
we O +
examined O +
the O +
levels O +
of O +
ras O +
p21 O +
in O +
the O +
sera O +
of O +
a O +
variety O +
of O +
human O +
cancer O +
patients O +
. O +

In O +
only O +
3 O +
out O +
of O +
13 O +
cases O +
, O +
representing O +
patients O +
with O +
adenocarcinomas O +
of O +
the O +
stomach O +
receiving O +
chemotherapy O +
, O +
was O +
ras O +
p21 O +
detected O +
at O +
elevated O +
levels O +
, O +
whereas O +
in O +
patients O +
with O +
the O +
following O +
types O +
of O +
cancer O +
no O +
substantial O +
change O +
in O +
serum O +
ras O +
p21 O +
was O +
observed O +
; O +
nine O +
with O +
breast O +
, O +
5 O +
colon O +
, O +
5 O +
lung O +
, O +
5 O +
ovarian O +
and O +
5 O +
hepatocellular O +
carcinomas O +
. O +

Serum O +
soluble O +
vascular O +
adhesion O +
protein O +
- O +
1 O +
is O +
a O +
valuable O +
prognostic O +
marker O +
in O +
gastric O +
cancer O +
. O +

BACKGROUND O +
: O +
Vascular O +
adhesion O +
protein O +
- O +
1 O +
( O +
VAP O +
- O +
1 O +
) O +
regulates O +
leukocyte O +
tissue O +
infiltration O +
. O +

Elevated O +
serum O +
soluble O +
VAP O +
- O +
1 O +
( O +
sVAP O +
- O +
1 O +
) O +
levels O +
occur O +
in O +
certain O +
diseases O +
having O +
an O +
inflammatory O +
component O +
. O +

We O +
previously O +
showed O +
in O +
colorectal O +
cancer O +
that O +
sVAP O +
- O +
1 O +
expression O +
is O +
significantly O +
higher O +
relative O +
to O +
controls O +
, O +
and O +
this O +
decreased O +
expression O +
is O +
associated O +
with O +
poor O +
prognosis O +
and O +
lymph O +
node O +
and O +
liver O +
metastasis O +
. O +

However O +
, O +
sVAP O +
- O +
1 O +
expression O +
has O +
not O +
been O +
described O +
for O +
gastric O +
cancer O +
. O +

This O +
study O +
determines O +
the O +
relationship O +
between O +
preoperative O +
serum O +
sVAP O +
- O +
1 O +
levels O +
and O +
clinicopathological O +
features O +
and O +
prognosis O +
in O +
gastric O +
cancer O +
. O +

METHODS O +
: O +
Preoperative O +
serum O +
was O +
collected O +
from O +
107 O +
gastric O +
cancer O +
patients O +
and O +
33 O +
normal O +
controls O +
. O +

sVAP O +
- O +
1 O +
levels O +
were O +
assayed O +
by O +
enzyme O +
- O +
linked O +
immunosorbent O +
assay O +
. O +

RESULTS O +
: O +
The O +
mean O +
sVAP O +
- O +
1 O +
level O +
for O +
cancer O +
patients O +
was O +
significantly O +
higher O +
relative O +
to O +
controls O +
, O +
and O +
decreased O +
with O +
disease O +
progression O +
. O +

Tumor O +
size O +
, O +
serosal O +
invasion O +
, O +
lymph O +
node O +
metastasis O +
, O +
peritoneal O +
dissemination O +
, O +
and O +
TNM O +
classification O +
was O +
significantly O +
correlated O +
with O +
sVAP O +
- O +
1 O +
level O +
. O +

sVAP O +
- O +
1 O +
is O +
also O +
an O +
independent O +
predictive O +
marker O +
for O +
lymph O +
node O +
metastasis O +
. O +

Patients O +
having O +
low O +
sVAP O +
- O +
1 O +
levels O +
had O +
significantly O +
poorer O +
prognosis O +
relative O +
to O +
patients O +
having O +
elevated O +
sVAP O +
- O +
1 O +
in O +
all O +
or O +
stages O +
I O +
- O +
III O +
gastric O +
cancer O +
patients O +
, O +
respectively O +
. O +

CONCLUSIONS O +
: O +
Low O +
sVAP O +
- O +
1 O +
levels O +
are O +
associated O +
with O +
poor O +
prognosis O +
in O +
gastric O +
cancer O +
. O +

Determining O +
sVAP O +
- O +
1 O +
levels O +
may O +
be O +
valuable O +
for O +
predicting O +
prognosis O +
and O +
lymph O +
node O +
metastasis O +
. O +

Diallyl O +
trisulfide O +
( O +
DATS O +
) O +
inhibits O +
mouse O +
colon O +
tumor O +
in O +
mouse O +
CT B-CellLine +
- I-CellLine +
26 I-CellLine +
cells O +
allograft O +
model O +
in O +
vivo O +
. O +

Our O +
earlier O +
studies O +
showed O +
that O +
DATS O +
induced O +
apoptosis O +
in O +
human O +
colon O +
cancer O +
HT29 B-CellLine +
and O +
colo B-CellLine +
205 I-CellLine +
cell O +
lines O +
in O +
vitro O +
. O +

However O +
, O +
there O +
is O +
no O +
report O +
to O +
show O +
that O +
DATS O +
induced O +
apoptosis O +
in O +
vitro O +
and O +
inhibited O +
CT26 B-CellLine +
cancer O +
cells O +
in O +
vivo O +
on O +
a O +
murine O +
allograft O +
animal O +
model O +
. O +

In O +
vitro O +
studies O +
, O +
the O +
results O +
indicated O +
that O +
DATS O +
induced O +
morphological O +
changes O +
and O +
induction O +
of O +
apoptosis O +
in O +
CT26 B-CellLine +
cells O +
. O +

In O +
vivo O +
studies O +
, O +
CT26 B-CellLine +
cancer O +
cells O +
were O +
implanted O +
into O +
BALB O +
/ O +
c O +
mice O +
and O +
groups O +
of O +
mice O +
were O +
treated O +
with O +
vehicle O +
, O +
DATS O +
( O +
10 O +
and O +
50 O +
mg O +
/ O +
kg O +
of O +
body O +
weight O +
) O +
. O +

DATS O +
were O +
injected O +
once O +
per O +
four O +
days O +
intraperitoneally O +
( O +
i O +
. O +
p O +
. O +
) O +
, O +
with O +
treatment O +
starting O +
4 O +
weeks O +
prior O +
to O +
cells O +
inoculation O +
. O +

Treatment O +
with O +
vehicle O +
or O +
with O +
10 O +
and O +
50 O +
mg O +
/ O +
kg O +
of O +
DATS O +
resulted O +
in O +
a O +
reduction O +
in O +
tumor O +
volume O +
and O +
weight O +
. O +

Tumor O +
volume O +
and O +
total O +
hemoglobin O +
in O +
allograft O +
mice O +
treated O +
with O +
50 O +
mg O +
/ O +
kg O +
DATS O +
were O +
significantly O +
smaller O +
than O +
that O +
in O +
the O +
control O +
group O +
. O +

These O +
findings O +
indicated O +
that O +
DATS O +
inhibits O +
tumor O +
growth O +
in O +
an O +
allograft O +
animal O +
model O +
. O +

Thus O +
, O +
DATS O +
may O +
represent O +
a O +
colon O +
cancer O +
preventive O +
agent O +
and O +
can O +
be O +
used O +
in O +
the O +
future O +
. O +

Metabolic O +
regulation O +
by O +
p53 O +
. O +

We O +
are O +
increasingly O +
aware O +
that O +
cellular O +
metabolism O +
plays O +
a O +
vital O +
role O +
in O +
diseases O +
such O +
as O +
cancer O +
, O +
and O +
that O +
p53 O +
is O +
an O +
important O +
regulator O +
of O +
metabolic O +
pathways O +
. O +

By O +
transcriptional O +
activation O +
and O +
other O +
means O +
, O +
p53 O +
is O +
able O +
to O +
contribute O +
to O +
the O +
regulation O +
of O +
glycolysis O +
, O +
oxidative O +
phosphorylation O +
, O +
glutaminolysis O +
, O +
insulin O +
sensitivity O +
, O +
nucleotide O +
biosynthesis O +
, O +
mitochondrial O +
integrity O +
, O +
fatty O +
acid O +
oxidation O +
, O +
antioxidant O +
response O +
, O +
autophagy O +
and O +
mTOR O +
signalling O +
. O +

The O +
ability O +
to O +
positively O +
and O +
negatively O +
regulate O +
many O +
of O +
these O +
pathways O +
, O +
combined O +
with O +
feedback O +
signalling O +
from O +
these O +
pathways O +
to O +
p53 O +
, O +
demonstrates O +
the O +
reciprocal O +
and O +
flexible O +
nature O +
of O +
the O +
regulation O +
, O +
facilitating O +
a O +
diverse O +
range O +
of O +
responses O +
to O +
metabolic O +
stress O +
. O +

Intriguingly O +
, O +
metabolic O +
stress O +
triggers O +
primarily O +
an O +
adaptive O +
( O +
rather O +
than O +
pro O +
- O +
apoptotic O +
) O +
p53 O +
response O +
, O +
and O +
p53 O +
is O +
emerging O +
as O +
an O +
important O +
regulator O +
of O +
metabolic O +
homeostasis O +
. O +

A O +
better O +
understanding O +
of O +
how O +
p53 O +
coordinates O +
metabolic O +
adaptation O +
will O +
facilitate O +
the O +
identification O +
of O +
novel O +
therapeutic O +
targets O +
and O +
will O +
also O +
illuminate O +
the O +
wider O +
role O +
of O +
p53 O +
in O +
human O +
biology O +
. O +

Use O +
of O +
DNA O +
microarray O +
and O +
small O +
animal O +
positron O +
emission O +
tomography O +
in O +
preclinical O +
drug O +
evaluation O +
of O +
RAF265 O +
, O +
a O +
novel O +
B O +
- O +
Raf O +
/ O +
VEGFR O +
- O +
2 O +
inhibitor O +
. O +

Positron O +
emission O +
tomography O +
( O +
PET O +
) O +
imaging O +
has O +
become O +
a O +
useful O +
tool O +
for O +
assessing O +
early O +
biologic O +
response O +
to O +
cancer O +
therapy O +
and O +
may O +
be O +
particularly O +
useful O +
in O +
the O +
development O +
of O +
new O +
cancer O +
therapeutics O +
. O +

RAF265 O +
, O +
a O +
novel O +
B O +
- O +
Raf O +
/ O +
vascular O +
endothelial O +
growth O +
factor O +
receptor O +
- O +
2 O +
inhibitor O +
, O +
was O +
evaluated O +
in O +
the O +
preclinical O +
setting O +
for O +
its O +
ability O +
to O +
inhibit O +
the O +
uptake O +
of O +
PET O +
tracers O +
in O +
the O +
A375 B-CellLine -
M I-CellLine +
( O +
B O +
- O +
Raf O +
( O +
V600E O +
) O +
) O +
human O +
melanoma O +
cell O +
line O +
. O +

RAF265 O +
inhibited O +
2 O +
- O +
deoxy O +
- O +
2 O +
- O +
[ O +
( O +
18 O +
) O +
F O +
] O +
fluoro O +
- O +
d O +
- O +
glucose O +
( O +
FDG O +
) O +
accumulation O +
in O +
cell O +
culture O +
at O +
28 O +
hours O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
. O +

RAF265 O +
also O +
inhibited O +
FDG O +
accumulation O +
in O +
tumor O +
xenografts O +
after O +
1 O +
day O +
of O +
drug O +
treatment O +
. O +

This O +
decrease O +
persisted O +
for O +
the O +
remaining O +
2 O +
weeks O +
of O +
treatment O +
. O +

DNA O +
microarray O +
analysis O +
of O +
treated O +
tumor O +
xenografts O +
revealed O +
significantly O +
decreased O +
expression O +
of O +
genes O +
regulating O +
glucose O +
and O +
thymidine O +
metabolism O +
and O +
revealed O +
changes O +
in O +
apoptotic O +
genes O +
, O +
suggesting O +
that O +
the O +
imaging O +
tracers O +
FDG O +
, O +
3 O +
- O +
deoxy O +
- O +
3 O +
- O +
[ O +
( O +
18 O +
) O +
F O +
] O +
fluorothymidine O +
, O +
and O +
annexin O +
V O +
could O +
serve O +
as O +
potential O +
imaging O +
biomarkers O +
for O +
RAF265 O +
therapy O +
monitoring O +
. O +

We O +
concluded O +
that O +
RAF265 O +
is O +
highly O +
efficacious O +
in O +
this O +
xenograft O +
model O +
of O +
human O +
melanoma O +
and O +
decreases O +
glucose O +
metabolism O +
as O +
measured O +
by O +
DNA O +
microarray O +
analysis O +
, O +
cell O +
culture O +
assays O +
, O +
and O +
small O +
animal O +
FDG O +
PET O +
scans O +
as O +
early O +
as O +
1 O +
day O +
after O +
treatment O +
. O +

Our O +
results O +
support O +
the O +
use O +
of O +
FDG O +
PET O +
in O +
clinical O +
trials O +
with O +
RAF265 O +
to O +
assess O +
early O +
tumor O +
response O +
. O +

DNA O +
microarray O +
analysis O +
and O +
small O +
animal O +
PET O +
studies O +
may O +
be O +
used O +
as O +
complementary O +
technologies O +
in O +
drug O +
development O +
. O +

DNA O +
microarray O +
analysis O +
allows O +
for O +
analysis O +
of O +
drug O +
effects O +
on O +
multiple O +
pathways O +
linked O +
to O +
cancer O +
and O +
can O +
suggest O +
corresponding O +
imaging O +
tracers O +
for O +
further O +
analysis O +
as O +
biomarkers O +
of O +
tumor O +
response O +
. O +

Predictive O +
value O +
of O +
serum O +
carbohydrate O +
antigen O +
19 O +
- O +
9 O +
in O +
malignant O +
intraductal O +
papillary O +
mucinous O +
neoplasms O +
. O +

BACKGROUND O +
: O +

The O +
goal O +
of O +
the O +
present O +
study O +
was O +
to O +
evaluate O +
the O +
predictive O +
value O +
of O +
serum O +
carbohydrate O +
antigen O +
19 O +
- O +
9 O +
( O +
CA O +
19 O +
- O +
9 O +
) O +
in O +
the O +
diagnosis O +
of O +
malignant O +
intraductal O +
papillary O +
mucinous O +
neoplasms O +
of O +
pancreas O +
( O +
IPMNs O +
) O +
. O +

METHODS O +
: O +

Eighty O +
- O +
six O +
patients O +
with O +
pathological O +
diagnosis O +
of O +
IPMNs O +
in O +
Zhongshan O +
Hospital O +
between O +
March O +
1999 O +
and O +
November O +
2008 O +
were O +
retrospectively O +
reviewed O +
. O +

Data O +
reflecting O +
clinical O +
characteristics O +
, O +
tumor O +
marker O +
level O +
, O +
and O +
prognosis O +
were O +
collected O +
. O +

The O +
potential O +
predictive O +
value O +
of O +
CA O +
19 O +
- O +
9 O +
was O +
analyzed O +
by O +
receiver O +
operating O +
characteristic O +
( O +
ROC O +
) O +
curve O +
. O +

RESULTS O +
: O +

Eighty O +
- O +
six O +
consecutive O +
patients O +
with O +
IPMNs O +
all O +
underwent O +
surgical O +
intervention O +
. O +

A O +
high O +
level O +
of O +
CA O +
19 O +
- O +
9 O +
or O +
carcinoembryonic O +
antigen O +
( O +
CEA O +
) O +
was O +
associated O +
with O +
more O +
advanced O +
stage O +
of O +
malignant O +
IPMNs O +
. O +

Carbohydrate O +
antigen O +
19 O +
- O +
9 O +
was O +
significant O +
for O +
judging O +
malignant O +
IPMNs O +
in O +
the O +
binary O +
logistic O +
regression O +
model O +
( O +
p O +
= O +
0 O +
. O +
047 O +
) O +
. O +

The O +
hazard O +
ratio O +
was O +
1 O +
. O +
014 O +
, O +
whose O +
95 O +
. O +
0 O +
% O +
confidence O +
interval O +
was O +
0 O +
. O +
91 O +
- O +
1 O +
. O +
028 O +
. O +

Receiver O +
operating O +
characteristic O +
analysis O +
showed O +
that O +
the O +
serum O +
CA O +
19 O +
- O +
9 O +
level O +
had O +
good O +
predictive O +
value O +
for O +
malignant O +
or O +
invasive O +
IPMNs O +
, O +
postoperative O +
survival O +
, O +
and O +
disease O +
- O +
specific O +
recurrence O +
. O +

The O +
area O +
under O +
the O +
curve O +
( O +
AUC O +
) O +
was O +
0 O +
. O +
856 O +
, O +
0 O +
. O +
893 O +
, O +
0 O +
. O +
815 O +
, O +
and O +
0 O +
. O +
857 O +
( O +
p O +
< O +
0 O +
. O +
05 O +
) O +
, O +
respectively O +
. O +

According O +
to O +
the O +
follow O +
- O +
up O +
, O +
mean O +
survival O +
time O +
for O +
groups O +
with O +
CA O +
19 O +
- O +
9 O +
> O +
63 O +
. O +
60 O +
U O +
/ O +
ml O +
was O +
dramatically O +
shorter O +
than O +
that O +
for O +
groups O +
with O +
CA O +
19 O +
- O +
9 O +
< O +
= O +
63 O +
. O +
60 O +
U O +
/ O +
ml O +
( O +
57 O +
. O +
38 O +
+ O +
/ O +
- O +
2 O +
. O +
85 O +
versus O +
29 O +
. O +
24 O +
+ O +
/ O +
- O +
5 O +
. O +
82 O +
[ O +
months O +
] O +
; O +
p O +
< O +
0 O +
. O +
01 O +
) O +
. O +

CONCLUSIONS O +
: O +

Serum O +
CA O +
19 O +
- O +
9 O +
level O +
has O +
good O +
predictive O +
value O +
for O +
malignant O +
or O +
invasive O +
IPMNs O +
. O +

Patients O +
with O +
CA O +
19 O +
- O +
9 O +
> O +
63 O +
. O +
60 O +
U O +
/ O +
ml O +
had O +
poor O +
postoperative O +
prognosis O +
in O +
IPMNs O +
. O +

Preoperative O +
abnormal O +
serum O +
CA O +
19 O +
- O +
9 O +
might O +
be O +
predictive O +
for O +
an O +
aggressive O +
surgical O +
intervention O +
in O +
IPMNs O +
. O +

Saliva O +
proteins O +
of O +
vector O +
Culicoides O +
modify O +
structure O +
and O +
infectivity O +
of O +
bluetongue O +
virus O +
particles O +
. O +

Bluetongue O +
virus O +
( O +
BTV O +
) O +
and O +
epizootic O +
haemorrhagic O +
disease O +
virus O +
( O +
EHDV O +
) O +
are O +
related O +
orbiviruses O +
, O +
transmitted O +
between O +
their O +
ruminant O +
hosts O +
primarily O +
by O +
certain O +
haematophagous O +
midge O +
vectors O +
( O +
Culicoides O +
spp O +
. O +
) O +
. O +

The O +
larger O +
of O +
the O +
BTV O +
outer O +
- O +
capsid O +
proteins O +
, O +
' O +
VP2 O +
' O +
, O +
can O +
be O +
cleaved O +
by O +
proteases O +
( O +
including O +
trypsin O +
or O +
chymotrypsin O +
) O +
, O +
forming O +
infectious O +
subviral O +
particles O +
( O +
ISVP O +
) O +
which O +
have O +
enhanced O +
infectivity O +
for O +
adult O +
Culicoides O +
, O +
or O +
KC O +
cells O +
( O +
a O +
cell O +
- O +
line O +
derived O +
from O +
C O +
. O +
sonorensis O +
) O +
. O +

We O +
demonstrate O +
that O +
VP2 O +
present O +
on O +
purified O +
virus O +
particles O +
from O +
3 O +
different O +
BTV O +
strains O +
can O +
also O +
be O +
cleaved O +
by O +
treatment O +
with O +
saliva O +
from O +
adult O +
Culicoides O +
. O +

The O +
saliva O +
proteins O +
from O +
C O +
. O +
sonorensis O +
( O +
a O +
competent O +
BTV O +
vector O +
) O +
, O +
cleaved O +
BTV O +
- O +
VP2 O +
more O +
efficiently O +
than O +
those O +
from O +
C O +
. O +
nubeculosus O +
( O +
a O +
less O +
competent O +
/ O +
non O +
- O +
vector O +
species O +
) O +
. O +

Electrophoresis O +
and O +
mass O +
spectrometry O +
identified O +
a O +
trypsin O +
- O +
like O +
protease O +
in O +
C O +
. O +
sonorensis O +
saliva O +
, O +
which O +
was O +
significantly O +
reduced O +
or O +
absent O +
from O +
C O +
. O +
nubeculosus O +
saliva O +
. O +

Incubating O +
purified O +
BTV O +
- O +
1 O +
with O +
C O +
. O +
sonorensis O +
saliva O +
proteins O +
also O +
increased O +
their O +
infectivity O +
for O +
KC O +
cells O +
~ O +
10 O +
fold O +
, O +
while O +
infectivity O +
for O +
BHK B-CellLine +
cells O +
was O +
reduced O +
by O +
2 O +
- O +
6 O +
fold O +
. O +

Treatment O +
of O +
an O +
' O +
eastern O +
' O +
strain O +
of O +
EHDV O +
- O +
2 O +
with O +
saliva O +
proteins O +
of O +
either O +
C O +
. O +
sonorensis O +
or O +
C O +
. O +
nubeculosus O +
cleaved O +
VP2 O +
, O +
but O +
a O +
' O +
western O +
' O +
strain O +
of O +
EHDV O +
- O +
2 O +
remained O +
unmodified O +
. O +

These O +
results O +
indicate O +
that O +
temperature O +
, O +
strain O +
of O +
virus O +
and O +
protein O +
composition O +
of O +
Culicoides O +
saliva O +
( O +
particularly O +
its O +
protease O +
content O +
which O +
is O +
dependent O +
upon O +
vector O +
species O +
) O +
, O +
can O +
all O +
play O +
a O +
significant O +
role O +
in O +
the O +
efficiency O +
of O +
VP2 O +
cleavage O +
, O +
influencing O +
virus O +
infectivity O +
. O +

Saliva O +
of O +
several O +
other O +
arthropod O +
species O +
has O +
previously O +
been O +
shown O +
to O +
increase O +
transmission O +
, O +
infectivity O +
and O +
virulence O +
of O +
certain O +
arboviruses O +
, O +
by O +
modulating O +
and O +
/ O +
or O +
suppressing O +
the O +
mammalian O +
immune O +
response O +
. O +

The O +
findings O +
presented O +
here O +
, O +
however O +
, O +
demonstrate O +
a O +
novel O +
mechanism O +
by O +
which O +
proteases O +
in O +
Culicoides O +
saliva O +
can O +
also O +
directly O +
modify O +
the O +
orbivirus O +
particle O +
structure O +
, O +
leading O +
to O +
increased O +
infectivity O +
specifically O +
for O +
Culicoides O +
cells O +
and O +
, O +
in O +
turn O +
, O +
efficiency O +
of O +
transmission O +
to O +
the O +
insect O +
vector O +
. O +

Systematic O +
proteomic O +
analysis O +
of O +
human O +
hepotacellular O +
carcinoma O +
cells O +
reveals O +
molecular O +
pathways O +
and O +
networks O +
involved O +
in O +
metastasis O +
. O +

Systematic O +
proteomic O +
studying O +
of O +
the O +
mechanism O +
of O +
hepatocellular O +
carcinoma O +
( O +
HCC O +
) O +
metastasis O +
remains O +
challenging O +
. O +

We O +
performed O +
comparative O +
proteomic O +
and O +
pathway O +
analysis O +
of O +
four O +
human O +
metastatic O +
HCC O +
cell O +
lines O +
to O +
identify O +
metastasis O +
- O +
associated O +
proteins O +
. O +

These O +
HCC O +
cell O +
lines O +
had O +
a O +
similar O +
genetic O +
background O +
but O +
with O +
an O +
increasing O +
potential O +
of O +
metastasis O +
. O +

Using O +
a O +
combination O +
of O +
two O +
dimensional O +
electrophoresis O +
( O +
2 O +
- O +
DE O +
) O +
and O +
MALDI O +
- O +
TOF O +
mass O +
spectrometry O +
, O +
a O +
total O +
of O +
125 O +
proteins O +
and O +
their O +
post O +
- O +
translational O +
modification O +
forms O +
or O +
isoforms O +
were O +
found O +
to O +
be O +
differentially O +
expressed O +
in O +
the O +
cell O +
lines O +
. O +

Among O +
them O +
, O +
29 O +
were O +
gradually O +
up O +
- O +
regulated O +
whereas O +
17 O +
were O +
down O +
- O +
regulated O +
with O +
increasing O +
metastatic O +
potential O +
. O +

Instead O +
of O +
a O +
traditional O +
single O +
- O +
gene O +
readout O +
, O +
global O +
bioinformatics O +
analysis O +
was O +
carried O +
out O +
, O +
which O +
revealed O +
that O +
the O +
glycolysis O +
pathway O +
was O +
the O +
most O +
significantly O +
enriched O +
pathway O +
. O +

The O +
heat O +
shock O +
proteins O +
( O +
HSPs O +
) O +
centered O +
and O +
NF O +
- O +
kappaB O +
centered O +
networks O +
were O +
also O +
enriched O +
in O +
the O +
result O +
, O +
which O +
may O +
imply O +
the O +
key O +
function O +
of O +
inflaming O +
on O +
metastasis O +
. O +

Meanwhile O +
, O +
knockdown O +
of O +
HDGF O +
, O +
an O +
up O +
- O +
regulated O +
protein O +
and O +
a O +
target O +
of O +
NF O +
- O +
kappaB O +
, O +
induced O +
cell O +
apoptosis O +
in O +
the O +
metastatic O +
HCC O +
cells O +
. O +

This O +
work O +
provides O +
a O +
demonstration O +
that O +
a O +
combination O +
of O +
bioinformatics O +
and O +
comparative O +
proteomics O +
can O +
help O +
in O +
finding O +
out O +
potential O +
biomarkers O +
associated O +
with O +
HCC O +
metastasis O +
on O +
the O +
level O +
of O +
pathways O +
. O +

Roles O +
of O +
brca2 O +
( O +
fancd1 O +
) O +
in O +
oocyte O +
nuclear O +
architecture O +
, O +
gametogenesis O +
, O +
gonad O +
tumors O +
, O +
and O +
genome O +
stability O +
in O +
zebrafish O +
. O +

Mild O +
mutations O +
in O +
BRCA2 O +
( O +
FANCD1 O +
) O +
cause O +
Fanconi O +
anemia O +
( O +
FA O +
) O +
when O +
homozygous O +
, O +
while O +
severe O +
mutations O +
cause O +
common O +
cancers O +
including O +
breast O +
, O +
ovarian O +
, O +
and O +
prostate O +
cancers O +
when O +
heterozygous O +
. O +

Here O +
we O +
report O +
a O +
zebrafish O +
brca2 O +
insertional O +
mutant O +
that O +
shares O +
phenotypes O +
with O +
human O +
patients O +
and O +
identifies O +
a O +
novel O +
brca2 O +
function O +
in O +
oogenesis O +
. O +

Experiments O +
showed O +
that O +
mutant O +
embryos O +
and O +
mutant O +
cells O +
in O +
culture O +
experienced O +
genome O +
instability O +
, O +
as O +
do O +
cells O +
in O +
FA O +
patients O +
. O +

In O +
wild O +
- O +
type O +
zebrafish O +
, O +
meiotic O +
cells O +
expressed O +
brca2 O +
; O +
and O +
, O +
unexpectedly O +
, O +
transcripts O +
in O +
oocytes O +
localized O +
asymmetrically O +
to O +
the O +
animal O +
pole O +
. O +

In O +
juvenile O +
brca2 O +
mutants O +
, O +
oocytes O +
failed O +
to O +
progress O +
through O +
meiosis O +
, O +
leading O +
to O +
female O +
- O +
to O +
- O +
male O +
sex O +
reversal O +
. O +

Adult O +
mutants O +
became O +
sterile O +
males O +
due O +
to O +
the O +
meiotic O +
arrest O +
of O +
spermatocytes O +
, O +
which O +
then O +
died O +
by O +
apoptosis O +
, O +
followed O +
by O +
neoplastic O +
proliferation O +
of O +
gonad O +
somatic O +
cells O +
that O +
was O +
similar O +
to O +
neoplasia O +
observed O +
in O +
ageing O +
dead O +
end O +
( O +
dnd O +
) O +
- O +
knockdown O +
males O +
, O +
which O +
lack O +
germ O +
cells O +
. O +

The O +
construction O +
of O +
animals O +
doubly O +
mutant O +
for O +
brca2 O +
and O +
the O +
apoptotic O +
gene O +
tp53 O +
( O +
p53 O +
) O +
rescued O +
brca2 O +
- O +
dependent O +
sex O +
reversal O +
. O +

Double O +
mutants O +
developed O +
oocytes O +
and O +
became O +
sterile O +
females O +
that O +
produced O +
only O +
aberrant O +
embryos O +
and O +
showed O +
elevated O +
risk O +
for O +
invasive O +
ovarian O +
tumors O +
. O +

Oocytes O +
in O +
double O +
- O +
mutant O +
females O +
showed O +
normal O +
localization O +
of O +
brca2 O +
and O +
pou5f1 O +
transcripts O +
to O +
the O +
animal O +
pole O +
and O +
vasa O +
transcripts O +
to O +
the O +
vegetal O +
pole O +
, O +
but O +
had O +
a O +
polarized O +
rather O +
than O +
symmetrical O +
nucleus O +
with O +
the O +
distribution O +
of O +
nucleoli O +
and O +
chromosomes O +
to O +
opposite O +
nuclear O +
poles O +
; O +
this O +
result O +
revealed O +
a O +
novel O +
role O +
for O +
Brca2 O +
in O +
establishing O +
or O +
maintaining O +
oocyte O +
nuclear O +
architecture O +
. O +

Mutating O +
tp53 O +
did O +
not O +
rescue O +
the O +
infertility O +
phenotype O +
in O +
brca2 O +
mutant O +
males O +
, O +
suggesting O +
that O +
brca2 O +
plays O +
an O +
essential O +
role O +
in O +
zebrafish O +
spermatogenesis O +
. O +

Overall O +
, O +
this O +
work O +
verified O +
zebrafish O +
as O +
a O +
model O +
for O +
the O +
role O +
of O +
Brca2 O +
in O +
human O +
disease O +
and O +
uncovered O +
a O +
novel O +
function O +
of O +
Brca2 O +
in O +
vertebrate O +
oocyte O +
nuclear O +
architecture O +
. O +

Induction O +
of O +
I O -
d O +
- O +
1 O +
by O +
FGF O +
- O +
2 O +
involves O +
activity O +
of O +
EGR O +
- O +
1 O +
and O +
sensitizes O +
neuroblastoma O +
cells O +
to O +
cell O +
death O +
. O +

Inhibitor O +
of O +
differentiation O +
- O +
1 O +
( O +
I O -
d O +
- O +
1 O +
) O +
is O +
a O +
member O +
of O +
helix O +
- O +
loop O +
- O +
helix O +
( O +
HLH O +
) O +
family O +
of O +
proteins O +
that O +
regulate O +
gene O +
transcription O +
through O +
their O +
inhibitory O +
binding O +
to O +
basic O +
- O +
HLH O +
transcription O +
factors O +
. O +

Similarly O +
to O +
other O +
members O +
of O +
this O +
family O +
, O +
I O -
d O +
- O +
1 O +
is O +
involved O +
in O +
the O +
repression O +
of O +
cell O +
differentiation O +
and O +
activation O +
of O +
cell O +
growth O +
. O +

The O +
dual O +
function O +
of O +
I O -
d O +
- O +
1 O +
, O +
inhibition O +
of O +
differentiation O +
, O +
and O +
stimulation O +
of O +
cell O +
proliferation O +
, O +
might O +
be O +
interdependent O +
, O +
as O +
cell O +
differentiation O +
is O +
generally O +
coupled O +
with O +
the O +
exit O +
from O +
the O +
cell O +
cycle O +
. O +

Fibroblast O +
growth O +
factor O +
- O +
2 O +
( O +
FGF O +
- O +
2 O +
) O +
has O +
been O +
reported O +
to O +
play O +
multiple O +
roles O +
in O +
different O +
biological O +
processes O +
during O +
development O +
of O +
the O +
central O +
nervous O +
system O +
( O +
CNS O +
) O +
. O +

In O +
addition O +
, O +
FGF O +
- O +
2 O +
has O +
been O +
described O +
to O +
induce O +
" O +
neuronal O +
- O +
like O +
" O +
differentiation O +
and O +
trigger O +
apoptosis O +
in O +
neuroblastoma O +
SK B-CellLine +
- I-CellLine +
N I-CellLine +
- I-CellLine +
MC I-CellLine +
cells O +
. O +

Although O +
regulation O +
of O +
I O -
d O +
- O +
1 O +
protein O +
by O +
several O +
mitogenic O +
factors O +
is O +
well O +
- O +
established O +
, O +
little O +
is O +
known O +
about O +
the O +
role O +
of O +
FGF O +
- O +
2 O +
in O +
the O +
regulation O +
of O +
I O -
d O +
- O +
1 O +
. O +

Using O +
human O +
neuroblastoma O +
cell O +
line O +
, O +
SK B-CellLine +
- I-CellLine +
N I-CellLine +
- I-CellLine +
MC I-CellLine +
, O +
we O +
found O +
that O +
treatment O +
of O +
these O +
cells O +
with O +
FGF O +
- O +
2 O +
resulted O +
in O +
early O +
induction O +
of O +
both O +
I O -
d O +
- O +
1 O +
mRNA O +
and O +
protein O +
. O +

The O +
induction O +
occurs O +
within O +
1 O +
h O +
from O +
FGF O +
- O +
2 O +
treatment O +
and O +
is O +
mediated O +
by O +
ERK1 O +
/ O +
2 O +
pathway O +
, O +
which O +
in O +
turn O +
stimulates O +
expression O +
of O +
the O +
early O +
growth O +
response O +
- O +
1 O +
( O +
Egr O +
- O +
1 O +
) O +
transcription O +
factor O +
. O +

We O +
also O +
demonstrate O +
direct O +
interaction O +
of O +
Egr O +
- O +
1 O +
with O +
I O -
d O +
- O +
1 O +
promoter O +
in O +
vitro O +
and O +
in O +
cell O +
culture O +
. O +

Finally O +
, O +
inhibition O +
of O +
I O -
d O +
- O +
1 O +
expression O +
results O +
in O +
G O +
( O +
2 O +
) O +
/ O +
M O +
accumulation O +
of O +
FGF O +
- O +
2 O +
- O +
treated O +
cells O +
and O +
delayed O +
cell O +
death O +
. O +

Vimentin O +
is O +
preferentially O +
expressed O +
in O +
human O +
breast O +
carcinomas O +
with O +
low O +
estrogen O +
receptor O +
and O +
high O +
Ki O +
- O +
67 O +
growth O +
fraction O +
. O +

Vimentin O +
expression O +
, O +
growth O +
fractions O +
( O +
GF O +
) O +
, O +
and O +
estrogen O +
receptor O +
( O +
ER O +
) O +
levels O +
were O +
determined O +
for O +
90 O +
untreated O +
primary O +
breast O +
carcinomas O +
. O +

Coexpression O +
of O +
keratin O +
and O +
vimentin O +
was O +
found O +
in O +
approximately O +
20 O +
% O +
of O +
the O +
tumors O +
regardless O +
of O +
menopausal O +
status O +
. O +

Vimentin O +
was O +
expressed O +
preferentially O +
in O +
tumor O +
cells O +
of O +
high O +
- O +
grade O +
ductal O +
breast O +
carcinomas O +
( O +
15 O +
of O +
28 O +
histologic O +
grade O +
3 O +
vs O +
. O +
0 O +
of O +
40 O +
grades O +
1 O +
and O +
2 O +
) O +
. O +

Vimentin O +
expression O +
was O +
found O +
preferentially O +
in O +
tumors O +
with O +
high O +
GF O +
( O +
greater O +
than O +
15 O +
% O +
Ki O +
- O +
67 O +
positive O +
by O +
immunoperoxidase O +
staining O +
) O +
and O +
low O +
ER O +
levels O +
( O +
less O +
than O +
60 O +
fmols O +
/ O +
mg O +
protein O +
by O +
a O +
monoclonal O +
enzyme O +
immunoassay O +
) O +
. O +

Sixty O +
- O +
eight O +
percent O +
of O +
tumors O +
in O +
this O +
group O +
were O +
vimentin O +
positive O +
and O +
88 O +
% O +
of O +
all O +
vimentin O +
- O +
positive O +
tumors O +
fell O +
into O +
this O +
category O +
. O +

More O +
than O +
50 O +
% O +
of O +
the O +
tumor O +
cells O +
coexpressed O +
vimentin O +
and O +
keratin O +
. O +

Thus O +
, O +
vimentin O +
expression O +
may O +
be O +
helpful O +
in O +
identifying O +
a O +
substantial O +
subset O +
of O +
ER O +
- O +
independent O +
breast O +
carcinomas O +
with O +
poor O +
prognostic O +
indicators O +
. O +

High O +
- O +
mobility O +
group O +
A2 O +
protein O +
modulates O +
hTERT O +
transcription O +
to O +
promote O +
tumorigenesis O +
. O +

The O +
high O +
- O +
mobility O +
group O +
A2 O +
gene O +
( O +
HMGA2 O +
) O +
is O +
one O +
of O +
the O +
most O +
frequently O +
amplified O +
genes O +
in O +
human O +
cancers O +
. O +

However O +
, O +
functions O +
of O +
HMGA2 O +
in O +
tumorigenesis O +
are O +
not O +
fully O +
understood O +
due O +
to O +
limited O +
knowledge O +
of O +
its O +
targets O +
in O +
tumor O +
cells O +
. O +

Our O +
study O +
reveals O +
a O +
novel O +
link O +
between O +
HMGA2 O +
and O +
the O +
regulation O +
of O +
human O +
telomerase O +
reverse O +
transcriptase O +
( O +
hTERT O +
) O +
, O +
the O +
catalytic O +
subunit O +
of O +
telomerase O +
, O +
which O +
offers O +
critical O +
insight O +
into O +
how O +
HMGA2 O +
contributes O +
to O +
tumorigenesis O +
. O +

The O +
expression O +
of O +
HMGA2 O +
modulates O +
the O +
expression O +
of O +
hTERT O +
, O +
resulting O +
in O +
cells O +
with O +
enhanced O +
telomerase O +
activities O +
and O +
increased O +
telomere O +
length O +
. O +

Treatment O +
with O +
suberoylanilide O +
hydroxamide O +
( O +
SAHA O +
) O +
, O +
a O +
histone O +
deacetylase O +
( O +
HDAC O +
) O +
inhibitor O +
, O +
causes O +
dose O +
- O +
dependent O +
hTERT O +
reporter O +
activation O +
, O +
mimicking O +
HMGA2 O +
overexpression O +
. O +

By O +
interacting O +
with O +
Sp1 O +
, O +
HMGA2 O +
interferes O +
with O +
the O +
recruitment O +
of O +
HDAC2 O +
to O +
the O +
hTERT O +
proximal O +
promoter O +
, O +
enhancing O +
localized O +
histone O +
H3 O +
- O +
K9 O +
acetylation O +
and O +
thereby O +
stimulating O +
hTERT O +
expression O +
and O +
telomerase O +
activity O +
. O +

Moreover O +
, O +
HMGA2 O +
knockdown O +
by O +
short O +
hairpin O +
HMGA2 O +
in O +
HepG2 B-CellLine +
cells O +
leads O +
to O +
progressive O +
telomere O +
shortening O +
and O +
a O +
concurrent O +
decrease O +
of O +
steady O +
- O +
state O +
hTERT O +
mRNA O +
levels O +
, O +
attenuating O +
their O +
ability O +
to O +
form O +
colonies O +
in O +
soft O +
agar O +
. O +

Importantly O +
, O +
HMGA2 O +
partially O +
replaces O +
the O +
function O +
of O +
hTERT O +
during O +
the O +
tumorigenic O +
transformation O +
of O +
normal O +
human O +
fibroblasts O +
. O +

These O +
findings O +
are O +
potentially O +
clinically O +
relevant O +
, O +
because O +
HMGA2 O +
expression O +
is O +
reported O +
to O +
be O +
upregulated O +
in O +
a O +
number O +
of O +
human O +
cancers O +
as O +
telomere O +
maintenance O +
is O +
essential O +
for O +
tumorigenesis O +
. O +

3 O +
- O +
[ O +
( O +
Methyl O +
- O +
carbamo O +
- O +
yl O +
) O +
amino O +
] O +
- O +
1H O +
- O +
isoindolium O +
chloride O +
. O +

The O +
title O +
compound O +
, O +
C O +
( O +
10 O +
) O +
H O +
( O +
12 O +
) O +
N O +
( O +
3 O +
) O +
O O +
( O +
+ O +
) O +
. O +
Cl O +
( O +
- O +
) O +
, O +
is O +
a O +
derivative O +
of O +
o O +
- O +
phthaldehyde O +
and O +
methyl O +
- O +
thio O +
- O +
urea O +
. O +

The O +
mol O +
- O +
ecules O +
form O +
dimers O +
through O +
intra O +
- O +
and O +
inter O +
- O +
molecular O +
N O +
- O +
H O +
. O +
. O +
. O +
O O +
hydrogen O +
bonds O +
. O +

The O +
dimers O +
are O +
further O +
linked O +
into O +
chains O +
through O +
one O +
C O +
- O +
H O +
. O +
. O +
. O +
Cl O +
and O +
two O +
N O +
- O +
H O +
. O +
. O +
. O +
Cl O +
hydrogen O +
bonds O +
. O +

mirAct O +
: O +
a O +
web O +
tool O +
for O +
evaluating O +
microRNA O +
activity O +
based O +
on O +
gene O +
expression O +
data O +
. O +

MicroRNAs O +
( O +
miRNAs O +
) O +
are O +
critical O +
regulators O +
in O +
the O +
complex O +
cellular O +
networks O +
. O +

The O +
mirAct O +
web O +
server O +
( O +
http O +
: O +
/ O +
/ O +
sysbio O +
. O +
ustc O +
. O +
edu O +
. O +
cn O +
/ O +
software O +
/ O +
mirAct O +
) O +
is O +
a O +
tool O +
designed O +
to O +
investigate O +
miRNA O +
activity O +
based O +
on O +
gene O +
- O +
expression O +
data O +
by O +
using O +
the O +
negative O +
regulation O +
relationship O +
between O +
miRNAs O +
and O +
their O +
target O +
genes O +
. O +

mirAct O +
supports O +
multiple O +
- O +
class O +
data O +
and O +
enables O +
clustering O +
analysis O +
based O +
on O +
computationally O +
determined O +
miRNA O +
activity O +
. O +

Here O +
, O +
we O +
describe O +
the O +
framework O +
of O +
mirAct O +
, O +
demonstrate O +
its O +
performance O +
by O +
comparing O +
with O +
other O +
similar O +
programs O +
and O +
exemplify O +
its O +
applications O +
using O +
case O +
studies O +
. O +

Non O +
- O +
heart O +
- O +
beating O +
organ O +
donation O +
in O +
Italy O +
. O +

In O +
2007 O +
the O +
non O +
- O +
heart O +
- O +
beating O +
organ O +
donation O +
( O +
NHBD O +
) O +
" O +
Programma O +
Alba O +
" O +
( O +
Sunrise O +
Programme O +
) O +
started O +
in O +
Pavia O +
, O +
Italy O +
. O +

The O +
initial O +
plan O +
was O +
to O +
cut O +
down O +
waiting O +
list O +
for O +
kidney O +
transplantation O +
, O +
while O +
its O +
final O +
aim O +
is O +
to O +
shorten O +
organ O +
transplantation O +
waiting O +
lists O +
. O +

When O +
compared O +
to O +
European O +
countries O +
and O +
the O +
USA O +
, O +
the O +
Italian O +
NHBD O +
program O +
has O +
taken O +
longer O +
to O +
get O +
established O +
. O +

Initially O +
Italian O +
physicians O +
were O +
not O +
entirely O +
aware O +
of O +
the O +
NHBD O +
organ O +
viability O +
for O +
transplantation O +
, O +
furthermore O +
ethical O +
issues O +
and O +
the O +
need O +
to O +
regulate O +
medical O +
requirements O +
to O +
Italian O +
law O +
slowed O +
down O +
the O +
NHBD O +
program O +
. O +

In O +
particular O +
, O +
Italian O +
legislation O +
provides O +
for O +
death O +
ascertainment O +
after O +
irreversible O +
cardiac O +
arrest O +
, O +
20 O +
- O +
minute O +
flat O +
electrocardiogram O +
. O +

This O +
no O +
- O +
touch O +
period O +
is O +
longer O +
when O +
compared O +
to O +
worldwide O +
legislation O +
, O +
and O +
organ O +
viability O +
has O +
been O +
a O +
main O +
concern O +
for O +
Italian O +
transplant O +
doctors O +
over O +
the O +
years O +
. O +

However O +
, O +
recent O +
data O +
let O +
up O +
to O +
40 O +
- O +
minute O +
warm O +
ischemia O +
time O +
to O +
preserve O +
organ O +
viability O +
; O +
this O +
has O +
encouraged O +
Pavia O +
' O +
s O +
group O +
to O +
establish O +
the O +
NHBD O +
" O +
Programma O +
Alba O +
" O +
. O +

It O +
was O +
designed O +
according O +
to O +
Italian O +
legislation O +
from O +
death O +
diagnosis O +
to O +
graft O +
placement O +
, O +
from O +
this O +
perspective O +
must O +
the O +
significant O +
role O +
of O +
the O +
Transplant O +
coordinator O +
be O +
recognized O +
. O +

Since O +
2007 O +
seven O +
kidneys O +
have O +
been O +
gathered O +
from O +
seven O +
NHBD O +
. O +

Of O +
these O +
, O +
six O +
NHBD O +
kidneys O +
have O +
been O +
transplanted O +
. O +

Currently O +
, O +
four O +
patients O +
are O +
out O +
of O +
dialysis O +
. O +

This O +
report O +
is O +
a O +
detailed O +
description O +
of O +
NHBD O +
" O +
Programma O +
Alba O +
" O +
and O +
its O +
preliminary O +
results O +
. O +

KISS1 O +
methylation O +
and O +
expression O +
as O +
tumor O +
stratification O +
biomarkers O +
and O +
clinical O +
outcome O +
prognosticators O +
for O +
bladder O +
cancer O +
patients O +
. O +

KISS1 O +
is O +
a O +
metastasis O +
suppressor O +
gene O +
that O +
is O +
lost O +
in O +
several O +
malignancies O +
, O +
including O +
bladder O +
cancer O +
. O +

We O +
tested O +
the O +
epigenetic O +
silencing O +
hypothesis O +
and O +
evaluated O +
the O +
biological O +
influence O +
of O +
KISS1 O +
methylation O +
on O +
its O +
expression O +
and O +
clinical O +
relevance O +
in O +
bladder O +
cancer O +
. O +

KISS1 O +
hypermethylation O +
was O +
frequent O +
in O +
bladder O +
cancer O +
cells O +
analyzed O +
by O +
methylation O +
- O +
specific O +
PCR O +
and O +
bisulfite O +
sequencing O +
and O +
was O +
associated O +
with O +
low O +
gene O +
expression O +
, O +
being O +
restored O +
in O +
vitro O +
by O +
demethylating O +
azacytidine O +
. O +

Hypermethylation O +
was O +
also O +
frequently O +
observed O +
in O +
a O +
large O +
series O +
of O +
bladder O +
tumors O +
( O +
83 O +
. O +
1 O +
% O +
, O +
n O +
= O +
804 O +
) O +
. O +

KISS1 O +
methylation O +
was O +
associated O +
with O +
increasing O +
stage O +
( O +
P O +
= O +
0 O +
. O +
001 O +
) O +
and O +
tumor O +
grade O +
( O +
P O +
= O +
0 O +
. O +
010 O +
) O +
. O +

KISS1 O +
methylation O +
was O +
associated O +
with O +
low O +
KISS1 O +
transcript O +
expression O +
by O +
quantitative O +
RT O +
- O +
PCR O +
( O +
P O +
= O +
0 O +
. O +
037 O +
) O +
. O +

KISS1 O +
transcript O +
expression O +
was O +
also O +
associated O +
with O +
histopathological O +
tumor O +
stage O +
( O +
P O +
< O +
0 O +
. O +
0005 O +
) O +
. O +

Low O +
transcript O +
expression O +
alone O +
( O +
P O +
= O +
0 O +
. O +
003 O +
) O +
or O +
combined O +
with O +
methylation O +
( O +
P O +
= O +
0 O +
. O +
019 O +
) O +
was O +
associated O +
with O +
poor O +
disease O +
- O +
specific O +
survival O +
( O +
n O +
= O +
205 O +
) O +
. O +

KISS1 O +
transcript O +
expression O +
remained O +
an O +
independent O +
prognosticator O +
in O +
multivariate O +
analyses O +
( O +
P O +
= O +
0 O +
. O +
017 O +
) O +
. O +

KISS1 O +
hypermethylation O +
was O +
identified O +
in O +
bladder O +
cancer O +
, O +
providing O +
a O +
potential O +
mechanistic O +
explanation O +
( O +
epigenetic O +
silencing O +
) O +
for O +
the O +
observed O +
loss O +
of O +
KISS1 O +
in O +
uroepithelial O +
malignancies O +
. O +

Associations O +
of O +
KISS1 O +
methylation O +
and O +
its O +
expression O +
with O +
histopathological O +
variables O +
and O +
poor O +
survival O +
suggest O +
the O +
utility O +
of O +
incorporating O +
KISS1 O +
measurement O +
using O +
paraffin O +
- O +
embedded O +
material O +
for O +
tumor O +
stratification O +
and O +
clinical O +
outcome O +
prognosis O +
of O +
patients O +
with O +
uroepithelial O +
neoplasias O +
. O +

Oscillatory O +
alpha O +
- O +
band O +
mechanisms O +
and O +
the O +
deployment O +
of O +
spatial O +
attention O +
to O +
anticipated O +
auditory O +
and O +
visual O +
target O +
locations O +
: O +
supramodal O +
or O +
sensory O +
- O +
specific O +
control O +
mechanisms O +
? O +

Oscillatory O +
alpha O +
- O +
band O +
activity O +
( O +
8 O +
- O +
15 O +
Hz O +
) O +
over O +
parieto O +
- O +
occipital O +
cortex O +
in O +
humans O +
plays O +
an O +
important O +
role O +
in O +
suppression O +
of O +
processing O +
for O +
inputs O +
at O +
to O +
- O +
be O +
- O +
ignored O +
regions O +
of O +
space O +
, O +
with O +
increased O +
alpha O +
- O +
band O +
power O +
observed O +
over O +
cortex O +
contralateral O +
to O +
locations O +
expected O +
to O +
contain O +
distractors O +
. O +

It O +
is O +
unclear O +
whether O +
similar O +
processes O +
operate O +
during O +
deployment O +
of O +
spatial O +
attention O +
in O +
other O +
sensory O +
modalities O +
. O +

Evidence O +
from O +
lesion O +
patients O +
suggests O +
that O +
parietal O +
regions O +
house O +
supramodal O +
representations O +
of O +
space O +
. O +

The O +
parietal O +
lobes O +
are O +
prominent O +
generators O +
of O +
alpha O +
oscillations O +
, O +
raising O +
the O +
possibility O +
that O +
alpha O +
is O +
a O +
neural O +
signature O +
of O +
supramodal O +
spatial O +
attention O +
. O +

Furthermore O +
, O +
when O +
spatial O +
attention O +
is O +
deployed O +
within O +
vision O +
, O +
processing O +
of O +
task O +
- O +
irrelevant O +
auditory O +
inputs O +
at O +
attended O +
locations O +
is O +
also O +
enhanced O +
, O +
pointing O +
to O +
automatic O +
links O +
between O +
spatial O +
deployments O +
across O +
senses O +
. O +

Here O +
, O +
we O +
asked O +
whether O +
lateralized O +
alpha O +
- O +
band O +
activity O +
is O +
also O +
evident O +
in O +
a O +
purely O +
auditory O +
spatial O +
- O +
cueing O +
task O +
and O +
whether O +
it O +
had O +
the O +
same O +
underlying O +
generator O +
configuration O +
as O +
in O +
a O +
purely O +
visuospatial O +
task O +
. O +

If O +
common O +
to O +
both O +
sensory O +
systems O +
, O +
this O +
would O +
provide O +
strong O +
support O +
for O +
" O +
supramodal O +
" O +
attention O +
theory O +
. O +

Alternately O +
, O +
alpha O +
- O +
band O +
differences O +
between O +
auditory O +
and O +
visual O +
tasks O +
would O +
support O +
a O +
sensory O +
- O +
specific O +
account O +
. O +

Lateralized O +
shifts O +
in O +
alpha O +
- O +
band O +
activity O +
were O +
indeed O +
observed O +
during O +
a O +
purely O +
auditory O +
spatial O +
task O +
. O +

Crucially O +
, O +
there O +
were O +
clear O +
differences O +
in O +
scalp O +
topographies O +
of O +
this O +
alpha O +
activity O +
depending O +
on O +
the O +
sensory O +
system O +
within O +
which O +
spatial O +
attention O +
was O +
deployed O +
. O +

Findings O +
suggest O +
that O +
parietally O +
generated O +
alpha O +
- O +
band O +
mechanisms O +
are O +
central O +
to O +
attentional O +
deployments O +
across O +
modalities O +
but O +
that O +
they O +
are O +
invoked O +
in O +
a O +
sensory O +
- O +
specific O +
manner O +
. O +

The O +
data O +
support O +
an O +
" O +
interactivity O +
account O +
, O +
" O +
whereby O +
a O +
supramodal O +
system O +
interacts O +
with O +
sensory O +
- O +
specific O +
control O +
systems O +
during O +
deployment O +
of O +
spatial O +
attention O +
. O +

[ O +
Expression O +
of O +
Merlin O +
protein O +
in O +
non O +
- O +
small O +
cell O +
lung O +
carcinoma O +
and O +
the O +
clinical O +
significance O +
] O +
. O +

OBJECTIVE O +
: O +
To O +
determine O +
the O +
expression O +
and O +
clinical O +
significance O +
of O +
Merlin O +
protein O +
in O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
( O +
NSCLC O +
) O +
. O +

METHODS O +
: O +
The O +
expression O +
of O +
Merlin O +
protein O +
in O +
45 O +
cases O +
of O +
NSCLC O +
and O +
adjacent O +
tissue O +
of O +
NSCLC O +
and O +
normal O +
lung O +
tissue O +
was O +
checked O +
by O +
immunohistochemistry O +
. O +

The O +
relation O +
between O +
the O +
expression O +
of O +
Merlin O +
protein O +
and O +
the O +
multiple O +
factors O +
of O +
pathological O +
type O +
, O +
gender O +
, O +
P O +
- O +
TNM O +
stage O +
, O +
differentiation O +
and O +
lymph O +
node O +
metastasis O +
was O +
analyzed O +
. O +

RESULTS O +
: O +
The O +
expression O +
rates O +
of O +
Merlin O +
protein O +
in O +
NSCLC O +
and O +
normal O +
lung O +
tissue O +
sections O +
were O +
73 O +
. O +
33 O +
% O +
and O +
15 O +
. O +
56 O +
% O +
, O +
respectively O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

The O +
expression O +
of O +
Merlin O +
protein O +
was O +
not O +
associated O +
with O +
the O +
pathological O +
type O +
, O +
gender O +
, O +
P O +
- O +
TNM O +
stage O +
, O +
differentiation O +
and O +
lymph O +
node O +
metastasis O +
( O +
P O +
> O +
0 O +
. O +
05 O +
) O +
. O +

CONCLUSION O +
: O +
Merlin O +
protein O +
might O +
contribute O +
to O +
the O +
initiation O +
of O +
metastasis O +
of O +
NSCLC O +
. O +

The O +
members O +
of O +
an O +
Epstein O +
- O +
Barr O +
virus O +
microRNA O +
cluster O +
cooperate O +
to O +
transform O +
B O +
lymphocytes O +
. O +

Epstein O +
- O +
Barr O +
virus O +
( O +
EBV O +
) O +
transforms O +
B O +
lymphocytes O +
through O +
the O +
expression O +
of O +
the O +
latent O +
viral O +
proteins O +
EBNA O +
and O +
latent O +
membrane O +
protein O +
( O +
LMP O +
) O +
. O +

Recently O +
, O +
it O +
has O +
become O +
apparent O +
that O +
microRNAs O +
( O +
miRNAs O +
) O +
also O +
contribute O +
to O +
EBV O +
' O +
s O +
oncogenic O +
properties O +
; O +
recombinant O +
EBVs O +
that O +
lack O +
the O +
BHRF1 O +
miRNA O +
cluster O +
display O +
a O +
reduced O +
ability O +
to O +
transform O +
B O +
lymphocytes O +
in O +
vitro O +
. O +

Furthermore O +
, O +
infected O +
cells O +
evince O +
a O +
marked O +
upregulation O +
of O +
the O +
EBNA O +
genes O +
. O +

Using O +
recombinant O +
viruses O +
that O +
lack O +
only O +
one O +
member O +
of O +
the O +
cluster O +
, O +
we O +
now O +
show O +
that O +
all O +
three O +
BHRF1 O +
miRNAs O +
contribute O +
to O +
B O +
- O +
cell O +
transformation O +
. O +

Recombinants O +
that O +
lacked O +
miR O +
- O +
BHRF1 O +
- O +
2 O +
or O +
miR O +
- O +
BHRF1 O +
- O +
3 O +
displayed O +
enhanced O +
EBNA O +
expression O +
initiated O +
at O +
the O +
Cp O +
and O +
Wp O +
promoters O +
. O +

Interestingly O +
, O +
we O +
find O +
that O +
the O +
deletion O +
of O +
miR O +
- O +
BHRF1 O +
- O +
2 O +
reduced O +
the O +
expression O +
level O +
of O +
miR O +
- O +
BHRF1 O +
- O +
3 O +
and O +
possibly O +
that O +
of O +
miR O +
- O +
BHRF1 O +
- O +
1 O +
, O +
demonstrating O +
that O +
the O +
expression O +
of O +
one O +
miRNA O +
can O +
potentiate O +
the O +
expression O +
of O +
other O +
miRNAs O +
located O +
in O +
the O +
same O +
cluster O +
. O +

Therefore O +
, O +
the O +
phenotypic O +
traits O +
of O +
the O +
miR O +
- O +
BHRF1 O +
- O +
2 O +
null O +
mutant O +
could O +
result O +
partly O +
from O +
reduced O +
miR O +
- O +
BHRF1 O +
- O +
1 O +
and O +
miR O +
- O +
BHRF1 O +
- O +
3 O +
expression O +
levels O +
. O +

Nevertheless O +
, O +
using O +
an O +
miR O +
- O +
BHRF1 O +
- O +
1 O +
and O +
miR O +
- O +
BHRF1 O +
- O +
3 O +
double O +
mutant O +
, O +
we O +
could O +
directly O +
assess O +
and O +
confirm O +
the O +
contribution O +
of O +
miR O +
- O +
BHRF1 O +
- O +
2 O +
to O +
B O +
- O +
cell O +
transformation O +
. O +

Furthermore O +
, O +
we O +
found O +
that O +
the O +
potentiating O +
effect O +
of O +
miR O +
- O +
BHRF1 O +
- O +
2 O +
on O +
miR O +
- O +
BHRF1 O +
- O +
3 O +
synthesis O +
can O +
be O +
reproduced O +
with O +
simple O +
expression O +
plasmids O +
, O +
provided O +
that O +
both O +
miRNAs O +
are O +
processed O +
from O +
the O +
same O +
transcript O +
. O +

Therefore O +
, O +
this O +
enhancing O +
effect O +
does O +
not O +
result O +
from O +
an O +
idiosyncrasy O +
of O +
the O +
EBV O +
genome O +
but O +
rather O +
reflects O +
a O +
general O +
property O +
of O +
these O +
miRNAs O +
. O +

This O +
study O +
highlights O +
the O +
advantages O +
of O +
arranging O +
the O +
BHRF1 O +
miRNAs O +
in O +
clusters O +
: O +
it O +
allows O +
the O +
synchronous O +
and O +
synergistic O +
expression O +
of O +
genetic O +
elements O +
that O +
cooperate O +
to O +
transform O +
their O +
target O +
cells O +
. O +

Hedgehog O +
signaling O +
: O +
networking O +
to O +
nurture O +
a O +
promalignant O +
tumor O +
microenvironment O +
. O +

In O +
addition O +
to O +
its O +
role O +
in O +
embryonic O +
development O +
, O +
the O +
Hedgehog O +
pathway O +
has O +
been O +
shown O +
to O +
be O +
an O +
active O +
participant O +
in O +
cancer O +
development O +
, O +
progression O +
, O +
and O +
metastasis O +
. O +

Although O +
this O +
pathway O +
is O +
activated O +
by O +
autocrine O +
signaling O +
by O +
Hedgehog O +
ligands O +
, O +
it O +
can O +
also O +
initiate O +
paracrine O +
signaling O +
with O +
cells O +
in O +
the O +
microenvironment O +
. O +

This O +
creates O +
a O +
network O +
of O +
Hedgehog O +
signaling O +
that O +
determines O +
the O +
malignant O +
behavior O +
of O +
the O +
tumor O +
cells O +
. O +

As O +
a O +
result O +
of O +
paracrine O +
signal O +
transmission O +
, O +
the O +
effects O +
of O +
Hedgehog O +
signaling O +
most O +
profoundly O +
influence O +
the O +
stromal O +
cells O +
that O +
constitute O +
the O +
tumor O +
microenvironment O +
. O +

The O +
stromal O +
cells O +
in O +
turn O +
produce O +
factors O +
that O +
nurture O +
the O +
tumor O +
. O +

Thus O +
, O +
such O +
a O +
resonating O +
cross O +
- O +
talk O +
can O +
amplify O +
Hedgehog O +
signaling O +
, O +
resulting O +
in O +
molecular O +
chatter O +
that O +
overall O +
promotes O +
tumor O +
progression O +
. O +

Inhibitors O +
of O +
Hedgehog O +
signaling O +
have O +
been O +
the O +
subject O +
of O +
intense O +
research O +
. O +

Several O +
of O +
these O +
inhibitors O +
are O +
currently O +
being O +
evaluated O +
in O +
clinical O +
trials O +
. O +

Here O +
, O +
we O +
review O +
the O +
role O +
of O +
the O +
Hedgehog O +
pathway O +
in O +
the O +
signature O +
characteristics O +
of O +
cancer O +
cells O +
that O +
determine O +
tumor O +
development O +
, O +
progression O +
, O +
and O +
metastasis O +
. O +

This O +
review O +
condenses O +
the O +
latest O +
findings O +
on O +
the O +
signaling O +
pathways O +
that O +
are O +
activated O +
and O +
/ O +
or O +
regulated O +
by O +
molecules O +
generated O +
from O +
Hedgehog O +
signaling O +
in O +
cancer O +
and O +
cites O +
promising O +
clinical O +
interventions O +
. O +

Finally O +
, O +
we O +
discuss O +
future O +
directions O +
for O +
identifying O +
the O +
appropriate O +
patients O +
for O +
therapy O +
, O +
developing O +
reliable O +
markers O +
of O +
efficacy O +
of O +
treatment O +
, O +
and O +
combating O +
resistance O +
to O +
Hedgehog O +
pathway O +
inhibitors O +
. O +

Analysis O +
of O +
molecular O +
aberrations O +
of O +
Wnt O +
pathway O +
gladiators O +
in O +
colorectal O +
cancer O +
in O +
the O +
Kashmiri O +
population O +
. O +

The O +
development O +
and O +
progression O +
of O +
colorectal O +
cancer O +
( O +
CRC O +
) O +
is O +
a O +
multi O +
- O +
step O +
process O +
, O +
and O +
the O +
Wnt O +
pathways O +
with O +
its O +
two O +
molecular O +
gladiators O +
adenomatous O +
polyposis O +
coli O +
( O +
APC O +
) O +
and O +
beta O +
- O +
catenin O +
plays O +
an O +
important O +
role O +
in O +
transforming O +
a O +
normal O +
tissue O +
into O +
a O +
malignant O +
one O +
. O +

In O +
this O +
study O +
, O +
we O +
aimed O +
to O +
investigate O +
the O +
role O +
of O +
aberrations O +
in O +
the O +
APC O +
and O +
beta O +
- O +
catenin O +
genes O +
in O +
the O +
pathogenesis O +
of O +
CRC O +
in O +
the O +
Kashmir O +
valley O +
, O +
and O +
to O +
correlate O +
it O +
with O +
various O +
clinicopathological O +
variables O +
. O +

We O +
examined O +
the O +
paired O +
tumour O +
and O +
normal O +
- O +
tissue O +
specimens O +
of O +
86 O +
CRC O +
patients O +
for O +
the O +
occurrence O +
of O +
aberrations O +
in O +
the O +
mutation O +
cluster O +
region O +
( O +
MCR O +
) O +
of O +
the O +
APC O +
gene O +
and O +
exon O +
3 O +
of O +
the O +
beta O +
- O +
catenin O +
gene O +
by O +
polymerase O +
chain O +
reaction O +
- O +
single O +
- O +
strand O +
conformation O +
polymorphism O +
( O +
PCR O +
- O +
SSCP O +
) O +
and O +
/ O +
or O +
PCR O +
- O +
direct O +
sequencing O +
. O +

Analysis O +
of O +
promoter O +
hypermethylation O +
of O +
the O +
APC O +
gene O +
was O +
also O +
carried O +
out O +
using O +
methylation O +
- O +
specific O +
PCR O +
( O +
MS O +
- O +
PCR O +
) O +
. O +

The O +
overall O +
mutation O +
rate O +
of O +
the O +
MCR O +
of O +
the O +
APC O +
gene O +
among O +
86 O +
CRC O +
cases O +
was O +
12 O +
. O +
8 O +
per O +
cent O +
( O +
11 O +
of O +
86 O +
) O +
. O +

Promoter O +
hypermethylation O +
of O +
APC O +
was O +
observed O +
in O +
54 O +
. O +
65 O +
per O +
cent O +
( O +
47 O +
of O +
86 O +
) O +
of O +
cases O +
. O +

Furthermore O +
, O +
we O +
found O +
a O +
significant O +
association O +
between O +
tumour O +
location O +
, O +
tumour O +
grade O +
and O +
node O +
status O +
and O +
the O +
methylation O +
status O +
of O +
the O +
APC O +
gene O +
( O +
p O +
< O +
= O +
0 O +
. O +
05 O +
) O +
. O +

Although O +
the O +
number O +
of O +
mutations O +
in O +
the O +
APC O +
and O +
beta O +
- O +
catenin O +
genes O +
in O +
our O +
CRC O +
cases O +
was O +
very O +
low O +
, O +
the O +
study O +
confirms O +
the O +
role O +
of O +
epigenetic O +
gene O +
silencing O +
of O +
the O +
pivotal O +
molecular O +
gladiator O +
, O +
APC O +
, O +
of O +
the O +
Wnt O +
pathway O +
in O +
the O +
development O +
of O +
CRC O +
in O +
the O +
Kashmiri O +
population O +
. O +

Massive O +
osteolysis O +
in O +
a O +
dog O +
resembling O +
Gorham O +
' O +
s O +
disease O +
in O +
humans O +
. O +

An O +
eight O +
- O +
month O +
- O +
old O +
mixed O +
- O +
breed O +
dog O +
was O +
presented O +
with O +
a O +
history O +
of O +
sudden O +
onset O +
pelvic O +
limb O +
lameness O +
. O +

Radiographic O +
and O +
computed O +
tomographic O +
examinations O +
demonstrated O +
an O +
osteolytic O +
process O +
involving O +
the O +
lumbar O +
spine O +
and O +
pelvis O +
. O +

A O +
comprehensive O +
work O +
- O +
up O +
including O +
serial O +
radiographic O +
skeletal O +
survey O +
, O +
biopsy O +
, O +
routine O +
laboratory O +
investigation O +
and O +
evaluation O +
of O +
parathyroid O +
hormone O +
( O +
PTH O +
) O +
and O +
25 O +
- O +
hydroxy O +
- O +
vitamin O +
D O +
levels O +
failed O +
to O +
reveal O +
any O +
underlying O +
cause O +
for O +
the O +
osteolysis O +
. O +

Conservative O +
treatment O +
using O +
the O +
bisphosphonate O +
drug O +
alendronate O +
and O +
oral O +
analgesic O +
medications O +
resulted O +
in O +
a O +
return O +
to O +
nearly O +
normal O +
long O +
- O +
term O +
function O +
, O +
despite O +
massive O +
lumbar O +
and O +
pelvic O +
osteolysis O +
. O +

The O +
clinical O +
, O +
radiological O +
and O +
histopathological O +
features O +
in O +
this O +
dog O +
are O +
reported O +
, O +
and O +
similarities O +
with O +
the O +
human O +
condition O +
known O +
as O +
Gorham O +
' O +
s O +
disease O +
are O +
discussed O +
. O +

Correlation O +
of O +
lymphatic O +
vessel O +
density O +
and O +
vascular O +
endothelial O +
growth O +
factor O +
with O +
nodal O +
metastasis O +
in O +
papillary O +
thyroid O +
microcarcinoma O +
. O +

BACKGROUND O +
: O +
The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
not O +
only O +
the O +
intratumoral O +
and O +
peritumoral O +
lymphatic O +
vessel O +
density O +
( O +
ILD O +
and O +
PLD O +
) O +
but O +
also O +
the O +
expression O +
of O +
vascular O +
endothelial O +
growth O +
factors O +
( O +
VEGFs O +
) O +
and O +
to O +
test O +
their O +
correlation O +
with O +
regional O +
lymph O +
nodal O +
metastases O +
in O +
papillary O +
thyroid O +
microcarcinoma O +
( O +
PTMC O +
) O +
. O +

METHODS O +
: O +
A O +
clinicopathologic O +
data O +
review O +
was O +
performed O +
in O +
60 O +
patients O +
with O +
PTMC O +
treated O +
with O +
total O +
thyroidectomies O +
involving O +
neck O +
dissections O +
. O +

The O +
patterns O +
of O +
lymphatic O +
vessels O +
, O +
the O +
expression O +
of O +
VEGFs O +
, O +
and O +
their O +
correlation O +
with O +
neck O +
metastases O +
were O +
assessed O +
. O +

RESULTS O +
: O +
PLD O +
was O +
significantly O +
higher O +
than O +
ILD O +
( O +
p O +
< O +
. O +
001 O +
) O +
. O +

Patients O +
with O +
high O +
PLD O +
( O +
> O +
8 O +
. O +
0 O +
) O +
showed O +
higher O +
rates O +
of O +
neck O +
metastases O +
than O +
low O +
PLD O +
( O +
< O +
= O +
8 O +
. O +
0 O +
) O +
( O +
74 O +
. O +
0 O +
% O +
vs O +
46 O +
. O +
8 O +
% O +
, O +
p O +
= O +
. O +
03 O +
) O +
. O +

Univariate O +
and O +
multivariate O +
analyses O +
revealed O +
high O +
PLD O +
as O +
the O +
only O +
independent O +
variable O +
predictive O +
of O +
neck O +
metastasis O +
. O +

The O +
expression O +
of O +
VEGFs O +
did O +
not O +
correlate O +
with O +
either O +
lymphatic O +
density O +
or O +
neck O +
metastasis O +
. O +

CONCLUSIONS O +
: O +
PLD O +
may O +
be O +
of O +
potential O +
benefit O +
in O +
the O +
prediction O +
of O +
neck O +
metastasis O +
in O +
PTMC O +
. O +

Inhibition O +
of O +
autophagy O +
potentiates O +
the O +
antitumor O +
effect O +
of O +
the O +
multikinase O +
inhibitor O +
sorafenib O +
in O +
hepatocellular O +
carcinoma O +
. O +

Multikinase O +
inhibitor O +
sorafenib O +
inhibits O +
proliferation O +
and O +
angiogenesis O +
of O +
tumors O +
by O +
suppressing O +
the O +
Raf O +
/ O +
MEK O +
/ O +
ERK O +
signaling O +
pathway O +
and O +
VEGF O +
receptor O +
tyrosine O +
kinase O +
. O +

It O +
significantly O +
prolongs O +
median O +
survival O +
of O +
patients O +
with O +
advanced O +
hepatocellular O +
carcinoma O +
( O +
HCC O +
) O +
but O +
the O +
response O +
is O +
disease O +
- O +
stabilizing O +
and O +
cytostatic O +
rather O +
than O +
one O +
of O +
tumor O +
regression O +
. O +

To O +
examine O +
the O +
mechanisms O +
underlying O +
the O +
relative O +
resistance O +
in O +
HCC O +
, O +
we O +
investigated O +
the O +
role O +
of O +
autophagy O +
, O +
an O +
evolutionarily O +
conserved O +
self O +
- O +
digestion O +
pathway O +
, O +
in O +
hepatoma O +
cells O +
in O +
vitro O +
and O +
in O +
vivo O +
. O +

Sorafenib O +
treatment O +
led O +
to O +
accumulation O +
of O +
autophagosomes O +
as O +
evidenced O +
by O +
conversion O +
from O +
LC3 O +
- O +
I O +
to O +
LC3 O +
- O +
II O +
observed O +
by O +
immunoblot O +
in O +
Huh7 B-CellLine +
, O +
HLF B-CellLine +
and O +
PLC B-CellLine +
/ I-CellLine +
PRF I-CellLine +
/ I-CellLine +
5 I-CellLine +
cells O +
. O +

This O +
induction O +
was O +
due O +
to O +
activation O +
of O +
autophagic O +
flux O +
, O +
as O +
there O +
was O +
further O +
increase O +
in O +
LC3 O +
- O +
II O +
expression O +
upon O +
treatment O +
with O +
lysosomal O +
inhibitors O +
, O +
clear O +
decline O +
of O +
the O +
autophagy O +
substrate O +
p62 O +
, O +
and O +
an O +
mRFP O +
- O +
GFP O +
- O +
LC3 O +
fluorescence O +
change O +
in O +
sorafenib O +
- O +
treated O +
hepatoma O +
cells O +
. O +

Sorafenib O +
inhibited O +
the O +
mammalian O +
target O +
of O +
rapamycin O +
complex O +
1 O +
and O +
its O +
inhibition O +
led O +
to O +
accumulation O +
of O +
LC3 O +
- O +
II O +
. O +

Pharmacological O +
inhibition O +
of O +
autophagic O +
flux O +
by O +
chloroquine O +
increased O +
apoptosis O +
and O +
decreased O +
cell O +
viability O +
in O +
hepatoma O +
cells O +
. O +

siRNA O +
- O +
mediated O +
knockdown O +
of O +
the O +
ATG7 O +
gene O +
also O +
sensitized O +
hepatoma O +
cells O +
to O +
sorafenib O +
. O +

Finally O +
, O +
sorafenib O +
induced O +
autophagy O +
in O +
Huh7 B-CellLine +
xenograft O +
tumors O +
in O +
nude O +
mice O +
and O +
coadministration O +
with O +
chloroquine O +
significantly O +
suppressed O +
tumor O +
growth O +
compared O +
with O +
sorafenib O +
alone O +
. O +

In O +
conclusion O +
, O +
sorafenib O +
administration O +
induced O +
autophagosome O +
formation O +
and O +
enhanced O +
autophagic O +
activity O +
, O +
which O +
conferred O +
a O +
survival O +
advantage O +
to O +
hepatoma O +
cells O +
. O +

Concomitant O +
inhibition O +
of O +
autophagy O +
may O +
be O +
an O +
attractive O +
strategy O +
for O +
unlocking O +
the O +
antitumor O +
potential O +
of O +
sorafenib O +
in O +
HCC O +
. O +

Desensitization O +
of O +
prostaglandin O +
F2 O +
alpha O +
- O +
stimulated O +
inositol O +
phosphate O +
generation O +
in O +
NIH B-CellLine +
- I-CellLine +
3T3 I-CellLine +
fibroblasts O +
transformed O +
by O +
overexpression O +
of O +
normal O +
c O +
- O +
Ha O +
- O +
ras O +
- O +
1 O +
, O +
c O +
- O +
Ki O +
- O +
ras O +
- O +
2 O +
and O +
c O +
- O +
N O +
- O +
ras O +
genes O +
. O +

The O +
stimulation O +
of O +
inositol O +
phosphate O +
generation O +
in O +
control O +
and O +
ras O +
- O +
gene O +
- O +
transformed O +
NIH B-CellLine +
- I-CellLine +
3T3 I-CellLine +
cells O +
by O +
prostaglandin O +
F2 O +
alpha O +
( O +
PGF2 O +
alpha O +
) O +
was O +
investigated O +
. O +

Compared O +
with O +
the O +
control O +
cells O +
, O +
a O +
desensitization O +
of O +
the O +
response O +
was O +
observed O +
in O +
cells O +
transformed O +
by O +
the O +
overexpression O +
of O +
N O +
- O +
, O +
Ha O +
- O +
, O +
or O +
Ki O +
- O +
ras O +
genes O +
. O +

This O +
desensitization O +
was O +
without O +
effect O +
upon O +
the O +
concentration O +
causing O +
half O +
- O +
maximal O +
effect O +
( O +
EC50 O +
) O +
, O +
dissociation O +
constant O +
( O +
Kd O +
) O +
or O +
number O +
of O +
PGF2 O +
alpha O +
receptors O +
. O +

Inhibition O +
of O +
PG O +
synthesis O +
was O +
without O +
effect O +
upon O +
desensitization O +
, O +
demonstrating O +
that O +
the O +
effect O +
was O +
not O +
agonist O +
- O +
induced O +
. O +

Desensitization O +
could O +
be O +
induced O +
in O +
NIH B-CellLine +
- I-CellLine +
3T3 I-CellLine +
cells O +
by O +
culturing O +
under O +
conditions O +
where O +
the O +
cells O +
were O +
all O +
in O +
the O +
exponential O +
growth O +
phase O +
, O +
or O +
by O +
a O +
12 O +
h O +
exposure O +
to O +
a O +
C O +
- O +
kinase O +
- O +
activating O +
phorbol O +
ester O +
. O +

These O +
results O +
suggest O +
that O +
desensitization O +
of O +
certain O +
agonist O +
- O +
induced O +
inositol O +
phospholipid O +
responses O +
in O +
ras O +
- O +
transformed O +
cells O +
is O +
a O +
consequence O +
of O +
increased O +
cell O +
proliferation O +
and O +
associated O +
amplification O +
in O +
C O +
- O +
kinase O +
activity O +
and O +
is O +
an O +
indirect O +
consequence O +
of O +
transformation O +
by O +
ras O +
. O +

Sunitinib O +
induces O +
apoptosis O +
in O +
pheochromocytoma O +
tumor O +
cells O +
by O +
inhibiting O +
VEGFR2 O +
/ O +
Akt O +
/ O +
mTOR O +
/ O +
S6K1 O +
pathways O +
through O +
modulation O +
of O +
Bcl O +
- O +
2 O +
and O +
BAD O +
. O +

Sunitinib O +
is O +
an O +
oral O +
multitargeted O +
receptor O +
tyrosine O +
kinase O +
inhibitor O +
with O +
antiangiogenic O +
and O +
antitumor O +
activity O +
that O +
mainly O +
targets O +
vascular O +
endothelial O +
growth O +
factor O +
receptors O +
( O +
VEGFRs O +
) O +
. O +

Very O +
recently O +
, O +
sunitinib O +
has O +
been O +
shown O +
to O +
be O +
an O +
active O +
agent O +
for O +
the O +
treatment O +
of O +
malignant O +
pheochromocytomas O +
. O +

However O +
, O +
it O +
is O +
unclear O +
whether O +
sunitinib O +
acts O +
only O +
through O +
an O +
antiangiogenic O +
mechanism O +
or O +
whether O +
it O +
may O +
also O +
directly O +
target O +
tumor O +
cells O +
. O +

Sunitinib O +
markedly O +
induced O +
apoptosis O +
of O +
PC12 B-CellLine +
cells O +
in O +
a O +
dose O +
- O +
dependent O +
and O +
time O +
- O +
dependent O +
manner O +
. O +

Furthermore O +
, O +
in O +
support O +
of O +
these O +
findings O +
, O +
we O +
found O +
that O +
sunitinib O +
induced O +
a O +
reduction O +
in O +
the O +
expression O +
of O +
the O +
antiapoptotic O +
molecule O +
Bcl O +
- O +
2 O +
as O +
well O +
as O +
dephosphorylation O +
of O +
the O +
proapoptotic O +
molecule O +
BAD O +
, O +
which O +
results O +
in O +
the O +
activation O +
of O +
BAD O +
in O +
these O +
cells O +
. O +

Consistent O +
with O +
these O +
apoptotic O +
effects O +
, O +
our O +
results O +
showed O +
that O +
sunitinib O +
inhibited O +
phosphorylation O +
of O +
Akt O +
and O +
mTOR O +
and O +
was O +
followed O +
by O +
a O +
reduction O +
of O +
S6K1 O +
, O +
which O +
is O +
a O +
well O +
- O +
known O +
target O +
of O +
mTOR O +
. O +

Knockdown O +
of O +
VEGFR O +
- O +
2 O +
attenuated O +
the O +
sunitinib O +
- O +
induced O +
effects O +
, O +
including O +
apoptosis O +
and O +
inhibition O +
of O +
signaling O +
pathways O +
such O +
as O +
the O +
phosphorylation O +
of O +
Akt O +
as O +
well O +
as O +
mTOR O +
, O +
and O +
Bcl O +
- O +
2 O +
, O +
which O +
confirmed O +
that O +
these O +
effects O +
could O +
be O +
mediated O +
by O +
VEGFR O +
- O +
2 O +
. O +

In O +
addition O +
, O +
silencing O +
of O +
S6K1 O +
induced O +
apoptosis O +
accompanied O +
by O +
a O +
decrease O +
in O +
the O +
phosphorylation O +
of O +
BAD O +
and O +
Bcl O +
- O +
2 O +
, O +
similar O +
to O +
that O +
observed O +
with O +
sunitinib O +
treatment O +
. O +

Thus O +
, O +
these O +
results O +
together O +
suggest O +
that O +
sunitinib O +
initially O +
exerts O +
its O +
apoptotic O +
effect O +
through O +
the O +
inhibition O +
of O +
VEGFR O +
- O +
2 O +
, O +
which O +
, O +
when O +
followed O +
by O +
reduction O +
of O +
its O +
downstream O +
effectors O +
, O +
including O +
Akt O +
/ O +
mTOR O +
/ O +
S6K1 O +
, O +
may O +
lead O +
to O +
inhibition O +
of O +
the O +
antiapoptotic O +
molecule O +
Bcl O +
- O +
2 O +
and O +
activation O +
of O +
the O +
proapoptotic O +
molecule O +
BAD O +
in O +
PC12 B-CellLine +
cells O +
. O +

However O +
, O +
PC12 B-CellLine +
cells O +
do O +
not O +
precisely O +
reflect O +
the O +
pathogenesis O +
of O +
malignant O +
cells O +
. O +

Therefore O +
, O +
we O +
confirmed O +
the O +
key O +
findings O +
by O +
replicating O +
these O +
experiments O +
in O +
human O +
neuroblastoma O +
SK B-CellLine +
- I-CellLine +
N I-CellLine +
- I-CellLine +
SH I-CellLine +
cells O +
. O +

Development O +
of O +
a O +
mouse O +
model O +
for O +
lymph O +
node O +
metastasis O +
with O +
endometrial O +
cancer O +
. O +

Controlling O +
lymph O +
node O +
metastasis O +
is O +
currently O +
a O +
key O +
issue O +
in O +
cancer O +
therapy O +
. O +

Lymph O +
node O +
metastasis O +
is O +
one O +
of O +
the O +
most O +
important O +
prognostic O +
factors O +
in O +
various O +
types O +
of O +
cancers O +
, O +
including O +
endometrial O +
cancer O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
- O +
C O +
( O +
VEGF O +
- O +
C O +
) O +
plays O +
a O +
crucial O +
role O +
in O +
lymphangiogenesis O +
, O +
and O +
is O +
implicated O +
to O +
play O +
an O +
important O +
role O +
in O +
lymph O +
node O +
metastasis O +
. O +

To O +
evaluate O +
the O +
role O +
of O +
VEGF O +
- O +
C O +
in O +
lymph O +
node O +
metastasis O +
, O +
we O +
developed O +
an O +
animal O +
model O +
by O +
using O +
an O +
endometrial O +
cancer O +
cell O +
line O +
, O +
HEC1A B-CellLine +
. O +

This O +
cell O +
line O +
is O +
not O +
invasive O +
by O +
nature O +
and O +
secretes O +
moderate O +
amounts O +
of O +
VEGF O +
- O +
C O +
; O +
intrauterine O +
injection O +
of O +
HEC1A B-CellLine +
cells O +
into O +
Balb O +
/ O +
c O +
nude O +
mice O +
resulted O +
in O +
uterine O +
cancer O +
with O +
lymph O +
node O +
metastasis O +
after O +
8 O +
weeks O +
. O +

To O +
analyze O +
the O +
contribution O +
of O +
VEGF O +
- O +
C O +
to O +
lymph O +
node O +
metastasis O +
, O +
its O +
corresponding O +
gene O +
was O +
stably O +
introduced O +
into O +
HEC1A B-CellLine +
cells O +
( O +
HEC1A B-CellLine +
/ O +
VEGF O +
- O +
C O +
) O +
, O +
which O +
then O +
produced O +
more O +
than O +
10 O +
times O +
the O +
amount O +
of O +
VEGF O +
- O +
C O +
. O +

The O +
number O +
of O +
lymph O +
node O +
metastases O +
was O +
significantly O +
higher O +
in O +
HEC1A B-CellLine +
/ I-CellLine +
VEGF I-CellLine +
- I-CellLine +
C I-CellLine +
cells O +
than O +
in O +
HEC1A B-CellLine +
cells O +
( O +
3 O +
. O +
2 O +
vs O +
1 O +
. O +
1 O +
nodes O +
/ O +
animal O +
, O +
respectively O +
) O +
. O +

Augmented O +
lymphangiogenesis O +
was O +
observed O +
within O +
tumors O +
when O +
HEC1A B-CellLine +
/ I-CellLine +
VEGF I-CellLine +
- I-CellLine +
C I-CellLine +
cells O +
were O +
inoculated O +
. O +

These O +
results O +
indicate O +
that O +
VEGF O +
- O +
C O +
plays O +
a O +
critical O +
role O +
in O +
lymph O +
node O +
metastasis O +
, O +
in O +
addition O +
to O +
serving O +
as O +
a O +
platform O +
to O +
test O +
the O +
efficacy O +
of O +
various O +
therapeutic O +
modalities O +
against O +
lymph O +
node O +
metastasis O +
. O +

[ O +
Rubella O +
in O +
Poland O +
in O +
2009 O +
] O +
. O +

In O +
Poland O +
, O +
7 O +
, O +
587 O +
cases O +
of O +
rubella O +
were O +
registered O +
in O +
2009 O +
( O +
incidence O +
19 O +
. O +
9 O +
per O +
100 O +
, O +
000 O +
population O +
) O +
. O +

According O +
to O +
a O +
new O +
rubella O +
case O +
definition O +
, O +
introduced O +
in O +
2009 O +
, O +
7 O +
( O +
0 O +
. O +
1 O +
% O +
) O +
cases O +
were O +
classified O +
as O +
confirmed O +
cases O +
, O +
30 O +
( O +
0 O +
. O +
4 O +
% O +
) O +
as O +
probable O +
. O +

One O +
case O +
of O +
congenital O +
rubella O +
syndrome O +
was O +
reported O +
. O +

The O +
incidence O +
in O +
men O +
( O +
26 O +
. O +
6 O +
) O +
was O +
1 O +
. O +
9 O +
- O +
times O +
higher O +
than O +
in O +
women O +
( O +
13 O +
. O +
6 O +
) O +
. O +

The O +
highest O +
incidence O +
was O +
observed O +
in O +
children O +
aged O +
7 O +
and O +
8 O +
years O +
( O +
180 O +
. O +
3 O +
and O +
175 O +
. O +
6 O +
, O +
respectively O +
) O +
. O +

No O +
rubella O +
deaths O +
were O +
registered O +
. O +

An O +
improvement O +
of O +
laboratory O +
diagnosis O +
of O +
reported O +
cases O +
is O +
necessary O +
to O +
assess O +
the O +
impact O +
of O +
2 O +
- O +
dose O +
immunization O +
implemented O +
in O +
2003 O +
on O +
rubella O +
epidemiology O +
in O +
Poland O +
. O +

Burns O +
from O +
hot O +
wheat O +
bags O +
: O +
a O +
public O +
safety O +
issue O +
. O +

Introduction O +
: O +
Wheat O +
bags O +
are O +
therapeutic O +
devices O +
that O +
are O +
heated O +
in O +
microwaves O +
and O +
commonly O +
used O +
to O +
provide O +
relief O +
from O +
muscle O +
and O +
joint O +
pain O +
. O +

The O +
Royal O +
Adelaide O +
Hospital O +
Burns O +
Unit O +
has O +
observed O +
a O +
number O +
of O +
patients O +
with O +
significant O +
burn O +
injuries O +
resulting O +
from O +
their O +
use O +
. O +

Despite O +
their O +
dangers O +
, O +
the O +
products O +
come O +
with O +
limited O +
safety O +
information O +
. O +

Methods O +
: O +
Data O +
were O +
collected O +
from O +
the O +
Burns O +
Unit O +
database O +
for O +
all O +
patients O +
admitted O +
with O +
burns O +
due O +
to O +
hot O +
wheat O +
bags O +
from O +
2004 O +
to O +
2009 O +
. O +

This O +
was O +
analyzed O +
to O +
determine O +
the O +
severity O +
of O +
the O +
burn O +
injury O +
and O +
identify O +
any O +
predisposing O +
factors O +
. O +

An O +
experimental O +
study O +
was O +
performed O +
to O +
measure O +
the O +
temperature O +
of O +
wheat O +
bags O +
when O +
heated O +
to O +
determine O +
their O +
potential O +
for O +
causing O +
thermal O +
injury O +
. O +

Results O +
: O +
11 O +
patients O +
were O +
admitted O +
with O +
burns O +
due O +
to O +
hot O +
wheat O +
bags O +
. O +

The O +
median O +
age O +
was O +
52 O +
years O +
and O +
the O +
mean O +
total O +
body O +
surface O +
area O +
was O +
1 O +
. O +
1 O +
% O +
. O +

All O +
burns O +
were O +
either O +
deep O +
dermal O +
( O +
45 O +
. O +
5 O +
% O +
) O +
or O +
full O +
thickness O +
( O +
54 O +
. O +
5 O +
% O +
) O +
. O +

Ten O +
patients O +
required O +
operative O +
management O +
. O +

Predisposing O +
factors O +
( O +
eg O +
, O +
neuropathy O +
) O +
to O +
thermal O +
injury O +
were O +
identified O +
in O +
7 O +
patients O +
. O +

The O +
experimental O +
study O +
showed O +
that O +
hot O +
wheat O +
bags O +
reached O +
temperatures O +
of O +
57 O +
. O +
3degreesC O +
( O +
135 O +
. O +
1degreesF O +
) O +
when O +
heated O +
according O +
to O +
instructions O +
, O +
63 O +
. O +
3degreesC O +
( O +
145 O +
. O +
9degreesF O +
) O +
in O +
a O +
1000 O +
W O +
microwave O +
and O +
69 O +
. O +
6degreesC O +
( O +
157 O +
. O +
3degreesF O +
) O +
on O +
reheating O +
. O +

Conclusions O +
: O +
Hot O +
wheat O +
bags O +
cause O +
serious O +
burn O +
injury O +
. O +

When O +
heated O +
improperly O +
, O +
they O +
can O +
reach O +
temperatures O +
high O +
enough O +
to O +
cause O +
epidermal O +
necrosis O +
in O +
a O +
short O +
period O +
of O +
time O +
. O +

Patients O +
with O +
impaired O +
temperature O +
sensation O +
are O +
particularly O +
at O +
risk O +
. O +

There O +
should O +
be O +
greater O +
public O +
awareness O +
of O +
the O +
dangers O +
of O +
wheat O +
bag O +
use O +
and O +
more O +
specific O +
safety O +
warnings O +
on O +
the O +
products O +
. O +

IL O +
- O +
17F O +
deficiency O +
inhibits O +
small O +
intestinal O +
tumorigenesis O +
in O +
ApcMin O +
/ O +
+ O +
mice O +
. O +

IL O +
- O +
17 O +
plays O +
an O +
important O +
role O +
in O +
gut O +
homeostasis O +
. O +

However O +
, O +
the O +
role O +
of O +
IL O +
- O +
17F O +
in O +
intestinal O +
tumorigenesis O +
has O +
not O +
been O +
addressed O +
. O +

Here O +
we O +
demonstrate O +
that O +
ablation O +
of O +
IL O +
- O +
17F O +
significantly O +
inhibits O +
spontaneous O +
intestinal O +
tumorigenesis O +
in O +
the O +
small O +
intestine O +
of O +
Apc O +
( O +
Min O +
/ O +
+ O +
) O +
mice O +
. O +

IL O +
- O +
17F O +
ablation O +
decreased O +
IL O +
- O +
1beta O +
and O +
Cox O +
- O +
2 O +
expression O +
as O +
well O +
as O +
IL O +
- O +
17 O +
receptor O +
C O +
( O +
IL O +
- O +
17RC O +
) O +
expression O +
, O +
which O +
were O +
increased O +
in O +
tumors O +
from O +
Apc O +
( O +
Min O +
/ O +
+ O +
) O +
mice O +
. O +

Lack O +
of O +
IL O +
- O +
17F O +
did O +
not O +
reverse O +
the O +
splenomegaly O +
but O +
partially O +
restored O +
thymic O +
atrophy O +
, O +
suggesting O +
a O +
local O +
effect O +
of O +
IL O +
- O +
17F O +
in O +
the O +
intestine O +
. O +

IL O +
- O +
17F O +
deficient O +
Apc O +
( O +
Min O +
/ O +
+ O +
) O +
mice O +
showed O +
a O +
significant O +
decrease O +
in O +
immune O +
cell O +
infiltration O +
in O +
the O +
lamina O +
propria O +
. O +

Interestingly O +
, O +
the O +
expression O +
of O +
IL O +
- O +
17A O +
from O +
CD4 O +
T O +
cells O +
in O +
the O +
lamina O +
propria O +
remains O +
unchanged O +
in O +
the O +
absence O +
of O +
IL O +
- O +
17F O +
. O +

Collectively O +
, O +
our O +
results O +
suggest O +
the O +
proinflammatory O +
and O +
essential O +
role O +
of O +
IL O +
- O +
17F O +
to O +
develop O +
spontaneous O +
intestinal O +
tumorigenesis O +
in O +
Apc O +
( O +
Min O +
/ O +
+ O +
) O +
mice O +
in O +
the O +
presence O +
of O +
IL O +
- O +
17A O +
. O +

Curcumin O +
inhibits O +
metastatic O +
progression O +
of O +
breast O +
cancer O +
cell O +
through O +
suppression O +
of O +
urokinase O +
- O +
type O +
plasminogen O +
activator O +
by O +
NF O +
- O +
kappa O +
B O +
signaling O +
pathways O +
. O +

Curcumin O +
( O +
1 O +
, O +
7 O +
- O +
bis O +
( O +
4 O +
- O +
hydroxy O +
- O +
3 O +
- O +
methoxyphenyl O +
) O +
- O +
1 O +
, O +
6 O +
- O +
heptadiene O +
- O +
3 O +
, O +
5 O +
- O +
dione O +
) O +
, O +
is O +
extracted O +
from O +
the O +
plant O +
Curcuma O +
longa O +
. O +

It O +
was O +
recently O +
reported O +
for O +
its O +
anticancer O +
effect O +
on O +
several O +
types O +
of O +
cancer O +
cells O +
in O +
vitro O +
however O +
, O +
the O +
molecular O +
mechanisms O +
of O +
this O +
anticancer O +
effect O +
are O +
not O +
fully O +
understood O +
. O +

In O +
the O +
present O +
study O +
, O +
we O +
evaluated O +
the O +
effects O +
of O +
curcumin O +
on O +
human O +
mammary O +
epithelial O +
carcinoma O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
. O +

Cells O +
were O +
treated O +
with O +
curcumin O +
and O +
examined O +
for O +
cell O +
viability O +
by O +
MTT O +
assay O +
. O +

The O +
cells O +
invasion O +
was O +
demonstrated O +
by O +
transwell O +
assay O +
. O +

The O +
binding O +
activity O +
of O +
NF O +
- O +
kappaB O +
to O +
DNA O +
was O +
examined O +
in O +
nuclear O +
extracts O +
using O +
Trans O +
- O +
AM O +
NF O +
- O +
kappaB O +
ELISA O +
kit O +
. O +

Western O +
blot O +
was O +
performed O +
to O +
detect O +
the O +
effect O +
of O +
curcumin O +
on O +
the O +
expression O +
of O +
uPA O +
. O +

Our O +
results O +
showed O +
that O +
curcumin O +
dose O +
- O +
dependently O +
inhibited O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
the O +
proliferation O +
of O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
. O +

Meanwhile O +
, O +
the O +
adhesion O +
and O +
invasion O +
ability O +
of O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
were O +
sharply O +
inhibited O +
when O +
treated O +
with O +
different O +
concentrations O +
of O +
curcumin O +
. O +

Curcumin O +
also O +
significantly O +
decreased O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
the O +
expression O +
of O +
uPA O +
and O +
NF O +
- O +
kappaB O +
DNA O +
binding O +
activity O +
, O +
respectively O +
. O +

It O +
is O +
concluded O +
that O +
curcumin O +
inhibits O +
the O +
adhesion O +
and O +
invasion O +
of O +
MCF B-CellLine +
- I-CellLine +
7 I-CellLine +
cells O +
through O +
down O +
- O +
regulating O +
the O +
protein O +
expression O +
of O +
uPA O +
via O +
of O +
NF O +
- O +
kappaB O +
activation O +
. O +

Accordingly O +
, O +
the O +
therapeutic O +
potential O +
of O +
curcumin O +
for O +
breast O +
cancer O +
deserves O +
further O +
study O +
. O +

Aglycon O +
of O +
rhizochalin O +
from O +
the O +
Rhizochalina O +
incrustata O +
induces O +
apoptosis O +
via O +
activation O +
of O +
AMP O +
- O +
activated O +
protein O +
kinase O +
in O +
HT B-CellLine +
- I-CellLine +
29 I-CellLine +
colon O +
cancer O +
cells O +
. O +

Rhizochalin O +
is O +
a O +
two O +
- O +
headed O +
sphingolipid O +
- O +
like O +
compound O +
isolated O +
from O +
the O +
sponge O +
Rhizochalina O +
incrustata O +
. O +

It O +
has O +
been O +
reported O +
that O +
rhizocalin O +
and O +
its O +
derivates O +
have O +
a O +
chemopreventive O +
and O +
chemotherapeutic O +
effect O +
. O +

However O +
, O +
the O +
molecular O +
mechanism O +
of O +
these O +
effects O +
is O +
not O +
understood O +
. O +

Here O +
, O +
we O +
demonstrate O +
that O +
aglycon O +
of O +
rhizochalin O +
( O +
AglRhz O +
) O +
from O +
the O +
Rhizochalina O +
incrustata O +
induces O +
AMP O +
- O +
activated O +
protein O +
kinase O +
( O +
AMPK O +
) O +
phosphorylation O +
, O +
and O +
thereby O +
inhibits O +
mammalian O +
target O +
of O +
rapamycin O +
( O +
mTOR O +
) O +
- O +
p70S6 O +
kinase O +
- O +
extracellular O +
signal O +
- O +
regulated O +
kinase O +
( O +
ERK O +
) O +
signaling O +
and O +
activator O +
protein O +
1 O +
( O +
AP O +
- O +
1 O +
) O +
activity O +
via O +
phosphorylation O +
of O +
Raptor O +
in O +
HT B-CellLine +
- I-CellLine +
29 I-CellLine +
cells O +
. O +

In O +
addition O +
, O +
AglRhz O +
induced O +
activation O +
of O +
caspase O +
- O +
3 O +
and O +
poly O +
( O +
ADP O +
- O +
ribose O +
) O +
polymerase O +
( O +
PARP O +
) O +
, O +
and O +
DNA O +
fragmentation O +
in O +
HT B-CellLine +
- I-CellLine +
29 I-CellLine +
cells O +
, O +
leads O +
to O +
induction O +
of O +
apoptosis O +
as O +
well O +
as O +
suppression O +
of O +
tumorigenicity O +
of O +
HT B-CellLine +
- I-CellLine +
29 I-CellLine +
cells O +
. O +

Notably O +
, O +
AglRhz O +
inhibits O +
insulin O +
- O +
like O +
growth O +
factor O +
( O +
IGF O +
) O +
- O +
1 O +
- O +
induced O +
AP O +
- O +
1 O +
activity O +
and O +
cell O +
transformation O +
in O +
JB6 B-CellLine +
Cl41 I-CellLine +
cells O +
. O +

Overall O +
, O +
our O +
findings O +
identify O +
AMPK O +
as O +
an O +
important O +
target O +
protein O +
for O +
mediating O +
the O +
anti O +
- O +
tumor O +
properties O +
of O +
AglRhz O +
in O +
HT B-CellLine +
- I-CellLine +
29 I-CellLine +
colon O +
cancer O +
cells O +
and O +
have O +
important O +
implication O +
for O +
sponges O +
, O +
the O +
most O +
important O +
marine O +
source O +
, O +
in O +
colon O +
cancer O +
. O +

Expression O +
of O +
thymidylate O +
synthase O +
and O +
dihydropyrimidine O +
dehydrogenase O +
in O +
primary O +
oral O +
squamous O +
cell O +
carcinoma O +
and O +
corresponding O +
metastases O +
in O +
cervical O +
lymph O +
nodes O +
: O +
association O +
with O +
the O +
metastasis O +
suppressor O +
CD82 O +
. O +

Thymidylate O +
synthase O +
( O +
TS O +
) O +
and O +
dihydropyrimidine O +
dehydrogenase O +
( O +
DPD O +
) O +
are O +
5 O +
- O +
fluorouracil O +
( O +
5 O +
- O +
FU O +
) O +
metabolizing O +
enzymes O +
and O +
are O +
involved O +
in O +
the O +
sensitivity O +
of O +
carcinoma O +
patients O +
to O +
5 O +
- O +
FU O +
. O +

Although O +
5 O +
- O +
FU O +
is O +
often O +
used O +
for O +
the O +
treatment O +
of O +
oral O +
carcinoma O +
, O +
there O +
has O +
not O +
been O +
any O +
investigation O +
into O +
the O +
expression O +
of O +
these O +
enzymes O +
in O +
metastatic O +
lymph O +
nodes O +
or O +
of O +
their O +
roles O +
in O +
the O +
effectiveness O +
of O +
5 O +
- O +
FU O +
in O +
treating O +
lymph O +
node O +
- O +
metastatic O +
cancer O +
. O +

Oral O +
squamous O +
cell O +
carcinoma O +
( O +
OSCC O +
) O +
often O +
metastasizes O +
to O +
the O +
lymph O +
nodes O +
, O +
and O +
these O +
enzymes O +
may O +
be O +
significant O +
in O +
the O +
survival O +
of O +
patients O +
with O +
this O +
disease O +
. O +

This O +
study O +
investigated O +
the O +
expression O +
of O +
TS O +
and O +
DPD O +
in O +
cervical O +
lymph O +
node O +
metastases O +
and O +
its O +
relationship O +
with O +
primary O +
OSCC O +
, O +
as O +
well O +
as O +
the O +
interaction O +
between O +
these O +
enzymes O +
and O +
Kangai O +
1 O +
( O +
KAI1 O +
/ O +
CD82 O +
) O +
which O +
is O +
a O +
metastasis O +
suppressor O +
protein O +
. O +

Surgical O +
specimens O +
from O +
20 O +
cases O +
of O +
OSCC O +
with O +
lymph O +
node O +
metastasis O +
, O +
20 O +
cases O +
of O +
OSCC O +
without O +
lymph O +
node O +
metastasis O +
, O +
and O +
10 O +
cases O +
of O +
normal O +
mucosa O +
were O +
examined O +
by O +
immunohistochemistry O +
. O +

The O +
relationship O +
between O +
TS O +
and O +
DPD O +
expression O +
and O +
clinicopathological O +
data O +
was O +
analyzed O +
. O +

TS O +
and O +
DPD O +
proteins O +
were O +
overexpressed O +
in O +
primary O +
OSCC O +
compared O +
to O +
that O +
in O +
normal O +
mucosa O +
. O +

TS O +
expression O +
of O +
the O +
primary O +
oral O +
cancer O +
cells O +
in O +
the O +
group O +
with O +
lymph O +
node O +
metastasis O +
was O +
higher O +
than O +
that O +
of O +
those O +
without O +
. O +

DPD O +
expression O +
did O +
not O +
significantly O +
correlate O +
with O +
the O +
occurrence O +
of O +
lymph O +
node O +
metastasis O +
, O +
nor O +
was O +
it O +
different O +
between O +
primary O +
oral O +
cancer O +
cells O +
and O +
cervical O +
metastases O +
. O +

CD82 O +
expression O +
was O +
significantly O +
reduced O +
in O +
lymph O +
node O +
metastases O +
. O +

These O +
findings O +
indicate O +
that O +
TS O +
and O +
CD82 O +
may O +
be O +
of O +
great O +
value O +
in O +
assessing O +
lymph O +
node O +
metastasis O +
of O +
OSCC O +
, O +
and O +
could O +
be O +
taken O +
as O +
new O +
targets O +
for O +
therapy O +
of O +
metastatic O +
OSCC O +
. O +

c O +
- O +
MYC O +
functions O +
as O +
a O +
molecular O +
switch O +
to O +
alter O +
the O +
response O +
of O +
human O +
mammary O +
epithelial O +
cells O +
to O +
oncostatin O +
M O +
. O +

Cytokines O +
play O +
an O +
important O +
role O +
in O +
creating O +
an O +
inflammatory O +
microenvironment O +
, O +
which O +
is O +
now O +
considered O +
a O +
hallmark O +
of O +
cancer O +
. O +

Although O +
tumor O +
cells O +
can O +
exploit O +
cytokine O +
signaling O +
to O +
promote O +
growth O +
, O +
invasion O +
, O +
and O +
metastasis O +
, O +
the O +
response O +
of O +
normal O +
and O +
premalignant O +
epithelial O +
cells O +
to O +
cytokines O +
present O +
in O +
a O +
developing O +
tumor O +
microenvironment O +
remains O +
unclear O +
. O +

Oncostatin O +
M O +
( O +
OSM O +
) O +
, O +
an O +
IL O +
- O +
6 O +
family O +
cytokine O +
responsible O +
for O +
STAT3 O +
activation O +
, O +
has O +
been O +
implicated O +
in O +
cancer O +
development O +
, O +
progression O +
, O +
invasion O +
, O +
and O +
metastasis O +
. O +

Paradoxically O +
, O +
OSM O +
can O +
also O +
suppress O +
the O +
growth O +
of O +
normal O +
cells O +
and O +
certain O +
tumor O +
- O +
derived O +
cell O +
lines O +
. O +

Using O +
isogenic O +
human O +
mammary O +
epithelial O +
cells O +
( O +
HMEC O +
) O +
at O +
different O +
stages O +
of O +
neoplastic O +
transformation O +
, O +
we O +
found O +
that O +
OSM O +
signaling O +
suppressed O +
c O +
- O +
MYC O +
expression O +
and O +
engaged O +
a O +
p16 O +
- O +
and O +
p53 O +
- O +
independent O +
growth O +
arrest O +
that O +
required O +
STAT3 O +
activity O +
. O +

Inhibition O +
of O +
STAT3 O +
activation O +
by O +
expressing O +
a O +
dominant O +
- O +
negative O +
STAT3 O +
protein O +
or O +
a O +
STAT3 O +
- O +
shRNA O +
prevented O +
the O +
OSM O +
- O +
mediated O +
arrest O +
. O +

In O +
addition O +
, O +
expression O +
of O +
c O +
- O +
MYC O +
from O +
a O +
constitutive O +
promoter O +
also O +
abrogated O +
the O +
STAT3 O +
- O +
mediated O +
arrest O +
, O +
and O +
strikingly O +
, O +
cooperated O +
with O +
OSM O +
to O +
promote O +
anchorage O +
- O +
independent O +
growth O +
( O +
AIG O +
) O +
, O +
a O +
property O +
associated O +
with O +
malignant O +
transformation O +
. O +

Cooperative O +
transformation O +
by O +
c O +
- O +
MYC O +
and O +
OSM O +
required O +
PI3 O -
K O +
and O +
AKT O +
signaling O +
, O +
showing O +
the O +
importance O +
of O +
multiple O +
signaling O +
pathways O +
downstream O +
of O +
the O +
OSM O +
receptor O +
in O +
defining O +
the O +
cellular O +
response O +
to O +
cytokines O +
. O +

These O +
findings O +
identify O +
c O +
- O +
MYC O +
as O +
an O +
important O +
molecular O +
switch O +
that O +
alters O +
the O +
cellular O +
response O +
to O +
OSM O +
- O +
mediated O +
signaling O +
from O +
tumor O +
suppressive O +
to O +
tumor O +
promoting O +
. O +

PTHrP O +
drives O +
breast O +
tumor O +
initiation O +
, O +
progression O +
, O +
and O +
metastasis O +
in O +
mice O +
and O +
is O +
a O +
potential O +
therapy O +
target O +
. O +

Parathyroid O +
hormone O +
- O +
related O +
protein O +
( O +
PTHrP O +
) O +
is O +
a O +
secreted O +
factor O +
expressed O +
in O +
almost O +
all O +
normal O +
fetal O +
and O +
adult O +
tissues O +
. O +

It O +
is O +
involved O +
in O +
a O +
wide O +
range O +
of O +
developmental O +
and O +
physiological O +
processes O +
, O +
including O +
serum O +
calcium O +
regulation O +
. O +

PTHrP O +
is O +
also O +
associated O +
with O +
the O +
progression O +
of O +
skeletal O +
metastases O +
, O +
and O +
its O +
dysregulated O +
expression O +
in O +
advanced O +
cancers O +
causes O +
malignancy O +
- O +
associated O +
hypercalcemia O +
. O +

Although O +
PTHrP O +
is O +
frequently O +
expressed O +
by O +
breast O +
tumors O +
and O +
other O +
solid O +
cancers O +
, O +
its O +
effects O +
on O +
tumor O +
progression O +
are O +
unclear O +
. O +

Here O +
, O +
we O +
demonstrate O +
in O +
mice O +
pleiotropic O +
involvement O +
of O +
PTHrP O +
in O +
key O +
steps O +
of O +
breast O +
cancer O +
- O +
it O +
influences O +
the O +
initiation O +
and O +
progression O +
of O +
primary O +
tumors O +
and O +
metastases O +
. O +

Pthrp O +
ablation O +
in O +
the O +
mammary O +
epithelium O +
of O +
the O +
PyMT O +
- O +
MMTV O +
breast O +
cancer O +
mouse O +
model O +
caused O +
a O +
delay O +
in O +
primary O +
tumor O +
initiation O +
, O +
inhibited O +
tumor O +
progression O +
, O +
and O +
reduced O +
metastasis O +
to O +
distal O +
sites O +
. O +

Mechanistically O +
, O +
it O +
reduced O +
expression O +
of O +
molecular O +
markers O +
of O +
cell O +
proliferation O +
( O +
Ki67 O +
) O +
and O +
angiogenesis O +
( O +
factor O +
VIII O +
) O +
, O +
antiapoptotic O +
factor O +
Bcl O +
- O +
2 O +
, O +
cell O +
- O +
cycle O +
progression O +
regulator O +
cyclin O +
D1 O +
, O +
and O +
survival O +
factor O +
AKT1 O +
. O +

PTHrP O +
also O +
influenced O +
expression O +
of O +
the O +
adhesion O +
factor O +
CXCR4 O +
, O +
and O +
coexpression O +
of O +
PTHrP O +
and O +
CXCR4 O +
was O +
crucial O +
for O +
metastatic O +
spread O +
. O +

Importantly O +
, O +
PTHrP O +
- O +
specific O +
neutralizing O +
antibodies O +
slowed O +
the O +
progression O +
and O +
metastasis O +
of O +
human O +
breast O +
cancer O +
xenografts O +
. O +

Our O +
data O +
identify O +
what O +
we O +
believe O +
to O +
be O +
new O +
functions O +
for O +
PTHrP O +
in O +
several O +
key O +
steps O +
of O +
breast O +
cancer O +
and O +
suggest O +
that O +
PTHrP O +
may O +
constitute O +
a O +
novel O +
target O +
for O +
therapeutic O +
intervention O +
. O +

Aquaporins O +
in O +
human O +
breast O +
cancer O +
: O +
identification O +
and O +
involvement O +
in O +
carcinogenesis O +
of O +
breast O +
cancer O +
. O +

BACKGROUND O +
AND O +
OBJECTIVES O +
: O +
Aquaporins O +
( O +
AQPs O +
) O +
play O +
important O +
roles O +
in O +
water O +
and O +
glycerol O +
transport O +
. O +

Recently O +
, O +
the O +
role O +
of O +
AQPs O +
in O +
human O +
carcinogenesis O +
has O +
become O +
an O +
area O +
of O +
great O +
interest O +
. O +

However O +
, O +
little O +
is O +
known O +
about O +
the O +
function O +
of O +
AQPs O +
in O +
human O +
breast O +
cancer O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
investigate O +
the O +
expression O +
profile O +
of O +
AQPs O +
in O +
human O +
breast O +
cancer O +
and O +
its O +
significance O +
. O +

METHODS O +
: O +
In O +
this O +
study O +
, O +
we O +
screened O +
the O +
expression O +
profile O +
of O +
AQP0 O +
- O +
12 O +
in O +
breast O +
cancer O +
tissues O +
and O +
corresponding O +
normal O +
tissues O +
by O +
RT O +
- O +
PCR O +
, O +
Western O +
blotting O +
and O +
immunohistochemistry O +
. O +

RESULTS O +
: O +
AQP1 O +
, O +
3 O +
- O +
5 O +
, O +
and O +
10 O +
- O +
12 O +
were O +
expressed O +
in O +
human O +
breast O +
cancer O +
and O +
/ O +
or O +
normal O +
breast O +
tissues O +
, O +
and O +
AQP1 O +
and O +
3 O +
- O +
5 O +
exhibited O +
differential O +
expression O +
. O +

AQP1 O +
was O +
expressed O +
in O +
cell O +
membranes O +
and O +
its O +
expression O +
was O +
higher O +
in O +
cancer O +
than O +
that O +
in O +
normal O +
tissues O +
. O +

AQP4 O +
was O +
expressed O +
in O +
the O +
cell O +
membrane O +
and O +
cytoplasm O +
and O +
was O +
detected O +
markedly O +
stronger O +
in O +
normal O +
than O +
in O +
cancer O +
tissues O +
. O +

AQP5 O +
was O +
expressed O +
mainly O +
in O +
cell O +
membranes O +
in O +
carcinoma O +
tissues O +
, O +
but O +
was O +
almost O +
absent O +
in O +
normal O +
breast O +
tissues O +
. O +

Expression O +
of O +
AQP5 O +
was O +
associated O +
with O +
cellular O +
differentiation O +
, O +
lymph O +
node O +
invasion O +
, O +
and O +
clinicopathological O +
staging O +
. O +

CONCLUSIONS O +
: O +
These O +
observations O +
suggested O +
that O +
several O +
subtypes O +
of O +
the O +
AQP O +
family O +
play O +
a O +
role O +
in O +
human O +
breast O +
carcinogenesis O +
. O +

Absence O +
of O +
antisperm O +
antibodies O +
in O +
anejaculatory O +
men O +
. O +

Antisperm O +
antibodies O +
were O +
assessed O +
in O +
the O +
serum O +
samples O +
of O +
73 O +
men O +
unable O +
to O +
ejaculate O +
naturally O +
and O +
on O +
the O +
sperm O +
cells O +
of O +
13 O +
of O +
these O +
men O +
. O +

None O +
of O +
the O +
serum O +
samples O +
were O +
found O +
to O +
be O +
positive O +
by O +
sperm O +
agglutination O +
or O +
sperm O +
immobilization O +
methods O +
and O +
antibodies O +
were O +
detected O +
by O +
an O +
immunobead O +
assay O +
on O +
the O +
sperm O +
cells O +
of O +
one O +
of O +
the O +
13 O +
men O +
examined O +
. O +

Research O +
and O +
discovery O +
of O +
the O +
first O +
human O +
cancer O +
virus O +
, O +
HTLV O +
- O +
1 O +
. O +

Human O +
T O +
- O +
cell O +
lymphoma O +
virus O +
( O +
HTLV O +
) O +
- O +
1 O +
was O +
the O +
first O +
human O +
retrovirus O +
to O +
be O +
discovered O +
. O +

It O +
has O +
been O +
recognized O +
as O +
the O +
cause O +
of O +
adult O +
T O +
- O +
cell O +
leukemia O +
( O +
ATL O +
) O +
. O +

In O +
addition O +
to O +
giving O +
a O +
historical O +
perspective O +
on O +
HTLV O +
- O +
1 O +
and O +
other O +
retrovirus O +
research O +
, O +
this O +
paper O +
discusses O +
the O +
origin O +
of O +
HTLV O +
- O +
1 O +
; O +
the O +
modes O +
of O +
transmission O +
and O +
global O +
epidemiology O +
of O +
HTLV O +
- O +
1 O +
infection O +
; O +
the O +
genome O +
of O +
HTLV O +
- O +
1 O +
and O +
the O +
mechanism O +
of O +
HTLV O +
- O +
1 O +
- O +
induced O +
leukemogenesis O +
; O +
the O +
role O +
of O +
HTLV O +
- O +
1 O +
in O +
other O +
diseases O +
, O +
and O +
recent O +
breakthroughs O +
in O +
ATL O +
therapy O +
. O +

Relationship O +
between O +
of O +
blood O +
flow O +
, O +
glucose O +
metabolism O +
, O +
protein O +
synthesis O +
, O +
glucose O +
and O +
ATP O +
content O +
in O +
experimentally O +
- O +
induced O +
glioma O +
( O +
RG1 O +
2 O +
. O +
2 O +
) O +
of O +
rat O +
brain O +
. O +

In O +
experimental O +
RG1 O +
2 O +
. O +
2 O +
glioma O +
of O +
rat O +
brain O +
, O +
local O +
blood O +
flow O +
, O +
glucose O +
utilization O +
, O +
protein O +
synthesis O +
, O +
glucose O +
and O +
ATP O +
content O +
were O +
measured O +
by O +
means O +
of O +
triple O +
tracer O +
autoradiography O +
and O +
bioluminescence O +
technique O +
, O +
respectively O +
, O +
to O +
determine O +
hemodynamic O +
and O +
metabolic O +
thresholds O +
for O +
local O +
tumor O +
energy O +
failure O +
. O +

Perfusion O +
thresholds O +
were O +
estimated O +
at O +
tumor O +
blood O +
flow O +
values O +
of O +
69 O +
. O +
0 O +
+ O +
/ O +
- O +
0 O +
. O +
1 O +
ml O +
/ O +
100 O +
g O +
/ O +
min O +
( O +
estimate O +
+ O +
/ O +
- O +
standard O +
error O +
) O +
and O +
of O +
69 O +
+ O +
/ O +
- O +
7 O +
. O +
1 O +
ml O +
/ O +
100 O +
g O +
/ O +
min O +
for O +
the O +
beginning O +
of O +
the O +
decline O +
in O +
regional O +
ATP O +
and O +
glucose O +
content O +
, O +
respectively O +
. O +

Metabolic O +
thresholds O +
were O +
derived O +
at O +
tumor O +
glucose O +
utilization O +
values O +
of O +
70 O +
. O +
6 O +
+ O +
/ O +
- O +
8 O +
. O +
3 O +
mumol O +
/ O +
100 O +
g O +
/ O +
min O +
for O +
reduced O +
protein O +
synthesis O +
, O +
of O +
55 O +
. O +
0 O +
+ O +
/ O +
- O +
0 O +
. O +
2 O +
mumol O +
/ O +
100 O +
g O +
/ O +
min O +
for O +
the O +
decrease O +
in O +
glucose O +
content O +
, O +
and O +
34 O +
. O +
7 O +
+ O +
/ O +
- O +
4 O +
. O +
7 O +
mumol O +
/ O +
100 O +
g O +
/ O +
min O +
for O +
decline O +
in O +
ATP O +
content O +
. O +

Our O +
results O +
suggest O +
that O +
blood O +
flow O +
limits O +
glucose O +
supply O +
to O +
tumor O +
tissue O +
at O +
much O +
higher O +
flow O +
rates O +
than O +
in O +
normal O +
brain O +
which O +
, O +
in O +
turn O +
, O +
is O +
associated O +
with O +
a O +
decrease O +
in O +
tumor O +
glucose O +
utilization O +
. O +

A O +
reduction O +
and O +
not O +
an O +
increase O +
in O +
tumor O +
glucose O +
availability O +
could O +
be O +
a O +
more O +
appropriate O +
strategy O +
for O +
the O +
induction O +
of O +
energy O +
failure O +
in O +
tumors O +
. O +

Selective O +
inhibition O +
of O +
nuclear O +
factor O +
- O +
kappaB O +
by O +
nuclear O +
factor O +
- O +
kappaB O +
essential O +
modulator O +
- O +
binding O +
domain O +
peptide O +
suppresses O +
the O +
metastasis O +
of O +
highly O +
metastatic O +
oral O +
squamous O +
cell O +
carcinoma O +
. O +

Nuclear O +
factor O +
- O +
kappaB O +
( O +
NF O +
- O +
kappaB O +
) O +
activation O +
contributes O +
to O +
the O +
development O +
of O +
metastasis O +
, O +
thus O +
leading O +
to O +
a O +
poor O +
prognosis O +
in O +
many O +
cancers O +
, O +
including O +
OSCC O +
. O +

However O +
, O +
little O +
in O +
vivo O +
experimental O +
data O +
are O +
available O +
about O +
the O +
effects O +
of O +
NF O +
- O +
kappaB O +
inhibition O +
on O +
OSCC O +
metastasis O +
. O +

OSCC B-CellLine +
sublines O +
were O +
established O +
from O +
a O +
GFP O +
- O +
expressing O +
parental O +
cell O +
line O +
, O +
GSAS B-CellLine +
, O +
and O +
designated O +
GSAS B-CellLine +
/ O +
N3 O +
and O +
N5 O +
according O +
to O +
the O +
in O +
vivo O +
passage O +
number O +
after O +
cervical O +
lymph O +
node O +
metastasis O +
by O +
a O +
serial O +
orthotopic O +
transplantation O +
model O +
. O +

In O +
vitro O +
migration O +
and O +
invasion O +
were O +
assessed O +
in O +
these O +
cells O +
, O +
and O +
the O +
NF O +
- O +
kappaB O +
activities O +
and O +
expression O +
of O +
NF O +
- O +
kappaB O +
- O +
regulated O +
metastasis O +
- O +
related O +
molecules O +
were O +
also O +
examined O +
. O +

In O +
in O +
vivo O +
experiments O +
, O +
the O +
metastasis O +
and O +
survival O +
of O +
tumor O +
- O +
engrafted O +
mice O +
were O +
monitored O +
. O +

Furthermore O +
, O +
the O +
effects O +
of O +
a O +
selective O +
NF O +
- O +
kappaB O +
inhibitor O +
, O +
NEMO O +
- O +
binding O +
domain O +
( O +
NBD O +
) O +
peptide O +
, O +
on O +
metastasis O +
in O +
GSAS B-CellLine +
/ O +
N5 O +
- O +
engrafted O +
mice O +
were O +
assessed O +
, O +
and O +
engrafted O +
tongue O +
tumors O +
were O +
immunohistochemically O +
examined O +
. O +

Highly O +
metastatic O +
GSAS B-CellLine +
/ O +
N3 O +
and O +
N5 O +
cells O +
showed O +
an O +
enhanced O +
NF O +
- O +
kappaB O +
activity O +
, O +
thus O +
contributing O +
to O +
increased O +
migration O +
, O +
invasion O +
, O +
and O +
a O +
poor O +
prognosis O +
compared O +
with O +
the O +
parent O +
cells O +
. O +

Furthermore O +
, O +
the O +
expression O +
levels O +
of O +
NF O +
- O +
kappaB O +
- O +
regulated O +
metastasis O +
- O +
related O +
molecules O +
, O +
such O +
as O +
fibronectin O +
, O +
beta1 O +
integrin O +
, O +
MMP O +
- O +
1 O +
, O +
- O +
2 O +
, O +
- O +
9 O +
, O +
and O +
- O +
14 O +
, O +
and O +
VEGF O +
- O +
C O +
, O +
were O +
upregulated O +
in O +
the O +
highly O +
metastatic O +
cells O +
. O +

The O +
NBD O +
peptide O +
suppressed O +
metastasis O +
and O +
tongue O +
tumor O +
growth O +
in O +
GSAS B-CellLine +
/ O +
N5 O +
- O +
inoculated O +
mice O +
, O +
and O +
was O +
accompanied O +
by O +
the O +
downregulation O +
of O +
the O +
NF O +
- O +
kappaB O +
- O +
regulated O +
metastasis O +
- O +
related O +
molecules O +
in O +
engrafted O +
tongue O +
tumors O +
. O +

Our O +
results O +
suggest O +
that O +
the O +
selective O +
inhibition O +
of O +
NF O +
- O +
kappaB O +
activation O +
by O +
NBD O +
peptide O +
may O +
provide O +
an O +
effective O +
approach O +
for O +
the O +
treatment O +
of O +
highly O +
metastatic O +
OSCC O +
. O +

beta O +
- O +
catenin O +
signaling O +
controls O +
metastasis O +
in O +
Braf O +
- O +
activated O +
Pten O +
- O +
deficient O +
melanomas O +
. O +

Malignant O +
melanoma O +
is O +
characterized O +
by O +
frequent O +
metastasis O +
, O +
however O +
, O +
specific O +
changes O +
that O +
regulate O +
this O +
process O +
have O +
not O +
been O +
clearly O +
delineated O +
. O +

Although O +
it O +
is O +
well O +
known O +
that O +
Wnt O +
signaling O +
is O +
frequently O +
dysregulated O +
in O +
melanoma O +
, O +
the O +
functional O +
implications O +
of O +
this O +
observation O +
are O +
unclear O +
. O +

By O +
modulating O +
beta O +
- O +
catenin O +
levels O +
in O +
a O +
mouse O +
model O +
of O +
melanoma O +
that O +
is O +
based O +
on O +
melanocyte O +
- O +
specific O +
Pten O +
loss O +
and O +
Braf O +
( O +
V600E O +
) O +
mutation O +
, O +
we O +
demonstrate O +
that O +
beta O +
- O +
catenin O +
is O +
a O +
central O +
mediator O +
of O +
melanoma O +
metastasis O +
to O +
the O +
lymph O +
nodes O +
and O +
lungs O +
. O +

In O +
addition O +
to O +
altering O +
metastasis O +
, O +
beta O +
- O +
catenin O +
levels O +
control O +
tumor O +
differentiation O +
and O +
regulate O +
both O +
MAPK O +
/ O +
Erk O +
and O +
PI3 O -
K O +
/ O +
Akt O +
signaling O +
. O +

Highly O +
metastatic O +
tumors O +
with O +
beta O +
- O +
catenin O +
stabilization O +
are O +
very O +
similar O +
to O +
a O +
subset O +
of O +
human O +
melanomas O +
. O +

Together O +
these O +
findings O +
establish O +
Wnt O +
signaling O +
as O +
a O +
metastasis O +
regulator O +
in O +
melanoma O +
. O +

Impaired O +
CK1 O +
delta O +
activity O +
attenuates O +
SV40 O +
- O +
induced O +
cellular O +
transformation O +
in O +
vitro O +
and O +
mouse O +
mammary O +
carcinogenesis O +
in O +
vivo O +
. O +

Simian O +
virus O +
40 O +
( O +
SV40 O +
) O +
is O +
a O +
powerful O +
tool O +
to O +
study O +
cellular O +
transformation O +
in O +
vitro O +
, O +
as O +
well O +
as O +
tumor O +
development O +
and O +
progression O +
in O +
vivo O +
. O +

Various O +
cellular O +
kinases O +
, O +
among O +
them O +
members O +
of O +
the O +
CK1 O +
family O +
, O +
play O +
an O +
important O +
role O +
in O +
modulating O +
the O +
transforming O +
activity O +
of O +
SV40 O +
, O +
including O +
the O +
transforming O +
activity O +
of O +
T O +
- O +
Ag O +
, O +
the O +
major O +
transforming O +
protein O +
of O +
SV40 O +
, O +
itself O +
. O +

Here O +
we O +
characterized O +
the O +
effects O +
of O +
mutant O +
CK1delta O +
variants O +
with O +
impaired O +
kinase O +
activity O +
on O +
SV40 O +
- O +
induced O +
cell O +
transformation O +
in O +
vitro O +
, O +
and O +
on O +
SV40 O +
- O +
induced O +
mammary O +
carcinogenesis O +
in O +
vivo O +
in O +
a O +
transgenic O +
/ O +
bi O +
- O +
transgenic O +
mouse O +
model O +
. O +

CK1delta O +
mutants O +
exhibited O +
a O +
reduced O +
kinase O +
activity O +
compared O +
to O +
wtCK1delta O +
in O +
in O +
vitro O +
kinase O +
assays O +
. O +

Molecular O +
modeling O +
studies O +
suggested O +
that O +
mutation O +
N172D O +
, O +
located O +
within O +
the O +
substrate O +
binding O +
region O +
, O +
is O +
mainly O +
responsible O +
for O +
impaired O +
mutCK1delta O +
activity O +
. O +

When O +
stably O +
over O +
- O +
expressed O +
in O +
maximal O +
transformed O +
SV B-CellLine +
- I-CellLine +
52 I-CellLine +
cells O +
, O +
CK1delta O +
mutants O +
induced O +
reversion O +
to O +
a O +
minimal O +
transformed O +
phenotype O +
by O +
dominant O +
- O +
negative O +
interference O +
with O +
endogenous O +
wtCK1delta O +
. O +

To O +
characterize O +
the O +
effects O +
of O +
CK1delta O +
on O +
SV40 O +
- O +
induced O +
mammary O +
carcinogenesis O +
, O +
we O +
generated O +
transgenic O +
mice O +
expressing O +
mutant O +
CK1delta O +
under O +
the O +
control O +
of O +
the O +
whey O +
acidic O +
protein O +
( O +
WAP O +
) O +
gene O +
promoter O +
, O +
and O +
crossed O +
them O +
with O +
SV40 O +
transgenic O +
WAP O +
- O +
T O +
- O +
antigen O +
( O +
WAP O +
- O +
T O +
) O +
mice O +
. O +

Both O +
WAP O +
- O +
T O +
mice O +
as O +
well O +
as O +
WAP O +
- O +
mutCK1delta O +
/ O +
WAP O +
- O +
T O +
bi O +
- O +
transgenic O +
mice O +
developed O +
breast O +
cancer O +
. O +

However O +
, O +
tumor O +
incidence O +
was O +
lower O +
and O +
life O +
span O +
was O +
significantly O +
longer O +
in O +
WAP O +
- O +
mutCK1delta O +
/ O +
WAP O +
- O +
T O +
bi O +
- O +
transgenic O +
animals O +
. O +

The O +
reduced O +
CK1delta O +
activity O +
did O +
not O +
affect O +
early O +
lesion O +
formation O +
during O +
tumorigenesis O +
, O +
suggesting O +
that O +
impaired O +
CK1delta O +
activity O +
reduces O +
the O +
probability O +
for O +
outgrowth O +
of O +
in O +
situ O +
carcinomas O +
to O +
invasive O +
carcinomas O +
. O +

The O +
different O +
tumorigenic O +
potential O +
of O +
SV40 O +
in O +
WAP O +
- O +
T O +
and O +
WAP O +
- O +
mutCK1delta O +
/ O +
WAP O +
- O +
T O +
tumors O +
was O +
also O +
reflected O +
by O +
a O +
significantly O +
different O +
expression O +
of O +
various O +
genes O +
known O +
to O +
be O +
involved O +
in O +
tumor O +
progression O +
, O +
specifically O +
of O +
those O +
involved O +
in O +
wnt O +
- O +
signaling O +
and O +
DNA O +
repair O +
. O +

Our O +
data O +
show O +
that O +
inactivating O +
mutations O +
in O +
CK1delta O +
impair O +
SV40 O +
- O +
induced O +
cellular O +
transformation O +
in O +
vitro O +
and O +
mouse O +
mammary O +
carcinogenesis O +
in O +
vivo O +
. O +

Mitochondrial O +
apoptosis O +
and O +
FAK O +
signaling O +
disruption O +
by O +
a O +
novel O +
histone O +
deacetylase O +
inhibitor O +
, O +
HTPB O +
, O +
in O +
antitumor O +
and O +
antimetastatic O +
mouse O +
models O +
. O +

BACKGROUND O +
: O +
Compound O +
targeting O +
histone O +
deacetylase O +
( O +
HDAC O +
) O +
represents O +
a O +
new O +
era O +
in O +
molecular O +
cancer O +
therapeutics O +
. O +

However O +
, O +
effective O +
HDAC O +
inhibitors O +
for O +
the O +
treatment O +
of O +
solid O +
tumors O +
remain O +
to O +
be O +
developed O +
. O +

METHODOLOGY O +
/ O +
PRINCIPAL O +
FINDINGS O +
: O +
Here O +
, O +
we O +
propose O +
a O +
novel O +
HDAC O +
inhibitor O +
, O +
N O +
- O +
Hydroxy O +
- O +
4 O +
- O +
( O +
4 O +
- O +
phenylbutyryl O +
- O +
amino O +
) O +
benzamide O +
( O +
HTPB O +
) O +
, O +
as O +
a O +
potential O +
chemotherapeutic O +
drug O +
for O +
solid O +
tumors O +
. O +

The O +
HDAC O +
inhibition O +
of O +
HTPB O +
was O +
confirmed O +
using O +
HDAC O +
activity O +
assay O +
. O +

The O +
antiproliferative O +
and O +
anti O +
- O +
migratory O +
mechanisms O +
of O +
HTPB O +
were O +
investigated O +
by O +
cell O +
proliferation O +
, O +
flow O +
cytometry O +
, O +
DNA O +
ladder O +
, O +
caspase O +
activity O +
, O +
Rho O +
activity O +
, O +
F O +
- O +
actin O +
polymerization O +
, O +
and O +
gelatin O +
- O +
zymography O +
for O +
matrix O +
metalloproteinases O +
( O +
MMPs O +
) O +
. O +

Mice O +
with O +
tumor O +
xenograft O +
and O +
experimental O +
metastasis O +
model O +
were O +
used O +
to O +
evaluate O +
effects O +
on O +
tumor O +
growth O +
and O +
metastasis O +
. O +

Our O +
results O +
indicated O +
that O +
HTPB O +
was O +
a O +
pan O +
- O +
HDAC O +
inhibitor O +
in O +
suppressing O +
cell O +
viability O +
specifically O +
of O +
lung O +
cancer O +
cells O +
but O +
not O +
of O +
the O +
normal O +
lung O +
cells O +
. O +

Upon O +
HTPB O +
treatment O +
, O +
cell O +
cycle O +
arrest O +
was O +
induced O +
and O +
subsequently O +
led O +
to O +
mitochondria O +
- O +
mediated O +
apoptosis O +
. O +

HTPB O +
disrupted O +
F O +
- O +
actin O +
dynamics O +
via O +
downregulating O +
RhoA O +
activity O +
. O +

Moreover O +
, O +
HTPB O +
inhibited O +
activity O +
of O +
MMP2 O +
and O +
MMP9 O +
, O +
reduced O +
integrin O +
- O +
beta1 O +
/ O +
focal O +
adhesion O +
complex O +
formation O +
and O +
decreased O +
pericellular O +
poly O +
- O +
fibronectin O +
assemblies O +
. O +

Finally O +
, O +
intraperitoneal O +
injection O +
or O +
oral O +
administration O +
of O +
HTPB O +
efficiently O +
inhibited O +
A549 B-CellLine +
xenograft O +
tumor O +
growth O +
in O +
vivo O +
without O +
side O +
effects O +
. O +

HTPB O +
delayed O +
lung O +
metastasis O +
of O +
4T1 B-CellLine +
mouse O +
breast O +
cancer O +
cells O +
. O +

Acetylation O +
of O +
histone O +
and O +
non O +
- O +
histone O +
proteins O +
, O +
induction O +
of O +
apoptotic O +
- O +
related O +
proteins O +
and O +
de O +
- O +
phosphorylation O +
of O +
focal O +
adhesion O +
kinase O +
were O +
confirmed O +
in O +
treated O +
mice O +
. O +

CONCLUSIONS O +
/ O +
SIGNIFICANCE O +
: O +
These O +
results O +
suggested O +
that O +
intrinsic O +
apoptotic O +
pathway O +
may O +
involve O +
in O +
anti O +
- O +
tumor O +
growth O +
effects O +
of O +
HTPB O +
in O +
lung O +
cancer O +
cells O +
. O +

HTPB O +
significantly O +
suppresses O +
tumor O +
metastasis O +
partly O +
through O +
inhibition O +
of O +
integrin O +
- O +
beta1 O +
/ O +
FAK O +
/ O +
MMP O +
/ O +
RhoA O +
/ O +
F O +
- O +
actin O +
pathways O +
. O +

We O +
have O +
provided O +
convincing O +
preclinical O +
evidence O +
that O +
HTPB O +
is O +
a O +
potent O +
HDAC O +
targeted O +
inhibitor O +
and O +
is O +
thus O +
a O +
promising O +
candidate O +
for O +
lung O +
cancer O +
chemotherapy O +
. O +

Inactivation O +
of O +
androgen O +
- O +
induced O +
regulator O +
ARD1 O +
inhibits O +
androgen O +
receptor O +
acetylation O +
and O +
prostate O +
tumorigenesis O +
. O +

Androgen O +
signaling O +
through O +
androgen O +
receptor O +
( O +
AR O +
) O +
is O +
critical O +
for O +
prostate O +
tumorigenesis O +
. O +

Given O +
that O +
AR O +
- O +
mediated O +
gene O +
regulation O +
is O +
enhanced O +
by O +
AR O +
coregulators O +
, O +
inactivation O +
of O +
those O +
coregulators O +
is O +
emerging O +
as O +
a O +
promising O +
therapy O +
for O +
prostate O +
cancer O +
( O +
PCa O +
) O +
. O +

Here O +
, O +
we O +
show O +
that O +
the O +
N O +
- O +
acetyltransferase O +
arrest O +
- O +
defect O +
1 O +
protein O +
( O +
ARD1 O +
) O +
functions O +
as O +
a O +
unique O +
AR O +
regulator O +
in O +
PCa O +
cells O +
. O +

ARD1 O +
is O +
up O +
- O +
regulated O +
in O +
human O +
PCa O +
cell O +
lines O +
and O +
primary O +
tumor O +
biopsies O +
. O +

The O +
expression O +
of O +
ARD1 O +
was O +
augmented O +
by O +
treatment O +
with O +
synthetic O +
androgen O +
( O +
R1881 O +
) O +
unless O +
AR O +
is O +
deficient O +
or O +
is O +
inhibited O +
by O +
AR O +
- O +
specific O +
siRNA O +
or O +
androgen O +
inhibitor O +
bicalutamide O +
( O +
Casodex O +
) O +
. O +

Depletion O +
of O +
ARD1 O +
by O +
shRNA O +
suppressed O +
PCa O +
cell O +
proliferation O +
, O +
anchorage O +
- O +
independent O +
growth O +
, O +
and O +
xenograft O +
tumor O +
formation O +
in O +
SCID O +
mice O +
, O +
suggesting O +
that O +
AR O +
- O +
dependent O +
ARD1 O +
expression O +
is O +
biologically O +
germane O +
. O +

Notably O +
, O +
ARD1 O +
was O +
critical O +
for O +
transcriptionally O +
regulating O +
a O +
number O +
of O +
AR O +
target O +
genes O +
that O +
are O +
involved O +
in O +
prostate O +
tumorigenesis O +
. O +

Furthermore O +
, O +
ARD1 O +
interacted O +
physically O +
with O +
and O +
acetylated O +
the O +
AR O +
protein O +
in O +
vivo O +
and O +
in O +
vitro O +
. O +

Because O +
AR O +
- O +
ARD1 O +
interaction O +
facilitated O +
the O +
AR O +
binding O +
to O +
its O +
targeted O +
promoters O +
for O +
gene O +
transcription O +
, O +
we O +
propose O +
that O +
ARD1 O +
functions O +
as O +
a O +
unique O +
AR O +
regulator O +
and O +
forms O +
a O +
positive O +
feedback O +
loop O +
for O +
AR O +
- O +
dependent O +
prostate O +
tumorigenesis O +
. O +

Disruption O +
of O +
AR O +
- O +
ARD1 O +
interactions O +
may O +
be O +
a O +
potent O +
intervention O +
for O +
androgen O +
- O +
dependent O +
PCa O +
therapy O +
. O +

The O +
role O +
of O +
He O -
s O +
genes O +
in O +
intestinal O +
development O +
, O +
homeostasis O +
and O +
tumor O +
formation O +
. O +

Notch O +
signaling O +
regulates O +
intestinal O +
development O +
, O +
homeostasis O +
and O +
tumorigenesis O +
, O +
but O +
its O +
precise O +
downstream O +
mechanism O +
remains O +
largely O +
unknown O +
. O +

Here O +
we O +
found O +
that O +
inactivation O +
of O +
the O +
Notch O +
effectors O +
Hes1 O +
, O +
Hes3 O +
and O +
Hes5 O +
, O +
but O +
not O +
Hes1 O +
alone O +
, O +
led O +
to O +
reduced O +
cell O +
proliferation O +
, O +
increased O +
secretory O +
cell O +
formation O +
and O +
altered O +
intestinal O +
structures O +
in O +
adult O +
mice O +
. O +

However O +
, O +
in O +
Apc O +
mutation O +
- O +
induced O +
intestinal O +
tumors O +
, O +
inactivation O +
of O +
Hes1 O +
alone O +
was O +
sufficient O +
for O +
reducing O +
tumor O +
cell O +
proliferation O +
and O +
inducing O +
differentiation O +
of O +
tumor O +
cells O +
into O +
all O +
types O +
of O +
intestinal O +
epithelial O +
cells O +
, O +
but O +
without O +
affecting O +
the O +
homeostasis O +
of O +
normal O +
crypts O +
owing O +
to O +
genetic O +
redundancy O +
. O +

These O +
results O +
indicated O +
that O +
He O -
s O +
genes O +
cooperatively O +
regulate O +
intestinal O +
development O +
and O +
homeostasis O +
and O +
raised O +
the O +
possibility O +
that O +
Hes1 O +
is O +
a O +
promising O +
target O +
to O +
induce O +
the O +
differentiation O +
of O +
tumor O +
cells O +
. O +

Activation O +
- O +
induced O +
cytidine O +
deaminase O +
in O +
antibody O +
diversification O +
and O +
chromosome O +
translocation O +
. O +

DNA O +
damage O +
, O +
rearrangement O +
, O +
and O +
mutation O +
of O +
the O +
human O +
genome O +
are O +
the O +
basis O +
of O +
carcinogenesis O +
and O +
thought O +
to O +
be O +
avoided O +
at O +
all O +
costs O +
. O +

An O +
exception O +
is O +
the O +
adaptive O +
immune O +
system O +
where O +
lymphocytes O +
utilize O +
programmed O +
DNA O +
damage O +
to O +
effect O +
antigen O +
receptor O +
diversification O +
. O +

Both O +
B O +
and O +
T O +
lymphocytes O +
diversify O +
their O +
antigen O +
receptors O +
through O +
RAG1 O +
/ O +
2 O +
mediated O +
recombination O +
, O +
but O +
B O +
cells O +
undergo O +
two O +
additional O +
processes O +
- O +
- O +
somatic O +
hypermutation O +
( O +
SHM O +
) O +
and O +
class O +
- O +
switch O +
recombination O +
( O +
CSR O +
) O +
, O +
both O +
initiated O +
by O +
activation O +
- O +
induced O +
cytidine O +
deaminase O +
( O +
AID O +
) O +
. O +

AID O +
deaminates O +
cytidines O +
in O +
DNA O +
resulting O +
in O +
U O +
: O +
G O +
mismatches O +
that O +
are O +
processed O +
into O +
point O +
mutations O +
in O +
SHM O +
or O +
double O +
- O +
strand O +
breaks O +
in O +
CSR O +
. O +

Although O +
AID O +
activity O +
is O +
focused O +
at O +
Immunoglobulin O +
( O +
Ig O +
) O +
gene O +
loci O +
, O +
it O +
also O +
targets O +
a O +
wide O +
array O +
of O +
non O +
- O +
Ig O +
genes O +
including O +
oncogenes O +
associated O +
with O +
lymphomas O +
. O +

Here O +
, O +
we O +
review O +
the O +
molecular O +
basis O +
of O +
AID O +
regulation O +
, O +
targeting O +
, O +
and O +
initiation O +
of O +
CSR O +
and O +
SHM O +
, O +
as O +
well O +
as O +
AID O +
' O +
s O +
role O +
in O +
generating O +
chromosome O +
translocations O +
that O +
contribute O +
to O +
lymphomagenesis O +
. O +

Expression O +
of O +
HER2 O +
and O +
bradykinin O +
B1 O +
receptors O +
in O +
precursor O +
lesions O +
of O +
gallbladder O +
carcinoma O +
. O +

AIM O +
: O +
To O +
determine O +
the O +
expression O +
of O +
HER2 O +
and O +
bradykinin O +
B O +
( O +
1 O +
) O +
receptors O +
( O +
B O +
( O +
1 O +
) O +
R O +
) O +
in O +
the O +
two O +
pathogenic O +
models O +
of O +
gallbladder O +
cancer O +
: O +
the O +
metaplasia O +
- O +
dysplasia O +
- O +
carcinoma O +
and O +
the O +
adenoma O +
- O +
carcinoma O +
pathways O +
. O +

METHODS O +
: O +
Receptor O +
proteins O +
were O +
visualized O +
by O +
immunohistochemistry O +
on O +
5 O +
- O +
mum O +
sections O +
of O +
paraffin O +
- O +
embedded O +
tissue O +
. O +

Expression O +
of O +
both O +
receptors O +
was O +
studied O +
in O +
biopsy O +
samples O +
from O +
92 O +
patients O +
( O +
6 O +
males O +
and O +
86 O +
females O +
; O +
age O +
ranging O +
from O +
28 O +
to O +
86 O +
years O +
, O +
mean O +
56 O +
years O +
) O +
. O +

High O +
HER2 O +
expression O +
in O +
specimens O +
was O +
additionally O +
investigated O +
by O +
fluorescence O +
in O +
situ O +
hybridization O +
. O +

Cell O +
proliferation O +
in O +
each O +
sample O +
was O +
assessed O +
by O +
using O +
the O +
Ki O +
- O +
67 O +
proliferation O +
marker O +
. O +

RESULTS O +
: O +
HER2 O +
receptor O +
protein O +
was O +
absent O +
in O +
adenomas O +
and O +
in O +
normal O +
gallbladder O +
epithelium O +
. O +

On O +
the O +
contrary O +
, O +
there O +
was O +
intense O +
staining O +
for O +
HER2 O +
on O +
the O +
basolateral O +
membrane O +
of O +
epithelial O +
cells O +
of O +
intestinal O +
metaplasia O +
( O +
22 O +
/ O +
24 O +
; O +
91 O +
. O +
7 O +
% O +
) O +
and O +
carcinoma O +
in O +
situ O +
( O +
9 O +
/ O +
10 O +
; O +
90 O +
% O +
) O +
, O +
the O +
lesions O +
that O +
displayed O +
a O +
significantly O +
high O +
proliferation O +
index O +
. O +

Protein O +
up O +
- O +
regulation O +
of O +
HER2 O +
in O +
the O +
epithelium O +
with O +
metaplasia O +
or O +
carcinoma O +
in O +
situ O +
was O +
not O +
accompanied O +
by O +
HER2 O +
gene O +
amplification O +
. O +

A O +
similar O +
result O +
was O +
observed O +
in O +
invasive O +
carcinomas O +
( O +
0 O +
/ O +
12 O +
) O +
. O +

The O +
B O +
( O +
1 O +
) O +
R O +
distribution O +
pattern O +
mirrored O +
that O +
of O +
HER2 O +
except O +
that O +
B O +
( O +
1 O +
) O +
R O +
was O +
additionally O +
observed O +
in O +
the O +
adenomas O +
. O +

The O +
B O +
( O +
1 O +
) O +
R O +
appeared O +
either O +
as O +
cytoplasmic O +
dots O +
or O +
labeling O +
on O +
the O +
apical O +
cell O +
membrane O +
of O +
the O +
cells O +
composing O +
the O +
epithelia O +
with O +
intestinal O +
metaplasia O +
( O +
24 O +
/ O +
24 O +
; O +
100 O +
% O +
) O +
and O +
carcinoma O +
in O +
situ O +
( O +
10 O +
/ O +
10 O +
; O +
100 O +
% O +
) O +
and O +
in O +
the O +
epithelial O +
cells O +
of O +
adenomas O +
. O +

In O +
contrast O +
, O +
both O +
HER2 O +
( O +
4 O +
/ O +
12 O +
; O +
33 O +
% O +
) O +
and O +
B O +
( O +
1 O +
) O +
R O +
( O +
1 O +
/ O +
12 O +
; O +
8 O +
. O +
3 O +
% O +
) O +
showed O +
a O +
low O +
expression O +
in O +
invasive O +
gallbladder O +
carcinomas O +
. O +

CONCLUSION O +
: O +
The O +
up O +
- O +
regulation O +
of O +
HER2 O +
and O +
B O +
( O +
1 O +
) O +
R O +
in O +
precursor O +
lesions O +
of O +
gallbladder O +
carcinoma O +
suggests O +
cross O +
- O +
talk O +
between O +
these O +
two O +
receptors O +
that O +
may O +
be O +
of O +
importance O +
in O +
the O +
modulation O +
of O +
cell O +
proliferation O +
in O +
gallbladder O +
carcinogenesis O +
. O +

Expression O +
of O +
basic O +
fibroblast O +
growth O +
factor O +
in O +
normal O +
human O +
tissues O +
. O +

The O +
distribution O +
of O +
basic O +
fibroblast O +
growth O +
factor O +
( O +
bFGF O +
) O +
was O +
studied O +
immunohistochemically O +
in O +
fresh O +
frozen O +
sections O +
of O +
normal O +
human O +
tissues O +
. O +

Immunodetection O +
was O +
performed O +
with O +
a O +
specific O +
anti O +
- O +
bFGF O +
mouse O +
monoclonal O +
antibody O +
that O +
was O +
found O +
to O +
react O +
with O +
recombinant O +
human O +
bFGF O +
in O +
Western O +
blot O +
analysis O +
, O +
and O +
to O +
specifically O +
neutralize O +
the O +
mitogenic O +
activity O +
of O +
bFGF O +
on O +
bovine O +
vascular O +
endothelial O +
cells O +
. O +

Expression O +
of O +
bFGF O +
on O +
normal O +
human O +
tissues O +
was O +
ubiquitously O +
detected O +
in O +
the O +
basement O +
membranes O +
of O +
all O +
size O +
blood O +
vessels O +
, O +
but O +
was O +
not O +
found O +
in O +
epidermal O +
or O +
epithelial O +
basement O +
membranes O +
of O +
a O +
variety O +
of O +
tissues O +
tested O +
. O +

Intensity O +
and O +
patterns O +
of O +
localization O +
in O +
blood O +
vessels O +
was O +
consistent O +
in O +
various O +
tissues O +
, O +
but O +
varied O +
among O +
different O +
regions O +
of O +
the O +
vascular O +
bed O +
. O +

Whereas O +
homogeneous O +
and O +
intense O +
immunoreactivity O +
were O +
observed O +
in O +
large O +
and O +
intermediate O +
size O +
blood O +
vessels O +
, O +
heterogeneity O +
of O +
expression O +
was O +
found O +
in O +
capillaries O +
. O +

The O +
most O +
intense O +
immunoreactivity O +
was O +
observed O +
in O +
branching O +
capillaries O +
. O +

Endothelial O +
cell O +
staining O +
was O +
heterogeneous O +
and O +
varied O +
in O +
different O +
regions O +
. O +

Strong O +
staining O +
for O +
bFGF O +
was O +
also O +
found O +
in O +
cardiac O +
muscle O +
fibers O +
, O +
smooth O +
muscle O +
cells O +
of O +
mid O +
- O +
size O +
blood O +
vessels O +
, O +
the O +
gut O +
and O +
the O +
myometrium O +
, O +
in O +
central O +
nervous O +
system O +
neurons O +
and O +
cerebellar O +
Purkinje O +
cells O +
, O +
and O +
on O +
epithelial O +
cells O +
of O +
the O +
bronchi O +
, O +
colon O +
, O +
endometrium O +
, O +
and O +
sweat O +
gland O +
ducts O +
of O +
the O +
skin O +
. O +

The O +
presence O +
of O +
bFGF O +
in O +
the O +
extracellular O +
compartment O +
of O +
a O +
diverse O +
variety O +
of O +
organs O +
may O +
play O +
a O +
role O +
in O +
angiogenesis O +
. O +

However O +
, O +
the O +
function O +
of O +
bFGF O +
in O +
parenchymal O +
cells O +
remains O +
to O +
be O +
determined O +
. O +

Incidence O +
of O +
BRAF O +
p O +
. O +
Val600Glu O +
and O +
p O +
. O +
Val600Lys O +
mutations O +
in O +
a O +
consecutive O +
series O +
of O +
183 O +
metastatic O +
melanoma O +
patients O +
from O +
a O +
high O +
incidence O +
region O +
. O +

AIM O +
: O +
Approximately O +
40 O +
- O +
60 O +
% O +
of O +
melanomas O +
from O +
Caucasian O +
populations O +
carry O +
activating O +
mutations O +
in O +
the O +
BRAF O +
oncogene O +
, O +
with O +
the O +
most O +
common O +
being O +
the O +
p O +
. O +
Val600Glu O +
( O +
V600E O +
) O +
hotspot O +
mutation O +
in O +
exon O +
15 O +
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
was O +
to O +
investigate O +
the O +
frequency O +
of O +
the O +
less O +
common O +
p O +
. O +
Val600Lys O +
( O +
V600 O -
K O +
) O +
mutation O +
in O +
metastatic O +
melanoma O +
from O +
a O +
high O +
incidence O +
region O +
. O +

METHOD O +
: O +
Dideoxy O +
sequencing O +
and O +
fluorescent O +
single O +
strand O +
conformation O +
analysis O +
were O +
used O +
to O +
screen O +
for O +
mutations O +
in O +
exon O +
15 O +
of O +
BRAF O +
in O +
183 O +
cases O +
of O +
metastatic O +
melanoma O +
. O +

RESULTS O +
: O +
The O +
overall O +
incidence O +
of O +
BRAF O +
mutation O +
( O +
89 O +
/ O +
183 O +
, O +
49 O +
% O +
) O +
was O +
very O +
similar O +
to O +
other O +
large O +
studies O +
of O +
Caucasian O +
populations O +
. O +

However O +
, O +
the O +
frequency O +
of O +
the O +
p O +
. O +
Val600Lys O +
mutation O +
was O +
higher O +
than O +
in O +
most O +
other O +
studies O +
and O +
comprised O +
almost O +
one O +
- O +
third O +
of O +
all O +
BRAF O +
mutations O +
in O +
our O +
cohort O +
( O +
27 O +
/ O +
89 O +
, O +
30 O +
% O +
) O +
. O +

CONCLUSION O +
: O +
BRAF O +
p O +
. O +
Val600Lys O +
mutations O +
were O +
present O +
at O +
a O +
relatively O +
high O +
frequency O +
in O +
this O +
cohort O +
of O +
metastatic O +
melanoma O +
patients O +
( O +
27 O +
/ O +
183 O +
, O +
15 O +
% O +
) O +
. O +

Assays O +
used O +
to O +
screen O +
for O +
BRAF O +
mutations O +
in O +
the O +
clinic O +
should O +
be O +
robust O +
enough O +
to O +
detect O +
the O +
p O +
. O +
Val600Lys O +
mutation O +
, O +
as O +
this O +
may O +
have O +
therapeutic O +
implications O +
. O +

[ O +
Biotechnological O +
and O +
biomedical O +
aspects O +
of O +
production O +
and O +
study O +
of O +
metal O +
cation O +
- O +
phospholipid O +
complexes O +
] O +
. O +

Problems O +
relating O +
to O +
the O +
technology O +
of O +
a O +
phospholipid O +
preparation O +
from O +
natural O +
materials O +
, O +
liposome O +
production O +
, O +
and O +
studies O +
into O +
the O +
mechanisms O +
of O +
interaction O +
between O +
metal O +
( O +
trace O +
elements O +
) O +
cations O +
and O +
model O +
bilayer O +
lipid O +
membranes O +
are O +
discussed O +
. O +

The O +
proposed O +
technology O +
of O +
extraction O +
allows O +
for O +
preparation O +
of O +
phospholipids O +
utilizable O +
for O +
liposome O +
formation O +
. O +

The O +
cation O +
specificity O +
of O +
lipid O +
bilayers O +
is O +
found O +
to O +
be O +
determined O +
by O +
the O +
presence O +
of O +
anionic O +
phosphate O +
adsorption O +
sites O +
on O +
their O +
surface O +
. O +

Overexpression O +
confers O +
an O +
oncogenic O +
potential O +
upon O +
the O +
eph O +
gene O +
. O +

The O +
eph O +
gene O +
encodes O +
a O +
putative O +
receptor O +
tyrosine O +
kinase O +
for O +
an O +
as O +
yet O +
unknown O +
ligand O +
. O +

Some O +
human O +
cancer O +
cells O +
have O +
been O +
found O +
to O +
overexpress O +
eph O +
mRNAs O +
without O +
gene O +
amplification O +
. O +

We O +
show O +
here O +
that O +
NIH3T3 B-CellLine +
cells O +
acquire O +
tumorigenic O +
ability O +
in O +
nude O +
mice O +
and O +
make O +
colonies O +
in O +
soft O +
agar O +
with O +
a O +
viral O +
LTR O +
( O +
Long O +
Terminal O +
Repeat O +
) O +
- O +
driven O +
artificial O +
expression O +
of O +
the O +
eph O +
gene O +
to O +
a O +
high O +
level O +
. O +

This O +
result O +
supports O +
the O +
alleged O +
contribution O +
of O +
overexpressed O +
receptor O +
tyrosine O +
kinases O +
to O +
cell O +
transformation O +
. O +

The O +
enlarging O +
clinical O +
spectrum O +
of O +
Lyme O +
disease O +
: O +
Lyme O +
cerebral O +
vasculitis O +
, O +
a O +
new O +
disease O +
entity O +
. O +

The O +
case O +
of O +
a O +
patient O +
with O +
cerebral O +
vasculitis O +
with O +
a O +
right O +
thalamic O +
infarct O +
associated O +
with O +
cerebral O +
spinal O +
fluid O +
Lyme O +
disease O +
is O +
presented O +
. O +

This O +
entity O +
has O +
not O +
been O +
described O +
in O +
the O +
United O +
States O +
, O +
and O +
only O +
one O +
similar O +
case O +
in O +
the O +
world O +
literature O +
could O +
be O +
found O +
. O +

The O +
patient O +
presented O +
with O +
a O +
progressive O +
headache O +
and O +
subsequent O +
development O +
of O +
grand O +
mal O +
seizure O +
activity O +
. O +

Lyme O +
disease O +
has O +
been O +
associated O +
with O +
cranial O +
nerve O +
palsies O +
, O +
peripheral O +
and O +
cranial O +
radiculopathies O +
, O +
aseptic O +
meningitis O +
, O +
encephalitic O +
symptoms O +
, O +
chorea O +
, O +
and O +
demyelinating O +
polyneuropathy O +
presenting O +
like O +
Guillain O +
- O +
Barre O +
syndrome O +
. O +

These O +
syndromes O +
can O +
occur O +
separately O +
or O +
in O +
combination O +
. O +

Stroke O +
and O +
strokelike O +
syndromes O +
have O +
been O +
attributed O +
to O +
Lyme O +
disease O +
. O +

The O +
literature O +
concerning O +
the O +
neurologic O +
manifestations O +
of O +
Lyme O +
disease O +
is O +
reviewed O +
. O +

Amplification O +
of O +
mineralocorticoid O +
activity O +
of O +
aldosterone O +
by O +
18 O +
- O +
hydroxy O +
- O +
corticosterone O +
and O +
18 O +
- O +
hydroxy O +
- O +
19 O +
- O +
nor O +
- O +
corticosterone O +
in O +
adrenalectomized O +
rats O +
. O +

A O +
combination O +
of O +
aldosterone O +
( O +
1 O +
micrograms O +
) O +
with O +
either O +
18 O +
- O +
OH O +
- O +
corticosterone O +
( O +
1 O +
micrograms O +
) O +
or O +
18 O +
- O +
OH O +
- O +
19 O +
- O +
norcorticosterone O +
( O +
1 O +
micrograms O +
) O +
injected O +
to O +
adrenalectomized O +
rats O +
indicated O +
an O +
amplification O +
of O +
mineralocorticoid O +
activity O +
as O +
expressed O +
by O +
Na O +
/ O +
K O +
ratio O +
in O +
urine O +
. O +

Without O +
aldosterone O +
their O +
mineralocorticoid O +
potency O +
was O +
negligible O +
. O +

Alterations O +
in O +
carbohydrate O +
metabolism O +
in O +
canine O +
lymphoma O +
. O +

Following O +
an O +
overnight O +
fast O +
, O +
blood O +
samples O +
were O +
obtained O +
from O +
14 O +
dogs O +
with O +
previously O +
untreated O +
lymphoma O +
before O +
and O +
5 O +
, O +
15 O +
, O +
30 O +
, O +
45 O +
, O +
60 O +
, O +
and O +
90 O +
minutes O +
following O +
an O +
intravenous O +
challenge O +
with O +
500 O +
mg O +
/ O +
kg O +
dextrose O +
. O +

Samples O +
were O +
assayed O +
for O +
glucose O +
, O +
lactate O +
, O +
and O +
insulin O +
concentrations O +
and O +
compared O +
statistically O +
with O +
ten O +
control O +
dogs O +
of O +
similar O +
weight O +
and O +
age O +
undergoing O +
an O +
identical O +
dextrose O +
challenge O +
. O +

Dogs O +
with O +
lymphoma O +
had O +
similar O +
glucose O +
tolerance O +
curves O +
when O +
compared O +
with O +
controls O +
. O +

Lactate O +
concentrations O +
were O +
significantly O +
higher O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
at O +
baseline O +
and O +
all O +
time O +
periods O +
of O +
the O +
glucose O +
tolerance O +
test O +
in O +
dogs O +
with O +
lymphoma O +
when O +
compared O +
with O +
controls O +
. O +

Rise O +
in O +
lactate O +
concentrations O +
over O +
baseline O +
levels O +
in O +
the O +
first O +
30 O +
minutes O +
of O +
the O +
glucose O +
tolerance O +
test O +
were O +
significantly O +
higher O +
in O +
dogs O +
with O +
lymphoma O +
( O +
P O +
= O +
0 O +
. O +
011 O +
) O +
. O +

Insulin O +
concentrations O +
were O +
significantly O +
higher O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
at O +
baseline O +
and O +
at O +
the O +
5 O +
- O +
, O +
45 O +
- O +
, O +
60 O +
- O +
, O +
and O +
90 O +
- O +
minute O +
time O +
periods O +
of O +
the O +
glucose O +
tolerance O +
test O +
in O +
dogs O +
with O +
lymphoma O +
. O +

Rise O +
in O +
insulin O +
concentrations O +
over O +
baseline O +
in O +
the O +
first O +
5 O +
minutes O +
of O +
the O +
glucose O +
tolerance O +
test O +
were O +
also O +
significantly O +
greater O +
in O +
dogs O +
with O +
lymphoma O +
( O +
P O +
= O +
0 O +
. O +
021 O +
) O +
. O +

These O +
results O +
indicate O +
carbohydrate O +
metabolism O +
is O +
altered O +
in O +
dogs O +
with O +
lymphoma O +
. O +

Many O +
of O +
these O +
alterations O +
parallel O +
those O +
observed O +
in O +
human O +
patients O +
suffering O +
from O +
cancer O +
cachexia O +
making O +
canine O +
lymphoma O +
a O +
potential O +
model O +
for O +
further O +
study O +
of O +
the O +
pathogenesis O +
and O +
therapy O +
of O +
cancer O +
cachexia O +
. O +

Retinal O +
revascularisation O +
in O +
diabetic O +
retinopathy O +
. O +

The O +
case O +
history O +
of O +
a O +
33 O +
- O +
year O +
- O +
old O +
diabetic O +
patient O +
who O +
has O +
had O +
diabetes O +
for O +
24 O +
years O +
is O +
presented O +
. O +

When O +
first O +
seen O +
in O +
1975 O +
he O +
had O +
bilateral O +
proliferative O +
retinopathy O +
with O +
new O +
vessels O +
in O +
the O +
retinal O +
periphery O +
. O +

He O +
had O +
large O +
areas O +
of O +
capillary O +
non O +
- O +
perfusion O +
lateral O +
to O +
the O +
macula O +
in O +
the O +
right O +
eye O +
associated O +
with O +
the O +
new O +
vessels O +
. O +

Nine O +
years O +
later O +
, O +
after O +
extensive O +
repeated O +
photocoagulation O +
, O +
revascularisation O +
of O +
large O +
areas O +
previously O +
not O +
perfused O +
were O +
seen O +
. O +

The O +
vessels O +
are O +
in O +
the O +
plane O +
of O +
the O +
retina O +
and O +
do O +
not O +
have O +
the O +
appearance O +
of O +
new O +
vessels O +
. O +

Members O +
of O +
the O +
src O +
and O +
ras O +
oncogene O +
families O +
supplant O +
the O +
epidermal O +
growth O +
factor O +
requirement O +
of O +
BALB O +
/ O +
MK O +
- O +
2 O +
keratinocytes O +
and O +
induce O +
distinct O +
alterations O +
in O +
their O +
terminal O +
differentiation O +
program O +
. O +

BALB O +
- O +
/ O +
MK O +
- O +
2 O +
mouse O +
epidermal O +
keratinocytes O +
required O +
epidermal O +
growth O +
factor O +
for O +
proliferation O +
and O +
terminally O +
differentiated O +
in O +
response O +
to O +
high O +
Ca2 O +
+ O +
concentration O +
. O +

Infection O +
with O +
retroviruses O +
containing O +
transforming O +
genes O +
of O +
the O +
src O +
and O +
ras O +
oncogene O +
families O +
led O +
to O +
rapid O +
loss O +
of O +
epidermal O +
growth O +
factor O +
dependence O +
, O +
in O +
some O +
cases O +
, O +
accompanied O +
by O +
alterations O +
in O +
cellular O +
morphology O +
. O +

The O +
virus O +
- O +
altered O +
cells O +
continued O +
to O +
proliferate O +
in O +
the O +
presence O +
of O +
high O +
levels O +
of O +
extracellular O +
calcium O +
but O +
exhibited O +
alterations O +
in O +
normal O +
keratinocyte O +
terminal O +
differentiation O +
that O +
appear O +
to O +
be O +
specific O +
to O +
the O +
particular O +
oncogene O +
. O +

These O +
alterations O +
bore O +
similarities O +
to O +
abnormalities O +
in O +
differentiation O +
observed O +
in O +
naturally O +
occurring O +
squamous O +
epithelial O +
malignancies O +
. O +

Experimental O +
drug O +
therapy O +
of O +
peritumoral O +
brain O +
edema O +
. O +

Four O +
drugs O +
with O +
potential O +
anti O +
- O +
peritumoral O +
brain O +
edema O +
activity O +
were O +
studied O +
using O +
the O +
VX2 O +
rabbit O +
brain O +
tumor O +
model O +
. O +

Meclofenamate O +
and O +
indomethacin O +
were O +
tested O +
in O +
an O +
attempt O +
to O +
confirm O +
recent O +
reports O +
of O +
anti O +
- O +
edema O +
activity O +
in O +
non O +
steroidal O +
anti O +
- O +
inflammatory O +
drugs O +
( O +
NSAID O +
' O +
s O +
) O +
. O +

The O +
' O +
angiostatic O +
' O +
steroids O +
17 O +
hydroxyprogesterone O +
and O +
epicortisol O +
were O +
tested O +
because O +
of O +
their O +
lack O +
of O +
glucocorticoid O +
and O +
mineralocorticoid O +
effects O +
and O +
their O +
structural O +
similarity O +
to O +
glucocorticoids O +
. O +

The O +
protein O +
and O +
water O +
component O +
of O +
brain O +
edema O +
were O +
indirectly O +
quantitated O +
. O +

None O +
of O +
the O +
test O +
drugs O +
demonstrated O +
significant O +
anti O +
- O +
edema O +
activity O +
. O +

This O +
work O +
does O +
not O +
confirm O +
reports O +
that O +
NSAID O +
' O +
s O +
have O +
anti O +
- O +
edema O +
activity O +
and O +
suggests O +
that O +
there O +
may O +
be O +
no O +
correlation O +
between O +
' O +
angiostatic O +
' O +
and O +
anti O +
- O +
edema O +
activity O +
in O +
certain O +
steroid O +
compounds O +
. O +

Gastric O +
microcirculatory O +
change O +
and O +
development O +
of O +
acute O +
gastric O +
mucosal O +
lesions O +
( O +
stress O +
ulcer O +
) O +
. O +

Concerning O +
the O +
pathogenesis O +
of O +
acute O +
gastric O +
mucosal O +
lesions O +
, O +
gastric O +
microcirculatory O +
change O +
has O +
drawn O +
attention O +
as O +
an O +
important O +
factor O +
. O +

In O +
view O +
of O +
this O +
fact O +
, O +
gastric O +
mucosal O +
blood O +
flow O +
and O +
microvascular O +
structure O +
were O +
investigated O +
in O +
normal O +
and O +
in O +
burn O +
stressed O +
rats O +
. O +

Moreover O +
, O +
alterations O +
in O +
acid O +
and O +
pepsin O +
activities O +
in O +
by O +
morphological O +
and O +
biochemical O +
procedures O +
in O +
order O +
to O +
evaluate O +
the O +
relationship O +
between O +
defensive O +
and O +
aggressive O +
factors O +
of O +
the O +
gastric O +
mucosa O +
. O +

Gastric O +
mucosal O +
blood O +
flow O +
decreased O +
significantly O +
in O +
early O +
period O +
after O +
induction O +
of O +
stress O +
( O +
p O +
less O +
than O +
0 O +
. O +
01 O +
) O +
. O +

The O +
incidence O +
of O +
ulceration O +
showed O +
a O +
correlative O +
relation O +
with O +
the O +
decrease O +
of O +
mucosal O +
blood O +
flow O +
. O +

Reduction O +
of O +
blood O +
flow O +
in O +
burn O +
was O +
due O +
to O +
opening O +
of O +
arteriovenular O +
shunt O +
and O +
it O +
appeared O +
that O +
this O +
was O +
responsible O +
for O +
mucosal O +
ischemia O +
and O +
congestion O +
. O +

Following O +
the O +
decrease O +
of O +
blood O +
flow O +
, O +
acid O +
output O +
was O +
lower O +
in O +
stress O +
than O +
that O +
in O +
control O +
. O +

Finally O +
, O +
the O +
results O +
of O +
these O +
studies O +
demonstrated O +
the O +
importance O +
of O +
defensive O +
factors O +
. O +

The O +
reduction O +
of O +
mucosal O +
blood O +
flow O +
resulted O +
in O +
the O +
sequence O +
of O +
events O +
that O +
led O +
to O +
formation O +
of O +
acute O +
gastric O +
mucosal O +
lesion O +
. O +

Identification O +
of O +
a O +
small O +
region O +
of O +
the O +
v O +
- O +
fos O +
gene O +
product O +
that O +
is O +
sufficient O +
for O +
transforming O +
potential O +
and O +
growth O +
- O +
stimulating O +
activity O +
. O +

To O +
analyze O +
the O +
structure O +
- O +
function O +
relationship O +
for O +
the O +
v O +
- O +
fos O +
protein O +
, O +
we O +
constructed O +
in O +
- O +
frame O +
insertion O +
and O +
deletion O +
mutants O +
of O +
the O +
v O +
- O +
fos O +
gene O +
carried O +
by O +
FBJ O +
- O +
MuSV O +
, O +
and O +
expressed O +
them O +
in O +
chicken O +
primary O +
cells O +
using O +
retrovirus O +
vectors O +
. O +

We O +
assessed O +
the O +
effects O +
of O +
these O +
mutations O +
on O +
the O +
ability O +
of O +
the O +
v O +
- O +
fos O +
protein O +
to O +
transform O +
chicken O +
embryo O +
fibroblasts O +
and O +
to O +
stimulate O +
cellular O +
proliferation O +
of O +
chicken O +
neuroretinal O +
cells O +
. O +

The O +
mutant O +
which O +
retains O +
only O +
the O +
central O +
region O +
of O +
the O +
v O +
- O +
fos O +
protein O +
( O +
Met111 O +
- O +
Ile206 O +
) O +
have O +
both O +
activities O +
, O +
but O +
the O +
mutants O +
which O +
have O +
deletions O +
in O +
this O +
region O +
, O +
and O +
one O +
of O +
the O +
mutants O +
that O +
has O +
a O +
four O +
amino O +
acid O +
insertion O +
in O +
it O +
, O +
lost O +
both O +
activities O +
. O +

The O +
central O +
region O +
that O +
is O +
sufficient O +
for O +
these O +
activities O +
includes O +
the O +
evolutionarily O +
highly O +
conserved O +
region O +
among O +
human O +
, O +
mouse O +
and O +
chicken O +
c O +
- O +
fos O +
proteins O +
. O +

Additionally O +
, O +
this O +
sequence O +
shares O +
some O +
homology O +
with O +
the O +
DNA O +
binding O +
domain O +
of O +
GCN4 O +
and O +
c O +
- O +
jun O +
protein O +
. O +

The O +
truncated O +
fos O +
protein O +
that O +
contains O +
only O +
part O +
of O +
the O +
central O +
region O +
is O +
not O +
phosphorylated O +
in O +
chicken O +
embryo O +
fibroblasts O +
, O +
indicating O +
that O +
phosphorylation O +
of O +
the O +
fos O +
protein O +
is O +
not O +
necessary O +
for O +
the O +
transforming O +
activity O +
. O +

Inhibition O +
by O +
retinoic O +
acid O +
of O +
type O +
IV O +
collagenolysis O +
and O +
invasion O +
through O +
reconstituted O +
basement O +
membrane O +
by O +
metastatic O +
rat O +
mammary O +
adenocarcinoma O +
cells O +
. O +

The O +
activity O +
of O +
type O +
IV O +
collagenase O +
, O +
which O +
enables O +
tumor O +
cells O +
to O +
degrade O +
collagen O +
type O +
IV O +
found O +
in O +
the O +
subendothelial O +
basement O +
membrane O +
, O +
has O +
been O +
correlated O +
with O +
the O +
metastatic O +
potential O +
in O +
several O +
tumor O +
types O +
, O +
including O +
the O +
rat O +
13762NF B-CellLine +
mammary O +
adenocarcinoma O +
cell O +
line O +
and O +
its O +
clones O +
. O +

In O +
this O +
study O +
, O +
we O +
examined O +
whether O +
all O +
- O +
trans O +
- O +
retinoic O +
acid O +
( O +
all O +
- O +
trans O +
- O +
RA O +
) O +
and O +
other O +
retinoids O +
, O +
which O +
exhibit O +
antitumor O +
activity O +
in O +
vitro O +
and O +
in O +
vivo O +
, O +
affect O +
the O +
collagenolytic O +
activity O +
of O +
metastatic O +
rat O +
13762NF B-CellLine +
mammary O +
adenocarcinoma O +
cells O +
. O +

Cells O +
of O +
the O +
highly O +
metastatic O +
lung O +
- O +
colonizing O +
clone O +
MTF7 B-CellLine +
. I-CellLine +
T35 I-CellLine +
. I-CellLine +
3 I-CellLine +
, O +
derived O +
from O +
the O +
13762NF B-CellLine +
cell O +
line O +
, O +
were O +
treated O +
for O +
3 O +
days O +
with O +
0 O +
. O +
1 O +
, O +
1 O +
, O +
or O +
10 O +
microM O +
all O +
- O +
trans O +
- O +
RA O +
, O +
harvested O +
, O +
and O +
seeded O +
on O +
[ O +
3H O +
] O +
proline O +
- O +
labeled O +
extracellular O +
matrix O +
deposited O +
by O +
cultured O +
rat O +
lung O +
endothelial O +
cells O +
or O +
on O +
a O +
film O +
of O +
purified O +
[ O +
3H O +
] O +
proline O +
- O +
labeled O +
type O +
IV O +
collagen O +
. O +

The O +
amount O +
of O +
radioactivity O +
released O +
into O +
the O +
medium O +
during O +
the O +
subsequent O +
24 O +
to O +
72 O +
h O +
was O +
measured O +
, O +
and O +
it O +
was O +
found O +
that O +
all O +
- O +
trans O +
- O +
RA O +
treatment O +
inhibited O +
degradation O +
of O +
extracellular O +
matrix O +
and O +
type O +
IV O +
collagen O +
by O +
50 O +
to O +
60 O +
% O +
. O +

This O +
effect O +
was O +
observed O +
whether O +
the O +
cells O +
had O +
been O +
treated O +
with O +
all O +
- O +
trans O +
- O +
RA O +
in O +
serum O +
- O +
free O +
medium O +
or O +
in O +
medium O +
supplemented O +
with O +
heat O +
- O +
inactivated O +
or O +
acid O +
- O +
treated O +
fetal O +
bovine O +
serum O +
. O +

The O +
growth O +
of O +
the O +
cells O +
was O +
not O +
inhibited O +
under O +
these O +
conditions O +
, O +
except O +
after O +
treatment O +
with O +
10 O +
microM O +
all O +
- O +
trans O +
- O +
RA O +
in O +
serum O +
- O +
free O +
medium O +
. O +

The O +
reduction O +
in O +
collagenolytic O +
activity O +
was O +
observed O +
in O +
viable O +
cells O +
as O +
well O +
as O +
in O +
conditioned O +
medium O +
. O +

A O +
24 O +
- O +
h O +
exposure O +
of O +
cells O +
to O +
all O +
- O +
trans O +
- O +
RA O +
was O +
sufficient O +
to O +
cause O +
a O +
30 O +
% O +
decrease O +
in O +
the O +
collagenolytic O +
activity O +
, O +
and O +
this O +
inhibitory O +
effect O +
was O +
reversible O +
. O +

The O +
direct O +
addition O +
of O +
all O +
- O +
trans O +
- O +
RA O +
to O +
conditioned O +
medium O +
had O +
no O +
effect O +
on O +
secreted O +
collagenase O +
activity O +
. O +

The O +
apparent O +
molecular O +
weights O +
of O +
the O +
collagenolytic O +
enzymes O +
were O +
determined O +
by O +
electrophoresis O +
of O +
cell O +
extracts O +
and O +
concentrated O +
conditioned O +
medium O +
in O +
type O +
IV O +
collagen O +
- O +
embedded O +
polyacrylamide O +
gels O +
followed O +
by O +
renaturation O +
and O +
activation O +
of O +
the O +
enzymes O +
within O +
the O +
gels O +
. O +

Two O +
major O +
type O +
IV O +
collagenolytic O +
metalloproteinases O +
exhibiting O +
molecular O +
weights O +
of O +
64 O +
, O +
000 O +
and O +
88 O +
, O +
000 O +
, O +
respectively O +
, O +
were O +
detected O +
by O +
this O +
method O +
. O +

These O +
two O +
enzymes O +
were O +
also O +
found O +
to O +
have O +
specificity O +
for O +
gelatin O +
. O +

The O +
Mr O +
64 O +
, O +
000 O +
enzyme O +
could O +
be O +
extracted O +
from O +
viable O +
cells O +
( O +
presumably O +
from O +
the O +
cell O +
membrane O +
) O +
by O +
2 O +
% O +
1 O +
- O +
butanol O +
. O +

Treatment O +
with O +
all O +
- O +
trans O +
- O +
RA O +
decreased O +
the O +
level O +
of O +
these O +
enzymes O +
in O +
the O +
cellular O +
, O +
cell O +
membrane O +
, O +
and O +
conditioned O +
medium O +
compartments O +
. O +
( O +
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O +
) O +

Type O +
- O +
A O +
cholecystokinin O +
receptors O +
in O +
CHP212 B-CellLine +
neuroblastoma O +
cells O +
: O +
evidence O +
for O +
association O +
with O +
G O +
protein O +
and O +
activation O +
of O +
phosphoinositide O +
hydrolysis O +
. O +

125I O +
- O +
Bolton O +
Hunter O +
- O +
cholecystokinin O +
octapeptide O +
( O +
BH O +
- O +
CCK8 O +
) O +
and O +
( O +
- O +
) O +
- O +
[ O +
3H O +
] O +
L O +
- O +
364718 O +
membrane O +
binding O +
assays O +
were O +
used O +
to O +
identify O +
and O +
characterize O +
cholecystokinin O +
( O +
CCK O +
) O +
receptors O +
in O +
CHP212 B-CellLine +
human O +
neuroblastoma O +
cells O +
. O +

The O +
ligand O +
binding O +
properties O +
of O +
CCK O +
receptors O +
in O +
these O +
cells O +
are O +
similar O +
to O +
those O +
found O +
in O +
pancreas O +
( O +
CCK O +
- O +
A O +
sites O +
) O +
and O +
differ O +
from O +
the O +
predominant O +
type O +
of O +
CCK O +
binding O +
site O +
found O +
in O +
brain O +
( O +
CCK O +
- O +
B O +
sites O +
) O +
. O +

The O +
specific O +
binding O +
of O +
125I O +
- O +
BH O +
- O +
CCK8 O +
but O +
not O +
( O +
- O +
) O +
- O +
[ O +
3H O +
] O +
L O +
- O +
364718 O +
was O +
reduced O +
by O +
the O +
metabolically O +
stable O +
GTP O +
analog O +
guanosine O +
5 O +
' O +
- O +
( O +
beta O +
- O +
delta O +
- O +
imido O +
) O +
trisphosphate O +
. O +

A O +
substantial O +
difference O +
in O +
the O +
Bmax O +
for O +
the O +
radiolabeled O +
agonist O +
( O +
125I O +
- O +
BH O +
- O +
CCK8 O +
) O +
and O +
antagonist O +
[ O +
( O +
- O +
) O +
- O +
[ O +
3H O +
] O +
L O +
- O +
364718 O +
] O +
was O +
noted O +
. O +

These O +
observations O +
are O +
consistent O +
with O +
CCK O +
receptors O +
existing O +
in O +
guanine O +
nucleotide O +
- O +
binding O +
protein O +
- O +
coupled O +
and O +
- O +
uncoupled O +
states O +
. O +

Similar O +
to O +
its O +
action O +
in O +
pancreatic O +
acinar O +
cells O +
, O +
CCK8 O +
( O +
S O +
) O +
stimulated O +
the O +
accumulation O +
of O +
[ O +
3H O +
] O +
inositol O +
phosphates O +
in O +
cells O +
prelabeled O +
with O +
[ O +
3H O +
] O +
myo O +
- O +
inositol O +
( O +
EC50 O +
= O +
3 O +
. O +
2 O +
+ O +
/ O +
- O +
0 O +
. O +
4 O +
nM O +
; O +
maximum O +
response O +
= O +
4 O +
. O +
5 O +
+ O +
/ O +
- O +
0 O +
. O +
4 O +
x O +
basal O +
) O +
. O +

The O +
intrinsic O +
activity O +
of O +
CCK O +
analogues O +
in O +
stimulating O +
phosphoinositide O +
hydrolysis O +
was O +
substantially O +
less O +
than O +
their O +
reported O +
intrinsic O +
activity O +
in O +
stimulating O +
phosphoinositide O +
hydrolysis O +
in O +
pancreatic O +
acinar O +
cells O +
. O +

The O +
CHP212 B-CellLine +
neuroblastoma O +
cell O +
may O +
serve O +
as O +
a O +
useful O +
model O +
for O +
the O +
recently O +
reported O +
CCK O +
- O +
A O +
binding O +
site O +
found O +
in O +
the O +
central O +
nervous O +
system O +
. O +

Energy O +
supply O +
of O +
the O +
mitotic O +
cell O +
cycle O +
and O +
the O +
Na O +
+ O +
/ O +
H O +
+ O +
- O +
antiport O +
in O +
ascites O +
tumors O +
. O +

The O +
activation O +
of O +
Na O +
+ O +
transport O +
is O +
due O +
to O +
the O +
exchange O +
of O +
protons O +
formed O +
via O +
glucose O +
conversion O +
into O +
lactate O +
for O +
Na O +
+ O +
, O +
i O +
. O +
e O +
. O +
, O +
to O +
the O +
stimulation O +
of O +
the O +
Na O +
+ O +
/ O +
H O +
+ O +
- O +
antiport O +
. O +

Experimental O +
results O +
and O +
theoretical O +
calculations O +
suggest O +
that O +
in O +
glucose O +
- O +
containing O +
medium O +
the O +
Na O +
+ O +
transport O +
increases O +
from O +
0 O +
. O +
75 O +
to O +
1 O +
. O +
78 O +
pmol O +
/ O +
hour O +
per O +
cell O +
. O +

The O +
permeability O +
of O +
plasma O +
membranes O +
for O +
K O +
+ O +
increases O +
2 O +
. O +
75 O +
fold O +
, O +
while O +
the O +
passive O +
flux O +
of O +
Na O +
+ O +
diminishes O +
. O +

The O +
intensity O +
of O +
O2 O +
adsorption O +
by O +
ascites O +
tumor O +
cells O +
does O +
not O +
practically O +
depend O +
on O +
the O +
monovalent O +
cation O +
concentration O +
gradient O +
between O +
the O +
cells O +
and O +
the O +
culture O +
medium O +
, O +
whereas O +
the O +
rate O +
of O +
glycolysis O +
decreases O +
simultaneously O +
with O +
the O +
diminution O +
of O +
the O +
concentration O +
gradient O +
. O +

In O +
synchronized O +
cultures O +
at O +
the O +
beginning O +
of O +
the O +
mitotic O +
cycle O +
, O +
the O +
bulk O +
of O +
ATP O +
resynthesized O +
via O +
glycolysis O +
is O +
utilized O +
for O +
the O +
synthesis O +
of O +
biopolymers O +
, O +
whereas O +
that O +
at O +
the O +
end O +
of O +
the O +
S O +
- O +
phase O +
and O +
in O +
the O +
G2 O +
- O +
phase O +
is O +
utilized O +
for O +
cation O +
transport O +
across O +
plasma O +
membranes O +
. O +

From O +
35 O +
to O +
100 O +
% O +
of O +
the O +
whole O +
amount O +
of O +
ATP O +
resynthesized O +
via O +
glycolysis O +
is O +
utilized O +
for O +
transport O +
purposes O +
. O +

It O +
is O +
concluded O +
that O +
the O +
observed O +
increase O +
in O +
the O +
Na O +
+ O +
/ O +
K O +
+ O +
ratio O +
in O +
ascites O +
tumor O +
cells O +
is O +
connected O +
with O +
their O +
enhanced O +
ability O +
to O +
synthesize O +
lactic O +
acid O +
. O +

Presumably O +
, O +
glycolysis O +
is O +
one O +
of O +
the O +
regulatory O +
mechanisms O +
of O +
intracellular O +
ratios O +
of O +
monovalent O +
cations O +
. O +

Endoscopic O +
injection O +
therapy O +
for O +
acute O +
upper O +
GI O +
bleeding O +
. O +

In O +
summary O +
, O +
we O +
have O +
found O +
this O +
technique O +
to O +
be O +
useful O +
in O +
patients O +
in O +
whom O +
coagulation O +
therapy O +
is O +
not O +
possible O +
or O +
effective O +
. O +

It O +
must O +
still O +
be O +
considered O +
a O +
technique O +
which O +
is O +
undergoing O +
evaluation O +
. O +

Prospective O +
randomized O +
trials O +
comparing O +
this O +
therapy O +
with O +
other O +
currently O +
available O +
therapies O +
such O +
a O +
electrocoagulation O +
, O +
laser O +
and O +
conservative O +
management O +
must O +
be O +
completed O +
to O +
firmly O +
define O +
its O +
place O +
in O +
treatment O +
strategy O +
for O +
acute O +
upper O +
GI O +
bleeding O +
. O +

Screening O +
method O +
for O +
insecticidal O +
activity O +
using O +
first O +
instars O +
of O +
black O +
blow O +
fly O +
( O +
Diptera O +
: O +
Calliphoridae O +
) O +
. O +

A O +
bioassay O +
method O +
suitable O +
for O +
rapid O +
mass O +
screening O +
of O +
fermentation O +
and O +
synthetic O +
organic O +
compounds O +
for O +
insecticidal O +
activity O +
is O +
described O +
. O +

The O +
test O +
, O +
which O +
uses O +
first O +
instars O +
of O +
susceptible O +
black O +
blow O +
fly O +
, O +
Phormia O +
regina O +
( O +
Meigen O +
) O +
, O +
in O +
a O +
bovine O +
serum O +
medium O +
, O +
detects O +
insecticidal O +
activity O +
with O +
reproducible O +
results O +
. O +

It O +
is O +
capable O +
of O +
selecting O +
the O +
most O +
active O +
compound O +
in O +
structure O +
- O +
activity O +
relationships O +
by O +
minimum O +
effective O +
dose O +
concentration O +
studies O +
. O +

The O +
bioassay O +
system O +
is O +
easy O +
to O +
operate O +
and O +
requires O +
only O +
a O +
minute O +
quantity O +
of O +
chemical O +
compound O +
. O +

Osteonectin O +
transcript O +
and O +
metastatic O +
behavior O +
in O +
v O +
- O +
Ki O +
- O +
ras O +
transformed O +
fibroblasts O +
. O +

Osteonectin O +
is O +
one O +
of O +
the O +
major O +
non O +
- O +
collagenous O +
proteins O +
of O +
bone O +
. O +

However O +
, O +
its O +
transcript O +
has O +
been O +
found O +
in O +
many O +
soft O +
, O +
extracellular O +
matrix O +
- O +
producing O +
tissues O +
; O +
an O +
osteonectin O +
- O +
related O +
protein O +
was O +
detected O +
in O +
tumor O +
basement O +
membrane O +
. O +

We O +
have O +
investigated O +
the O +
expression O +
of O +
osteonectin O +
gene O +
in O +
fresh O +
BALB B-CellLine +
/ I-CellLine +
c I-CellLine +
fibroblasts O +
transformed O +
by O +
v O +
- O +
Ki O +
- O +
ras O +
. O +

Transformed O +
cells O +
exhibited O +
lower O +
levels O +
of O +
RNA O +
as O +
compared O +
with O +
normal O +
fibroblasts O +
. O +

The O +
transformed O +
cells O +
were O +
cloned O +
after O +
in O +
vivo O +
tumorigenic O +
assay O +
, O +
and O +
4 O +
clones O +
were O +
analyzed O +
for O +
osteonectin O +
expression O +
by O +
Northern O +
blots O +
. O +

Two O +
of O +
them O +
were O +
selected O +
for O +
high O +
or O +
low O +
osteonectin O +
expression O +
and O +
tested O +
in O +
vivo O +
in O +
spontaneous O +
and O +
artificial O +
metastasis O +
assays O +
. O +

High O +
osteonectin O +
expression O +
was O +
correlated O +
with O +
high O +
lung O +
colonization O +
. O +

When O +
10 O +
( O +
5 O +
) O +
cells O +
were O +
injected O +
i O +
. O +
v O +
. O +
, O +
median O +
colony O +
value O +
was O +
55 O +
and O +
20 O +
in O +
higher O +
expressor O +
vs O +
. O +
lower O +
expressor O +
respectively O +
( O +
p O +
less O +
than O +
0 O +
. O +
005 O +
) O +
. O +

Spontaneous O +
metastasis O +
indicates O +
a O +
possible O +
reverse O +
correlation O +
. O +

Our O +
data O +
align O +
osteonectin O +
with O +
other O +
matrix O +
- O +
components O +
and O +
adhesion O +
molecules O +
in O +
affecting O +
potential O +
metastatic O +
spreading O +
of O +
transformed O +
cells O +
. O +

Early O +
post O +
- O +
mortem O +
metabolism O +
and O +
muscle O +
shortening O +
in O +
the O +
Pectoralis O +
major O +
muscle O +
of O +
broiler O +
chickens O +
. O +

Three O +
experiments O +
were O +
conducted O +
to O +
examine O +
the O +
effects O +
of O +
sodium O +
pentobarbital O +
( O +
SP O +
) O +
, O +
iodoacetate O +
( O +
IO O +
) O +
, O +
tubocurarine O +
( O +
TC O +
) O +
, O +
and O +
surgical O +
denervation O +
( O +
DN O +
) O +
on O +
early O +
rigor O +
development O +
in O +
broiler O +
breast O +
muscle O +
. O +

In O +
Experiment O +
1 O +
, O +
birds O +
were O +
either O +
anesthetized O +
or O +
not O +
with O +
SP O +
before O +
receiving O +
an O +
injection O +
of O +
IO O +
or O +
TC O +
or O +
maintained O +
as O +
noninjected O +
controls O +
. O +

Experiment O +
2 O +
was O +
identical O +
except O +
that O +
a O +
treatment O +
of O +
denervation O +
of O +
the O +
breast O +
muscle O +
was O +
added O +
. O +

Experiment O +
3 O +
was O +
conducted O +
to O +
contrast O +
birds O +
at O +
1 O +
day O +
( O +
DN1 O +
) O +
and O +
3 O +
days O +
( O +
DN3 O +
) O +
denervation O +
prior O +
to O +
slaughter O +
to O +
nonoperated O +
controls O +
. O +

Measurements O +
of O +
muscle O +
lactate O +
, O +
ATP O +
, O +
R O +
value O +
( O +
ratio O +
of O +
inosine O +
to O +
adenine O +
nucleotides O +
) O +
, O +
pH O +
, O +
sarcomere O +
lengths O +
, O +
and O +
shear O +
were O +
used O +
to O +
evaluate O +
treatment O +
effects O +
. O +

Results O +
for O +
Experiment O +
1 O +
showed O +
no O +
significant O +
differences O +
among O +
treatment O +
and O +
control O +
groups O +
for O +
ATP O +
and O +
lactate O +
contents O +
, O +
R O +
values O +
, O +
or O +
sarcomere O +
lengths O +
; O +
however O +
, O +
significantly O +
lower O +
pH O +
and O +
higher O +
shear O +
values O +
were O +
observed O +
for O +
control O +
birds O +
. O +

In O +
Experiment O +
2 O +
, O +
no O +
significant O +
differences O +
were O +
observed O +
among O +
the O +
treatment O +
groups O +
for O +
ATP O +
, O +
R O +
values O +
, O +
or O +
sarcomere O +
lengths O +
. O +

However O +
, O +
lactate O +
and O +
shear O +
values O +
were O +
significantly O +
lower O +
, O +
and O +
pH O +
higher O +
, O +
for O +
the O +
DN O +
and O +
SP O +
treated O +
birds O +
. O +

Experiment O +
3 O +
resulted O +
in O +
lower O +
lactate O +
and O +
higher O +
pH O +
values O +
for O +
the O +
DN3 O +
treatment O +
in O +
comparison O +
with O +
both O +
DN1 O +
and O +
control O +
groups O +
. O +

Results O +
of O +
these O +
studies O +
indicate O +
that O +
the O +
use O +
of O +
SP O +
and O +
DN O +
can O +
be O +
used O +
to O +
alter O +
the O +
early O +
profiles O +
of O +
rigor O +
development O +
. O +

Effects O +
of O +
hypertension O +
and O +
sympathetic O +
denervation O +
on O +
cerebral O +
blood O +
flow O +
in O +
newborn O +
pigs O +
. O +

To O +
investigate O +
the O +
potential O +
role O +
of O +
sympathetic O +
nerves O +
in O +
preventing O +
pronounced O +
increases O +
in O +
cerebral O +
blood O +
flow O +
, O +
we O +
evaluated O +
the O +
effects O +
of O +
abrupt O +
hypertension O +
on O +
the O +
cerebral O +
circulation O +
of O +
newborn O +
pigs O +
with O +
intact O +
cerebral O +
sympathetic O +
innervation O +
and O +
after O +
cerebral O +
sympathetic O +
denervation O +
. O +

Epinephrine O +
infusion O +
was O +
used O +
to O +
induce O +
abrupt O +
increases O +
in O +
mean O +
( O +
+ O +
/ O +
- O +
SEM O +
) O +
arterial O +
pressure O +
( O +
innervated O +
pigs O +
, O +
62 O +
+ O +
/ O +
- O +
3 O +
mm O +
of O +
Hg O +
to O +
115 O +
+ O +
/ O +
- O +
3 O +
mm O +
of O +
Hg O +
; O +
denervated O +
pigs O +
, O +
71 O +
+ O +
/ O +
- O +
4 O +
mm O +
of O +
Hg O +
to O +
132 O +
+ O +
/ O +
- O +
4 O +
mm O +
of O +
Hg O +
) O +
that O +
remained O +
increased O +
for O +
the O +
3 O +
minutes O +
of O +
the O +
study O +
. O +

Abrupt O +
hypertension O +
increased O +
blood O +
flow O +
to O +
all O +
brain O +
regions O +
. O +

In O +
denervated O +
pigs O +
, O +
the O +
increased O +
flow O +
to O +
the O +
cerebrum O +
was O +
prolonged O +
, O +
compared O +
with O +
that O +
in O +
pigs O +
with O +
intact O +
sympathetic O +
innervation O +
. O +

Differences O +
between O +
pigs O +
of O +
the O +
innervated O +
and O +
denervated O +
groups O +
were O +
not O +
apparent O +
, O +
with O +
respect O +
to O +
blood O +
flow O +
to O +
any O +
other O +
region O +
( O +
caudate O +
region O +
, O +
brain O +
stem O +
, O +
cerebellum O +
) O +
. O +

In O +
newborn O +
pigs O +
, O +
sympathetic O +
nerves O +
may O +
attenuate O +
hypertension O +
- O +
induced O +
increases O +
in O +
blood O +
flow O +
to O +
the O +
cerebrum O +
, O +
but O +
do O +
not O +
appear O +
to O +
affect O +
flow O +
to O +
the O +
rest O +
of O +
the O +
brain O +
. O +

[ O +
Tumor O +
metastasis O +
and O +
the O +
fibrinolytic O +
system O +
] O +
. O +

Metastatic O +
spread O +
of O +
malignant O +
tumor O +
appears O +
to O +
correlate O +
with O +
activation O +
of O +
the O +
fibrolytic O +
system O +
. O +

The O +
role O +
of O +
fibrinolysis O +
in O +
growth O +
and O +
metastasis O +
was O +
examined O +
in O +
Lewis O +
lung O +
carcinoma O +
of O +
mice O +
. O +

The O +
inhibition O +
of O +
fibrinolysis O +
or O +
proteases O +
decreased O +
the O +
primary O +
tumor O +
growth O +
and O +
pulmonary O +
metastasis O +
, O +
whereas O +
the O +
activation O +
of O +
fibrinolysis O +
or O +
proteases O +
increased O +
the O +
number O +
of O +
metastatic O +
foci O +
in O +
the O +
lung O +
. O +

Electronmicroscopically O +
, O +
thrombus O +
formation O +
in O +
the O +
primary O +
site O +
prevented O +
tumor O +
invasion O +
and O +
metastasis O +
formation O +
. O +

Plasminogen O +
activator O +
( O +
PA O +
) O +
content O +
of O +
excised O +
tumors O +
was O +
determined O +
by O +
SDS O +
- O +
PAGE O +
, O +
and O +
major O +
PA O +
was O +
found O +
to O +
be O +
urokinase O +
( O +
UK O +
) O +
type O +
. O +

Immunohistochemical O +
study O +
with O +
specific O +
antisera O +
was O +
done O +
. O +

When O +
tumor O +
cells O +
possessed O +
a O +
high O +
level O +
of O +
UK O +
, O +
laminin O +
and O +
type O +
IV O +
collagen O +
, O +
components O +
of O +
the O +
basement O +
membrane O +
, O +
disappeared O +
from O +
tumor O +
tissues O +
. O +

These O +
findings O +
suggest O +
that O +
PA O +
through O +
protease O +
cascade O +
plays O +
a O +
role O +
in O +
tumor O +
invasion O +
and O +
metastasis O +
. O +

Clinically O +
, O +
patients O +
with O +
advanced O +
cancer O +
are O +
usually O +
in O +
a O +
hypercoagulable O +
state O +
with O +
elevated O +
fibrinogen O +
, O +
and O +
fibrin O +
deposition O +
around O +
tumor O +
mass O +
is O +
a O +
serious O +
problem O +
in O +
cancer O +
chemotherapy O +
. O +

UK O +
infusion O +
prior O +
to O +
5 O +
- O +
fluorouracil O +
increased O +
tissue O +
concentration O +
of O +
antitumor O +
agent O +
. O +

However O +
, O +
development O +
of O +
consumption O +
coagulopathy O +
characterized O +
by O +
progression O +
from O +
hypercoagulable O +
state O +
to O +
disseminated O +
intravascular O +
coagulation O +
has O +
also O +
been O +
found O +
in O +
several O +
cases O +
. O +

[ O +
Intraepithelial O +
neoplasm O +
of O +
the O +
uterine O +
cervix O +
and O +
angiogenesis O +
: O +
morphologic O +
study O +
] O +

Thirty O +
uterine O +
cervix O +
specimens O +
sampled O +
following O +
conization O +
or O +
total O +
hysterectomy O +
were O +
studied O +
using O +
histology O +
, O +
histoenzymology O +
( O +
vessel O +
phosphatase O +
alkaline O +
activity O +
) O +
, O +
and O +
immunohistochemistry O +
( O +
demonstration O +
of O +
laminin O +
and O +
type O +
IV O +
collagen O +
in O +
epithelium O +
and O +
vessel O +
basement O +
membranes O +
) O +
. O +

Pathologic O +
conditions O +
included O +
dystrophia O +
, O +
moderate O +
dysplasia O +
, O +
severe O +
dysplasia O +
, O +
and O +
intraepithelial O +
carcinoma O +
. O +

Results O +
were O +
compared O +
to O +
findings O +
in O +
a O +
control O +
group O +
. O +

We O +
found O +
that O +
the O +
severity O +
of O +
vascular O +
abnormalities O +
correlated O +
positively O +
with O +
the O +
severity O +
of O +
histologic O +
epithelial O +
lesions O +
; O +
this O +
finding O +
is O +
consistent O +
with O +
colposcopic O +
results O +
. O +

Anarchic O +
angiogenesis O +
with O +
large O +
, O +
moniliform O +
, O +
tortuous O +
vessels O +
was O +
seen O +
in O +
severe O +
dysplasias O +
and O +
carcinomas O +
. O +

The O +
vascular O +
anomalies O +
seem O +
to O +
precede O +
the O +
development O +
of O +
histologic O +
lesions O +
in O +
some O +
instances O +
. O +

Histogenesis O +
of O +
the O +
abnormal O +
vessels O +
may O +
involve O +
production O +
of O +
an O +
angiogenic O +
factor O +
by O +
the O +
cancerized O +
epithelia O +
. O +

Glycolysis O +
and O +
glutaminolysis O +
in O +
perifused O +
Ehrlich O +
ascites O +
tumour O +
cells O +
. O +

A O +
perifusion O +
system O +
was O +
designed O +
in O +
order O +
to O +
study O +
glucose O +
and O +
glutamine O +
metabolism O +
by O +
freshly O +
harvested O +
Ehrlich O +
ascites O +
tumour O +
cells O +
in O +
steady O +
state O +
conditions O +
. O +

Cells O +
were O +
perifused O +
in O +
the O +
presence O +
of O +
5 O +
mM O +
glucose O +
, O +
0 O +
. O +
5 O +
mM O +
glutamine O +
or O +
5 O +
mM O +
glucose O +
and O +
0 O +
. O +
5 O +
mM O +
glutamine O +
. O +

The O +
results O +
in O +
steady O +
state O +
reveal O +
that O +
both O +
substrates O +
glucose O +
and O +
glutamine O +
are O +
continuously O +
wasted O +
by O +
tumour O +
cells O +
, O +
excreting O +
two O +
moles O +
of O +
lactate O +
per O +
mol O +
of O +
glucose O +
and O +
one O +
mol O +
of O +
glutamate O +
and O +
ammonia O +
per O +
mol O +
of O +
glutamine O +
consumed O +
into O +
the O +
medium O +
. O +

Glutamine O +
consumption O +
in O +
the O +
presence O +
of O +
glucose O +
was O +
higher O +
than O +
with O +
glutamine O +
alone O +
. O +

Invagination O +
of O +
the O +
otic O +
placode O +
: O +
normal O +
development O +
and O +
experimental O +
manipulation O +
. O +

The O +
inner O +
ear O +
forms O +
from O +
paired O +
ectodermal O +
primordia O +
that O +
lie O +
to O +
either O +
side O +
of O +
the O +
developing O +
hindbrain O +
. O +

Initially O +
each O +
primordium O +
forms O +
a O +
shallow O +
depression O +
in O +
the O +
ectodermal O +
surface O +
. O +

Invagination O +
to O +
form O +
an O +
otic O +
pit O +
coincides O +
with O +
the O +
formation O +
of O +
several O +
deep O +
folds O +
in O +
the O +
epithelial O +
surface O +
. O +

An O +
initial O +
fold O +
appears O +
parallel O +
to O +
the O +
embryonic O +
axis O +
and O +
at O +
the O +
junction O +
of O +
the O +
rhombencephalon O +
with O +
somitomeric O +
mesoderm O +
. O +

This O +
is O +
followed O +
by O +
formation O +
of O +
cranial O +
and O +
caudal O +
folds O +
perpendicular O +
to O +
the O +
axis O +
and O +
minor O +
folds O +
that O +
are O +
within O +
the O +
pit O +
formed O +
by O +
earlier O +
folding O +
. O +

The O +
central O +
region O +
of O +
the O +
otic O +
primordium O +
remains O +
in O +
close O +
apposition O +
to O +
the O +
lateral O +
surface O +
of O +
the O +
neural O +
tube O +
during O +
the O +
process O +
of O +
fold O +
formation O +
, O +
until O +
the O +
otic O +
pit O +
becomes O +
quite O +
deep O +
. O +

At O +
that O +
time O +
, O +
mesenchymal O +
cells O +
penetrate O +
between O +
the O +
two O +
layers O +
. O +

Experimental O +
analysis O +
of O +
invagination O +
supports O +
the O +
conclusion O +
that O +
otic O +
invagination O +
is O +
controlled O +
differently O +
from O +
that O +
of O +
similar O +
organ O +
primordia O +
, O +
such O +
as O +
the O +
eye O +
and O +
thyroid O +
. O +

Whereas O +
these O +
other O +
primordia O +
can O +
be O +
stimulated O +
to O +
undergo O +
normal O +
morphogenetic O +
shape O +
changes O +
precociously O +
by O +
treatments O +
that O +
presumably O +
activate O +
motile O +
processes O +
in O +
the O +
cytoskeleton O +
, O +
the O +
same O +
conditions O +
have O +
little O +
effect O +
on O +
the O +
otic O +
placode O +
. O +

Similarly O +
, O +
neither O +
inhibitors O +
of O +
calcium O +
transport O +
nor O +
inactivators O +
of O +
calmodulin O +
activity O +
prevent O +
otic O +
pit O +
formation O +
, O +
while O +
these O +
drugs O +
block O +
invagination O +
of O +
other O +
primordia O +
. O +

These O +
results O +
suggest O +
that O +
otic O +
invagination O +
may O +
be O +
caused O +
by O +
changes O +
in O +
the O +
surrounding O +
tissues O +
rather O +
than O +
by O +
an O +
activation O +
of O +
motility O +
within O +
the O +
primordium O +
. O +

Anaplastic O +
and O +
sarcomatoid O +
carcinoma O +
of O +
the O +
small O +
intestine O +
: O +
a O +
clinicopathologic O +
study O +
. O +

Carcinomas O +
involving O +
the O +
jejunum O +
and O +
ileum O +
are O +
rare O +
tumors O +
. O +

During O +
a O +
review O +
of O +
small O +
intestinal O +
neoplasms O +
, O +
six O +
primary O +
carcinomas O +
of O +
jejunum O +
or O +
ileum O +
with O +
an O +
anaplastic O +
and O +
sarcomatoid O +
histology O +
were O +
identified O +
. O +

At O +
presentation O +
, O +
three O +
of O +
the O +
patients O +
had O +
symptoms O +
related O +
to O +
metastatic O +
disease O +
and O +
three O +
had O +
symptoms O +
referable O +
to O +
the O +
local O +
tumor O +
. O +

The O +
tumors O +
were O +
large O +
( O +
greater O +
than O +
4 O +
. O +
5 O +
cm O +
in O +
diameter O +
) O +
, O +
usually O +
endophytic O +
masses O +
composed O +
of O +
large O +
cells O +
with O +
eosinophilic O +
cytoplasm O +
, O +
anaplastic O +
nuclei O +
, O +
and O +
prominent O +
nucleoli O +
. O +

In O +
many O +
areas O +
, O +
the O +
cells O +
had O +
a O +
spindled O +
configuration O +
. O +

Mucin O +
positivity O +
was O +
identified O +
in O +
all O +
six O +
cases O +
. O +

Electron O +
microscopic O +
findings O +
in O +
two O +
cases O +
were O +
indicative O +
of O +
epithelial O +
differentiation O +
. O +

The O +
tumors O +
behaved O +
aggressively O +
; O +
all O +
five O +
patients O +
for O +
whom O +
there O +
was O +
clinical O +
follow O +
- O +
up O +
died O +
of O +
metastases O +
within O +
40 O +
months O +
. O +

The O +
six O +
anaplastic O +
and O +
sarcomatoid O +
carcinomas O +
were O +
compared O +
with O +
29 O +
typical O +
adenocarcinomas O +
arising O +
in O +
the O +
jejunum O +
or O +
ileum O +
. O +

Only O +
two O +
of O +
the O +
latter O +
group O +
had O +
symptoms O +
referable O +
to O +
distant O +
metastases O +
at O +
presentation O +
. O +

These O +
tumors O +
also O +
tended O +
to O +
be O +
smaller O +
at O +
presentation O +
( O +
11 O +
tumors O +
were O +
less O +
than O +
4 O +
cm O +
in O +
greatest O +
dimension O +
) O +
. O +

Of O +
25 O +
patients O +
with O +
typical O +
adenocarcinomas O +
who O +
had O +
acceptable O +
follow O +
- O +
up O +
, O +
18 O +
( O +
72 O +
% O +
) O +
died O +
of O +
disease O +
and O +
five O +
( O +
20 O +
% O +
) O +
were O +
alive O +
with O +
no O +
evidence O +
of O +
disease O +
after O +
5 O +
years O +
. O +

We O +
conclude O +
that O +
anaplastic O +
and O +
sarcomatoid O +
carcinoma O +
is O +
a O +
rare O +
variant O +
of O +
small O +
intestinal O +
carcinoma O +
with O +
an O +
aggressive O +
clinical O +
course O +
. O +

Time O +
course O +
of O +
transmitter O +
action O +
at O +
the O +
sympathetic O +
neuroeffector O +
junction O +
in O +
rodent O +
vascular O +
and O +
non O +
- O +
vascular O +
smooth O +
muscle O +
. O +

1 O +
. O +

Transmitter O +
release O +
from O +
sympathetic O +
postganglionic O +
nerve O +
terminals O +
innervating O +
the O +
guinea O +
- O +
pig O +
and O +
mouse O +
vas O +
deferens O +
and O +
the O +
rat O +
tail O +
artery O +
has O +
been O +
studied O +
in O +
vitro O +
by O +
focal O +
extracellular O +
recording O +
with O +
particular O +
emphasis O +
on O +
the O +
time O +
course O +
of O +
transmitter O +
action O +
underlying O +
the O +
intracellular O +
potential O +
changes O +
. O +

2 O +
. O +

In O +
the O +
absence O +
of O +
stimulation O +
, O +
spontaneous O +
excitatory O +
junction O +
currents O +
( O +
SEJCs O +
) O +
were O +
recorded O +
with O +
amplitudes O +
up O +
to O +
500 O +
microV O +
and O +
durations O +
between O +
40 O +
and O +
100 O +
ms O +
. O +

SEJCs O +
were O +
unaffected O +
by O +
the O +
competitive O +
alpha O +
- O +
adrenoceptor O +
antagonist O +
prazosin O +
but O +
blocked O +
by O +
alpha O +
, O +
beta O +
- O +
methylene O +
ATP O +
which O +
desensitizes O +
P2 O +
- O +
purinoceptors O +
. O +

3 O +
. O +

During O +
trains O +
of O +
supramaximal O +
stimuli O +
at O +
0 O +
. O +
1 O +
- O +
4 O +
Hz O +
stimulus O +
locked O +
excitatory O +
junction O +
currents O +
( O +
EJCs O +
) O +
were O +
evoked O +
intermittently O +
from O +
the O +
population O +
of O +
varicosities O +
located O +
under O +
the O +
suction O +
electrode O +
. O +

4 O +
. O +

SEJCs O +
were O +
similar O +
in O +
amplitude O +
and O +
time O +
course O +
to O +
EJCs O +
evoked O +
by O +
low O +
- O +
frequency O +
stimulation O +
in O +
the O +
same O +
attachment O +
in O +
all O +
three O +
tissues O +
. O +

5 O +
. O +

SEJCs O +
recorded O +
using O +
either O +
a O +
conventional O +
AC O +
amplifier O +
or O +
a O +
patch O +
clamp O +
amplifier O +
had O +
the O +
same O +
time O +
course O +
. O +

6 O +
. O +

These O +
studies O +
show O +
that O +
the O +
time O +
course O +
of O +
the O +
current O +
underlying O +
the O +
excitatory O +
junction O +
potential O +
is O +
brief O +
and O +
essentially O +
the O +
same O +
in O +
three O +
different O +
tissues O +
. O +

The O +
prolonged O +
time O +
course O +
of O +
the O +
excitatory O +
junction O +
potential O +
in O +
different O +
tissues O +
can O +
be O +
accounted O +
for O +
by O +
the O +
passive O +
membrane O +
properties O +
. O +

Phase O +
II O +
trial O +
with O +
D O +
- O +
Trp O +
- O +
6 O +
- O +
LH O +
- O +
RH O +
in O +
prostatic O +
carcinoma O +
: O +
comparison O +
with O +
other O +
hormonal O +
agents O +
. O +

Various O +
approaches O +
to O +
hormonal O +
treatment O +
of O +
prostate O +
carcinoma O +
are O +
discussed O +
. O +

Eighty O +
- O +
one O +
patients O +
with O +
prostatic O +
carcinoma O +
, O +
eight O +
with O +
stage O +
B O +
, O +
nine O +
with O +
stage O +
C O +
, O +
and O +
64 O +
with O +
stage O +
D O +
disease O +
, O +
were O +
treated O +
subcutaneously O +
daily O +
for O +
3 O +
months O +
with O +
the O +
LH O +
- O +
RH O +
agonist O +
D O +
- O +
Trp O +
- O +
6 O +
- O +
LH O +
- O +
RH O +
( O +
Decapeptyl O +
) O +
in O +
order O +
to O +
evaluate O +
the O +
incidence O +
of O +
remissions O +
according O +
to O +
WHO O +
recommendations O +
for O +
oncologic O +
trials O +
. O +

The O +
findings O +
were O +
compared O +
to O +
those O +
obtained O +
with O +
other O +
hormonal O +
therapies O +
of O +
prostatic O +
carcinoma O +
according O +
to O +
the O +
statistical O +
method O +
of O +
" O +
expected O +
response O +
rate O +
" O +
as O +
adapted O +
by O +
Lee O +
and O +
Wesley O +
for O +
phase O +
II O +
trials O +
. O +

Treatment O +
with O +
D O +
- O +
Trp O +
- O +
6 O +
- O +
LH O +
- O +
RH O +
greatly O +
reduced O +
serum O +
LH O +
and O +
testosterone O +
levels O +
without O +
raising O +
serum O +
prolactin O +
. O +

After O +
1 O +
- O +
2 O +
weeks O +
of O +
therapy O +
, O +
there O +
was O +
relief O +
of O +
subjective O +
symptoms O +
and O +
a O +
reversal O +
of O +
the O +
signs O +
of O +
prostatism O +
as O +
well O +
as O +
a O +
marked O +
decrease O +
in O +
bone O +
pain O +
. O +

At O +
90 O +
days O +
52 O +
patients O +
had O +
complete O +
relief O +
of O +
prostatism O +
and O +
21 O +
had O +
only O +
mild O +
signs O +
and O +
symptoms O +
. O +

Seventy O +
patients O +
were O +
experiencing O +
no O +
bone O +
pain O +
and O +
an O +
additional O +
six O +
had O +
only O +
mild O +
pain O +
. O +

Prostatic O +
size O +
, O +
evaluated O +
by O +
rectal O +
examination O +
and O +
transabdominal O +
ultrasonography O +
, O +
reverted O +
to O +
normal O +
in O +
26 O +
. O +
4 O +
% O +
of O +
patients O +
( O +
complete O +
remission O +
) O +
and O +
was O +
reduced O +
by O +
more O +
than O +
50 O +
% O +
in O +
an O +
additional O +
17 O +
. O +
6 O +
% O +
( O +
partial O +
remission O +
) O +
, O +
the O +
overall O +
rate O +
of O +
complete O +
plus O +
partial O +
regression O +
of O +
prostatic O +
enlargement O +
being O +
44 O +
% O +
. O +

Scans O +
showed O +
a O +
major O +
improvement O +
of O +
bone O +
lesions O +
in O +
14 O +
. O +
8 O +
% O +
of O +
cases O +
. O +

This O +
response O +
increased O +
to O +
37 O +
% O +
after O +
more O +
than O +
6 O +
months O +
of O +
follow O +
- O +
up O +
. O +

Prostatic O +
acid O +
phosphatase O +
levels O +
were O +
decreased O +
by O +
more O +
than O +
50 O +
% O +
in O +
61 O +
% O +
of O +
the O +
patients O +
, O +
but O +
this O +
test O +
appears O +
to O +
be O +
a O +
less O +
valid O +
marker O +
than O +
the O +
lipid O +
- O +
associated O +
sialic O +
acid O +
( O +
LASA O +
) O +
. O +

The O +
increase O +
in O +
LASA O +
before O +
treatment O +
and O +
a O +
reduction O +
after O +
treatment O +
can O +
frequently O +
be O +
correlated O +
with O +
the O +
objective O +
volume O +
of O +
the O +
neoplasms O +
. O +

No O +
flare O +
- O +
up O +
of O +
the O +
disease O +
was O +
encountered O +
, O +
and O +
there O +
were O +
no O +
side O +
effects O +
except O +
for O +
impotence O +
. O +

Statistical O +
analyses O +
of O +
results O +
by O +
the O +
method O +
of O +
Lee O +
and O +
Wesley O +
indicated O +
that O +
the O +
incidence O +
of O +
complete O +
and O +
partial O +
regression O +
( O +
CR O +
and O +
PR O +
) O +
observed O +
with O +
D O +
- O +
Trp O +
- O +
6 O +
- O +
LH O +
- O +
RH O +
was O +
not O +
significantly O +
different O +
from O +
that O +
recorded O +
in O +
previous O +
studies O +
for O +
another O +
LH O +
- O +
RH O +
analog O +
, O +
Buserelin O +
. O +

However O +
, O +
CR O +
and O +
PR O +
obtained O +
with O +
D O +
- O +
Trp O +
- O +
6 O +
- O +
LH O +
- O +
RH O +
( O +
44 O +
% O +
) O +
were O +
significantly O +
higher O +
than O +
with O +
subcapsular O +
orchiectomy O +
( O +
22 O +
% O +
) O +
. O +

Hormonal O +
effects O +
and O +
some O +
other O +
actions O +
of O +
D O +
- O +
Trp O +
- O +
6 O +
- O +
LH O +
- O +
RH O +
were O +
compared O +
and O +
contrasted O +
with O +
those O +
produced O +
by O +
castration O +
, O +
estrogens O +
, O +
antiandrogens O +
, O +
and O +
progestogens O +
. O +
( O +
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O +
) O +

On O +
the O +
mechanism O +
of O +
glycolysis O +
stimulation O +
by O +
neutral O +
detergents O +
in O +
3T3 B-CellLine +
and O +
Ehrlich O +
ascites O +
tumor O +
cells O +
. O +

Glycolysis O +
of O +
3T3 B-CellLine +
and O +
Ehrlich O +
ascites O +
tumor O +
cells O +
was O +
greatly O +
enhanced O +
by O +
Nonidet O +
P O +
- O +
40 O +
or O +
Triton O +
X O +
- O +
100 O +
at O +
about O +
100 O +
micrograms O +
/ O +
mg O +
cell O +
protein O +
. O +

This O +
enhanced O +
glycolysis O +
was O +
partly O +
sensitive O +
to O +
rutamycin O +
and O +
partly O +
sensitive O +
to O +
ouabain O +
, O +
suggesting O +
that O +
the O +
detergent O +
released O +
the O +
control O +
of O +
the O +
ATPase O +
of O +
the O +
mitochondria O +
and O +
of O +
the O +
plasma O +
membrane O +
Na O +
+ O +
K O +
+ O +
- O +
ATPase O +
. O +

Nonidet O +
P O +
- O +
40 O +
had O +
no O +
effect O +
on O +
glycolysis O +
in O +
cell O +
- O +
free O +
extracts O +
from O +
Ehrlich O +
ascites O +
tumor O +
cells O +
to O +
which O +
soluble O +
mitochondrial O +
ATPase O +
was O +
added O +
. O +

Measuring O +
ouabain O +
- O +
sensitive O +
22Na O +
efflux O +
and O +
using O +
ouabain O +
- O +
sensitive O +
lactate O +
production O +
as O +
a O +
measure O +
of O +
ATP O +
hydrolysis O +
by O +
the O +
Na O +
+ O +
K O +
+ O +
pump O +
, O +
it O +
was O +
shown O +
that O +
Nonidet O +
P O +
- O +
40 O +
greatly O +
decreased O +
the O +
efficiency O +
of O +
the O +
Na O +
+ O +
K O +
+ O +
pump O +
. O +

Quercetin O +
increased O +
the O +
efficiency O +
of O +
pumping O +
in O +
EAT O +
cells O +
both O +
in O +
the O +
absence O +
and O +
presence O +
of O +
the O +
detergent O +
. O +

Elevated O +
levels O +
of O +
diacylglycerol O +
and O +
decreased O +
phorbol O +
ester O +
sensitivity O +
in O +
ras O +
- O +
transformed O +
fibroblasts O +
. O +

Diacylglycerol O +
( O +
DG O +
) O +
plays O +
a O +
central O +
role O +
in O +
phospholipid O +
metabolism O +
and O +
is O +
an O +
endogenous O +
activator O +
of O +
protein O +
kinase O +
C O +
. O +

We O +
have O +
suggested O +
that O +
constitutive O +
activation O +
of O +
this O +
kinase O +
is O +
one O +
mechanism O +
by O +
which O +
oncogenes O +
transform O +
cells O +
. O +

The O +
ras O +
- O +
encoded O +
proteins O +
are O +
similar O +
to O +
regulatory O +
G O +
- O +
proteins O +
and O +
are O +
candidates O +
for O +
the O +
unknown O +
G O +
- O +
protein O +
that O +
modulates O +
phosphatidylinositol O +
( O +
PI O +
) O +
turnover O +
. O +

Differences O +
in O +
polyphosphoinositide O +
metabolism O +
have O +
been O +
reported O +
for O +
ras O +
- O +
transformed O +
cells O +
. O +

But O +
because O +
these O +
experiments O +
were O +
performed O +
on O +
confluent O +
cultures O +
of O +
established O +
cell O +
lines O +
, O +
the O +
differences O +
are O +
difficult O +
to O +
attribute O +
to O +
ras O +
transformation O +
. O +

Here O +
we O +
show O +
that O +
exponentially O +
growing O +
NIH B-CellLine +
3T3 I-CellLine +
fibroblasts O +
recently O +
transformed O +
by O +
Ha O +
- O +
ras O +
or O +
Ki O +
- O +
ras O +
possess O +
elevated O +
DG O +
concentrations O +
without O +
significant O +
alterations O +
in O +
the O +
levels O +
of O +
other O +
polyphosphoinositide O +
metabolites O +
. O +

The O +
basal O +
phosphorylation O +
of O +
protein O +
kinase O +
C O +
substrate O +
of O +
relative O +
molecular O +
mass O +
( O +
Mr O +
) O +
80 O +
, O +
000 O +
( O +
80 O -
K O +
) O +
is O +
significantly O +
increased O +
in O +
all O +
the O +
ras O +
- O +
transformed O +
cell O +
lines O +
. O +

Surprisingly O +
, O +
however O +
, O +
further O +
phosphorylation O +
of O +
this O +
protein O +
on O +
addition O +
of O +
phorbol O +
ester O +
was O +
greatly O +
reduced O +
. O +

Ha O +
- O +
ras O +
cells O +
also O +
show O +
less O +
binding O +
of O +
phorbol O +
ester O +
than O +
control O +
cells O +
, O +
suggesting O +
that O +
elevation O +
of O +
DG O +
causes O +
partial O +
down O +
- O +
regulation O +
in O +
addition O +
to O +
activation O +
of O +
protein O +
kinase O +
C O +
. O +

Epidermal O +
growth O +
factor O +
and O +
its O +
receptor O +
. O +

Epidermal O +
growth O +
factor O +
( O +
EGF O +
) O +
binds O +
with O +
high O +
affinity O +
and O +
specificity O +
to O +
a O +
single O +
site O +
on O +
the O +
external O +
domain O +
of O +
its O +
transmembrane O +
receptor O +
to O +
activate O +
the O +
tyrosine O +
protein O +
kinase O +
activity O +
of O +
its O +
cytoplasmic O +
portion O +
. O +

The O +
EGF O +
receptor O +
gene O +
is O +
amplified O +
and O +
over O +
- O +
expressed O +
in O +
several O +
human O +
tumors O +
, O +
suggesting O +
that O +
increased O +
concentrations O +
of O +
the O +
proto O +
- O +
oncogene O +
leads O +
to O +
constitutive O +
activity O +
similar O +
to O +
that O +
seen O +
with O +
oncogene O +
erb O +
B O +
. O +

Synthesis O +
and O +
degradation O +
of O +
the O +
EGF O +
receptor O +
are O +
regulated O +
, O +
in O +
addition O +
, O +
covalent O +
modification O +
by O +
phosphorylation O +
regulates O +
activity O +
of O +
the O +
receptor O +
protein O +
. O +

Intramolecular O +
self O +
- O +
phosphorylation O +
of O +
Tyr1173 O +
removes O +
a O +
competitive O +
inhibitory O +
constraint O +
to O +
enhance O +
phosphorylation O +
of O +
substrates O +
. O +

Phosphorylation O +
of O +
Thr654 O +
by O +
protein O +
kinase O +
C O +
decreases O +
high O +
affinity O +
EGF O +
binding O +
and O +
EGF O +
- O +
stimulated O +
tyrosine O +
protein O +
kinase O +
activity O +
, O +
providing O +
a O +
mechanism O +
for O +
heterologous O +
regulation O +
of O +
the O +
EGF O +
receptor O +
by O +
tumor O +
promoters O +
and O +
other O +
ligand O +
X O +
receptor O +
complexes O +
. O +

Extensive O +
regulation O +
contributes O +
to O +
normal O +
growth O +
control O +
, O +
abrogation O +
of O +
regulatory O +
controls O +
contributes O +
to O +
uncontrolled O +
growth O +
as O +
seen O +
with O +
erb O +
B O +
transformation O +
and O +
EGF O +
receptor O +
gene O +
amplification O +
in O +
human O +
tumors O +
. O +

Malate O +
- O +
citrate O +
cycle O +
during O +
glycolysis O +
and O +
glutaminolysis O +
in O +
Ehrlich O +
ascites O +
tumor O +
cells O +
. O +

The O +
malate O +
- O +
citrate O +
cycle O +
was O +
studied O +
during O +
aerobic O +
glycolysis O +
and O +
glutaminolysis O +
in O +
a O +
strain O +
of O +
Ehrlich O +
ascites O +
tumor O +
cells O +
which O +
showed O +
a O +
very O +
low O +
malate O +
- O +
aspartate O +
shuttle O +
system O +
activity O +
. O +

The O +
experimental O +
approach O +
includes O +
: O +
estimation O +
of O +
mitochondrial O +
NAD O +
[ O +
P O +
] O +
+ O +
- O +
dependent O +
malic O +
enzyme O +
activity O +
; O +
respiratory O +
activity O +
of O +
freshly O +
harvested O +
or O +
fasted O +
cells O +
, O +
and O +
of O +
isolated O +
mitochondria O +
; O +
and O +
determination O +
of O +
the O +
metabolites O +
involved O +
in O +
the O +
glycolytic O +
and O +
glutaminolytic O +
pathways O +
. O +

The O +
results O +
suggest O +
that O +
in O +
this O +
strain O +
, O +
the O +
malate O +
- O +
citrate O +
shuttle O +
is O +
not O +
an O +
effective O +
pathway O +
for O +
transferring O +
glycolytic O +
reducing O +
equivalents O +
from O +
cytosol O +
to O +
mitochondria O +
. O +

Less O +
than O +
15 O +
% O +
of O +
the O +
glucose O +
uptake O +
was O +
affected O +
by O +
the O +
1 O +
, O +
2 O +
, O +
3 O +
- O +
benzenetricarboxylate O +
inhibition O +
of O +
the O +
malate O +
- O +
citrate O +
shuttle O +
. O +

Moreover O +
, O +
in O +
the O +
presence O +
of O +
glucose O +
, O +
the O +
malate O +
- O +
citrate O +
cycle O +
did O +
not O +
appear O +
to O +
play O +
an O +
important O +
role O +
in O +
the O +
glutaminolytic O +
process O +
. O +

The O +
present O +
work O +
supports O +
and O +
extends O +
the O +
finding O +
of O +
previous O +
studies O +
, O +
since O +
the O +
results O +
showed O +
that O +
the O +
glucose O +
metabolism O +
depressed O +
the O +
oxidative O +
processes O +
in O +
Ehrlich O +
ascites O +
tumor O +
mitochondria O +
, O +
not O +
only O +
alone O +
, O +
but O +
also O +
in O +
the O +
presence O +
of O +
glutamine O +
. O +

Interestingly O +
, O +
the O +
high O +
glutamine O +
uptake O +
was O +
maintained O +
in O +
the O +
presence O +
of O +
glucose O +
. O +

Differential O +
secretion O +
of O +
proteins O +
and O +
glycoproteins O +
by O +
livers O +
of O +
immature O +
and O +
adult O +
rats O +
. O +

Effect O +
of O +
antimicrotubule O +
drugs O +
. O +

This O +
study O +
was O +
initiated O +
to O +
re O +
- O +
examine O +
reported O +
differences O +
in O +
the O +
action O +
of O +
antimicrotubule O +
agents O +
on O +
plasma O +
protein O +
secretion O +
from O +
livers O +
of O +
immature O +
versus O +
adult O +
rats O +
. O +

The O +
aim O +
was O +
( O +
1 O +
) O +
to O +
determine O +
the O +
composition O +
and O +
to O +
monitor O +
the O +
secretion O +
of O +
various O +
plasma O +
proteins O +
and O +
glycoproteins O +
from O +
liver O +
slices O +
labeled O +
in O +
vitro O +
with O +
specific O +
amino O +
acids O +
and O +
sugar O +
residues O +
, O +
and O +
( O +
2 O +
) O +
to O +
correlate O +
observed O +
differences O +
in O +
secretion O +
of O +
these O +
proteins O +
with O +
structural O +
changes O +
in O +
the O +
hepatocytes O +
of O +
the O +
different O +
aged O +
animals O +
. O +

For O +
the O +
most O +
part O +
, O +
slices O +
of O +
liver O +
from O +
fetal O +
( O +
term O +
) O +
, O +
neonatal O +
( O +
4 O +
- O +
to O +
5 O +
days O +
old O +
) O +
, O +
and O +
adult O +
rats O +
( O +
70 O +
days O +
old O +
) O +
were O +
incubated O +
with O +
radioactive O +
amino O +
acids O +
or O +
various O +
tritiated O +
sugars O +
specific O +
for O +
N O +
- O +
linked O +
core O +
oligosaccharide O +
and O +
/ O +
or O +
N O +
- O +
linked O +
terminal O +
oligosaccharide O +
chains O +
. O +

Our O +
findings O +
indicate O +
that O +
liver O +
slices O +
of O +
fetal O +
and O +
neonatal O +
rats O +
are O +
efficient O +
in O +
synthesizing O +
plasma O +
proteins O +
including O +
fully O +
glycosylated O +
glycoproteins O +
. O +

The O +
secretion O +
of O +
glycosylated O +
and O +
nonglycosylated O +
proteins O +
believed O +
to O +
be O +
processed O +
through O +
Golgi O +
complexes O +
was O +
inhibited O +
to O +
the O +
same O +
extent O +
( O +
approximately O +
70 O +
- O +
80 O +
% O +
) O +
by O +
antimicrotubule O +
agents O +
, O +
regardless O +
of O +
the O +
age O +
of O +
the O +
host O +
animal O +
. O +

However O +
, O +
other O +
proteins O +
and O +
glycoproteins O +
secreted O +
by O +
livers O +
of O +
immature O +
rats O +
were O +
found O +
to O +
be O +
relatively O +
insensitive O +
( O +
i O +
. O +
e O +
. O +
inhibited O +
to O +
only O +
30 O +
- O +
40 O +
% O +
) O +
to O +
the O +
action O +
of O +
various O +
antimicrotubule O +
drugs O +
. O +

The O +
glycoproteins O +
were O +
found O +
to O +
lack O +
N O +
- O +
linked O +
terminal O +
sugars O +
( O +
although O +
the O +
glycoproteins O +
did O +
contain O +
N O +
- O +
linked O +
core O +
sugars O +
) O +
, O +
and O +
it O +
is O +
likely O +
that O +
the O +
drug O +
- O +
insensitive O +
proteins O +
bypassed O +
critical O +
glycosylating O +
sites O +
in O +
the O +
Golgi O +
compartment O +
prior O +
to O +
release O +
. O +

Overall O +
, O +
these O +
findings O +
support O +
earlier O +
data O +
showing O +
that O +
antimicrotubule O +
drugs O +
have O +
a O +
special O +
impact O +
on O +
Golgi O +
- O +
associated O +
events O +
in O +
liver O +
cells O +
. O +

To O +
what O +
extent O +
these O +
findings O +
are O +
related O +
to O +
the O +
action O +
of O +
microtubules O +
remains O +
to O +
be O +
seen O +
. O +

Multi O +
- O +
step O +
neoplastic O +
transformation O +
of O +
normal O +
human O +
fibroblasts O +
by O +
Co O +
- O +
60 O +
gamma O +
rays O +
and O +
Ha O +
- O +
ras O +
oncogenes O +
. O +

As O +
reported O +
previously O +
( O +
Namba O +
et O +
al O +
. O +
, O +
1985 O +
; O +
Namba O +
, O +
1985 O +
) O +
, O +
normal O +
human O +
fibroblasts O +
were O +
transformed O +
into O +
immortal O +
cells O +
with O +
abnormal O +
karyotypes O +
by O +
Co O +
- O +
60 O +
gamma O +
- O +
ray O +
irradiation O +
. O +

These O +
immortally O +
transformed O +
cells O +
( O +
KMST B-CellLine +
- I-CellLine +
6 I-CellLine +
) O +
showed O +
no O +
clonability O +
in O +
soft O +
agar O +
and O +
were O +
not O +
tumorigenic O +
. O +

However O +
, O +
by O +
treatment O +
with O +
Ha O +
- O +
ras O +
oncogenes O +
derived O +
from O +
a O +
human O +
lung O +
carcinoma O +
or O +
Harvey O +
murine O +
sarcoma O +
virus O +
, O +
the O +
KMST B-CellLine +
- I-CellLine +
6 I-CellLine +
cells O +
acquired O +
elevated O +
clonability O +
in O +
soft O +
agar O +
and O +
transplantability O +
in O +
nude O +
mice O +
. O +

All O +
the O +
tumors O +
produced O +
grew O +
progressively O +
without O +
showing O +
regression O +
and O +
killed O +
the O +
mice O +
. O +

The O +
tumors O +
were O +
also O +
serially O +
transplantable O +
into O +
other O +
mice O +
. O +

The O +
Ha O +
- O +
ras O +
oncogene O +
alone O +
did O +
not O +
convert O +
normal O +
human O +
fibroblasts O +
into O +
either O +
immortal O +
or O +
tumorigenic O +
cells O +
. O +

Our O +
current O +
data O +
suggest O +
that O +
gamma O +
rays O +
worked O +
as O +
an O +
initiator O +
of O +
carcinogenesis O +
in O +
normal O +
human O +
cells O +
, O +
giving O +
rise O +
to O +
chromosome O +
aberrations O +
and O +
immortality O +
, O +
and O +
the O +
Ha O +
- O +
ras O +
oncogene O +
played O +
a O +
role O +
in O +
the O +
progression O +
of O +
the O +
immortally O +
transformed O +
cell O +
population O +
to O +
a O +
neoplastic O +
one O +
showing O +
enhanced O +
colony O +
formation O +
in O +
soft O +
agar O +
and O +
tumorigenicity O +
in O +
nude O +
mice O +
. O +

N O +
- O +
methyl O +
- O +
N O +
- O +
nitrosourea O +
- O +
induced O +
transformation O +
of O +
rat O +
urothelial O +
cells O +
in O +
vitro O +
is O +
not O +
mediated O +
by O +
activation O +
of O +
ras O +
oncogenes O +
. O +

Adult O +
rat O +
urothelial O +
cells O +
were O +
transformed O +
in O +
vitro O +
following O +
treatment O +
with O +
a O +
single O +
dose O +
of O +
N O +
- O +
methyl O +
- O +
N O +
- O +
nitrosourea O +
( O +
MNU O +
) O +
or O +
MNU O +
treatment O +
followed O +
by O +
promotion O +
with O +
sodium O +
saccharin O +
. O +

This O +
in O +
vitro O +
transformation O +
process O +
involves O +
multiple O +
steps O +
: O +
slow O +
- O +
growing O +
' O +
pre O +
- O +
neoplastic O +
' O +
epithelial O +
foci O +
are O +
induced O +
70 O +
- O +
100 O +
days O +
after O +
MNU O +
treatment O +
and O +
from O +
such O +
foci O +
rapidly O +
proliferating O +
immortal O +
cell O +
lines O +
were O +
established O +
, O +
some O +
of O +
which O +
became O +
tumorigenic O +
after O +
a O +
further O +
latent O +
period O +
. O +

A O +
series O +
of O +
epithelial O +
cell O +
lines O +
and O +
a O +
single O +
fibroblast O +
cell O +
line O +
established O +
in O +
this O +
way O +
were O +
analysed O +
for O +
the O +
presence O +
of O +
transforming O +
genes O +
by O +
DNA O +
transfection O +
into O +
NIH3T3 B-CellLine +
cells O +
. O +

None O +
of O +
the O +
epithelial O +
cell O +
lines O +
induced O +
foci O +
in O +
a O +
focus O +
formation O +
assay O +
. O +

The O +
single O +
non O +
- O +
epithelial O +
line O +
induced O +
foci O +
and O +
was O +
found O +
to O +
contain O +
an O +
activated O +
c O +
- O +
Ki O +
- O +
ras O +
gene O +
with O +
a O +
G O +
- O +
- O +
- O +
- O +
A O +
transition O +
in O +
codon O +
12 O +
. O +

To O +
assay O +
for O +
the O +
possible O +
presence O +
of O +
transforming O +
genes O +
which O +
were O +
not O +
active O +
in O +
a O +
focus O +
formation O +
assay O +
, O +
two O +
of O +
the O +
epithelial O +
lines O +
were O +
analysed O +
further O +
by O +
co O +
- O +
transfection O +
with O +
a O +
dominant O +
selectable O +
marker O +
, O +
followed O +
by O +
selection O +
and O +
inoculation O +
into O +
nude O +
mice O +
. O +

No O +
tumours O +
were O +
induced O +
within O +
the O +
latent O +
period O +
for O +
tumour O +
production O +
by O +
control O +
cells O +
transfected O +
with O +
NIH3T3 B-CellLine +
cell O +
DNA O +
( O +
40 O +
- O +
60 O +
days O +
) O +
. O +

These O +
results O +
suggest O +
that O +
there O +
is O +
cell O +
type O +
specificity O +
for O +
oncogene O +
activation O +
during O +
in O +
vitro O +
rat O +
bladder O +
transformation O +
initiated O +
by O +
a O +
single O +
carcinogen O +
and O +
that O +
ras O +
gene O +
activation O +
is O +
not O +
a O +
necessary O +
step O +
in O +
urothelial O +
transformation O +
in O +
vitro O +
. O +

The O +
posterior O +
tether O +
in O +
scoliosis O +
. O +

The O +
hypothesis O +
that O +
a O +
localized O +
lordosis O +
, O +
or O +
tethering O +
of O +
the O +
posterior O +
elements O +
of O +
the O +
spine O +
, O +
is O +
the O +
primary O +
cause O +
of O +
the O +
vertebral O +
rotation O +
in O +
idiopathic O +
scoliosis O +
was O +
investigated O +
in O +
anatomic O +
specimens O +
of O +
human O +
and O +
calf O +
spinal O +
columns O +
. O +

The O +
specimens O +
were O +
axially O +
loaded O +
with O +
and O +
without O +
a O +
posterior O +
tether O +
created O +
using O +
Zielke O +
instrumentation O +
. O +

Lateral O +
deflection O +
and O +
axial O +
rotation O +
were O +
monitored O +
roentgenographically O +
. O +

The O +
vertebrae O +
of O +
tethered O +
spines O +
showed O +
increased O +
rotation O +
in O +
the O +
direction O +
associated O +
with O +
idiopathic O +
scoliosis O +
. O +

The O +
spinous O +
processes O +
moved O +
toward O +
the O +
concavity O +
at O +
the O +
apex O +
of O +
the O +
induced O +
lateral O +
curve O +
. O +

Conversely O +
, O +
untethered O +
spines O +
either O +
exhibited O +
little O +
rotation O +
or O +
rotated O +
in O +
the O +
opposite O +
direction O +
; O +
the O +
spinous O +
processes O +
moved O +
toward O +
the O +
convexity O +
of O +
the O +
curve O +
. O +

Rotations O +
toward O +
the O +
convexity O +
occur O +
in O +
rotational O +
kyphosis O +
. O +

Thus O +
the O +
hypothesis O +
that O +
idiopathic O +
scoliosis O +
is O +
a O +
rotational O +
lordosis O +
is O +
substantiated O +
; O +
the O +
characteristic O +
rotation O +
can O +
be O +
explained O +
with O +
the O +
aid O +
of O +
a O +
geometric O +
model O +
. O +

Glutamine O +
and O +
glucose O +
as O +
energy O +
substrates O +
for O +
Ehrlich O +
ascites O +
tumour O +
cells O +
. O +

Energy O +
metabolism O +
of O +
freshly O +
harvested O +
Ehrlich O +
ascites O +
tumour O +
cells O +
in O +
the O +
presence O +
of O +
5 O +
mM O +
glucose O +
and O +
/ O +
or O +
0 O +
. O +
5 O +
mM O +
glutamine O +
was O +
studied O +
. O +

The O +
rate O +
of O +
oxygen O +
utilization O +
was O +
not O +
altered O +
by O +
the O +
addition O +
of O +
0 O +
. O +
5 O +
mM O +
glutamine O +
; O +
5 O +
mM O +
glucose O +
induced O +
an O +
inhibition O +
of O +
respiration O +
. O +

In O +
the O +
presence O +
of O +
both O +
glucose O +
and O +
glutamine O +
, O +
the O +
Crabtree O +
effect O +
decreased O +
. O +

In O +
these O +
conditions O +
, O +
the O +
rates O +
of O +
oxygen O +
uptake O +
, O +
the O +
CO2 O +
evolution O +
and O +
the O +
changes O +
in O +
the O +
redox O +
states O +
of O +
cytochromes O +
indicate O +
that O +
glucose O +
is O +
preferred O +
by O +
Ehrlich O +
ascites O +
tumour O +
cells O +
as O +
energy O +
substrate O +
. O +

Glucose O +
decreased O +
the O +
rate O +
of O +
glutamine O +
utilization O +
by O +
34 O +
% O +
. O +

On O +
the O +
other O +
hand O +
, O +
glutaminolysis O +
did O +
not O +
inhibit O +
glycolysis O +
. O +

Sensitivity O +
analysis O +
of O +
the O +
influence O +
of O +
source O +
- O +
term O +
and O +
environmental O +
parameters O +
on O +
the O +
radiological O +
risk O +
of O +
coal O +
- O +
fired O +
plants O +
. O +

A O +
sensitivity O +
analysis O +
was O +
undertaken O +
to O +
determine O +
the O +
influence O +
of O +
different O +
source O +
- O +
term O +
and O +
environmental O +
parameters O +
on O +
the O +
radiological O +
risks O +
from O +
a O +
coal O +
- O +
fired O +
plant O +
( O +
CFP O +
) O +
. O +

It O +
was O +
found O +
that O +
the O +
release O +
rate O +
of O +
radionuclides O +
and O +
the O +
effective O +
release O +
height O +
most O +
significantly O +
influence O +
radiological O +
risk O +
. O +

Site O +
characteristics O +
, O +
such O +
as O +
rain O +
scavenging O +
coefficients O +
and O +
food O +
acquirement O +
habits O +
, O +
have O +
a O +
lesser O +
influence O +
, O +
and O +
some O +
parameters O +
, O +
such O +
as O +
time O +
delay O +
before O +
ingestion O +
of O +
contaminated O +
food O +
, O +
have O +
practically O +
no O +
influence O +
on O +
the O +
radiological O +
impact O +
of O +
a O +
CFP O +
. O +

The O +
contribution O +
to O +
radiation O +
risks O +
of O +
different O +
exposure O +
modes O +
( O +
i O +
. O +
e O +
. O +
inhalation O +
, O +
ingestion O +
and O +
contact O +
with O +
ground O +
surface O +
) O +
were O +
also O +
analyzed O +
, O +
as O +
well O +
as O +
of O +
specific O +
radionuclides O +
and O +
human O +
body O +
organs O +
. O +

Results O +
of O +
the O +
sensitivity O +
analysis O +
were O +
interpreted O +
in O +
terms O +
of O +
the O +
characteristics O +
of O +
the O +
fuel O +
, O +
facilities O +
and O +
site O +
of O +
a O +
CFP O +
. O +

It O +
is O +
concluded O +
that O +
by O +
proper O +
choice O +
of O +
coal O +
, O +
furnace O +
, O +
ash O +
filtration O +
and O +
stack O +
height O +
, O +
as O +
well O +
as O +
by O +
proper O +
siting O +
, O +
the O +
radiological O +
impact O +
of O +
a O +
CFP O +
can O +
be O +
drastically O +
reduced O +
. O +

Cigarette O +
smoking O +
and O +
alveolar O +
bone O +
height O +
in O +
subjects O +
with O +
a O +
high O +
standard O +
of O +
oral O +
hygiene O +
. O +

Smokers O +
and O +
non O +
- O +
smokers O +
were O +
compared O +
with O +
respect O +
to O +
alveolar O +
bone O +
height O +
. O +

The O +
study O +
covered O +
235 O +
subjects O +
aged O +
21 O +
- O +
60 O +
years O +
, O +
72 O +
of O +
whom O +
were O +
smokers O +
. O +

Oral O +
hygiene O +
status O +
and O +
dental O +
care O +
habits O +
were O +
above O +
average O +
and O +
of O +
equal O +
standard O +
in O +
both O +
groups O +
( O +
PlI O +
= O +
0 O +
. O +
9 O +
) O +
. O +

Alveolar O +
bone O +
height O +
was O +
assessed O +
on O +
radiographs O +
and O +
expressed O +
as O +
% O +
of O +
the O +
root O +
length O +
. O +

Alveolar O +
bone O +
height O +
was O +
significantly O +
reduced O +
in O +
smokers O +
as O +
compared O +
to O +
non O +
- O +
smokers O +
, O +
the O +
mean O +
+ O +
/ O +
- O +
SEM O +
being O +
77 O +
. O +
9 O +
+ O +
/ O +
- O +
1 O +
. O +
3 O +
% O +
and O +
82 O +
. O +
8 O +
+ O +
/ O +
- O +
0 O +
. O +
6 O +
% O +
, O +
respectively O +
( O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
. O +

Regression O +
analysis O +
suggested O +
that O +
periodontal O +
breakdown O +
judged O +
from O +
loss O +
of O +
alveolar O +
bone O +
over O +
time O +
was O +
more O +
accelerated O +
in O +
smokers O +
than O +
non O +
- O +
smokers O +
. O +

The O +
lower O +
bone O +
height O +
in O +
smokers O +
remained O +
when O +
age O +
and O +
oral O +
hygiene O +
were O +
allowed O +
for O +
. O +

It O +
is O +
concluded O +
that O +
smoking O +
is O +
a O +
risk O +
factor O +
for O +
periodontal O +
health O +
. O +

Growth O +
state O +
- O +
dependent O +
regulation O +
of O +
protein O +
kinase O +
C O +
in O +
normal O +
and O +
transformed O +
murine O +
cells O +
. O +

We O +
determined O +
whether O +
growth O +
state O +
can O +
influence O +
the O +
action O +
of O +
protein O +
kinase O +
C O +
by O +
measuring O +
protein O +
kinase O +
C O +
activity O +
in O +
growing O +
and O +
stationary O +
cultures O +
of O +
normal O +
and O +
transformed O +
cells O +
. O +

Two O +
approaches O +
were O +
used O +
to O +
measure O +
protein O +
kinase O +
C O +
: O +
assay O +
of O +
intact O +
cells O +
for O +
inhibition O +
of O +
epidermal O +
growth O +
factor O +
( O +
EGF O +
) O +
binding O +
in O +
response O +
to O +
phorbol O +
dibutyrate O +
( O +
PDBu O +
) O +
; O +
and O +
assay O +
of O +
detergent O +
extracts O +
for O +
total O +
calcium O +
, O +
phospholipid O +
- O +
dependent O +
kinase O +
activity O +
. O +

In O +
extracts O +
of O +
growing O +
and O +
stationary O +
Swiss B-CellLine +
3T3 I-CellLine +
cells O +
, O +
the O +
total O +
amount O +
of O +
protein O +
kinase O +
C O +
activity O +
was O +
similar O +
, O +
indicating O +
that O +
growth O +
state O +
does O +
not O +
alter O +
the O +
level O +
of O +
enzyme O +
in O +
the O +
cell O +
. O +

The O +
short O +
- O +
term O +
response O +
of O +
Swiss B-CellLine +
3T3 I-CellLine +
cells O +
to O +
an O +
activator O +
of O +
protein O +
kinase O +
C O +
also O +
appeared O +
to O +
be O +
independent O +
of O +
growth O +
state O +
, O +
since O +
the O +
50 O +
% O +
effective O +
dose O +
for O +
PDBu O +
inhibition O +
of O +
EGF O +
binding O +
to O +
its O +
receptor O +
was O +
approximately O +
7 O +
nM O +
for O +
both O +
growth O +
conditions O +
. O +

In O +
contrast O +
, O +
the O +
response O +
of O +
cells O +
to O +
long O +
- O +
term O +
treatment O +
with O +
PDBu O +
was O +
significantly O +
different O +
depending O +
upon O +
the O +
initial O +
growth O +
state O +
of O +
the O +
cells O +
. O +

In O +
both O +
growth O +
states O +
, O +
PDBu O +
caused O +
loss O +
of O +
protein O +
kinase O +
C O +
activity O +
, O +
which O +
reflected O +
a O +
loss O +
in O +
protein O +
mass O +
as O +
determined O +
by O +
immunoblotting O +
with O +
antiserum O +
to O +
protein O +
kinase O +
C O +
. O +

However O +
, O +
the O +
maximum O +
decrease O +
approached O +
100 O +
% O +
in O +
stationary O +
cultures O +
versus O +
approximately O +
75 O +
% O +
in O +
growing O +
cells O +
. O +

Protein O +
kinase O +
C O +
levels O +
in O +
several O +
transformed O +
cell O +
lines O +
were O +
subject O +
to O +
down O +
modulation O +
in O +
a O +
similar O +
growth O +
state O +
- O +
dependent O +
manner O +
. O +

Further O +
, O +
the O +
inhibition O +
of O +
EGF O +
binding O +
by O +
tumor O +
promoters O +
following O +
long O +
- O +
term O +
treatment O +
of O +
Swiss B-CellLine +
3T3 I-CellLine +
cells O +
with O +
PDBu O +
also O +
varied O +
with O +
growth O +
state O +
. O +

In O +
down O +
modulated O +
growing O +
cells O +
, O +
PDBu O +
caused O +
almost O +
complete O +
inhibition O +
of O +
EGF O +
binding O +
, O +
whereas O +
in O +
down O +
modulated O +
stationary O +
cells O +
, O +
minimal O +
inhibition O +
of O +
EGF O +
binding O +
by O +
PDBu O +
was O +
observed O +
. O +

These O +
results O +
suggest O +
that O +
prolonged O +
treatment O +
with O +
tumor O +
promoters O +
alters O +
the O +
sensitivity O +
of O +
cells O +
to O +
activators O +
of O +
protein O +
kinase O +
C O +
in O +
a O +
growth O +
state O +
- O +
dependent O +
manner O +
. O +

Suppression O +
and O +
re O +
- O +
expression O +
of O +
transformed O +
phenotype O +
in O +
hybrids O +
of O +
HA O +
- O +
ras O +
- O +
1 O +
- O +
transformed O +
rat B-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
and O +
early O +
- O +
passage O +
rat O +
embryonic O +
fibroblasts O +
. O +

Rat B-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
which O +
had O +
been O +
transformed O +
with O +
the O +
activated O +
Ha O +
- O +
ras O +
- O +
1 O +
gene O +
from O +
human O +
EJ B-CellLine +
bladder O +
carcinoma O +
cells O +
were O +
fused O +
with O +
diploid O +
embryonic O +
rat O +
fibroblasts O +
. O +

Four O +
selected O +
cell O +
hybrids O +
expressed O +
the O +
human O +
transforming O +
gene O +
product O +
p21 O +
at O +
levels O +
of O +
10 O +
to O +
30 O +
% O +
compared O +
to O +
100 O +
% O +
in O +
the O +
transformed O +
parental O +
cells O +
. O +

The O +
hybrid O +
cells O +
, O +
however O +
, O +
exhibited O +
normal O +
morphology O +
, O +
anchorage O +
requirement O +
for O +
proliferation O +
, O +
and O +
largely O +
extended O +
latency O +
periods O +
of O +
tumorigenicity O +
in O +
newborn O +
rats O +
. O +

Tumorigenic O +
hybrid O +
derivatives O +
contained O +
lower O +
numbers O +
of O +
chromosomes O +
than O +
the O +
tetraploid O +
parental O +
hybrids O +
. O +

DNA O +
of O +
the O +
non O +
- O +
tumorigenic O +
cell O +
hybrids O +
transformed O +
Rat B-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
to O +
anchorage O +
- O +
independent O +
proliferation O +
as O +
expected O +
for O +
the O +
transforming O +
human O +
Ha O +
- O +
ras O +
gene O +
present O +
in O +
the O +
donor O +
DNA O +
. O +

We O +
conclude O +
that O +
the O +
transforming O +
properties O +
of O +
the O +
activated O +
Ha O +
- O +
ras O +
gene O +
in O +
Rat B-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
can O +
be O +
suppressed O +
at O +
the O +
post O +
- O +
translational O +
level O +
by O +
the O +
presence O +
of O +
the O +
genome O +
from O +
diploid O +
embryonic O +
rat O +
fibroblasts O +
but O +
additional O +
controls O +
of O +
expression O +
of O +
the O +
transforming O +
gene O +
are O +
likely O +
to O +
exist O +
. O +

Normal O +
cells O +
contain O +
suppressor O +
gene O +
( O +
s O +
) O +
which O +
safeguard O +
these O +
cells O +
against O +
transformation O +
by O +
the O +
product O +
of O +
the O +
transforming O +
Ha O +
- O +
ras O +
- O +
1 O +
oncogene O +
. O +

Antishock O +
trousers O +
: O +
a O +
collective O +
review O +
. O +

Antishock O +
trousers O +
have O +
become O +
an O +
integral O +
part O +
of O +
emergency O +
medical O +
care O +
for O +
many O +
traumatic O +
and O +
life O +
- O +
threatening O +
emergencies O +
. O +

This O +
article O +
represents O +
a O +
summary O +
of O +
the O +
current O +
state O +
of O +
knowledge O +
concerning O +
the O +
use O +
of O +
this O +
device O +
. O +

A O +
brief O +
history O +
of O +
the O +
development O +
of O +
antishock O +
garments O +
is O +
discussed O +
. O +

This O +
is O +
followed O +
by O +
a O +
discussion O +
of O +
human O +
clinical O +
studies O +
and O +
results O +
of O +
clinical O +
research O +
on O +
hemodynamics O +
, O +
respiration O +
, O +
use O +
in O +
head O +
injury O +
, O +
and O +
effects O +
on O +
vascular O +
hemostasis O +
. O +

Indications O +
, O +
contraindications O +
, O +
complications O +
, O +
and O +
recommended O +
procedure O +
for O +
use O +
are O +
discussed O +
. O +

Based O +
on O +
randomized O +
prospective O +
studies O +
, O +
antishock O +
garments O +
have O +
not O +
, O +
as O +
yet O +
, O +
been O +
shown O +
to O +
improve O +
patient O +
morbidity O +
or O +
mortality O +
. O +

Proper O +
use O +
of O +
antishock O +
garments O +
requires O +
an O +
understanding O +
of O +
both O +
their O +
function O +
and O +
their O +
limitations O +
. O +

Measurement O +
of O +
serum O +
glycosylated O +
proteins O +
and O +
glycosylated O +
low O +
density O +
lipoprotein O +
fraction O +
in O +
diabetes O +
mellitus O +
. O +

A O +
simple O +
method O +
was O +
developed O +
for O +
estimating O +
serum O +
glycosylated O +
protein O +
levels O +
using O +
gel O +
filtration O +
with O +
Bio O +
- O +
Gel O +
P6 O +
by O +
determining O +
the O +
protein O +
and O +
sugar O +
content O +
in O +
the O +
void O +
volume O +
fraction O +
. O +

The O +
glycosylated O +
protein O +
levels O +
( O +
GSP O +
) O +
correlated O +
well O +
with O +
fasting O +
blood O +
sugar O +
levels O +
and O +
glycosylated O +
albumin O +
level O +
( O +
G O +
- O +
ALB O +
) O +
determined O +
by O +
affinity O +
chromatography O +
with O +
Blue O +
Sepharose O +
CL6B O +
. O +

The O +
glycosylation O +
level O +
of O +
heparin O +
- O +
citrate O +
precipitable O +
fraction O +
of O +
serum O +
which O +
predominantly O +
contained O +
low O +
density O +
lipoprotein O +
( O +
G O +
- O +
LDL O +
) O +
also O +
correlated O +
well O +
with O +
GSP O +
and O +
LDL O +
- O +
cholesterol O +
levels O +
. O +

Significantly O +
different O +
values O +
were O +
obtained O +
for O +
GSP O +
, O +
G O +
- O +
ALB O +
, O +
and O +
G O +
- O +
LDL O +
between O +
normals O +
and O +
diabetics O +
. O +

Combined O +
aortic O +
, O +
mitral O +
and O +
tricuspid O +
surgery O +
: O +
results O +
in O +
78 O +
patients O +
. O +

Between O +
1968 O +
and O +
1984 O +
, O +
78 O +
patients O +
( O +
mean O +
age O +
43 O +
, O +
range O +
14 O +
to O +
65 O +
years O +
) O +
underwent O +
combined O +
aortic O +
, O +
mitral O +
and O +
tricuspid O +
surgery O +
( O +
22 O +
triple O +
valve O +
replacements O +
, O +
56 O +
aortic O +
valve O +
replacements O +
with O +
tricuspid O +
conservative O +
surgery O +
and O +
mitral O +
valve O +
replacement O +
( O +
N O +
= O +
48 O +
) O +
, O +
or O +
commissuroplasty O +
( O +
N O +
= O +
8 O +
) O +
. O +

Pre O +
- O +
operative O +
consequences O +
of O +
valvular O +
disease O +
( O +
mainly O +
mixed O +
valve O +
disease O +
) O +
were O +
severe O +
as O +
assessed O +
by O +
functional O +
class O +
( O +
72 O +
pts O +
in O +
III O +
or O +
IV O +
NYHA O +
) O +
, O +
cardiomegaly O +
( O +
CTR O +
: O +
62 O +
+ O +
/ O +
- O +
6 O +
% O +
) O +
, O +
increase O +
of O +
mean O +
pulmonary O +
arterial O +
and O +
wedge O +
pressures O +
( O +
respectively O +
30 O +
+ O +
/ O +
- O +
12 O +
and O +
19 O +
+ O +
/ O +
- O +
6 O +
mmHg O +
) O +
decrease O +
in O +
cardiac O +
index O +
( O +
2 O +
. O +
1 O +
+ O +
/ O +
- O +
0 O +
. O +
5 O +
l O +
min O +
- O +
1 O +
m O +
- O +
2 O +
) O +
, O +
LV O +
dilatation O +
( O +
LV O +
end O +
diastolic O +
volume O +
: O +
184 O +
+ O +
/ O +
- O +
86 O +
ml O +
m O +
- O +
2 O +
) O +
and O +
impairment O +
of O +
LV O +
systolic O +
function O +
( O +
LV O +
ejection O +
fraction O +
: O +
50 O +
+ O +
/ O +
- O +
12 O +
% O +
) O +
. O +

Operative O +
mortality O +
rate O +
was O +
11 O +
. O +
5 O +
% O +
. O +

The O +
69 O +
survivors O +
were O +
all O +
followed O +
up O +
, O +
for O +
a O +
mean O +
of O +
56 O +
months O +
( O +
2 O +
to O +
207 O +
) O +
. O +

16 O +
late O +
deaths O +
occurred O +
. O +

Actuarial O +
survival O +
rate O +
at O +
10 O +
years O +
was O +
58 O +
. O +
4 O +
% O +
, O +
and O +
greatly O +
influenced O +
by O +
pre O +
- O +
operative O +
NYHA O +
class O +
. O +

Linearized O +
rates O +
of O +
thromboembolic O +
events O +
, O +
valve O +
thrombosis O +
and O +
haemorrhage O +
were O +
respectively O +
6 O +
. O +
4 O +
, O +
1 O +
. O +
5 O +
and O +
1 O +
. O +
2 O +
% O +
pt O +
- O +
1 O +
yr O +
- O +
1 O +
. O +

Those O +
of O +
infective O +
endocarditis O +
, O +
periprosthetic O +
leak O +
, O +
reoperation O +
and O +
valve O +
failure O +
were O +
0 O +
. O +
6 O +
, O +
3 O +
. O +
3 O +
and O +
4 O +
. O +
9 O +
% O +
pt O +
- O +
1 O +
yr O +
- O +
1 O +
respectively O +
. O +

At O +
9 O +
years O +
, O +
42 O +
% O +
of O +
the O +
patients O +
were O +
in O +
NYHA O +
class O +
I O +
or O +
II O +
and O +
free O +
from O +
complications O +
. O +

Torsade O +
de O +
pointes O +
during O +
loading O +
with O +
amiodarone O +
. O +

Torsade O +
de O +
pointes O +
represents O +
a O +
potential O +
complication O +
of O +
chronic O +
amiodarone O +
therapy O +
. O +

Several O +
reports O +
have O +
emphasized O +
the O +
need O +
for O +
a O +
loading O +
dose O +
in O +
order O +
to O +
achieve O +
therapeutic O +
blood O +
levels O +
rapidly O +
. O +

We O +
report O +
a O +
case O +
of O +
torsade O +
de O +
pointes O +
following O +
a O +
single O +
oral O +
dose O +
of O +
amiodarone O +
( O +
1400 O +
mg O +
or O +
30 O +
mg O +
kg O +
- O +
1 O +
) O +
administered O +
after O +
short O +
intravenous O +
loading O +
for O +
prevention O +
of O +
paroxysmal O +
atrial O +
flutter O +
. O +

Torsades O +
de O +
pointes O +
were O +
preceded O +
and O +
associated O +
with O +
marked O +
QT O +
prolongation O +
and O +
bradycardia O +
. O +

This O +
report O +
suggests O +
that O +
careful O +
monitoring O +
of O +
patients O +
undergoing O +
oral O +
amiodarone O +
loading O +
is O +
necessary O +
. O +

Conjunctival O +
hypoxia O +
in O +
diabetes O +
mellitus O +
. O +

A O +
frequently O +
cited O +
theory O +
for O +
the O +
pathogenesis O +
of O +
neovascularization O +
in O +
diabetic O +
retinopathy O +
is O +
that O +
retinal O +
hypoxia O +
and O +
/ O +
or O +
ischemia O +
release O +
a O +
factor O +
which O +
stimulates O +
neovascularization O +
. O +

To O +
the O +
authors O +
' O +
knowledge O +
, O +
there O +
is O +
no O +
direct O +
in O +
vivo O +
evidence O +
in O +
the O +
human O +
proving O +
this O +
theory O +
. O +

One O +
hundred O +
and O +
twenty O +
- O +
two O +
diabetic O +
subjects O +
were O +
studied O +
to O +
see O +
whether O +
worsening O +
retinopathy O +
was O +
associated O +
with O +
changes O +
in O +
conjunctival O +
oxygen O +
tension O +
( O +
pO2 O +
) O +
. O +

Diabetics O +
without O +
retinopathy O +
had O +
a O +
conjunctival O +
pO2 O +
which O +
was O +
similar O +
to O +
an O +
age O +
- O +
matched O +
normal O +
population O +
. O +

Diabetics O +
with O +
only O +
background O +
retinopathy O +
had O +
a O +
significantly O +
lower O +
conjunctival O +
pO2 O +
than O +
those O +
without O +
retinopathy O +
( O +
P O +
less O +
than O +
0 O +
. O +
01 O +
) O +
. O +

Diabetics O +
with O +
proliferative O +
retinopathy O +
showed O +
a O +
conjunctival O +
pO2 O +
that O +
was O +
significantly O +
lower O +
than O +
either O +
of O +
the O +
first O +
two O +
groups O +
( O +
P O +
less O +
than O +
0 O +
. O +
05 O +
) O +
. O +

The O +
lowest O +
value O +
of O +
all O +
was O +
found O +
in O +
patients O +
with O +
rubeosis O +
iridis O +
. O +

Duration O +
of O +
diabetes O +
alone O +
did O +
not O +
correlate O +
significantly O +
to O +
conjunctival O +
pO2 O +
. O +

These O +
findings O +
support O +
the O +
hypoxic O +
theory O +
of O +
diabetic O +
neovascular O +
retinopathy O +
. O +

Unsatisfactory O +
forehead O +
scar O +
following O +
face O +
lift O +
. O +

The O +
W O +
- O +
plasty O +
scar O +
revision O +
technique O +
has O +
been O +
found O +
to O +
be O +
effective O +
in O +
the O +
repair O +
of O +
the O +
difficult O +
and O +
cosmetically O +
unsatisfactory O +
hairline O +
scar O +
following O +
the O +
ill O +
- O +
advised O +
face O +
lift O +
technique O +
that O +
excises O +
forehead O +
skin O +
. O +

Clinical O +
evaluation O +
of O +
radiotherapy O +
for O +
Graves O +
' O +
ophthalmopathy O +
. O +

Seventeen O +
patients O +
with O +
moderately O +
severe O +
ophthalmopathy O +
due O +
to O +
Graves O +
' O +
disease O +
were O +
treated O +
by O +
cobalt O +
or O +
supervoltage O +
radiotherapy O +
. O +

All O +
patients O +
complained O +
of O +
diplopia O +
. O +

The O +
mean O +
proptosis O +
value O +
was O +
21 O +
. O +
4 O +
mm O +
. O +

Three O +
patients O +
( O +
18 O +
% O +
) O +
showed O +
good O +
response O +
, O +
7 O +
( O +
41 O +
% O +
) O +
moderate O +
and O +
7 O +
minimal O +
or O +
no O +
response O +
. O +

Improvement O +
was O +
noted O +
mainly O +
in O +
soft O +
tissue O +
changes O +
and O +
diplopia O +
, O +
while O +
proptosis O +
decreased O +
in O +
only O +
5 O +
patients O +
. O +

All O +
except O +
one O +
patient O +
who O +
had O +
marked O +
extraocular O +
muscle O +
involvement O +
revealed O +
by O +
computed O +
tomography O +
responded O +
to O +
treatment O +
. O +

These O +
data O +
indicate O +
that O +
radiotherapy O +
may O +
be O +
indicated O +
in O +
patients O +
with O +
progressive O +
ophthalmopathy O +
, O +
especially O +
in O +
those O +
who O +
are O +
associated O +
with O +
extraocular O +
muscle O +
enlargement O +
. O +

The O +
origin O +
of O +
yolk O +
- O +
DNA O +
in O +
Xenopus O +
laevis O +
. O +

Xenopus O +
laevis O +
serum O +
and O +
plasma O +
was O +
found O +
to O +
contain O +
an O +
average O +
of O +
25 O +
microgram O +
DNA O +
/ O +
ml O +
. O +

Isolated O +
X O +
. O +
laevis O +
oocytes O +
incubated O +
in O +
medium O +
containing O +
25 O +
microgram O +
DNA O +
/ O +
ml O +
labeled O +
with O +
either O +
125I O +
, O +
32P O +
or O +
14C O +
and O +
from O +
three O +
different O +
sources O +
( O +
bovine O +
, O +
E O +
. O +
coli O +
and O +
X O +
. O +
laevis O +
) O +
, O +
incorporated O +
the O +
label O +
at O +
an O +
average O +
rate O +
of O +
0 O +
. O +
11 O +
ng O +
. O +
mm O +
- O +
2 O +
. O +
hr O +
- O +
1 O +
. O +

Sucrose O +
gradient O +
fractionation O +
of O +
oocytes O +
revealed O +
that O +
40 O +
- O +
75 O +
% O +
of O +
the O +
acid O +
- O +
precipitable O +
label O +
incorporated O +
was O +
associated O +
with O +
the O +
yolk O +
platelets O +
. O +

Additional O +
incubations O +
of O +
oocytes O +
in O +
unlabeled O +
medium O +
demonstrated O +
that O +
the O +
DNA O +
incorporated O +
into O +
the O +
yolk O +
platelets O +
was O +
undergoing O +
turnover O +
; O +
only O +
20 O +
% O +
of O +
the O +
yolk O +
- O +
associated O +
DNA O +
was O +
still O +
present O +
after O +
a O +
one O +
- O +
week O +
incubation O +
. O +

Our O +
data O +
suggest O +
that O +
yolk O +
- O +
DNA O +
arises O +
by O +
the O +
adventitious O +
uptake O +
of O +
DNA O +
present O +
in O +
the O +
maternal O +
serum O +
by O +
vitellogenic O +
oocytes O +
. O +

New O +
functions O +
of O +
epidermal O +
growth O +
factor O +
: O +
stimulation O +
of O +
capillary O +
endothelial O +
cell O +
migration O +
and O +
matrix O +
dependent O +
proliferation O +
. O +

The O +
proliferative O +
response O +
of O +
bovine O +
retinal O +
capillary O +
endothelial O +
cells O +
to O +
EGF O +
is O +
dependent O +
upon O +
attaching O +
the O +
cells O +
to O +
a O +
matrix O +
of O +
fibronectin O +
. O +

Bovine O +
capillary O +
endothelial O +
cells O +
are O +
also O +
stimulated O +
to O +
actively O +
migrate O +
when O +
exposed O +
to O +
EGF O +
in O +
vitro O +
. O +

These O +
activities O +
provide O +
an O +
explanation O +
for O +
the O +
angiogenic O +
properties O +
of O +
EGF O +
in O +
vivo O +
. O +

Capillary O +
cell O +
migration O +
and O +
proliferation O +
are O +
proposed O +
as O +
sensitive O +
quantifiable O +
bioassays O +
to O +
explore O +
the O +
functional O +
domains O +
of O +
the O +
EGF O +
molecule O +
. O +

Studies O +
on O +
the O +
inactivation O +
of O +
these O +
properties O +
of O +
EGF O +
by O +
specific O +
cleavage O +
of O +
the O +
molecule O +
with O +
CNBr O +
or O +
proteases O +
suggest O +
that O +
an O +
intact O +
loop O +
composed O +
in O +
part O +
by O +
amino O +
acid O +
residues O +
20 O +
to O +
31 O +
is O +
essential O +
for O +
at O +
least O +
some O +
functions O +
. O +

The O +
effect O +
of O +
aflatoxin O +
B1 O +
on O +
the O +
utilization O +
of O +
serum O +
calcium O +
. O +

The O +
mathematical O +
analysis O +
for O +
plasma O +
disappearance O +
curve O +
of O +
aflatoxicosed O +
animals O +
, O +
subsequently O +
injected O +
with O +
45Ca O +
was O +
determined O +
. O +

The O +
analysis O +
showed O +
that O +
the O +
three O +
main O +
compartments O +
of O +
the O +
calcium O +
pool O +
( O +
plasma O +
, O +
bone O +
and O +
the O +
labile O +
calcium O +
pool O +
on O +
the O +
surface O +
of O +
bone O +
and O +
soft O +
tissues O +
) O +
had O +
been O +
affected O +
. O +

Specifically O +
, O +
the O +
fractional O +
rate O +
constant O +
for O +
migration O +
of O +
45Ca O +
from O +
plasma O +
pool O +
to O +
the O +
labile O +
pool O +
had O +
been O +
diminished O +
to O +
its O +
third O +
value O +
. O +

This O +
led O +
to O +
a O +
corresponding O +
reduction O +
in O +
the O +
calcium O +
content O +
of O +
the O +
bone O +
ash O +
. O +

The O +
probable O +
mechanism O +
by O +
which O +
aflatoxin O +
B1 O +
affects O +
calcium O +
dynamics O +
may O +
be O +
interpreted O +
by O +
the O +
inhibitory O +
effect O +
of O +
aflatoxin O +
in O +
the O +
hydroxylation O +
mechanism O +
of O +
vitamin O +
D3 O +
into O +
an O +
active O +
intermediate O +
. O +

During O +
aflatoxicosis O +
( O +
induction O +
of O +
15 O +
days O +
) O +
the O +
animals O +
entered O +
a O +
state O +
of O +
calcium O +
deficiency O +
, O +
secondary O +
to O +
intestinal O +
absorption O +
inhibition O +
. O +

This O +
was O +
followed O +
by O +
bone O +
resorption O +
and O +
disturbance O +
of O +
the O +
fractional O +
removal O +
rate O +
constant O +
among O +
different O +
calcium O +
compartments O +
. O +

Low O +
- O +
level O +
X O +
- O +
radiation O +
effects O +
on O +
functional O +
vascular O +
changes O +
in O +
Syrian O +
hamster O +
cheek O +
pouch O +
epithelium O +
during O +
hydrocarbon O +
carcinogenesis O +
. O +

Effects O +
of O +
repeated O +
low O +
- O +
level O +
X O +
radiation O +
on O +
functional O +
microvascular O +
changes O +
in O +
hamster O +
cheek O +
pouch O +
epithelium O +
during O +
and O +
following O +
carcinogenesis O +
by O +
7 O +
, O +
12 O +
- O +
dimethylbenz O +
[ O +
a O +
] O +
anthracene O +
( O +
DMBA O +
) O +
were O +
studied O +
. O +

Prior O +
studies O +
showed O +
enhancement O +
of O +
such O +
carcinogenesis O +
by O +
repeated O +
20 O +
rad O +
head O +
and O +
neck O +
X O +
- O +
radiation O +
exposures O +
, O +
and O +
it O +
was O +
proposed O +
that O +
one O +
possible O +
mechanism O +
was O +
radiogenic O +
alteration O +
of O +
the O +
functional O +
microvasculature O +
in O +
a O +
manner O +
which O +
favored O +
subsequent O +
tumor O +
development O +
. O +

Hamsters O +
were O +
treated O +
with O +
either O +
radiation O +
, O +
DMBA O +
, O +
radiation O +
+ O +
DMBA O +
, O +
or O +
no O +
treatment O +
. O +

Animals O +
were O +
sacrificed O +
at O +
3 O +
- O +
week O +
intervals O +
from O +
0 O +
to O +
39 O +
weeks O +
after O +
treatments O +
began O +
. O +

Pouch O +
vascular O +
volume O +
and O +
permeability O +
changes O +
were O +
studied O +
by O +
fractional O +
distributions O +
of O +
radiotracers O +
and O +
were O +
analyzed O +
by O +
a O +
variety O +
of O +
statistical O +
methods O +
which O +
explored O +
the O +
vascular O +
parameters O +
, O +
treatment O +
types O +
, O +
elapsed O +
time O +
, O +
presence O +
of O +
the O +
carcinogen O +
, O +
and O +
histopathologic O +
changes O +
. O +

All O +
treatments O +
resulted O +
in O +
significant O +
changes O +
in O +
vascular O +
volume O +
with O +
time O +
, O +
while O +
only O +
DMBA O +
treatments O +
alone O +
resulted O +
in O +
significant O +
changes O +
in O +
vascular O +
permeability O +
with O +
time O +
. O +

Prior O +
to O +
the O +
appearances O +
of O +
frank O +
neoplasms O +
, O +
volumetric O +
changes O +
in O +
DMBA O +
only O +
and O +
radiation O +
only O +
groups O +
were O +
similar O +
, O +
while O +
volume O +
changes O +
in O +
DMBA O +
+ O +
radiation O +
groups O +
increased O +
slowly O +
to O +
a O +
peak O +
later O +
than O +
in O +
other O +
groups O +
and O +
then O +
declined O +
steadily O +
to O +
levels O +
similar O +
to O +
the O +
radiation O +
only O +
group O +
. O +

As O +
in O +
prior O +
studies O +
, O +
there O +
were O +
significant O +
vascular O +
volume O +
differences O +
between O +
DMBA O +
and O +
DMBA O +
+ O +
radiation O +
groups O +
of O +
tumor O +
- O +
bearing O +
cheek O +
pouches O +
. O +

DMBA O +
maxima O +
were O +
significantly O +
higher O +
than O +
those O +
of O +
DMBA O +
+ O +
radiation O +
. O +

Radiation O +
significantly O +
affected O +
DMBA O +
- O +
associated O +
vascular O +
volume O +
and O +
permeability O +
changes O +
during O +
carcinogenesis O +
. O +

Several O +
possible O +
explanations O +
for O +
the O +
relationship O +
of O +
these O +
changes O +
to O +
the O +
enhancement O +
of O +
DMBA O +
carcinogenesis O +
include O +
: O +
radiation O +
blocking O +
normal O +
capillary O +
proliferative O +
and O +
/ O +
or O +
dilatory O +
responses O +
to O +
inflammation O +
secondary O +
to O +
neoplastic O +
changes O +
; O +
radiation O +
- O +
induced O +
focal O +
increases O +
in O +
the O +
pericapillary O +
connective O +
tissue O +
histohematic O +
barrier O +
, O +
stimulating O +
angiogenesis O +
but O +
reducing O +
nutrient O +
diffusion O +
; O +
radiation O +
exposures O +
sensitizing O +
vascular O +
endothelium O +
to O +
subsequent O +
angiogenic O +
stimulation O +
from O +
premalignant O +
tissues O +
; O +
DMBA O +
vascular O +
and O +
epithelial O +
effects O +
partially O +
or O +
completely O +
blocking O +
radiation O +
effects O +
on O +
epithelial O +
and O +
/ O +
or O +
endothelial O +
cells O +
; O +
and O +
radiation O +
damage O +
to O +
vessel O +
walls O +
partially O +
or O +
fully O +
inhibiting O +
normal O +
physiologic O +
mechanisms O +
of O +
repairing O +
DMBA O +
damage O +
to O +
the O +
vessels O +
. O +

Immunoglobulins O +
associated O +
with O +
elevated O +
riboflavin O +
binding O +
by O +
plasma O +
from O +
cancer O +
patients O +
. O +

Plasma O +
from O +
182 O +
patients O +
with O +
different O +
malignant O +
diseases O +
was O +
tested O +
for O +
riboflavin O +
binding O +
by O +
immunoglobulins O +
, O +
which O +
have O +
been O +
recently O +
identified O +
as O +
major O +
carriers O +
of O +
this O +
micronutrient O +
. O +

A O +
wide O +
range O +
of O +
binding O +
( O +
5 O +
. O +
9 O +
to O +
130 O +
pmole O +
/ O +
ml O +
plasma O +
) O +
was O +
observed O +
, O +
and O +
significant O +
elevations O +
were O +
found O +
for O +
patients O +
having O +
breast O +
cancer O +
( O +
21 O +
. O +
2 O +
+ O +
/ O +
- O +
1 O +
. O +
9 O +
, O +
P O +
less O +
than O +
0 O +
. O +
05 O +
) O +
and O +
melanoma O +
( O +
25 O +
. O +
7 O +
+ O +
/ O +
- O +
1 O +
. O +
9 O +
, O +
P O +
less O +
than O +
0 O +
. O +
001 O +
) O +
compared O +
to O +
controls O +
( O +
15 O +
. O +
5 O +
+ O +
/ O +
- O +
1 O +
. O +
9 O +
) O +
. O +

The O +
proteins O +
responsible O +
for O +
a O +
majority O +
of O +
the O +
higher O +
binding O +
were O +
identified O +
as O +
immunoglobulins O +
, O +
based O +
on O +
their O +
elution O +
from O +
gel O +
filtration O +
columns O +
and O +
the O +
removal O +
of O +
57 O +
- O +
88 O +
% O +
of O +
the O +
non O +
- O +
albumin O +
binding O +
by O +
treating O +
of O +
plasma O +
with O +
Protein O +
A O +
- O +
agarose O +
. O +

The O +
binding O +
was O +
only O +
weakly O +
related O +
to O +
the O +
total O +
concentration O +
of O +
immunoglobulins O +
( O +
r O +
= O +
0 O +
. O +
11 O +
by O +
linear O +
regression O +
analysis O +
) O +
, O +
however O +
, O +
and O +
is O +
apparently O +
due O +
to O +
a O +
subclass O +
that O +
is O +
elevated O +
in O +
some O +
types O +
of O +
cancer O +
. O +

Elevated O +
levels O +
of O +
these O +
immunoglobulins O +
may O +
contribute O +
to O +
the O +
lower O +
urinary O +
levels O +
and O +
clearance O +
of O +
riboflavin O +
in O +
cancer O +
. O +

Mast O +
cells O +
and O +
tumors O +
. O +

The O +
specific O +
enhancement O +
of O +
tumor O +
proliferation O +
in O +
vitro O +
. O +

Mast O +
cells O +
were O +
found O +
to O +
be O +
unique O +
among O +
the O +
peritoneal O +
leukocytes O +
by O +
virtue O +
of O +
their O +
capacity O +
to O +
enhance O +
profoundly O +
the O +
proliferation O +
of O +
a O +
variety O +
of O +
tumors O +
in O +
vitro O +
. O +

This O +
phenomenon O +
occurs O +
at O +
mast O +
cell O +
/ O +
tumor O +
ratios O +
which O +
reflect O +
the O +
stoichiometry O +
of O +
host O +
cell O +
/ O +
tumor O +
relationships O +
in O +
vivo O +
. O +

The O +
growth O +
factor O +
was O +
found O +
to O +
reside O +
in O +
mast O +
cell O +
granules O +
and O +
was O +
identified O +
as O +
heparin O +
by O +
sequential O +
purification O +
and O +
enzymatic O +
degradation O +
. O +

This O +
cellular O +
interaction O +
was O +
tumor O +
- O +
specific O +
, O +
although O +
isolated O +
granules O +
could O +
enhance O +
fibroblast O +
proliferation O +
. O +

The O +
findings O +
are O +
discussed O +
in O +
relation O +
to O +
previous O +
morphologic O +
studies O +
, O +
reports O +
of O +
in O +
vitro O +
mast O +
- O +
cell O +
- O +
mediated O +
tumor O +
cytotoxicity O +
, O +
and O +
the O +
role O +
of O +
mast O +
cells O +
in O +
angiogenesis O +
and O +
connective O +
tissue O +
proliferation O +
. O +

Management O +
of O +
the O +
tortuous O +
internal O +
carotid O +
artery O +
. O +

The O +
tortuous O +
internal O +
carotid O +
artery O +
as O +
the O +
basis O +
of O +
cerebral O +
vascular O +
insufficiency O +
is O +
a O +
controversial O +
entity O +
, O +
as O +
such O +
lesions O +
frequently O +
occur O +
without O +
neurologic O +
symptoms O +
. O +

However O +
, O +
some O +
tortuous O +
vessels O +
are O +
associated O +
with O +
significant O +
carotid O +
atherosclerotic O +
disease O +
requiring O +
a O +
specific O +
surgical O +
approach O +
. O +

This O +
formed O +
the O +
basis O +
of O +
our O +
report O +
. O +

Symptoms O +
of O +
cerebrovascular O +
insufficiency O +
in O +
association O +
with O +
a O +
tortuous O +
internal O +
carotid O +
artery O +
was O +
encountered O +
in O +
27 O +
of O +
853 O +
carotid O +
endarterectomies O +
over O +
a O +
22 O +
year O +
period O +
. O +

Stenosis O +
of O +
hemodynamic O +
significance O +
was O +
noted O +
in O +
nine O +
patients O +
and O +
irregularities O +
or O +
ulceration O +
were O +
noted O +
in O +
the O +
rest O +
. O +

With O +
the O +
standard O +
technique O +
of O +
carotid O +
endarterectomy O +
, O +
removal O +
of O +
plaque O +
from O +
a O +
tortuous O +
vessel O +
leads O +
to O +
loss O +
of O +
the O +
stenting O +
effect O +
provided O +
by O +
the O +
plaque O +
such O +
that O +
angulation O +
occlusion O +
is O +
likely O +
to O +
occur O +
. O +

The O +
optimal O +
reconstruction O +
in O +
our O +
experience O +
is O +
eversion O +
endarterectomy O +
by O +
transection O +
and O +
lower O +
reimplantation O +
of O +
the O +
internal O +
carotid O +
artery O +
on O +
the O +
common O +
carotid O +
artery O +
. O +

Our O +
experience O +
with O +
17 O +
such O +
procedures O +
in O +
15 O +
patients O +
has O +
been O +
presented O +
. O +

Postpartum O +
rubella O +
immunization O +
: O +
association O +
with O +
development O +
of O +
prolonged O +
arthritis O +
, O +
neurological O +
sequelae O +
, O +
and O +
chronic O +
rubella O +
viremia O +
. O +

Six O +
women O +
developed O +
chronic O +
long O +
- O +
term O +
arthropathy O +
after O +
postpartum O +
immunization O +
against O +
rubella O +
. O +

All O +
individuals O +
developed O +
acute O +
polyarticular O +
arthritis O +
within O +
12 O +
days O +
to O +
three O +
weeks O +
postimmunization O +
and O +
have O +
had O +
continuing O +
chronic O +
or O +
recurrent O +
arthralgia O +
or O +
arthritis O +
for O +
two O +
to O +
seven O +
years O +
after O +
vaccination O +
. O +

Acute O +
neurological O +
manifestations O +
, O +
consisting O +
of O +
carpal O +
tunnel O +
syndrome O +
or O +
multiple O +
paresthesiae O +
, O +
developed O +
postvaccination O +
in O +
three O +
women O +
. O +

Two O +
have O +
developed O +
continuing O +
active O +
or O +
chronic O +
recurrent O +
episodes O +
of O +
blurred O +
vision O +
, O +
paresthesiae O +
, O +
and O +
painful O +
limb O +
syndromes O +
together O +
with O +
recurrent O +
joint O +
symptoms O +
. O +

Chronic O +
rubella O +
viremia O +
has O +
been O +
detected O +
in O +
peripheral O +
blood O +
mononuclear O +
cell O +
( O +
MNC O +
) O +
populations O +
in O +
five O +
of O +
the O +
six O +
women O +
up O +
to O +
six O +
years O +
after O +
vaccination O +
. O +

In O +
addition O +
rubella O +
virus O +
was O +
isolated O +
from O +
breast O +
milk O +
MNCs O +
in O +
one O +
individual O +
at O +
nine O +
months O +
postvaccination O +
and O +
from O +
peripheral O +
blood O +
MNCs O +
in O +
two O +
of O +
four O +
breast O +
- O +
fed O +
infants O +
studied O +
at O +
12 O +
- O +
18 O +
months O +
of O +
age O +
. O +

Immune O +
responses O +
to O +
rubella O +
virus O +
studied O +
at O +
sequential O +
intervals O +
after O +
vaccination O +
correlated O +
with O +
development O +
of O +
rheumatologic O +
and O +
neurological O +
manifestations O +
. O +

Rapid O +
enzyme O +
analysis O +
of O +
amniotic O +
fluid O +
phospholipids O +
containing O +
choline O +
: O +
a O +
comparison O +
with O +
the O +
lecithin O +
to O +
sphingomyelin O +
ratio O +
in O +
prenatal O +
assessment O +
of O +
fetal O +
lung O +
maturity O +
. O +

The O +
relation O +
between O +
the O +
choline O +
containing O +
surfactant O +
phospholipids O +
lecithin O +
and O +
sphingomyelin O +
in O +
amniotic O +
fluid O +
and O +
fetal O +
lung O +
maturity O +
is O +
well O +
established O +
. O +

An O +
enzymatic O +
method O +
that O +
had O +
been O +
automated O +
and O +
optimised O +
for O +
use O +
on O +
a O +
centrifugal O +
analyser O +
was O +
used O +
to O +
measure O +
the O +
total O +
choline O +
containing O +
phospholipids O +
in O +
amniotic O +
fluid O +
. O +

The O +
total O +
time O +
taken O +
for O +
this O +
assay O +
was O +
10 O +
minutes O +
. O +

The O +
results O +
obtained O +
from O +
100 O +
patient O +
samples O +
, O +
using O +
this O +
procedure O +
, O +
compared O +
favourably O +
with O +
the O +
results O +
obtained O +
by O +
the O +
thin O +
layer O +
chromatography O +
procedure O +
used O +
to O +
determine O +
the O +
lecithin O +
to O +
sphingomyelin O +
ratio O +
( O +
r O +
= O +
0 O +
. O +
93 O +
) O +
. O +

A O +
clinical O +
study O +
of O +
60 O +
patients O +
showed O +
that O +
this O +
assay O +
predicted O +
prenatal O +
respiratory O +
distress O +
syndrome O +
as O +
well O +
as O +
the O +
lecithin O +
to O +
sphingomyelin O +
ratios O +
. O +

The O +
advantage O +
of O +
this O +
assay O +
over O +
existing O +
procedures O +
is O +
that O +
it O +
requires O +
minimum O +
preparation O +
of O +
the O +
specimen O +
and O +
no O +
extraction O +
, O +
is O +
quick O +
, O +
and O +
shows O +
a O +
high O +
degree O +
of O +
precision O +
. O +

[ O +
Histophysiology O +
and O +
histopathology O +
of O +
the O +
adrenals O +
in O +
experimental O +
hypokinesia O +
] O +
. O +

In O +
experiments O +
on O +
male O +
rats O +
in O +
the O +
course O +
of O +
3 O +
- O +
month O +
hypokinesia O +
phasic O +
changes O +
were O +
observed O +
in O +
the O +
relative O +
adrenal O +
gland O +
weight O +
, O +
in O +
the O +
volume O +
of O +
the O +
cell O +
nuclei O +
of O +
the O +
glomerular O +
, O +
fasicular O +
zones O +
and O +
the O +
medulla O +
, O +
in O +
the O +
activity O +
of O +
the O +
succinic O +
dehydrogenase O +
, O +
alkaline O +
and O +
acid O +
phosphatases O +
, O +
in O +
the O +
RNA O +
and O +
catecholamine O +
content O +
. O +

These O +
changes O +
are O +
associated O +
with O +
variations O +
in O +
the O +
secretion O +
and O +
biosynthesis O +
of O +
the O +
hormones O +
of O +
the O +
cortical O +
and O +
the O +
medullary O +
layer O +
of O +
the O +
adrenal O +
glands O +
during O +
the O +
hypokinetic O +
stress O +
development O +
. O +

Cardiac O +
gap O +
junction O +
configuration O +
after O +
an O +
uncoupling O +
treatment O +
as O +
a O +
function O +
of O +
time O +
. O +

Rabbit O +
ventricle O +
either O +
was O +
fixed O +
in O +
glutaraldehyde O +
without O +
injury O +
( O +
control O +
) O +
or O +
was O +
injured O +
before O +
fixation O +
, O +
presumably O +
causing O +
electrical O +
uncoupling O +
of O +
the O +
gap O +
junctions O +
. O +

All O +
tissue O +
was O +
then O +
processed O +
for O +
freeze O +
- O +
fracture O +
. O +

Replicas O +
of O +
control O +
gap O +
junctions O +
exhibited O +
irregular O +
packing O +
of O +
the O +
P O +
- O +
face O +
particles O +
and O +
E O +
- O +
face O +
pits O +
. O +

Average O +
center O +
- O +
to O +
- O +
center O +
spacing O +
of O +
the O +
particles O +
was O +
10 O +
. O +
5 O +
nm O +
. O +

Tissue O +
fixed O +
1 O +
- O +
5 O +
min O +
after O +
injury O +
showed O +
clumping O +
of O +
gap O +
junctional O +
particles O +
and O +
pits O +
. O +

Within O +
the O +
clumps O +
, O +
the O +
particles O +
and O +
pits O +
were O +
hexagonally O +
packed O +
and O +
the O +
center O +
- O +
to O +
- O +
center O +
spacing O +
of O +
the O +
particles O +
averaged O +
9 O +
. O +
5 O +
nm O +
. O +

In O +
tissue O +
fixed O +
15 O +
- O +
30 O +
min O +
after O +
injury O +
, O +
the O +
clumps O +
of O +
gap O +
junctional O +
particles O +
had O +
coalesced O +
into O +
a O +
homogeneous O +
structure O +
in O +
most O +
junctions O +
. O +

The O +
packing O +
of O +
the O +
particles O +
and O +
pits O +
was O +
hexagonal O +
and O +
the O +
spacing O +
of O +
the O +
particles O +
averaged O +
9 O +
. O +
5 O +
nm O +
. O +

A O +
few O +
pieces O +
of O +
rabbit O +
atrium O +
were O +
frozen O +
without O +
prior O +
fixation O +
or O +
cryoprotection O +
to O +
try O +
to O +
assess O +
the O +
effect O +
of O +
glutarldehyde O +
fixation O +
on O +
gap O +
junction O +
structure O +
. O +

In O +
this O +
tissue O +
the O +
gap O +
junctional O +
particles O +
were O +
irregularly O +
packed O +
and O +
their O +
spacing O +
averaged O +
10 O +
. O +
0 O +
nm O +
. O +

Absence O +
of O +
effect O +
of O +
prenatal O +
ethanol O +
on O +
adult O +
emotionality O +
and O +
ethanol O +
consumption O +
in O +
rats O +
. O +

Lower O +
peak O +
blood O +
ethanol O +
concentrations O +
after O +
1 O +
and O +
2 O +
g O +
of O +
ethanol O +
per O +
kg O +
were O +
found O +
in O +
pregnant O +
rats O +
than O +
in O +
virgin O +
females O +
. O +

No O +
significant O +
differences O +
in O +
adult O +
" O +
emotionality O +
" O +
or O +
ethanol O +
consumption O +
were O +
found O +
in O +
rats O +
exposed O +
to O +
prenatal O +
alcohol O +
and O +
in O +
pair O +
- O +
fed O +
and O +
untreated O +
controls O +
. O +

Tropical O +
splenomegaly O +
syndrome O +
in O +
Zambia O +
: O +
further O +
observations O +
and O +
effects O +
of O +
cycloguanil O +
and O +
proguanil O +
. O +

Nineteen O +
Zambian O +
patients O +
with O +
the O +
tropical O +
splenomegaly O +
syndrome O +
and O +
sinusoidal O +
lymphocytosis O +
on O +
liver O +
biopsy O +
were O +
studied O +
. O +

The O +
association O +
of O +
macrobulinaemia O +
with O +
the O +
tropical O +
splenomegaly O +
syndrome O +
has O +
again O +
been O +
confirmed O +
. O +

Sixteen O +
patients O +
were O +
treated O +
with O +
antimalarials O +
- O +
12 O +
with O +
cycloguanil O +
pamoate O +
alone O +
, O +
3 O +
with O +
cycloguanil O +
and O +
proguanil O +
, O +
and O +
1 O +
with O +
proguanil O +
alone O +
. O +

Twelve O +
patients O +
were O +
observed O +
for O +
periods O +
of O +
sufficient O +
length O +
for O +
the O +
drug O +
effect O +
to O +
be O +
assessed O +
, O +
and O +
in O +
11 O +
there O +
was O +
a O +
good O +
response O +
in O +
terms O +
of O +
decrease O +
in O +
spleen O +
size O +
. O +
Cycloguanil O +
pamoate O +
may O +
be O +
of O +
value O +
both O +
for O +
prophylaxis O +
and O +
treatment O +
in O +
areas O +
where O +
tropical O +
splenomegaly O +
syndrome O +
is O +
endemic O +
. O +

Regulation O +
of O +
glucosyl O +
- O +
and O +
fructosyltransferase O +
synthesis O +
by O +
continuous O +
cultures O +
of O +
Streptococcus O +
mutans O +
. O +

Streptococcus O +
mutans O +
strains O +
Ingbritt O +
, O +
and O +
its O +
derivative O +
B7 O +
which O +
had O +
been O +
passaged O +
through O +
monkeys O +
, O +
have O +
been O +
used O +
to O +
investigate O +
how O +
the O +
synthesis O +
of O +
extracellular O +
glucosyl O +
- O +
and O +
fructosyltransferases O +
is O +
regulated O +
. O +

The O +
most O +
active O +
enzyme O +
from O +
carbon O +
- O +
limited O +
continuous O +
cultures O +
was O +
a O +
fructosyltransferase O +
; O +
enzymes O +
catalysing O +
the O +
formation O +
of O +
water O +
- O +
insoluble O +
glucans O +
from O +
sucrose O +
were O +
relatively O +
inactive O +
. O +

Dextransucrase O +
( O +
EC O +
2 O +
. O +
4 O +
. O +
1 O +
. O +
5 O +
) O +
, O +
which O +
catalyses O +
soluble O +
glucan O +
synthesis O +
, O +
was O +
most O +
active O +
in O +
the O +
supernatant O +
fluid O +
from O +
cultures O +
grown O +
with O +
excess O +
glucose O +
, O +
fructose O +
or O +
sucrose O +
, O +
but O +
full O +
activity O +
was O +
detected O +
only O +
when O +
the O +
enzyme O +
was O +
incubated O +
with O +
both O +
sucrose O +
and O +
dextran O +
. O +

Little O +
dextransucrase O +
activity O +
was O +
detected O +
in O +
carbon O +
- O +
limited O +
cultures O +
. O +

It O +
is O +
concluded O +
that O +
glucosyl O +
- O +
and O +
fructosyltransferases O +
are O +
constitutive O +
enzymes O +
in O +
that O +
they O +
are O +
synthesized O +
at O +
similar O +
rates O +
during O +
growth O +
with O +
an O +
excess O +
of O +
the O +
substrate O +
or O +
of O +
the O +
products O +
of O +
the O +
reactions O +
which O +
they O +
catalyse O +
. O +

Although O +
the O +
Ingbritt O +
strain O +
was O +
originally O +
isolated O +
from O +
a O +
carious O +
lesion O +
, O +
it O +
is O +
now O +
a O +
poor O +
source O +
of O +
glucosyltransferase O +
activity O +
. O +

Glucosyltransferases O +
were O +
extremely O +
active O +
in O +
cultures O +
of O +
a O +
recent O +
clinical O +
isolate O +
, O +
strain O +
3209 O +
, O +
and O +
were O +
apparently O +
induced O +
during O +
growth O +
with O +
excess O +
glucose O +
. O +

Differences O +
between O +
the O +
arterial O +
and O +
the O +
venous O +
pathomorphology O +
in O +
Buerger O +
' O +
s O +
disease O +
. O +

Morphological O +
lesions O +
were O +
found O +
to O +
be O +
different O +
in O +
arteries O +
and O +
in O +
veins O +
, O +
in O +
9 O +
cases O +
of O +
Buerger O +
' O +
s O +
disease O +
. O +

The O +
arterial O +
lesions O +
were O +
not O +
characteristic O +
and O +
consisted O +
of O +
non O +
- O +
specific O +
inflammation O +
, O +
thrombosis O +
and O +
obliteration O +
which O +
also O +
occur O +
in O +
many O +
other O +
disease O +
. O +

In O +
contrast O +
, O +
in O +
addition O +
to O +
wall O +
infiltration O +
and O +
thrombosis O +
, O +
the O +
veins O +
showed O +
microabscesses O +
and O +
giant O +
cell O +
granulomas O +
, O +
which O +
we O +
believe O +
to O +
be O +
absent O +
in O +
all O +
other O +
known O +
diseases O +
. O +

The O +
affected O +
venous O +
segment O +
exhibited O +
a O +
variety O +
of O +
lesions O +
. O +

In O +
the O +
earliest O +
period O +
, O +
the O +
morphological O +
aspect O +
of O +
inflammation O +
in O +
arteries O +
and O +
veins O +
was O +
fairly O +
similar O +
. O +

In O +
a O +
late O +
periods O +
, O +
that O +
is O +
those O +
of O +
vascular O +
obliteration O +
, O +
the O +
arteries O +
and O +
veins O +
did O +
not O +
show O +
any O +
distinguishing O +
morphological O +
differences O +
. O +

Scanning O +
electron O +
microscopy O +
of O +
vascular O +
casts O +
in O +
experimental O +
ocular O +
vasoproliferation O +
. O +

Scanning O +
electron O +
microscopy O +
of O +
vascular O +
casts O +
was O +
used O +
to O +
investigate O +
three O +
experimental O +
models O +
of O +
neovascularization O +
. O +

In O +
each O +
experimental O +
situation O +
, O +
the O +
casts O +
provided O +
a O +
valuable O +
three O +
dimensional O +
representation O +
of O +
the O +
newly O +
formed O +
blood O +
vessels O +
and O +
permitted O +
subclassification O +
of O +
the O +
vessels O +
within O +
normal O +
and O +
proliferating O +
vascular O +
networks O +
. O +

They O +
defined O +
also O +
the O +
predominant O +
origin O +
of O +
new O +
vessels O +
from O +
venules O +
and O +
capillaries O +
, O +
and O +
enabled O +
the O +
evolution O +
of O +
proliferating O +
vessels O +
into O +
arterioles O +
and O +
venules O +
to O +
be O +
documented O +
. O +

Although O +
vascular O +
casts O +
must O +
be O +
interpreted O +
with O +
caution O +
in O +
light O +
of O +
the O +
possibility O +
of O +
incomplete O +
filling O +
and O +
other O +
artifacts O +
, O +
they O +
are O +
a O +
valuable O +
tool O +
in O +
the O +
study O +
of O +
ocular O +
vasoproliferation O +
. O +

Identification O +
of O +
the O +
putative O +
transforming O +
protein O +
of O +
the O +
human O +
T O +
- O +
cell O +
leukemia O +
viruses O +
HTLV O +
- O +
I O +
and O +
HTLV O +
- O +
II O +
. O +

The O +
human O +
T O +
- O +
cell O +
leukemia O +
viruses O +
HTLV O +
- O +
I O +
and O +
HTLV O +
- O +
II O +
are O +
unique O +
among O +
the O +
transforming O +
retroviruses O +
of O +
vertebrates O +
in O +
their O +
ability O +
to O +
transform O +
human O +
T O +
cells O +
in O +
vitro O +
and O +
in O +
their O +
close O +
association O +
with O +
human O +
malignancies O +
( O +
T O +
- O +
cell O +
lymphomas O +
and O +
leukemia O +
) O +
. O +

Their O +
genomes O +
are O +
relatively O +
simple O +
, O +
containing O +
the O +
genes O +
gag O +
, O +
pol O +
, O +
env O +
, O +
and O +
a O +
3 O +
' O +
region O +
termed O +
" O +
X O +
. O +
" O +
This O +
3 O +
' O +
region O +
may O +
be O +
responsible O +
for O +
the O +
transforming O +
potential O +
of O +
the O +
viruses O +
. O +

The O +
existence O +
of O +
proteins O +
encoded O +
by O +
the O +
3 O +
' O +
region O +
has O +
been O +
postulated O +
on O +
the O +
basis O +
of O +
multiple O +
open O +
reading O +
frames O +
. O +

In O +
the O +
present O +
study O +
this O +
region O +
is O +
shown O +
to O +
contain O +
a O +
gene O +
encoding O +
a O +
protein O +
of O +
40 O +
kilodaltons O +
in O +
HTLV O +
- O +
I O +
and O +
37 O +
kilodaltons O +
in O +
HTLV O +
- O +
II O +
. O +

It O +
is O +
proposed O +
that O +
these O +
proteins O +
be O +
called O +
, O +
respectively O +
, O +
p40xI O +
and O +
p37xII O +
. O +

Participation O +
of O +
p53 O +
cellular O +
tumour O +
antigen O +
in O +
transformation O +
of O +
normal O +
embryonic O +
cells O +
. O +

The O +
cellular O +
tumour O +
antigen O +
p53 O +
is O +
found O +
at O +
elevated O +
levels O +
in O +
a O +
wide O +
variety O +
of O +
transformed O +
cells O +
( O +
for O +
reviews O +
see O +
refs O +
1 O +
, O +
2 O +
) O +
. O +

Very O +
little O +
is O +
yet O +
known O +
about O +
the O +
precise O +
relationship O +
of O +
p53 O +
to O +
malignant O +
transformation O +
. O +

Although O +
the O +
increase O +
in O +
p53 O +
levels O +
could O +
be O +
a O +
secondary O +
by O +
- O +
product O +
of O +
the O +
transformed O +
state O +
, O +
it O +
is O +
equally O +
possible O +
that O +
p53 O +
is O +
actively O +
involved O +
in O +
altering O +
cellular O +
growth O +
properties O +
, O +
especially O +
as O +
it O +
has O +
been O +
implicated O +
in O +
the O +
regulation O +
of O +
normal O +
cell O +
proliferation O +
. O +

We O +
sought O +
to O +
test O +
whether O +
p53 O +
could O +
behave O +
in O +
a O +
manner O +
similar O +
to O +
known O +
genes O +
in O +
a O +
biological O +
test O +
system O +
, O +
and O +
we O +
demonstrate O +
here O +
that O +
p53 O +
can O +
cooperate O +
with O +
the O +
activated O +
Ha O +
- O +
ras O +
oncogene O +
to O +
transform O +
normal O +
embryonic O +
cells O +
. O +

The O +
resultant O +
foci O +
contain O +
cells O +
of O +
a O +
markedly O +
altered O +
morphology O +
which O +
produce O +
high O +
levels O +
of O +
p53 O +
. O +

Cell O +
lines O +
established O +
from O +
such O +
foci O +
elicit O +
tumours O +
in O +
syngeneic O +
animals O +
. O +

Dynorphin O +
is O +
contained O +
within O +
hippocampal O +
mossy O +
fibers O +
: O +
immunochemical O +
alterations O +
after O +
kainic O +
acid O +
administration O +
and O +
colchicine O +
- O +
induced O +
neurotoxicity O +
. O +

Antisera O +
raised O +
against O +
synthetic O +
dynorphin O +
or O +
[ O +
Leu5 O +
] O +
enkephalin O +
demonstrate O +
immunostaining O +
in O +
hippocampal O +
mossy O +
fibers O +
and O +
in O +
dentate O +
granule O +
cells O +
. O +

However O +
, O +
dynorphin O +
immunoreactivity O +
( O +
ir O +
) O +
appears O +
to O +
be O +
denser O +
in O +
immunocytochemical O +
preparations O +
and O +
is O +
quantitatively O +
greater O +
by O +
radioimmunoassay O +
than O +
enkephalin O +
- O +
ir O +
. O +

Immunostaining O +
with O +
dynorphin O +
antisera O +
is O +
eliminated O +
by O +
adsorption O +
with O +
1 O +
- O +
100 O +
microM O +
dynorphin O +
- O +
17 O +
whereas O +
immunostaining O +
with O +
enkephalin O +
antisera O +
is O +
eliminated O +
by O +
adsorption O +
with O +
1 O +
- O +
100 O +
microM O +
[ O +
Leu5 O +
] O +
enkephalin O +
, O +
dynorphin O +
- O +
17 O +
, O +
dynorphin O +
- O +
( O +
1 O +
- O +
13 O +
) O +
, O +
or O +
alpha O +
- O +
neo O +
- O +
endorphin O +
. O +

Intrahippocampal O +
colchicine O +
injections O +
, O +
which O +
selectively O +
destroy O +
dentate O +
granule O +
cells O +
, O +
significantly O +
decrease O +
the O +
dynorphin O +
- O +
ir O +
and O +
enkephalin O +
- O +
ir O +
levels O +
in O +
rat O +
hippocampus O +
. O +

Intraventricularly O +
administered O +
kainic O +
acid O +
, O +
which O +
selectively O +
destroys O +
CA3 O +
- O +
4 O +
pyramidal O +
cells O +
, O +
results O +
in O +
an O +
increase O +
of O +
enkephalin O +
immunostaining O +
in O +
mossy O +
fibers O +
and O +
a O +
significant O +
increase O +
in O +
enkephalin O +
- O +
ir O +
by O +
radioimmunoassay O +
in O +
whole O +
hippocampus O +
. O +

The O +
enkephalin O +
- O +
ir O +
cells O +
and O +
fibers O +
in O +
entorhinal O +
/ O +
perirhinal O +
cortex O +
, O +
which O +
innervate O +
rat O +
hippocampus O +
and O +
dentate O +
gyrus O +
, O +
do O +
not O +
contain O +
dynorphin O +
- O +
ir O +
. O +

Interaction O +
between O +
cellular O +
and O +
viral O +
genes O +
in O +
the O +
expression O +
of O +
the O +
RSV O +
- O +
induced O +
transformation O +
- O +
specific O +
cell O +
- O +
surface O +
antigen O +
VCSA O +
. O +

Transformation O +
of O +
BHK B-CellLine +
hamster O +
fibroblasts O +
by O +
an O +
env O +
- O +
strain O +
of O +
Rous O +
sarcoma O +
virus O +
( O +
RSV O +
) O +
leads O +
to O +
the O +
appearance O +
at O +
the O +
cell O +
surface O +
of O +
a O +
virus O +
- O +
induced O +
nonvirion O +
antigen O +
( O +
VCSA O +
) O +
, O +
specific O +
for O +
transformation O +
, O +
whose O +
expression O +
is O +
controlled O +
by O +
the O +
transforming O +
src O +
gene O +
. O +

Previous O +
work O +
has O +
shown O +
that O +
a O +
rabbit O +
anti O +
- O +
VCSA O +
serum O +
lyses O +
specifically O +
, O +
in O +
the O +
presence O +
of O +
complement O +
, O +
51Cr O +
- O +
labelled O +
RSV O +
- O +
transformed O +
cells O +
from O +
different O +
animal O +
species O +
. O +

Now O +
, O +
by O +
competition O +
experiments O +
with O +
a O +
panel O +
of O +
different O +
unlabelled O +
cells O +
we O +
show O +
that O +
the O +
VCSA O +
expressed O +
on O +
RSV O +
- O +
transformed O +
hamster O +
fibroblasts O +
is O +
a O +
complex O +
of O +
at O +
least O +
three O +
distinct O +
antigenic O +
specificities O +
: O +
( O +
1 O +
) O +
one O +
expressed O +
on O +
all O +
RSV O +
- O +
transformed O +
fibroblasts O +
, O +
regardless O +
their O +
species O +
and O +
the O +
subgroup O +
or O +
strain O +
of O +
the O +
transforming O +
virus O +
; O +
( O +
2 O +
) O +
one O +
cross O +
- O +
reacting O +
with O +
a O +
cell O +
- O +
surface O +
antigen O +
( O +
CSA O +
) O +
expressed O +
at O +
various O +
degrees O +
on O +
untransformed O +
avian O +
fibroblasts O +
, O +
but O +
not O +
on O +
mammalian O +
fibroblasts O +
; O +
( O +
3 O +
) O +
one O +
species O +
- O +
specific O +
, O +
present O +
only O +
on O +
RSV O +
- O +
transformed O +
hamster O +
fibroblasts O +
. O +

It O +
is O +
concluded O +
that O +
VCSA O +
is O +
a O +
complex O +
of O +
several O +
antigenic O +
determinants O +
, O +
and O +
that O +
some O +
of O +
these O +
differ O +
in O +
different O +
cells O +
transformed O +
by O +
RSV O +
. O +

This O +
observation O +
indicates O +
that O +
VCSA O +
expression O +
at O +
the O +
cell O +
surface O +
is O +
likely O +
to O +
be O +
the O +
result O +
of O +
the O +
interaction O +
between O +
the O +
viral O +
src O +
gene O +
product O +
pp60src O +
with O +
host O +
cell O +
gene O +
( O +
s O +
) O +
or O +
gene O +
product O +
( O +
s O +
) O +
, O +
rather O +
than O +
the O +
simple O +
expression O +
of O +
this O +
molecule O +
at O +
the O +
cell O +
surface O +
. O +

Angiogenesis O +
: O +
initiation O +
and O +
control O +
. O +

From O +
in O +
vivo O +
experiments O +
using O +
new O +
methods O +
such O +
as O +
the O +
rabbit O +
cornea O +
, O +
it O +
is O +
now O +
becoming O +
clear O +
that O +
the O +
growth O +
of O +
a O +
capillary O +
involves O +
an O +
ordered O +
sequence O +
of O +
events O +
that O +
includes O +
lysis O +
of O +
the O +
basement O +
membrane O +
of O +
a O +
parent O +
venule O +
, O +
directional O +
migration O +
of O +
capillary O +
endothelial O +
cells O +
toward O +
the O +
angiogenic O +
stimulus O +
, O +
lumen O +
formation O +
, O +
development O +
of O +
branches O +
, O +
and O +
anastomosis O +
of O +
the O +
tip O +
of O +
one O +
tube O +
with O +
another O +
to O +
form O +
a O +
loop O +
. O +

It O +
is O +
also O +
clear O +
that O +
diffusible O +
angiogenic O +
stimuli O +
can O +
be O +
released O +
not O +
only O +
from O +
most O +
solid O +
tumors O +
, O +
but O +
also O +
from O +
at O +
least O +
three O +
non O +
- O +
neoplastic O +
cells O +
. O +

These O +
include O +
activated O +
macrophages O +
, O +
sensitized O +
lymphocytes O +
, O +
and O +
adipocytes O +
. O +

Other O +
normal O +
tissues O +
can O +
also O +
stimulate O +
angiogenesis O +
, O +
but O +
the O +
type O +
of O +
cell O +
giving O +
rise O +
to O +
the O +
angiogenic O +
stimulus O +
is O +
unknown O +
, O +
and O +
the O +
period O +
of O +
angiogenic O +
stimulation O +
is O +
brief O +
. O +

With O +
the O +
recent O +
ability O +
to O +
clone O +
capillary O +
endothelial O +
cells O +
and O +
to O +
carry O +
them O +
in O +
long O +
- O +
term O +
culture O +
, O +
it O +
has O +
been O +
possible O +
to O +
further O +
delineate O +
the O +
mechanism O +
of O +
capillary O +
growth O +
. O +

In O +
vitro O +
studies O +
have O +
shown O +
that O +
the O +
mast O +
cell O +
seems O +
to O +
behave O +
as O +
a O +
helper O +
cell O +
for O +
capillary O +
endothelial O +
cells O +
, O +
in O +
some O +
way O +
speeding O +
up O +
their O +
rate O +
of O +
directional O +
migration O +
. O +

At O +
this O +
writing O +
, O +
heparin O +
appears O +
to O +
be O +
the O +
principal O +
mast O +
cell O +
factor O +
responsible O +
for O +
this O +
effect O +
on O +
capillary O +
endothelial O +
cells O +
. O +

One O +
theoretical O +
possibility O +
is O +
that O +
mast O +
cells O +
may O +
prepare O +
the O +
matrix O +
, O +
perhaps O +
by O +
slow O +
release O +
of O +
heparin O +
, O +
so O +
that O +
capillary O +
sprouts O +
can O +
more O +
easily O +
move O +
through O +
it O +
toward O +
their O +
angiogenic O +
target O +
. O +

While O +
the O +
study O +
of O +
angiogenesis O +
as O +
a O +
phenomenon O +
is O +
still O +
in O +
an O +
early O +
phase O +
, O +
it O +
has O +
become O +
possible O +
, O +
by O +
using O +
a O +
combination O +
of O +
in O +
vitro O +
and O +
in O +
vivo O +
techniques O +
, O +
to O +
more O +
thoroughly O +
understand O +
the O +
initiation O +
and O +
control O +
of O +
capillary O +
growth O +
. O +

Role O +
of O +
interleukin O +
1 O +
in O +
antigen O +
- O +
specific O +
T O +
cell O +
proliferation O +
. O +

The O +
role O +
of O +
interleukin O +
1 O +
( O +
IL O +
1 O +
) O +
in O +
human O +
antigen O +
- O +
specific O +
T O +
cell O +
proliferation O +
was O +
examined O +
. O +

Nylon O +
wool O +
- O +
purified O +
T O +
cells O +
proliferated O +
in O +
the O +
presence O +
of O +
autologous O +
monocytes O +
( O +
Mo O +
. O +
) O +
pulsed O +
for O +
18 O +
h O +
with O +
tetanus O +
toxoid O +
( O +
TT O +
) O +
antigen O +
( O +
Mo O +
. O +
TT O +
) O +
. O +

Irradiation O +
of O +
Mo O +
. O +
TT O +
with O +
ultraviolet O +
( O +
UV O +
) O +
light O +
( O +
72 O +
J O +
/ O +
m2 O +
) O +
abolished O +
their O +
capacity O +
to O +
support O +
T O +
cell O +
proliferation O +
and O +
drastically O +
reduced O +
their O +
capacity O +
to O +
secrete O +
IL O +
1 O +
after O +
stimulation O +
with O +
Staphylococcus O +
albus O +
. O +

The O +
defect O +
in O +
antigen O +
presentation O +
induced O +
by O +
UV O +
irradiation O +
of O +
Mo O +
. O +
TT O +
was O +
reversed O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
by O +
the O +
addition O +
of O +
two O +
different O +
preparations O +
containing O +
human O +
interleukin O +
1 O +
( O +
IL O +
1 O +
) O +
. O +

The O +
first O +
preparation O +
consisted O +
of O +
supernatants O +
of O +
Mo O +
. O +
stimulated O +
with O +
Con O +
A O +
for O +
18 O +
hr O +
and O +
in O +
which O +
Con O +
A O +
activity O +
was O +
blocked O +
by O +
alpha O +
- O +
D O +
- O +
methyl O +
- O +
mannoside O +
( O +
Mo O +
. O +
- O +
Con O +
A O +
- O +
Sup O +
) O +
. O +

The O +
second O +
preparation O +
consisted O +
of O +
human O +
IL O +
1 O +
partially O +
purified O +
from O +
supernatants O +
of O +
human O +
peripheral O +
blood O +
mononuclear O +
cells O +
stimulated O +
with O +
S O +
. O +
albus O +
. O +

This O +
IL O +
1 O +
copurified O +
with O +
human O +
leukocyte O +
pyrogen O +
( O +
LP O +
) O +
and O +
was O +
termed O +
IL O +
1 O +
/ O +
LP O +
. O +

Both O +
IL O +
1 O +
- O +
containing O +
preparations O +
enhanced O +
the O +
response O +
of O +
C57BL O +
/ O +
6 O +
mouse O +
thymocytes O +
to O +
phytohemagglutinin O +
. O +

A O +
rabbit O +
antibody O +
to O +
human O +
IL O +
1 O +
/ O +
LP O +
inhibited O +
the O +
capacity O +
of O +
T O +
cells O +
to O +
proliferate O +
in O +
response O +
to O +
Mo O +
. O +
TT O +
and O +
inhibited O +
the O +
capacity O +
of O +
Mo O +
. O +
- O +
Con O +
A O +
- O +
Sup O +
to O +
reconstitute O +
the O +
T O +
cell O +
response O +
to O +
UV O +
- O +
irradiated O +
Mo O +
. O +
TT O +
. O +

IL O +
1 O +
/ O +
LP O +
was O +
not O +
necessary O +
for O +
T O +
cells O +
to O +
recognize O +
the O +
immunogenic O +
moiety O +
presented O +
by O +
Mo O +
. O +
, O +
because O +
monolayers O +
of O +
UV O +
- O +
irradiated O +
Mo O +
. O +
TT O +
were O +
equivalent O +
to O +
monolayers O +
of O +
unirradiated O +
MO O +
. O +
TT O +
in O +
their O +
capacity O +
to O +
adsorb O +
TT O +
- O +
reactive O +
T O +
cells O +
specifically O +
. O +

Furthermore O +
, O +
the O +
addition O +
of O +
rabbit O +
antibody O +
to O +
IL O +
1 O +
/ O +
LP O +
did O +
not O +
interfere O +
with O +
the O +
capacity O +
of O +
UV O +
- O +
irradiated O +
Mo O +
. O +
TT O +
to O +
adsorb O +
TT O +
- O +
reactive O +
T O +
cells O +
. O +

The O +
results O +
obtained O +
in O +
this O +
study O +
indicate O +
that O +
IL O +
1 O +
is O +
involved O +
in O +
optimal O +
antigen O +
- O +
driven O +
proliferation O +
of O +
human O +
T O +
lymphocytes O +
. O +

Ca O +
+ O +
+ O +
distribution O +
after O +
Na O +
+ O +
pump O +
inhibition O +
in O +
cultured O +
neonatal O +
rat O +
myocardial O +
cells O +
. O +

The O +
influence O +
of O +
inhibition O +
of O +
the O +
Na O +
+ O +
pump O +
, O +
with O +
secondary O +
stimulation O +
of O +
Na O +
+ O +
- O +
Ca O +
+ O +
+ O +
exchange O +
, O +
on O +
cellular O +
Ca O +
+ O +
+ O +
distribution O +
is O +
examined O +
using O +
the O +
on O +
- O +
line O +
scintillation O +
disk O +
technique O +
and O +
cultured O +
neonatal O +
rat O +
myocardial O +
cells O +
. O +

Under O +
control O +
conditions O +
, O +
La O +
+ O +
+ O +
+ O +
displaced O +
78 O +
. O +
1 O +
+ O +
/ O +
- O +
1 O +
. O +
13 O +
% O +
( O +
SEM O +
) O +
of O +
the O +
total O +
cell O +
associated O +
45Ca O +
. O +

Application O +
of O +
1 O +
mm O +
ouabain O +
or O +
reduction O +
of O +
[ O +
K O +
+ O +
] O +
o O +
to O +
0 O +
. O +
5 O +
mM O +
resulted O +
in O +
a O +
net O +
increase O +
of O +
10 O +
. O +
6 O +
+ O +
/ O +
- O +
1 O +
. O +
3 O +
% O +
and O +
13 O +
. O +
8 O +
+ O +
/ O +
- O +
2 O +
% O +
, O +
respectively O +
, O +
in O +
total O +
cell O +
- O +
associated O +
Ca O +
+ O +
+ O +
. O +

Of O +
this O +
added O +
45Ca O +
, O +
75 O +
. O +
9 O +
+ O +
/ O +
- O +
2 O +
. O +
7 O +
% O +
and O +
78 O +
. O +
4 O +
+ O +
/ O +
- O +
2 O +
. O +
1 O +
% O +
, O +
respectively O +
remained O +
La O +
+ O +
+ O +
+ O +
- O +
displaceable O +
. O +

The O +
45Ca O +
- O +
binding O +
characteristics O +
of O +
isolated O +
sarcolemma O +
, O +
prepared O +
from O +
the O +
cultured O +
neonatal O +
rat O +
myocardial O +
cells O +
using O +
the O +
gas O +
dissection O +
technique O +
, O +
were O +
examined O +
. O +

When O +
treated O +
with O +
either O +
ouabain O +
or O +
low O +
[ O +
K O +
+ O +
] O +
o O +
solutions O +
, O +
sarcolemmal O +
45Ca O +
binding O +
did O +
not O +
change O +
. O +

This O +
result O +
indicates O +
that O +
functional O +
, O +
intact O +
tissue O +
is O +
necessary O +
to O +
observe O +
the O +
Ca O +
+ O +
+ O +
increase O +
. O +

Treatment O +
of O +
the O +
cells O +
with O +
verapamil O +
before O +
and O +
during O +
ouabain O +
exposure O +
failed O +
to O +
inhibit O +
the O +
ouabain O +
- O +
induced O +
increase O +
in O +
cell O +
- O +
associated O +
45Ca O +
. O +

The O +
evidence O +
indicates O +
that O +
inhibition O +
of O +
the O +
Na O +
+ O +
- O +
pump O +
, O +
and O +
secondary O +
stimulation O +
of O +
Na O +
+ O +
- O +
Ca O +
+ O +
+ O +
exchange O +
, O +
result O +
in O +
a O +
net O +
increase O +
of O +
11 O +
- O +
15 O +
% O +
in O +
cell O +
- O +
associated O +
Ca O +
+ O +
+ O +
, O +
78 O +
% O +
of O +
which O +
remains O +
La O +
+ O +
+ O +
+ O +
- O +
displaceable O +
and O +
is O +
, O +
therefore O +
, O +
localized O +
to O +
the O +
sarcolemma O +
- O +
glycocalyx O +
complex O +
. O +

Phosphorylation O +
- O +
induced O +
mobility O +
shift O +
in O +
phospholamban O +
in O +
sodium O +
dodecyl O +
sulfate O +
- O +
polyacrylamide O +
gels O +
. O +

Evidence O +
for O +
a O +
protein O +
structure O +
consisting O +
of O +
multiple O +
identical O +
phosphorylatable O +
subunits O +
. O +

Phosphorylation O +
of O +
purified O +
phospholamban O +
isolated O +
from O +
canine O +
cardiac O +
sarcoplasmic O +
reticulum O +
vesicles O +
decreased O +
the O +
electrophoretic O +
mobility O +
of O +
the O +
protein O +
in O +
sodium O +
dodecyl O +
sulfate O +
( O +
SDS O +
) O +
- O +
polyacrylamide O +
gels O +
. O +

Different O +
mobility O +
forms O +
of O +
phospholamban O +
in O +
SDS O +
gels O +
were O +
visualized O +
both O +
by O +
direct O +
protein O +
staining O +
and O +
by O +
autoradiography O +
. O +

Unphosphorylated O +
phospholamban O +
migrated O +
with O +
an O +
apparent O +
Mr O +
= O +
25 O +
, O +
000 O +
in O +
SDS O +
gels O +
; O +
maximal O +
phosphorylation O +
of O +
phospholamban O +
by O +
cAMP O +
- O +
or O +
Ca2 O +
+ O +
- O +
calmodulin O +
- O +
dependent O +
protein O +
kinase O +
increased O +
the O +
apparent O +
Mr O +
to O +
27 O +
, O +
000 O +
. O +

Partial O +
phosphorylation O +
of O +
phospholamban O +
by O +
either O +
protein O +
kinase O +
gave O +
intermediate O +
mobility O +
forms O +
of O +
molecular O +
weights O +
between O +
25 O +
, O +
000 O +
and O +
27 O +
, O +
000 O +
, O +
suggesting O +
that O +
more O +
than O +
one O +
phosphorylation O +
site O +
was O +
present O +
on O +
the O +
holoprotein O +
for O +
each O +
activity O +
. O +

Boiling O +
of O +
phospholamban O +
in O +
SDS O +
dissociated O +
the O +
holoprotein O +
into O +
an O +
apparently O +
homogeneous O +
class O +
of O +
low O +
molecular O +
weight O +
" O +
monomers O +
. O +
" O +
Only O +
two O +
mobility O +
forms O +
of O +
monomeric O +
phospholamban O +
were O +
observed O +
in O +
SDS O +
gels O +
after O +
phosphorylation O +
by O +
cAMP O +
- O +
dependent O +
protein O +
kinase O +
, O +
corresponding O +
to O +
9 O +
- O +
kDa O +
dephospho O +
- O +
and O +
11 O +
- O +
kDa O +
phosphoproteins O +
. O +

All O +
of O +
the O +
9 O +
- O +
kDa O +
protein O +
could O +
be O +
phosphorylated O +
and O +
converted O +
into O +
the O +
11 O +
- O +
kDa O +
mobility O +
form O +
, O +
suggesting O +
the O +
presence O +
of O +
only O +
one O +
site O +
of O +
phosphorylation O +
on O +
a O +
single O +
type O +
of O +
monomer O +
for O +
cAMP O +
- O +
dependent O +
protein O +
kinase O +
. O +

Simultaneous O +
phosphorylation O +
of O +
monomeric O +
phospholamban O +
by O +
cAMP O +
- O +
dependent O +
protein O +
kinase O +
and O +
Ca2 O +
+ O +
- O +
calmodulin O +
- O +
dependent O +
protein O +
kinase O +
gave O +
an O +
additional O +
mobility O +
form O +
of O +
the O +
protein O +
, O +
suggesting O +
that O +
different O +
sites O +
of O +
phosphorylation O +
were O +
present O +
for O +
each O +
activity O +
on O +
each O +
monomer O +
. O +

Incomplete O +
dissociation O +
of O +
the O +
holoprotein O +
by O +
boiling O +
it O +
in O +
a O +
relatively O +
low O +
concentration O +
of O +
SDS O +
facilitated O +
the O +
detection O +
of O +
five O +
major O +
mobility O +
forms O +
of O +
the O +
protein O +
in O +
SDS O +
gels O +
, O +
and O +
the O +
mobilities O +
of O +
all O +
of O +
these O +
forms O +
were O +
decreased O +
by O +
phosphorylation O +
. O +

We O +
propose O +
that O +
the O +
high O +
molecular O +
weight O +
form O +
of O +
phospholamban O +
is O +
a O +
multimer O +
of O +
electrophoretically O +
indistinguishable O +
monomers O +
, O +
each O +
of O +
which O +
contains O +
a O +
different O +
phosphorylation O +
site O +
for O +
cAMP O +
- O +
dependent O +
protein O +
kinase O +
activity O +
and O +
Ca2 O +
+ O +
- O +
calmodulin O +
- O +
dependent O +
protein O +
kinase O +
activity O +
. O +

Phosphorylation O +
of O +
phospholamban O +
at O +
multiple O +
sites O +
is O +
responsible O +
for O +
the O +
various O +
mobility O +
forms O +
of O +
the O +
holoprotein O +
detected O +
in O +
SDS O +
- O +
polyacrylamide O +
gels O +
. O +

Protection O +
from O +
experimental O +
ocular O +
herpetic O +
keratitis O +
by O +
a O +
heat O +
- O +
killed O +
virus O +
vaccine O +
. O +

New O +
Zealand O +
white O +
rabbits O +
were O +
given O +
limbal O +
inoculations O +
of O +
a O +
heat O +
- O +
killed O +
suspension O +
of O +
herpes O +
simplex O +
virus O +
( O +
HSV O +
) O +
in O +
a O +
lysate O +
of O +
human O +
embryonic O +
kidney O +
cells O +
. O +

At O +
intervals O +
of O +
four O +
to O +
14 O +
days O +
, O +
the O +
animals O +
were O +
challenged O +
by O +
intrastromal O +
inoculation O +
with O +
10 O +
, O +
000 O +
plaque O +
- O +
forming O +
units O +
of O +
viable O +
HSV O +
. O +

Epithelial O +
keratitis O +
, O +
disciform O +
edema O +
, O +
and O +
necrotizing O +
keratitis O +
with O +
neovascularization O +
of O +
the O +
cornea O +
developed O +
in O +
control O +
animals O +
. O +

Epithelial O +
keratitis O +
and O +
corneal O +
edema O +
also O +
developed O +
in O +
the O +
immunized O +
animals O +
during O +
the O +
first O +
week O +
after O +
virus O +
challenge O +
, O +
but O +
these O +
symptoms O +
rapidly O +
resolved O +
during O +
the O +
following O +
weeks O +
. O +

The O +
absence O +
of O +
iritis O +
, O +
neovascularization O +
, O +
and O +
necrotizing O +
keratitis O +
in O +
the O +
corneas O +
of O +
the O +
immunized O +
animals O +
was O +
particularly O +
striking O +
. O +

Cells O +
transformed O +
by O +
Rous O +
sarcoma O +
virus O +
release O +
transforming O +
growth O +
factors O +
. O +

Chicken O +
embryo O +
fibroblasts O +
and O +
hamster O +
BHK B-CellLine +
cells O +
transformed O +
by O +
Rous O +
sarcoma O +
virus O +
( O +
RSV O +
) O +
release O +
in O +
their O +
culture O +
media O +
growth O +
factors O +
which O +
enhance O +
markedly O +
anchorage O +
- O +
independent O +
colony O +
formation O +
in O +
gelified O +
medium O +
, O +
at O +
the O +
restrictive O +
temperature O +
( O +
41 O +
degrees O +
5 O +
C O +
) O +
, O +
of O +
chicken O +
embryo O +
fibroblasts O +
( O +
CEF O +
) O +
infected O +
by O +
RSV O +
mutants O +
with O +
a O +
ts O +
mutation O +
of O +
the O +
src O +
gene O +
. O +

This O +
action O +
is O +
not O +
observed O +
with O +
uninfected O +
CEF O +
, O +
and O +
, O +
therefore O +
, O +
appears O +
to O +
require O +
some O +
expression O +
of O +
the O +
viral O +
src O +
gene O +
in O +
the O +
target O +
cells O +
. O +

The O +
enhancing O +
factors O +
are O +
proteins O +
related O +
to O +
the O +
family O +
of O +
the O +
transforming O +
growth O +
factors O +
( O +
TGFs O +
) O +
by O +
their O +
molecular O +
weight O +
( O +
about O +
20 O +
kd O +
) O +
, O +
their O +
heat O +
and O +
acid O +
resistance O +
, O +
and O +
their O +
sensitivity O +
to O +
dithiothreitol O +
. O +

They O +
do O +
not O +
compete O +
with O +
125I O +
EGF O +
for O +
binding O +
on O +
the O +
EGF O +
receptors O +
of O +
the O +
membrane O +
of O +
A431 B-CellLine +
cells O +
. O +

As O +
chicken O +
embryo O +
fibroblasts O +
are O +
devoid O +
of O +
EGF O +
receptors O +
, O +
their O +
activity O +
is O +
not O +
potentiated O +
by O +
EGF O +
. O +

The O +
genetics O +
of O +
transformation O +
by O +
SV O +
40 O +
. O +

Experiments O +
using O +
the O +
tsA O +
58 O +
allele O +
of O +
the O +
SV O +
40 O +
- O +
A O +
gene O +
have O +
demonstrated O +
that O +
the O +
SV O +
40 O +
large O +
T O +
- O +
antigen O +
is O +
strictly O +
required O +
both O +
for O +
immortalization O +
and O +
induction O +
anchorage O +
independence O +
of O +
cells O +
. O +

It O +
has O +
been O +
suggested O +
that O +
the O +
immortalized O +
phenotype O +
is O +
mediated O +
by O +
an O +
extra O +
cellular O +
factor O +
. O +

The O +
synthesis O +
and O +
/ O +
or O +
the O +
excretion O +
of O +
this O +
factor O +
in O +
a O +
medium O +
is O +
controlled O +
by O +
the O +
A O +
gene O +
. O +

Effects O +
of O +
growth O +
temperature O +
, O +
47 O +
- O +
megadalton O +
plasmid O +
, O +
and O +
calcium O +
deficiency O +
on O +
the O +
outer O +
membrane O +
protein O +
porin O +
and O +
lipopolysaccharide O +
composition O +
of O +
Yersinia O +
pestis O +
EV76 O +
. O +

The O +
expression O +
of O +
several O +
virulence O +
determinants O +
of O +
Yersinia O +
pestis O +
is O +
known O +
to O +
be O +
dependent O +
on O +
the O +
in O +
vitro O +
growth O +
temperature O +
. O +

One O +
of O +
these O +
, O +
calcium O +
dependence O +
, O +
is O +
associated O +
with O +
the O +
presence O +
of O +
a O +
47 O +
- O +
megadalton O +
plasmid O +
. O +

We O +
have O +
examined O +
the O +
effects O +
of O +
incubation O +
temperature O +
, O +
calcium O +
in O +
the O +
growth O +
medium O +
, O +
the O +
presence O +
of O +
the O +
47 O +
- O +
megadalton O +
plasmid O +
on O +
the O +
outer O +
membrane O +
protein O +
, O +
and O +
the O +
lipopolysaccharide O +
composition O +
of O +
Y O +
. O +
pestis O +
EV76 O +
. O +

When O +
cells O +
were O +
grown O +
at O +
37 O +
degrees O +
C O +
as O +
opposed O +
to O +
26 O +
degrees O +
C O +
, O +
a O +
change O +
in O +
lipopolysaccharide O +
composition O +
and O +
a O +
decrease O +
in O +
the O +
amount O +
of O +
an O +
outer O +
membrane O +
protein O +
( O +
protein O +
E O +
) O +
were O +
observed O +
. O +

The O +
lipopolysaccharide O +
obtained O +
from O +
cells O +
incubated O +
at O +
37 O +
degrees O +
C O +
had O +
a O +
lower O +
proportion O +
of O +
2 O +
keto O +
- O +
3 O +
- O +
deoxyoctanate O +
, O +
a O +
lower O +
phosphate O +
to O +
2 O +
- O +
keto O +
- O +
3 O +
- O +
deoxyoctanate O +
ratio O +
, O +
and O +
an O +
increased O +
gel O +
mobility O +
upon O +
sodium O +
dodecyl O +
sulfate O +
- O +
polyacrylamide O +
gel O +
electrophoresis O +
when O +
compared O +
with O +
lipopolysaccharide O +
obtained O +
from O +
cells O +
grown O +
at O +
26 O +
degrees O +
C O +
. O +

Because O +
of O +
its O +
growth O +
temperature O +
- O +
related O +
abundance O +
, O +
we O +
investigated O +
the O +
nature O +
of O +
protein O +
E O +
. O +

This O +
protein O +
had O +
physical O +
properties O +
similar O +
to O +
those O +
of O +
other O +
enterobacterial O +
porins O +
, O +
including O +
apparent O +
formation O +
of O +
an O +
oligomer O +
on O +
sodium O +
dodecyl O +
sulfate O +
- O +
polyacrylamide O +
gels O +
when O +
solubilized O +
at O +
low O +
temperature O +
, O +
acidic O +
isoelectric O +
point O +
, O +
and O +
strong O +
noncovalent O +
association O +
with O +
the O +
peptidoglycan O +
. O +

Protein O +
E O +
was O +
purified O +
and O +
shown O +
to O +
form O +
an O +
aqueous O +
channel O +
in O +
planar O +
lipid O +
membranes O +
with O +
a O +
conductance O +
of O +
1 O +
. O +
1 O +
nS O +
in O +
1 O +
M O +
KCl O +
. O +

In O +
addition O +
to O +
growth O +
temperature O +
- O +
related O +
alterations O +
in O +
the O +
lipopolysaccharide O +
and O +
porin O +
components O +
of O +
the O +
outer O +
membrane O +
, O +
the O +
amount O +
of O +
three O +
spots O +
in O +
two O +
- O +
dimensional O +
polyacrylamide O +
gels O +
was O +
shown O +
to O +
be O +
related O +
to O +
the O +
temperature O +
or O +
the O +
presence O +
of O +
calcium O +
during O +
growth O +
. O +

One O +
of O +
these O +
spots O +
was O +
shown O +
to O +
contain O +
residual O +
unmodified O +
portions O +
of O +
two O +
major O +
heat O +
- O +
modifiable O +
proteins O +
which O +
failed O +
to O +
shift O +
to O +
their O +
heat O +
- O +
modified O +
positions O +
on O +
gels O +
, O +
despite O +
solubilization O +
at O +
100 O +
degrees O +
C O +
for O +
10 O +
min O +
before O +
electrophoresis O +
. O +

The O +
other O +
two O +
spots O +
were O +
the O +
heat O +
- O +
modified O +
and O +
unmodified O +
forms O +
of O +
another O +
outer O +
membrane O +
protein O +
( O +
J O +
) O +
which O +
did O +
not O +
appear O +
in O +
the O +
isoelectric O +
focusing O +
gel O +
of O +
cells O +
grown O +
at O +
37 O +
degrees O +
C O +
. O +

It O +
is O +
proposed O +
that O +
the O +
appearance O +
of O +
these O +
spots O +
in O +
two O +
- O +
dimensional O +
analyses O +
is O +
related O +
to O +
the O +
lipopolysaccharide O +
composition O +
of O +
the O +
cells O +
from O +
which O +
the O +
outer O +
membrane O +
is O +
derived O +
and O +
reflects O +
lipopolysaccharide O +
- O +
protein O +
interactions O +
or O +
calcium O +
- O +
protein O +
interactions O +
. O +

Protein O +
kinase O +
activities O +
in O +
immune O +
complexes O +
of O +
simian O +
virus O +
40 O +
large O +
T O +
- O +
antigen O +
and O +
transformation O +
- O +
associated O +
cellular O +
p53 O +
protein O +
. O +

Immune O +
complex O +
kinase O +
assays O +
in O +
the O +
simian O +
virus O +
40 O +
system O +
were O +
performed O +
by O +
incubation O +
of O +
immunoprecipitates O +
containing O +
tumor O +
antigens O +
with O +
[ O +
gamma O +
- O +
32P O +
] O +
ATP O +
, O +
followed O +
by O +
analysis O +
of O +
any O +
phosphoacceptor O +
proteins O +
. O +

These O +
assays O +
yielded O +
mainly O +
the O +
viral O +
large O +
T O +
- O +
antigen O +
and O +
, O +
in O +
particular O +
, O +
the O +
associated O +
cellular O +
p53 O +
as O +
endogenous O +
substrates O +
. O +

The O +
nature O +
of O +
these O +
substrates O +
was O +
confirmed O +
by O +
proteolysis O +
techniques O +
. O +

Under O +
specific O +
conditions O +
, O +
casein O +
could O +
be O +
used O +
as O +
an O +
exogenous O +
substrate O +
as O +
well O +
. O +

The O +
kinase O +
reactions O +
showed O +
preference O +
for O +
ATP O +
and O +
MgCl2 O +
instead O +
of O +
GTP O +
or O +
MnCl2 O +
. O +

Both O +
phosphoserine O +
and O +
phosphothreonine O +
, O +
but O +
in O +
no O +
case O +
phosphotyrosine O +
, O +
were O +
detected O +
after O +
an O +
immune O +
complex O +
kinase O +
reaction O +
. O +

Apparently O +
, O +
several O +
in O +
vivo O +
phosphorylation O +
sites O +
were O +
recognized O +
in O +
vitro O +
in O +
both O +
large O +
T O +
- O +
antigen O +
and O +
p53 O +
, O +
but O +
the O +
presence O +
of O +
some O +
artifactual O +
sites O +
could O +
not O +
be O +
completely O +
excluded O +
. O +

Although O +
contaminating O +
kinases O +
were O +
detectable O +
in O +
the O +
immune O +
complexes O +
, O +
at O +
least O +
the O +
p53 O +
molecules O +
were O +
phosphorylated O +
in O +
vitro O +
in O +
a O +
more O +
specific O +
way O +
. O +

This O +
followed O +
from O +
several O +
characteristics O +
of O +
the O +
immune O +
complex O +
kinase O +
reactions O +
and O +
especially O +
from O +
the O +
strong O +
inhibition O +
of O +
p53 O +
phosphorylation O +
by O +
two O +
anti O +
- O +
large O +
- O +
T O +
monoclonal O +
antibodies O +
. O +

It O +
was O +
shown O +
that O +
large O +
T O +
- O +
antigen O +
showed O +
associated O +
kinase O +
activity O +
, O +
although O +
none O +
of O +
our O +
results O +
could O +
unambiguously O +
demonstrate O +
an O +
intrinsic O +
kinase O +
activity O +
of O +
this O +
protein O +
. O +

Finally O +
, O +
anti O +
- O +
p53 O +
monoclonal O +
antibodies O +
only O +
slightly O +
affected O +
in O +
vitro O +
phosphorylation O +
reactions O +
, O +
whereas O +
a O +
p53 O +
molecule O +
from O +
a O +
simian O +
virus O +
40 O +
- O +
free O +
, O +
chemically O +
transformed O +
human O +
cell O +
line O +
was O +
not O +
phosphorylated O +
in O +
vitro O +
under O +
any O +
condition O +
tested O +
. O +

Thus O +
, O +
it O +
is O +
highly O +
unlikely O +
that O +
the O +
p53 O +
molecule O +
per O +
se O +
carries O +
intrinsic O +
or O +
even O +
associated O +
kinase O +
activities O +
. O +

Molecular O +
events O +
leading O +
to O +
enhanced O +
glucose O +
transport O +
in O +
Rous O +
sarcoma O +
virus O +
- O +
transformed O +
cells O +
. O +

Transformation O +
by O +
Rous O +
sarcoma O +
virus O +
results O +
in O +
a O +
dramatic O +
increase O +
in O +
the O +
rate O +
at O +
which O +
the O +
transformed O +
cells O +
transport O +
glucose O +
across O +
the O +
cell O +
membrane O +
. O +

The O +
increased O +
transport O +
rate O +
is O +
a O +
consequence O +
of O +
an O +
increased O +
number O +
of O +
transporters O +
in O +
the O +
transformed O +
cells O +
. O +

Utilizing O +
antibody O +
raised O +
against O +
the O +
purified O +
human O +
erythrocyte O +
glucose O +
transporter O +
, O +
we O +
have O +
identified O +
the O +
glucose O +
transporter O +
as O +
a O +
membrane O +
glycoprotein O +
with O +
a O +
monomer O +
Mr O +
of O +
approximately O +
41 O +
, O +
000 O +
. O +

The O +
increased O +
rate O +
of O +
glucose O +
transport O +
is O +
dependent O +
on O +
the O +
activity O +
of O +
pp60src O +
, O +
the O +
transforming O +
protein O +
of O +
Rous O +
sarcoma O +
virus O +
. O +

This O +
protein O +
has O +
been O +
shown O +
to O +
be O +
a O +
protein O +
kinase O +
that O +
phosphorylates O +
on O +
tyrosine O +
residues O +
. O +

We O +
have O +
examined O +
the O +
tyrosine O +
phosphorylation O +
of O +
a O +
major O +
cellular O +
protein O +
of O +
Mr O +
36 O +
, O +
000 O +
in O +
cells O +
infected O +
with O +
a O +
panel O +
of O +
partially O +
transforming O +
mutants O +
of O +
Rous O +
sarcoma O +
virus O +
. O +

One O +
of O +
these O +
mutants O +
( O +
CU2 O +
) O +
increases O +
the O +
rate O +
of O +
glucose O +
transport O +
only O +
slightly O +
and O +
does O +
not O +
render O +
the O +
infected O +
cells O +
fully O +
anchorage O +
independent O +
or O +
tumorigenic O +
( O +
although O +
other O +
transformation O +
parameters O +
are O +
fully O +
induced O +
) O +
. O +

Cells O +
infected O +
with O +
this O +
mutant O +
display O +
a O +
36 O +
, O +
000 O +
- O +
dalton O +
protein O +
that O +
is O +
phosphorylated O +
to O +
a O +
considerably O +
lesser O +
extent O +
than O +
cells O +
infected O +
with O +
wild O +
- O +
type O +
virus O +
. O +

Analyses O +
of O +
this O +
sort O +
may O +
help O +
to O +
identify O +
the O +
cellular O +
targets O +
of O +
pp60src O +
whose O +
phosphorylation O +
is O +
necessary O +
for O +
the O +
increased O +
glucose O +
transport O +
rate O +
. O +

Preliminary O +
evidence O +
for O +
a O +
pyridine O +
nucleotide O +
cycle O +
in O +
Bordetella O +
pertussis O +
. O +

Preliminary O +
evidence O +
that O +
Bordetella O +
pertussis O +
has O +
a O +
functional O +
pyridine O +
nucleotide O +
cycle O +
was O +
the O +
observation O +
that O +
[ O +
14C O +
] O +
- O +
nicotinic O +
acid O +
was O +
rapidly O +
metabolized O +
during O +
its O +
uptake O +
by O +
the O +
bacteria O +
to O +
pyridine O +
nucleotides O +
and O +
nicotinamide O +
. O +

Nicotinamide O +
deamidase O +
activity O +
, O +
necessary O +
for O +
the O +
completion O +
of O +
the O +
cycle O +
by O +
conversion O +
of O +
nicotinamide O +
to O +
nicotinic O +
acid O +
, O +
was O +
found O +
in O +
a O +
soluble O +
extract O +
( O +
20 O +
000 O +
X O +
g O +
supernatant O +
) O +
of O +
B O +
. O +
pertussis O +
cell O +
lysates O +
. O +

Use O +
of O +
monoclonal O +
antibodies O +
to O +
investigate O +
a O +
possible O +
role O +
of O +
thyroglobulin O +
in O +
the O +
pathogenesis O +
of O +
Graves O +
' O +
ophthalmopathy O +
. O +

One O +
possible O +
mechanism O +
for O +
Graves O +
' O +
ophthalmopathy O +
is O +
that O +
the O +
progressive O +
orbital O +
inflammation O +
is O +
initiated O +
by O +
formation O +
of O +
thyroglobulin O +
( O +
Tg O +
) O +
- O +
anti O +
- O +
Tg O +
immune O +
complexes O +
at O +
sites O +
of O +
Tg O +
binding O +
to O +
extraocular O +
muscle O +
membranes O +
. O +

In O +
this O +
study O +
monoclonal O +
antibodies O +
( O +
MCAB O +
) O +
against O +
human O +
Tg O +
were O +
used O +
as O +
probes O +
( O +
1 O +
) O +
to O +
identify O +
Tg O +
in O +
eye O +
muscle O +
membranes O +
prepared O +
from O +
normal O +
subjects O +
and O +
( O +
2 O +
) O +
to O +
measure O +
binding O +
of O +
human O +
Tg O +
and O +
Tg O +
- O +
anti O +
- O +
Tg O +
immune O +
complexes O +
to O +
eye O +
muscle O +
membranes O +
. O +

Reactivity O +
of O +
anti O +
- O +
Tg O +
MCAB O +
with O +
Tg O +
, O +
thyroid O +
, O +
and O +
eye O +
muscle O +
membranes O +
was O +
determined O +
by O +
binding O +
of O +
[ O +
125I O +
] O +
anti O +
- O +
Tg O +
monoclonal O +
antibody O +
, O +
an O +
enzyme O +
- O +
linked O +
immunosorbent O +
assay O +
( O +
ELISA O +
) O +
, O +
and O +
the O +
indirect O +
immunofluorescence O +
technique O +
. O +

Seven O +
membrane O +
fractions O +
, O +
prepared O +
by O +
differential O +
sucrose O +
gradient O +
centrifugation O +
, O +
were O +
used O +
. O +

Whereas O +
[ O +
125I O +
] O +
anti O +
- O +
Tg O +
MCAB O +
bound O +
to O +
all O +
thyroid O +
membrane O +
fractions O +
tested O +
, O +
no O +
[ O +
125I O +
] O +
anti O +
- O +
Tg O +
bound O +
to O +
eye O +
muscle O +
membranes O +
. O +

Similarly O +
, O +
reactivity O +
of O +
anti O +
- O +
Tg O +
MCAB O +
with O +
eye O +
muscle O +
membranes O +
was O +
not O +
demonstrated O +
in O +
ELISA O +
or O +
immunofluorescence O +
tests O +
. O +

Although O +
Tg O +
- O +
anti O +
- O +
Tg O +
immune O +
complexes O +
bound O +
to O +
thyroid O +
membranes O +
, O +
such O +
complexes O +
did O +
not O +
bind O +
to O +
eye O +
muscle O +
membranes O +
. O +

Significant O +
binding O +
of O +
[ O +
125I O +
] O +
human O +
Tg O +
to O +
eye O +
muscle O +
or O +
thyroid O +
membranes O +
was O +
not O +
demonstrated O +
for O +
any O +
membrane O +
preparation O +
. O +

On O +
the O +
other O +
hand O +
moderate O +
, O +
but O +
significant O +
, O +
binding O +
to O +
skeletal O +
muscle O +
was O +
shown O +
. O +

Similar O +
results O +
were O +
found O +
using O +
an O +
ELISA O +
. O +

Binding O +
of O +
[ O +
125I O +
] O +
anti O +
- O +
Tg O +
- O +
Tg O +
complexes O +
of O +
[ O +
125I O +
] O +
Tg O +
to O +
thyroid O +
and O +
eye O +
muscle O +
membranes O +
was O +
not O +
affected O +
by O +
the O +
presence O +
of O +
normal O +
human O +
serum O +
, O +
phosphate O +
ions O +
, O +
pH O +
, O +
or O +
incubation O +
temperature O +
, O +
conditions O +
claimed O +
by O +
others O +
to O +
be O +
critical O +
for O +
Tg O +
and O +
Tg O +
- O +
anti O +
- O +
Tg O +
immune O +
complex O +
binding O +
. O +

Since O +
Tg O +
is O +
not O +
present O +
in O +
normal O +
human O +
eye O +
muscle O +
a O +
major O +
role O +
of O +
Tg O +
, O +
or O +
Tg O +
- O +
anti O +
- O +
Tg O +
immune O +
complexes O +
, O +
in O +
the O +
pathogenesis O +
of O +
Graves O +
' O +
ophthalmopathy O +
appears O +
to O +
have O +
been O +
excluded O +
by O +
these O +
findings O +
. O +

DNA O +
methylation O +
and O +
expression O +
of O +
HLA O +
- O +
DR O +
alpha O +
. O +

B O +
- O +
cell O +
lines O +
established O +
from O +
two O +
individuals O +
with O +
T O +
- O +
cell O +
acute O +
lymphocytic O +
leukemia O +
( O +
T O +
- O +
ALL O +
) O +
express O +
HLA O +
- O +
DR O +
antigens O +
, O +
whereas O +
the O +
isogenic O +
T O +
- O +
cells O +
do O +
not O +
. O +

The O +
lack O +
of O +
expression O +
correlates O +
with O +
a O +
lack O +
of O +
detectable O +
HLA O +
- O +
DR O +
mRNA O +
. O +

All O +
of O +
the O +
DR O +
alpha O +
DNA O +
sequences O +
detected O +
by O +
a O +
cloned O +
DR O +
alpha O +
cDNA O +
probe O +
are O +
contained O +
in O +
a O +
BglII O +
fragment O +
which O +
varies O +
slightly O +
in O +
size O +
( O +
4 O +
. O +
0 O +
to O +
4 O +
. O +
8 O +
kilobases O +
) O +
from O +
one O +
individual O +
to O +
another O +
. O +

In O +
DNA O +
from O +
the O +
T O +
- O +
cells O +
not O +
expressing O +
DR O +
alpha O +
mRNA O +
, O +
all O +
of O +
the O +
potential O +
HpaII O +
sites O +
within O +
the O +
BglII O +
fragment O +
appeared O +
to O +
be O +
methylated O +
. O +

In O +
contrast O +
, O +
at O +
least O +
some O +
of O +
these O +
sites O +
were O +
not O +
methylated O +
in O +
DNA O +
from O +
the O +
B O +
- O +
cells O +
expressing O +
high O +
levels O +
of O +
DR O +
alpha O +
mRNA O +
. O +

Treatment O +
of O +
these O +
T O +
- O +
cells O +
with O +
5 O +
- O +
azacytidine O +
resulted O +
in O +
the O +
induction O +
of O +
DR O +
surface O +
antigen O +
expression O +
, O +
the O +
appearance O +
of O +
DR O +
alpha O +
mRNA O +
, O +
and O +
the O +
partial O +
demethylation O +
of O +
the O +
DR O +
alpha O +
DNA O +
sequences O +
. O +

T O +
- O +
cell O +
lines O +
established O +
from O +
human O +
T O +
- O +
cell O +
leukemia O +
- O +
lymphoma O +
virus O +
associated O +
T O +
- O +
cell O +
neoplasias O +
, O +
in O +
contrast O +
to O +
the O +
T O +
- O +
cell O +
acute O +
lymphocytic O +
leukemia O +
cell O +
lines O +
, O +
expressed O +
both O +
DR O +
antigens O +
and O +
DR O +
alpha O +
mRNA O +
; O +
the O +
HpaII O +
sites O +
within O +
the O +
BglII O +
fragment O +
of O +
DR O +
alpha O +
DNA O +
of O +
these O +
human O +
T O +
- O +
cell O +
leukemia O +
- O +
lymphoma O +
virus O +
- O +
positive O +
T O +
- O +
cell O +
lines O +
were O +
in O +
all O +
cases O +
at O +
least O +
partially O +
unmethylated O +
. O +

Uncultured O +
peripheral O +
blood O +
T O +
- O +
cells O +
from O +
human O +
T O +
- O +
cell O +
leukemia O +
- O +
lymphoma O +
virus O +
- O +
infected O +
individuals O +
expressed O +
DR O +
antigens O +
at O +
a O +
low O +
level O +
, O +
and O +
the O +
DR O +
alpha O +
locus O +
was O +
partially O +
unmethylated O +
. O +

After O +
48 O +
h O +
in O +
culture O +
, O +
DR O +
antigen O +
expression O +
was O +
substantially O +
increased O +
, O +
but O +
no O +
significant O +
changes O +
were O +
observed O +
in O +
methylation O +
of O +
the O +
DR O +
alpha O +
locus O +
or O +
in O +
the O +
amount O +
of O +
DR O +
mRNA O +
which O +
was O +
present O +
. O +

This O +
suggests O +
that O +
expression O +
of O +
DR O +
antigens O +
also O +
can O +
be O +
modulated O +
post O +
- O +
transcriptionally O +
. O +

Oesophageal O +
candidiasis O +
and O +
croup O +
in O +
a O +
child O +
with O +
defective O +
neutrophil O +
motility O +
. O +

Severe O +
oesophageal O +
candidiasis O +
and O +
croup O +
due O +
to O +
involvement O +
of O +
the O +
larynx O +
developed O +
insidiously O +
in O +
a O +
girl O +
aged O +
20 O +
months O +
. O +

There O +
had O +
been O +
delayed O +
separation O +
of O +
the O +
umbilical O +
cord O +
and O +
repeated O +
infections O +
associated O +
with O +
a O +
defect O +
of O +
neutrophil O +
motility O +
. O +

The O +
significance O +
of O +
the O +
early O +
clinical O +
features O +
was O +
not O +
fully O +
appreciated O +
and O +
the O +
diagnosis O +
considered O +
only O +
when O +
stricture O +
of O +
the O +
oesophagus O +
became O +
evident O +
. O +

She O +
was O +
treated O +
with O +
oral O +
ketoconazole O +
100 O +
mg O +
daily O +
. O +

After O +
one O +
month O +
' O +
s O +
treatment O +
there O +
was O +
striking O +
radiological O +
improvement O +
apart O +
from O +
the O +
persistence O +
of O +
the O +
oesophageal O +
stricture O +
. O +

The O +
croup O +
resolved O +
completely O +
but O +
there O +
was O +
only O +
partial O +
relief O +
of O +
dysphagia O +
because O +
of O +
the O +
residual O +
stricture O +
. O +

We O +
would O +
emphasis O +
that O +
candidiasis O +
should O +
be O +
anticipated O +
and O +
treated O +
vigorously O +
in O +
children O +
with O +
such O +
a O +
defect O +
of O +
neutrophil O +
motility O +
. O +

Rapid O +
micromeasurement O +
of O +
lactate O +
in O +
whole O +
blood O +
. O +

A O +
new O +
lactate O +
sensor O +
makes O +
it O +
possible O +
to O +
measure O +
the O +
lactate O +
content O +
of O +
whole O +
blood O +
directly O +
in O +
less O +
than O +
1 O +
min O +
, O +
using O +
only O +
a O +
10 O +
- O +
microL O +
blood O +
sample O +
. O +

The O +
procedure O +
works O +
equally O +
well O +
with O +
plasma O +
, O +
serum O +
, O +
spinal O +
fluid O +
, O +
other O +
body O +
fluids O +
, O +
or O +
tissue O +
homogenates O +
. O +

The O +
instrument O +
is O +
calibrated O +
with O +
lactate O +
standards O +
between O +
0 O +
and O +
15 O +
mMol O +
/ O +
L O +
. O +

The O +
sensor O +
, O +
a O +
polarographic O +
enzyme O +
electrode O +
, O +
gives O +
a O +
current O +
which O +
is O +
a O +
linear O +
function O +
of O +
the O +
lactate O +
concentration O +
. O +

There O +
is O +
no O +
interference O +
from O +
glucose O +
, O +
pyruvate O +
, O +
alcohol O +
, O +
ascorbate O +
, O +
anticoagulants O +
, O +
lidocaine O +
, O +
acetaminophen O +
, O +
or O +
other O +
drugs O +
and O +
metabolites O +
commonly O +
encountered O +
in O +
critically O +
ill O +
patients O +
. O +

The O +
lactate O +
sensor O +
is O +
composed O +
of O +
a O +
peroxide O +
sensor O +
and O +
an O +
enzyme O +
transducer O +
membrane O +
. O +

The O +
lactate O +
is O +
stoichiometrically O +
converted O +
to O +
pyruvate O +
and O +
hydrogen O +
peroxide O +
by O +
lactate O +
oxygen O +
oxidoreductase O +
derived O +
from O +
Pediococcus O +
species O +
. O +

The O +
oxygen O +
required O +
for O +
the O +
enzymatic O +
oxidation O +
is O +
supplied O +
via O +
an O +
air O +
- O +
permeable O +
silicone O +
elastomeric O +
membrane O +
used O +
for O +
stirring O +
. O +

Comparison O +
of O +
our O +
new O +
electroenzymatic O +
method O +
with O +
the O +
Boehringer O +
- O +
Mannheim O +
photoenzymatic O +
method O +
gives O +
correlations O +
of O +
0 O +
. O +
997 O +
for O +
both O +
whole O +
blood O +
and O +
plasma O +
. O +

The O +
effect O +
of O +
translocations O +
on O +
the O +
cellular O +
myc O +
gene O +
in O +
Burkitt O +
lymphomas O +
. O +

Chromosomal O +
translocations O +
are O +
found O +
to O +
be O +
a O +
characteristic O +
feature O +
of O +
Burkitt O +
lymphomas O +
. O +

Similar O +
translocations O +
are O +
found O +
in O +
mouse O +
plasmacytomas O +
and O +
both O +
diseases O +
involve O +
interchanges O +
between O +
one O +
of O +
the O +
immunoglobulin O +
loci O +
and O +
DNA O +
in O +
the O +
vicinity O +
of O +
the O +
myc O +
gene O +
. O +

The O +
structure O +
of O +
the O +
myc O +
gene O +
has O +
been O +
elucidated O +
from O +
studies O +
on O +
translocated O +
versions O +
of O +
the O +
gene O +
. O +

Activation O +
of O +
the O +
myc O +
gene O +
may O +
play O +
a O +
role O +
in O +
transformation O +
by O +
promoting O +
growth O +
of O +
the O +
cells O +
bearing O +
the O +
rearranged O +
chromosomes O +
. O +

Preparation O +
and O +
physicochemical O +
and O +
immunological O +
characterization O +
of O +
polysaccharide O +
- O +
outer O +
membrane O +
protein O +
complexes O +
of O +
Neisseria O +
meningitidis O +
. O +

A O +
crude O +
complex O +
containing O +
group O +
C O +
polysaccharide O +
, O +
outer O +
membrane O +
proteins O +
, O +
and O +
lipopolysaccharide O +
( O +
LPS O +
) O +
was O +
isolated O +
from O +
the O +
cell O +
- O +
free O +
culture O +
liquid O +
of O +
Neisseria O +
meningitidis O +
serogroup O +
C O +
, O +
serotype O +
2a O +
. O +

Group O +
C O +
polysaccharide O +
and O +
LPS O +
were O +
removed O +
from O +
this O +
complex O +
, O +
resulting O +
in O +
an O +
outer O +
membrane O +
complex O +
and O +
a O +
purified O +
complex O +
, O +
respectively O +
. O +

Analysis O +
by O +
electron O +
microscopy O +
showed O +
the O +
outer O +
membrane O +
origin O +
of O +
the O +
crude O +
complex O +
and O +
the O +
outer O +
membrane O +
complex O +
, O +
whereas O +
such O +
a O +
structure O +
was O +
absent O +
in O +
the O +
purified O +
complex O +
. O +

Sodium O +
dodecyl O +
sulfate O +
- O +
polyacrylamide O +
gel O +
electrophoresis O +
patterns O +
of O +
the O +
three O +
complexes O +
were O +
identical O +
. O +

Pyrolysis O +
- O +
mass O +
spectrometry O +
data O +
correlated O +
well O +
with O +
those O +
obtained O +
by O +
the O +
biochemical O +
assays O +
and O +
suggested O +
a O +
low O +
LPS O +
content O +
in O +
the O +
purified O +
complex O +
and O +
a O +
low O +
polysaccharide O +
content O +
in O +
the O +
outer O +
membrane O +
complex O +
. O +

The O +
purified O +
complex O +
was O +
shown O +
to O +
be O +
nonpyrogenic O +
and O +
could O +
be O +
prepared O +
with O +
the O +
same O +
yield O +
as O +
that O +
of O +
purified O +
polysaccharide O +
. O +

The O +
immunogenic O +
activities O +
of O +
the O +
complexes O +
were O +
studied O +
in O +
mice O +
. O +

The O +
antibodies O +
were O +
measured O +
by O +
the O +
enzyme O +
- O +
linked O +
immunosorbent O +
assay O +
; O +
and O +
the O +
bactericidal O +
antibody O +
assay O +
. O +

All O +
complexes O +
induced O +
immunoglobulin O +
G O +
antibodies O +
to O +
group O +
C O +
polysaccharide O +
as O +
well O +
as O +
to O +
the O +
serotype O +
antigen O +
, O +
although O +
the O +
removal O +
of O +
polysaccharide O +
and O +
LPS O +
resulted O +
in O +
a O +
reduction O +
of O +
the O +
immunogenic O +
activities O +
of O +
outer O +
membrane O +
complex O +
and O +
purified O +
complex O +
, O +
respectively O +
. O +

A O +
second O +
dose O +
of O +
all O +
complexes O +
produced O +
a O +
clear O +
booster O +
effect O +
of O +
both O +
antibody O +
responses O +
. O +

The O +
antibodies O +
were O +
bactericidal O +
. O +

[ O +
Suppurated O +
acute O +
obstructive O +
cholangitis O +
. O +
Anatomoclinical O +
and O +
therapeutic O +
aspects O +
] O +
. O +

A O +
total O +
of O +
134 O +
cases O +
are O +
discussed O +
, O +
with O +
suppurated O +
acute O +
obstructive O +
angiocholitis O +
, O +
that O +
underwent O +
surgical O +
treatment O +
over O +
a O +
period O +
of O +
10 O +
years O +
, O +
representing O +
12 O +
, O +
8 O +
% O +
of O +
the O +
total O +
number O +
of O +
organic O +
obstructions O +
of O +
the O +
hepato O +
- O +
choledocus O +
. O +

From O +
the O +
standpoint O +
of O +
the O +
etiopathogenic O +
mechanisms O +
the O +
angiocholitis O +
was O +
determined O +
by O +
biliary O +
lithiasis O +
in O +
59 O +
cases O +
, O +
by O +
sclerosis O +
of O +
the O +
Oddi O +
sphincter O +
in O +
5 O +
cases O +
, O +
by O +
postoperative O +
cicatriceal O +
stenosis O +
of O +
the O +
main O +
biliary O +
pathway O +
in O +
2 O +
cases O +
, O +
by O +
hepatic O +
hydatitosis O +
in O +
16 O +
cases O +
, O +
by O +
Vater O +
ampuloma O +
in O +
10 O +
cases O +
by O +
cancers O +
of O +
the O +
main O +
biliary O +
pathway O +
in O +
40 O +
cases O +
and O +
by O +
the O +
congenital O +
cyst O +
of O +
the O +
choledocus O +
in O +
one O +
case O +
. O +

The O +
high O +
frequency O +
was O +
noted O +
, O +
of O +
the O +
severe O +
forms O +
of O +
ictero O +
- O +
uremigenic O +
angiocholitis O +
( O +
representing O +
68 O +
cases O +
, O +
or O +
50 O +
, O +
7 O +
% O +
of O +
the O +
total O +
, O +
with O +
a O +
death O +
rate O +
of O +
34 O +
% O +
) O +
. O +

Medico O +
- O +
surgical O +
treatment O +
should O +
be O +
performed O +
as O +
early O +
as O +
possible O +
, O +
and O +
it O +
must O +
be O +
intensive O +
, O +
complex O +
, O +
and O +
adapted O +
to O +
the O +
anatomo O +
- O +
clinical O +
forms O +
. O +

The O +
authors O +
performed O +
evacuation O +
choledocotomy O +
with O +
external O +
draining O +
in O +
22 O +
cases O +
( O +
3 O +
deaths O +
) O +
, O +
and O +
choledoco O +
- O +
duodenal O +
anastomosis O +
in O +
46 O +
cases O +
( O +
10 O +
deaths O +
) O +
, O +
choledoco O +
- O +
jejunostomia O +
in O +
3 O +
cases O +
, O +
Oddi O +
sphincterotomia O +
in O +
12 O +
cases O +
( O +
2 O +
deaths O +
) O +
ampulectomia O +
in O +
5 O +
cases O +
( O +
2 O +
deaths O +
) O +
. O +

Peripheral O +
bilio O +
- O +
hepatodigestive O +
anastomoses O +
were O +
performed O +
in O +
40 O +
cases O +
with O +
5 O +
deaths O +
. O +

[ O +
Reactive O +
states O +
among O +
psychopathic O +
personalities O +
of O +
different O +
clinical O +
groups O +
] O +
. O +

On O +
the O +
basis O +
of O +
a O +
clinical O +
follow O +
- O +
up O +
of O +
71 O +
psychopaths O +
with O +
manifestations O +
of O +
reactive O +
psychosis O +
, O +
the O +
authors O +
established O +
the O +
clinico O +
- O +
typological O +
characteristics O +
of O +
both O +
groups O +
of O +
pathology O +
and O +
the O +
system O +
of O +
correlations O +
between O +
them O +
. O +

They O +
also O +
described O +
the O +
structure O +
of O +
the O +
psychopathic O +
and O +
psychogenic O +
syndromes O +
, O +
the O +
type O +
of O +
psychopathic O +
personality O +
reaction O +
and O +
the O +
form O +
of O +
psychogenic O +
responses O +
and O +
proved O +
statistically O +
their O +
close O +
interrelationship O +
. O +

Data O +
were O +
obtained O +
on O +
some O +
general O +
regularities O +
of O +
interrelations O +
of O +
reactive O +
psychoses O +
with O +
a O +
psychopathic O +
background O +
which O +
are O +
important O +
for O +
the O +
prognosis O +
, O +
prophylaxis O +
and O +
therapy O +
of O +
reactive O +
states O +
. O +

Hemostasis O +
and O +
mechanism O +
of O +
action O +
of O +
selective O +
antimetastatic O +
drugs O +
in O +
mice O +
bearing O +
Lewis O +
lung O +
carcinoma O +
. O +

The O +
selective O +
antimetastatic O +
agents O +
p O +
- O +
( O +
3 O +
, O +
3 O +
- O +
dimethyl O +
- O +
1 O +
- O +
triazeno O +
) O +
benzoic O +
acid O +
potassium O +
salt O +
( O +
DM O +
- O +
COOK O +
) O +
, O +
5 O +
- O +
( O +
3 O +
, O +
3 O +
- O +
dimethyl O +
- O +
1 O +
- O +
triazeno O +
) O +
imidazole O +
- O +
4 O +
- O +
carboxamide O +
( O +
DTIC O +
) O +
and O +
( O +
+ O +
/ O +
- O +
) O +
1 O +
, O +
2 O +
- O +
di O +
( O +
3 O +
, O +
5 O +
- O +
dioxopiperazin O +
- O +
1 O +
- O +
yl O +
) O +
propane O +
( O +
ICRF O +
- O +
159 O +
) O +
have O +
been O +
shown O +
to O +
markedly O +
depress O +
the O +
formation O +
of O +
spontaneous O +
hematogenous O +
metastases O +
in O +
mice O +
bearing O +
s O +
. O +
c O +
. O +

Lewis O +
lung O +
carcinoma O +
, O +
with O +
a O +
mechanism O +
unrelated O +
to O +
cytotoxicity O +
for O +
tumor O +
cells O +
. O +

The O +
effects O +
on O +
hemostasis O +
of O +
DM O +
- O +
COOK O +
, O +
DTIC O +
and O +
ICRF O +
- O +
159 O +
have O +
thus O +
been O +
examined O +
in O +
comparison O +
with O +
those O +
of O +
a O +
purely O +
cytotoxic O +
agent O +
, O +
cyclophosphamide O +
, O +
in O +
mice O +
bearing O +
i O +
. O +
m O +
. O +

Lewis O +
lung O +
carcinoma O +
. O +

The O +
parameters O +
considered O +
are O +
the O +
number O +
of O +
platelets O +
and O +
their O +
aggregability O +
, O +
prothrombin O +
and O +
partial O +
thromboplastin O +
times O +
, O +
plasma O +
fibrinogen O +
concentration O +
and O +
tumor O +
cell O +
procoagulant O +
activity O +
. O +

Slight O +
variations O +
are O +
caused O +
by O +
drug O +
treatment O +
in O +
tumor O +
- O +
bearing O +
mice O +
as O +
compared O +
with O +
untreated O +
tumor O +
- O +
bearing O +
controls O +
; O +
the O +
pattern O +
of O +
effects O +
of O +
the O +
selective O +
antimetastatic O +
agents O +
does O +
not O +
differ O +
from O +
that O +
of O +
the O +
reference O +
cytotoxic O +
compound O +
used O +
, O +
cyclophosphamide O +
. O +

These O +
data O +
thus O +
indicate O +
that O +
the O +
effects O +
on O +
hemostasis O +
of O +
the O +
drugs O +
examined O +
can O +
contribute O +
only O +
marginally O +
to O +
their O +
antimetastatic O +
action O +
, O +
since O +
more O +
pronounced O +
effects O +
on O +
hemostasis O +
have O +
been O +
shown O +
to O +
be O +
required O +
to O +
significantly O +
affect O +
metastasis O +
formation O +
. O +

Purification O +
and O +
characterization O +
of O +
various O +
esterases O +
from O +
rat O +
liver O +
. O +

The O +
major O +
rat O +
liver O +
microsomal O +
esterases O +
acting O +
on O +
o O +
- O +
nitrophenylacetate O +
with O +
isoelectric O +
points O +
5 O +
. O +
0 O +
, O +
5 O +
. O +
5 O +
, O +
6 O +
. O +
1 O +
and O +
6 O +
. O +
4 O +
were O +
resolved O +
by O +
isoelectric O +
focusing O +
. O +

Molecular O +
weights O +
were O +
determined O +
by O +
sedimentation O +
analysis O +
in O +
isokinetic O +
gradients O +
of O +
sucrose O +
and O +
, O +
after O +
purification O +
, O +
in O +
sodium O +
dodecyl O +
sulphate O +
/ O +
polyacrylamide O +
gel O +
electrophoresis O +
. O +

Their O +
subunit O +
molecular O +
weights O +
were O +
between O +
57 O +
000 O +
and O +
60 O +
000 O +
. O +

They O +
behaved O +
as O +
monomers O +
except O +
the O +
pI O +
- O +
6 O +
. O +
1 O +
enzyme O +
which O +
behaved O +
as O +
a O +
trimer O +
. O +

Esterases O +
of O +
pI O +
5 O +
. O +
0 O +
, O +
pI O +
6 O +
. O +
1 O +
and O +
pI O +
6 O +
. O +
4 O +
behaved O +
like O +
glycoproteins O +
of O +
the O +
polymannose O +
type O +
in O +
the O +
presence O +
of O +
125I O +
- O +
labelled O +
concanavalin O +
A O +
. O +

Preparations O +
of O +
the O +
pI O +
- O +
5 O +
. O +
0 O +
enzyme O +
contained O +
two O +
esterases O +
of O +
highly O +
homologous O +
structure O +
. O +

Antibodies O +
directed O +
against O +
this O +
preparation O +
did O +
not O +
inhibit O +
but O +
precipitated O +
pI O +
- O +
5 O +
. O +
0 O +
esterase O +
activity O +
quantitatively O +
. O +

They O +
did O +
not O +
react O +
with O +
the O +
pI O +
- O +
6 O +
. O +
1 O +
and O +
pI O +
- O +
6 O +
. O +
4 O +
esterases O +
but O +
precipitated O +
several O +
nonimmunologically O +
related O +
esterases O +
. O +

Two O +
of O +
these O +
enzymes O +
were O +
inducible O +
by O +
phenobarbital O +
. O +

Total O +
activity O +
was O +
very O +
low O +
in O +
3 O +
- O +
day O +
- O +
old O +
animals O +
. O +

Individual O +
esterase O +
activities O +
rose O +
at O +
different O +
rates O +
during O +
development O +
; O +
the O +
enzyme O +
focusing O +
near O +
pI O +
5 O +
. O +
0 O +
was O +
about O +
three O +
times O +
more O +
active O +
in O +
adult O +
females O +
than O +
in O +
males O +
. O +

All O +
microsomal O +
esterases O +
are O +
located O +
on O +
the O +
luminal O +
side O +
of O +
the O +
endoplasmic O +
reticulum O +
. O +

Hippocampal O +
afterdischarge O +
interferes O +
with O +
storage O +
of O +
spatial O +
information O +
in O +
a O +
working O +
memory O +
test O +
. O +

In O +
an O +
attempt O +
to O +
impair O +
spatial O +
working O +
memory O +
by O +
reversible O +
functional O +
blockade O +
rather O +
than O +
by O +
irreversible O +
lesion O +
of O +
the O +
hippocampus O +
, O +
eight O +
male O +
hooded O +
rats O +
were O +
trained O +
to O +
asymptotic O +
performance O +
of O +
1 O +
. O +
2 O +
to O +
1 O +
. O +
4 O +
errors O +
per O +
trial O +
in O +
the O +
spatial O +
12 O +
- O +
choice O +
apparatus O +
( O +
Bure O +
s O +
et O +
al O +
. O +
1982 O +
) O +
, O +
formally O +
similar O +
to O +
the O +
radial O +
maze O +
. O +

The O +
rats O +
were O +
implanted O +
with O +
hippocampal O +
stimulating O +
and O +
recording O +
electrodes O +
, O +
which O +
were O +
used O +
for O +
eliciting O +
and O +
monitoring O +
hippocampal O +
afterdischarge O +
( O +
HAD O +
) O +
lasting O +
for O +
at O +
least O +
20 O +
s O +
. O +

In O +
Experiment O +
1 O +
, O +
HAD O +
elicited O +
1 O +
or O +
10 O +
min O +
before O +
testing O +
increased O +
the O +
incidence O +
of O +
errors O +
to O +
2 O +
. O +
75 O +
or O +
2 O +
. O +
50 O +
per O +
trial O +
, O +
respectively O +
, O +
but O +
the O +
performance O +
still O +
remained O +
above O +
chance O +
level O +
( O +
4 O +
. O +
18 O +
) O +
. O +

In O +
Experiment O +
2 O +
, O +
interruption O +
of O +
the O +
trial O +
by O +
1 O +
, O +
10 O +
, O +
20 O +
and O +
30 O +
min O +
intervals O +
inserted O +
between O +
choices O +
6 O +
and O +
7 O +
increased O +
the O +
incidence O +
of O +
errors O +
in O +
choices O +
7 O +
to O +
12 O +
to O +
1 O +
. O +
0 O +
, O +
1 O +
. O +
5 O +
, O +
2 O +
. O +
1 O +
and O +
2 O +
. O +
5 O +
, O +
respectively O +
. O +

HAD O +
elicited O +
immediately O +
after O +
choice O +
6 O +
increased O +
error O +
incidence O +
in O +
the O +
subsequent O +
6 O +
choices O +
performed O +
after O +
1 O +
- O +
min O +
or O +
10 O +
- O +
min O +
intervals O +
to O +
3 O +
. O +
1 O +
or O +
2 O +
. O +
75 O +
, O +
respectively O +
, O +
i O +
. O +
e O +
. O +
to O +
the O +
chance O +
level O +
of O +
3 O +
errors O +
in O +
6 O +
choices O +
. O +

It O +
is O +
concluded O +
that O +
HAD O +
elicits O +
transient O +
shortening O +
of O +
the O +
memory O +
span O +
for O +
newly O +
acquired O +
spatial O +
information O +
( O +
anterograde O +
effect O +
) O +
and O +
erases O +
the O +
current O +
spatial O +
working O +
memory O +
record O +
( O +
retrograde O +
effect O +
) O +
. O +

Inhibition O +
by O +
N O +
- O +
( O +
phosphonacetyl O +
) O +
- O +
L O +
- O +
aspartate O +
of O +
Ehrlich O +
ascites O +
tumour O +
growth O +
and O +
glucose O +
transport O +
. O +

N O +
- O +
( O +
Phosphonacetyl O +
) O +
- O +
L O +
- O +
aspartate O +
( O +
PALA O +
) O +
suppressed O +
the O +
growth O +
of O +
Ehrlich O +
ascites O +
tumour O +
cells O +
in O +
vivo O +
in O +
a O +
dose O +
- O +
dependent O +
manner O +
. O +

Simultaneously O +
as O +
the O +
growth O +
rate O +
decreased O +
, O +
the O +
cellular O +
uptake O +
of O +
glucose O +
and O +
the O +
density O +
of O +
a O +
class O +
of O +
glucose O +
- O +
reversible O +
binding O +
sites O +
for O +
cytochalasin O +
B O +
on O +
the O +
cell O +
surface O +
were O +
also O +
found O +
to O +
be O +
reduced O +
. O +

There O +
is O +
a O +
highly O +
significant O +
correlation O +
between O +
the O +
magnitude O +
of O +
changes O +
in O +
the O +
number O +
of O +
cytochalasin O +
B O +
binding O +
sites O +
and O +
the O +
magnitude O +
of O +
changes O +
in O +
glucose O +
uptake O +
. O +

The O +
physiological O +
significance O +
of O +
these O +
observations O +
are O +
discussed O +
. O +

[ O +
In O +
vitro O +
studies O +
of O +
the O +
thyroid O +
gland O +
regulation O +
principles O +
and O +
their O +
evaluation O +
] O +
. O +

The O +
free O +
fractions O +
of O +
the O +
thyroid O +
hormone O +
further O +
the O +
metabolism O +
of O +
the O +
body O +
cells O +
and O +
regulate O +
the O +
synthesis O +
of O +
the O +
thyroid O +
hormone O +
. O +

Once O +
the O +
level O +
of O +
FT3 O +
and O +
FT4 O +
decreases O +
. O +

With O +
the O +
help O +
of O +
a O +
liberation O +
of O +
the O +
hormone O +
stimulating O +
the O +
thyroid O +
gland O +
from O +
the O +
anterior O +
lobe O +
of O +
the O +
pituitary O +
gland O +
the O +
lack O +
of O +
thyroid O +
hormone O +
is O +
corrected O +
. O +

The O +
synthesis O +
and O +
secretion O +
of O +
the O +
thyroid O +
gland O +
stimulating O +
hormone O +
is O +
induced O +
by O +
the O +
thyreotropin O +
releasing O +
hormone O +
which O +
is O +
given O +
by O +
the O +
hypothalamus O +
. O +

Moreover O +
, O +
the O +
organism O +
is O +
able O +
as O +
needed O +
to O +
carry O +
out O +
the O +
monodiodation O +
of O +
LT4 O +
to O +
biologically O +
active O +
LT3 O +
or O +
biologically O +
inactive O +
so O +
- O +
called O +
revers O +
T3 O +
( O +
RT3 O +
) O +
. O +

The O +
estimation O +
of O +
thyroid O +
gland O +
stimulating O +
hormone O +
before O +
and O +
30 O +
minutes O +
after O +
intravenous O +
application O +
of O +
thyreotropin O +
releasing O +
hormone O +
has O +
its O +
main O +
importance O +
for O +
the O +
early O +
recognition O +
of O +
a O +
disturbance O +
of O +
the O +
regulating O +
circle O +
hypophysis O +
- O +
thyroid O +
gland O +
, O +
above O +
all O +
in O +
the O +
diagnosis O +
of O +
clinically O +
not O +
yet O +
manifest O +
clinical O +
pictures O +
, O +
such O +
as O +
the O +
latent O +
hypothyreosis O +
and O +
the O +
latent O +
hyperthyreosis O +
, O +
respectively O +
( O +
Basedow O +
hyperthyreosis O +
and O +
thyroidal O +
autonomy O +
) O +
. O +

According O +
to O +
the O +
questioning O +
the O +
estimations O +
of O +
the O +
levels O +
of O +
the O +
thyroid O +
hormones O +
and O +
of O +
the O +
thyroid O +
gland O +
stimulating O +
hormone O +
should O +
be O +
used O +
stepwise O +
. O +

Relationship O +
of O +
self O +
- O +
concept O +
during O +
late O +
pregnancy O +
to O +
neonatal O +
perception O +
and O +
parenting O +
profile O +
. O +

Thirty O +
- O +
one O +
gravidas O +
were O +
studied O +
to O +
examine O +
the O +
relationship O +
between O +
a O +
woman O +
' O +
s O +
feelings O +
about O +
herself O +
during O +
late O +
pregnancy O +
, O +
her O +
perception O +
of O +
her O +
newborn O +
, O +
and O +
her O +
profile O +
of O +
parenting O +
. O +

The O +
Tennessee O +
Self O +
- O +
Concept O +
Scale O +
was O +
completed O +
during O +
the O +
third O +
trimester O +
of O +
pregnancy O +
, O +
the O +
Neonatal O +
Perception O +
Inventory O +
I O +
at O +
one O +
- O +
to O +
- O +
two O +
days O +
postpartum O +
, O +
and O +
the O +
Neonatal O +
Perception O +
Inventory O +
II O +
and O +
the O +
Michigan O +
Screening O +
Profile O +
of O +
Parenting O +
at O +
four O +
- O +
to O +
- O +
six O +
weeks O +
postpartum O +
. O +

When O +
considered O +
separately O +
, O +
no O +
positive O +
significant O +
relationships O +
were O +
found O +
between O +
scores O +
on O +
these O +
variables O +
. O +

However O +
, O +
all O +
subjects O +
with O +
negative O +
scores O +
on O +
both O +
self O +
- O +
concept O +
and O +
neonatal O +
perception O +
had O +
negative O +
scores O +
on O +
at O +
least O +
two O +
subscales O +
of O +
the O +
parenting O +
profile O +
. O +

Differential O +
reactivity O +
of O +
the O +
functional O +
sulfhydryl O +
groups O +
of O +
cysteine O +
- O +
32 O +
and O +
cysteine O +
- O +
35 O +
present O +
in O +
the O +
reduced O +
form O +
of O +
thioredoxin O +
from O +
Escherichia O +
coli O +
. O +

Only O +
one O +
of O +
the O +
sulfhydryl O +
groups O +
from O +
Cys O +
- O +
32 O +
and O +
Cys O +
- O +
35 O +
in O +
the O +
active O +
center O +
of O +
native O +
Escherichia O +
coli O +
thioredoxin O +
- O +
( O +
SH O +
) O +
2 O +
was O +
alkylated O +
by O +
excess O +
iodoacetic O +
acid O +
at O +
pH O +
values O +
below O +
8 O +
. O +
0 O +
. O +

Both O +
groups O +
reacted O +
in O +
the O +
protein O +
denatured O +
with O +
4 O +
. O +
5 O +
M O +
guanidine O +
hydrochloride O +
. O +

The O +
second O +
order O +
rate O +
of O +
alkylation O +
of O +
thioredoxin O +
- O +
( O +
SH O +
) O +
2 O +
with O +
1 O +
eq O +
of O +
iodoacetic O +
acid O +
was O +
pH O +
- O +
dependent O +
and O +
showed O +
independent O +
initial O +
reactions O +
of O +
one O +
thiolate O +
ion O +
with O +
a O +
pK O +
value O +
of O +
6 O +
. O +
7 O +
and O +
a O +
second O +
with O +
a O +
pK O +
value O +
close O +
to O +
9 O +
. O +
0 O +
. O +

The O +
same O +
pH O +
dependence O +
was O +
observed O +
for O +
alkylation O +
with O +
iodoacetamide O +
but O +
the O +
apparent O +
rate O +
constant O +
, O +
107 O +
M O +
- O +
1 O +
S O +
- O +
1 O +
at O +
pH O +
7 O +
. O +
2 O +
, O +
was O +
about O +
20 O +
- O +
fold O +
higher O +
than O +
the O +
corresponding O +
rate O +
with O +
iodoacetate O +
. O +

The O +
sulfhydryl O +
group O +
with O +
a O +
pK O +
value O +
of O +
6 O +
. O +
7 O +
was O +
shown O +
to O +
belong O +
to O +
Cys O +
- O +
32 O +
by O +
labeling O +
thioredoxin O +
with O +
[ O +
14C O +
] O +
iodoacetic O +
acid O +
followed O +
by O +
complete O +
alkylation O +
with O +
[ O +
3H O +
] O +
iodoacetate O +
and O +
amino O +
acid O +
sequence O +
analysis O +
of O +
peptides O +
from O +
the O +
active O +
center O +
. O +

The O +
abnormally O +
low O +
pK O +
value O +
of O +
Cys O +
- O +
32 O +
is O +
suggested O +
to O +
arise O +
by O +
electrostatic O +
influence O +
from O +
a O +
positive O +
charge O +
on O +
the O +
amino O +
group O +
of O +
Lys O +
- O +
36 O +
. O +

A O +
mechanism O +
of O +
action O +
for O +
thioredoxin O +
- O +
( O +
SH O +
) O +
2 O +
as O +
a O +
protein O +
disulfide O +
reductase O +
has O +
been O +
formulated O +
. O +

This O +
is O +
based O +
on O +
an O +
initial O +
nucleophilic O +
attack O +
by O +
the O +
thiolate O +
of O +
Cys O +
- O +
32 O +
with O +
the O +
formation O +
of O +
an O +
unstable O +
transient O +
mixed O +
disulfide O +
involving O +
Cys O +
- O +
32 O +
and O +
one O +
of O +
the O +
sulfurs O +
in O +
the O +
substrate O +
. O +

This O +
is O +
followed O +
by O +
a O +
conformational O +
change O +
and O +
a O +
nucleophilic O +
attack O +
of O +
Cys O +
- O +
35 O +
to O +
give O +
the O +
14 O +
- O +
membered O +
disulfide O +
ring O +
in O +
thioredoxin O +
- O +
S2 O +
and O +
the O +
dithiol O +
of O +
the O +
substrate O +
. O +

Subretinal O +
neovascularization O +
following O +
rubella O +
retinopathy O +
. O +

A O +
17 O +
- O +
year O +
- O +
old O +
girl O +
and O +
an O +
11 O +
- O +
year O +
- O +
old O +
girl O +
with O +
rubella O +
retinopathy O +
had O +
decreased O +
vision O +
in O +
one O +
eye O +
secondary O +
to O +
subretinal O +
neovascularization O +
and O +
hemorrhage O +
. O +

In O +
both O +
cases O +
a O +
disciform O +
scar O +
with O +
permanent O +
decrease O +
in O +
central O +
vision O +
resulted O +
. O +

Verrucous O +
carcinoma O +
of O +
the O +
endometrium O +
- O +
- O +
a O +
unique O +
neoplasm O +
with O +
long O +
survival O +
. O +

A O +
case O +
of O +
verrucous O +
carcinoma O +
of O +
the O +
endometrium O +
with O +
long O +
survival O +
is O +
described O +
. O +

It O +
represents O +
the O +
first O +
of O +
its O +
type O +
to O +
be O +
recorded O +
in O +
this O +
site O +
. O +

The O +
literature O +
on O +
verrucous O +
carcinoma O +
and O +
on O +
other O +
cases O +
of O +
squamous O +
carcinoma O +
of O +
the O +
endometrium O +
is O +
briefly O +
reviewed O +
. O +

Effects O +
of O +
3 O +
- O +
chloromethylthiochromone O +
- O +
1 O +
, O +
1 O +
- O +
dioxide O +
on O +
nucleic O +
acid O +
, O +
protein O +
, O +
and O +
aerobic O +
and O +
anaerobic O +
metabolism O +
of O +
Ehrlich O +
ascites O +
tumor O +
cells O +
. O +

3 O +
- O +
Chloromethylthiochromone O +
- O +
1 O +
, O +
1 O +
- O +
dioxide O +
was O +
observed O +
to O +
be O +
a O +
potent O +
inhibitor O +
of O +
Ehrlich O +
ascites O +
carcinoma O +
growth O +
and O +
a O +
moderate O +
inhibitor O +
of O +
P B-CellLine +
- I-CellLine +
388 I-CellLine +
lymphocytic O +
leukemia O +
growth O +
at O +
10 O +
mg O +
/ O +
kg O +
/ O +
day O +
. O +

Preliminary O +
in O +
vitro O +
studies O +
showed O +
that O +
the O +
agents O +
significantly O +
inhibited O +
RNA O +
and O +
DNA O +
synthesis O +
in O +
Ehrlich O +
ascites O +
cells O +
. O +

In O +
vivo O +
studies O +
after O +
dosing O +
on O +
Days O +
6 O +
, O +
7 O +
, O +
and O +
8 O +
demonstrated O +
the O +
same O +
reductions O +
in O +
nucleic O +
acid O +
synthesis O +
and O +
a O +
moderate O +
reduction O +
in O +
protein O +
synthesis O +
. O +

The O +
primary O +
site O +
of O +
nucleic O +
acid O +
synthesis O +
, O +
which O +
was O +
blocked O +
by O +
3 O +
- O +
chloromethylthiochromone O +
, O +
was O +
at O +
orotidine O +
monophosphate O +
decarboxylase O +
in O +
the O +
primidine O +
pathway O +
. O +

Other O +
enzymes O +
, O +
in O +
anaerobic O +
and O +
aerobic O +
glycolysis O +
, O +
which O +
were O +
blocked O +
include O +
hexokinase O +
, O +
phosphofructokinase O +
, O +
succinic O +
and O +
alpha O +
- O +
ketoglutarate O +
dehydrogenases O +
, O +
as O +
well O +
as O +
States O +
3 O +
and O +
4 O +
of O +
oxidative O +
phosphorylation O +
. O +

Metabolic O +
alterations O +
in O +
a O +
noncachectic O +
animal O +
tumor O +
system O +
. O +

The O +
increased O +
energy O +
expended O +
by O +
the O +
host O +
to O +
synthesize O +
substrate O +
, O +
which O +
is O +
utilized O +
by O +
the O +
tumor O +
, O +
is O +
a O +
potential O +
cause O +
of O +
cancer O +
cachexia O +
. O +

In O +
vivo O +
glucose O +
and O +
alanine O +
kinetics O +
were O +
examined O +
by O +
tracer O +
methodology O +
in O +
a O +
sarcoma O +
- O +
bearing O +
rat O +
model O +
. O +

The O +
effects O +
of O +
3 O +
- O +
mercaptopicolinic O +
acid O +
, O +
a O +
potent O +
inhibitor O +
of O +
gluconeogenesis O +
, O +
was O +
also O +
examined O +
on O +
this O +
model O +
. O +

Both O +
tumor O +
- O +
bearing O +
( O +
TB O +
) O +
and O +
nontumor O +
bearing O +
( O +
NTB O +
) O +
animals O +
were O +
gaining O +
weight O +
prior O +
to O +
study O +
and O +
the O +
tumors O +
were O +
relatively O +
small O +
. O +

The O +
TB O +
animals O +
had O +
significantly O +
lower O +
plasma O +
glucose O +
and O +
higher O +
blood O +
lactic O +
acid O +
levels O +
compared O +
with O +
NTB O +
animals O +
. O +

After O +
inhibition O +
of O +
gluconeogenesis O +
, O +
the O +
plasma O +
glucose O +
decreased O +
and O +
the O +
blood O +
lactate O +
increased O +
significantly O +
more O +
in O +
TB O +
than O +
NTB O +
animals O +
. O +

The O +
glucose O +
turnover O +
rate O +
was O +
significantly O +
greater O +
in O +
TB O +
compared O +
with O +
NTB O +
animals O +
, O +
as O +
was O +
the O +
rate O +
of O +
glucose O +
recycling O +
and O +
the O +
rate O +
of O +
gluconeogenesis O +
( O +
alanine O +
leads O +
to O +
glucose O +
) O +
, O +
both O +
energy O +
demanding O +
processes O +
. O +

These O +
results O +
suggest O +
that O +
the O +
tumor O +
- O +
bearing O +
animal O +
, O +
even O +
prior O +
to O +
significant O +
cachexia O +
, O +
has O +
an O +
excess O +
demand O +
for O +
energy O +
, O +
the O +
provision O +
of O +
which O +
may O +
be O +
a O +
significant O +
factor O +
in O +
malignant O +
cachexia O +
. O +

[ O +
Organization O +
of O +
pectoral O +
muscle O +
motor O +
neurons O +
in O +
the O +
rat O +
. O +
Contribution O +
to O +
the O +
study O +
of O +
the O +
axillary O +
arch O +
( O +
Achselbogen O +
) O +
] O +
. O +

In O +
spite O +
of O +
their O +
role O +
of O +
the O +
forelimb O +
activity O +
, O +
the O +
organization O +
of O +
the O +
mammalian O +
pectoral O +
muscles O +
remains O +
unclear O +
. O +

In O +
order O +
to O +
get O +
more O +
information O +
, O +
we O +
have O +
studied O +
, O +
qualitatively O +
and O +
quantitatively O +
, O +
the O +
motor O +
pools O +
of O +
the O +
various O +
pectoral O +
muscles O +
in O +
the O +
rat O +
( O +
musculus O +
pectoralis O +
major O +
, O +
musculus O +
pectoralis O +
minor O +
and O +
musculus O +
panniculus O +
carnosus O +
) O +
. O +

The O +
method O +
applied O +
was O +
the O +
retrograde O +
transport O +
of O +
horseradish O +
peroxidase O +
by O +
the O +
peripheral O +
nerves O +
supplying O +
the O +
various O +
muscles O +
. O +

The O +
results O +
provided O +
the O +
precise O +
localization O +
within O +
the O +
ventral O +
horn O +
of O +
the O +
motor O +
neurons O +
from O +
the O +
pectoral O +
muscles O +
which O +
were O +
all O +
in O +
the O +
most O +
ventral O +
part O +
of O +
the O +
gray O +
matter O +
. O +

Three O +
distinct O +
motor O +
pools O +
were O +
observed O +
, O +
which O +
confirms O +
the O +
functional O +
identity O +
of O +
each O +
muscle O +
. O +

The O +
motor O +
neurons O +
of O +
m O +
. O +
panniculus O +
carnosus O +
exhibited O +
some O +
particularities O +
. O +

They O +
were O +
4 O +
times O +
more O +
numerous O +
than O +
those O +
from O +
m O +
. O +
pectoralis O +
major O +
, O +
they O +
occupied O +
the O +
whole O +
ventral O +
edge O +
of O +
the O +
ventral O +
horn O +
, O +
from O +
its O +
medial O +
part O +
to O +
its O +
lateral O +
tip O +
. O +

The O +
cell O +
size O +
was O +
different O +
from O +
that O +
of O +
the O +
other O +
muscles O +
. O +

These O +
results O +
were O +
discussed O +
, O +
according O +
to O +
the O +
role O +
of O +
this O +
muscle O +
, O +
which O +
links O +
the O +
forelimb O +
to O +
the O +
whole O +
trunk O +
. O +

In O +
mammals O +
, O +
m O +
. O +
panniculus O +
carnosus O +
constitutes O +
, O +
with O +
musculus O +
latissimus O +
dorsi O +
, O +
the O +
axillary O +
arch O +
( O +
Achselbogen O +
) O +
. O +

A O +
small O +
area O +
of O +
overlapping O +
between O +
the O +
motor O +
pools O +
of O +
these O +
two O +
muscles O +
was O +
observed O +
. O +

It O +
was O +
suggested O +
that O +
the O +
muscular O +
fibers O +
from O +
the O +
axillary O +
arch O +
were O +
innervated O +
by O +
the O +
same O +
, O +
well O +
- O +
defined O +
spinal O +
area O +
, O +
independent O +
of O +
the O +
muscle O +
from O +
which O +
they O +
originate O +
. O +

An O +
unusual O +
case O +
of O +
benign O +
mucous O +
membrane O +
pemphigoid O +
. O +

This O +
case O +
of O +
benign O +
mucous O +
membrane O +
pemphigoid O +
( O +
BMMP O +
) O +
is O +
unusual O +
in O +
that O +
blistering O +
, O +
scarring O +
lesions O +
were O +
confined O +
to O +
the O +
skin O +
for O +
15 O +
years O +
before O +
mucous O +
membranes O +
were O +
involved O +
. O +

The O +
onset O +
of O +
this O +
disorder O +
at O +
the O +
age O +
of O +
38 O +
is O +
also O +
unusual O +
. O +

Detailed O +
immunological O +
investigation O +
was O +
performed O +
on O +
this O +
patient O +
but O +
the O +
results O +
in O +
no O +
way O +
clarify O +
the O +
present O +
confusion O +
regarding O +
the O +
immunopathological O +
processes O +
in O +
BMMP O +
related O +
to O +
those O +
operative O +
in O +
bullous O +
pemphigoid O +
. O +

Mast O +
cell O +
heparin O +
stimulates O +
migration O +
of O +
capillary O +
endothelial O +
cells O +
in O +
vitro O +
. O +

Migration O +
of O +
capillary O +
endothelial O +
cells O +
is O +
an O +
important O +
component O +
of O +
angiogenesis O +
in O +
vivo O +
. O +

Increased O +
numbers O +
of O +
mast O +
cells O +
have O +
been O +
associated O +
with O +
several O +
types O +
of O +
angiogenesis O +
. O +

We O +
have O +
used O +
a O +
quantitative O +
assay O +
in O +
vitro O +
to O +
demonstrate O +
that O +
mast O +
cells O +
release O +
a O +
factor O +
that O +
significantly O +
increases O +
bovine O +
capillary O +
endothelial O +
cell O +
migration O +
. O +

The O +
factor O +
is O +
present O +
in O +
medium O +
conditioned O +
by O +
mast O +
cells O +
as O +
well O +
as O +
lysates O +
of O +
mast O +
cells O +
. O +

The O +
stimulatory O +
effect O +
of O +
mast O +
cells O +
on O +
migration O +
is O +
specific O +
for O +
capillary O +
endothelial O +
cells O +
. O +

Furthermore O +
, O +
mast O +
cells O +
have O +
no O +
mitogenic O +
activity O +
for O +
capillary O +
endothelial O +
cells O +
. O +

Of O +
all O +
the O +
secretory O +
products O +
of O +
mast O +
cells O +
tested O +
, O +
only O +
heparin O +
stimulated O +
capillary O +
endothelial O +
cell O +
migration O +
in O +
vitro O +
. O +

Heparin O +
preparations O +
from O +
a O +
variety O +
of O +
sources O +
stimulated O +
capillary O +
endothelial O +
cell O +
migration O +
to O +
the O +
same O +
degree O +
but O +
did O +
not O +
stimulate O +
migration O +
of O +
several O +
other O +
cell O +
types O +
. O +

The O +
migration O +
activity O +
of O +
heparin O +
and O +
mast O +
cell O +
conditioned O +
medium O +
was O +
blocked O +
by O +
specific O +
antagonists O +
of O +
heparin O +
( O +
protamine O +
and O +
heparinase O +
) O +
, O +
but O +
not O +
by O +
chondroitinase O +
ABC O +
. O +

The O +
migration O +
activity O +
of O +
mast O +
cell O +
conditioned O +
medium O +
was O +
resistant O +
to O +
heat O +
( O +
100 O +
degrees O +
C O +
) O +
and O +
incubation O +
with O +
proteolytic O +
enzymes O +
. O +

These O +
results O +
suggest O +
that O +
the O +
role O +
of O +
mast O +
cells O +
in O +
angiogenesis O +
may O +
be O +
to O +
enhance O +
migration O +
of O +
the O +
endothelial O +
cells O +
of O +
growing O +
capillaries O +
. O +

The O +
inhibition O +
of O +
cultured O +
myoblast O +
differentiation O +
by O +
the O +
simian O +
virus O +
40 O +
large O +
T O +
antigen O +
occurs O +
after O +
myogenin O +
expression O +
and O +
Rb O +
up O +
- O +
regulation O +
and O +
is O +
not O +
exerted O +
by O +
transformation O +
- O +
competent O +
cytoplasmic O +
mutants O +
. O +

We O +
have O +
investigated O +
the O +
mechanism O +
by O +
which O +
the O +
simian O +
virus O +
40 O +
large O +
T O +
antigen O +
( O +
SVLT O +
) O +
interferes O +
with O +
the O +
differentiation O +
of O +
C2 B-CellLine +
myoblasts O +
. O +

SVLT O +
mutants O +
, O +
defective O +
either O +
in O +
the O +
Rb O +
binding O +
site O +
, O +
near O +
the O +
N O +
- O +
terminal O +
end O +
, O +
in O +
a O +
region O +
that O +
affects O +
binding O +
to O +
p53 O +
, O +
or O +
in O +
the O +
nuclear O +
transport O +
signal O +
, O +
were O +
also O +
employed O +
to O +
determine O +
whether O +
the O +
interference O +
was O +
especially O +
dependent O +
on O +
these O +
functional O +
domains O +
. O +

It O +
was O +
found O +
that O +
wild O +
- O +
type O +
( O +
wt O +
) O +
SVLT O +
strongly O +
inhibited O +
the O +
terminal O +
differentiation O +
of O +
mouse O +
C2 B-CellLine +
myoblasts O +
, O +
but O +
this O +
arrest O +
occurred O +
only O +
after O +
the O +
synthesis O +
of O +
myogenin O +
, O +
an O +
initial O +
step O +
in O +
biochemical O +
differentiation O +
. O +

Neither O +
the O +
synthesis O +
nor O +
some O +
basic O +
activities O +
of O +
MyoD O +
appeared O +
to O +
be O +
affected O +
by O +
wt O +
SVLT O +
. O +

In O +
these O +
transformants O +
, O +
mitogen O +
depletion O +
elicited O +
an O +
increase O +
in O +
the O +
Rb O +
level O +
comparable O +
to O +
that O +
in O +
normal O +
C2 B-CellLine +
cells O +
; O +
wt O +
SVLT O +
, O +
however O +
, O +
promoted O +
the O +
phosphorylation O +
of O +
a O +
large O +
part O +
of O +
the O +
induced O +
Rb O +
. O +

Mutations O +
affecting O +
nuclear O +
transport O +
were O +
far O +
more O +
critical O +
for O +
the O +
ability O +
to O +
interfere O +
with O +
myogenic O +
differentiation O +
than O +
were O +
those O +
affecting O +
the O +
transforming O +
potential O +
; O +
cytoplasmic O +
SVLT O +
expression O +
was O +
fully O +
compatible O +
with O +
the O +
terminal O +
differentiation O +
of O +
C2 B-CellLine +
cells O +
, O +
despite O +
enabling O +
them O +
to O +
grow O +
in O +
semisolid O +
medium O +
, O +
thus O +
showing O +
that O +
the O +
myogenesis O +
- O +
inhibiting O +
property O +
can O +
be O +
dissociated O +
from O +
transforming O +
competence O +
. O +

The O +
remaining O +
SVLT O +
mutants O +
presented O +
different O +
degrees O +
of O +
ability O +
to O +
inhibit O +
differentiation O +
( O +
as O +
shown O +
by O +
the O +
expression O +
of O +
tissue O +
- O +
specific O +
markers O +
in O +
transformants O +
) O +
. O +

The O +
inhibiting O +
mutants O +
, O +
including O +
the O +
Rb O +
binding O +
site O +
mutant O +
, O +
were O +
able O +
to O +
promote O +
a O +
higher O +
state O +
of O +
Rb O +
phosphorylation O +
than O +
that O +
observed O +
in O +
either O +
normal O +
cells O +
or O +
cytoplasmic O +
- O +
SVLT O +
transformants O +
. O +

A O +
transcript O +
from O +
the O +
long O +
terminal O +
repeats O +
of O +
a O +
murine O +
retrovirus O +
associated O +
with O +
trans O +
activation O +
of O +
cellular O +
genes O +
. O +

Infection O +
of O +
human O +
or O +
murine O +
cells O +
with O +
murine O +
leukemia O +
viruses O +
rapidly O +
increases O +
the O +
expression O +
of O +
a O +
number O +
of O +
genes O +
that O +
belong O +
to O +
the O +
immunoglobulin O +
superfamily O +
and O +
are O +
involved O +
in O +
T O +
- O +
lymphocyte O +
activation O +
, O +
including O +
the O +
class O +
I O +
major O +
histocompatibility O +
complex O +
antigens O +
. O +

We O +
have O +
reported O +
recently O +
that O +
the O +
long O +
terminal O +
repeat O +
( O +
LTR O +
) O +
of O +
Moloney O +
murine O +
leukemia O +
virus O +
encodes O +
a O +
trans O +
activator O +
which O +
induces O +
transcription O +
and O +
expression O +
of O +
class O +
I O +
major O +
histocompatibility O +
complex O +
genes O +
and O +
certain O +
cytokine O +
genes O +
. O +

The O +
portion O +
of O +
the O +
LTR O +
responsible O +
for O +
trans O +
activation O +
was O +
mapped O +
by O +
deletions O +
to O +
lie O +
within O +
the O +
U3 O +
region O +
. O +

We O +
demonstrate O +
here O +
that O +
a O +
transcript O +
is O +
initiated O +
within O +
the O +
U3 O +
region O +
and O +
that O +
its O +
presence O +
correlates O +
with O +
the O +
trans O +
- O +
activating O +
activity O +
. O +

Analysis O +
of O +
the O +
LTR O +
region O +
reveals O +
a O +
potential O +
internal O +
promoter O +
element O +
for O +
RNA O +
polymerase O +
III O +
transcription O +
within O +
the O +
U3 O +
region O +
. O +

Studies O +
with O +
polymerase O +
inhibitors O +
suggest O +
that O +
this O +
LTR O +
transcript O +
, O +
designated O +
let O +
( O +
LTR O +
- O +
encoded O +
trans O +
activator O +
) O +
, O +
is O +
a O +
product O +
of O +
RNA O +
polymerase O +
III O +
. O +

The O +
mechanisms O +
whereby O +
RNA O +
leukemia O +
viruses O +
cause O +
lymphoid O +
neoplasia O +
after O +
a O +
long O +
latent O +
period O +
have O +
been O +
extensively O +
studied O +
but O +
are O +
only O +
partially O +
understood O +
. O +

The O +
region O +
of O +
the O +
LTR O +
identified O +
here O +
as O +
being O +
important O +
in O +
trans O +
activation O +
has O +
recently O +
been O +
shown O +
to O +
be O +
a O +
critical O +
determinant O +
of O +
the O +
leukemogenicity O +
and O +
latency O +
of O +
Moloney O +
murine O +
leukemia O +
virus O +
. O +

These O +
findings O +
suggest O +
a O +
novel O +
mechanism O +
of O +
retrovirus O +
- O +
induced O +
activation O +
of O +
cellular O +
gene O +
expression O +
, O +
potentially O +
contributing O +
to O +
leukemogenesis O +
. O +

Cancer O +
progression O +
and O +
p53 O +
. O +

In O +
a O +
complex O +
organism O +
, O +
somatic O +
cells O +
are O +
under O +
intermittent O +
selection O +
pressure O +
for O +
the O +
emergence O +
of O +
mutants O +
that O +
can O +
survive O +
environmental O +
insults O +
and O +
that O +
can O +
grow O +
autonomously O +
despite O +
adverse O +
conditions O +
. O +

Repeated O +
rounds O +
of O +
mutation O +
, O +
selection O +
, O +
and O +
proliferation O +
may O +
lead O +
to O +
cancer O +
. O +

The O +
organism O +
prevents O +
malignant O +
transformation O +
by O +
assuring O +
accurate O +
DNA O +
repair O +
before O +
cell O +
division O +
, O +
by O +
forcing O +
the O +
death O +
of O +
cells O +
with O +
excessive O +
DNA O +
damage O +
, O +
and O +
by O +
placing O +
limits O +
on O +
the O +
replicative O +
lifespans O +
of O +
most O +
somatic O +
cells O +
. O +

The O +
p53 O +
gene O +
is O +
a O +
" O +
guardian O +
of O +
the O +
genome O +
" O +
- O +
- O +
it O +
regulates O +
multiple O +
components O +
of O +
the O +
DNA O +
damage O +
control O +
response O +
and O +
promotes O +
cellular O +
senescence O +
. O +

Disabling O +
mutations O +
and O +
deletions O +
of O +
p53 O +
occur O +
in O +
50 O +
% O +
of O +
human O +
tumours O +
. O +

p53 O +
- O +
deficient O +
cancers O +
are O +
often O +
unstable O +
, O +
aggressive O +
, O +
and O +
resistant O +
to O +
therapy O +
. O +

Anti O +
- O +
transforming O +
growth O +
factor O +
( O +
TGF O +
) O +
- O +
beta O +
antibodies O +
inhibit O +
breast O +
cancer O +
cell O +
tumorigenicity O +
and O +
increase O +
mouse O +
spleen O +
natural O +
killer O +
cell O +
activity O +
. O +

Implications O +
for O +
a O +
possible O +
role O +
of O +
tumor O +
cell O +
/ O +
host O +
TGF O +
- O +
beta O +
interactions O +
in O +
human O +
breast O +
cancer O +
progression O +
. O +

TGF O +
- O +
beta O +
effects O +
on O +
angiogenesis O +
, O +
stroma O +
formation O +
, O +
and O +
immune O +
function O +
suggest O +
its O +
possible O +
involvement O +
in O +
tumor O +
progression O +
. O +

This O +
hypothesis O +
was O +
tested O +
using O +
the O +
2G7 O +
IgG2b O +
, O +
which O +
neutralizes O +
TGF O +
- O +
beta O +
1 O +
, O +
- O +
beta O +
2 O +
, O +
and O +
- O +
beta O +
3 O +
, O +
and O +
the O +
MDA B-CellLine +
- I-CellLine +
231 I-CellLine +
human O +
breast O +
cancer O +
cell O +
line O +
. O +

Inoculation O +
of O +
these O +
cells O +
in O +
athymic O +
mice O +
decreases O +
mouse O +
spleen O +
natural O +
killer O +
( O +
NK O +
) O +
cell O +
activity O +
. O +

Intraperitoneal O +
injections O +
of O +
2G7 O +
starting O +
1 O +
d O +
after O +
intraperitoneal O +
inoculation O +
of O +
tumor O +
cells O +
suppressed O +
intraabdominal O +
tumor O +
and O +
lung O +
metastases O +
, O +
whereas O +
the O +
nonneutralizing O +
anti O +
- O +
TGF O +
- O +
beta O +
12H5 O +
IgG2a O +
had O +
no O +
effect O +
. O +

2G7 O +
transiently O +
inhibited O +
growth O +
of O +
established O +
MDA B-CellLine +
- I-CellLine +
231 I-CellLine +
subcutaneous O +
tumors O +
. O +

Histologically O +
, O +
both O +
2G7 O +
- O +
treated O +
and O +
control O +
tumors O +
were O +
identical O +
. O +

Intraperitoneal O +
administration O +
of O +
2G7 O +
resulted O +
in O +
a O +
marked O +
increase O +
in O +
mouse O +
spleen O +
NK O +
cell O +
activity O +
. O +

2G7 O +
did O +
not O +
inhibit O +
MDA B-CellLine +
- I-CellLine +
231 I-CellLine +
primary O +
tumor O +
or O +
metastases O +
formation O +
, O +
nor O +
did O +
it O +
stimulate O +
NK O +
cell O +
- O +
mediated O +
cytotoxicity O +
in O +
beige O +
NK O +
- O +
deficient O +
nude O +
mice O +
. O +

Finally O +
, O +
serum O +
- O +
free O +
conditioned O +
medium O +
from O +
MDA B-CellLine +
- I-CellLine +
231 I-CellLine +
cells O +
inhibited O +
the O +
NK O +
cell O +
activity O +
of O +
human O +
blood O +
lymphocytes O +
. O +

This O +
inhibition O +
was O +
blocked O +
by O +
the O +
neutralizing O +
anti O +
- O +
TGF O +
- O +
beta O +
2G7 O +
antibody O +
but O +
not O +
by O +
a O +
nonspecific O +
IgG2 O +
. O +

These O +
data O +
support O +
a O +
possible O +
role O +
for O +
tumor O +
cell O +
TGF O +
- O +
beta O +
in O +
the O +
progression O +
of O +
mammary O +
carcinomas O +
by O +
suppressing O +
host O +
immune O +
surveillance O +
. O +

The O +
Met O +
proto O +
- O +
oncogene O +
mesenchymal O +
to O +
epithelial O +
cell O +
conversion O +
. O +

Coexpression O +
of O +
the O +
human O +
Met O +
receptor O +
and O +
its O +
ligand O +
, O +
hepatocyte O +
growth O +
factor O +
/ O +
scatter O +
factor O +
( O +
HGF O +
/ O +
SF O +
) O +
, O +
in O +
NIH B-CellLine +
3T3 I-CellLine +
fibroblasts O +
causes O +
the O +
cells O +
to O +
become O +
tumorigenic O +
in O +
nude O +
mice O +
. O +

The O +
resultant O +
tumors O +
display O +
lumen O +
- O +
like O +
morphology O +
, O +
contain O +
carcinoma O +
- O +
like O +
focal O +
areas O +
with O +
intercellular O +
junctions O +
resembling O +
desmosomes O +
, O +
and O +
coexpress O +
epithelial O +
( O +
cytokeratin O +
) O +
and O +
mesenchymal O +
( O +
vimentin O +
) O +
cytoskeletal O +
markers O +
. O +

The O +
tumor O +
cells O +
also O +
display O +
enhanced O +
expression O +
of O +
desmosomal O +
and O +
tight O +
- O +
junction O +
proteins O +
. O +

The O +
apparent O +
mesenchymal O +
to O +
epithelial O +
conversion O +
of O +
the O +
tumor O +
cells O +
mimics O +
the O +
conversion O +
that O +
occurs O +
during O +
embryonic O +
kidney O +
development O +
, O +
suggesting O +
that O +
Met O +
- O +
HGF O +
/ O +
SF O +
signaling O +
plays O +
a O +
role O +
in O +
this O +
process O +
as O +
well O +
as O +
in O +
tumors O +
that O +
express O +
both O +
epithelial O +
and O +
mesenchymal O +
markers O +
. O +

Additional O +
tests O +
of O +
interest O +
to O +
the O +
dermatologist O +
. O +

The O +
carcinoid O +
syndrome O +
and O +
its O +
clinical O +
manifestations O +
have O +
been O +
discussed O +
. O +

The O +
standard O +
laboratory O +
test O +
for O +
making O +
that O +
diagnosis O +
is O +
urinary O +
5 O +
- O +
HIAA O +
levels O +
but O +
newer O +
, O +
more O +
sensitive O +
tests O +
may O +
also O +
be O +
available O +
. O +

Molecular O +
mediators O +
of O +
interactions O +
with O +
extracellular O +
matrix O +
components O +
in O +
metastasis O +
and O +
angiogenesis O +
. O +

Metastasis O +
and O +
tumor O +
angiogenesis O +
are O +
invasive O +
phenomena O +
and O +
share O +
many O +
common O +
properties O +
at O +
the O +
physiological O +
level O +
and O +
some O +
similarities O +
at O +
the O +
molecular O +
level O +
. O +

Each O +
consists O +
of O +
repetitive O +
cycles O +
of O +
interaction O +
with O +
adjacent O +
extracellular O +
matrix O +
components O +
by O +
mediating O +
cellular O +
adhesion O +
, O +
matrix O +
dissolution O +
, O +
and O +
cellular O +
motility O +
to O +
achieve O +
metastasis O +
of O +
cancer O +
cells O +
or O +
neovascularization O +
of O +
tumors O +
. O +

Molecular O +
factors O +
which O +
implement O +
this O +
triad O +
of O +
events O +
are O +
reviewed O +
, O +
as O +
are O +
several O +
signal O +
transduction O +
components O +
which O +
may O +
regulate O +
them O +
. O +

Some O +
potentially O +
promising O +
prognostic O +
, O +
diagnostic O +
, O +
and O +
therapeutic O +
modalities O +
for O +
tumor O +
angiogenesis O +
and O +
metastatic O +
disease O +
are O +
also O +
discussed O +
. O +

Enhanced O +
DNA O +
- O +
binding O +
activity O +
of O +
a O +
Stat3 O +
- O +
related O +
protein O +
in O +
cells O +
transformed O +
by O +
the O +
Src O +
oncoprotein O +
. O +

Cytokines O +
and O +
growth O +
factors O +
induce O +
tyrosine O +
phosphorylation O +
of O +
signal O +
transducers O +
and O +
activators O +
of O +
transcription O +
( O +
STATs O +
) O +
that O +
directly O +
activate O +
gene O +
expression O +
. O +

Cells O +
stably O +
transformed O +
by O +
the O +
Src O +
oncogene O +
tyrosine O +
kinase O +
were O +
examined O +
for O +
STAT O +
protein O +
activation O +
. O +

Assays O +
of O +
electrophoretic O +
mobility O +
, O +
DNA O +
- O +
binding O +
specificity O +
, O +
and O +
antigenicity O +
indicated O +
that O +
Stat3 O +
or O +
a O +
closely O +
related O +
STAT O +
family O +
member O +
was O +
constitutively O +
activated O +
by O +
the O +
Src O +
oncoprotein O +
. O +

Induction O +
of O +
this O +
DNA O +
- O +
binding O +
activity O +
was O +
accompanied O +
by O +
tyrosine O +
phosphorylation O +
of O +
Stat3 O +
and O +
correlated O +
with O +
Src O +
transformation O +
. O +

These O +
findings O +
demonstrate O +
that O +
Src O +
can O +
activate O +
STAT O +
signaling O +
pathways O +
and O +
raise O +
the O +
possibility O +
that O +
Stat3 O +
contributes O +
to O +
oncogenesis O +
by O +
Src O +
. O +

Ultraviolet O +
B O +
irradiation O +
promotes O +
tumorigenic O +
and O +
metastatic O +
properties O +
in O +
primary O +
cutaneous O +
melanoma O +
via O +
induction O +
of O +
interleukin O +
8 O +
. O +

UV O +
radiation O +
has O +
been O +
shown O +
to O +
play O +
a O +
role O +
in O +
the O +
initiation O +
of O +
human O +
cutaneous O +
melanoma O +
, O +
but O +
its O +
role O +
in O +
the O +
development O +
of O +
malignant O +
melanoma O +
to O +
the O +
metastatic O +
state O +
is O +
not O +
very O +
well O +
defined O +
. O +

Although O +
previous O +
studies O +
have O +
concentrated O +
on O +
the O +
effect O +
of O +
UV O +
- O +
B O +
on O +
the O +
host O +
immune O +
response O +
, O +
the O +
effect O +
of O +
UV O +
- O +
B O +
on O +
the O +
tumor O +
cells O +
was O +
not O +
elucidated O +
. O +

Here O +
we O +
show O +
that O +
UV O +
- O +
B O +
can O +
induce O +
interleukin O +
8 O +
( O +
IL O +
- O +
8 O +
) O +
mRNA O +
and O +
protein O +
secretion O +
in O +
human O +
cutaneous O +
melanoma O +
with O +
negligible O +
expression O +
of O +
IL O +
- O +
8 O +
. O +

UV O +
- O +
B O +
- O +
induced O +
IL O +
- O +
8 O +
was O +
constitutively O +
expressed O +
60 O +
days O +
after O +
irradiation O +
in O +
tumors O +
implanted O +
in O +
mice O +
. O +

Induction O +
of O +
IL O +
- O +
8 O +
was O +
UV O +
- O +
B O +
dose O +
dependent O +
and O +
blocked O +
by O +
cyclohexamide O +
, O +
indicating O +
that O +
de O +
novo O +
protein O +
synthesis O +
is O +
required O +
for O +
its O +
expression O +
. O +

The O +
UV O +
- O +
irradiated O +
cells O +
demonstrated O +
enhanced O +
tumorigenicity O +
and O +
metastatic O +
potential O +
in O +
nude O +
mice O +
. O +

The O +
increase O +
in O +
tumorigenicity O +
and O +
metastatic O +
ability O +
could O +
be O +
explained O +
by O +
the O +
increase O +
in O +
Mr O +
72 O +
, O +
000 O +
type O +
IV O +
collagenase O +
activity O +
and O +
angiogenesis O +
attributed O +
to O +
the O +
induction O +
of O +
IL O +
- O +
8 O +
after O +
irradiation O +
. O +

The O +
acquisition O +
of O +
the O +
metastatic O +
phenotype O +
induced O +
by O +
UV O +
- O +
B O +
could O +
not O +
be O +
attributed O +
to O +
abnormalities O +
in O +
the O +
p53 O +
or O +
MTS O +
- O +
1 O +
( O +
p16INK4 O +
) O +
genes O +
. O +

To O +
the O +
best O +
of O +
our O +
knowledge O +
, O +
this O +
is O +
the O +
first O +
report O +
to O +
show O +
that O +
UV O +
- O +
B O +
can O +
increase O +
the O +
aggressiveness O +
of O +
human O +
cutaneous O +
melanoma O +
for O +
growth O +
and O +
metastasis O +
. O +

Suppressed O +
transformation O +
and O +
induced O +
differentiation O +
of O +
HER O +
- O +
2 O +
/ O +
neu O +
- O +
overexpressing O +
breast O +
cancer O +
cells O +
by O +
emodin O +
. O +

The O +
amplification O +
and O +
overexpression O +
of O +
the O +
HER O +
- O +
2 O +
/ O +
neu O +
proto O +
- O +
oncogene O +
, O +
which O +
encodes O +
the O +
tyrosine O +
kinase O +
receptor O +
p185neu O +
, O +
have O +
been O +
observed O +
frequently O +
in O +
tumors O +
from O +
human O +
breast O +
cancer O +
patients O +
and O +
are O +
correlated O +
with O +
poor O +
prognosis O +
. O +

To O +
explore O +
the O +
potential O +
of O +
chemotherapy O +
directed O +
at O +
the O +
tyrosine O +
kinase O +
of O +
p185neu O +
, O +
we O +
have O +
found O +
that O +
emodin O +
( O +
3 O +
- O +
methyl O +
- O +
1 O +
, O +
6 O +
, O +
8 O +
- O +
trihydroxyanthraquinone O +
) O +
, O +
a O +
tyrosine O +
kinase O +
inhibitor O +
, O +
suppresses O +
autophosphorylation O +
and O +
transphosphorylation O +
activities O +
of O +
HER O +
- O +
2 O +
/ O +
neu O +
tyrosine O +
kinase O +
, O +
resulting O +
in O +
tyrosine O +
hypophosphorylation O +
of O +
p185neu O +
in O +
HER O +
- O +
2 O +
/ O +
neu O +
- O +
overexpressing O +
breast O +
cancer O +
cells O +
. O +

Emodin O +
, O +
at O +
a O +
40 O +
- O +
microM O +
concentration O +
, O +
which O +
repressed O +
tyrosine O +
kinase O +
of O +
p185neu O +
, O +
efficiently O +
inhibited O +
both O +
anchorage O +
- O +
dependent O +
and O +
anchorage O +
- O +
independent O +
growth O +
of O +
HER O +
- O +
2 O +
/ O +
neu O +
- O +
overexpressing O +
breast O +
cancer O +
cells O +
. O +

However O +
, O +
the O +
inhibition O +
was O +
much O +
less O +
effective O +
for O +
those O +
cells O +
expressing O +
basal O +
levels O +
of O +
p185neu O +
under O +
the O +
same O +
conditions O +
. O +

Emodin O +
also O +
induced O +
differentiation O +
of O +
HER O +
- O +
2 O +
/ O +
neu O +
- O +
overexpressing O +
breast O +
cancer O +
cells O +
by O +
exhibiting O +
a O +
morphological O +
maturation O +
property O +
of O +
large O +
lacy O +
nuclei O +
surrounded O +
by O +
sizable O +
flat O +
cytoplasm O +
and O +
by O +
showing O +
a O +
measurable O +
production O +
of O +
large O +
lipid O +
droplets O +
, O +
which O +
is O +
a O +
marker O +
of O +
mature O +
breast O +
cells O +
. O +

Therefore O +
, O +
our O +
results O +
indicate O +
that O +
emodin O +
inhibits O +
HER O +
- O +
2 O +
/ O +
neu O +
tyrosine O +
kinase O +
activity O +
and O +
preferentially O +
suppresses O +
growth O +
and O +
induces O +
differentiation O +
of O +
HER O +
- O +
2 O +
/ O +
neu O +
- O +
overexpressing O +
cancer O +
cells O +
. O +

These O +
results O +
may O +
have O +
chemotherapeutic O +
implications O +
for O +
using O +
emodin O +
to O +
target O +
HER O +
- O +
2 O +
/ O +
neu O +
- O +
overexpressing O +
cancer O +
cells O +
. O +

The O +
LHRH O +
pulse O +
generator O +
: O +
a O +
mediobasal O +
hypothalamic O +
location O +
. O +

The O +
location O +
and O +
mechanism O +
of O +
LHRH O +
pulse O +
generator O +
are O +
discussed O +
based O +
on O +
our O +
series O +
of O +
experiments O +
. O +

Suckling O +
stimulus O +
is O +
a O +
novel O +
stimulus O +
that O +
inhibits O +
LH O +
pulses O +
without O +
any O +
cooperation O +
from O +
ovarian O +
steroids O +
, O +
unlike O +
other O +
stimuli O +
such O +
as O +
stress O +
, O +
photoperiod O +
etc O +
. O +

It O +
is O +
directly O +
involved O +
in O +
suppressing O +
the O +
activity O +
of O +
the O +
LHRH O +
pulse O +
generator O +
. O +

The O +
information O +
from O +
teats O +
suckled O +
by O +
pups O +
or O +
babies O +
is O +
conveyed O +
dorsally O +
to O +
the O +
mediobasal O +
hypothalamus O +
( O +
MBH O +
) O +
, O +
where O +
the O +
LHRH O +
pulse O +
generator O +
may O +
be O +
located O +
. O +

Experiments O +
using O +
various O +
types O +
of O +
deafferentation O +
and O +
fetal O +
brain O +
tissue O +
transplantation O +
confirmed O +
that O +
the O +
LHRH O +
pulse O +
generator O +
is O +
located O +
in O +
the O +
MBH O +
and O +
suggested O +
that O +
LHRH O +
pulse O +
generator O +
consists O +
of O +
nonLHRH O +
neurons O +
. O +

Endogenous O +
excitatory O +
amino O +
acid O +
is O +
one O +
of O +
the O +
possible O +
neurotransmitters O +
that O +
regulate O +
LHRH O +
release O +
at O +
the O +
nerve O +
terminal O +
in O +
ME O +
. O +

Bicistronic O +
retroviral O +
vector O +
reveals O +
capacity O +
of O +
v O +
- O +
erbA O +
to O +
induce O +
erythroleukemia O +
and O +
to O +
co O +
- O +
operate O +
with O +
v O +
- O +
myb O +
. O +

Previous O +
studies O +
have O +
shown O +
that O +
v O +
- O +
erbA O +
and O +
v O +
- O +
myb O +
can O +
induce O +
the O +
proliferation O +
of O +
avian O +
erythroid O +
cells O +
in O +
culture O +
. O +

To O +
study O +
the O +
combined O +
effects O +
of O +
v O +
- O +
erbA O +
and O +
v O +
- O +
myb O +
, O +
the O +
two O +
oncogenes O +
were O +
engineered O +
into O +
a O +
retrovirus O +
bicistronic O +
vector O +
with O +
an O +
internal O +
ribosomal O +
entry O +
site O +
( O +
IRES O +
) O +
or O +
into O +
a O +
vector O +
with O +
a O +
splice O +
acceptor O +
( O +
SPL O +
) O +
. O +

This O +
allowed O +
coexpression O +
of O +
the O +
two O +
proteins O +
and O +
a O +
comparison O +
with O +
the O +
same O +
vector O +
containing O +
either O +
v O +
- O +
erbA O +
or O +
v O +
- O +
myb O +
only O +
. O +

Both O +
the O +
erbA O +
IRES O +
and O +
the O +
erbA O +
/ O +
myb O +
IRES O +
virus O +
constructs O +
transformed O +
erythroid O +
cells O +
after O +
infection O +
of O +
bone O +
marrow O +
or O +
blastoderm O +
cultures O +
. O +

The O +
erbA O +
/ O +
myb O +
IRES O +
virus O +
exhibited O +
a O +
5 O +
- O +
10 O +
- O +
fold O +
higher O +
transformed O +
colony O +
forming O +
efficiency O +
than O +
the O +
erbA O +
IRES O +
virus O +
in O +
the O +
blastoderm O +
assay O +
. O +

Surprisingly O +
, O +
when O +
injected O +
into O +
chicken O +
embryos O +
in O +
the O +
presence O +
of O +
helper O +
virus O +
, O +
both O +
viruses O +
induced O +
an O +
erythroleukemia O +
in O +
about O +
half O +
of O +
the O +
animals O +
. O +

In O +
contrast O +
, O +
no O +
leukemia O +
was O +
observed O +
with O +
a O +
myb O +
IRES O +
virus O +
, O +
with O +
spliced O +
vectors O +
containing O +
v O +
- O +
erbA O +
alone O +
or O +
v O +
- O +
erbA O +
in O +
combination O +
with O +
v O +
- O +
myb O +
, O +
nor O +
with O +
erbA O +
IRES O +
and O +
erbA O +
/ O +
myb O +
IRES O +
viruses O +
produced O +
in O +
the O +
absence O +
of O +
helper O +
virus O +
. O +

The O +
average O +
latency O +
of O +
leukemia O +
induction O +
was O +
shorter O +
for O +
the O +
erbA O +
/ O +
myb O +
IRES O +
virus O +
( O +
3 O +
. O +
5 O +
weeks O +
) O +
than O +
for O +
the O +
erbA O +
IRES O +
virus O +
( O +
5 O +
weeks O +
) O +
. O +

Nevertheless O +
, O +
for O +
both O +
viruses O +
the O +
leukemic O +
blasts O +
retained O +
full O +
factor O +
dependence O +
for O +
growth O +
. O +

These O +
results O +
show O +
that O +
v O +
- O +
erbA O +
is O +
capable O +
of O +
inducing O +
an O +
erythroleukemia O +
when O +
expressed O +
by O +
a O +
high O +
titer O +
bicistronic O +
retrovirus O +
under O +
conditions O +
of O +
virus O +
spreading O +
and O +
that O +
its O +
in O +
vitro O +
and O +
in O +
vivo O +
transforming O +
potential O +
can O +
be O +
enhanced O +
by O +
v O +
- O +
myb O +
. O +

Cancer O +
metastasis O +
: O +
negative O +
regulation O +
by O +
an O +
invasion O +
- O +
suppressor O +
complex O +
. O +

Invasion O +
is O +
the O +
hallmark O +
of O +
tumor O +
malignancy O +
. O +

We O +
situate O +
invasion O +
within O +
microecosystems O +
comprising O +
neoplastic O +
cells O +
as O +
well O +
as O +
host O +
cells O +
. O +

Modulation O +
of O +
invasion O +
within O +
such O +
systems O +
is O +
ascribed O +
to O +
balances O +
between O +
promoter O +
and O +
suppressor O +
pathways O +
. O +

The O +
E O +
- O +
cadherin O +
/ O +
alpha O +
- O +
, O +
beta O +
- O +
, O +
gamma O +
- O +
catenin O +
complex O +
has O +
an O +
invasion O +
- O +
suppressor O +
function O +
as O +
evidenced O +
by O +
transfections O +
either O +
with O +
sense O +
cDNA O +
encoding O +
these O +
molecules O +
or O +
with O +
antisense O +
cDNA O +
inhibiting O +
their O +
expression O +
. O +

Loss O +
of O +
heterozygosity O +
at O +
the O +
E O +
- O +
Cadherin O +
( O +
uvo O +
) O +
locus O +
has O +
been O +
reported O +
, O +
but O +
mutations O +
in O +
the O +
E O +
- O +
cadherin O +
gene O +
seem O +
to O +
be O +
rare O +
. O +

Downregulation O +
of O +
E O +
- O +
cadherin O +
occurred O +
at O +
the O +
level O +
of O +
transcription O +
or O +
of O +
mRNA O +
stability O +
. O +

Ex O +
vivo O +
cultures O +
from O +
invasive O +
tumors O +
or O +
metastases O +
produced O +
cells O +
that O +
were O +
homogeneously O +
E O +
- O +
cadherin O +
- O +
positive O +
and O +
noninvasive O +
in O +
vitro O +
. O +

These O +
observations O +
have O +
led O +
to O +
the O +
idea O +
that O +
factors O +
in O +
the O +
host O +
downmodulate O +
the O +
E O +
- O +
cadherin O +
complex O +
and O +
promote O +
invasion O +
most O +
probably O +
in O +
a O +
transient O +
way O +
. O +

VEGF165 O +
expressed O +
by O +
a O +
replication O +
- O +
deficient O +
recombinant O +
adenovirus O +
vector O +
induces O +
angiogenesis O +
in O +
vivo O +
. O +

To O +
evaluate O +
the O +
concept O +
that O +
localized O +
delivery O +
of O +
angiogenic O +
factors O +
via O +
virus O +
- O +
mediated O +
gene O +
transfer O +
may O +
be O +
useful O +
in O +
the O +
treatment O +
of O +
ischemic O +
disorders O +
, O +
the O +
replication O +
- O +
deficient O +
adenovirus O +
( O +
Ad O +
) O +
vector O +
AdCMV O +
. O +
VEGF165 O +
( O +
where O +
CMV O +
is O +
cytomegalovirus O +
and O +
VEGF O +
is O +
vascular O +
endothelial O +
growth O +
factor O +
) O +
containing O +
the O +
cDNA O +
for O +
human O +
VEGF165 O +
, O +
a O +
secreted O +
endothelial O +
cell O +
- O +
specific O +
angiogenic O +
growth O +
factor O +
, O +
was O +
constructed O +
. O +

Human O +
umbilical O +
vein O +
endothelial O +
cells O +
( O +
HUVECs O +
) O +
and O +
rat O +
aorta O +
smooth O +
muscle O +
cells O +
( O +
RASMCs O +
) O +
infected O +
with O +
AdCMV O +
. O +
VEGF165 O +
( O +
5 O +
and O +
20 O +
plaque O +
- O +
forming O +
units O +
[ O +
pfu O +
] O +
per O +
cell O +
) O +
demonstrated O +
VEGF O +
mRNA O +
expression O +
and O +
protein O +
secretion O +
into O +
the O +
supernatant O +
. O +

Furthermore O +
, O +
the O +
conditioned O +
medium O +
from O +
these O +
cells O +
enhanced O +
vascular O +
permeability O +
in O +
vivo O +
. O +

In O +
contrast O +
, O +
neither O +
VEGF O +
mRNA O +
nor O +
secreted O +
protein O +
was O +
found O +
in O +
uninfected O +
HUVECs O +
or O +
RASMCs O +
or O +
in O +
cells O +
infected O +
with O +
the O +
control O +
vector O +
AdCMV O +
. O +
beta O +
gal O +
( O +
where O +
beta O +
gal O +
is O +
beta O +
- O +
galactosidase O +
) O +
. O +

Assessment O +
of O +
starved O +
HUVECs O +
at O +
14 O +
days O +
demonstrated O +
sixfold O +
more O +
cells O +
for O +
AdCMV O +
. O +
VEGF165 O +
- O +
infected O +
HUVECs O +
( O +
20 O +
pfu O +
per O +
cell O +
) O +
than O +
for O +
either O +
infected O +
or O +
uninfected O +
control O +
cells O +
. O +

RASMC O +
proliferation O +
was O +
unaffected O +
by O +
infection O +
with O +
AdCMV O +
. O +
VEGF165 O +
. O +

When O +
plated O +
in O +
2 O +
% O +
serum O +
on O +
dishes O +
precoated O +
with O +
reconstituted O +
basement O +
membrane O +
( O +
Matrigel O +
) O +
, O +
HUVECs O +
infected O +
with O +
AdCMV O +
. O +
VEGF165 O +
( O +
20 O +
pfu O +
per O +
cell O +
) O +
differentiated O +
into O +
capillary O +
- O +
like O +
structures O +
. O +

Under O +
similar O +
conditions O +
, O +
both O +
uninfected O +
HUVECs O +
and O +
HUVECs O +
infected O +
with O +
AdCMV O +
. O +
beta O +
gal O +
did O +
not O +
differentiate O +
. O +

To O +
evaluate O +
the O +
ability O +
of O +
AdCMV O +
. O +
VEGF165 O +
to O +
function O +
in O +
vivo O +
, O +
either O +
AdCMV O +
. O +

VEGF165 O +
or O +
AdCMV O +
. O +
beta O +
gal O +
( O +
2 O +
x O +
10 O +
( O +
10 O +
) O +
pfu O +
) O +
was O +
resuspended O +
in O +
0 O +
. O +
5 O +
mL O +
Matrigel O +
and O +
injected O +
subcutaneously O +
into O +
mice O +
. O +

Immunohistochemical O +
staining O +
demonstrated O +
VEGF O +
in O +
the O +
tissues O +
surrounding O +
the O +
Matrigel O +
plugs O +
containing O +
AdCMV O +
. O +
VEGF165 O +
up O +
to O +
3 O +
weeks O +
after O +
injection O +
, O +
whereas O +
no O +
VEGF O +
was O +
found O +
in O +
the O +
control O +
plugs O +
with O +
AdCMV O +
. O +
beta O +
gal O +
. O +

Two O +
weeks O +
after O +
injection O +
, O +
there O +
was O +
histological O +
evidence O +
of O +
neovascularization O +
in O +
the O +
tissues O +
surrounding O +
the O +
Matrigel O +
containing O +
AdCMV O +
. O +
VEGF165 O +
, O +
whereas O +
no O +
significant O +
angiogenesis O +
was O +
observed O +
in O +
response O +
to O +
AdCMV O +
. O +
beta O +
gal O +
. O +

Furthermore O +
, O +
the O +
Matrigel O +
plugs O +
with O +
AdCMV O +
. O +
VEGF165 O +
demonstrated O +
hemoglobin O +
content O +
fourfold O +
higher O +
than O +
the O +
plugs O +
with O +
AdCMV O +
. O +
beta O +
gal O +
. O +

Together O +
, O +
these O +
in O +
vitro O +
and O +
in O +
vivo O +
studies O +
are O +
consistent O +
with O +
the O +
concept O +
that O +
Ad O +
vectors O +
may O +
provide O +
a O +
useful O +
strategy O +
for O +
efficient O +
local O +
delivery O +
of O +
VEGF165 O +
in O +
the O +
treatment O +
of O +
ischemic O +
diseases O +
. O +

Identification O +
of O +
NAB1 O +
, O +
a O +
repressor O +
of O +
NGFI O +
- O +
A O +
- O +
and O +
Krox20 O +
- O +
mediated O +
transcription O +
. O +

NGFI O +
- O +
A O +
( O +
also O +
called O +
Egr1 O +
, O +
Zif268 O +
, O +
or O +
Krox24 O +
) O +
and O +
the O +
closely O +
related O +
proteins O +
Krox20 O +
, O +
NGFI O +
- O +
C O +
, O +
and O +
Egr3 O +
are O +
zinc O +
- O +
finger O +
transcription O +
factors O +
encoded O +
by O +
immediate O +
- O +
early O +
genes O +
which O +
are O +
induced O +
by O +
a O +
wide O +
variety O +
of O +
extracellular O +
stimuli O +
. O +

NGFI O +
- O +
A O +
has O +
been O +
implicated O +
in O +
cell O +
proliferation O +
, O +
macrophage O +
differentiation O +
, O +
synaptic O +
activation O +
, O +
and O +
long O +
- O +
term O +
potentiation O +
, O +
whereas O +
Krox20 O +
is O +
critical O +
for O +
proper O +
hindbrain O +
segmentation O +
and O +
peripheral O +
nerve O +
myelination O +
. O +

In O +
previous O +
work O +
, O +
a O +
structure O +
/ O +
function O +
analysis O +
of O +
NGFI O +
- O +
A O +
revealed O +
a O +
34 O +
- O +
aa O +
inhibitory O +
domain O +
that O +
was O +
hypothesized O +
to O +
be O +
the O +
target O +
of O +
a O +
cellular O +
factor O +
that O +
represses O +
NGFI O +
- O +
A O +
transcriptional O +
activity O +
. O +

Using O +
the O +
yeast O +
two O +
- O +
hybrid O +
system O +
, O +
we O +
have O +
isolated O +
a O +
cDNA O +
clone O +
which O +
encodes O +
a O +
protein O +
that O +
interacts O +
with O +
this O +
inhibitory O +
domain O +
and O +
inhibits O +
the O +
ability O +
of O +
NGFI O +
- O +
A O +
to O +
activate O +
transcription O +
. O +

This O +
NGFI O +
- O +
A O +
- O +
binding O +
protein O +
, O +
NAB1 O +
, O +
is O +
a O +
570 O +
- O +
aa O +
nuclear O +
protein O +
that O +
bears O +
no O +
obvious O +
sequence O +
homology O +
to O +
known O +
proteins O +
. O +

NAB1 O +
also O +
represses O +
Krox20 O +
activity O +
, O +
but O +
it O +
does O +
not O +
influence O +
Egr3 O +
or O +
NGFI O +
- O +
G O +
, O +
thus O +
providing O +
a O +
mechanism O +
for O +
the O +
differential O +
regulation O +
of O +
this O +
family O +
of O +
immediate O +
- O +
early O +
transcription O +
factors O +
. O +

Metastatic O +
NIH B-CellLine +
3T3 I-CellLine +
x O +
LTA B-CellLine +
cell O +
hybrids O +
express O +
72 O +
kDa O +
type O +
IV O +
collagenase O +
. O +

We O +
previously O +
reported O +
that O +
the O +
murine O +
fibroblast O +
cell O +
line O +
LTA B-CellLine +
is O +
tumorigenic O +
but O +
non O +
- O +
metastatic O +
, O +
and O +
is O +
non O +
- O +
responsive O +
to O +
a O +
transfected O +
H O +
- O +
ras O +
oncogene O +
. O +

In O +
contrast O +
, O +
NIH B-CellLine +
3T3 I-CellLine +
cells O +
are O +
non O +
- O +
tumorigenic O +
but O +
are O +
ras O +
- O +
responsive O +
and O +
become O +
metastatic O +
when O +
transfected O +
with O +
ras O +
. O +

Somatic O +
cell O +
hybrids O +
between O +
LTA B-CellLine +
and O +
NIH B-CellLine +
3T3 I-CellLine +
cells O +
are O +
tumorigenic O +
, O +
metastatic O +
and O +
ras O +
- O +
responsive O +
. O +

Here O +
we O +
examined O +
expression O +
of O +
type O +
IV O +
collagenases O +
in O +
parental O +
LTA B-CellLine +
and O +
NIH B-CellLine +
3T3 I-CellLine +
cells O +
( O +
with O +
and O +
without O +
ras O +
) O +
and O +
four O +
metastatic O +
LTA B-CellLine +
x O +
NIH B-CellLine +
3T3 I-CellLine +
hybrids O +
( O +
also O +
with O +
and O +
without O +
ras O +
) O +
. O +

Parental O +
NIH B-CellLine +
3T3 I-CellLine +
- O +
derived O +
cells O +
had O +
both O +
72 O +
kDa O +
and O +
92 O +
kDa O +
gelatinase O +
activities O +
, O +
and O +
LTA B-CellLine +
- O +
derived O +
cells O +
had O +
either O +
aberrantly O +
sized O +
approximately O +
90 O +
kDa O +
activity O +
alone O +
or O +
neither O +
enzyme O +
activity O +
. O +

All O +
four O +
metastatic O +
hybrids O +
expressed O +
60 O +
- O +
72 O +
kDa O +
gelatinase O +
activity O +
, O +
while O +
three O +
of O +
them O +
also O +
had O +
92 O +
kDa O +
activity O +
and O +
one O +
had O +
only O +
minimal O +
92 O +
kDa O +
activity O +
. O +

Thus O +
the O +
metastatic O +
phenotype O +
of O +
the O +
hybrids O +
was O +
associated O +
with O +
expression O +
of O +
72 O +
kDa O +
gelatinase O +
. O +

Levels O +
of O +
RNA O +
for O +
tissue O +
inhibitors O +
of O +
metalloproteinases O +
( O +
TIMP O +
- O +
1 O +
, O +
TIMP O +
- O +
2 O +
) O +
were O +
relatively O +
constant O +
, O +
suggesting O +
independent O +
regulation O +
of O +
type O +
IV O +
collagenases O +
and O +
their O +
inhibitors O +
. O +

Southern O +
blotting O +
and O +
probing O +
with O +
PCR O +
- O +
synthesized O +
cDNA O +
fragments O +
of O +
the O +
mouse O +
72 O +
kDa O +
type O +
IV O +
collagenase O +
gene O +
showed O +
that O +
this O +
gene O +
was O +
present O +
in O +
all O +
cells O +
although O +
the O +
structure O +
of O +
this O +
gene O +
in O +
one O +
of O +
the O +
three O +
LTA B-CellLine +
cell O +
lines O +
differed O +
from O +
that O +
of O +
the O +
other O +
cells O +
. O +

Our O +
results O +
suggest O +
that O +
a O +
key O +
change O +
in O +
the O +
metastatic O +
hybrids O +
, O +
relative O +
to O +
non O +
- O +
metastatic O +
parental O +
LTA B-CellLine +
cells O +
, O +
is O +
induction O +
of O +
expression O +
of O +
72 O +
kDa O +
type O +
IV O +
collagenase O +
. O +

Central O +
nervous O +
system O +
infection O +
with O +
Eikenella O +
corrodens O +
: O +
report O +
of O +
two O +
cases O +
. O +

Two O +
cases O +
of O +
central O +
nervous O +
system O +
infections O +
from O +
which O +
E O +
. O +
corrodens O +
has O +
been O +
isolated O +
are O +
reported O +
. O +

The O +
portals O +
of O +
entry O +
, O +
clinical O +
course O +
, O +
and O +
antimicrobial O +
responses O +
conform O +
to O +
other O +
reports O +
in O +
the O +
literature O +
. O +

The O +
importance O +
of O +
obtaining O +
careful O +
anaerobic O +
cultures O +
is O +
emphasized O +
. O +

Neoplastic O +
progression O +
of O +
human O +
colorectal O +
cancer O +
is O +
associated O +
with O +
overexpression O +
of O +
the O +
stromelysin O +
- O +
3 O +
and O +
BM O +
- O +
40 O +
/ O +
SPARC O +
genes O +
. O +

The O +
interaction O +
of O +
neoplastic O +
cells O +
with O +
the O +
extracellular O +
matrix O +
is O +
a O +
critical O +
event O +
for O +
the O +
initiation O +
of O +
cancer O +
invasion O +
and O +
metastasis O +
. O +

This O +
study O +
was O +
designed O +
to O +
evaluate O +
the O +
potential O +
implication O +
of O +
stromelysin O +
- O +
3 O +
( O +
ST3 O +
) O +
, O +
a O +
newly O +
identified O +
member O +
of O +
the O +
matrix O +
- O +
degrading O +
metalloproteinase O +
family O +
, O +
and O +
of O +
BM O +
- O +
40 O +
/ O +
SPARC O +
, O +
a O +
glycoprotein O +
associated O +
with O +
the O +
extracellular O +
matrix O +
, O +
during O +
the O +
progression O +
of O +
human O +
colorectal O +
cancers O +
. O +

We O +
analyzed O +
the O +
relative O +
abundance O +
of O +
ST3 O +
and O +
BM O +
- O +
40 O +
/ O +
SPARC O +
transcripts O +
by O +
Northern O +
blot O +
, O +
and O +
their O +
distribution O +
by O +
in O +
situ O +
hybridization O +
, O +
in O +
normal O +
mucosa O +
, O +
benign O +
adenomas O +
, O +
and O +
primary O +
colorectal O +
adenocarcinomas O +
and O +
their O +
liver O +
metastases O +
. O +

The O +
ST3 O +
and O +
BM O +
- O +
40 O +
/ O +
SPARC O +
transcripts O +
were O +
overexpressed O +
in O +
primary O +
colorectal O +
cancers O +
and O +
their O +
liver O +
metastases O +
compared O +
to O +
non O +
- O +
neoplastic O +
mucosa O +
. O +

These O +
transcripts O +
were O +
localized O +
in O +
stromal O +
fibroblasts O +
adjacent O +
to O +
the O +
neoplastic O +
foci O +
. O +

Overexpression O +
of O +
ST3 O +
correlated O +
with O +
the O +
progression O +
of O +
human O +
colorectal O +
tumors O +
toward O +
local O +
invasion O +
and O +
liver O +
metastasis O +
. O +

Induction O +
of O +
these O +
genes O +
also O +
occurred O +
in O +
diverticulitis O +
and O +
digestive O +
neoplasms O +
such O +
as O +
gastric O +
and O +
esophageal O +
carcinomas O +
. O +

Comparative O +
immunohistochemical O +
study O +
of O +
primary O +
and O +
metastatic O +
carcinomas O +
of O +
the O +
liver O +
. O +

Distinguishing O +
primary O +
hepatocellular O +
carcinoma O +
( O +
HCC O +
) O +
from O +
metastatic O +
carcinomas O +
to O +
the O +
liver O +
is O +
often O +
difficult O +
, O +
if O +
not O +
impossible O +
, O +
particularly O +
in O +
needle O +
biopsy O +
and O +
fine O +
- O +
needle O +
aspiration O +
specimens O +
. O +

In O +
an O +
attempt O +
to O +
identify O +
a O +
specific O +
immunohistochemical O +
profile O +
that O +
would O +
distinguish O +
HCC O +
from O +
metastatic O +
carcinomas O +
, O +
we O +
studied O +
56 O +
HCCs O +
, O +
8 O +
cholangiocarcinomas O +
, O +
and O +
24 O +
metastatic O +
adenocarcinomas O +
with O +
monoclonal O +
antibodies O +
to O +
alpha O +
- O +
fetoprotein O +
( O +
AFP O +
) O +
, O +
keratin O +
( O +
AE1 O +
, O +
AE3 O +
, O +
and O +
CAM5 O +
. O +
2 O +
) O +
, O +
Leu O +
- O +
M1 O +
, O +
human O +
milk O +
fat O +
globule O +
( O +
HMFG O +
- O +
2 O +
) O +
, O +
tumor O +
- O +
associated O +
glycoprotein O +
- O +
72 O +
( O +
B72 O +
. O +
3 O +
) O +
, O +
epithelial O +
specific O +
membrane O +
antigen O +
( O +
Ber O +
- O +
EP4 O +
) O +
, O +
and O +
BCA O +
- O +
225 O +
( O +
CU O +
- O +
18 O +
) O +
. O +

Both O +
monoclonal O +
and O +
polyclonal O +
( O +
mCEA O +
and O +
pCEA O +
) O +
antibodies O +
to O +
carcinoembryonic O +
antigen O +
also O +
were O +
used O +
. O +

Metastatic O +
adenocarcinomas O +
were O +
often O +
positive O +
for O +
CU O +
- O +
18 O +
( O +
71 O +
% O +
) O +
, O +
Leu O +
- O +
M1 O +
( O +
75 O +
% O +
) O +
, O +
B72 O +
. O +
3 O +
( O +
50 O +
% O +
) O +
, O +
HMFG O +
- O +
2 O +
( O +
67 O +
% O +
) O +
, O +
Ber O +
- O +
EP4 O +
( O +
83 O +
% O +
) O +
and O +
mCEA O +
( O +
71 O +
% O +
) O +
. O +

Using O +
these O +
antibodies O +
, O +
the O +
frequency O +
of O +
positivity O +
for O +
HCC O +
was O +
9 O +
% O +
, O +
16 O +
% O +
, O +
11 O +
% O +
, O +
20 O +
% O +
, O +
36 O +
% O +
, O +
and O +
11 O +
% O +
, O +
respectively O +
. O +

CU O +
- O +
18 O +
was O +
the O +
only O +
monoclonal O +
antibody O +
in O +
which O +
there O +
was O +
a O +
significant O +
difference O +
in O +
positive O +
rates O +
between O +
HCC O +
and O +
metastatic O +
adenocarcinomas O +
. O +

Most O +
HCCs O +
( O +
71 O +
% O +
) O +
revealed O +
a O +
bile O +
canalicular O +
staining O +
pattern O +
with O +
pCEA O +
. O +

Because O +
this O +
staining O +
pattern O +
was O +
absent O +
in O +
metastatic O +
carcinomas O +
, O +
pCEA O +
appears O +
to O +
be O +
useful O +
in O +
confirming O +
a O +
diagnosis O +
of O +
HCC O +
. O +

AE1 O +
, O +
AE3 O +
and O +
CAM5 O +
. O +
2 O +
antibodies O +
were O +
not O +
useful O +
in O +
distinguishing O +
HCC O +
from O +
metastatic O +
carcinomas O +
. O +

Each O +
cholangiocarcinoma O +
shared O +
a O +
staining O +
profile O +
similar O +
to O +
that O +
of O +
metastatic O +
carcinomas O +
. O +

Heparin O +
- O +
steroid O +
conjugates O +
: O +
new O +
angiogenesis O +
inhibitors O +
with O +
antitumor O +
activity O +
in O +
mice O +
. O +

Inhibitors O +
of O +
angiogenesis O +
hold O +
potential O +
in O +
the O +
treatment O +
of O +
cancer O +
and O +
other O +
diseases O +
where O +
the O +
disease O +
is O +
caused O +
or O +
maintained O +
by O +
the O +
inappropriate O +
growth O +
of O +
blood O +
vessels O +
. O +

In O +
the O +
present O +
study O +
, O +
a O +
novel O +
inhibitor O +
of O +
angiogenesis O +
was O +
synthesized O +
by O +
covalently O +
linking O +
a O +
nonanticoagulating O +
derivative O +
of O +
heparin O +
, O +
heparin O +
adipic O +
hydrazide O +
( O +
HAH O +
) O +
, O +
by O +
an O +
acid O +
- O +
labile O +
bond O +
to O +
the O +
antiangiogenic O +
steroid O +
, O +
cortisol O +
. O +

The O +
rationale O +
was O +
that O +
the O +
heparin O +
derivative O +
, O +
which O +
binds O +
to O +
sulfated O +
polyanion O +
receptors O +
on O +
endothelial O +
cells O +
, O +
should O +
concentrate O +
the O +
steroid O +
on O +
the O +
surface O +
of O +
vascular O +
endothelial O +
cells O +
. O +

Endocytosis O +
of O +
the O +
conjugate O +
and O +
decomposition O +
of O +
the O +
acid O +
- O +
labile O +
linkage O +
inside O +
lysosomes O +
and O +
other O +
acidic O +
intracellular O +
compartments O +
should O +
then O +
lead O +
to O +
release O +
of O +
the O +
cortisol O +
and O +
expression O +
of O +
its O +
antiproliferative O +
activity O +
. O +

Analysis O +
of O +
the O +
stability O +
of O +
HAH O +
- O +
cortisol O +
showed O +
that O +
it O +
was O +
stable O +
at O +
pH O +
7 O +
. O +
4 O +
and O +
broke O +
down O +
rapidly O +
( O +
t1 O +
/ O +
2 O +
15 O +
min O +
) O +
at O +
pH O +
4 O +
. O +
8 O +
at O +
37 O +
degrees O +
C O +
. O +

Treatment O +
of O +
murine O +
pulmonary O +
capillary O +
endothelial O +
cells O +
with O +
HAH O +
- O +
cortisol O +
at O +
10 O +
( O +
- O +
5 O +
) O +
M O +
( O +
with O +
respect O +
to O +
cortisol O +
) O +
suppressed O +
their O +
DNA O +
synthesis O +
by O +
50 O +
% O +
and O +
inhibited O +
their O +
migration O +
into O +
wounded O +
areas O +
of O +
confluent O +
monolayers O +
. O +

HAH O +
- O +
cortisol O +
at O +
10 O +
( O +
- O +
4 O +
) O +
M O +
( O +
with O +
respect O +
to O +
cortisol O +
) O +
did O +
not O +
suppress O +
the O +
DNA O +
synthesis O +
of O +
Lewis O +
lung O +
carcinoma O +
cells O +
. O +

Daily O +
i O +
. O +
p O +
. O +
injections O +
of O +
HAH O +
- O +
cortisol O +
into O +
mice O +
bearing O +
s O +
. O +
c O +
. O +
sponge O +
implants O +
retarded O +
vascularization O +
of O +
the O +
sponge O +
, O +
and O +
injections O +
directly O +
into O +
the O +
sponge O +
abolished O +
vascularization O +
for O +
as O +
long O +
as O +
the O +
injections O +
were O +
continued O +
. O +

Daily O +
i O +
. O +
v O +
. O +
injections O +
of O +
HAH O +
- O +
cortisol O +
at O +
doses O +
causing O +
no O +
apparent O +
toxicity O +
retarded O +
the O +
growth O +
of O +
solid O +
s O +
. O +
c O +
. O +

Lewis O +
lung O +
carcinomas O +
in O +
mice O +
by O +
up O +
to O +
65 O +
% O +
. O +

In O +
all O +
of O +
these O +
assays O +
, O +
equivalent O +
treatments O +
with O +
a O +
mixture O +
of O +
the O +
HAH O +
plus O +
cortisol O +
was O +
significantly O +
less O +
effective O +
. O +

The O +
antiproliferative O +
effect O +
of O +
HAH O +
- O +
cortisol O +
on O +
endothelial O +
cells O +
appeared O +
independent O +
of O +
the O +
glucocorticoid O +
activity O +
of O +
the O +
steroid O +
since O +
HAH O +
conjugated O +
to O +
5 O +
beta O +
- O +
pregnane O +
- O +
3 O +
alpha O +
, O +
17 O +
alpha O +
, O +
21 O +
- O +
triol O +
- O +
20 O +
- O +
one O +
, O +
a O +
steroid O +
lacking O +
glucocorticoid O +
or O +
mineralocorticoid O +
activity O +
, O +
was O +
even O +
more O +
effective O +
at O +
inhibiting O +
DNA O +
synthesis O +
by O +
murine O +
pulmonary O +
capillary O +
endothelial O +
cells O +
than O +
was O +
HAH O +
- O +
cortisol O +
. O +

In O +
conclusion O +
, O +
HAH O +
- O +
cortisol O +
represents O +
the O +
prototype O +
of O +
a O +
new O +
class O +
of O +
angiogenesis O +
inhibitors O +
for O +
the O +
treatment O +
of O +
cancer O +
and O +
other O +
angiogenic O +
diseases O +
. O +

Colorimetrical O +
rate O +
assay O +
for O +
urinary O +
dipeptidyl O +
peptidase O +
IV O +
( O +
DPPIV O +
) O +
activity O +
using O +
a O +
new O +
substrate O +
. O +

We O +
synthesized O +
a O +
new O +
substrate O +
glycyl O +
- O +
L O +
- O +
proline O +
3 O +
, O +
5 O +
- O +
dibromo O +
- O +
4 O +
- O +
hydroxyanilide O +
( O +
Gly O +
- O +
Pro O +
- O +
DBAP O +
) O +
, O +
for O +
dipeptidyl O +
peptidase O +
IV O +
( O +
DPPIV O +
) O +
. O +

Its O +
hydrolysis O +
by O +
DPPIV O +
resulted O +
in O +
the O +
formation O +
of O +
a O +
chromophore O +
, O +
2 O +
, O +
6 O +
- O +
dibromophenol O +
- O +
indo O +
- O +
p O +
- O +
xylenol O +
, O +
and O +
its O +
maximal O +
absorption O +
wavelength O +
( O +
600 O +
nm O +
) O +
was O +
longer O +
than O +
that O +
of O +
p O +
- O +
nitroaniline O +
( O +
415 O +
nm O +
) O +
released O +
from O +
conventional O +
substrate O +
, O +
glycyl O +
- O +
L O +
- O +
proline O +
p O +
- O +
nitroanilide O +
( O +
Gly O +
- O +
Pro O +
- O +
pNA O +
) O +
. O +

We O +
also O +
established O +
the O +
rate O +
assay O +
for O +
urinary O +
DPPIV O +
activity O +
using O +
Gly O +
- O +
Pro O +
- O +
DBAP O +
. O +

The O +
optimum O +
pH O +
was O +
between O +
8 O +
. O +
5 O +
and O +
9 O +
. O +
0 O +
. O +

The O +
apparent O +
Km O +
was O +
1 O +
. O +
1 O +
mmol O +
/ O +
1 O +
. O +

The O +
detectable O +
range O +
was O +
2 O +
. O +
5 O +
- O +
350 O +
U O +
/ O +
l O +
. O +

No O +
changes O +
in O +
blank O +
values O +
occurred O +
throughout O +
the O +
enzyme O +
reaction O +
in O +
the O +
optimum O +
pH O +
. O +

Its O +
value O +
was O +
also O +
much O +
lower O +
than O +
Gly O +
- O +
Pro O +
- O +
pNA O +
. O +

CVs O +
for O +
within O +
- O +
run O +
and O +
between O +
- O +
run O +
were O +
1 O +
. O +
1 O +
% O +
( O +
n O +
= O +
10 O +
) O +
and O +
3 O +
. O +
0 O +
% O +
( O +
n O +
= O +
10 O +
) O +
, O +
respectively O +
. O +

Among O +
tested O +
peptidases O +
, O +
only O +
DPPIV O +
could O +
hydrolyze O +
Gly O +
- O +
Pro O +
- O +
DBAP O +
. O +

Among O +
the O +
protease O +
inhibitors O +
, O +
only O +
two O +
, O +
diprotin O +
- O +
A O +
and O +
phenylmethylsulfonyl O +
fluoride O +
( O +
PMSA O +
) O +
, O +
could O +
inhibit O +
DPPIV O +
activity O +
. O +

The O +
present O +
method O +
did O +
not O +
interfere O +
with O +
urinary O +
ingredients O +
such O +
as O +
hemoglobin O +
. O +

The O +
correlation O +
between O +
the O +
present O +
( O +
y O +
) O +
and O +
conventional O +
( O +
x O +
) O +
methods O +
is O +
presented O +
by O +
the O +
equation O +
y O +
= O +
1 O +
. O +
121x O +
+ O +
0 O +
. O +
096 O +
( O +
r O +
= O +
0 O +
. O +
993 O +
) O +
. O +

Thus O +
the O +
present O +
method O +
provides O +
practical O +
advantages O +
over O +
the O +
conventional O +
method O +
for O +
routine O +
laboratory O +
use O +
. O +

Primary O +
hyperparathyroidism O +
and O +
the O +
heart O +
: O +
cardiac O +
abnormalities O +
correlated O +
to O +
clinical O +
and O +
biochemical O +
data O +
. O +

Comparing O +
patients O +
with O +
primary O +
hyperparathyroidism O +
( O +
PHP O +
) O +
to O +
a O +
normocalcemic O +
control O +
population O +
, O +
those O +
with O +
PHP O +
have O +
a O +
higher O +
incidence O +
of O +
cardiovascular O +
disease O +
and O +
cardiac O +
abnormalities O +
. O +

This O +
study O +
aimed O +
at O +
correlating O +
cardiac O +
findings O +
( O +
valvular O +
and O +
myocardial O +
calcification O +
, O +
myocardial O +
hypertrophy O +
) O +
with O +
clinical O +
data O +
( O +
age O +
, O +
sex O +
, O +
clinical O +
manifestation O +
, O +
nephrolithiasis O +
, O +
nephrocalcinosis O +
, O +
hypertension O +
, O +
skeletal O +
abnormalities O +
, O +
hypercalcemic O +
syndrome O +
) O +
and O +
biochemical O +
data O +
( O +
serum O +
calcium O +
, O +
serum O +
phosphate O +
, O +
serum O +
iPTH O +
level O +
, O +
serum O +
creatinine O +
) O +
. O +

A O +
group O +
of O +
132 O +
consecutive O +
patients O +
with O +
surgically O +
verified O +
PHP O +
( O +
94 O +
women O +
, O +
38 O +
men O +
; O +
ages O +
15 O +
- O +
86 O +
, O +
mean O +
age O +
57 O +
+ O +
/ O +
- O +
16 O +
years O +
) O +
were O +
included O +
in O +
this O +
study O +
. O +

Blood O +
chemistry O +
, O +
clinical O +
presentation O +
, O +
radiography O +
, O +
and O +
echocardiography O +
were O +
carried O +
out O +
in O +
all O +
patients O +
for O +
univariate O +
and O +
multivariate O +
analyses O +
of O +
all O +
parameters O +
. O +

There O +
was O +
no O +
statistical O +
correlation O +
between O +
clinical O +
symptoms O +
, O +
biochemical O +
data O +
, O +
and O +
cardiac O +
calcific O +
alterations O +
. O +

Typical O +
skeletal O +
manifestations O +
( O +
osteolysis O +
/ O +
subperiostal O +
resorption O +
) O +
and O +
valvular O +
calcifications O +
were O +
significantly O +
correlated O +
to O +
left O +
ventricular O +
hypertrophy O +
( O +
p O +
= O +
0 O +
. O +
005 O +
) O +
. O +

Cardiac O +
abnormalities O +
such O +
as O +
calcific O +
myocardial O +
deposits O +
or O +
mitral O +
and O +
aortic O +
valvular O +
calcifications O +
do O +
not O +
correlate O +
with O +
laboratory O +
findings O +
and O +
clinical O +
presentation O +
at O +
the O +
time O +
of O +
diagnosis O +
. O +

There O +
was O +
no O +
biochemical O +
or O +
clinical O +
variable O +
that O +
could O +
predict O +
the O +
frequency O +
or O +
severity O +
of O +
valvular O +
sclerosis O +
or O +
calcific O +
deposits O +
in O +
the O +
myocardium O +
. O +

However O +
, O +
PHP O +
- O +
related O +
skeletal O +
abnormalities O +
and O +
valvular O +
calcification O +
were O +
predicting O +
factors O +
for O +
left O +
ventricular O +
hypertrophy O +
, O +
a O +
reversible O +
cardiac O +
manifestation O +
of O +
PHP O +
. O +

Myocardial O +
hypertrophy O +
is O +
more O +
often O +
found O +
with O +
classic O +
symptomatic O +
PHP O +
with O +
osseous O +
abnormalities O +
. O +

Childhood O +
conscientiousness O +
and O +
longevity O +
: O +
health O +
behaviors O +
and O +
cause O +
of O +
death O +
. O +

Previous O +
research O +
showed O +
that O +
conscientiousness O +
( O +
social O +
dependability O +
) O +
in O +
childhood O +
predicted O +
longevity O +
in O +
an O +
archival O +
prospective O +
cohort O +
study O +
of O +
bright O +
children O +
first O +
studied O +
by O +
Terman O +
in O +
the O +
1920s O +
( O +
H O +
. O +
S O +
. O +
Friedman O +
et O +
al O +
. O +
, O +
1993 O +
) O +
. O +

Possible O +
behavioral O +
mechanisms O +
for O +
this O +
robust O +
association O +
are O +
now O +
examined O +
by O +
gathering O +
cause O +
of O +
death O +
information O +
and O +
by O +
considering O +
the O +
possible O +
mediating O +
influences O +
of O +
drinking O +
alcohol O +
, O +
smoking O +
, O +
and O +
overeating O +
. O +

Survival O +
analyses O +
( O +
N O +
= O +
1 O +
, O +
215 O +
) O +
suggest O +
that O +
the O +
protective O +
effect O +
of O +
conscientiousness O +
is O +
not O +
primarily O +
due O +
to O +
accident O +
avoidance O +
and O +
can O -
not O +
be O +
mostly O +
explained O +
by O +
abstinence O +
from O +
unhealthy O +
substance O +
intake O +
. O +

Conscientiousness O +
may O +
have O +
more O +
wide O +
- O +
ranging O +
effects O +
on O +
health O +
- O +
relevant O +
activities O +
. O +

Selenoperoxidase O +
- O +
dependent O +
glutathione O +
cycle O +
activity O +
in O +
peroxide O +
- O +
challenged O +
leukemia O +
cells O +
. O +

Murine O +
leukemia O +
L1210 B-CellLine +
cells O +
rendered O +
deficient O +
in O +
glutathione O +
peroxidase O +
( O +
GPX O +
) O +
and O +
phospholipid O +
hydroperoxide O +
glutathione O +
peroxidase O +
( O +
PHGPX O +
) O +
by O +
Se O +
deprivation O +
( O +
L O +
. O +
Se O +
( O +
- O +
) O +
cells O +
) O +
were O +
found O +
to O +
be O +
more O +
sensitive O +
to O +
tert O +
- O +
butyl O +
hydroperoxide O +
( O +
t O +
- O +
BuOOH O +
) O +
cytotoxicity O +
than O +
Se O +
- O +
replete O +
controls O +
( O +
L O +
. O +
Se O +
( O +
+ O +
) O +
cells O +
) O +
. O +

Human O +
K562 B-CellLine +
cells O +
, O +
which O +
express O +
PHGPX O +
, O +
but O +
not O +
GPX O +
, O +
were O +
also O +
more O +
sensitive O +
to O +
t O +
- O +
BuOOH O +
in O +
the O +
Se O +
- O +
deficient O +
( O +
K O +
. O +
Se O +
( O +
- O +
) O +
) O +
than O +
Se O +
- O +
satisfied O +
( O +
K O +
. O +
Se O +
( O +
+ O +
) O +
) O +
condition O +
. O +

In O +
examining O +
the O +
metabolic O +
basis O +
for O +
selenoperoxidase O +
- O +
dependent O +
resistance O +
, O +
we O +
found O +
that O +
glucose O +
- O +
replete O +
Se O +
( O +
- O +
) O +
cells O +
reduce O +
t O +
- O +
BuOOH O +
to O +
t O +
- O +
butanol O +
far O +
more O +
slowly O +
than O +
Se O +
( O +
+ O +
) O +
cells O +
, O +
the O +
ratio O +
of O +
the O +
first O +
- O +
order O +
rate O +
constants O +
approximating O +
that O +
of O +
the O +
GPX O +
activities O +
( O +
L1210 B-CellLine +
cells O +
) O +
or O +
PHGPX O +
activities O +
( O +
K562 B-CellLine +
cells O +
) O +
. O +

Monitoring O +
peroxide O +
- O +
induced O +
changes O +
in O +
GSH O +
and O +
GSSG O +
gave O +
consistent O +
results O +
; O +
e O +
. O +
g O +
. O +
, O +
glucose O +
- O +
depleted O +
L O +
. O +
Se O +
( O +
+ O +
) O +
cells O +
exhibited O +
a O +
first O +
order O +
loss O +
of O +
GSH O +
that O +
was O +
substantially O +
faster O +
than O +
that O +
of O +
glucose O +
- O +
depleted O +
L O +
. O +
Se O +
( O +
- O +
) O +
cells O +
. O +

Under O +
the O +
conditions O +
used O +
, O +
peroxide O +
- O +
induced O +
conversion O +
of O +
GSH O +
to O +
GSSG O +
could O +
be O +
stoichiometrically O +
reversed O +
by O +
resupplying O +
D O +
- O +
glucose O +
, O +
indicating O +
that O +
no O +
significant O +
lysis O +
or O +
GSSG O +
efflux O +
and O +
/ O +
or O +
interchange O +
had O +
taken O +
place O +
. O +

The O +
apparent O +
first O +
- O +
order O +
rate O +
constant O +
for O +
GSH O +
decay O +
increased O +
progressively O +
for O +
L1210 B-CellLine +
cells O +
expressing O +
a O +
range O +
of O +
GPX O +
activities O +
from O +
approximately O +
5 O +
% O +
to O +
100 O +
% O +
, O +
demonstrating O +
that O +
peroxide O +
detoxification O +
is O +
strictly O +
dependent O +
on O +
enzyme O +
content O +
. O +

The O +
initial O +
rate O +
of O +
14CO2 O +
release O +
from O +
D O +
- O +
[ O +
1 O +
- O +
14C O +
] O +
glucose O +
supplied O +
in O +
the O +
medium O +
was O +
much O +
greater O +
for O +
L O +
. O +
Se O +
( O +
+ O +
) O +
or O +
K O +
. O +
Se O +
( O +
+ O +
) O +
cells O +
than O +
for O +
their O +
respective O +
Se O +
( O +
- O +
) O +
counterparts O +
, O +
consistent O +
with O +
greater O +
hexose O +
monophosphate O +
shunt O +
activity O +
in O +
the O +
former O +
. O +

These O +
results O +
highlight O +
the O +
importance O +
of O +
selenoperoxidase O +
action O +
in O +
the O +
glutathione O +
cycle O +
as O +
a O +
means O +
by O +
which O +
tumor O +
cells O +
cope O +
with O +
hydroperoxide O +
stress O +
. O +

Differential O +
expression O +
and O +
mutation O +
of O +
NME O +
genes O +
in O +
autologous O +
cultured O +
human O +
melanoma O +
cells O +
with O +
different O +
metastatic O +
potentials O +
. O +

The O +
putative O +
metastasis O +
suppressor O +
genes O +
, O +
NME1 O +
( O +
nm23 O +
- O +
1 O +
) O +
and O +
NME2 O +
( O +
nm23 O +
- O +
2 O +
) O +
, O +
were O +
examined O +
in O +
a O +
model O +
system O +
we O +
developed O +
to O +
approximate O +
the O +
dissemination O +
of O +
melanoma O +
from O +
a O +
primary O +
skin O +
tumor O +
. O +

We O +
utilized O +
two O +
autologous O +
human O +
melanoma O +
cell O +
lines O +
, O +
IV B-CellLine +
Cl I-CellLine +
1 I-CellLine +
and O +
IV B-CellLine +
Cl I-CellLine +
3 I-CellLine +
, O +
which O +
displayed O +
qualitatively O +
different O +
metastatic O +
phenotypes O +
following O +
subdermal O +
inoculation O +
into O +
nude O +
mice O +
. O +

Highly O +
metastatic O +
IV B-CellLine +
Cl I-CellLine +
1 I-CellLine +
cells O +
expressed O +
approximately O +
5 O +
fold O +
lower O +
levels O +
of O +
protein O +
encoded O +
by O +
NME O +
genes O +
than O +
non O +
- O +
metastatic O +
IV B-CellLine +
Cl I-CellLine +
3 I-CellLine +
cells O +
. O +

Similar O +
differences O +
in O +
NME O +
protein O +
levels O +
were O +
observed O +
in O +
tumors O +
induced O +
by O +
the O +
two O +
cell O +
lines O +
in O +
nude O +
mice O +
. O +

There O +
were O +
no O +
differences O +
in O +
NME O +
mRNA O +
levels O +
between O +
these O +
two O +
cell O +
lines O +
, O +
suggesting O +
that O +
expression O +
of O +
these O +
proteins O +
is O +
regulated O +
at O +
a O +
post O +
- O +
transcriptional O +
level O +
. O +

We O +
found O +
a O +
ser122 O +
- O +
pro O +
mutation O +
in O +
the O +
NME2 O +
gene O +
of O +
metastatic O +
IV B-CellLine +
Cl I-CellLine +
1 I-CellLine +
cells O +
. O +

A O +
similar O +
ser120 O +
- O +
gly O +
mutation O +
in O +
NME1 O +
has O +
been O +
found O +
in O +
human O +
neuroblastoma O +
, O +
suggesting O +
that O +
mutation O +
in O +
this O +
region O +
may O +
be O +
a O +
general O +
phenomenon O +
related O +
to O +
tumor O +
progression O +
. O +

These O +
mutations O +
may O +
have O +
functional O +
consequences O +
since O +
they O +
eliminate O +
potential O +
phosphorylation O +
sites O +
and O +
may O +
affect O +
the O +
tertiary O +
structure O +
of O +
mature O +
protein O +
complexes O +
. O +

Image O +
- O +
directed O +
and O +
color O +
Doppler O +
studies O +
of O +
gallbladder O +
tumors O +
. O +

Thirteen O +
cases O +
of O +
primary O +
adenocarcinoma O +
of O +
the O +
gallbladder O +
( O +
GB O +
) O +
, O +
1 O +
of O +
malignant O +
fibrous O +
histocytoma O +
, O +
3 O +
of O +
metastatic O +
adenocarcinoma O +
, O +
5 O +
of O +
adenoma O +
, O +
5 O +
of O +
polypus O +
, O +
2 O +
of O +
xanthogranuloma O +
, O +
6 O +
of O +
chronic O +
cholecystitis O +
, O +
4 O +
of O +
acute O +
cholecystitis O +
, O +
and O +
8 O +
of O +
subacute O +
cholecystitis O +
were O +
studied O +
by O +
image O +
- O +
directed O +
and O +
color O +
Doppler O +
ultrasonography O +
( O +
CDUS O +
) O +
. O +

All O +
of O +
the O +
14 O +
cases O +
of O +
primary O +
GB O +
cancer O +
( O +
10 O +
masses O +
, O +
4 O +
thickening O +
wall O +
) O +
were O +
found O +
to O +
have O +
a O +
high O +
velocity O +
arterial O +
blood O +
flow O +
signal O +
in O +
the O +
wall O +
of O +
the O +
GB O +
. O +

In O +
contrast O +
, O +
the O +
3 O +
cases O +
of O +
metastatic O +
cancer O +
of O +
the O +
GB O +
had O +
no O +
blood O +
flow O +
signal O +
in O +
the O +
wall O +
of O +
the O +
GB O +
. O +

For O +
the O +
30 O +
cases O +
of O +
benign O +
lesions O +
of O +
the O +
GB O +
, O +
only O +
in O +
12 O +
cases O +
was O +
a O +
low O +
velocity O +
blood O +
flow O +
signal O +
found O +
. O +

Nine O +
of O +
10 O +
cases O +
of O +
primary O +
GB O +
malignancy O +
were O +
found O +
to O +
have O +
high O +
velocity O +
arterial O +
blood O +
flow O +
signals O +
in O +
the O +
tumor O +
masses O +
. O +

No O +
blood O +
flow O +
signal O +
was O +
observed O +
in O +
the O +
masses O +
of O +
13 O +
cases O +
( O +
3 O +
of O +
metastatic O +
adenocarcinoma O +
, O +
5 O +
of O +
adenoma O +
, O +
5 O +
of O +
polypus O +
) O +
. O +

An O +
abnormal O +
high O +
velocity O +
arterial O +
blood O +
flow O +
signal O +
observed O +
within O +
masses O +
in O +
the O +
GB O +
or O +
in O +
the O +
GB O +
wall O +
is O +
a O +
significant O +
feature O +
of O +
primary O +
GB O +
cancer O +
and O +
thus O +
helps O +
to O +
differentiate O +
primary O +
GB O +
cancer O +
from O +
metastatic O +
and O +
benign O +
lesions O +
of O +
the O +
GB O +
. O +

Differential O +
effects O +
of O +
carbachol O +
on O +
calcium O +
entry O +
and O +
release O +
in O +
CHO B-CellLine +
cells O +
expressing O +
the O +
m3 O +
muscarinic O +
receptor O +
. O +

Calcium O +
signalling O +
was O +
examined O +
in O +
CHO B-CellLine +
- I-CellLine +
k1 I-CellLine +
cells O +
that O +
stably O +
express O +
the O +
m3 O +
subtype O +
of O +
the O +
muscarinic O +
receptor O +
. O +

The O +
calcium O +
indicator O +
Fura O +
- O +
2 O +
was O +
retained O +
in O +
these O +
cells O +
only O +
in O +
the O +
presence O +
of O +
probenecid O +
( O +
1 O +
mM O +
) O +
, O +
suggesting O +
that O +
Fura O +
- O +
2 O +
efflux O +
was O +
mediated O +
by O +
an O +
organic O +
anion O +
transporter O +
. O +

The O +
addition O +
of O +
carbachol O +
( O +
CCh O +
) O +
to O +
Fura O +
- O +
2 O +
loaded O +
cells O +
in O +
suspension O +
caused O +
a O +
rapid O +
transient O +
increase O +
in O +
intracellular O +
calcium O +
[ O +
Ca O +
] O +
i O +
followed O +
by O +
a O +
smaller O +
sustained O +
plateau O +
phase O +
. O +

The O +
transient O +
rise O +
in O +
[ O +
Ca O +
] O +
i O +
was O +
dose O +
- O +
dependent O +
with O +
a O +
threshold O +
response O +
of O +
89 O +
+ O +
/ O +
- O +
18 O +
nM O +
above O +
baseline O +
with O +
10 O +
nM O +
CCh O +
and O +
a O +
maximum O +
stimulation O +
of O +
734 O +
+ O +
/ O +
- O +
46 O +
nM O +
with O +
10 O +
microM O +
CCh O +
. O +

This O +
phase O +
was O +
accompanied O +
by O +
a O +
similar O +
dose O +
- O +
dependent O +
stimulation O +
of O +
total O +
inositol O +
phosphate O +
production O +
and O +
was O +
assumed O +
to O +
be O +
generated O +
by O +
release O +
from O +
intracellular O +
stores O +
of O +
the O +
endoplasmic O +
reticulum O +
( O +
ER O +
) O +
. O +

The O +
sustained O +
increase O +
in O +
[ O +
Ca O +
] O +
i O +
was O +
generated O +
by O +
entry O +
from O +
the O +
extracellular O +
bath O +
since O +
it O +
was O +
blocked O +
by O +
pretreatment O +
with O +
La3 O +
+ O +
( O +
1 O +
microM O +
) O +
and O +
was O +
absent O +
when O +
bath O +
calcium O +
was O +
chelated O +
with O +
EGTA O +
. O +

This O +
phase O +
was O +
not O +
dependent O +
on O +
CCh O +
dose O +
, O +
and O +
a O +
stimulation O +
of O +
[ O +
Ca O +
] O +
i O +
of O +
approximately O +
90 O +
nM O +
above O +
baseline O +
was O +
observed O +
with O +
CCh O +
concentrations O +
between O +
50 O +
nM O +
and O +
10 O +
microM O +
. O +

With O +
this O +
dose O +
range O +
, O +
the O +
rate O +
of O +
Mn2 O +
+ O +
quenching O +
of O +
Fura O +
- O +
2 O +
at O +
the O +
Ca O +
- O +
insensitive O +
excitation O +
wavelength O +
of O +
360 O +
nm O +
was O +
likewise O +
maximally O +
stimulated O +
. O +

At O +
lower O +
CCh O +
concentrations O +
( O +
10 O +
- O +
50 O +
nM O +
) O +
, O +
it O +
was O +
clear O +
that O +
the O +
activation O +
of O +
Ca O +
entry O +
could O +
not O +
be O +
dissociated O +
from O +
a O +
threshold O +
release O +
of O +
Ca O +
from O +
intracellular O +
stores O +
. O +

The O +
phorbol O +
ester O +
PMA O +
, O +
which O +
uncouples O +
the O +
muscarinic O +
receptor O +
from O +
phospholipase O +
C O +
, O +
reduced O +
the O +
transient O +
rise O +
in O +
[ O +
Ca O +
] O +
i O +
by O +
approximately O +
50 O +
% O +
with O +
little O +
or O +
no O +
effect O +
on O +
Ca O +
entry O +
at O +
higher O +
CCh O +
levels O +
( O +
> O +
or O +
= O +
1 O +
microM O +
) O +
. O +

At O +
lower O +
CCh O +
concentrations O +
( O +
< O +
or O +
= O +
100 O +
nM O +
) O +
however O +
, O +
pretreatment O +
with O +
PMA O +
completely O +
blocked O +
all O +
Ca O +
mobilization O +
and O +
supports O +
the O +
contention O +
that O +
Ca O +
entry O +
is O +
coupled O +
to O +
Ca O +
release O +
from O +
stores O +
or O +
to O +
store O +
depletion O +
. O +

The O +
emptying O +
of O +
inositol O +
trisphosphate O +
- O +
sensitive O +
stores O +
with O +
thapsigargin O +
( O +
10 O +
nM O +
) O +
stimulated O +
Ca O +
entry O +
and O +
also O +
the O +
rate O +
of O +
Mn2 O +
+ O +
quenching O +
. O +

Store O +
depletion O +
by O +
incubation O +
in O +
Ca O +
- O +
free O +
media O +
likewise O +
stimulated O +
Mn2 O +
+ O +
uptake O +
without O +
a O +
rise O +
in O +
[ O +
Ca O +
] O +
i O +
. O +

Our O +
data O +
are O +
therefore O +
consistent O +
with O +
a O +
' O +
capacitative O +
' O +
coupling O +
model O +
, O +
whereby O +
the O +
activation O +
of O +
the O +
plasma O +
membrane O +
receptor O +
leads O +
to O +
an O +
InsP3 O +
- O +
induced O +
change O +
in O +
the O +
degree O +
of O +
filling O +
of O +
the O +
ER O +
Ca O +
pool O +
. O +
( O +
ABSTRACT O +
TRUNCATED O +
AT O +
400 O +
WORDS O +
) O +

Down O +
- O +
regulation O +
of O +
collagen O +
XII O +
in O +
transformed O +
mesenchymal O +
cells O +
. O +

Collagen O +
XII O +
is O +
a O +
complex O +
multidomain O +
protein O +
associated O +
with O +
the O +
surface O +
of O +
interstitial O +
collagen O +
fibrils O +
. O +

This O +
protein O +
is O +
produced O +
in O +
large O +
amounts O +
by O +
fibroblasts O +
cultivated O +
in O +
vitro O +
. O +

However O +
, O +
it O +
is O +
completely O +
absent O +
from O +
cells O +
transformed O +
by O +
the O +
oncogene O +
v O +
- O +
myc O +
or O +
v O +
- O +
src O +
and O +
from O +
cells O +
derived O +
from O +
a O +
methylcholanthrene O +
- O +
induced O +
fibrosarcoma O +
. O +

Since O +
all O +
these O +
cells O +
lack O +
any O +
mRNA O +
for O +
collagen O +
, O +
XII O +
, O +
it O +
seems O +
likely O +
that O +
the O +
synthesis O +
is O +
blocked O +
at O +
the O +
transcriptional O +
level O +
. O +

Experiments O +
with O +
a O +
temperature O +
- O +
sensitive O +
mutant O +
of O +
Rous O +
sarcoma O +
virus O +
demonstrated O +
that O +
a O +
single O +
oncogene O +
product O +
is O +
sufficient O +
to O +
inhibit O +
the O +
synthesis O +
. O +

A O +
reduction O +
in O +
the O +
expression O +
of O +
collagen O +
XII O +
might O +
have O +
profound O +
effects O +
on O +
the O +
stability O +
of O +
the O +
extracellular O +
matrix O +
of O +
transformed O +
cells O +
. O +

Comparative O +
NMR O +
study O +
of O +
a O +
differentiated O +
rat O +
hepatoma O +
and O +
its O +
dedifferentiated O +
subclone O +
cultured O +
as O +
spheroids O +
and O +
as O +
implanted O +
tumors O +
. O +

H4IIEC3 B-CellLine +
( O +
H4 B-CellLine +
) O +
, O +
a O +
differentiated O +
rat O +
hepatoma O +
line O +
and O +
H5 B-CellLine +
, O +
its O +
dedifferentiated O +
subclone O +
, O +
were O +
investigated O +
as O +
proliferating O +
spheroids O +
and O +
as O +
implanted O +
subcutaneous O +
tumors O +
in O +
juvenile O +
rats O +
. O +

H4 B-CellLine +
cells O +
formed O +
tight O +
, O +
round O +
spheroids O +
whereas O +
H5 B-CellLine +
cells O +
formed O +
loose O +
, O +
grape O +
- O +
like O +
structures O +
. O +

31P O +
MR O +
spectra O +
showed O +
that O +
phosphocreatine O +
was O +
present O +
in O +
H5 B-CellLine +
spheroids O +
but O +
not O +
in O +
H4 B-CellLine +
spheroids O +
or O +
tumors O +
. O +

[ O +
13C O +
] O +
Lactate O +
production O +
from O +
[ O +
13C O +
] O +
glucose O +
, O +
with O +
no O +
detectable O +
uptake O +
of O +
[ O +
13C O +
] O +
alanine O +
, O +
indicated O +
that O +
energy O +
production O +
in O +
H5 B-CellLine +
spheroids O +
was O +
primarily O +
via O +
glycolysis O +
. O +

No O +
[ O +
13C O +
] O +
glucose O +
utilization O +
was O +
detected O +
in O +
H4 B-CellLine +
spheroids O +
, O +
but O +
uptake O +
of O +
alanine O +
and O +
accumulation O +
of O +
labeled O +
lactate O +
, O +
glutamate O +
and O +
glutamine O +
indicated O +
oxidation O +
via O +
the O +
tricarboxylic O +
acid O +
( O +
TCA O +
) O +
cycle O +
. O +

Tumors O +
of O +
H4 B-CellLine +
cells O +
were O +
well O +
perfused O +
, O +
unlike O +
tumors O +
of O +
H5 B-CellLine +
cells O +
which O +
were O +
highly O +
necrotic O +
. O +

Following O +
i O +
. O +
v O +
. O +
infusion O +
with O +
[ O +
13C O +
] O +
alanine O +
, O +
[ O +
13C O +
] O +
lactate O +
and O +
glutamate O +
, O +
evidence O +
of O +
oxidation O +
via O +
the O +
TCA O +
cycle O +
, O +
were O +
observed O +
in O +
H4 B-CellLine +
tumors O +
. O +

Thus O +
the O +
results O +
obtained O +
by O +
31P O +
and O +
13C O +
MRS O +
correlated O +
with O +
the O +
differentiation O +
state O +
of O +
H4 B-CellLine +
and O +
H5 B-CellLine +
spheroids O +
and O +
tumors O +
. O +

Modulation O +
of O +
apoptosis O +
in O +
human O +
myeloid O +
leukemic O +
cells O +
by O +
GM O +
- O +
CSF O +
. O +

Apoptosis O +
( O +
programmed O +
cell O +
death O +
) O +
regulates O +
cell O +
population O +
size O +
. O +

To O +
determine O +
the O +
mechanisms O +
whereby O +
hematopoietic O +
growth O +
factors O +
( O +
HGFs O +
) O +
modulate O +
apoptosis O +
in O +
human O +
myeloid O +
leukemic O +
cells O +
, O +
we O +
evaluated O +
the O +
roles O +
of O +
protein O +
and O +
mRNA O +
synthesis O +
for O +
altering O +
apoptosis O +
in O +
growth O +
factor O +
- O +
stimulated O +
vs O +
. O +
quiescent O +
leukemic O +
TF1 B-CellLine +
cells O +
. O +

Lysates O +
of O +
cells O +
from O +
the O +
granulocyte O +
- O +
macrophage O +
colony O +
- O +
stimulating O +
factor O +
( O +
GM O +
- O +
CSF O +
) O +
- O +
dependent O +
myeloid O +
leukemic O +
cell O +
line O +
TF1 B-CellLine +
were O +
separated O +
into O +
high O +
molecular O +
weight O +
( O +
HMW O +
) O +
pellets O +
of O +
intact O +
DNA O +
and O +
supernatants O +
of O +
fragmented O +
low O +
MW O +
( O +
LMW O +
) O +
DNA O +
, O +
and O +
the O +
DNA O +
purified O +
from O +
these O +
fractions O +
was O +
quantified O +
. O +

In O +
the O +
absence O +
of O +
both O +
GM O +
- O +
CSF O +
and O +
fetal O +
bovine O +
serum O +
( O +
FBS O +
) O +
, O +
70 O +
% O +
of O +
the O +
DNA O +
was O +
fragmented O +
after O +
3 O +
days O +
in O +
culture O +
, O +
with O +
a O +
characteristic O +
apoptotic O +
ladder O +
- O +
like O +
pattern O +
on O +
agarose O +
gel O +
electrophoresis O +
, O +
whereas O +
this O +
proportion O +
had O +
initially O +
been O +
< O +
5 O +
% O +
. O +

In O +
contrast O +
, O +
less O +
than O +
5 O +
% O +
of O +
the O +
DNA O +
was O +
fragmented O +
in O +
cells O +
incubated O +
with O +
GM O +
- O +
CSF O +
plus O +
FBS O +
or O +
GM O +
- O +
CSF O +
alone O +
. O +

Delayed O +
addition O +
of O +
GM O +
- O +
CSF O +
, O +
but O +
not O +
FBS O +
, O +
permitted O +
partial O +
rescue O +
of O +
the O +
cells O +
, O +
inhibiting O +
increasing O +
rates O +
of O +
accumulation O +
of O +
fragmented O +
DNA O +
. O +

When O +
the O +
macro O +
- O +
molecular O +
synthesis O +
inhibitor O +
cycloheximide O +
( O +
CHX O +
) O +
or O +
actinomycin O +
D O +
( O +
Act O +
D O +
) O +
was O +
present O +
for O +
26 O +
hours O +
in O +
the O +
absence O +
of O +
GM O +
- O +
CSF O +
and O +
FBS O +
, O +
apoptosis O +
was O +
inhibited O +
. O +

In O +
contrast O +
, O +
in O +
the O +
presence O +
of O +
GM O +
- O +
CSF O +
or O +
FBS O +
, O +
apoptosis O +
was O +
enhanced O +
upon O +
addition O +
of O +
CHX O +
or O +
Act O +
D O +
. O +

The O +
latter O +
effect O +
persisted O +
even O +
with O +
the O +
late O +
addition O +
of O +
CHX O +
. O +

These O +
findings O +
indicate O +
that O +
disparate O +
mechanisms O +
of O +
enhancing O +
or O +
inhibiting O +
apoptosis O +
exist O +
in O +
myeloid O +
leukemic O +
cells O +
related O +
to O +
environmental O +
conditions O +
, O +
including O +
HGF O +
- O +
regulated O +
cellular O +
synthesis O +
of O +
distinct O +
proteins O +
and O +
mRNA O +
. O +

Effects O +
of O +
doxycycline O +
on O +
in O +
vitro O +
growth O +
, O +
migration O +
, O +
and O +
gelatinase O +
activity O +
of O +
breast O +
carcinoma O +
cells O +
. O +

Metastatic O +
disease O +
is O +
one O +
of O +
the O +
major O +
causes O +
of O +
death O +
from O +
cancer O +
in O +
human O +
beings O +
. O +

Several O +
enzyme O +
systems O +
have O +
been O +
implicated O +
in O +
the O +
metastatic O +
process O +
, O +
but O +
the O +
metalloproteinases O +
( O +
MPs O +
) O +
appear O +
to O +
be O +
the O +
major O +
group O +
involved O +
in O +
most O +
instances O +
of O +
neoplastic O +
invasion O +
. O +

Increased O +
MP O +
activity O +
has O +
been O +
correlated O +
with O +
the O +
metastatic O +
potential O +
of O +
many O +
cancers O +
, O +
including O +
breast O +
cancer O +
. O +

MPs O +
also O +
play O +
a O +
role O +
in O +
tumor O +
angiogenesis O +
. O +

Tetracyclines O +
are O +
antimicrobial O +
agents O +
that O +
can O +
suppress O +
MP O +
activity O +
in O +
a O +
variety O +
of O +
tissues O +
, O +
including O +
gingiva O +
, O +
bone O +
, O +
and O +
cartilage O +
. O +

Several O +
reports O +
have O +
indicated O +
that O +
tetracyclines O +
can O +
suppress O +
tumor O +
MPs O +
as O +
well O +
. O +

A O +
synthetic O +
tetracycline O +
, O +
doxycycline O +
, O +
inhibits O +
migration O +
of O +
human O +
MDA B-CellLine +
- I-CellLine +
MB I-CellLine +
- I-CellLine +
435 I-CellLine +
breast O +
adenocarcinoma O +
cells O +
through O +
a O +
reconstituted O +
basement O +
membrane O +
( O +
Matrigel O +
) O +
, O +
an O +
assay O +
used O +
as O +
an O +
in O +
vitro O +
surrogate O +
for O +
the O +
in O +
vivo O +
process O +
of O +
tumor O +
invasion O +
through O +
basement O +
membranes O +
. O +

Additionally O +
, O +
doxycycline O +
diminishes O +
the O +
proliferation O +
of O +
this O +
breast O +
cancer O +
cell O +
line O +
and O +
also O +
decreases O +
its O +
gelatinolytic O +
activity O +
, O +
as O +
determined O +
by O +
gel O +
zymography O +
. O +

[ O +
The O +
erbB O +
gene O +
family O +
: O +
significance O +
for O +
tumor O +
development O +
, O +
prognosis O +
and O +
new O +
therapeutic O +
modalities O +
] O +
. O +

RNA O +
and O +
DNA O +
viruses O +
can O +
be O +
transforming O +
and O +
tumourigenic O +
agents O +
. O +

The O +
transformation O +
is O +
a O +
consequence O +
of O +
the O +
ability O +
of O +
viruses O +
to O +
integrate O +
into O +
the O +
host O +
cell O +
' O +
s O +
DNA O +
and O +
to O +
produce O +
transforming O +
proteins O +
. O +

These O +
proteins O +
are O +
mainly O +
produced O +
by O +
specific O +
integral O +
parts O +
of O +
the O +
viral O +
genome O +
, O +
the O +
oncogenes O +
. O +

Comparison O +
between O +
RNA O +
/ O +
DNA O +
sequence O +
of O +
viral O +
oncogenes O +
and O +
normal O +
human O +
genome O +
of O +
non O +
- O +
transformed O +
cells O +
revealed O +
high O +
sequence O +
similarities O +
in O +
specific O +
genomic O +
areas O +
, O +
which O +
were O +
named O +
cellular O +
proto O +
- O +
oncogens O +
. O +

They O +
are O +
important O +
components O +
of O +
the O +
growth O +
regulatory O +
pathways O +
in O +
normal O +
cells O +
. O +

The O +
accumulation O +
of O +
genetic O +
alterations O +
of O +
some O +
proto O +
- O +
oncogens O +
, O +
like O +
the O +
erbB O +
- O +
family O +
, O +
may O +
be O +
part O +
of O +
the O +
mechanism O +
, O +
by O +
which O +
malignant O +
cells O +
can O +
acquire O +
a O +
selective O +
growth O +
advantage O +
. O +

The O +
epidermal O +
growth O +
factor O +
receptor O +
( O +
EGF O +
- O +
R O +
, O +
c O +
- O +
erbB1 O +
) O +
, O +
Her O +
- O +
2 O +
/ O +
neu O +
( O +
c O +
- O +
erbB2 O +
) O +
, O +
and O +
c O +
- O +
erbB3 O +
are O +
members O +
of O +
the O +
erbB O +
- O +
family O +
. O +

The O +
detection O +
of O +
increased O +
abundance O +
of O +
EGF O +
- O +
R O +
or O +
Her O +
- O +
2 O +
/ O +
neu O +
proteins O +
in O +
human O +
tumours O +
can O +
provide O +
additional O +
information O +
on O +
the O +
disease O +
- O +
free O +
survival O +
and O +
overall O +
survival O +
for O +
patients O +
with O +
breast O +
, O +
ovarian O +
, O +
endometrial O +
or O +
cervical O +
cancer O +
. O +

Molecular O +
and O +
cell O +
- O +
physiological O +
analyses O +
have O +
improved O +
the O +
understanding O +
of O +
tumour O +
biology O +
and O +
provide O +
the O +
opportunity O +
for O +
new O +
therapeutic O +
approaches O +
. O +

Monoclonal O +
antibody O +
targeted O +
therapy O +
directed O +
against O +
EGF O +
- O +
R O +
or O +
Her O +
- O +
2 O +
/ O +
neu O +
, O +
the O +
use O +
of O +
anti O +
- O +
sense O +
oligonucleotides O +
and O +
oligodeoxynucleotides O +
, O +
and O +
the O +
application O +
of O +
tyrosine O +
kinase O +
and O +
protein O +
C O +
- O +
kinase O +
inhibitors O +
are O +
currently O +
being O +
investigated O +
. O +

Transforming O +
growth O +
factor O +
beta O +
1 O +
promotes O +
spontaneous O +
transformation O +
of O +
cultured O +
rat O +
liver O +
epithelial O +
cells O +
. O +

The O +
neoplastic O +
transformation O +
of O +
cultured O +
rat O +
liver O +
epithelial O +
cells O +
by O +
various O +
means O +
has O +
consistently O +
been O +
associated O +
with O +
the O +
development O +
of O +
resistance O +
to O +
the O +
mito O +
- O +
inhibitory O +
effect O +
of O +
transforming O +
growth O +
factor O +
beta O +
( O +
TGF O +
- O +
beta O +
) O +
, O +
suggesting O +
that O +
such O +
phenotype O +
plays O +
a O +
mechanistic O +
role O +
during O +
the O +
transformation O +
of O +
these O +
cells O +
. O +

We O +
have O +
studied O +
the O +
induction O +
of O +
the O +
" O +
TGF O +
- O +
beta O +
- O +
resistant O +
" O +
phenotype O +
in O +
a O +
clonal O +
strain O +
of O +
early O +
passage O +
WB B-CellLine +
- I-CellLine +
F344 I-CellLine +
normal O +
cultured O +
rat O +
liver O +
epithelial O +
cells O +
, O +
the O +
proliferation O +
of O +
which O +
was O +
markedly O +
inhibited O +
by O +
TGF O +
- O +
beta O +
. O +

The O +
control O +
WB O +
cells O +
in O +
continuous O +
culture O +
slowly O +
developed O +
TGF O +
- O +
beta O +
resistance O +
. O +

However O +
, O +
when O +
the O +
same O +
cells O +
were O +
exposed O +
to O +
step O +
- O +
wise O +
increases O +
of O +
TGF O +
- O +
beta O +
concentration O +
in O +
their O +
culture O +
medium O +
, O +
the O +
development O +
of O +
TGF O +
- O +
beta O +
resistance O +
was O +
accelerated O +
. O +

Cells O +
which O +
had O +
been O +
grown O +
in O +
medium O +
containing O +
1 O +
ng O +
/ O +
ml O +
TGF O +
- O +
beta O +
developed O +
colony O +
- O +
forming O +
capacity O +
in O +
soft O +
agar O +
containing O +
epidermal O +
growth O +
factor O +
. O +

Cells O +
which O +
were O +
grown O +
in O +
media O +
containing O +
5 O +
and O +
10 O +
ng O +
/ O +
ml O +
TGF O +
- O +
beta O +
demonstrated O +
a O +
low O +
level O +
of O +
colony O +
- O +
forming O +
efficiency O +
in O +
soft O +
agar O +
medium O +
without O +
added O +
epidermal O +
growth O +
factor O +
and O +
tumorigenicity O +
in O +
isogeneic O +
rats O +
. O +

These O +
TGF O +
- O +
beta O +
- O +
resistant O +
cells O +
also O +
exhibited O +
progressively O +
increasing O +
levels O +
of O +
expression O +
of O +
the O +
c O +
- O +
fos O +
and O +
and O +
myc O +
mRNA O +
, O +
and O +
increased O +
resistance O +
to O +
the O +
cytotoxicity O +
of O +
Adriamycin O +
and O +
melphalan O +
. O +

The O +
latter O +
phenomenon O +
was O +
accompanied O +
by O +
an O +
increase O +
in O +
the O +
mdr O +
- O +
1 O +
mRNA O +
expression O +
, O +
cellular O +
glutathione O +
level O +
, O +
and O +
glutathione O +
S O +
- O +
transferase O +
activity O +
. O +

The O +
results O +
suggest O +
that O +
chronic O +
exposure O +
to O +
high O +
concentration O +
of O +
TGF O +
- O +
beta O +
promotes O +
the O +
spontaneous O +
neoplastic O +
transformation O +
of O +
cultured O +
rat O +
liver O +
epithelial O +
cells O +
, O +
and O +
that O +
this O +
process O +
may O +
represent O +
one O +
of O +
the O +
mechanisms O +
of O +
cellular O +
adaptation O +
for O +
induction O +
of O +
the O +
multidrug O +
- O +
resistant O +
phenotype O +
during O +
the O +
carcinogenesis O +
of O +
epithelial O +
cells O +
. O +

Human O +
cytomegalovirus O +
elevates O +
levels O +
of O +
the O +
cellular O +
protein O +
p53 O +
in O +
infected O +
fibroblasts O +
. O +

Human O +
cytomegalovirus O +
( O +
HCMV O +
) O +
, O +
like O +
other O +
DNA O +
tumor O +
viruses O +
, O +
induces O +
morphological O +
transformation O +
of O +
cells O +
in O +
vitro O +
and O +
stimulates O +
host O +
cell O +
macromolecular O +
synthesis O +
in O +
infected O +
cells O +
. O +

Since O +
other O +
DNA O +
tumor O +
viruses O +
, O +
such O +
as O +
simian O +
virus O +
40 O +
and O +
adenovirus O +
, O +
have O +
previously O +
been O +
shown O +
to O +
interact O +
with O +
cellular O +
protein O +
p53 O +
, O +
we O +
investigated O +
whether O +
infection O +
of O +
cells O +
by O +
HCMV O +
would O +
modulate O +
cellular O +
p53 O +
levels O +
. O +

Our O +
results O +
indicate O +
that O +
HCMV O +
elevates O +
cellular O +
p53 O +
levels O +
on O +
the O +
order O +
of O +
10 O +
- O +
to O +
20 O +
- O +
fold O +
in O +
infected O +
fibroblasts O +
. O +

The O +
induction O +
of O +
elevated O +
p53 O +
levels O +
was O +
dependent O +
upon O +
the O +
presence O +
of O +
active O +
virus O +
and O +
was O +
prevented O +
by O +
neutralizing O +
antibody O +
. O +

The O +
induction O +
of O +
elevated O +
p53 O +
levels O +
was O +
determined O +
not O +
to O +
be O +
due O +
to O +
virus O +
- O +
receptor O +
interactions O +
or O +
HCMV O +
late O +
events O +
. O +

The O +
induction O +
of O +
elevated O +
p53 O +
levels O +
commenced O +
at O +
immediate O +
- O +
early O +
times O +
of O +
the O +
HCMV O +
multiplication O +
cycle O +
( O +
6 O +
h O +
postinfection O +
) O +
and O +
reached O +
maximal O +
levels O +
by O +
24 O +
h O +
postinfection O +
, O +
before O +
most O +
of O +
the O +
HCMV O +
DNA O +
synthesis O +
was O +
initiated O +
. O +

HCMV O +
immediate O +
- O +
early O +
proteins O +
were O +
clearly O +
shown O +
to O +
be O +
responsible O +
for O +
elevating O +
p53 O +
levels O +
in O +
infected O +
fibroblasts O +
; O +
expression O +
of O +
HCMV O +
immediate O +
- O +
early O +
region O +
1 O +
and O +
2 O +
proteins O +
resulted O +
in O +
elevation O +
of O +
p53 O +
levels O +
in O +
transfected O +
human O +
fibroblasts O +
. O +

This O +
is O +
the O +
first O +
report O +
of O +
increased O +
p53 O +
levels O +
caused O +
by O +
HCMV O +
in O +
infected O +
fibroblasts O +
. O +

Appetite O +
regulation O +
by O +
serotoninergic O +
mechanisms O +
and O +
effects O +
of O +
d O +
- O +
fenfluramine O +
. O +

In O +
this O +
literature O +
review O +
, O +
evidence O +
is O +
presented O +
for O +
the O +
theory O +
that O +
the O +
neurotransmitter O +
, O +
serotonin O +
( O +
5 O +
- O +
hydroxytryptamine O +
, O +
5HT O +
) O +
, O +
in O +
medial O +
hypothalamic O +
centres O +
is O +
an O +
important O +
regulator O +
for O +
appetite O +
and O +
for O +
the O +
selection O +
of O +
major O +
food O +
constituents O +
. O +

High O +
local O +
levels O +
of O +
5HT O +
cause O +
a O +
reduction O +
of O +
appetite O +
and O +
a O +
preference O +
for O +
protein O +
, O +
low O +
levels O +
the O +
opposite O +
. O +

The O +
main O +
antagonistic O +
system O +
is O +
noradrenergic O +
. O +

The O +
drug O +
d O +
- O +
fenfluramine O +
mimics O +
the O +
effects O +
of O +
5HT O +
by O +
releasing O +
5HT O +
from O +
serotoninergic O +
nerve O +
endings O +
and O +
inhibiting O +
its O +
neuronal O +
re O +
- O +
uptake O +
. O +

Further O +
experimental O +
data O +
prove O +
that O +
a O +
high O +
- O +
carbohydrate O +
, O +
low O +
- O +
protein O +
diet O +
promotes O +
uptake O +
of O +
serum O +
tryptophan O +
in O +
the O +
brain O +
and O +
its O +
conversion O +
into O +
5HT O +
. O +

Hence O +
, O +
this O +
serotoninergic O +
system O +
may O +
function O +
as O +
a O +
self O +
- O +
regulatory O +
mechanism O +
. O +

In O +
patients O +
with O +
decreased O +
peripheral O +
insulin O +
sensitivity O +
, O +
the O +
system O +
may O +
be O +
disturbed O +
, O +
causing O +
overconsumption O +
of O +
carbohydrates O +
. O +

This O +
is O +
sometimes O +
compulsive O +
( O +
" O +
carbohydrate O +
craving O +
" O +
) O +
. O +

It O +
may O +
be O +
presumed O +
that O +
in O +
the O +
treatment O +
of O +
obesity O +
, O +
in O +
addition O +
to O +
the O +
use O +
of O +
serotoninergic O +
drugs O +
, O +
successes O +
with O +
reducing O +
diets O +
may O +
be O +
enhanced O +
by O +
including O +
periods O +
of O +
high O +
- O +
carbohydrate O +
, O +
low O +
- O +
protein O +
intake O +
. O +

It O +
would O +
be O +
worthwhile O +
to O +
explore O +
whether O +
similar O +
alimentary O +
self O +
- O +
regulatory O +
mechanisms O +
of O +
neurotransmitter O +
function O +
exist O +
in O +
other O +
regulatory O +
systems O +
. O +

Comparison O +
of O +
image O +
( O +
CAS O +
200 O +
) O +
and O +
flow O +
cytometry O +
determined O +
DNA O +
content O +
of O +
paraffin O +
- O +
embedded O +
Hodgkin O +
' O +
s O +
disease O +
tissue O +
. O +

To O +
assess O +
the O +
reliability O +
of O +
DNA O +
estimation O +
using O +
image O +
cytometry O +
, O +
deparaffinized O +
lymph O +
nodes O +
from O +
70 O +
patients O +
with O +
Hodgkin O +
' O +
s O +
disease O +
were O +
examined O +
and O +
the O +
results O +
obtained O +
were O +
compared O +
with O +
those O +
from O +
flow O +
cytometry O +
. O +

Image O +
analysis O +
without O +
discriminating O +
between O +
the O +
various O +
cell O +
types O +
, O +
as O +
found O +
in O +
Hodgkin O +
' O +
s O +
disease O +
, O +
revealed O +
no O +
separate O +
aneuploid O +
peak O +
. O +

Selecting O +
on O +
morphologically O +
defined O +
nuclear O +
types O +
DNA O +
aneuploidy O +
was O +
detected O +
in O +
20 O +
% O +
of O +
the O +
cases O +
( O +
14 O +
/ O +
70 O +
) O +
. O +

The O +
aneuploid O +
populations O +
were O +
limited O +
to O +
the O +
population O +
of O +
nuclei O +
defined O +
as O +
Reed O +
- O +
Sternberg O +
( O +
RS O +
) O +
- O +
like O +
or O +
medium O +
- O +
sized O +
lymphocytes O +
. O +

Benign O +
lymph O +
nodes O +
DNA O +
aneuploidy O +
was O +
not O +
found O +
in O +
any O +
of O +
the O +
controls O +
. O +

Comparison O +
of O +
DNA O +
histograms O +
obtained O +
by O +
image O +
and O +
flow O +
cytometry O +
showed O +
aneuploid O +
peaks O +
using O +
image O +
cytometry O +
in O +
4 O +
of O +
30 O +
diploid O +
and O +
10 O +
of O +
40 O +
aneuploid O +
flow O +
histograms O +
. O +

In O +
conclusion O +
, O +
image O +
analysis O +
using O +
the O +
CAS O +
200 O +
system O +
as O +
compared O +
to O +
flow O +
cytometry O +
is O +
more O +
time O +
- O +
consuming O +
and O +
less O +
sensitive O +
to O +
assess O +
ploidy O +
status O +
, O +
although O +
it O +
may O +
provide O +
extra O +
information O +
in O +
some O +
selected O +
cases O +
. O +

Evidence O +
is O +
obtained O +
that O +
DNA O +
aneuploidy O +
in O +
Hodgkin O +
' O +
s O +
disease O +
is O +
preferentially O +
expressed O +
by O +
cells O +
with O +
the O +
RS O +
/ O +
H O +
- O +
like O +
and O +
medium O +
- O +
sized O +
lymphocyte O +
morphology O +
. O +

Inhibition O +
of O +
calmodulin O +
- O +
dependent O +
myosin O +
light O +
- O +
chain O +
kinase O +
by O +
growth O +
- O +
hormone O +
- O +
releasing O +
factor O +
and O +
vasoactive O +
intestinal O +
peptide O +
. O +

In O +
view O +
of O +
the O +
ability O +
of O +
calmodulin O +
to O +
bind O +
vasoactive O +
intestinal O +
peptide O +
( O +
VIP O +
) O +
and O +
growth O +
- O +
hormone O +
- O +
releasing O +
factor O +
( O +
GRF O +
) O +
with O +
high O +
affinity O +
[ O +
Stallwood O +
, O +
Brugger O +
, O +
Baggenstoss O +
, O +
Stemmer O +
, O +
Shiraga O +
, O +
Landers O +
and O +
Paul O +
( O +
1992 O +
) O +
J O +
. O +
Biol O +
. O +
Chem O +
. O +
267 O +
, O +
19617 O +
- O +
19621 O +
] O +
, O +
the O +
effects O +
of O +
these O +
neuropeptides O +
on O +
a O +
model O +
calmodulin O +
- O +
dependent O +
enzyme O +
, O +
myosin O +
light O +
- O +
chain O +
kinase O +
( O +
MLCK O +
) O +
, O +
were O +
studied O +
. O +

Both O +
peptides O +
were O +
potent O +
inhibitors O +
of O +
MLCK O +
activity O +
. O +

The O +
inhibition O +
of O +
enzyme O +
activity O +
by O +
VIP O +
and O +
GRF O +
was O +
progressively O +
overcome O +
with O +
increasing O +
calmodulin O +
concentrations O +
, O +
with O +
no O +
inhibition O +
observed O +
at O +
a O +
saturating O +
calmodulin O +
concentration O +
. O +

Nanomolar O +
concentrations O +
of O +
MLCK O +
blocked O +
the O +
formation O +
of O +
calmodulin O +
- O +
[ O +
125I O +
- O +
Tyr10 O +
] O +
VIP O +
complexes O +
. O +

These O +
data O +
provide O +
support O +
for O +
a O +
functional O +
role O +
of O +
VIP O +
and O +
GRF O +
binding O +
by O +
calmodulin O +
. O +

Cyclin O +
D1 O +
/ O +
bcl O +
- O +
1 O +
cooperates O +
with O +
myc O +
genes O +
in O +
the O +
generation O +
of O +
B O +
- O +
cell O +
lymphoma O +
in O +
transgenic O +
mice O +
. O +

The O +
chromosomal O +
translocation O +
t O +
( O +
11 O +
: O +
14 O +
) O +
is O +
associated O +
with O +
human O +
lymphoid O +
neoplasia O +
affecting O +
centrocytic O +
B O +
- O +
cells O +
of O +
intermediate O +
differentiation O +
. O +

As O +
a O +
consequence O +
the O +
cyclin O +
D1 O +
( O +
bcl O +
- O +
1 O +
) O +
gene O +
is O +
juxtaposed O +
to O +
the O +
immunoglobulin O +
heavy O +
chain O +
enhancer O +
E O +
mu O +
. O +

To O +
show O +
that O +
transcriptional O +
activation O +
of O +
cyclin O +
D1 O +
is O +
causally O +
involved O +
in O +
the O +
generation O +
of O +
B O +
- O +
cell O +
neoplasia O +
we O +
have O +
generated O +
transgenic O +
mice O +
that O +
carry O +
a O +
cyclin O +
D1 O +
gene O +
under O +
the O +
transcriptional O +
control O +
of O +
the O +
E O +
mu O +
element O +
. O +

E O +
mu O +
cyclin O +
D1 O +
transgenic O +
mice O +
show O +
only O +
very O +
subtle O +
alterations O +
in O +
the O +
cycling O +
behaviour O +
of O +
B O +
- O +
cell O +
populations O +
in O +
the O +
bone O +
marrow O +
compared O +
with O +
normal O +
mice O +
and O +
do O +
not O +
develop O +
lymphoid O +
tumours O +
. O +

However O +
, O +
E O +
mu O +
- O +
directed O +
coexpression O +
of O +
cyclin O +
D1 O +
and O +
N O +
- O +
MYC O +
or O +
L O +
- O +
MYC O +
in O +
double O +
transgenic O +
mice O +
reveals O +
a O +
strong O +
cooperative O +
effect O +
between O +
MYC O +
and O +
cyclin O +
D1 O +
provoking O +
the O +
rapid O +
development O +
of O +
clonal O +
pre O +
- O +
B O +
and O +
B O +
- O +
cell O +
lymphomas O +
. O +

Interestingly O +
, O +
crossing O +
of O +
cyclin O +
D1 O +
transgenic O +
mice O +
with O +
E O +
mu O +
L O +
- O +
myc O +
transgenics O +
that O +
express O +
their O +
transgene O +
in O +
both O +
B O +
- O +
and O +
T O +
- O +
cells O +
but O +
predominantly O +
develop O +
T O +
- O +
cell O +
tumours O +
leads O +
in O +
double O +
transgenics O +
exclusively O +
to O +
B O +
- O +
cell O +
neoplasia O +
. O +

The O +
data O +
presented O +
here O +
demonstrate O +
that O +
transcriptional O +
activation O +
of O +
cyclin O +
D1 O +
can O +
oncogenically O +
transform O +
B O +
- O +
cells O +
in O +
concert O +
with O +
a O +
myc O +
gene O +
. O +

They O +
establish O +
cyclin O +
D1 O +
as O +
a O +
proto O +
- O +
oncogene O +
whose O +
activity O +
appears O +
to O +
depend O +
on O +
a O +
specific O +
cell O +
type O +
as O +
well O +
as O +
on O +
a O +
specific O +
cooperating O +
partner O +
and O +
link O +
disturbances O +
in O +
the O +
regulation O +
of O +
cell O +
cycle O +
progression O +
to O +
the O +
development O +
of O +
human O +
malignancies O +
. O +

Imaging O +
techniques O +
for O +
the O +
assessment O +
of O +
body O +
composition O +
. O +

Three O +
imaging O +
methods O +
, O +
ultrasound O +
imaging O +
( O +
UI O +
) O +
, O +
computer O +
- O +
assisted O +
axial O +
tomography O +
( O +
CAT O +
) O +
and O +
magnetic O +
resonance O +
imaging O +
( O +
MRI O +
) O +
, O +
are O +
widely O +
used O +
in O +
medicine O +
. O +

Their O +
application O +
to O +
the O +
assessment O +
of O +
body O +
composition O +
in O +
nutrition O +
research O +
is O +
still O +
being O +
explored O +
and O +
developed O +
. O +

Ultrasound O +
imaging O +
yields O +
poor O +
image O +
quality O +
but O +
, O +
because O +
it O +
is O +
cheap O +
and O +
safe O +
, O +
deserves O +
further O +
exploration O +
. O +

Both O +
CAT O +
and O +
MRI O +
can O +
produce O +
images O +
with O +
good O +
discrimination O +
among O +
bone O +
, O +
muscle O +
and O +
adipose O +
tissue O +
. O +

Movement O +
artifacts O +
tend O +
to O +
be O +
more O +
serious O +
in O +
MRI O +
than O +
in O +
CAT O +
due O +
to O +
the O +
longer O +
imaging O +
time O +
. O +

On O +
the O +
other O +
hand O +
, O +
the O +
X O +
- O +
ray O +
exposure O +
in O +
CAT O +
is O +
likely O +
to O +
limit O +
its O +
use O +
in O +
human O +
nutrition O +
research O +
. O +

Repeated O +
measurements O +
of O +
tissue O +
volumes O +
by O +
CAT O +
and O +
MRI O +
give O +
similar O +
CV O +
. O +

In O +
both O +
CAT O +
and O +
MRI O +
, O +
intra O +
- O +
abdominal O +
adipose O +
tissue O +
presents O +
greater O +
problems O +
of O +
measurement O +
than O +
subcutaneous O +
adipose O +
tissue O +
. O +

Validation O +
studies O +
with O +
77 O +
- O +
kg O +
pigs O +
of O +
MRI O +
, O +
using O +
13 O +
slices O +
, O +
predicted O +
total O +
body O +
lipid O +
with O +
residual O +
standard O +
deviation O +
of O +
1 O +
. O +
9 O +
% O +
. O +

In O +
validating O +
any O +
of O +
these O +
methods O +
, O +
account O +
should O +
be O +
take O +
of O +
the O +
extent O +
to O +
which O +
the O +
information O +
they O +
give O +
can O +
augment O +
that O +
given O +
by O +
more O +
simple O +
measures O +
like O +
age O +
and O +
weight O +
. O +

[ O +
Preliminary O +
results O +
of O +
observing O +
18 O +
cases O +
of O +
retinoblastoma O +
carried O +
within O +
the O +
international O +
research O +
program O +
RICS O +
] O +
. O +

In O +
the O +
years O +
1988 O +
- O +
1989 O +
, O +
the O +
Ophthalmological O +
Clinic O +
in O +
Cracow O +
took O +
part O +
in O +
the O +
International O +
Research O +
Programme O +
on O +
Retinoblastoma O +
as O +
one O +
of O +
28 O +
clinical O +
centres O +
in O +
14 O +
countries O +
. O +

The O +
study O +
included O +
18 O +
children O +
with O +
retinoblastoma O +
, O +
in O +
most O +
cases O +
in O +
the O +
advanced O +
stadium O +
of O +
the O +
disease O +
. O +

As O +
a O +
rule O +
, O +
the O +
eyes O +
filled O +
with O +
tumours O +
were O +
enucleated O +
, O +
and O +
the O +
less O +
advanced O +
cases O +
were O +
treated O +
with O +
combined O +
methods O +
applying O +
radiation O +
with O +
60Co O +
plaques O +
with O +
xenon O +
arc O +
photocoagulation O +
, O +
cryopexy O +
, O +
and O +
chemotherapy O +
. O +

In O +
18 O +
treated O +
children O +
23 O +
eyes O +
were O +
enucleated O +
( O +
in O +
5 O +
children O +
both O +
eyes O +
, O +
in O +
6 O +
children O +
with O +
bilateral O +
retinoblastoma O +
1 O +
eye O +
, O +
and O +
7 O +
eyes O +
in O +
all O +
unilateral O +
cases O +
) O +
. O +

Six O +
eyes O +
with O +
less O +
advanced O +
lesions O +
were O +
treated O +
with O +
combined O +
methods O +
. O +

One O +
child O +
died O +
because O +
of O +
metastases O +
to O +
the O +
brain O +
. O +

The O +
obtained O +
data O +
reveal O +
that O +
retinoblastoma O +
is O +
diagnosed O +
too O +
late O +
, O +
which O +
decreases O +
the O +
chance O +
of O +
cure O +
and O +
causes O +
great O +
danger O +
for O +
the O +
life O +
of O +
the O +
child O +
. O +

Identification O +
of O +
latency O +
- O +
associated O +
transcripts O +
that O +
map O +
antisense O +
to O +
the O +
ICP4 O +
homolog O +
gene O +
of O +
Marek O +
' O +
s O +
disease O +
virus O +
. O +

Two O +
small O +
RNAs O +
( O +
0 O +
. O +
9 O +
and O +
0 O +
. O +
75 O +
kb O +
) O +
, O +
named O +
Marek O +
' O +
s O +
disease O +
virus O +
( O +
MDV O +
) O +
small O +
RNAs O +
( O +
MSRs O +
) O +
and O +
a O +
10 O +
- O +
kb O +
RNA O +
, O +
all O +
of O +
which O +
map O +
antisense O +
to O +
the O +
MDV O +
ICP4 O +
homolog O +
gene O +
, O +
have O +
been O +
readily O +
detected O +
in O +
MDCC B-CellLine +
- I-CellLine +
MSB1 I-CellLine +
MDV O +
- O +
transformed O +
T O +
- O +
lymphoblastoid O +
cells O +
. O +

These O +
RNAs O +
were O +
not O +
detectable O +
in O +
reticuloendotheliosis O +
virus O +
- O +
transformed O +
T O +
cells O +
. O +

When O +
MDV O +
was O +
reactivated O +
by O +
treatment O +
of O +
lymphoblastoid O +
cells O +
with O +
25 O +
micrograms O +
of O +
iododeoxyuridine O +
per O +
ml O +
, O +
the O +
relative O +
levels O +
of O +
the O +
transcripts O +
decreased O +
. O +

These O +
RNAs O +
were O +
not O +
detected O +
by O +
Northern O +
( O +
RNA O +
) O +
hybridization O +
in O +
productively O +
infected O +
chicken O +
embryo O +
fibroblasts O +
48 O +
h O +
postinfection O +
; O +
however O +
, O +
they O +
were O +
apparent O +
140 O +
h O +
postinfection O +
. O +

By O +
using O +
Northern O +
hybridization O +
, O +
RNase O +
protection O +
assays O +
, O +
and O +
primer O +
extension O +
analysis O +
, O +
the O +
MSRs O +
were O +
determined O +
to O +
map O +
antisense O +
to O +
the O +
predicted O +
translational O +
start O +
site O +
of O +
the O +
ICP4 O +
homolog O +
gene O +
. O +

The O +
conclusion O +
most O +
consistent O +
with O +
the O +
data O +
is O +
that O +
the O +
two O +
MSRs O +
are O +
overlapping O +
, O +
spliced O +
RNAs O +
. O +

Both O +
small O +
RNAs O +
contain O +
a O +
latency O +
promoter O +
binding O +
factor O +
consensus O +
recognition O +
sequence O +
located O +
toward O +
their O +
5 O +
' O +
ends O +
as O +
well O +
as O +
two O +
potential O +
ICP4 O +
recognition O +
consensus O +
sequences O +
, O +
one O +
in O +
each O +
orientation O +
. O +

The O +
region O +
contains O +
a O +
number O +
of O +
small O +
open O +
reading O +
frames O +
on O +
each O +
side O +
and O +
within O +
the O +
MSRs O +
. O +

Although O +
the O +
exact O +
endpoints O +
are O +
unknown O +
, O +
the O +
large O +
10 O +
- O +
kb O +
species O +
spans O +
the O +
entire O +
ICP4 O +
homolog O +
region O +
. O +

We O +
believe O +
that O +
this O +
group O +
of O +
RNAs O +
, O +
which O +
map O +
antisense O +
to O +
the O +
ICP4 O +
homolog O +
gene O +
, O +
are O +
latency O +
- O +
associated O +
transcripts O +
of O +
MDV O +
. O +

Elevated O +
expression O +
of O +
the O +
junB O +
proto O +
- O +
oncogene O +
is O +
essential O +
for O +
v O +
- O +
fos O +
induced O +
transformation O +
of O +
Rat B-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
. O +

We O +
previously O +
described O +
the O +
isolation O +
of O +
non O +
- O +
tumorigenic O +
revertants O +
from O +
mutagenized O +
populations O +
of O +
v O +
- O +
fos O +
- O +
transformed O +
Rat B-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
( O +
Zarbl O +
et O +
al O +
. O +
, O +
1987 O +
) O +
. O +

In O +
the O +
present O +
study O +
we O +
examined O +
the O +
possibility O +
that O +
the O +
revertant O +
phenotype O +
resulted O +
from O +
mutations O +
that O +
altered O +
the O +
expression O +
or O +
activities O +
of O +
the O +
c O +
- O +
jun O +
or O +
junB O +
proto O +
- O +
oncogenes O +
. O +

The O +
results O +
demonstrated O +
that O +
levels O +
of O +
the O +
c O +
- O +
jun O +
mRNA O +
and O +
protein O +
were O +
unchanged O +
in O +
the O +
revertants O +
when O +
compared O +
to O +
the O +
transformed O +
parental O +
cells O +
, O +
and O +
ectopic O +
overexpression O +
of O +
c O +
- O +
jun O +
failed O +
to O +
retransform O +
the O +
revertants O +
. O +

Although O +
one O +
mutant O +
allele O +
was O +
detected O +
in O +
revertant O +
EMS B-CellLine +
- I-CellLine +
1 I-CellLine +
- I-CellLine +
19 I-CellLine +
, O +
overexpression O +
of O +
this O +
mutant O +
allele O +
failed O +
to O +
inhibit O +
v O +
- O +
fos O +
induced O +
cell O +
transformation O +
. O +

Together O +
these O +
results O +
indicated O +
that O +
the O +
revertant O +
phenotype O +
did O +
not O +
result O +
from O +
altered O +
expression O +
or O +
mutations O +
in O +
the O +
c O +
- O +
jun O +
gene O +
. O +

In O +
contrast O +
to O +
the O +
results O +
obtained O +
with O +
c O +
- O +
jun O +
, O +
the O +
levels O +
of O +
junB O +
mRNA O +
and O +
protein O +
were O +
found O +
to O +
be O +
reduced O +
two O +
- O +
or O +
threefold O +
in O +
revertant O +
EMS B-CellLine +
- I-CellLine +
1 I-CellLine +
- I-CellLine +
19 I-CellLine +
. O +

Ectopic O +
overexpression O +
of O +
junB O +
induced O +
transformation O +
of O +
revertant O +
EMS B-CellLine +
- I-CellLine +
1 I-CellLine +
- I-CellLine +
19 I-CellLine +
, O +
but O +
failed O +
to O +
transform O +
Rat B-CellLine +
- I-CellLine +
1 I-CellLine +
cells O +
. O +

Moreover O +
, O +
about O +
10 O +
% O +
of O +
v O +
- O +
fos O +
transformed O +
cells O +
transfected O +
with O +
vectors O +
that O +
express O +
antisense O +
junB O +
mRNA O +
acquired O +
a O +
non O +
- O +
transformed O +
phenotype O +
. O +

Together O +
these O +
results O +
indicate O +
that O +
expression O +
of O +
junB O +
above O +
a O +
threshold O +
level O +
is O +
essential O +
for O +
v O +
- O +
fos O +
- O +
induced O +
transformation O +
of O +
Rat B-CellLine +
- I-CellLine +
1 I-CellLine +
fibroblasts O +
. O +

Increased O +
expression O +
of O +
specific O +
protein O +
tyrosine O +
phosphatases O +
in O +
human O +
breast O +
epithelial O +
cells O +
neoplastically O +
transformed O +
by O +
the O +
neu O +
oncogene O +
. O +

Protein O +
tyrosine O +
phosphorylation O +
/ O +
dephosphorylation O +
is O +
a O +
fundamental O +
mechanism O +
in O +
the O +
regulation O +
of O +
cell O +
proliferation O +
and O +
neoplastic O +
transformation O +
; O +
this O +
metabolic O +
process O +
is O +
modulated O +
by O +
the O +
opposing O +
activities O +
of O +
protein O +
tyrosine O +
kinases O +
and O +
protein O +
tyrosine O +
phosphatases O +
( O +
PTPases O +
) O +
. O +

While O +
the O +
role O +
of O +
protein O +
tyrosine O +
kinases O +
has O +
been O +
examined O +
extensively O +
in O +
human O +
breast O +
tumorigenesis O +
, O +
the O +
role O +
of O +
PTPases O +
in O +
this O +
process O +
is O +
virtually O +
unknown O +
. O +

To O +
address O +
this O +
issue O +
, O +
an O +
activated O +
neu O +
oncogene O +
was O +
introduced O +
into O +
an O +
immortalized O +
nontumorigenic O +
human O +
breast O +
epithelial O +
cell O +
line O +
( O +
184B5 B-CellLine +
) O +
. O +

This O +
resulted O +
in O +
a O +
substantial O +
increase O +
in O +
P185neu O +
expression O +
, O +
which O +
led O +
to O +
the O +
formation O +
of O +
progressively O +
growing O +
carcinomas O +
after O +
such O +
cells O +
were O +
inoculated O +
into O +
athymic O +
nude O +
mice O +
. O +

Importantly O +
, O +
a O +
striking O +
increase O +
in O +
the O +
expression O +
of O +
specific O +
PTPases O +
, O +
LAR O +
and O +
PTP1B O +
, O +
was O +
observed O +
in O +
3 O +
independently O +
neu O +
transformed O +
cell O +
lines O +
and O +
their O +
derived O +
tumors O +
. O +

This O +
elevation O +
was O +
verified O +
at O +
both O +
the O +
mRNA O +
and O +
protein O +
levels O +
. O +

TC O +
- O +
PTP O +
PTPase O +
expression O +
was O +
only O +
slightly O +
increased O +
in O +
these O +
neu O +
transformed O +
cells O +
, O +
and O +
no O +
expression O +
of O +
CD45 O +
PTPase O +
was O +
observed O +
. O +

The O +
level O +
of O +
neu O +
expression O +
, O +
as O +
well O +
as O +
the O +
differential O +
expression O +
between O +
P185neu O +
and O +
LAR O +
/ O +
PTP1B O +
, O +
directly O +
correlated O +
with O +
tumorigenicity O +
. O +

Furthermore O +
, O +
rat O +
mammary O +
carcinomas O +
with O +
elevated O +
neu O +
expression O +
( O +
neu O +
- O +
induced O +
) O +
also O +
had O +
sharply O +
elevated O +
LAR O +
- O +
PTPase O +
expression O +
when O +
compared O +
to O +
rat O +
mammary O +
carcinomas O +
with O +
little O +
or O +
no O +
neu O +
expression O +
( O +
7 O +
, O +
12 O +
- O +
dimethylbenzanthracene O +
induced O +
) O +
; O +
the O +
level O +
of O +
expression O +
of O +
LAR O +
PTPase O +
was O +
directly O +
correlated O +
with O +
the O +
level O +
of O +
neu O +
expression O +
. O +

Thus O +
, O +
our O +
results O +
provide O +
the O +
first O +
evidence O +
that O +
, O +
in O +
human O +
breast O +
carcinoma O +
cells O +
and O +
in O +
rat O +
mammary O +
carcinomas O +
that O +
have O +
an O +
induced O +
increase O +
in O +
neu O +
expression O +
, O +
a O +
consistent O +
and O +
substantial O +
increase O +
in O +
the O +
expression O +
of O +
specific O +
PTPases O +
occurs O +
. O +

The O +
relationship O +
between O +
P185neu O +
- O +
protein O +
tyrosine O +
kinase O +
expression O +
and O +
specific O +
PTPase O +
expression O +
may O +
play O +
a O +
critical O +
role O +
in O +
human O +
breast O +
tumorigenesis O +
. O +

Epilepsy O +
in O +
Down O +
syndrome O +
: O +
clinical O +
aspects O +
and O +
possible O +
mechanisms O +
. O +

Although O +
epilepsy O +
is O +
more O +
common O +
in O +
persons O +
with O +
trisomy O +
21 O +
( O +
Down O +
syndrome O +
) O +
than O +
in O +
the O +
general O +
population O +
, O +
the O +
mechanisms O +
by O +
which O +
seizures O +
are O +
generated O +
in O +
this O +
population O +
have O +
received O +
little O +
attention O +
. O +

It O +
is O +
likely O +
that O +
this O +
increased O +
seizure O +
susceptibility O +
is O +
due O +
to O +
a O +
combination O +
of O +
medical O +
risk O +
factors O +
and O +
inherent O +
neurologic O +
abnormalities O +
characteristic O +
of O +
Down O +
syndrome O +
. O +

In O +
this O +
review O +
clinical O +
aspects O +
of O +
seizures O +
among O +
individuals O +
with O +
Down O +
syndrome O +
were O +
described O +
and O +
possible O +
mechanisms O +
by O +
which O +
the O +
trisomy O +
21 O +
brain O +
may O +
generate O +
seizures O +
were O +
explored O +
. O +

In O +
vivo O +
effects O +
of O +
insulin O +
on O +
tumor O +
and O +
skeletal O +
muscle O +
glucose O +
metabolism O +
in O +
patients O +
with O +
lymphoma O +
. O +

BACKGROUND O +
: O +
The O +
anabolic O +
properties O +
of O +
insulin O +
have O +
been O +
suggested O +
for O +
use O +
to O +
reverse O +
malnutrition O +
associated O +
with O +
cancer O +
. O +

The O +
host O +
and O +
tumor O +
sensitivities O +
to O +
insulin O +
are O +
critical O +
for O +
such O +
treatments O +
, O +
which O +
aim O +
to O +
improve O +
patient O +
nutrition O +
. O +

The O +
authors O +
studied O +
insulin O +
effects O +
on O +
tumor O +
and O +
skeletal O +
muscle O +
metabolism O +
with O +
2 O +
- O +
[ O +
18F O +
] O +
- O +
fluoro O +
- O +
2 O +
- O +
deoxy O +
- O +
D O +
- O +
glucose O +
( O +
[ O +
18F O +
] O +
FDG O +
) O +
and O +
positron O +
emission O +
tomography O +
( O +
PET O +
) O +
. O +

METHODS O +
: O +
Six O +
patients O +
with O +
lymphoma O +
twice O +
underwent O +
[ O +
18F O +
] O +
FDG O +
- O +
PET O +
imaging O +
: O +
once O +
after O +
fasting O +
overnight O +
and O +
once O +
during O +
euglycemic O +
hyperinsulinemic O +
clamp O +
. O +

The O +
dynamic O +
uptake O +
of O +
the O +
glucose O +
analogue O +
[ O +
18F O +
] O +
FDG O +
was O +
measured O +
in O +
diseased O +
nodes O +
and O +
upper O +
arm O +
skeletal O +
muscle O +
in O +
both O +
metabolic O +
states O +
. O +

The O +
[ O +
18F O +
] O +
FDG O +
uptake O +
in O +
muscle O +
and O +
the O +
whole O +
body O +
glucose O +
use O +
during O +
euglycemic O +
hyperinsulinemic O +
clamp O +
were O +
compared O +
with O +
those O +
of O +
weight O +
- O +
matched O +
healthy O +
subjects O +
studied O +
under O +
similar O +
circumstances O +
. O +

RESULTS O +
: O +
In O +
lymphomatous O +
tissue O +
, O +
[ O +
18F O +
] O +
FDG O +
uptake O +
rates O +
were O +
similar O +
in O +
overnight O +
fasting O +
and O +
euglycemic O +
hyperinsulinemic O +
clamp O +
( O +
38 O +
+ O +
/ O +
- O +
10 O +
versus O +
41 O +
+ O +
/ O +
- O +
9 O +
mumol O +
/ O +
100 O +
g O +
/ O +
minute O +
, O +
not O +
significant O +
) O +
, O +
whereas O +
glucose O +
uptake O +
in O +
skeletal O +
muscle O +
was O +
increased O +
by O +
insulin O +
( O +
1 O +
. O +
7 O +
+ O +
/ O +
- O +
0 O +
. O +
2 O +
versus O +
3 O +
. O +
8 O +
+ O +
/ O +
- O +
0 O +
. O +
5 O +
mumol O +
/ O +
100 O +
g O +
/ O +
minute O +
, O +
P O +
= O +
0 O +
. O +
012 O +
) O +
. O +

Both O +
basal O +
( O +
2 O +
. O +
3 O +
+ O +
/ O +
- O +
0 O +
. O +
2 O +
mumol O +
/ O +
100 O +
g O +
/ O +
minute O +
, O +
P O +
= O +
0 O +
. O +
061 O +
) O +
and O +
insulin O +
- O +
stimulated O +
( O +
8 O +
. O +
5 O +
+ O +
/ O +
- O +
1 O +
. O +
9 O +
mumol O +
/ O +
100 O +
g O +
/ O +
minute O +
, O +
P O +
= O +
0 O +
. O +
055 O +
) O +
skeletal O +
arm O +
muscle O +
glucose O +
uptake O +
rates O +
were O +
higher O +
in O +
control O +
subjects O +
than O +
in O +
patients O +
. O +

Whole O +
body O +
glucose O +
use O +
was O +
55 O +
% O +
lower O +
in O +
patients O +
than O +
in O +
control O +
subjects O +
( O +
17 O +
+ O +
/ O +
- O +
3 O +
mumol O +
/ O +
kg O +
/ O +
minute O +
versus O +
38 O +
+ O +
/ O +
- O +
3 O +
mumol O +
/ O +
kg O +
/ O +
minute O +
, O +
P O +
= O +
0 O +
. O +
002 O +
) O +
, O +
consistent O +
with O +
insulin O +
resistance O +
in O +
cancer O +
. O +

CONCLUSIONS O +
: O +
We O +
found O +
that O +
insulin O +
does O +
not O +
induce O +
major O +
changes O +
in O +
glucose O +
uptake O +
of O +
lymphomatous O +
tissue O +
. O +

Although O +
insulin O +
sensitivity O +
of O +
skeletal O +
muscle O +
was O +
also O +
reduced O +
in O +
patients O +
with O +
lymphoma O +
, O +
the O +
net O +
insulin O +
effect O +
may O +
counteract O +
imbalance O +
between O +
glucose O +
uptake O +
of O +
tumor O +
and O +
muscle O +
, O +
offering O +
a O +
potential O +
means O +
to O +
circumvent O +
at O +
least O +
some O +
metabolic O +
abnormalities O +
found O +
in O +
cancer O +
. O +

Kinins O +
contribute O +
to O +
the O +
improvement O +
of O +
insulin O +
sensitivity O +
during O +
treatment O +
with O +
angiotensin O +
converting O +
enzyme O +
inhibitor O +
. O +

Although O +
angiotensin O +
converting O +
enzyme O +
inhibitors O +
and O +
alpha O +
1 O +
- O +
blockers O +
have O +
been O +
reported O +
to O +
improve O +
insulin O +
sensitivity O +
, O +
their O +
mechanisms O +
of O +
action O +
have O +
not O +
been O +
elucidated O +
. O +

To O +
investigate O +
the O +
role O +
of O +
kinins O +
in O +
insulin O +
sensitivity O +
, O +
we O +
treated O +
4 O +
- O +
week O +
- O +
old O +
spontaneously O +
hypertensive O +
rats O +
with O +
either O +
an O +
angiotensin O +
converting O +
enzyme O +
inhibitor O +
( O +
enalapril O +
) O +
, O +
an O +
alpha O +
1 O +
- O +
blocker O +
( O +
doxazosin O +
) O +
, O +
or O +
an O +
angiotensin O +
II O +
antagonist O +
( O +
losartan O +
) O +
for O +
3 O +
weeks O +
. O +

A O +
control O +
group O +
received O +
no O +
drugs O +
. O +

In O +
addition O +
, O +
18 O +
rats O +
treated O +
with O +
enalapril O +
or O +
doxazosin O +
received O +
a O +
simultaneous O +
administration O +
of O +
a O +
kinin O +
antagonist O +
( O +
Hoe O +
140 O +
) O +
. O +

Glucose O +
clamp O +
testing O +
was O +
performed O +
in O +
each O +
group O +
. O +

Enalapril O +
( O +
128 O +
+ O +
/ O +
- O +
1 O +
mmHg O +
) O +
and O +
doxazosin O +
( O +
132 O +
+ O +
/ O +
- O +
2 O +
mmHg O +
) O +
decreased O +
mean O +
blood O +
pressure O +
compared O +
with O +
control O +
levels O +
( O +
148 O +
+ O +
/ O +
- O +
1 O +
mmHg O +
) O +
( O +
P O +
< O +
. O +
01 O +
) O +
. O +

The O +
glucose O +
requirement O +
for O +
the O +
clamp O +
test O +
during O +
the O +
administration O +
of O +
enalapril O +
( O +
25 O +
. O +
8 O +
+ O +
/ O +
- O +
0 O +
. O +
5 O +
mg O +
/ O +
kg O +
per O +
minute O +
) O +
or O +
doxazosin O +
( O +
28 O +
. O +
6 O +
+ O +
/ O +
- O +
0 O +
. O +
7 O +
mg O +
/ O +
kg O +
per O +
minute O +
) O +
was O +
higher O +
than O +
that O +
of O +
the O +
control O +
group O +
( O +
19 O +
. O +
8 O +
+ O +
/ O +
- O +
0 O +
. O +
5 O +
mg O +
/ O +
kg O +
per O +
minute O +
) O +
( O +
P O +
< O +
. O +
05 O +
) O +
. O +

Although O +
Hoe O +
140 O +
did O +
not O +
alter O +
the O +
glucose O +
requirement O +
of O +
doxazosin O +
( O +
27 O +
. O +
8 O +
+ O +
/ O +
- O +
0 O +
. O +
5 O +
mg O +
/ O +
kg O +
per O +
minute O +
) O +
, O +
it O +
decreased O +
that O +
of O +
enalapril O +
( O +
22 O +
. O +
6 O +
+ O +
/ O +
- O +
0 O +
. O +
9 O +
mg O +
/ O +
kg O +
per O +
minute O +
) O +
( O +
P O +
< O +
. O +
05 O +
) O +
without O +
affecting O +
the O +
changes O +
in O +
mean O +
blood O +
pressure O +
induced O +
by O +
enalapril O +
. O +

In O +
addition O +
, O +
losartan O +
decreased O +
mean O +
blood O +
pressure O +
but O +
did O +
not O +
affect O +
the O +
glucose O +
requirement O +
. O +

Thus O +
, O +
the O +
improvement O +
in O +
insulin O +
sensitivity O +
produced O +
by O +
an O +
angiotensin O +
converting O +
enzyme O +
inhibitor O +
is O +
mostly O +
dependent O +
on O +
kinins O +
but O +
not O +
on O +
angiotensin O +
II O +
antagonism O +
, O +
and O +
an O +
alpha O +
1 O +
- O +
blocker O +
improves O +
insulin O +
sensitivity O +
irrespective O +
of O +
kinins O +
. O +

H O +
- O +
ras O +
mutations O +
in O +
human O +
pituitary O +
carcinoma O +
metastases O +
. O +

Molecular O +
mechanisms O +
of O +
pituitary O +
tumorigenesis O +
were O +
studied O +
using O +
Polymerase O +
chain O +
reaction O +
- O +
single O +
stranded O +
conformational O +
polymorphism O +
with O +
DNA O +
sequencing O +
to O +
identify O +
potential O +
mutations O +
in O +
the O +
ras O +
protooncogenes O +
and O +
the O +
tumor O +
suppressor O +
gene O +
p53 O +
in O +
invasive O +
pituitary O +
adenomas O +
and O +
carcinomas O +
. O +

Sequencing O +
of O +
exons O +
5 O +
through O +
8 O +
of O +
the O +
p53 O +
gene O +
revealed O +
no O +
mutations O +
, O +
nor O +
were O +
mutations O +
detected O +
in O +
the O +
N O +
- O +
or O +
K O +
- O +
ras O +
protooncogenes O +
in O +
four O +
of O +
the O +
carcinomas O +
and O +
their O +
respective O +
metastatic O +
deposits O +
. O +

Point O +
mutations O +
of O +
H O +
- O +
ras O +
however O +
, O +
were O +
identified O +
in O +
three O +
distant O +
metastatic O +
pituitary O +
tumor O +
secondaries O +
, O +
but O +
not O +
in O +
their O +
respective O +
primary O +
pituitary O +
carcinomas O +
, O +
or O +
in O +
six O +
invasive O +
adenomas O +
. O +

Two O +
of O +
the O +
mutations O +
included O +
a O +
G O +
to O +
C O +
substitution O +
at O +
codon O +
12 O +
, O +
and O +
a O +
G O +
to O +
A O +
substitution O +
at O +
codon O +
18 O +
, O +
resulting O +
in O +
a O +
glycine O +
to O +
arginine O +
, O +
and O +
an O +
alanine O +
to O +
threonine O +
change O +
at O +
these O +
amino O +
acids O +
, O +
respectively O +
. O +

A O +
third O +
mutation O +
involved O +
a O +
single O +
base O +
pair O +
( O +
adenine O +
) O +
deletion O +
in O +
codon O +
3 O +
of O +
H O +
- O +
ras O +
which O +
causes O +
a O +
frame O +
shift O +
, O +
resulting O +
in O +
a O +
termination O +
signal O +
at O +
codon O +
19 O +
. O +

These O +
results O +
suggest O +
that O +
point O +
mutations O +
in O +
p53 O +
and O +
ras O +
are O +
not O +
associated O +
with O +
pituitary O +
tumorigenesis O +
, O +
however O +
, O +
point O +
mutations O +
of O +
the O +
H O +
- O +
ras O +
gene O +
may O +
be O +
important O +
in O +
the O +
formation O +
and O +
or O +
growth O +
of O +
pituitary O +
metastases O +
. O +

This O +
observed O +
genomic O +
instability O +
will O +
be O +
of O +
value O +
in O +
predicting O +
the O +
potential O +
metastatic O +
behavior O +
of O +
these O +
aggressive O +
pituitary O +
tumors O +
. O +

Distribution O +
and O +
predictors O +
of O +
depressive O +
symptoms O +
in O +
osteoarthritis O +
. O +

OBJECTIVE O +
: O +

To O +
determine O +
the O +
prevalence O +
and O +
correlates O +
of O +
depressive O +
symptoms O +
in O +
a O +
sample O +
of O +
elderly O +
persons O +
with O +
osteoarthritis O +
( O +
OA O +
) O +
. O +

METHODS O +
: O +

Secondary O +
analysis O +
of O +
cross O +
sectional O +
interview O +
data O +
from O +
108 O +
community O +
living O +
persons O +
age O +
50 O +
or O +
over O +
who O +
met O +
American O +
College O +
of O +
Rheumatology O +
clinical O +
criteria O +
for O +
OA O +
of O +
the O +
hip O +
and O +
/ O +
or O +
knee O +
. O +

RESULTS O +
: O +

The O +
prevalence O +
of O +
substantial O +
depressive O +
symptomatology O +
appeared O +
to O +
be O +
no O +
greater O +
than O +
would O +
be O +
expected O +
in O +
the O +
general O +
population O +
for O +
this O +
age O +
group O +
. O +

However O +
, O +
persons O +
currently O +
under O +
a O +
physician O +
' O +
s O +
care O +
for O +
OA O +
were O +
significantly O +
more O +
depressed O +
than O +
those O +
not O +
under O +
care O +
, O +
and O +
, O +
with O +
the O +
exception O +
of O +
those O +
who O +
had O +
post O +
- O +
high O +
school O +
education O +
, O +
depression O +
was O +
a O +
better O +
predictor O +
of O +
being O +
under O +
care O +
than O +
OA O +
symptoms O +
. O +

The O +
direct O +
and O +
interactive O +
effects O +
of O +
3 O +
variables O +
- O +
- O +
education O +
, O +
age O +
and O +
self O +
- O +
perceived O +
impact O +
of O +
the O +
OA O +
problem O +
- O +
- O +
were O +
found O +
to O +
explain O +
40 O +
% O +
of O +
variance O +
in O +
depression O +
scores O +
in O +
the O +
total O +
sample O +
and O +
50 O +
% O +
among O +
those O +
currently O +
receiving O +
care O +
. O +

Younger O +
and O +
less O +
educated O +
subjects O +
had O +
relatively O +
more O +
depressive O +
symptoms O +
and O +
, O +
furthermore O +
, O +
in O +
this O +
subgroup O +
the O +
correlation O +
between O +
OA O +
impact O +
and O +
depression O +
was O +
high O +
. O +

CONCLUSIONS O +
: O +

The O +
importance O +
of O +
assessing O +
depression O +
in O +
persons O +
who O +
seek O +
care O +
for O +
OA O +
is O +
supported O +
. O +

Furthermore O +
, O +
our O +
results O +
suggest O +
that O +
the O +
observed O +
relationship O +
between O +
education O +
and O +
arthritis O +
outcomes O +
could O +
be O +
mediated O +
, O +
at O +
least O +
in O +
part O +
, O +
by O +
depression O +
. O +

Methotrexate O +
osteopathy O +
in O +
rheumatic O +
disease O +
. O +

OBJECTIVE O +
: O +

To O +
determine O +
whether O +
two O +
adults O +
with O +
stress O +
fractures O +
receiving O +
low O +
weekly O +
doses O +
of O +
methotrexate O +
had O +
methotrexate O +
osteopathy O +
. O +

CASE O +
REPORTS O +
: O +

Two O +
adult O +
patients O +
developed O +
features O +
consistent O +
with O +
methotrexate O +
osteopathy O +
while O +
receiving O +
low O +
weekly O +
doses O +
of O +
methotrexate O +
. O +

METHODS O +
: O +

Iliac O +
crest O +
biopsy O +
samples O +
were O +
taken O +
and O +
bone O +
histomorphometry O +
carried O +
out O +
. O +

RESULTS O +
: O +

Symptoms O +
resolved O +
when O +
the O +
methotrexate O +
was O +
discontinued O +
. O +

Bone O +
histology O +
showed O +
changes O +
consistent O +
with O +
osteoblast O +
inhibition O +
by O +
methotrexate O +
. O +

CONCLUSIONS O +
: O +

When O +
given O +
in O +
low O +
doses O +
for O +
prolonged O +
periods O +
, O +
methotrexate O +
may O +
have O +
adverse O +
effects O +
on O +
bone O +
, O +
particularly O +
in O +
post O +
- O +
menopausal O +
women O +
. O +

Overexpression O +
of O +
Glut O +
- O +
1 O +
glucose O +
transporter O +
in O +
human O +
breast O +
cancer O +
. O +

An O +
immunohistochemical O +
study O +
. O +

BACKGROUND O +
: O +
Breast O +
cancers O +
have O +
higher O +
than O +
normal O +
glucose O +
metabolism O +
, O +
but O +
the O +
mechanism O +
of O +
glucose O +
entry O +
into O +
these O +
tumors O +
is O +
not O +
well O +
understood O +
. O +

METHODS O +
: O +
The O +
expression O +
of O +
five O +
facilitative O +
glucose O +
transporters O +
, O +
Glut O +
- O +
1 O +
( O +
erythrocyte O +
type O +
) O +
, O +
Glut O +
- O +
2 O +
( O +
liver O +
type O +
) O +
, O +
Glut O +
- O +
3 O +
( O +
brain O +
type O +
) O +
, O +
Glut O +
- O +
4 O +
( O +
muscle O +
/ O +
fat O +
type O +
) O +
, O +
and O +
Glut O +
- O +
5 O +
( O +
small O +
intestine O +
type O +
) O +
, O +
was O +
studied O +
by O +
immunohistochemistry O +
of O +
paraffin O +
sections O +
from O +
12 O +
primary O +
human O +
breast O +
cancers O +
and O +
8 O +
lymph O +
node O +
metastases O +
from O +
2 O +
patients O +
. O +

Rat O +
tissues O +
known O +
to O +
express O +
these O +
glucose O +
transporters O +
were O +
used O +
as O +
controls O +
. O +

RESULTS O +
: O +
All O +
the O +
primary O +
breast O +
cancers O +
and O +
the O +
lymph O +
node O +
metastases O +
were O +
positive O +
for O +
Glut O +
- O +
1 O +
. O +

This O +
transporter O +
was O +
expressed O +
on O +
the O +
cell O +
membrane O +
and O +
in O +
the O +
cytoplasm O +
of O +
the O +
tumor O +
cells O +
, O +
but O +
exhibited O +
marked O +
intratumoral O +
and O +
intertumoral O +
variability O +
in O +
the O +
proportions O +
of O +
positive O +
cells O +
and O +
the O +
intensity O +
of O +
staining O +
. O +

Staining O +
of O +
the O +
normal O +
mammary O +
epithelium O +
, O +
if O +
present O +
, O +
was O +
much O +
lower O +
than O +
observed O +
in O +
tumor O +
cells O +
from O +
the O +
same O +
patient O +
. O +

Glut O +
- O +
2 O +
was O +
expressed O +
in O +
all O +
of O +
the O +
tumors O +
, O +
but O +
the O +
intensity O +
of O +
staining O +
was O +
not O +
consistently O +
stronger O +
than O +
that O +
seen O +
in O +
healthy O +
breast O +
. O +

Clusters O +
of O +
Glut O +
- O +
4 O +
- O +
positive O +
granule O +
were O +
observed O +
in O +
cells O +
in O +
six O +
of O +
the O +
tumors O +
. O +

None O +
of O +
the O +
tumors O +
or O +
the O +
healthy O +
breast O +
in O +
the O +
tissues O +
studied O +
expressed O +
Glut O +
- O +
3 O +
or O +
Glut O +
- O +
5 O +
. O +

CONCLUSIONS O +
: O +
Higher O +
expression O +
of O +
the O +
glucose O +
transporter O +
Glut O +
- O +
1 O +
by O +
breast O +
cancer O +
cells O +
compared O +
with O +
the O +
healthy O +
breast O +
tissue O +
is O +
common O +
. O +

Increased O +
glucose O +
transporter O +
protein O +
expression O +
may O +
contribute O +
to O +
the O +
increased O +
uptake O +
of O +
2 O +
- O +
[ O +
18F O +
] O +
- O +
fluoro O +
- O +
2 O +
- O +
deoxy O +
- O +
D O +
- O +
glucose O +
( O +
FDG O +
) O +
by O +
these O +
tumors O +
observed O +
by O +
positron O +
emission O +
tomography O +
( O +
PET O +
) O +
imaging O +
. O +

Methodologies O +
for O +
measuring O +
carcinogen O +
adducts O +
in O +
humans O +
. O +

In O +
summary O +
, O +
although O +
some O +
of O +
the O +
more O +
optimistic O +
aspirations O +
for O +
human O +
biomonitoring O +
studies O +
envisaged O +
a O +
decade O +
ago O +
have O +
not O +
been O +
realized O +
thus O +
far O +
, O +
some O +
considerable O +
advances O +
have O +
been O +
made O +
. O +

The O +
examples O +
cited O +
above O +
indicate O +
that O +
the O +
feasibility O +
of O +
biomonitoring O +
has O +
been O +
clearly O +
established O +
. O +

In O +
addition O +
, O +
they O +
demonstrate O +
the O +
need O +
for O +
preliminary O +
biomarker O +
testing O +
and O +
validation O +
through O +
transitional O +
studies O +
prior O +
to O +
their O +
field O +
application O +
. O +

In O +
the O +
next O +
decade O +
of O +
research O +
into O +
carcinogen O +
adducts O +
in O +
humans O +
, O +
continued O +
improvements O +
in O +
the O +
reproducibility O +
and O +
specificity O +
of O +
assays O +
for O +
DNA O +
adducts O +
will O +
be O +
needed O +
. O +

Perhaps O +
the O +
increasing O +
use O +
of O +
hybrid O +
methodologies O +
to O +
concentrate O +
adducts O +
followed O +
by O +
specific O +
chemical O +
analyses O +
will O +
allow O +
such O +
adducts O +
to O +
be O +
monitored O +
more O +
precisely O +
. O +

Of O +
course O +
, O +
further O +
basic O +
research O +
into O +
the O +
mechanisms O +
of O +
carcinogenesis O +
will O +
allow O +
the O +
measurement O +
of O +
specific O +
novel O +
markers O +
which O +
are O +
more O +
closely O +
tied O +
to O +
the O +
disease O +
endpoint O +
than O +
adducts O +
. O +

The O +
development O +
of O +
new O +
assays O +
for O +
determining O +
metabolic O +
phenotypes O +
and O +
genotypes O +
relevant O +
to O +
carcinogenesis O +
should O +
improve O +
our O +
estimates O +
of O +
susceptibility O +
( O +
46 O +
- O +
48 O +
) O +
. O +

Such O +
new O +
approaches O +
along O +
with O +
the O +
sustained O +
improvement O +
of O +
current O +
assays O +
will O +
allow O +
molecular O +
approaches O +
to O +
continue O +
to O +
enrich O +
cancer O +
epidemiology O +
in O +
the O +
future O +
. O +

Effect O +
of O +
1 O +
- O +
alkylpyrrolidine O +
N O +
- O +
oxides O +
on O +
energy O +
metabolism O +
of O +
cancer O +
cells O +
. O +

The O +
main O +
purpose O +
of O +
the O +
present O +
investigation O +
was O +
to O +
study O +
the O +
effect O +
of O +
a O +
homologous O +
series O +
of O +
1 O +
- O +
alkylpyrrolidine O +
N O +
- O +
oxides O +
on O +
ATP O +
- O +
producing O +
processes O +
in O +
Ehrlich O +
ascites O +
and O +
L1210 B-CellLine +
murine O +
leukemia O +
cells O +
. O +

The O +
effect O +
on O +
aerobic O +
glucose O +
consumption O +
, O +
lactic O +
acid O +
formation O +
, O +
content O +
of O +
total O +
( O +
T O +
- O +
SH O +
) O +
and O +
non O +
- O +
protein O +
thiol O +
groups O +
( O +
NP O +
- O +
SH O +
) O +
, O +
endogenous O +
respiration O +
and O +
the O +
level O +
of O +
ATP O +
in O +
tumor O +
cells O +
incubated O +
in O +
vitro O +
was O +
investigated O +
. O +

1 O +
- O +
Tetradecylpyrrolidine O +
N O +
- O +
oxide O +
( O +
TPNO O +
) O +
, O +
one O +
of O +
the O +
most O +
active O +
compounds O +
, O +
immediately O +
after O +
addition O +
to O +
the O +
suspension O +
of O +
Ehrlich O +
cells O +
in O +
an O +
ice O +
bath O +
, O +
decreased O +
the O +
level O +
of O +
ATP O +
to O +
the O +
same O +
extent O +
over O +
the O +
whole O +
concentration O +
range O +
. O +

After O +
2 O +
h O +
incubation O +
at O +
37 O +
degrees O +
C O +
the O +
drop O +
in O +
the O +
ATP O +
level O +
was O +
lower O +
. O +

The O +
decrease O +
in O +
ATP O +
level O +
might O +
be O +
explained O +
through O +
the O +
interaction O +
of O +
the O +
amine O +
oxide O +
with O +
the O +
cell O +
membrane O +
integrity O +
. O +

High O +
density O +
of O +
somatostatin O +
receptors O +
in O +
veins O +
surrounding O +
human O +
cancer O +
tissue O +
: O +
role O +
in O +
tumor O +
- O +
host O +
interaction O +
? O +

Somatostatin O +
receptors O +
were O +
detected O +
in O +
peritumoral O +
veins O +
of O +
various O +
human O +
cancer O +
tissue O +
specimens O +
. O +

Vascular O +
and O +
neoplastic O +
tissue O +
from O +
14 O +
colonic O +
adenocarcinomas O +
, O +
13 O +
carcinoids O +
, O +
6 O +
renal O +
- O +
cell O +
carcinomas O +
and O +
7 O +
malignant O +
lymphomas O +
were O +
analyzed O +
for O +
somatostatin O +
receptors O +
by O +
use O +
of O +
quantitative O +
receptor O +
autoradiography O +
. O +

In O +
colonic O +
carcinoma O +
specimens O +
, O +
the O +
peritumoral O +
vessels O +
expressed O +
a O +
high O +
density O +
of O +
somatostatin O +
receptors O +
, O +
whereas O +
the O +
neoplastic O +
tissue O +
itself O +
was O +
receptor O +
- O +
negative O +
in O +
many O +
cases O +
. O +

In O +
contrast O +
, O +
the O +
incidence O +
and O +
density O +
of O +
somatostatin O +
receptors O +
in O +
peritumoral O +
vessels O +
was O +
low O +
in O +
well O +
- O +
differentiated O +
gastrointestinal O +
and O +
bronchial O +
carcinoids O +
, O +
in O +
contrast O +
to O +
the O +
high O +
density O +
of O +
such O +
receptors O +
in O +
the O +
carcinoid O +
tumor O +
tissue O +
. O +

Autochthonous O +
vessels O +
surrounding O +
other O +
tumors O +
such O +
as O +
renal O +
- O +
cell O +
carcinomas O +
or O +
malignant O +
lymphomas O +
also O +
frequently O +
expressed O +
somatostatin O +
receptors O +
. O +

In O +
all O +
cases O +
, O +
the O +
somatostatin O +
receptors O +
were O +
localized O +
in O +
veins O +
, O +
particularly O +
in O +
the O +
smooth O +
- O +
muscle O +
cell O +
layer O +
. O +

They O +
exhibited O +
specific O +
and O +
high O +
- O +
affinity O +
binding O +
of O +
somatostatin O +
- O +
14 O +
, O +
somatostatin O +
- O +
28 O +
and O +
octreotide O +
, O +
suggesting O +
a O +
preferential O +
expression O +
of O +
the O +
SSTR2 O +
receptor O +
subtype O +
. O +

Since O +
the O +
vessels O +
of O +
normal O +
non O +
- O +
neoplastic O +
human O +
tissues O +
, O +
e O +
. O +
g O +
. O +
of O +
intestine O +
or O +
lymphatic O +
organs O +
, O +
have O +
few O +
somatostatin O +
receptors O +
, O +
the O +
increased O +
somatostatin O +
receptor O +
expression O +
in O +
peritumoral O +
vessels O +
observed O +
in O +
this O +
study O +
may O +
be O +
linked O +
to O +
the O +
neoplastic O +
process O +
itself O +
. O +

The O +
results O +
suggest O +
that O +
somatostatin O +
and O +
somatostatin O +
receptors O +
may O +
play O +
a O +
regulatory O +
role O +
for O +
hemodynamic O +
tumor O +
- O +
host O +
interactions O +
, O +
possibly O +
involving O +
tumor O +
stroma O +
generation O +
, O +
tumor O +
environment O +
, O +
angiogenesis O +
and O +
, O +
particularly O +
, O +
vascular O +
drainage O +
of O +
poorly O +
differentiated O +
neoplasms O +
. O +

[ O +
Treatment O +
of O +
the O +
diabetic O +
foot O +
by O +
hyperbaric O +
oxygen O +
] O +

Diabetic O +
foot O +
wounds O +
are O +
consequences O +
of O +
the O +
neuropathy O +
and O +
the O +
small O +
and O +
large O +
vessel O +
disease O +
that O +
complicate O +
diabetes O +
. O +

At O +
the O +
cellular O +
level O +
, O +
the O +
result O +
is O +
hypoxia O +
which O +
impairs O +
wound O +
healing O +
. O +

Hyperbaric O +
oxygenation O +
( O +
HBO O +
) O +
may O +
be O +
a O +
useful O +
adjuvant O +
to O +
wound O +
care O +
. O +

It O +
leads O +
to O +
enhanced O +
oxygenation O +
of O +
the O +
affected O +
tissues O +
, O +
has O +
an O +
antiseptic O +
effect O +
, O +
reduces O +
edema O +
, O +
and O +
accelerates O +
collagen O +
production O +
and O +
angiogenesis O +
, O +
thus O +
enhancing O +
tissue O +
repair O +
. O +

14 O +
diabetics O +
with O +
chronic O +
nonhealing O +
wounds O +
which O +
did O +
not O +
respond O +
to O +
treatment O +
for O +
at O +
least O +
3 O +
months O +
were O +
treated O +
by O +
HBO O +
. O +

All O +
had O +
palpable O +
pedal O +
pulses O +
. O +

Transcutaneous O +
measurements O +
of O +
tissue O +
pO2 O +
showed O +
elevation O +
from O +
20 O +
+ O +
/ O +
- O +
10 O +
mm O +
Hg O +
during O +
air O +
breathing O +
to O +
643 O +
+ O +
/ O +
- O +
242 O +
mm O +
Hg O +
while O +
breathing O +
pure O +
oxygen O +
at O +
2 O +
. O +
5 O +
ATA O +
. O +

They O +
were O +
treated O +
with O +
HBO O +
in O +
56 O +
+ O +
/ O +
- O +
10 O +
consecutive O +
HBO O +
sessions O +
. O +

In O +
11 O +
there O +
was O +
complete O +
wound O +
healing O +
, O +
while O +
in O +
1 O +
there O +
was O +
partial O +
response O +
, O +
in O +
1 O +
minimal O +
response O +
, O +
and O +
in O +
1 O +
a O +
transient O +
response O +
. O +

HBO O +
is O +
useful O +
in O +
chronic O +
nonhealing O +
wounds O +
of O +
the O +
diabetic O +
foot O +
and O +
of O +
the O +
diabetic O +
foot O +
with O +
impending O +
amputation O +
. O +

It O +
is O +
a O +
safe O +
mode O +
of O +
therapy O +
, O +
but O +
further O +
studies O +
are O +
required O +
to O +
establish O +
its O +
efficacy O +
and O +
to O +
ascertain O +
which O +
diabetic O +
patients O +
and O +
wounds O +
will O +
benefit O +
the O +
most O +
from O +
it O +
. O +

Chelation O +
treatment O +
of O +
neurological O +
Wilson O +
' O +
s O +
disease O +
. O +

The O +
results O +
of O +
chelation O +
treatment O +
of O +
137 O +
patients O +
presenting O +
with O +
neurological O +
Wilson O +
' O +
s O +
disease O +
are O +
described O +
, O +
together O +
with O +
the O +
more O +
commonly O +
observed O +
toxic O +
reactions O +
to O +
the O +
various O +
drugs O +
employed O +
. O +

Fifty O +
- O +
seven O +
patients O +
made O +
an O +
excellent O +
response O +
to O +
treatment O +
and O +
became O +
symptom O +
free O +
. O +

Thirty O +
- O +
six O +
patients O +
made O +
a O +
good O +
recovery O +
, O +
but O +
were O +
left O +
with O +
some O +
minor O +
neurological O +
deficit O +
. O +

Twenty O +
- O +
four O +
patients O +
had O +
a O +
poor O +
response O +
: O +
although O +
the O +
disease O +
process O +
was O +
arrested O +
they O +
were O +
left O +
more O +
or O +
less O +
disabled O +
. O +

Twenty O +
patients O +
died O +
: O +
nine O +
had O +
little O +
or O +
no O +
treatment O +
, O +
but O +
11 O +
died O +
despite O +
apparently O +
adequate O +
chelation O +
therapy O +
. O +

There O +
was O +
no O +
obvious O +
reason O +
for O +
this O +
failure O +
. O +

The O +
liver O +
copper O +
level O +
was O +
estimated O +
in O +
six O +
of O +
these O +
patients O +
: O +
it O +
was O +
still O +
significantly O +
elevated O +
in O +
only O +
one O +
, O +
but O +
in O +
all O +
four O +
in O +
whom O +
it O +
was O +
possible O +
to O +
make O +
the O +
determination O +
, O +
the O +
concentration O +
of O +
copper O +
in O +
the O +
basal O +
ganglia O +
was O +
in O +
excess O +
of O +
45 O +
micrograms O +
/ O +
g O +
wet O +
weight O +
. O +

It O +
was O +
not O +
apparent O +
why O +
adequate O +
therapy O +
failed O +
to O +
remove O +
copper O +
from O +
the O +
brains O +
of O +
these O +
patients O +
. O +

There O +
was O +
no O +
obvious O +
clinical O +
, O +
histological O +
or O +
biochemical O +
indicator O +
of O +
failure O +
to O +
respond O +
to O +
treatment O +
. O +

Initial O +
deterioration O +
before O +
improvement O +
was O +
seen O +
in O +
30 O +
patients O +
: O +
the O +
prognosis O +
for O +
a O +
useful O +
recovery O +
was O +
not O +
necessarily O +
worse O +
than O +
that O +
in O +
patients O +
who O +
did O +
not O +
show O +
this O +
phenomenon O +
. O +

Transformation O +
- O +
associated O +
cytokine O +
9E3 O +
/ O +
CEF4 O +
is O +
chemotactic O +
for O +
chicken O +
peripheral O +
blood O +
mononuclear O +
cells O +
. O +

9E3 O +
/ O +
CEF4 O +
, O +
which O +
is O +
released O +
from O +
transformed O +
chicken O +
embryo O +
fibroblasts O +
( O +
CEF O +
) O +
, O +
is O +
a O +
member O +
of O +
the O +
platelet O +
factor O +
4 O +
family O +
of O +
inflammatory O +
proteins O +
and O +
may O +
be O +
the O +
avian O +
homolog O +
of O +
interleukin O +
- O +
8 O +
. O +

Since O +
the O +
function O +
of O +
9E3 O +
/ O +
CEF4 O +
is O +
unknown O +
, O +
we O +
examined O +
the O +
effect O +
of O +
the O +
protein O +
on O +
mitogenicity O +
and O +
chemotaxis O +
, O +
as O +
well O +
as O +
its O +
expression O +
, O +
in O +
fibroblasts O +
and O +
peripheral O +
blood O +
cells O +
. O +

9E3 O +
/ O +
CEF4 O +
mRNA O +
was O +
expressed O +
in O +
chicken O +
peripheral O +
blood O +
monocytes O +
, O +
and O +
its O +
expression O +
was O +
stimulated O +
by O +
incubation O +
of O +
the O +
monocytes O +
with O +
lipopolysaccharide O +
or O +
phorbol O +
myristic O +
acetate O +
. O +

Boyden O +
double O +
- O +
membrane O +
analysis O +
of O +
chemotaxis O +
showed O +
that O +
9E3 O +
/ O +
CEF4 O +
was O +
chemotactic O +
for O +
chicken O +
peripheral O +
blood O +
mononuclear O +
cells O +
, O +
as O +
well O +
as O +
for O +
heterophils O +
. O +

Untransformed O +
CEF O +
and O +
CEF O +
transformed O +
with O +
Rous O +
sarcoma O +
virus O +
also O +
migrated O +
to O +
9E3 O +
/ O +
CEF4 O +
protein O +
, O +
as O +
measured O +
by O +
Boyden O +
single O +
- O +
membrane O +
analysis O +
. O +

9E3 O +
/ O +
CEF4 O +
was O +
slightly O +
mitogenic O +
for O +
CEF O +
, O +
causing O +
a O +
doubling O +
of O +
[ O +
3H O +
] O +
thymidine O +
uptake O +
when O +
added O +
to O +
serum O +
- O +
starved O +
CEF O +
. O +
9E3 O +
/ O +
CEF4 O +
was O +
found O +
associated O +
not O +
only O +
with O +
the O +
cell O +
and O +
in O +
the O +
culture O +
medium O +
of O +
Rous O +
sarcoma O +
virus O +
- O +
transformed O +
CEF O +
but O +
also O +
with O +
the O +
extracellular O +
matrix O +
. O +

The O +
in O +
vivo O +
role O +
of O +
9E3 O +
/ O +
CEF4 O +
may O +
be O +
involved O +
with O +
chemotaxis O +
and O +
metastasis O +
, O +
rather O +
than O +
with O +
direct O +
stimulation O +
of O +
mitogenicity O +
. O +

Lactotransferrin O +
binding O +
to O +
its O +
platelet O +
receptor O +
inhibits O +
platelet O +
aggregation O +
. O +

A O +
fluorescent O +
lactotransferrin O +
probe O +
was O +
prepared O +
by O +
coupling O +
5 O +
- O +
( O +
( O +
[ O +
2 O +
- O +
( O +
carbhydrazino O +
) O +
methyl O +
] O +
- O +
thio O +
) O +
acetyl O +
) O +
amino O +
fluorescein O +
to O +
aldehyde O +
groups O +
that O +
were O +
produced O +
by O +
a O +
mild O +
periodic O +
- O +
acid O +
oxidation O +
of O +
the O +
glycan O +
moieties O +
of O +
lactotransferrin O +
. O +

In O +
this O +
manner O +
, O +
the O +
receptor O +
- O +
binding O +
site O +
of O +
the O +
lactotransferrin O +
remains O +
active O +
in O +
contrast O +
to O +
the O +
binding O +
site O +
of O +
the O +
lactotransferrin O +
derivatized O +
with O +
fluorescein O +
isothiocyanate O +
. O +

The O +
fluorescent O +
probe O +
allowed O +
us O +
to O +
characterize O +
, O +
by O +
flow O +
cytometry O +
, O +
the O +
binding O +
of O +
lactotransferrin O +
to O +
non O +
- O +
activated O +
human O +
platelets O +
. O +

The O +
putative O +
lactotransferrin O +
platelet O +
receptor O +
was O +
purified O +
and O +
its O +
immunological O +
and O +
physico O +
- O +
chemical O +
properties O +
were O +
found O +
to O +
be O +
very O +
similar O +
to O +
those O +
of O +
the O +
receptor O +
previously O +
isolated O +
from O +
activated O +
human O +
lymphocytes O +
. O +

Lactotransferrin O +
inhibits O +
ADP O +
- O +
induced O +
platelet O +
aggregation O +
at O +
concentrations O +
down O +
to O +
5 O +
nM O +
, O +
which O +
can O +
be O +
reached O +
in O +
the O +
plasma O +
after O +
leukocyte O +
degranulation O +
. O +

Inhibition O +
of O +
platelet O +
aggregation O +
was O +
also O +
observed O +
with O +
the O +
N O +
- O +
terminal O +
fragment O +
of O +
lactotransferrin O +
( O +
residues O +
3 O +
- O +
281 O +
; O +
50 O +
% O +
inhibition O +
= O +
2 O +
microM O +
) O +
and O +
with O +
CFQWQRNMRKVRGPPVSC O +
synthetic O +
octodecapeptide O +
( O +
residues O +
20 O +
- O +
37 O +
; O +
50 O +
% O +
inhibition O +
= O +
20 O +
microM O +
) O +
corresponding O +
to O +
one O +
of O +
the O +
two O +
external O +
loops O +
( O +
residues O +
28 O +
- O +
34 O +
and O +
39 O +
- O +
42 O +
) O +
where O +
we O +
recently O +
located O +
the O +
receptor O +
- O +
binding O +
site O +
. O +

The O +
activity O +
( O +
50 O +
% O +
inhibition O +
= O +
500 O +
microM O +
) O +
of O +
the O +
tetrapeptide O +
KRDS O +
( O +
residues O +
39 O +
- O +
42 O +
) O +
, O +
which O +
has O +
already O +
been O +
described O +
, O +
was O +
at O +
least O +
25 O +
- O +
times O +
and O +
16000 O +
- O +
times O +
lower O +
than O +
the O +
activity O +
of O +
the O +
octodecapeptide O +
and O +
of O +
the O +
lactotransferrin O +
molecules O +
, O +
respectively O +
. O +

Finally O +
, O +
the O +
inhibition O +
was O +
demonstrated O +
to O +
be O +
mediated O +
by O +
a O +
mechanism O +
which O +
requires O +
the O +
binding O +
of O +
lactotransferrin O +
to O +
its O +
putative O +
receptor O +
and O +
not O +
to O +
platelet O +
glycoprotein O +
IIb O +
- O +
IIIa O +
. O +

Vitamins O +
regulate O +
gene O +
expression O +
and O +
induce O +
differentiation O +
and O +
growth O +
inhibition O +
in O +
cancer O +
cells O +
. O +

Their O +
relevance O +
in O +
cancer O +
prevention O +
. O +

Although O +
several O +
hypotheses O +
for O +
human O +
carcinogenesis O +
have O +
been O +
proposed O +
, O +
the O +
specific O +
genetic O +
changes O +
that O +
cause O +
normal O +
cells O +
to O +
become O +
cancer O +
cells O +
have O +
not O +
been O +
identified O +
. O +

In O +
spite O +
of O +
uncertainties O +
regarding O +
the O +
mechanisms O +
of O +
carcinogenesis O +
, O +
several O +
vitamins O +
such O +
as O +
beta O +
- O +
carotene O +
and O +
vitamins O +
A O +
, O +
C O +
, O +
and O +
E O +
, O +
which O +
can O +
reduce O +
the O +
risk O +
of O +
cancer O +
, O +
have O +
been O +
identified O +
, O +
using O +
animal O +
and O +
in O +
vitro O +
models O +
of O +
carcinogenesis O +
. O +

These O +
studies O +
have O +
led O +
to O +
a O +
hypothesis O +
that O +
the O +
supplemental O +
intake O +
of O +
these O +
vitamins O +
may O +
reduce O +
the O +
risk O +
of O +
cancer O +
. O +

This O +
hypothesis O +
in O +
humans O +
can O +
be O +
tested O +
only O +
by O +
intervention O +
trials O +
that O +
are O +
in O +
progress O +
. O +

Prospective O +
and O +
retrospective O +
case O +
- O +
controlled O +
experimental O +
designs O +
are O +
not O +
suitable O +
for O +
testing O +
the O +
above O +
hypothesis O +
. O +

The O +
fact O +
that O +
some O +
vitamins O +
induce O +
cell O +
differentiation O +
and O +
/ O +
or O +
growth O +
inhibition O +
in O +
tumor O +
cells O +
in O +
culture O +
suggests O +
that O +
the O +
use O +
of O +
these O +
vitamins O +
in O +
cancer O +
prevention O +
has O +
a O +
cellular O +
basis O +
. O +

In O +
addition O +
to O +
having O +
a O +
direct O +
effect O +
on O +
tumor O +
cells O +
, O +
vitamins O +
such O +
as O +
alpha O +
- O +
tocopheryl O +
succinate O +
and O +
beta O +
- O +
carotene O +
enhance O +
the O +
effect O +
of O +
other O +
agents O +
that O +
induce O +
differentiation O +
in O +
tumor O +
cells O +
. O +

Some O +
vitamins O +
like O +
beta O +
- O +
carotene O +
, O +
retinoic O +
acid O +
, O +
alpha O +
- O +
tocopheryl O +
succinate O +
, O +
and O +
vitamin O +
D O +
also O +
regulate O +
the O +
expressions O +
of O +
certain O +
oncogenes O +
and O +
cellular O +
genes O +
. O +

These O +
are O +
exciting O +
new O +
functions O +
of O +
vitamins O +
that O +
nobody O +
could O +
have O +
predicted O +
only O +
a O +
few O +
years O +
ago O +
. O +

Increased O +
nm23 O +
- O +
H1 O +
and O +
nm23 O +
- O +
H2 O +
messenger O +
RNA O +
expression O +
and O +
absence O +
of O +
mutations O +
in O +
colon O +
carcinomas O +
of O +
low O +
and O +
high O +
metastatic O +
potential O +
. O +

BACKGROUND O +
: O +
The O +
murine O +
nm23 O +
gene O +
suppresses O +
the O +
metastatic O +
behavior O +
of O +
malignant O +
rodent O +
tumor O +
lines O +
, O +
and O +
reduced O +
nm23 O +
expression O +
correlates O +
with O +
increased O +
likelihood O +
of O +
lymph O +
node O +
metastases O +
in O +
human O +
breast O +
cancers O +
. O +

More O +
recent O +
data O +
have O +
demonstrated O +
the O +
existence O +
of O +
two O +
human O +
nm23 O +
gene O +
homologues O +
, O +
nm23 O +
- O +
H1 O +
and O +
nm23 O +
- O +
H2 O +
, O +
and O +
have O +
shown O +
that O +
deletion O +
of O +
nm23 O +
- O +
H1 O +
alleles O +
occurs O +
in O +
some O +
colon O +
carcinomas O +
associated O +
with O +
poor O +
prognosis O +
. O +

These O +
findings O +
suggest O +
that O +
nm23 O +
- O +
H1 O +
encodes O +
for O +
suppression O +
of O +
colon O +
carcinoma O +
metastasis O +
. O +

In O +
contrast O +
, O +
we O +
have O +
previously O +
reported O +
that O +
total O +
nm23 O +
messenger O +
RNA O +
( O +
mRNA O +
) O +
expression O +
is O +
increased O +
to O +
similar O +
levels O +
in O +
colon O +
tumors O +
of O +
both O +
high O +
and O +
low O +
metastatic O +
potential O +
. O +

PURPOSE O +
: O +
This O +
study O +
was O +
designed O +
to O +
reconcile O +
our O +
previous O +
findings O +
with O +
the O +
recent O +
report O +
of O +
nm23 O +
- O +
H1 O +
allelic O +
deletion O +
in O +
human O +
colon O +
cancers O +
associated O +
with O +
poor O +
prognosis O +
. O +

Our O +
purpose O +
was O +
to O +
examine O +
human O +
colon O +
cancers O +
for O +
inactivation O +
of O +
two O +
candidate O +
metastasis O +
suppressor O +
genes O +
, O +
nm23 O +
- O +
H1 O +
and O +
nm23 O +
- O +
H2 O +
, O +
either O +
by O +
mutation O +
or O +
by O +
loss O +
of O +
gene O +
transcription O +
. O +

METHODS O +
: O +
We O +
used O +
ribonuclease O +
protection O +
assays O +
to O +
analyze O +
human O +
colon O +
tumors O +
for O +
the O +
level O +
of O +
nm23 O +
- O +
H1 O +
( O +
43 O +
samples O +
) O +
and O +
nm23 O +
- O +
H2 O +
( O +
41 O +
samples O +
) O +
transcript O +
( O +
mRNA O +
) O +
expression O +
and O +
the O +
presence O +
of O +
mutations O +
that O +
could O +
inactivate O +
potential O +
suppressor O +
function O +
. O +

RESULTS O +
: O +
We O +
detected O +
only O +
wild O +
- O +
type O +
nm23 O +
- O +
H1 O +
and O +
nm23 O +
- O +
H2 O +
mRNA O +
. O +

Expression O +
of O +
nm23 O +
- O +
H1 O +
mRNA O +
increased O +
in O +
33 O +
of O +
41 O +
colon O +
tumors O +
, O +
and O +
expression O +
of O +
nm23 O +
- O +
H2 O +
mRNA O +
was O +
elevated O +
in O +
28 O +
of O +
41 O +
colon O +
tumors O +
relative O +
to O +
that O +
in O +
matched O +
normal O +
mucosa O +
. O +

Increases O +
in O +
these O +
mRNA O +
levels O +
were O +
similar O +
in O +
tumors O +
of O +
both O +
low O +
and O +
high O +
metastatic O +
potential O +
. O +

CONCLUSIONS O +
: O +
These O +
results O +
suggest O +
that O +
, O +
despite O +
correlation O +
of O +
nm23 O +
- O +
H1 O +
allelic O +
deletions O +
with O +
colon O +
cancers O +
associated O +
with O +
poor O +
prognosis O +
, O +
nm23 O +
- O +
H1 O +
and O +
nm23 O +
- O +
H2 O +
alleles O +
do O +
not O +
directly O +
mediate O +
metastasis O +
suppression O +
in O +
colon O +
carcinoma O +
. O +

Our O +
results O +
leave O +
unexplained O +
the O +
observation O +
that O +
nm23 O +
- O +
H1 O +
allelic O +
deletion O +
correlates O +
with O +
metastatic O +
potential O +
of O +
colon O +
carcinomas O +
. O +

IMPLICATIONS O +
: O +
These O +
findings O +
also O +
contrast O +
with O +
the O +
demonstration O +
of O +
nm23 O +
metastasis O +
suppressor O +
activity O +
in O +
murine O +
melanoma O +
and O +
with O +
the O +
correlation O +
of O +
loss O +
of O +
nm23 O +
expression O +
in O +
breast O +
cancer O +
with O +
poor O +
prognosis O +
. O +

It O +
may O +
be O +
that O +
metastasis O +
suppression O +
by O +
the O +
nm23 O +
gene O +
is O +
a O +
tissue O +
- O +
specific O +
phenomenon O +
. O +

E O +
mu O +
- O +
bcl O +
- O +
2 O +
transgene O +
facilitates O +
spontaneous O +
transformation O +
of O +
early O +
pre O +
- O +
B O +
and O +
immunoglobulin O +
- O +
secreting O +
cells O +
but O +
not O +
T O +
cells O +
. O +

To O +
assess O +
the O +
lymphoid O +
tumorigenic O +
potential O +
of O +
bcl O +
- O +
2 O +
, O +
mice O +
of O +
five O +
independent O +
strains O +
expressing O +
a O +
bcl O +
- O +
2 O +
transgene O +
in O +
B O +
and O +
/ O +
or O +
T O +
cells O +
were O +
monitored O +
for O +
disease O +
up O +
to O +
12 O +
months O +
of O +
age O +
. O +

Lymphoma O +
prevalence O +
was O +
minimal O +
in O +
the O +
T O +
lineage O +
but O +
significant O +
, O +
although O +
low O +
( O +
3 O +
- O +
15 O +
% O +
) O +
, O +
in O +
the O +
B O +
lineage O +
. O +

The O +
principal O +
types O +
of O +
tumors O +
were O +
plasmacytomas O +
secreting O +
immunoglobulin O +
and O +
novel O +
lymphomas O +
that O +
expressed O +
markers O +
such O +
as O +
Sca O +
- O +
1 O +
, O +
CD4 O +
, O +
Thy O +
- O +
1 O +
, O +
CD34 O +
and O +
CD45 O +
( O +
B220 O +
) O +
, O +
consistent O +
with O +
an O +
origin O +
very O +
early O +
in O +
B O +
- O +
lymphoid O +
development O +
. O +

Rearrangement O +
of O +
the O +
c O +
- O +
myc O +
gene O +
was O +
common O +
in O +
the O +
plasmacytomas O +
, O +
implying O +
a O +
synergistic O +
role O +
for O +
myc O +
and O +
bcl O +
- O +
2 O +
in O +
their O +
etiology O +
, O +
but O +
was O +
not O +
detected O +
in O +
the O +
lymphomas O +
. O +

Appearance O +
of O +
tumorous O +
phenotypes O +
in O +
goldfish O +
erythrophores O +
transfected O +
with O +
ras O +
, O +
src O +
, O +
and O +
myc O +
oncogenes O +
and O +
spontaneous O +
differentiation O +
of O +
the O +
transformants O +
in O +
vitro O +
. O +

When O +
goldfish O +
erythrophores O +
isolated O +
from O +
the O +
skin O +
by O +
tissue O +
digestion O +
and O +
centrifugation O +
in O +
a O +
Percoll O +
density O +
gradient O +
were O +
transfected O +
in O +
a O +
monolayer O +
- O +
culture O +
with O +
v O +
- O +
Ha O +
- O +
ras O +
or O +
v O +
- O +
src O +
oncogene O +
either O +
singly O +
or O +
in O +
combination O +
with O +
v O +
- O +
myc O +
by O +
means O +
of O +
calcium O +
phosphate O +
- O +
DNA O +
co O +
- O +
precipitation O +
, O +
there O +
appeared O +
a O +
certain O +
number O +
of O +
transformants O +
manifesting O +
a O +
chromatoblast O +
- O +
like O +
profile O +
and O +
tumorous O +
phenotypes O +
as O +
seen O +
in O +
the O +
capability O +
for O +
unlimited O +
growth O +
, O +
and O +
piling O +
- O +
up O +
in O +
a O +
monolayer O +
- O +
culture O +
or O +
colony O +
formation O +
in O +
semi O +
- O +
solid O +
soft O +
agar O +
. O +

After O +
successive O +
growth O +
in O +
vitro O +
for O +
longer O +
than O +
one O +
month O +
which O +
was O +
scarcely O +
observed O +
with O +
the O +
erythrophores O +
, O +
the O +
vast O +
majority O +
of O +
such O +
transformants O +
began O +
to O +
differentiate O +
into O +
erythrophores O +
and O +
ceased O +
proliferation O +
spontaneously O +
. O +

The O +
onset O +
of O +
their O +
differentiation O +
was O +
ascertained O +
by O +
the O +
deposition O +
of O +
marker O +
pteridine O +
pigments O +
. O +

None O +
of O +
the O +
transformants O +
differentiated O +
into O +
melanophores O +
or O +
iridophores O +
or O +
other O +
neural O +
crest O +
derivatives O +
as O +
seen O +
in O +
goldfish O +
erythrophoroma O +
cells O +
. O +

Little O +
difference O +
was O +
observed O +
in O +
their O +
transforming O +
efficiency O +
( O +
0 O +
. O +
2 O +
- O +
0 O +
. O +
3 O +
transformants O +
/ O +
micrograms O +
DNA O +
) O +
between O +
the O +
combinations O +
of O +
oncogenes O +
applied O +
but O +
a O +
tendency O +
was O +
noted O +
that O +
cells O +
transfected O +
with O +
ras O +
or O +
src O +
in O +
combination O +
with O +
myc O +
developed O +
the O +
capacity O +
to O +
grow O +
for O +
a O +
longer O +
period O +
and O +
differentiated O +
at O +
a O +
later O +
stage O +
than O +
those O +
transfected O +
solely O +
with O +
ras O +
or O +
src O +
. O +

One O +
cell O +
line O +
( O +
ESM B-CellLine +
- I-CellLine +
1 I-CellLine +
) O +
derived O +
from O +
the O +
erythrophores O +
transfected O +
with O +
src O +
/ O +
myc O +
grew O +
successively O +
over O +
nine O +
months O +
, O +
indicating O +
its O +
acquisition O +
of O +
immortality O +
. O +

The O +
expression O +
of O +
the O +
transfected O +
oncogenes O +
in O +
this O +
cell O +
line O +
was O +
examined O +
in O +
comparison O +
with O +
the O +
erythrophoroma O +
cells O +
by O +
Western O +
and O +
Northern O +
blot O +
analyses O +
. O +

[ O +
Prehospital O +
service O +
in O +
Denmark O +
] O +
. O +

In O +
Denmark O +
, O +
emergency O +
ambulances O +
are O +
dispatched O +
by O +
41 O +
centres O +
manned O +
either O +
by O +
trained O +
firemen O +
( O +
in O +
Copenhagen O +
) O +
or O +
policemen O +
( O +
outside O +
Copenhagen O +
) O +
. O +

In O +
1990 O +
, O +
emergency O +
ambulance O +
calls O +
totalled O +
284 O +
, O +
000 O +
. O +

Utilisation O +
of O +
emergency O +
ambulance O +
services O +
increases O +
with O +
urbanisation O +
. O +

A O +
doctor O +
- O +
manned O +
ambulance O +
is O +
in O +
operation O +
in O +
Copenhagen O +
, O +
and O +
in O +
some O +
other O +
large O +
towns O +
anaesthesiology O +
and O +
intensive O +
care O +
teams O +
can O +
be O +
dispatched O +
from O +
hospital O +
to O +
give O +
on O +
- O +
the O +
- O +
spot O +
care O +
. O +

In O +
less O +
populated O +
areas O +
, O +
some O +
general O +
practitioners O +
give O +
advanced O +
life O +
- O +
support O +
. O +

Although O +
many O +
areas O +
are O +
serviced O +
by O +
ambulances O +
equipped O +
with O +
defibrillators O +
, O +
the O +
majority O +
of O +
patients O +
receive O +
only O +
basic O +
life O +
- O +
support O +
from O +
ambulance O +
personnel O +
. O +

New O +
initiatives O +
resulting O +
from O +
a O +
recent O +
report O +
by O +
a O +
commission O +
appointed O +
by O +
central O +
authorities O +
, O +
and O +
focused O +
on O +
prehospital O +
treatment O +
, O +
are O +
expected O +
to O +
improve O +
the O +
service O +
by O +
raising O +
the O +
level O +
of O +
training O +
given O +
to O +
ambulance O +
personnel O +
. O +

Tumorigenic O +
activity O +
of O +
rho O +
genes O +
from O +
Aplysia O +
californica O +
. O +

rho O +
genes O +
have O +
been O +
found O +
in O +
both O +
lower O +
and O +
higher O +
eucaryotes O +
. O +

They O +
code O +
for O +
proteins O +
of O +
21 O +
kDa O +
, O +
highly O +
conserved O +
in O +
evolution O +
, O +
which O +
belong O +
to O +
the O +
superfamily O +
of O +
ras O +
GTPases O +
. O +

Among O +
the O +
members O +
of O +
this O +
superfamily O +
there O +
are O +
proteins O +
with O +
a O +
regulatory O +
function O +
, O +
such O +
as O +
ras O +
, O +
and O +
proteins O +
involved O +
in O +
vesicular O +
trafficking O +
, O +
such O +
as O +
the O +
family O +
of O +
rab O +
proteins O +
. O +

We O +
have O +
investigated O +
the O +
putative O +
role O +
of O +
rho O +
proteins O +
from O +
Aplysia O +
californica O +
as O +
transforming O +
GTPases O +
utilizing O +
the O +
wild O +
- O +
type O +
and O +
a O +
Val O +
- O +
14 O +
mutant O +
, O +
equivalent O +
to O +
the O +
oncogenic O +
Val O +
- O +
12 O +
mutation O +
of O +
ras O +
genes O +
found O +
in O +
animal O +
and O +
human O +
tumors O +
. O +

Over O +
- O +
expression O +
of O +
either O +
rho O +
gene O +
was O +
sufficient O +
to O +
confer O +
anchorage O +
- O +
and O +
serum O +
- O +
independent O +
growth O +
. O +

Moreover O +
, O +
when O +
introduced O +
into O +
nude O +
mice O +
, O +
selected O +
clones O +
generated O +
from O +
either O +
gene O +
were O +
able O +
to O +
induce O +
tumors O +
, O +
although O +
those O +
carrying O +
the O +
mutated O +
version O +
were O +
more O +
efficient O +
. O +

Pathological O +
analysis O +
indicated O +
that O +
generated O +
tumors O +
corresponded O +
to O +
well O +
- O +
differentiated O +
fibrosarcomas O +
with O +
distinct O +
and O +
intersecting O +
bundles O +
and O +
spindle O +
cells O +
. O +

By O +
contrast O +
, O +
ras O +
- O +
induced O +
tumors O +
were O +
poorly O +
differentiated O +
fibrosarcomas O +
. O +

Thus O +
, O +
our O +
results O +
indicate O +
that O +
under O +
appropriate O +
conditions O +
rho O +
genes O +
function O +
as O +
oncogenes O +
and O +
may O +
have O +
a O +
role O +
in O +
the O +
regulation O +
of O +
proliferation O +
in O +
fibroblast O +
cells O +
. O +

Immune O +
consequences O +
of O +
burn O +
injury O +
. O +

The O +
purpose O +
of O +
the O +
immune O +
system O +
is O +
to O +
protect O +
cells O +
from O +
invasion O +
by O +
microorganisms O +
. O +

The O +
body O +
has O +
three O +
equally O +
important O +
interactive O +
immune O +
defense O +
systems O +
, O +
all O +
of O +
which O +
are O +
profoundly O +
disrupted O +
with O +
major O +
burn O +
injury O +
. O +

The O +
immune O +
response O +
to O +
burn O +
injury O +
is O +
immediate O +
, O +
prolonged O +
, O +
and O +
severe O +
. O +

The O +
end O +
result O +
in O +
individuals O +
surviving O +
burn O +
shock O +
is O +
immunosuppression O +
, O +
with O +
increased O +
susceptibility O +
to O +
potentially O +
fatal O +
systemic O +
burn O +
wound O +
or O +
pulmonary O +
sepsis O +
. O +

Nursing O +
actions O +
to O +
support O +
the O +
humoral O +
and O +
cell O +
- O +
mediated O +
immune O +
system O +
of O +
the O +
burned O +
patient O +
include O +
providing O +
nutritional O +
support O +
to O +
maintain O +
serum O +
protein O +
levels O +
at O +
optimal O +
levels O +
; O +
measures O +
to O +
decrease O +
edema O +
and O +
promote O +
angiogenesis O +
in O +
areas O +
of O +
partial O +
- O +
thickness O +
injury O +
; O +
meticulous O +
treatment O +
of O +
the O +
wound O +
to O +
prevent O +
infection O +
and O +
promote O +
healing O +
; O +
monitoring O +
of O +
antibiotic O +
use O +
; O +
conservative O +
use O +
of O +
invasive O +
techniques O +
, O +
including O +
intubation O +
and O +
vascular O +
access O +
devices O +
; O +
maintenance O +
of O +
fluid O +
and O +
electrolyte O +
balance O +
and O +
body O +
temperature O +
; O +
and O +
energy O +
conservation O +
measures O +
. O +

Autocrine O +
angiogenic O +
vascular O +
prosthesis O +
with O +
bone O +
marrow O +
transplantation O +
. O +

Synthetic O +
vascular O +
prostheses O +
are O +
foreign O +
bodies O +
, O +
so O +
that O +
blood O +
coagulation O +
can O +
occur O +
on O +
their O +
luminal O +
surfaces O +
, O +
causing O +
graft O +
occlusion O +
very O +
frequently O +
in O +
prostheses O +
of O +
small O +
diameter O +
. O +

A O +
vascular O +
prosthesis O +
needs O +
angiogenesis O +
for O +
endothelialization O +
of O +
the O +
luminal O +
surface O +
, O +
as O +
endothelial O +
cells O +
have O +
natural O +
and O +
permanent O +
antithrombogenic O +
properties O +
. O +

To O +
induce O +
capillary O +
growth O +
into O +
the O +
graft O +
, O +
we O +
developed O +
a O +
method O +
of O +
transplanting O +
bone O +
marrow O +
cells O +
, O +
which O +
are O +
primitive O +
, O +
strong O +
enough O +
to O +
survive O +
, O +
and O +
create O +
blood O +
cells O +
, O +
resulting O +
in O +
the O +
inducement O +
of O +
capillary O +
growth O +
. O +

In O +
an O +
animal O +
experiment O +
, O +
marrow O +
cells O +
were O +
infiltrated O +
into O +
the O +
walls O +
of O +
long O +
- O +
fibril O +
expanded O +
polytetrafluoroethylene O +
( O +
ePTFE O +
) O +
vascular O +
grafts O +
. O +

The O +
grafts O +
were O +
implanted O +
in O +
the O +
abdominal O +
aortic O +
position O +
of O +
24 O +
dogs O +
autologously O +
. O +

Marrow O +
cells O +
survived O +
and O +
continued O +
exogenous O +
hemopoiesis O +
for O +
up O +
to O +
six O +
months O +
and O +
were O +
immunohistochemically O +
reactive O +
to O +
basic O +
fibroblast O +
growth O +
factor O +
( O +
bFGF O +
) O +
. O +

All O +
the O +
grafts O +
older O +
than O +
three O +
weeks O +
had O +
complete O +
endothelialization O +
and O +
maintained O +
their O +
patency O +
. O +

Twenty O +
grafts O +
without O +
bone O +
marrow O +
were O +
implanted O +
as O +
controls O +
. O +

Endothelialization O +
was O +
present O +
at O +
anastomotic O +
sites O +
, O +
but O +
other O +
areas O +
were O +
covered O +
with O +
fresh O +
thrombi O +
. O +

Four O +
out O +
of O +
seven O +
control O +
grafts O +
were O +
patent O +
with O +
endothelial O +
cell O +
lining O +
at O +
six O +
months O +
, O +
but O +
three O +
were O +
occluded O +
and O +
one O +
of O +
the O +
four O +
grafts O +
was O +
still O +
covered O +
with O +
a O +
thrombus O +
layer O +
. O +

Bone O +
marrow O +
with O +
its O +
unique O +
native O +
properties O +
produced O +
autocrine O +
angiogenicity O +
in O +
the O +
graft O +
. O +

Toward O +
a O +
theory O +
regarding O +
the O +
pathogenesis O +
of O +
the O +
systemic O +
inflammatory O +
response O +
syndrome O +
: O +
what O +
we O +
do O +
and O +
do O +
not O +
know O +
about O +
cytokine O +
regulation O +
. O +

OBJECTIVES O +
: O +

The O +
systemic O +
inflammatory O +
response O +
syndrome O +
( O +
SIRS O +
) O +
is O +
the O +
massive O +
inflammatory O +
reaction O +
resulting O +
from O +
systemic O +
mediator O +
release O +
that O +
may O +
lead O +
to O +
multiple O +
organ O +
dysfunction O +
. O +

The O +
objective O +
of O +
this O +
review O +
article O +
is O +
to O +
analyze O +
the O +
roles O +
of O +
cytokines O +
, O +
cytokine O +
production O +
, O +
and O +
the O +
relationship O +
of O +
cytokine O +
production O +
to O +
the O +
development O +
of O +
SIRS O +
. O +

DATA O +
SOURCES O +
: O +

Previous O +
research O +
and O +
clinical O +
studies O +
related O +
to O +
cytokines O +
and O +
their O +
relationship O +
to O +
SIRS O +
. O +

STUDY O +
SELECTION O +
: O +

From O +
the O +
studies O +
reviewed O +
, O +
three O +
critical O +
questions O +
are O +
addressed O +
. O +

First O +
, O +
what O +
is O +
the O +
definition O +
of O +
increased O +
cytokine O +
concentrations O +
? O +

Second O +
, O +
what O +
other O +
systemic O +
illnesses O +
besides O +
sepsis O +
can O +
alter O +
cytokine O +
concentrations O +
? O +

Third O +
, O +
what O +
are O +
the O +
right O +
cytokines O +
to O +
measure O +
? O +

DATA O +
SYNTHESIS O +
: O +

This O +
article O +
postulates O +
a O +
three O +
- O +
stage O +
development O +
of O +
SIRS O +
, O +
in O +
which O +
stage O +
1 O +
is O +
a O +
local O +
production O +
of O +
cytokines O +
in O +
response O +
to O +
an O +
injury O +
or O +
infection O +
. O +

Stage O +
2 O +
is O +
the O +
protective O +
release O +
of O +
a O +
small O +
amount O +
of O +
cytokines O +
into O +
the O +
body O +
' O +
s O +
circulation O +
. O +

Stage O +
3 O +
is O +
the O +
massive O +
systemic O +
reaction O +
where O +
cytokines O +
turn O +
destructive O +
by O +
compromising O +
the O +
integrity O +
of O +
the O +
capillary O +
walls O +
and O +
flooding O +
end O +
organs O +
. O +

CONCLUSIONS O +
: O +

While O +
cytokines O +
are O +
generally O +
viewed O +
as O +
a O +
destructive O +
development O +
in O +
the O +
patient O +
that O +
generally O +
leads O +
to O +
multiple O +
organ O +
dysfunction O +
, O +
cytokines O +
also O +
protect O +
the O +
body O +
when O +
localized O +
. O +

It O +
will O +
be O +
necessary O +
to O +
study O +
the O +
positive O +
effects O +
of O +
cytokines O +
while O +
also O +
studying O +
their O +
role O +
in O +
causing O +
SIRS O +
. O +

It O +
will O +
also O +
be O +
important O +
to O +
investigate O +
the O +
relationship O +
between O +
cytokines O +
and O +
their O +
blockers O +
in O +
SIRS O +
. O +

Application O +
of O +
clonal O +
analysis O +
. O +

Differential O +
diagnosis O +
for O +
synchronous O +
primary O +
ovarian O +
and O +
endometrial O +
cancers O +
and O +
metastatic O +
cancer O +
. O +

Simultaneous O +
involvement O +
of O +
the O +
endometrium O +
and O +
the O +
ovary O +
by O +
carcinoma O +
is O +
a O +
familiar O +
problem O +
in O +
the O +
routine O +
practice O +
of O +
surgical O +
pathology O +
. O +

Such O +
cases O +
may O +
be O +
considered O +
either O +
examples O +
of O +
a O +
single O +
primary O +
carcinoma O +
with O +
metastasis O +
or O +
as O +
synchronous O +
primary O +
neoplasms O +
. O +

The O +
distinction O +
between O +
these O +
two O +
possibilities O +
is O +
made O +
based O +
on O +
clinicopathologic O +
observations O +
, O +
and O +
therefore O +
may O +
not O +
be O +
definitive O +
. O +

In O +
the O +
present O +
study O +
, O +
the O +
authors O +
used O +
molecular O +
techniques O +
to O +
analyze O +
the O +
clonal O +
composition O +
of O +
five O +
cases O +
of O +
concurrent O +
adenocarcinomas O +
of O +
the O +
endometrium O +
and O +
ovary O +
that O +
were O +
clinicopathologically O +
diagnosed O +
as O +
synchronous O +
primary O +
tumors O +
. O +

Patterns O +
of O +
X O +
- O +
chromosome O +
inactivation O +
, O +
mutations O +
in O +
the O +
K O +
- O +
ras O +
gene O +
, O +
mutations O +
or O +
allelic O +
loss O +
of O +
the O +
p53 O +
gene O +
, O +
or O +
human O +
papillomavirus O +
detection O +
were O +
identical O +
in O +
both O +
endometrial O +
and O +
ovarian O +
lesions O +
in O +
three O +
of O +
the O +
cases O +
suggesting O +
that O +
those O +
three O +
cases O +
represented O +
single O +
primary O +
tumors O +
with O +
metastases O +
. O +

In O +
both O +
of O +
the O +
other O +
two O +
cases O +
, O +
the O +
patterns O +
of O +
X O +
- O +
chromosome O +
inactivation O +
clearly O +
demonstrated O +
the O +
presence O +
of O +
independent O +
primary O +
tumors O +
. O +

The O +
application O +
of O +
molecular O +
technology O +
may O +
play O +
an O +
important O +
role O +
for O +
the O +
differential O +
diagnosis O +
between O +
synchronous O +
primary O +
carcinomas O +
and O +
a O +
single O +
carcinoma O +
with O +
metastasis O +
. O +

Pancreatic O +
somatostatin O +
- O +
secreting O +
gangliocytic O +
paraganglioma O +
with O +
lymph O +
node O +
metastases O +
. O +

Gangliocytic O +
paraganglioma O +
( O +
GPG O +
) O +
with O +
local O +
lymph O +
node O +
metastasis O +
was O +
found O +
in O +
the O +
pancreas O +
of O +
a O +
74 O +
- O +
yr O +
- O +
old O +
female O +
who O +
presented O +
with O +
diarrhea O +
, O +
steatorrhea O +
, O +
vomiting O +
, O +
nausea O +
, O +
and O +
abdominal O +
pain O +
. O +

A O +
Whipple O +
procedure O +
led O +
to O +
a O +
complete O +
resolution O +
of O +
these O +
symptoms O +
and O +
a O +
return O +
of O +
an O +
elevated O +
stomatostatin O +
level O +
to O +
normal O +
. O +

This O +
is O +
the O +
first O +
description O +
of O +
GPG O +
in O +
this O +
location O +
and O +
the O +
first O +
endocrinologically O +
active O +
GPG O +
. O +

Molecular O +
biology O +
of O +
cervical O +
cancer O +
and O +
its O +
precursors O +
. O +

Cervical O +
cancer O +
develops O +
from O +
well O +
- O +
defined O +
precursor O +
lesions O +
referred O +
to O +
as O +
either O +
cervical O +
intraepithelial O +
neoplasia O +
or O +
squamous O +
intraepithelial O +
lesions O +
. O +

It O +
is O +
now O +
known O +
that O +
specific O +
types O +
of O +
human O +
papillomaviruses O +
( O +
HPV O +
) O +
are O +
the O +
principal O +
etiologic O +
agents O +
for O +
both O +
cervical O +
cancer O +
and O +
its O +
precursors O +
. O +

The O +
high O +
- O +
oncogenic O +
- O +
risk O +
HPV O +
types O +
associated O +
with O +
invasive O +
cervical O +
cancer O +
produce O +
two O +
oncoproteins O +
, O +
designated O +
E6 O +
and O +
E7 O +
, O +
which O +
interact O +
with O +
endogenous O +
cell O +
cycle O +
regulatory O +
proteins O +
, O +
including O +
p53 O +
and O +
Rb O +
. O +

The O +
interaction O +
of O +
virally O +
derived O +
and O +
endogenous O +
cellular O +
proteins O +
converges O +
in O +
deregulation O +
of O +
cell O +
cycle O +
progression O +
and O +
appears O +
to O +
be O +
critical O +
for O +
the O +
development O +
of O +
cervical O +
cancers O +
. O +

However O +
, O +
the O +
development O +
of O +
cervical O +
cancer O +
is O +
a O +
multistep O +
process O +
that O +
can O -
not O +
be O +
explained O +
simply O +
by O +
infection O +
with O +
specific O +
types O +
of O +
HPV O +
. O +

One O +
additional O +
event O +
that O +
appears O +
to O +
play O +
a O +
role O +
in O +
tumor O +
progression O +
is O +
integration O +
of O +
HPV O +
DNA O +
into O +
the O +
host O +
genome O +
. O +

Integration O +
of O +
HPV O +
DNA O +
frequently O +
disrupts O +
the O +
E2 O +
open O +
reading O +
frames O +
, O +
resulting O +
in O +
overexpression O +
of O +
the O +
E6 O +
and O +
E7 O +
oncoproteins O +
and O +
possibly O +
causing O +
genomic O +
instability O +
. O +

Additional O +
cofactors O +
and O +
mutational O +
events O +
may O +
be O +
important O +
in O +
the O +
pathogenesis O +
of O +
invasive O +
cervical O +
cancers O +
and O +
may O +
include O +
chromosomal O +
rearrangements O +
, O +
loss O +
of O +
constitutional O +
heterozygosity O +
, O +
and O +
proto O +
- O +
oncogene O +
activation O +
. O +

Cell O +
surface O +
binding O +
characteristics O +
correlate O +
with O +
consensus O +
type O +
I O +
interferon O +
enhanced O +
activity O +
. O +

The O +
binding O +
characteristics O +
of O +
a O +
genetically O +
engineered O +
consensus O +
interferon O +
with O +
unusually O +
high O +
biologic O +
activity O +
were O +
compared O +
to O +
the O +
characteristics O +
of O +
recombinant O +
interferon O +
- O +
alpha O +
2 O +
. O +

Both O +
interferon O +
- O +
alpha O +
2 O +
and O +
the O +
consensus O +
interferon O +
produced O +
typical O +
biphasic O +
Scatchard O +
plots O +
, O +
indicating O +
multiple O +
independent O +
binding O +
sites O +
. O +

The O +
consensus O +
interferon O +
, O +
which O +
exhibited O +
a O +
biologic O +
potency O +
more O +
than O +
10 O +
- O +
fold O +
greater O +
than O +
all O +
other O +
type O +
I O +
interferons O +
, O +
also O +
exhibited O +
binding O +
site O +
affinities O +
greater O +
than O +
those O +
for O +
IFN O +
- O +
alpha O +
2b O +
. O +

In O +
addition O +
, O +
a O +
larger O +
number O +
of O +
high O +
, O +
and O +
low O +
- O +
affinity O +
cell O +
surface O +
sites O +
were O +
recognized O +
by O +
the O +
consensus O +
interferon O +
, O +
resulting O +
in O +
equivalent O +
numbers O +
of O +
sites O +
at O +
reduced O +
molar O +
concentrations O +
compared O +
to O +
IFN O +
- O +
a2b O +
. O +

Thus O +
, O +
at O +
any O +
given O +
biologic O +
activity O +
, O +
similar O +
numbers O +
of O +
sites O +
were O +
bound O +
by O +
the O +
consensus O +
interferon O +
and O +
IFN O +
- O +
alpha O +
2 O +
, O +
despite O +
differences O +
in O +
their O +
molar O +
concentrations O +
. O +

No O +
differences O +
in O +
internalization O +
kinetics O +
were O +
identified O +
between O +
the O +
two O +
interferons O +
, O +
indicating O +
that O +
the O +
differences O +
in O +
cell O +
surface O +
binding O +
may O +
be O +
sufficient O +
to O +
produce O +
the O +
differences O +
in O +
biologic O +
activity O +
. O +

Human O +
immunodeficiency O +
virus O +
type O +
1 O +
viral O +
background O +
plays O +
a O +
major O +
role O +
in O +
development O +
of O +
resistance O +
to O +
protease O +
inhibitors O +
. O +

The O +
observed O +
in O +
vitro O +
and O +
in O +
vivo O +
benefit O +
of O +
combination O +
treatment O +
with O +
anti O +
- O +
human O +
immunodeficiency O +
virus O +
( O +
HIV O +
) O +
agents O +
prompted O +
us O +
to O +
examine O +
the O +
potential O +
of O +
resistance O +
development O +
when O +
two O +
protease O +
inhibitors O +
are O +
used O +
concurrently O +
. O +

Recombinant O +
HIV O +
- O +
1 O +
( O +
NL4 O +
- O +
3 O +
) O +
proteases O +
containing O +
combined O +
resistance O +
mutations O +
associated O +
with O +
BMS O +
- O +
186318 O +
and O +
A O +
- O +
77003 O +
( O +
or O +
saquinavir O +
) O +
were O +
either O +
inactive O +
or O +
had O +
impaired O +
enzyme O +
activity O +
. O +

Subsequent O +
construction O +
of O +
HIV O +
- O +
1 O +
( O +
NL4 O +
- O +
3 O +
) O +
proviral O +
clones O +
containing O +
the O +
same O +
mutations O +
yielded O +
viruses O +
that O +
were O +
severely O +
impaired O +
in O +
growth O +
or O +
nonviable O +
, O +
confirming O +
that O +
combination O +
therapy O +
may O +
be O +
advantageous O +
. O +

However O +
, O +
passage O +
of O +
BMS O +
- O +
186318 O +
- O +
resistant O +
HIV O +
- O +
1 O +
( O +
RF O +
) O +
in O +
the O +
presence O +
of O +
either O +
saquinavir O +
or O +
SC52151 O +
, O +
which O +
represented O +
sequential O +
drug O +
treatment O +
, O +
produced O +
viable O +
viruses O +
resistant O +
to O +
both O +
BMS O +
- O +
186318 O +
and O +
the O +
second O +
compound O +
. O +

The O +
predominant O +
breakthrough O +
virus O +
contained O +
the O +
G48V O +
/ O +
A71 O -
T O +
/ O +
V82A O +
protease O +
mutations O +
. O +

The O +
clone O +
- O +
purified O +
RF O +
( O +
G48V O +
/ O +
A71 O -
T O +
/ O +
V82A O +
) O +
virus O +
, O +
unlike O +
the O +
corresponding O +
defective O +
NL4 O +
- O +
3 O +
triple O +
mutant O +
, O +
grew O +
well O +
and O +
displayed O +
cross O +
- O +
resistance O +
to O +
four O +
distinct O +
protease O +
inhibitors O +
. O +

Chimeric O +
virus O +
and O +
in O +
vitro O +
mutagenesis O +
studies O +
indicated O +
that O +
the O +
RF O +
- O +
specific O +
protease O +
sequence O +
, O +
specifically O +
the O +
Ile O +
at O +
residue O +
10 O +
, O +
enabled O +
the O +
NL4 O +
- O +
3 O +
strain O +
with O +
the O +
triple O +
mutant O +
to O +
grow O +
. O +

Our O +
results O +
clearly O +
indicate O +
that O +
viral O +
genetic O +
background O +
will O +
play O +
a O +
key O +
role O +
in O +
determining O +
whether O +
cross O +
- O +
resistance O +
variants O +
will O +
arise O +
. O +

The O +
effects O +
of O +
radiation O +
on O +
neovascularization O +
in O +
a O +
rat O +
model O +
. O +

It O +
is O +
thought O +
that O +
radiation O +
treatment O +
inhibits O +
neovascularization O +
of O +
recipient O +
and O +
/ O +
or O +
graft O +
tissues O +
, O +
and O +
this O +
may O +
account O +
in O +
part O +
for O +
abnormalities O +
in O +
wound O +
healing O +
associated O +
with O +
radiation O +
therapy O +
. O +

We O +
have O +
examined O +
this O +
hypothesis O +
using O +
a O +
model O +
that O +
measures O +
the O +
neovascularization O +
of O +
an O +
implanted O +
foreign O +
material O +
. O +

Expanded O +
polytetrafluoroethylene O +
( O +
PTFE O +
) O +
sheets O +
were O +
implanted O +
adjacent O +
to O +
both O +
superficial O +
epigastric O +
vascular O +
pedicles O +
of O +
63 O +
rats O +
distributed O +
into O +
7 O +
groups O +
( O +
n O +
= O +
7 O +
) O +
that O +
differed O +
with O +
respect O +
to O +
dose O +
and O +
timing O +
of O +
irradiation O +
. O +

Zero O +
to O +
10 O +
daily O +
fractions O +
of O +
electron O +
- O +
beam O +
radiation O +
( O +
300 O +
cGy O +
each O +
) O +
were O +
delivered O +
to O +
the O +
implant O +
in O +
the O +
right O +
groin O +
, O +
while O +
the O +
implant O +
in O +
the O +
left O +
groin O +
served O +
as O +
a O +
nonirradiated O +
internal O +
control O +
. O +

Unirradiated O +
animals O +
showed O +
equal O +
neovascularization O +
of O +
both O +
implants O +
. O +

Rats O +
that O +
were O +
irradiated O +
twice O +
( O +
single O +
fractions O +
at O +
0 O +
and O +
24 O +
hours O +
after O +
implantation O +
) O +
did O +
not O +
show O +
a O +
significant O +
decrease O +
in O +
the O +
neovascularization O +
of O +
the O +
irradiated O +
implant O +
compared O +
with O +
the O +
contralateral O +
control O +
implant O +
. O +

In O +
contrast O +
, O +
the O +
implants O +
that O +
were O +
irradiated O +
three O +
times O +
( O +
single O +
fractions O +
at O +
0 O +
, O +
24 O +
, O +
and O +
48 O +
hours O +
after O +
implantation O +
) O +
demonstrated O +
significantly O +
diminished O +
( O +
greater O +
than O +
25 O +
percent O +
, O +
p O +
less O +
than O +
0 O +
. O +
05 O +
) O +
neovascularization O +
beyond O +
day O +
7 O +
, O +
whereas O +
implants O +
irradiated O +
only O +
at O +
48 O +
hours O +
after O +
implantation O +
did O +
not O +
. O +

Interestingly O +
, O +
neovascularization O +
of O +
the O +
implants O +
irradiated O +
with O +
10 O +
fractions O +
( O +
3000 O +
cGy O +
) O +
was O +
not O +
significantly O +
decreased O +
compared O +
with O +
irradiation O +
with O +
three O +
fractions O +
( O +
900 O +
cGy O +
) O +
. O +

Irradiation O +
delivered O +
before O +
implantation O +
( O +
900 O +
cGy O +
) O +
inhibited O +
neovascularization O +
significantly O +
less O +
than O +
the O +
same O +
dose O +
administered O +
after O +
implantation O +
. O +

The O +
results O +
of O +
this O +
study O +
suggest O +
that O +
a O +
subclinical O +
cumulative O +
dose O +
of O +
900 O +
cGy O +
is O +
the O +
threshold O +
for O +
impaired O +
tissue O +
revascularization O +
provided O +
that O +
treatment O +
is O +
delivered O +
immediately O +
after O +
implantation O +
over O +
a O +
48 O +
- O +
hour O +
interval O +
. O +

Stimulation O +
of O +
endothelial O +
cell O +
migration O +
by O +
vascular O +
permeability O +
factor O +
/ O +
vascular O +
endothelial O +
growth O +
factor O +
through O +
cooperative O +
mechanisms O +
involving O +
the O +
alphavbeta3 O +
integrin O +
, O +
osteopontin O +
, O +
and O +
thrombin O +
. O +

We O +
have O +
identified O +
several O +
mechanisms O +
by O +
which O +
the O +
angiogenic O +
cytokine O +
vascular O +
permeability O +
factor O +
/ O +
vascular O +
endothelial O +
growth O +
factor O +
( O +
VPF O +
/ O +
VEGF O +
) O +
likely O +
regulates O +
endothelial O +
cells O +
( O +
EC O +
) O +
migration O +
. O +

VPF O +
/ O +
VEGF O +
induced O +
dermal O +
microvascular O +
EC O +
expression O +
of O +
mRNAs O +
encoding O +
the O +
alphav O +
and O +
beta3 O +
integrin O +
subunits O +
resulting O +
in O +
increased O +
levels O +
of O +
the O +
alphavbeta3 O +
heterodimer O +
at O +
the O +
cell O +
surface O +
, O +
and O +
VPF O +
/ O +
VEGF O +
also O +
induced O +
mRNA O +
encoding O +
osteopontin O +
( O +
OPN O +
) O +
, O +
an O +
alphavbeta3 O +
ligand O +
. O +

OPN O +
promoted O +
EC O +
migration O +
in O +
vitro O +
; O +
and O +
VPF O +
/ O +
VEGF O +
induction O +
of O +
alphavbeta3 O +
was O +
accompanied O +
by O +
increased O +
EC O +
migration O +
toward O +
OPN O +
. O +

Because O +
thrombin O +
cleavage O +
of O +
OPN O +
results O +
in O +
substantial O +
enhancement O +
of O +
OPN O +
' O +
s O +
adhesive O +
properties O +
, O +
and O +
because O +
VPF O +
/ O +
VEGF O +
promotes O +
increased O +
microvascular O +
permeability O +
leading O +
to O +
activation O +
of O +
the O +
extrinsic O +
coagulation O +
pathway O +
, O +
we O +
also O +
investigated O +
whether O +
VPF O +
/ O +
VEGF O +
facilitates O +
thrombin O +
cleavage O +
of O +
OPN O +
in O +
vivo O +
. O +

Consistent O +
with O +
this O +
hypothesis O +
, O +
co O +
- O +
injection O +
of O +
VPF O +
/ O +
VEGF O +
together O +
with O +
OPN O +
resulted O +
in O +
rapid O +
cleavage O +
of O +
OPN O +
by O +
endogenous O +
thrombin O +
. O +

Furthermore O +
, O +
in O +
comparison O +
with O +
native O +
OPN O +
, O +
thrombin O +
- O +
cleaved O +
OPN O +
stimulated O +
a O +
greater O +
rate O +
of O +
EC O +
migration O +
in O +
vitro O +
, O +
which O +
was O +
additive O +
to O +
the O +
increased O +
migration O +
associated O +
with O +
induction O +
of O +
alpha O +
v O +
beta O +
3 O +
. O +

Thus O +
, O +
these O +
data O +
demonstrate O +
cooperative O +
mechanisms O +
for O +
VPF O +
/ O +
VEGF O +
regulation O +
of O +
EC O +
migration O +
involving O +
the O +
alphavbeta3 O +
integrin O +
, O +
the O +
alphavbeta3 O +
ligand O +
OPN O +
, O +
and O +
thrombin O +
cleavage O +
of O +
OPN O +
. O +

These O +
findings O +
also O +
illustrate O +
an O +
operational O +
link O +
between O +
VPF O +
/ O +
VEGF O +
induction O +
of O +
EC O +
gene O +
expression O +
and O +
VPF O +
/ O +
VEGF O +
enhancement O +
of O +
microvascular O +
permeability O +
, O +
suggesting O +
that O +
these O +
distinct O +
biological O +
activities O +
may O +
act O +
accordingly O +
to O +
stimulate O +
EC O +
migration O +
during O +
angiogenesis O +
. O +

Referral O +
bias O +
among O +
health O +
workers O +
in O +
studies O +
using O +
hospitalization O +
as O +
a O +
proxy O +
measure O +
of O +
the O +
underlying O +
incidence O +
rate O +
. O +

Contacts O +
with O +
health O +
services O +
like O +
hospitals O +
or O +
general O +
practitioners O +
are O +
usually O +
the O +
only O +
available O +
proxy O +
measure O +
of O +
incidence O +
of O +
disease O +
in O +
studies O +
based O +
on O +
secondary O +
data O +
and O +
differential O +
referrals O +
or O +
care O +
- O +
seeking O +
behavior O +
often O +
bias O +
such O +
proxy O +
measures O +
. O +

In O +
former O +
analyses O +
based O +
on O +
the O +
Occupational O +
Hospitalization O +
Register O +
in O +
Denmark O +
assisting O +
nurses O +
had O +
high O +
Standardized O +
Hospitalization O +
Ratios O +
for O +
many O +
diseases O +
. O +

It O +
was O +
, O +
however O +
, O +
suspected O +
that O +
it O +
fully O +
or O +
partly O +
was O +
due O +
to O +
a O +
referral O +
bias O +
or O +
self O +
- O +
selection O +
to O +
hospital O +
treatment O +
rather O +
than O +
exposures O +
to O +
occupational O +
hazards O +
. O +

The O +
aim O +
of O +
the O +
present O +
study O +
is O +
to O +
evaluate O +
the O +
referral O +
bias O +
hypothesis O +
by O +
comparing O +
hospitalization O +
and O +
mortality O +
data O +
for O +
health O +
workers O +
for O +
a O +
disease O +
category O +
with O +
a O +
high O +
mortality O +
. O +

Cohorts O +
of O +
all O +
gainfully O +
employed O +
20 O +
- O +
to O +
59 O +
- O +
year O +
- O +
old O +
Danes O +
were O +
formed O +
in O +
order O +
to O +
compare O +
Standardized O +
Mortality O +
Ratios O +
and O +
Standardized O +
Hospitalization O +
Ratios O +
of O +
ischemic O +
heart O +
disease O +
( O +
IHD O +
) O +
in O +
occupational O +
groups O +
. O +

The O +
follow O +
- O +
up O +
period O +
was O +
10 O +
years O +
. O +

For O +
most O +
of O +
the O +
investigated O +
occupational O +
groups O +
a O +
similar O +
disease O +
pattern O +
was O +
found O +
whether O +
hospitalization O +
or O +
death O +
was O +
used O +
as O +
the O +
outcome O +
measure O +
. O +

In O +
" O +
nurse O +
assistants O +
" O +
a O +
statistically O +
significant O +
higher O +
risk O +
was O +
, O +
however O +
, O +
found O +
using O +
hospitalization O +
due O +
to O +
IHD O +
as O +
the O +
end O +
point O +
rather O +
than O +
mortality O +
. O +

Additional O +
analysis O +
did O +
not O +
support O +
the O +
hypothesis O +
that O +
the O +
finding O +
could O +
be O +
explained O +
by O +
differentiated O +
hospitalization O +
due O +
to O +
social O +
factors O +
. O +

The O +
true O +
incidence O +
rates O +
of O +
the O +
disease O +
need O +
not O +
be O +
equally O +
well O +
described O +
by O +
proxy O +
measures O +
such O +
as O +
hospitalization O +
diagnosis O +
or O +
death O +
diagnosis O +
in O +
all O +
occupational O +
groups O +
. O +

Differential O +
access O +
to O +
medical O +
treatment O +
in O +
some O +
groups O +
may O +
lead O +
to O +
bias O +
when O +
hospital O +
data O +
are O +
used O +
as O +
proxy O +
measures O +
for O +
the O +
underlying O +
incidence O +
rates O +
. O +

Prognostic O +
value O +
of O +
angiogenesis O +
in O +
operable O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
. O +

Tumour O +
angiogenesis O +
is O +
an O +
important O +
factor O +
for O +
tumour O +
growth O +
and O +
metastasis O +
. O +

Although O +
some O +
recent O +
reports O +
suggest O +
that O +
microvessel O +
counts O +
in O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
are O +
related O +
to O +
a O +
poor O +
disease O +
outcome O +
, O +
the O +
results O +
were O +
not O +
conclusive O +
and O +
were O +
not O +
compared O +
with O +
other O +
molecular O +
prognostic O +
markers O +
. O +

In O +
the O +
present O +
study O +
, O +
the O +
vascular O +
grade O +
was O +
assessed O +
in O +
107 O +
( O +
T1 O +
, O +
2 O +
- O +
N0 O +
, O +
1 O +
) O +
operable O +
non O +
- O +
small O +
cell O +
lung O +
carcinomas O +
, O +
using O +
the O +
JC70 O +
monoclonal O +
antibody O +
to O +
CD31 O +
. O +

Three O +
vascular O +
grades O +
were O +
defined O +
with O +
appraisal O +
by O +
eye O +
and O +
by O +
Chalkley O +
counting O +
: O +
high O +
( O +
Chalkley O +
score O +
7 O +
- O +
12 O +
) O +
, O +
medium O +
( O +
5 O +
- O +
6 O +
) O +
, O +
and O +
low O +
( O +
2 O +
- O +
4 O +
) O +
. O +

There O +
was O +
a O +
significant O +
correlation O +
between O +
eye O +
appraisal O +
and O +
Chalkley O +
counting O +
( O +
P O +
less O +
than O +
0 O +
. O +
0001 O +
) O +
. O +

Vascular O +
grade O +
was O +
not O +
related O +
to O +
histology O +
, O +
grade O +
, O +
proliferation O +
index O +
( O +
Ki67 O +
) O +
, O +
or O +
EGFR O +
or O +
p53 O +
expression O +
. O +

Tumours O +
from O +
younger O +
patients O +
had O +
a O +
higher O +
grade O +
of O +
angiogenesis O +
( O +
P O +
= O +
0 O +
. O +
05 O +
) O +
. O +

Apart O +
from O +
the O +
vascular O +
grade O +
, O +
none O +
of O +
the O +
other O +
factors O +
examined O +
was O +
statistically O +
related O +
to O +
lymph O +
node O +
metastasis O +
( O +
P O +
less O +
than O +
0 O +
. O +
0001 O +
) O +
. O +

A O +
univariate O +
analysis O +
of O +
survival O +
showed O +
that O +
vascular O +
grade O +
was O +
the O +
most O +
significant O +
prognostic O +
factor O +
( O +
P O +
= O +
0 O +
. O +
0004 O +
) O +
, O +
followed O +
by O +
N O +
- O +
stage O +
( O +
P O +
= O +
0 O +
. O +
001 O +
) O +
. O +

In O +
a O +
multivariate O +
analysis O +
, O +
N O +
- O +
stage O +
and O +
vascular O +
grade O +
were O +
not O +
found O +
to O +
be O +
independent O +
prognostic O +
factors O +
, O +
since O +
they O +
were O +
strongly O +
related O +
to O +
each O +
other O +
. O +

Excluding O +
N O +
- O +
stage O +
, O +
vascular O +
grade O +
was O +
the O +
only O +
independent O +
prognostic O +
factor O +
( O +
P O +
= O +
0 O +
. O +
007 O +
) O +
. O +

Kaplan O +
- O +
Meier O +
survival O +
curves O +
showed O +
a O +
statistically O +
significant O +
worse O +
prognosis O +
for O +
patients O +
with O +
high O +
vascular O +
grade O +
, O +
but O +
no O +
difference O +
was O +
observed O +
between O +
low O +
and O +
medium O +
vascular O +
grade O +
. O +

These O +
data O +
suggest O +
that O +
angiogenesis O +
in O +
operable O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
is O +
a O +
major O +
prognostic O +
factor O +
for O +
survival O +
and O +
, O +
among O +
the O +
parameters O +
tested O +
, O +
is O +
the O +
only O +
factor O +
related O +
to O +
cancer O +
cell O +
migration O +
to O +
lymph O +
nodes O +
. O +

The O +
integration O +
of O +
vascular O +
grading O +
in O +
clinical O +
trials O +
on O +
adjuvant O +
chemotherapy O +
and O +
/ O +
or O +
radiotherapy O +
could O +
substantially O +
contribute O +
in O +
defining O +
groups O +
of O +
operable O +
patients O +
who O +
might O +
benefit O +
from O +
cytotoxic O +
treatment O +
. O +

The O +
impact O +
of O +
multiskilling O +
on O +
quality O +
of O +
care O +
. O +

Hospital O +
finances O +
in O +
the O +
USA O +
are O +
in O +
a O +
crisis O +
. O +

While O +
profits O +
earned O +
from O +
the O +
healthcare O +
industry O +
appear O +
to O +
be O +
at O +
an O +
all O +
- O +
time O +
high O +
, O +
individual O +
hospitals O +
are O +
going O +
bankrupt O +
. O +

Hospitals O +
are O +
not O +
generating O +
sufficient O +
income O +
to O +
pay O +
their O +
expenses O +
given O +
how O +
they O +
have O +
traditionally O +
operated O +
. O +

Hence O +
, O +
we O +
are O +
witnessing O +
the O +
merger O +
and O +
consolidation O +
of O +
competitors O +
, O +
resulting O +
in O +
significantly O +
fewer O +
hospital O +
beds O +
in O +
certain O +
geographical O +
areas O +
. O +

In O +
addition O +
to O +
the O +
strategy O +
of O +
closing O +
hospital O +
beds O +
, O +
severe O +
budget O +
restrictions O +
are O +
impacting O +
upon O +
all O +
remaining O +
services O +
within O +
the O +
hospitals O +
. O +

Vitamin O +
E O +
inhibits O +
experimental O +
carcinogenesis O +
and O +
tumour O +
angiogenesis O +
. O +

In O +
an O +
experiment O +
in O +
which O +
vitamin O +
E O +
inhibited O +
carcinogenesis O +
, O +
it O +
was O +
found O +
that O +
tumour O +
angiogenesis O +
and O +
tumour O +
growth O +
- O +
factor O +
alpha O +
( O +
TGF O +
alpha O +
) O +
expression O +
were O +
also O +
inhibited O +
. O +

Forty O +
male O +
golden O +
hamsters O +
were O +
divided O +
into O +
four O +
equal O +
groups O +
. O +

Group O +
1 O +
animals O +
had O +
the O +
left O +
buccal O +
pouches O +
painted O +
three O +
times O +
weekly O +
with O +
7 O +
, O +
12 O +
- O +
dimethylbenz O +
( O +
a O +
) O +
anthracene O +
( O +
DMBA O +
) O +
for O +
14 O +
weeks O +
. O +

Group O +
2 O +
animals O +
had O +
the O +
same O +
procedure O +
of O +
DMBA O +
applications O +
but O +
also O +
received O +
alpha O +
tocopherol O +
. O +

Groups O +
3 O +
and O +
4 O +
were O +
vitamin O +
E O +
and O +
untreated O +
controls O +
. O +

Angiogenesis O +
was O +
studied O +
with O +
factor O +
8 O +
- O +
related O +
antigen O +
( O +
F8 O +
- O +
RA O +
) O +
which O +
identifies O +
endothelial O +
cells O +
. O +

TGF O +
alpha O +
was O +
studied O +
with O +
the O +
appropriate O +
antibody O +
. O +

Staining O +
was O +
effected O +
by O +
the O +
standard O +
avidin O +
- O +
biotin O +
horseradish O +
peroxidase O +
system O +
. O +

Mean O +
tumour O +
volume O +
was O +
significantly O +
lower O +
in O +
the O +
DMBA O +
- O +
vitamin O +
E O +
group O +
compared O +
to O +
the O +
tumour O +
control O +
group O +
. O +

Angiogenesis O +
was O +
significantly O +
inhibited O +
in O +
the O +
DMBA O +
- O +
vitamin O +
E O +
group O +
and O +
TGF O +
alpha O +
expression O +
was O +
also O +
inhibited O +
. O +

It O +
is O +
suggested O +
that O +
inhibition O +
of O +
tumour O +
angiogenesis O +
by O +
vitamin O +
E O +
may O +
be O +
an O +
additional O +
mechanism O +
for O +
the O +
anticancer O +
action O +
of O +
vitamin O +
E O +
. O +

Acetaminophen O +
and O +
hepatic O +
dysfunction O +
in O +
infectious O +
mononucleosis O +
. O +

Two O +
family O +
members O +
developed O +
severe O +
hepatitic O +
dysfunction O +
in O +
association O +
with O +
infectious O +
mononucleosis O +
and O +
acetaminophen O +
administration O +
. O +

Since O +
severe O +
hepatitis O +
is O +
an O +
extremely O +
rare O +
complication O +
of O +
infectious O +
mononucleosis O +
, O +
we O +
postulate O +
that O +
the O +
hepatic O +
dysfunction O +
was O +
induced O +
by O +
acetaminophen O +
. O +

Syndecan O +
- O +
1 O +
expression O +
in O +
mammary O +
epithelial O +
tumor O +
cells O +
is O +
E O +
- O +
cadherin O +
- O +
dependent O +
. O +

E O +
- O +
cadherin O +
is O +
a O +
Ca O +
( O +
2 O +
+ O +
) O +
- O +
dependent O +
cell O +
- O +
cell O +
adhesion O +
molecule O +
, O +
which O +
is O +
mainly O +
expressed O +
in O +
epithelial O +
cells O +
. O +

Recent O +
studies O +
have O +
shown O +
that O +
E O +
- O +
cadherin O +
has O +
an O +
important O +
role O +
as O +
an O +
invasion O +
suppressor O +
molecule O +
in O +
epithelial O +
tumor O +
cells O +
. O +

Syndecan O +
- O +
1 O +
is O +
a O +
cell O +
surface O +
proteoglycan O +
that O +
has O +
been O +
implicated O +
in O +
a O +
number O +
of O +
cellular O +
functions O +
including O +
cell O +
- O +
cell O +
adhesion O +
, O +
cell O +
- O +
matrix O +
anchorage O +
and O +
growth O +
factor O +
presentation O +
for O +
signalling O +
receptors O +
. O +

Its O +
suppression O +
has O +
also O +
been O +
shown O +
to O +
be O +
associated O +
with O +
malignant O +
transformation O +
of O +
epithelial O +
cells O +
. O +

In O +
order O +
to O +
better O +
understand O +
the O +
coordinated O +
regulation O +
of O +
cell O +
- O +
cell O +
and O +
cell O +
- O +
matrix O +
interactions O +
during O +
malignant O +
transformation O +
, O +
we O +
have O +
studied O +
the O +
expression O +
of O +
syndecan O +
- O +
1 O +
in O +
malignant O +
mammary O +
tumor O +
cells O +
genetically O +
manipulated O +
for O +
E O +
- O +
cadherin O +
expression O +
. O +

In O +
invasive O +
NM B-CellLine +
- I-CellLine +
e I-CellLine +
- O +
ras O +
- O +
MAC1 O +
cells O +
, O +
where O +
E O +
- O +
cadherin O +
was O +
partially O +
downregulated O +
by O +
specific O +
antisense O +
RNA O +
, O +
syndecan O +
- O +
1 O +
expression O +
was O +
suppressed O +
. O +

Furthermore O +
, O +
transfection O +
of O +
E O +
- O +
cadherin O +
cDNA O +
into O +
invasive O +
NM B-CellLine +
- I-CellLine +
f I-CellLine +
- O +
ras O +
- O +
TD O +
cells O +
resulted O +
in O +
the O +
upregulation O +
of O +
syndecan O +
- O +
1 O +
expression O +
in O +
association O +
with O +
decreased O +
invasiveness O +
. O +

In O +
both O +
cases O +
, O +
regulation O +
of O +
syndecan O +
- O +
1 O +
occurred O +
post O +
- O +
transcriptionally O +
, O +
since O +
syndecan O +
- O +
1 O +
mRNA O +
levels O +
remained O +
unchanged O +
. O +

Instead O +
, O +
a O +
translational O +
regulation O +
is O +
suggested O +
, O +
since O +
syndecan O +
- O +
1 O +
core O +
protein O +
synthesis O +
was O +
E O +
- O +
cadherin O +
dependent O +
. O +

Another O +
cell O +
adhesion O +
protein O +
, O +
beta O +
1 O +
- O +
integrin O +
was O +
not O +
affected O +
by O +
E O +
- O +
cadherin O +
expression O +
. O +

The O +
data O +
provide O +
an O +
example O +
of O +
coordinated O +
changes O +
in O +
the O +
expression O +
of O +
two O +
cell O +
adhesion O +
molecules O +
, O +
syndecan O +
- O +
1 O +
and O +
E O +
- O +
cadherin O +
during O +
epithelial O +
cell O +
transformation O +
. O +

Curcumin O +
induces O +
apoptosis O +
in O +
immortalized O +
NIH B-CellLine +
3T3 I-CellLine +
and O +
malignant O +
cancer O +
cell O +
lines O +
. O +

Curcumin O +
, O +
which O +
is O +
a O +
widely O +
used O +
dietary O +
pigment O +
and O +
spice O +
, O +
has O +
been O +
demonstrated O +
to O +
be O +
an O +
effective O +
inhibitor O +
of O +
tumor O +
promotion O +
in O +
mouse O +
skin O +
carcinogenesis O +
. O +

We O +
report O +
that O +
curcumin O +
induces O +
cell O +
shrinkage O +
, O +
chromatin O +
condensation O +
, O +
and O +
DNA O +
fragmentation O +
, O +
characteristics O +
of O +
apoptosis O +
, O +
in O +
immortalized O +
mouse O +
embryo O +
fibroblast O +
NIH B-CellLine +
3T3 I-CellLine +
erb O +
B2 O +
oncogene O +
- O +
transformed O +
NIH B-CellLine +
3T3 I-CellLine +
, O +
mouse O +
sarcoma O +
S180 B-CellLine +
, O +
human O +
colon O +
cancer O +
cell O +
HT B-CellLine +
- I-CellLine +
29 I-CellLine +
, O +
human O +
kidney O +
cancer O +
cell O +
293 B-CellLine +
, O +
and O +
human O +
hepatocellular O +
carcinoma O +
Hep B-CellLine +
G2 I-CellLine +
cells O +
, O +
but O +
not O +
in O +
primary O +
culture O +
of O +
mouse O +
embryonic O +
fibroblast O +
C3H B-CellLine +
10T1 I-CellLine +
/ I-CellLine +
2 I-CellLine +
, O +
rat O +
embryonic O +
fibroblast O +
, O +
and O +
human O +
foreskin O +
fibroblast O +
cells O +
in O +
a O +
concentration O +
- O +
and O +
time O +
- O +
dependent O +
manner O +
. O +

Many O +
cellular O +
and O +
biochemical O +
effects O +
of O +
curcumin O +
in O +
mouse O +
fibroblast O +
cells O +
have O +
been O +
reported O +
, O +
such O +
as O +
inhibition O +
of O +
protein O +
kinase O +
C O +
( O +
PKC O +
) O +
activity O +
induced O +
by O +
phorbol O +
12 O +
- O +
myristate O +
13 O +
- O +
acetate O +
treatment O +
, O +
inhibition O +
of O +
tyrosine O +
protein O +
kinase O +
activity O +
, O +
and O +
inhibition O +
of O +
arachidonic O +
acid O +
( O +
AA O +
) O +
metabolism O +
. O +

Treatment O +
of O +
NIH B-CellLine +
3T3 I-CellLine +
cells O +
with O +
the O +
PKC O +
inhibitor O +
staurosporine O +
, O +
the O +
tyrosine O +
kinase O +
inhibitor O +
herbimycin O +
A O +
, O +
and O +
the O +
AA O +
metabolism O +
inhibitor O +
quinacrine O +
induces O +
apoptotic O +
cell O +
death O +
. O +

These O +
results O +
suggest O +
that O +
, O +
in O +
some O +
immortalized O +
and O +
transformed O +
cells O +
, O +
blocking O +
the O +
cellular O +
signal O +
transduction O +
might O +
trigger O +
the O +
induction O +
of O +
apoptosis O +
. O +

c O +
- O +
erb O +
B2 O +
overexpression O +
decreases O +
the O +
benefit O +
of O +
adjuvant O +
tamoxifen O +
in O +
early O +
- O +
stage O +
breast O +
cancer O +
without O +
axillary O +
lymph O +
node O +
metastases O +
. O +

PURPOSE O +
: O +
We O +
studied O +
retrospectively O +
the O +
interaction O +
between O +
c O +
- O +
erbB2 O +
overexpression O +
and O +
adjuvant O +
tomoxifen O +
in O +
node O +
- O +
negative O +
breast O +
cancer O +
patients O +
enrolled O +
in O +
the O +
Gruppo O +
Universitario O +
Napoletano O +
1 O +
( O +
GUN O +
- O +
1 O +
) O +
trial O +
. O +

PATIENTS O +
AND O +
METHODS O +
: O +
c O +
- O +
erbB2 O +
, O +
evaluated O +
by O +
immunohistochemistry O +
in O +
145 O +
of O +
173 O +
patients O +
randomly O +
assigned O +
to O +
2 O +
- O +
year O +
adjuvant O +
tamoxifen O +
or O +
no O +
further O +
therapy O +
, O +
was O +
considered O +
overexpressed O +
if O +
greater O +
than O +
10 O +
% O +
of O +
the O +
cells O +
showed O +
specific O +
membrane O +
staining O +
. O +

The O +
role O +
of O +
each O +
prognostic O +
variable O +
and O +
their O +
independent O +
effect O +
were O +
studied O +
using O +
the O +
Cox O +
model O +
. O +

Disease O +
- O +
free O +
( O +
DFS O +
) O +
and O +
overall O +
( O +
OAS O +
) O +
survival O +
curves O +
were O +
estimated O +
by O +
the O +
Kaplan O +
- O +
Meier O +
method O +
. O +

RESULTS O +
: O +
As O +
of O +
November O +
30 O +
, O +
1994 O +
, O +
the O +
median O +
follow O +
- O +
up O +
period O +
was O +
12 O +
years O +
. O +

c O +
- O +
erbB2 O +
was O +
overexpressed O +
in O +
43 O +
of O +
145 O +
patients O +
( O +
29 O +
. O +
7 O +
% O +
) O +
, O +
which O +
directly O +
correlated O +
with O +
tumor O +
size O +
and O +
inversely O +
with O +
estrogen O +
receptor O +
( O +
ER O +
) O +
level O +
. O +

At O +
univariate O +
analysis O +
, O +
overexpression O +
of O +
c O +
- O +
erbB2 O +
did O +
not O +
affect O +
either O +
DFS O +
or O +
OAS O +
; O +
tamoxifen O +
had O +
a O +
greater O +
effect O +
on O +
reducing O +
the O +
risk O +
of O +
recurrence O +
than O +
of O +
death O +
. O +

Addition O +
of O +
c O +
- O +
erbB2 O +
to O +
a O +
multivariate O +
Cox O +
model O +
that O +
contained O +
menopausal O +
status O +
, O +
tumor O +
size O +
, O +
nuclear O +
grade O +
, O +
and O +
treatment O +
as O +
covariates O +
did O +
not O +
affect O +
the O +
significance O +
of O +
the O +
model O +
for O +
DSF O +
or O +
OAS O +
, O +
whereas O +
addition O +
of O +
the O +
first O +
- O +
order O +
interaction O +
between O +
c O +
- O +
erbB2 O +
and O +
tamoxifen O +
was O +
statistically O +
significant O +
both O +
for O +
DFS O +
and O +
OAS O +
. O +

The O +
same O +
result O +
was O +
obtained O +
when O +
the O +
model O +
contained O +
ER O +
status O +
and O +
ER O +
- O +
tamoxifen O +
interaction O +
. O +

Indeed O +
, O +
adjuvant O +
tamoxifen O +
significantly O +
prolonged O +
DFS O +
and O +
OAS O +
in O +
c O +
- O +
erbB2 O +
- O +
negative O +
cases O +
, O +
whereas O +
it O +
had O +
no O +
effect O +
on O +
DFS O +
and O +
OAS O +
in O +
c O +
- O +
erbB2 O +
- O +
positive O +
patients O +
. O +

CONCLUSION O +
: O +
In O +
early O +
- O +
stage O +
breast O +
cancer O +
patients O +
, O +
overexpression O +
of O +
c O +
- O +
erbB2 O +
is O +
a O +
marker O +
of O +
lack O +
of O +
efficacy O +
of O +
adjuvant O +
tamoxifen O +
. O +

Gene O +
transfer O +
of O +
naked O +
DNA O +
encoding O +
for O +
three O +
isoforms O +
of O +
vascular O +
endothelial O +
growth O +
factor O +
stimulates O +
collateral O +
development O +
in O +
vivo O +
. O +

Vascular O +
endothelial O +
growth O +
factor O +
( O +
VEGF O +
) O +
is O +
a O +
naturally O +
secreted O +
endothelial O +
cell O +
- O +
specific O +
mitogen O +
. O +

We O +
investigated O +
the O +
hypothesis O +
that O +
naked O +
DNA O +
encoding O +
for O +
VEGF O +
could O +
be O +
used O +
in O +
a O +
strategy O +
of O +
arterial O +
gene O +
therapy O +
to O +
stimulate O +
collateral O +
artery O +
development O +
. O +

Plasmid O +
DNA O +
encoding O +
each O +
of O +
the O +
three O +
principal O +
human O +
VEGF O +
isoforms O +
( O +
phVEGF121 O +
, O +
phVEGF165 O +
, O +
or O +
phVEGF189 O +
) O +
was O +
applied O +
to O +
the O +
hydrogel O +
polymer O +
coating O +
of O +
an O +
angioplasty O +
balloon O +
and O +
delivered O +
percutaneously O +
to O +
one O +
iliac O +
artery O +
of O +
rabbits O +
with O +
operatively O +
induced O +
hindlimb O +
ischemia O +
. O +

Compared O +
with O +
control O +
animals O +
transfected O +
with O +
LacZ O +
, O +
site O +
- O +
specific O +
transfection O +
of O +
phVEGF O +
resulted O +
in O +
augmented O +
collateral O +
vessel O +
development O +
documented O +
by O +
serial O +
angiography O +
, O +
and O +
improvement O +
in O +
calf O +
blood O +
pressure O +
ratio O +
( O +
ischemic O +
to O +
normal O +
limb O +
) O +
, O +
resting O +
and O +
maximum O +
blood O +
flow O +
, O +
and O +
capillary O +
to O +
myocyte O +
ratio O +
. O +

Similar O +
results O +
were O +
obtained O +
with O +
phVEGF121 O +
, O +
phVEGF165 O +
, O +
and O +
phVEGF189 O +
, O +
which O +
suggests O +
that O +
these O +
isoforms O +
are O +
biologically O +
equivalent O +
with O +
respect O +
to O +
in O +
vivo O +
angiogenesis O +
. O +

The O +
fact O +
that O +
viral O +
or O +
other O +
adjunctive O +
vectors O +
were O +
not O +
required O +
further O +
suggests O +
that O +
secreted O +
gene O +
products O +
may O +
have O +
potential O +
therapeutic O +
utility O +
even O +
when O +
the O +
number O +
of O +
successfully O +
transfected O +
cells O +
remains O +
low O +
. O +

Arterial O +
gene O +
transfer O +
of O +
naked O +
DNA O +
encoding O +
for O +
a O +
secreted O +
angiogenic O +
cytokine O +
, O +
thus O +
, O +
represents O +
a O +
potential O +
alternative O +
to O +
recombinant O +
protein O +
administration O +
for O +
stimulating O +
collateral O +
vessel O +
development O +
. O +

Metastasis O +
- O +
associated O +
5T4 O +
antigen O +
disrupts O +
cell O +
- O +
cell O +
contacts O +
and O +
induces O +
cellular O +
motility O +
in O +
epithelial O +
cells O +
. O +

The O +
5T4 O +
antigen O +
is O +
defined O +
by O +
a O +
monoclonal O +
antibody O +
( O +
MAb O +
) O +
specific O +
for O +
human O +
trophoblast O +
. O +

It O +
is O +
also O +
expressed O +
by O +
many O +
types O +
of O +
tumour O +
cell O +
and O +
has O +
been O +
associated O +
with O +
metastasis O +
and O +
poor O +
clinical O +
outcome O +
in O +
a O +
number O +
of O +
cancers O +
. O +

This O +
pattern O +
of O +
expression O +
is O +
consistent O +
with O +
a O +
mechanistic O +
involvement O +
of O +
5T4 O +
molecules O +
in O +
the O +
spread O +
of O +
cancer O +
cells O +
. O +

The O +
5T4 O +
antigen O +
is O +
a O +
transmembrane O +
glycoprotein O +
with O +
a O +
310 O +
amino O +
acid O +
extracellular O +
domain O +
and O +
a O +
44 O +
amino O +
acid O +
cytoplasmic O +
domain O +
. O +

Transfection O +
of O +
full O +
- O +
length O +
5T4 O +
cDNA O +
into O +
epithelial O +
cells O +
alters O +
cell O +
- O +
cell O +
contacts O +
and O +
cellular O +
motility O +
. O +

Thus O +
, O +
in O +
5T4 O +
- O +
transfected O +
CL B-CellLine +
- I-CellLine +
S1 I-CellLine +
murine O +
mammary O +
cells O +
, O +
5T4 O +
expression O +
is O +
associated O +
with O +
dendritic O +
morphology O +
, O +
accompanied O +
by O +
abrogation O +
of O +
actin O +
/ O +
cadherin O +
- O +
containing O +
contacts O +
and O +
increased O +
motility O +
. O +

In O +
transfected O +
MDCK O +
canine O +
kidney O +
epithelial O +
cells O +
, O +
5T4 O +
over O +
- O +
expression O +
also O +
results O +
in O +
increased O +
motility O +
, O +
but O +
disruption O +
of O +
cell O +
- O +
cell O +
contacts O +
, O +
either O +
by O +
culturing O +
cells O +
in O +
low O +
calcium O +
medium O +
or O +
by O +
addition O +
of O +
HGF O +
/ O +
SF O +
, O +
is O +
needed O +
. O +

The O +
effects O +
of O +
5T4 O +
expression O +
on O +
morphology O +
and O +
motility O +
are O +
separable O +
since O +
cells O +
transfected O +
with O +
a O +
truncated O +
form O +
of O +
5T4 O +
cDNA O +
in O +
which O +
the O +
cytoplasmic O +
domain O +
is O +
deleted O +
reveal O +
that O +
the O +
latter O +
is O +
necessary O +
to O +
abrogate O +
actin O +
/ O +
cadherin O +
- O +
containing O +
contacts O +
but O +
does O +
not O +
influence O +
the O +
effects O +
on O +
motility O +
. O +

Thus O +
, O +
5T4 O +
molecules O +
can O +
deliver O +
signals O +
through O +
both O +
the O +
extracellular O +
and O +
intracellular O +
domains O +
, O +
and O +
the O +
resultant O +
effects O +
are O +
consistent O +
with O +
a O +
role O +
for O +
5T4 O +
molecules O +
in O +
invasion O +
processes O +
. O +

Induction O +
of O +
p18INK4c O +
and O +
its O +
predominant O +
association O +
with O +
CDK4 O +
and O +
CDK6 O +
during O +
myogenic O +
differentiation O +
. O +

Terminal O +
cell O +
differentiation O +
involves O +
permanent O +
withdrawal O +
from O +
the O +
cell O +
division O +
cycle O +
. O +

The O +
inhibitors O +
of O +
cyclin O +
- O +
dependent O +
kinases O +
( O +
CDKs O +
) O +
are O +
potential O +
molecules O +
functioning O +
to O +
couple O +
cell O +
cycle O +
arrest O +
and O +
cell O +
differentiation O +
. O +

In O +
murine O +
C2C12 B-CellLine +
myoblast O +
cells O +
, O +
G1 O +
CDK O +
enzymes O +
( O +
CDK2 O +
, O +
CDK4 O +
, O +
and O +
CDK6 O +
) O +
associate O +
with O +
four O +
CDK O +
inhibitors O +
: O +
p18INK4c O +
, O +
p19INK4d O +
, O +
p21 O +
, O +
and O +
p27Kip1 O +
. O +

During O +
induced O +
myogenesis O +
, O +
p21 O +
and O +
its O +
associated O +
CDK O +
proteins O +
underwent O +
an O +
initial O +
increase O +
followed O +
by O +
a O +
decrease O +
as O +
cells O +
became O +
terminally O +
differentiated O +
. O +

The O +
level O +
of O +
p27 O +
protein O +
gradually O +
increased O +
, O +
but O +
the O +
amount O +
of O +
total O +
associated O +
CDK O +
proteins O +
remained O +
unchanged O +
. O +

p19 O +
protein O +
decreased O +
gradually O +
during O +
differentiation O +
, O +
as O +
did O +
its O +
associated O +
CDK4 O +
protein O +
. O +

In O +
contrast O +
, O +
p18 O +
protein O +
increased O +
50 O +
- O +
fold O +
, O +
from O +
negligible O +
levels O +
in O +
proliferating O +
myoblasts O +
to O +
clearly O +
detectable O +
levels O +
within O +
8 O +
- O +
12 O +
h O +
of O +
myogenic O +
induction O +
. O +

This O +
initial O +
rise O +
was O +
followed O +
by O +
a O +
precipitous O +
increase O +
between O +
12 O +
and O +
24 O +
h O +
postinduction O +
, O +
with O +
p18 O +
protein O +
finally O +
accumulating O +
to O +
its O +
highest O +
level O +
in O +
terminally O +
differentiated O +
cells O +
. O +

Induction O +
of O +
p18 O +
correlated O +
with O +
increased O +
and O +
sequential O +
complex O +
formation O +
- O +
- O +
first O +
increasing O +
association O +
with O +
CDK6 O +
and O +
then O +
with O +
CDK4 O +
over O +
the O +
course O +
of O +
myogenic O +
differentiation O +
. O +

All O +
of O +
the O +
CDK6 O +
and O +
half O +
of O +
the O +
CDK4 O +
were O +
complexed O +
with O +
p18 O +
in O +
terminally O +
differentiated O +
C2C12 B-CellLine +
cells O +
as O +
well O +
as O +
in O +
adult O +
mouse O +
muscle O +
tissue O +
. O +

Finally O +
, O +
kinase O +
activity O +
of O +
CDK2 O +
and O +
CDK4 O +
decreases O +
as O +
C2C12 B-CellLine +
cells O +
differentiate O +
, O +
whereas O +
the O +
CDK6 O +
kinase O +
activity O +
is O +
low O +
in O +
both O +
proliferating O +
myoblasts O +
and O +
differentiated O +
myotubes O +
. O +

Our O +
results O +
indicate O +
that O +
p18 O +
may O +
play O +
a O +
critical O +
role O +
in O +
causing O +
and O +
/ O +
or O +
maintaining O +
permanent O +
cell O +
cycle O +
arrest O +
associated O +
with O +
mature O +
muscle O +
formation O +
. O +

Defective O +
biliary O +
copper O +
excretion O +
in O +
Wilson O +
' O +
s O +
disease O +
: O +
the O +
role O +
of O +
caeruloplasmin O +
. O +

Previous O +
studies O +
have O +
failed O +
to O +
explain O +
the O +
link O +
between O +
copper O +
accumulation O +
and O +
abnormal O +
caeruloplasmin O +
expression O +
in O +
Wilson O +
' O +
s O +
disease O +
. O +

Furthermore O +
, O +
despite O +
the O +
isolation O +
of O +
a O +
candidate O +
gene O +
for O +
Wilson O +
' O +
s O +
disease O +
, O +
which O +
predicts O +
a O +
defective O +
copper O +
transport O +
protein O +
, O +
the O +
localization O +
of O +
this O +
putative O +
protein O +
and O +
its O +
relationship O +
to O +
the O +
pathway O +
involved O +
in O +
copper O +
excretion O +
and O +
to O +
caeruloplasmin O +
remain O +
unknown O +
. O +

We O +
now O +
present O +
evidence O +
that O +
caeruloplasmin O +
, O +
the O +
major O +
plasma O +
copper O +
- O +
carrying O +
protein O +
, O +
is O +
present O +
in O +
the O +
liver O +
in O +
Wilson O +
' O +
s O +
disease O +
, O +
and O +
thus O +
that O +
reduced O +
circulating O +
levels O +
of O +
the O +
protein O +
result O +
from O +
a O +
post O +
- O +
translational O +
defect O +
in O +
the O +
secretory O +
pathway O +
. O +

We O +
have O +
also O +
identified O +
a O +
novel O +
form O +
of O +
caeruloplasmin O +
, O +
molecular O +
weight O +
125 O +
kD O +
, O +
which O +
we O +
propose O +
may O +
act O +
as O +
the O +
carrier O +
for O +
excretory O +
copper O +
into O +
bile O +
, O +
since O +
it O +
is O +
normally O +
present O +
in O +
both O +
liver O +
and O +
bile O +
, O +
although O +
largely O +
absent O +
from O +
serum O +
, O +
and O +
undetectable O +
in O +
bile O +
from O +
Wilson O +
' O +
s O +
disease O +
patients O +
. O +

The O +
presence O +
of O +
this O +
form O +
of O +
caeruloplasmin O +
in O +
Wilson O +
' O +
s O +
disease O +
liver O +
suggests O +
that O +
a O +
related O +
post O +
- O +
translational O +
defect O +
may O +
also O +
be O +
responsible O +
for O +
its O +
absence O +
from O +
bile O +
in O +
Wilson O +
' O +
s O +
disease O +
. O +

This O +
study O +
thus O +
provides O +
the O +
first O +
plausible O +
explanation O +
of O +
a O +
link O +
between O +
the O +
defective O +
copper O +
excretion O +
and O +
the O +
reduced O +
plasma O +
caeruloplasmin O +
, O +
which O +
characterize O +
Wilson O +
' O +
s O +
disease O +
. O +

Functional O +
model O +
of O +
benign O +
paroxysmal O +
positional O +
vertigo O +
using O +
an O +
isolated O +
frog O +
semicircular O +
canal O +
. O +

Bull O +
frogs O +
posterior O +
semicircular O +
canals O +
( O +
psc O +
) O +
wee O +
used O +
to O +
simulate O +
the O +
condition O +
of O +
benign O +
paroxysmal O +
positional O +
vertigo O +
( O +
BPPV O +
) O +
. O +

The O +
psc O +
was O +
isolated O +
in O +
frog O +
Ringer O +
' O +
s O +
solution O +
, O +
and O +
the O +
saccular O +
otoconia O +
were O +
used O +
as O +
a O +
responsible O +
material O +
to O +
stimulate O +
the O +
cupula O +
. O +

When O +
the O +
otoconia O +
were O +
placed O +
on O +
the O +
cupular O +
surface O +
to O +
mimic O +
the O +
condition O +
of O +
cupulolithiasis O +
, O +
the O +
psc O +
ampullary O +
nerve O +
action O +
potentials O +
instantaneously O +
changed O +
according O +
to O +
the O +
direction O +
of O +
the O +
gravity O +
produced O +
by O +
otoconia O +
. O +

When O +
the O +
otoconia O +
were O +
dropped O +
into O +
the O +
canal O +
to O +
mimic O +
the O +
condition O +
of O +
moving O +
otoconia O +
in O +
the O +
canal O +
, O +
the O +
action O +
potentials O +
changed O +
together O +
with O +
the O +
otoconial O +
flow O +
after O +
a O +
latent O +
period O +
. O +

Both O +
cupulolithiasis O +
and O +
moving O +
otoconia O +
are O +
possibly O +
valid O +
mechanisms O +
of O +
BPPV O +
, O +
since O +
they O +
effectively O +
stimulate O +
the O +
cupula O +
. O +

However O +
, O +
moving O +
otoconia O +
with O +
a O +
latent O +
period O +
would O +
better O +
explain O +
clinical O +
features O +
of O +
BPPV O +
. O +

Do O +
we O +
know O +
how O +
much O +
people O +
like O +
one O +
another O +
? O +

Metaperception O +
is O +
a O +
person O +
' O +
s O +
perception O +
about O +
a O +
second O +
person O +
' O +
s O +
perception O +
of O +
a O +
third O +
person O +
. O +

The O +
purpose O +
of O +
this O +
article O +
is O +
to O +
examine O +
the O +
accuracy O +
of O +
metaperceptions O +
of O +
liking O +
. O +

A O +
related O +
question O +
concerns O +
whether O +
the O +
heuristics O +
of O +
balance O +
, O +
reciprocity O +
, O +
and O +
agreement O +
are O +
used O +
by O +
perceivers O +
when O +
forming O +
such O +
judgments O +
. O +

The O +
authors O +
present O +
analyses O +
from O +
5 O +
diverse O +
research O +
studies O +
that O +
used O +
an O +
adaptation O +
of O +
the O +
social O +
relations O +
model O +
for O +
triads O +
( O +
C O +
. O +
F O +
. O +
Bond O +
, O +
E O +
. O +
M O +
. O +
Horn O +
, O +
& O +
D O +
. O +
A O +
. O +
Kenny O +
, O +
in O +
press O +
) O +
. O +

The O +
results O +
indicate O +
that O +
people O +
know O +
how O +
much O +
people O +
like O +
one O +
another O +
, O +
even O +
with O +
small O +
amounts O +
of O +
information O +
. O +

Although O +
there O +
is O +
evidence O +
for O +
the O +
use O +
of O +
heuristics O +
, O +
particularly O +
reciprocity O +
and O +
agreement O +
, O +
accuracy O +
is O +
sometimes O +
enhanced O +
by O +
using O +
these O +
heuristics O +
. O +

Genetic O +
heterogeneity O +
evidenced O +
by O +
low O +
incidence O +
of O +
KAL O +
- O +
1 O +
gene O +
mutations O +
in O +
sporadic O +
cases O +
of O +
gonadotropin O +
- O +
releasing O +
hormone O +
deficiency O +
. O +

Isolated O +
GnRH O +
deficiency O +
is O +
a O +
heritable O +
condition O +
characterized O +
by O +
a O +
functional O +
deficit O +
in O +
GnRH O +
secretion O +
. O +

Familial O +
cases O +
with O +
different O +
modes O +
of O +
inheritance O +
have O +
been O +
described O +
, O +
and O +
the O +
gene O +
responsible O +
for O +
the O +
X O +
- O +
linked O +
form O +
( O +
KAL O +
- O +
1 O +
) O +
has O +
been O +
identified O +
. O +

However O +
, O +
sporadic O +
cases O +
with O +
no O +
documented O +
family O +
history O +
of O +
GnRH O +
deficiency O +
account O +
for O +
the O +
majority O +
of O +
the O +
affected O +
patients O +
. O +

For O +
this O +
reason O +
, O +
we O +
sought O +
to O +
determine O +
the O +
frequency O +
with O +
which O +
KAL O +
- O +
1 O +
gene O +
mutations O +
occur O +
in O +
patients O +
with O +
sporadic O +
GnRH O +
deficiency O +
. O +

Only O +
1 O +
of O +
21 O +
patients O +
with O +
sporadic O +
GnRH O +
deficiency O +
was O +
found O +
to O +
bear O +
a O +
defect O +
in O +
the O +
KAL O +
- O +
1 O +
gene O +
( O +
a O +
deletion O +
of O +
14 O +
bases O +
starting O +
at O +
codon O +
464 O +
) O +
. O +

Three O +
types O +
of O +
polymorphic O +
single O +
base O +
substitutions O +
with O +
no O +
apparent O +
correlation O +
with O +
GnRH O +
deficiency O +
were O +
also O +
detected O +
in O +
several O +
patients O +
. O +

In O +
each O +
of O +
3 O +
different O +
patients O +
with O +
an O +
X O +
- O +
linked O +
mode O +
of O +
inheritance O +
, O +
3 O +
genetic O +
defects O +
, O +
2 O +
point O +
mutations O +
and O +
a O +
small O +
intragenic O +
deletion O +
, O +
were O +
detected O +
. O +

These O +
defects O +
consist O +
of O +
a O +
single O +
base O +
mutation O +
introducing O +
a O +
stop O +
codon O +
at O +
position O +
328 O +
, O +
a O +
single O +
base O +
mutation O +
resulting O +
in O +
a O +
phenylalanine O +
to O +
leucine O +
substitution O +
at O +
position O +
517 O +
, O +
and O +
a O +
9 O +
- O +
base O +
deletion O +
at O +
the O +
3 O +
' O +
- O +
exon O +
- O +
intron O +
splice O +
site O +
of O +
exon O +
8 O +
, O +
respectively O +
. O +

All O +
identified O +
genetic O +
defects O +
occur O +
within O +
the O +
fibronectin O +
type O +
III O +
repeats O +
of O +
the O +
predicted O +
protein O +
encoded O +
by O +
the O +
KAL O +
- O +
1 O +
gene O +
. O +

In O +
conclusion O +
, O +
our O +
study O +
indicates O +
that O +
the O +
incidence O +
of O +
genetic O +
defects O +
within O +
the O +
coding O +
region O +
of O +
the O +
KAL O +
- O +
1 O +
gene O +
in O +
patients O +
with O +
sporadic O +
GnRH O +
deficiency O +
is O +
low O +
( O +
5 O +
- O +
8 O +
% O +
) O +
, O +
thus O +
supporting O +
the O +
idea O +
that O +
the O +
X O +
- O +
linked O +
form O +
of O +
inheritance O +
represents O +
the O +
least O +
common O +
form O +
of O +
the O +
disease O +
. O +

[ O +
Considerations O +
regarding O +
two O +
cases O +
of O +
macromastia O +
( O +
author O +
' O +
s O +
transl O +
) O +
] O +
. O +

Two O +
cases O +
of O +
macromastia O +
have O +
been O +
shown O +
; O +
one O +
which O +
appeared O +
during O +
puberty O +
, O +
the O +
other O +
during O +
menopause O +
. O +

Histopathological O +
examination O +
has O +
demonstrated O +
for O +
the O +
both O +
cases O +
a O +
cystic O +
degeneracy O +
of O +
the O +
glandular O +
tissue O +
with O +
a O +
hyperplazia O +
and O +
hypertrophy O +
of O +
the O +
conjunctive O +
tissue O +
. O +

The O +
pathogeny O +
of O +
macromastia O +
is O +
being O +
discussed O +
and O +
it O +
is O +
demonstrated O +
both O +
the O +
role O +
of O +
hypophysis O +
hormones O +
( O +
prolactine O +
and O +
growth O +
hormone O +
) O +
and O +
of O +
ovarian O +
hormones O +
( O +
estrogens O +
) O +
. O +

The O +
treatment O +
was O +
surgical O +
for O +
the O +
both O +
cases O +
. O +

The O +
effect O +
of O +
early O +
diagnosis O +
and O +
treatment O +
in O +
cystic O +
fibrosis O +
: O +
a O +
seven O +
- O +
year O +
study O +
of O +
16 O +
sibling O +
pairs O +
. O +

Data O +
on O +
16 O +
sibling O +
pairs O +
with O +
cystic O +
fibrosis O +
were O +
analyzed O +
to O +
test O +
the O +
hypothesis O +
that O +
early O +
treatment O +
of O +
this O +
condition O +
improves O +
prognosis O +
. O +

Younger O +
siblings O +
' O +
conditions O +
were O +
diagnosed O +
before O +
1 O +
year O +
of O +
age O +
, O +
usually O +
before O +
the O +
onset O +
of O +
pulmonary O +
disease O +
. O +

Older O +
siblings O +
' O +
conditions O +
were O +
diagnosed O +
after O +
1 O +
year O +
of O +
age O +
and O +
after O +
the O +
onset O +
of O +
pulmonary O +
disease O +
. O +

Although O +
the O +
sibling O +
pairs O +
received O +
similar O +
treatment O +
, O +
comparison O +
at O +
7 O +
years O +
of O +
age O +
showed O +
that O +
the O +
younger O +
siblings O +
had O +
significantly O +
better O +
chest O +
roentgenogram O +
scores O +
, O +
total O +
clinical O +
scores O +
, O +
residual O +
lung O +
volumes O +
, O +
and O +
ratios O +
of O +
residual O +
volume O +
to O +
total O +
lung O +
volume O +
. O +

Younger O +
siblings O +
also O +
required O +
fewer O +
hospital O +
admissions O +
to O +
control O +
their O +
lung O +
disease O +
. O +

The O +
results O +
suggest O +
that O +
, O +
in O +
general O +
, O +
early O +
initiation O +
of O +
therapy O +
is O +
beneficial O +
for O +
patients O +
with O +
cystic O +
fibrosis O +
. O +

Comparison O +
of O +
transformation O +
by O +
manganese O +
sulfate O +
and O +
5 O +
- O +
azacytidine O +
in O +
Rat B-CellLine +
6 I-CellLine +
cells O +
overexpressing O +
the O +
c O +
- O +
myc O +
oncogene O +
. O +

Rat B-CellLine +
6 I-CellLine +
cells O +
are O +
not O +
transformed O +
by O +
treatment O +
with O +
the O +
well O +
- O +
known O +
carcinogens O +
benzo O +
[ O +
a O +
] O +
pyrene O +
( O +
BP O +
) O +
or O +
N O +
- O +
methyl O +
- O +
N O +
- O +
nitro O +
- O +
N O +
' O +
- O +
nitrosoguanidine O +
( O +
MNNG O +
) O +
. O +

Upon O +
retroviral O +
transduction O +
of O +
the O +
mouse O +
c O +
- O +
myc O +
gene O +
, O +
Rat B-CellLine +
6 I-CellLine +
cells O +
showed O +
mildly O +
altered O +
morphology O +
and O +
formed O +
microcolonies O +
in O +
soft O +
agar O +
; O +
furthermore O +
, O +
they O +
could O +
be O +
transformed O +
by O +
BP O +
and O +
MNNG O +
to O +
form O +
large O +
colonies O +
in O +
agar O +
( O +
Hsiao O +
et O +
al O +
. O +
( O +
1992 O +
) O +
Mol O +
. O +
Carcinogenesis O +
, O +
5 O +
, O +
140 O +
- O +
154 O +
) O +
. O +

In O +
the O +
current O +
report O +
, O +
we O +
tested O +
the O +
sensitivity O +
of O +
the O +
c O +
- O +
myc O +
- O +
overexpressing O +
cells O +
( O +
Rat B-CellLine +
6 I-CellLine +
/ O +
c O +
- O +
myc O +
) O +
to O +
two O +
additional O +
chemicals O +
: O +
5 O +
- O +
azacytidine O +
and O +
MnSO4 O +
. O +

These O +
chemicals O +
differ O +
from O +
the O +
direct O +
- O +
acting O +
mutagens O +
tested O +
previously O +
. O +

5 O +
- O +
Azacytidine O +
, O +
a O +
potent O +
DNA O +
methylation O +
inhibitor O +
, O +
induced O +
growth O +
of O +
large O +
colonies O +
in O +
soft O +
agar O +
cultures O +
of O +
Rat B-CellLine +
6 I-CellLine +
or O +
Rat B-CellLine +
6 I-CellLine +
/ O +
c O +
- O +
myc O +
cells O +
. O +

On O +
the O +
other O +
hand O +
, O +
MnSO4 O +
only O +
induced O +
transformation O +
in O +
Rat B-CellLine +
6 I-CellLine +
/ O +
c O +
- O +
myc O +
cells O +
, O +
but O +
not O +
the O +
parental O +
Rat B-CellLine +
6 I-CellLine +
cells O +
. O +

Transformants O +
induced O +
by O +
5 O +
- O +
azacytidine O +
lost O +
c O +
- O +
myc O +
- O +
induced O +
apoptotic O +
cell O +
death O +
, O +
whereas O +
MnSO4 O +
- O +
induced O +
transformants O +
showed O +
a O +
higher O +
degree O +
of O +
apoptosis O +
than O +
the O +
parental O +
Rat B-CellLine +
6 I-CellLine +
/ O +
c O +
- O +
myc O +
cells O +
. O +

These O +
results O +
suggest O +
that O +
MnSO4 O +
co O +
- O +
operates O +
with O +
overexpressed O +
c O +
- O +
myc O +
in O +
inducing O +
transformation O +
, O +
while O +
5 O +
- O +
azacytidine O +
transformation O +
is O +
independent O +
of O +
c O +
- O +
myc O +
overexpression O +
and O +
may O +
involve O +
alterations O +
in O +
the O +
regulation O +
of O +
apoptosis O +
. O +

Fas O +
- O +
signaling O +
and O +
effects O +
on O +
receptor O +
tyrosine O +
kinase O +
signal O +
transduction O +
in O +
human O +
breast O +
epithelial O +
cells O +
. O +

Fas O +
- O +
mediated O +
cell O +
death O +
was O +
examined O +
in O +
MCF B-CellLine +
- I-CellLine +
10AT I-CellLine +
preneoplastic O +
human O +
breast O +
epithelial O +
cells O +
. O +

Treatment O +
with O +
anti O +
- O +
Fas O +
for O +
48 O +
h O +
induced O +
apoptosis O +
with O +
cells O +
exhibiting O +
typical O +
apoptotic O +
features O +
including O +
loss O +
of O +
cell O +
contact O +
, O +
condensation O +
of O +
chromatin O +
, O +
and O +
increased O +
staining O +
of O +
the O +
nuclear O +
membrane O +
. O +

DNA O +
fragmentation O +
occurred O +
in O +
response O +
to O +
anti O +
- O +
Fas O +
treatment O +
. O +

Anti O +
- O +
Fas O +
treatment O +
resulted O +
in O +
decreased O +
p53 O +
protein O +
levels O +
, O +
while O +
bcl O +
- O +
2 O +
and O +
bax O +
protein O +
levels O +
remained O +
unaffected O +
. O +

Cells O +
treated O +
with O +
anti O +
- O +
Fas O +
also O +
exhibited O +
increased O +
tyrosine O +
phosphorylation O +
of O +
the O +
c O +
- O +
met O +
growth O +
factor O +
receptor O +
tyrosine O +
kinase O +
. O +

Immunoprecipitation O +
experiments O +
demonstrated O +
that O +
Fas O +
associated O +
with O +
c O +
- O +
erbB2 O +
and O +
c O +
- O +
met O +
in O +
untreated O +
cells O +
. O +

Treatment O +
with O +
anti O +
- O +
Fas O +
, O +
however O +
, O +
significantly O +
decreased O +
Fas O +
- O +
c O +
- O +
erbB2 O +
and O +
Fas O +
- O +
c O +
- O +
met O +
association O +
. O +

Anti O +
- O +
Fas O +
treatment O +
of O +
these O +
cells O +
caused O +
a O +
significant O +
decrease O +
in O +
p120 O +
- O +
GAP O +
levels O +
, O +
ERK O +
- O +
1 O +
levels O +
, O +
and O +
phosphorylation O +
, O +
as O +
well O +
as O +
Grb2 O +
- O +
Sosl O +
and O +
MEK O +
- O +
1 O +
- O +
ERK O +
- O +
1 O +
association O +
. O +

These O +
results O +
show O +
that O +
Fas O +
- O +
signaling O +
exerted O +
a O +
suppressive O +
effect O +
on O +
p53 O +
levels O +
and O +
on O +
downstream O +
effectors O +
of O +
receptor O +
tyrosine O +
kinase O +
signal O +
transduction O +
, O +
thereby O +
ensuring O +
cell O +
death O +
. O +

Prevention O +
of O +
hepatic O +
tumor O +
metastases O +
in O +
rats O +
with O +
herpes O +
viral O +
vaccines O +
and O +
gamma O +
- O +
interferon O +
. O +

Previous O +
studies O +
showed O +
that O +
gammaIFN O +
decreases O +
metastatic O +
hepatic O +
tumor O +
growth O +
by O +
stimulating O +
Kupffer O +
cells O +
( O +
KC O +
) O +
. O +

The O +
present O +
studies O +
examine O +
whether O +
lymphocyte O +
stimulation O +
via O +
cells O +
engineered O +
to O +
secrete O +
GM O +
- O +
CSF O +
or O +
IL O +
- O +
2 O +
decreases O +
hepatic O +
tumor O +
growth O +
, O +
and O +
whether O +
stimulation O +
of O +
both O +
macrophages O +
and O +
lymphocytes O +
is O +
more O +
effective O +
than O +
either O +
individually O +
. O +

Rats O +
were O +
immunized O +
with O +
irradiated O +
hepatoma O +
cells O +
transduced O +
by O +
herpes O +
viral O +
amplicon O +
vectors O +
containing O +
the O +
genes O +
for O +
GM O +
- O +
CSF O +
, O +
IL O +
- O +
2 O +
or O +
LacZ O +
. O +

On O +
day O +
18 O +
, O +
half O +
of O +
each O +
group O +
was O +
treated O +
with O +
5 O +
x O +
10 O +
( O +
4 O +
) O +
U O +
gammaIFN O +
, O +
or O +
saline O +
intraperitoneally O +
for O +
3 O +
d O +
. O +

On O +
day O +
21 O +
, O +
all O +
rats O +
received O +
5 O +
x O +
10 O +
( O +
5 O +
) O +
hepatoma O +
cells O +
intrasplenically O +
. O +

On O +
day O +
41 O +
, O +
rats O +
were O +
killed O +
and O +
tumor O +
nodules O +
were O +
counted O +
. O +

Separate O +
rats O +
underwent O +
splenocyte O +
and O +
KC O +
harvest O +
for O +
assessment O +
of O +
lymphocyte O +
- O +
and O +
macrophage O +
- O +
mediated O +
tumor O +
cell O +
kill O +
in O +
vitro O +
. O +

GM O +
- O +
CSF O +
or O +
IL O +
- O +
2 O +
vaccines O +
or O +
gammaIFN O +
decreased O +
tumor O +
nodules O +
significantly O +
( O +
GM O +
- O +
CSF O +
13 O +
+ O +
/ O +
- O +
4 O +
, O +
IL O +
- O +
2 O +
14 O +
+ O +
/ O +
- O +
6 O +
vs O +
. O +
control O +
75 O +
+ O +
/ O +
- O +
24 O +
, O +
P O +
< O +
0 O +
. O +
001 O +
) O +
. O +

Combination O +
therapy O +
was O +
more O +
effective O +
, O +
and O +
completely O +
eliminated O +
tumor O +
in O +
4 O +
of O +
12 O +
IFN O +
- O +
GM O +
- O +
CSF O +
and O +
8 O +
of O +
11 O +
IFN O +
- O +
IL O +
- O +
2 O +
animals O +
. O +

Additional O +
rats O +
underwent O +
partial O +
hepatectomy O +
, O +
an O +
immunosuppressive O +
procedure O +
known O +
to O +
accelerate O +
the O +
growth O +
of O +
hepatic O +
tumor O +
, O +
following O +
tumor O +
challenge O +
. O +

Therapy O +
was O +
equally O +
effective O +
in O +
this O +
immunosuppressive O +
setting O +
. O +

Vaccination O +
is O +
associated O +
with O +
enhancement O +
of O +
splenocyte O +
- O +
mediated O +
tumoricidal O +
activity O +
, O +
whereas O +
the O +
effect O +
of O +
gammaIFN O +
is O +
mediated O +
by O +
KC O +
. O +

GM O +
- O +
CSF O +
and O +
IL O +
- O +
2 O +
vaccine O +
therapy O +
and O +
pretreatment O +
with O +
gammaIFN O +
represent O +
effective O +
strategies O +
in O +
reducing O +
hepatic O +
tumor O +
. O +

Combination O +
therapy O +
targets O +
both O +
lymphocytes O +
and O +
macrophages O +
, O +
and O +
is O +
more O +
effective O +
in O +
reducing O +
tumor O +
than O +
either O +
therapy O +
alone O +
. O +

[ O +
Effects O +
of O +
carcinostatic O +
agents O +
in O +
the O +
hematogenous O +
metastasis O +
of O +
cancer O +
] O +
. O +

The O +
experimental O +
studies O +
in O +
vitro O +
and O +
in O +
vivo O +
were O +
performed O +
to O +
investigate O +
the O +
effects O +
of O +
carcinostatic O +
agents O +
in O +
the O +
adhesion O +
of O +
cancer O +
cells O +
to O +
endothelial O +
cells O +
. O +

Certain O +
carcinostatic O +
agents O +
induce O +
the O +
expression O +
of O +
E O +
- O +
selectin O +
on O +
endothelial O +
cells O +
and O +
enhance O +
the O +
expression O +
of O +
carbohydrate O +
ligands O +
on O +
cancer O +
cells O +
. O +

Consequently O +
, O +
increased O +
adhesion O +
of O +
cancer O +
cells O +
to O +
endothelial O +
cells O +
was O +
observed O +
by O +
the O +
treatment O +
of O +
carcinostatic O +
agents O +
. O +

In O +
the O +
trans O +
- O +
splenic O +
hepatic O +
metastasis O +
model O +
using O +
nude O +
mice O +
, O +
the O +
augmentation O +
of O +
cancer O +
metastasis O +
was O +
observed O +
by O +
the O +
treatment O +
of O +
carcinostatic O +
agents O +
. O +

From O +
the O +
above O +
, O +
we O +
concluded O +
that O +
carcinostatic O +
agents O +
may O +
increase O +
the O +
metastatic O +
ability O +
of O +
cancer O +
cells O +
in O +
patients O +
with O +
cancer O +
. O +

Procedural O +
memory O +
stimulation O +
in O +
Alzheimer O +
' O +
s O +
disease O +
: O +
impact O +
of O +
a O +
training O +
programme O +
. O +

The O +
study O +
evaluates O +
the O +
efficacy O +
of O +
a O +
procedural O +
memory O +
stimulation O +
programme O +
in O +
mild O +
and O +
mild O +
- O +
moderate O +
Alzheimer O +
' O +
s O +
disease O +
( O +
AD O +
) O +
. O +

Twenty O +
basic O +
and O +
instrumental O +
activities O +
of O +
daily O +
living O +
have O +
been O +
selected O +
, O +
and O +
divided O +
into O +
two O +
groups O +
, O +
comparable O +
for O +
difficulty O +
. O +

Ten O +
normal O +
elderly O +
subjects O +
( O +
age O +
68 O +
. O +
0 O +
+ O +
/ O +
- O +
4 O +
. O +
8 O +
years O +
; O +
MMSE O +
score O +
: O +
28 O +
. O +
7 O +
+ O +
/ O +
- O +
0 O +
. O +
9 O +
; O +
education O +
: O +
7 O +
. O +
6 O +
+ O +
/ O +
- O +
3 O +
. O +
5 O +
years O +
) O +
were O +
asked O +
to O +
perform O +
the O +
two O +
groups O +
of O +
daily O +
activities O +
and O +
the O +
time O +
required O +
to O +
perform O +
the O +
tasks O +
of O +
each O +
group O +
was O +
recorded O +
and O +
used O +
as O +
a O +
reference O +
. O +

Ten O +
mild O +
and O +
mild O +
- O +
moderate O +
AD O +
patients O +
( O +
age O +
77 O +
. O +
2 O +
+ O +
/ O +
- O +
5 O +
. O +
3 O +
years O +
; O +
MMSE O +
score O +
: O +
19 O +
. O +
8 O +
+ O +
/ O +
- O +
3 O +
. O +
5 O +
; O +
education O +
: O +
7 O +
. O +
3 O +
+ O +
/ O +
- O +
4 O +
. O +
7 O +
years O +
) O +
without O +
major O +
behavioural O +
disturbances O +
constituted O +
the O +
experimental O +
group O +
. O +

Patients O +
were O +
evaluated O +
in O +
all O +
20 O +
daily O +
activities O +
and O +
the O +
time O +
employed O +
was O +
recorded O +
at O +
baseline O +
and O +
after O +
a O +
3 O +
- O +
week O +
training O +
( O +
1 O +
h O +
/ O +
d O +
, O +
5 O +
d O +
/ O +
week O +
) O +
period O +
. O +

Five O +
patients O +
were O +
trained O +
during O +
the O +
3 O +
weeks O +
on O +
half O +
of O +
the O +
20 O +
daily O +
activities O +
and O +
the O +
other O +
five O +
patients O +
were O +
trained O +
on O +
the O +
remainder O +
. O +

This O +
procedure O +
was O +
adopted O +
in O +
order O +
to O +
detect O +
separately O +
the O +
improvement O +
in O +
" O +
trained O +
" O +
and O +
" O +
not O +
trained O +
" O +
activities O +
, O +
allowing O +
to O +
control O +
better O +
the O +
effects O +
of O +
the O +
intervention O +
. O +

The O +
assessment O +
of O +
the O +
functional O +
impact O +
of O +
the O +
training O +
was O +
directly O +
measured O +
, O +
through O +
the O +
variation O +
of O +
time O +
employed O +
to O +
perform O +
tasks O +
before O +
and O +
after O +
training O +
. O +

After O +
3 O +
weeks O +
of O +
training O +
a O +
significant O +
improvement O +
was O +
observed O +
for O +
the O +
trained O +
activities O +
, O +
from O +
3 O +
. O +
6 O +
to O +
1 O +
. O +
9 O +
standard O +
deviations O +
below O +
the O +
performance O +
of O +
the O +
normal O +
elderly O +
controls O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

AD O +
patients O +
improved O +
also O +
in O +
not O +
- O +
trained O +
activities O +
from O +
3 O +
. O +
5 O +
to O +
2 O +
. O +
7 O +
standard O +
deviations O +
below O +
the O +
controls O +
' O +
performance O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

The O +
rehabilitation O +
of O +
activities O +
of O +
daily O +
living O +
through O +
developing O +
procedural O +
memory O +
strategies O +
may O +
be O +
effective O +
in O +
mild O +
and O +
mild O +
- O +
moderate O +
AD O +
patients O +
. O +

Regulation O +
of O +
p53 O +
- O +
dependent O +
apoptosis O +
, O +
transcriptional O +
repression O +
, O +
and O +
cell O +
transformation O +
by O +
phosphorylation O +
of O +
the O +
55 O +
- O +
kilodalton O +
E1B O +
protein O +
of O +
human O +
adenovirus O +
type O +
5 O +
. O +

The O +
adenovirus O +
type O +
5 O +
55 O +
- O +
kDa O +
E1B O +
protein O +
( O +
E1B O +
- O +
55kDa O +
) O +
cooperates O +
with O +
E1A O +
gene O +
products O +
to O +
induce O +
cell O +
transformation O +
. O +

E1A O +
proteins O +
stimulate O +
DNA O +
synthesis O +
and O +
cell O +
proliferation O +
; O +
however O +
, O +
they O +
also O +
cause O +
rapid O +
cell O +
death O +
by O +
p53 O +
- O +
dependent O +
and O +
p53 O +
- O +
independent O +
apoptosis O +
. O +

It O +
is O +
believed O +
that O +
the O +
role O +
of O +
the O +
E1B O +
- O +
55kDa O +
protein O +
in O +
transformation O +
is O +
to O +
protect O +
against O +
p53 O +
- O +
dependent O +
apoptosis O +
by O +
binding O +
to O +
and O +
inactivating O +
p53 O +
. O +

It O +
has O +
been O +
shown O +
previously O +
that O +
the O +
55 O +
- O +
kDa O +
polypeptide O +
abrogates O +
p53 O +
- O +
mediated O +
transactivation O +
and O +
that O +
mutants O +
defective O +
in O +
p53 O +
binding O +
are O +
unable O +
to O +
cooperate O +
with O +
E1A O +
in O +
transformation O +
. O +

We O +
have O +
previously O +
mapped O +
phosphorylation O +
sites O +
near O +
the O +
carboxy O +
terminus O +
of O +
the O +
E1B O +
- O +
55kDa O +
protein O +
at O +
Ser O +
- O +
490 O +
and O +
Ser O +
- O +
491 O +
, O +
which O +
lie O +
within O +
casein O +
kinase O +
II O +
consensus O +
sequences O +
. O +

Conversion O +
of O +
these O +
sites O +
to O +
alanine O +
residues O +
greatly O +
reduced O +
transforming O +
activity O +
, O +
and O +
although O +
the O +
mutant O +
55 O +
- O +
kDa O +
protein O +
was O +
found O +
to O +
interact O +
with O +
p53 O +
at O +
normal O +
levels O +
, O +
it O +
was O +
somewhat O +
defective O +
for O +
suppression O +
of O +
p53 O +
transactivation O +
activity O +
. O +

We O +
now O +
report O +
that O +
a O +
nearby O +
residue O +
, O +
Thr O +
- O +
495 O +
, O +
also O +
appears O +
to O +
be O +
phosphorylated O +
. O +

We O +
demonstrate O +
directly O +
that O +
the O +
wild O +
- O +
type O +
55 O +
- O +
kDa O +
protein O +
is O +
able O +
to O +
block O +
E1A O +
- O +
induced O +
p53 O +
- O +
dependent O +
apoptosis O +
, O +
whereas O +
cells O +
infected O +
by O +
mutant O +
pm490 O +
/ O +
1 O +
/ O +
5A O +
, O +
which O +
contains O +
alanine O +
residues O +
at O +
all O +
three O +
phosphorylation O +
sites O +
, O +
exhibited O +
extensive O +
DNA O +
fragmentation O +
and O +
classic O +
apoptotic O +
cell O +
death O +
. O +

The O +
E1B O +
- O +
55kDa O +
product O +
has O +
been O +
shown O +
to O +
exhibit O +
intrinsic O +
transcriptional O +
repression O +
activity O +
when O +
localized O +
to O +
promoters O +
, O +
such O +
as O +
by O +
fusion O +
with O +
the O +
GAL4 O +
DNA O +
- O +
binding O +
domain O +
, O +
even O +
in O +
the O +
absence O +
of O +
p53 O +
. O +

Such O +
repression O +
activity O +
was O +
totally O +
absent O +
with O +
mutant O +
pm490 O +
/ O +
1 O +
/ O +
5A O +
. O +

These O +
data O +
suggested O +
that O +
inhibition O +
of O +
p53 O +
- O +
dependent O +
apoptosis O +
may O +
depend O +
on O +
the O +
transcriptional O +
repression O +
function O +
of O +
the O +
55 O +
- O +
kDa O +
protein O +
, O +
which O +
appears O +
to O +
be O +
regulated O +
be O +
phosphorylation O +
at O +
the O +
carboxy O +
terminus O +
. O +

Non O +
- O +
invasive O +
grading O +
of O +
primary O +
brain O +
tumours O +
: O +
results O +
of O +
a O +
comparative O +
study O +
between O +
SPET O +
with O +
123I O +
- O +
alpha O +
- O +
methyl O +
tyrosine O +
and O +
PET O +
with O +
18F O +
- O +
deoxyglucose O +
. O +

Use O +
of O +
iodine O +
- O +
123 O +
- O +
alpha O +
- O +
methyl O +
tyrosine O +
( O +
123I O +
- O +
IMT O +
) O +
allows O +
investigation O +
of O +
the O +
amino O +
acid O +
transport O +
rate O +
in O +
gliomas O +
. O +

It O +
was O +
the O +
aim O +
of O +
this O +
study O +
to O +
compare O +
the O +
value O +
of O +
measurement O +
of O +
glucose O +
metabolism O +
with O +
that O +
of O +
measurement O +
of O +
123I O +
- O +
IMT O +
uptake O +
for O +
the O +
non O +
- O +
invasive O +
grading O +
of O +
brain O +
tumours O +
. O +

The O +
study O +
population O +
comprised O +
23 O +
patients O +
with O +
histopathologically O +
proven O +
primary O +
brain O +
tumours O +
; O +
14 O +
had O +
high O +
- O +
grade O +
gliomas O +
, O +
and O +
nine O +
low O +
- O +
grade O +
brain O +
neoplasms O +
. O +

Glucose O +
metabolism O +
was O +
studied O +
using O +
an O +
ECAT O +
EXACT O +
47 O +
positron O +
emission O +
tomography O +
( O +
PET O +
) O +
camera O +
and O +
fluorine O +
- O +
18 O +
fluorodeoxyglucose O +
( O +
18F O +
- O +
FDG O +
) O +
; O +
123I O +
- O +
IMT O +
uptake O +
was O +
measured O +
with O +
the O +
triple O +
- O +
headed O +
single O +
- O +
photon O +
emission O +
tomography O +
( O +
SPET O +
) O +
camera O +
, O +
MULTISPECT O +
3 O +
. O +

18F O +
- O +
FDG O +
and O +
123I O +
- O +
IMT O +
uptake O +
was O +
quantified O +
as O +
ratios O +
between O +
the O +
uptake O +
by O +
the O +
tumour O +
and O +
contralateral O +
regions O +
of O +
reference O +
. O +

Glucose O +
metabolism O +
and O +
amino O +
acid O +
uptake O +
of O +
the O +
brain O +
tumours O +
correlated O +
significantly O +
( O +
r O +
= O +
0 O +
. O +
71 O +
, O +
P O +
< O +
0 O +
. O +
001 O +
) O +
. O +

Assuming O +
discrimination O +
thresholds O +
between O +
high O +
- O +
grade O +
and O +
low O +
- O +
grade O +
tumours O +
of O +
0 O +
. O +
8 O +
for O +
18F O +
- O +
FDG O +
uptake O +
and O +
1 O +
. O +
8 O +
for O +
123I O +
- O +
IMT O +
uptake O +
, O +
the O +
accuracy O +
values O +
of O +
18F O +
- O +
FDG O +
PET O +
and O +
123I O +
- O +
IMT O +
SPET O +
for O +
differentiating O +
between O +
high O +
- O +
grade O +
and O +
low O +
- O +
grade O +
tumours O +
were O +
21 O +
/ O +
23 O +
( O +
91 O +
% O +
) O +
and O +
19 O +
/ O +
23 O +
( O +
83 O +
% O +
) O +
, O +
respectively O +
. O +

The O +
difference O +
in O +
diagnostic O +
performance O +
was O +
not O +
significant O +
on O +
receiver O +
operating O +
characteristic O +
analysis O +
( O +
P O +
> O +
0 O +
. O +
4 O +
) O +
. O +

It O +
is O +
concluded O +
that O +
there O +
is O +
no O +
major O +
difference O +
between O +
the O +
PET O +
investigation O +
of O +
glucose O +
metabolism O +
and O +
the O +
less O +
expensive O +
SPET O +
measurement O +
of O +
amino O +
acid O +
uptake O +
in O +
terms O +
of O +
their O +
accuracy O +
in O +
evaluating O +
the O +
malignancy O +
grade O +
of O +
primary O +
brain O +
tumours O +
. O +

This O +
encourages O +
the O +
performance O +
of O +
further O +
studies O +
to O +
analyse O +
the O +
potential O +
impact O +
of O +
123I O +
- O +
IMT O +
SPET O +
on O +
the O +
therapeutic O +
management O +
of O +
patients O +
with O +
brain O +
tumours O +
. O +

Some O +
findings O +
concerning O +
beliefs O +
about O +
alcoholism O +
. O +

The O +
beliefs O +
that O +
alcoholics O +
hold O +
about O +
alcoholism O +
and O +
themselves O +
, O +
and O +
the O +
beliefs O +
that O +
hospital O +
staff O +
and O +
other O +
personnel O +
hold O +
about O +
alcoholism O +
, O +
were O +
investigated O +
using O +
methods O +
derived O +
from O +
the O +
repertory O +
grid O +
, O +
with O +
anonymous O +
facial O +
photographs O +
as O +
elements O +
. O +

Data O +
are O +
presented O +
as O +
to O +
the O +
degree O +
of O +
association O +
of O +
various O +
characteristics O +
with O +
alcoholism O +
for O +
the O +
various O +
groups O +
. O +

Differences O +
between O +
groups O +
, O +
and O +
overall O +
changes O +
during O +
group O +
psychotherapy O +
for O +
patients O +
were O +
small O +
. O +

The O +
relative O +
contribution O +
of O +
personal O +
and O +
shared O +
aspects O +
of O +
belief O +
was O +
measured O +
. O +

It O +
was O +
found O +
that O +
the O +
agreement O +
between O +
groups O +
was O +
high O +
and O +
closely O +
similar O +
to O +
that O +
predictable O +
from O +
consistencies O +
within O +
groups O +
. O +

It O +
is O +
concluded O +
that O +
there O +
may O +
be O +
a O +
very O +
general O +
stereotype O +
of O +
alcoholism O +
, O +
consistent O +
with O +
a O +
personality O +
disorder O +
concept O +
which O +
is O +
implicitly O +
held O +
even O +
in O +
the O +
face O +
of O +
nominal O +
acceptance O +
of O +
other O +
concepts O +
. O +

The O +
self O +
constructs O +
of O +
alcoholics O +
were O +
found O +
to O +
be O +
complex O +
. O +

In O +
a O +
small O +
follow O +
- O +
up O +
study O +
of O +
patients O +
, O +
there O +
was O +
found O +
to O +
be O +
a O +
relationship O +
of O +
poor O +
outcome O +
with O +
tightness O +
of O +
construing O +
for O +
key O +
constructs O +
after O +
psychotherapy O +
. O +

The O +
implications O +
of O +
the O +
findings O +
are O +
discussed O +
briefly O +
. O +

The O +
effects O +
of O +
oxidative O +
stress O +
on O +
in O +
vivo O +
brain O +
GSH O +
turnover O +
in O +
young O +
and O +
mature O +
mice O +
. O +

Glutathione O +
( O +
GSH O +
) O +
synthetase O +
activities O +
and O +
GSH O +
turnover O +
rates O +
were O +
examined O +
during O +
severe O +
oxidative O +
stress O +
in O +
the O +
mouse O +
brain O +
as O +
induced O +
by O +
t O +
- O +
butylhydroperoxide O +
( O +
t O +
- O +
BuOOH O +
) O +
. O +

Brain O +
GSH O +
synthetase O +
activities O +
in O +
8 O +
- O +
mo O +
- O +
old O +
mice O +
in O +
the O +
cortex O +
, O +
striatum O +
, O +
thalamus O +
, O +
hippocampus O +
, O +
midbrain O +
, O +
and O +
cerebellum O +
were O +
found O +
to O +
increase O +
following O +
t O +
- O +
BuOOH O +
treatment O +
. O +

The O +
effect O +
of O +
GSH O +
synthesis O +
on O +
brain O +
GSH O +
turnover O +
rates O +
for O +
2 O +
- O +
and O +
8 O +
- O +
mo O +
- O +
old O +
mice O +
were O +
determined O +
after O +
intracerebroventricular O +
( O +
icv O +
) O +
injection O +
of O +
[ O +
35S O +
] O +
cysteine O +
. O +

Rate O +
constants O +
for O +
GSH O +
turnover O +
were O +
determined O +
by O +
least O +
- O +
squares O +
iterative O +
minimization O +
from O +
the O +
specific O +
activity O +
data O +
from O +
20 O +
min O +
to O +
108 O +
h O +
after O +
[ O +
35S O +
] O +
cysteine O +
administration O +
. O +

GSH O +
and O +
glutathione O +
disulfide O +
( O +
GSSG O +
) O +
specific O +
activities O +
were O +
determined O +
after O +
separation O +
by O +
high O +
- O +
pressure O +
liquid O +
chromatography O +
( O +
HPLC O +
) O +
. O +

The O +
half O +
- O +
life O +
of O +
GSH O +
in O +
the O +
2 O +
- O +
mo O +
- O +
old O +
mouse O +
was O +
59 O +
. O +
5 O +
h O +
and O +
in O +
the O +
8 O +
- O +
mo O +
- O +
old O +
mouse O +
was O +
79 O +
. O +
1 O +
h O +
. O +

In O +
summary O +
, O +
defense O +
mechanisms O +
against O +
oxidative O +
stress O +
in O +
the O +
brain O +
differ O +
with O +
age O +
. O +

Young O +
mice O +
can O +
increase O +
the O +
cellular O +
availability O +
of O +
GSH O +
, O +
whereas O +
mature O +
mice O +
can O +
increase O +
GSH O +
synthetase O +
activity O +
during O +
oxidative O +
stress O +
. O +

These O +
differences O +
make O +
mature O +
mice O +
more O +
susceptible O +
to O +
brain O +
oxidative O +
damage O +
. O +

Changes O +
in O +
plasminogen O +
activator O +
inhibitor O +
- O +
1 O +
levels O +
in O +
non O +
- O +
small O +
cell O +
lung O +
cancer O +
. O +

Increased O +
urokinase O +
plasminogen O +
activator O +
( O +
uPA O +
) O +
levels O +
are O +
increased O +
in O +
a O +
number O +
of O +
malignancies O +
and O +
have O +
been O +
correlated O +
with O +
decreased O +
disease O +
- O +
free O +
interval O +
and O +
decreased O +
overall O +
survival O +
. O +

We O +
have O +
, O +
therefore O +
, O +
examined O +
components O +
of O +
this O +
plasminogen O +
activating O +
system O +
in O +
patients O +
with O +
Non O +
- O +
Small O +
Cell O +
Lung O +
Cancer O +
( O +
NSCLC O +
) O +
. O +

Levels O +
of O +
uPA O +
, O +
urokinase O +
- O +
plasminogen O +
activator O +
receptor O +
( O +
uPAR O +
) O +
and O +
plasminogen O +
activator O +
inhibitor O +
- O +
1 O +
( O +
PAI O +
- O +
1 O +
) O +
were O +
measured O +
semiquantitatively O +
in O +
paraffin O +
sections O +
of O +
tumours O +
from O +
147 O +
patients O +
with O +
NSCLC O +
. O +

Immunohistochemically O +
stained O +
sections O +
of O +
tumour O +
were O +
allocated O +
a O +
score O +
for O +
stain O +
intensity O +
and O +
results O +
correlated O +
to O +
: O +
survival O +
; O +
tumour O +
stage O +
( O +
T O +
) O +
; O +
nodal O +
stage O +
( O +
N O +
) O +
; O +
stage O +
grouping O +
( O +
I O +
to O +
IIIb O +
) O +
, O +
survival O +
status O +
and O +
sex O +
. O +

Increased O +
levels O +
of O +
PAI O +
- O +
1 O +
were O +
associated O +
with O +
a O +
decreased O +
survival O +
in O +
squamous O +
cell O +
carcinoma O +
( O +
SCC O +
) O +
X2 O +
= O +
5 O +
. O +
72 O +
, O +
p O +
= O +
0 O +
. O +
017 O +
( O +
n O +
= O +
74 O +
) O +
. O +

There O +
was O +
a O +
significant O +
positive O +
relationship O +
between O +
PAI O +
- O +
1 O +
levels O +
and O +
N O +
- O +
stage O +
( O +
p O +
= O +
< O +
0 O +
. O +
05 O +
) O +
, O +
presence O +
of O +
nodal O +
metastases O +
( O +
p O +
= O +
< O +
0 O +
. O +
05 O +
) O +
, O +
stage O +
grouping O +
( O +
p O +
= O +
< O +
0 O +
. O +
01 O +
) O +
and O +
extent O +
of O +
disease O +
( O +
p O +
= O +
< O +
0 O +
. O +
05 O +
) O +
in O +
the O +
total O +
group O +
and O +
the O +
SCC O +
subgroup O +
, O +
but O +
not O +
adenocarcinoma O +
. O +

There O +
was O +
a O +
significant O +
positive O +
relationship O +
between O +
PAI O +
- O +
1 O +
levels O +
and O +
T O +
- O +
stage O +
( O +
p O +
= O +
< O +
0 O +
. O +
05 O +
) O +
in O +
the O +
total O +
group O +
, O +
and O +
survival O +
status O +
( O +
p O +
= O +
< O +
0 O +
. O +
05 O +
) O +
in O +
the O +
SCC O +
subgroup O +
alone O +
. O +

uPA O +
and O +
uPAR O +
levels O +
were O +
not O +
significantly O +
associated O +
with O +
tumour O +
staging O +
or O +
survival O +
. O +

We O +
conclude O +
that O +
increased O +
PAI O +
- O +
1 O +
antigen O +
levels O +
may O +
be O +
associated O +
with O +
a O +
decreased O +
survival O +
in O +
patients O +
with O +
SCC O +
. O +

Insulin O +
- O +
like O +
growth O +
factor O +
I O +
induces O +
tumor O +
hexokinase O +
RNA O +
expression O +
in O +
cancer O +
cells O +
. O +

Increased O +
glycolysis O +
is O +
a O +
characteristic O +
of O +
cancer O +
cells O +
. O +

Though O +
less O +
efficient O +
in O +
energy O +
production O +
, O +
it O +
ensures O +
continuous O +
supply O +
of O +
energy O +
and O +
phosphometabolites O +
for O +
biosynthesis O +
enabling O +
metastatic O +
and O +
less O +
vascularized O +
cancer O +
cells O +
to O +
proliferate O +
even O +
under O +
hypoxic O +
conditions O +
. O +

Since O +
hexokinase O +
is O +
the O +
first O +
rate O +
limiting O +
enzyme O +
in O +
the O +
glycolytic O +
pathway O +
, O +
elevated O +
levels O +
of O +
Type O +
II O +
like O +
hexokinase O +
in O +
tumors O +
are O +
of O +
great O +
significance O +
in O +
this O +
context O +
. O +

Under O +
normal O +
conditions O +
insulin O +
regulates O +
expression O +
of O +
hexokinase O +
Type O +
II O +
isoenzyme O +
, O +
which O +
is O +
predominantly O +
expressed O +
in O +
muscle O +
. O +

On O +
the O +
other O +
hand O +
cancer O +
cells O +
overexpress O +
insulin O +
- O +
like O +
growth O +
factors O +
and O +
their O +
receptors O +
which O +
mimic O +
many O +
activities O +
of O +
insulin O +
. O +

This O +
prompted O +
us O +
to O +
examine O +
a O +
hypothesis O +
that O +
insulin O +
- O +
like O +
growth O +
factors O +
may O +
be O +
responsible O +
for O +
overexpression O +
of O +
tumor O +
hexokinase O +
. O +

Our O +
experiments O +
demonstrate O +
that O +
insulin O +
- O +
like O +
growth O +
factor O +
I O +
indeed O +
induces O +
hexokinase O +
gene O +
expression O +
in O +
a O +
concentration O +
and O +
time O +
dependent O +
manner O +
in O +
two O +
cancer O +
cell O +
lines O +
we O +
studied O +
. O +

The O +
Wilms O +
tumor O +
suppressor O +
gene O +
WT1 O +
induces O +
G1 O +
arrest O +
and O +
apoptosis O +
in O +
myeloblastic O +
leukemia O +
M1 B-CellLine +
cells O +
. O +

WT1 O +
was O +
isolated O +
as O +
a O +
tumor O +
suppressor O +
gene O +
of O +
Wilms O +
tumor O +
. O +

However O +
, O +
high O +
expression O +
of O +
WT1 O +
correlates O +
with O +
poor O +
prognosis O +
in O +
acute O +
leukemia O +
. O +

In O +
addition O +
suppression O +
of O +
WT1 O +
expression O +
by O +
WT1 O +
anti O +
- O +
sense O +
oligonucleotide O +
inhibits O +
proliferation O +
of O +
leukemia O +
cells O +
, O +
suggesting O +
that O +
WT1 O +
is O +
important O +
for O +
their O +
proliferation O +
. O +

To O +
further O +
elucidate O +
the O +
biological O +
significance O +
of O +
WT1 O +
in O +
leukemic O +
cell O +
growth O +
, O +
we O +
overexpressed O +
exogenous O +
WT1 O +
in O +
murine O +
M1 B-CellLine +
myeloblastic O +
leukemia O +
cells O +
using O +
the O +
isopropyl O +
- O +
beta O +
- O +
D O +
- O +
thiogalactoside O +
( O +
IPTG O +
) O +
- O +
controlled O +
expression O +
system O +
. O +

We O +
found O +
that O +
induction O +
of O +
one O +
splicing O +
variant O +
of O +
WT1 O +
[ O +
WT1 O +
- O +
17AA O +
( O +
+ O +
) O +
- O +
KTS O +
( O +
- O +
) O +
] O +
in O +
M1 B-CellLine +
cells O +
induces O +
cell O +
cycle O +
arrest O +
and O +
apoptotic O +
cell O +
death O +
. O +

These O +
results O +
suggest O +
that O +
the O +
role O +
of O +
WT1 O +
is O +
different O +
depending O +
on O +
the O +
type O +
of O +
leukemia O +
cell O +
in O +
which O +
it O +
is O +
expressed O +
. O +

[ O +
Expression O +
of O +
metastasis O +
suppressor O +
gene O +
nm23 O +
in O +
human O +
hepatocellular O +
carcinoma O +
] O +
. O +

For O +
the O +
purpose O +
of O +
investigating O +
the O +
relationship O +
between O +
the O +
metastatic O +
potential O +
of O +
the O +
tumor O +
as O +
well O +
as O +
the O +
expression O +
of O +
nm23 O +
- O +
H1 O +
mRNA O +
, O +
and O +
for O +
determing O +
the O +
location O +
of O +
the O +
positive O +
sites O +
in O +
the O +
cells O +
, O +
tumor O +
metastasis O +
suppressor O +
gene O +
nm23 O +
- O +
H1 O +
in O +
human O +
hepatocellular O +
carcinoma O +
( O +
and O +
the O +
nonneoplastic O +
area O +
surrounding O +
the O +
tumor O +
) O +
was O +
detected O +
by O +
in O +
situ O +
hybridization O +
using O +
digoxiginin O +
- O +
labeled O +
nm23 O +
- O +
H1 O +
antisense O +
complementary O +
RNA O +
probe O +
. O +

The O +
primary O +
results O +
indicated O +
( O +
i O +
) O +
positive O +
results O +
of O +
in O +
situ O +
hybridization O +
are O +
presence O +
of O +
granules O +
or O +
masses O +
in O +
the O +
cytoplasm O +
; O +
( O +
ii O +
) O +
the O +
less O +
expression O +
of O +
nm23 O +
- O +
H1 O +
mRNA O +
, O +
the O +
higher O +
metastatic O +
rate O +
of O +
the O +
human O +
hepatocellular O +
carcinoma O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
; O +
( O +
iii O +
) O +
expression O +
of O +
nm23 O +
- O +
H1 O +
mRNA O +
dose O +
not O +
correlate O +
with O +
some O +
other O +
factors O +
such O +
as O +
tumor O +
size O +
and O +
the O +
background O +
of O +
other O +
liver O +
diseases O +
. O +

Monitoring O +
the O +
efficiency O +
of O +
interferon O +
- O +
alpha O +
therapy O +
in O +
chronic O +
myelogenous O +
leukemia O +
( O +
CML O +
) O +
patients O +
by O +
competitive O +
polymerase O +
chain O +
reaction O +
. O +

Interferon O +
alpha O +
( O +
IFN O +
- O +
alpha O +
) O +
induces O +
cytogenetic O +
responses O +
of O +
variable O +
degree O +
in O +
patients O +
with O +
CML O +
. O +

We O +
sought O +
to O +
establish O +
the O +
relationship O +
between O +
BCR O +
- O +
ABL O +
transcript O +
numbers O +
measured O +
by O +
competitive O +
two O +
- O +
step O +
reverse O +
transcription O +
polymerase O +
chain O +
reaction O +
( O +
RT O +
- O +
PCR O +
) O +
and O +
cytogenetic O +
status O +
in O +
CML O +
patients O +
treated O +
with O +
IFN O +
- O +
alpha O +
. O +

All O +
398 O +
samples O +
from O +
163 O +
patients O +
investigated O +
by O +
RT O +
- O +
PCR O +
were O +
positive O +
for O +
BCR O +
- O +
ABL O +
transcripts O +
. O +

In O +
order O +
to O +
standardize O +
results O +
for O +
variability O +
in O +
RNA O +
and O +
cDNA O +
quality O +
, O +
we O +
quantified O +
total O +
ABL O +
transcripts O +
in O +
each O +
sample O +
as O +
internal O +
control O +
. O +

The O +
BCR O +
- O +
ABL O +
/ O +
ABL O +
ratios O +
correlated O +
with O +
the O +
cytogenetic O +
results O +
. O +

Quantitative O +
nested O +
PCR O +
allowed O +
the O +
detection O +
of O +
residual O +
BCR O +
- O +
ABL O +
transcripts O +
in O +
all O +
complete O +
cytogenetic O +
responders O +
on O +
IFN O +
- O +
alpha O +
. O +

We O +
conclude O +
that O +
competitive O +
PCR O +
with O +
internal O +
controls O +
is O +
a O +
reliable O +
method O +
for O +
monitoring O +
patients O +
on O +
IFN O +
- O +
alpha O +
and O +
reduces O +
the O +
need O +
for O +
repeated O +
marrow O +
investigations O +
. O +

Suppression O +
of O +
tumor O +
growth O +
by O +
the O +
3 O +
' O +
untranslated O +
region O +
of O +
mel O +
- O +
18 O +
in O +
3Y1 B-CellLine +
cells O +
transformed O +
by O +
the O +
E6 O +
and O +
E7 O +
genes O +
of O +
human O +
papillomavirus O +
type O +
18 O +
. O +

By O +
introducing O +
a O +
cDNA O +
library O +
derived O +
from O +
rat O +
embryonic O +
fibroblast O +
cells O +
, O +
we O +
isolated O +
several O +
morphologically O +
flat O +
revertants O +
of O +
rat O +
3Y1 B-CellLine +
cells O +
transformed O +
by O +
the O +
E6 O +
and O +
E7 O +
genes O +
of O +
human O +
papillomavirus O +
type O +
18 O +
( O +
HPV18 O +
) O +
. O +

From O +
one O +
of O +
the O +
revertants O +
, O +
we O +
recovered O +
a O +
0 O +
. O +
2 O +
- O +
kb O +
cDNA O +
, O +
N56 O +
, O +
that O +
suppresses O +
the O +
tumor O +
growth O +
of O +
the O +
transformed O +
3Y1 B-CellLine +
cells O +
irrespective O +
of O +
the O +
expression O +
of O +
the O +
E6 O +
and O +
E7 O +
genes O +
. O +

The O +
nucleotide O +
sequence O +
of O +
the O +
cDNA O +
was O +
shown O +
to O +
be O +
identical O +
to O +
that O +
of O +
the O +
3 O +
' O +
untranslated O +
region O +
of O +
a O +
putative O +
mammalian O +
polycomb O +
group O +
gene O +
, O +
mel O +
- O +
18 O +
. O +

[ O +
Treatment O +
of O +
acute O +
liver O +
failure O +
in O +
children O +
] O +
. O +

Among O +
the O +
main O +
causes O +
of O +
acute O +
liver O +
failure O +
( O +
ALF O +
) O +
in O +
children O +
, O +
metabolic O +
diseases O +
( O +
especially O +
in O +
infants O +
) O +
, O +
viral O +
and O +
toxin O +
or O +
drug O +
induced O +
hepatitis O +
are O +
the O +
most O +
frequent O +
. O +

The O +
cause O +
remains O +
, O +
however O +
, O +
undetermined O +
in O +
about O +
30 O +
% O +
of O +
the O +
cases O +
. O +

Management O +
must O +
be O +
conducted O +
in O +
a O +
pediatric O +
hepatology O +
unit O +
or O +
intensive O +
care O +
unit O +
in O +
relation O +
with O +
a O +
pediatric O +
transplant O +
team O +
in O +
order O +
: O +
1 O +
) O +
to O +
perform O +
urgent O +
etiological O +
diagnosis O +
; O +
2 O +
) O +
to O +
initiate O +
specific O +
therapy O +
and O +
symptomatic O +
treatment O +
; O +
3 O +
) O +
to O +
evaluate O +
the O +
severity O +
and O +
prognosis O +
of O +
liver O +
disease O +
for O +
selection O +
of O +
children O +
for O +
emergency O +
liver O +
transplantation O +
; O +
4 O +
) O +
to O +
evaluate O +
contraindications O +
to O +
liver O +
transplantation O +
. O +

The O +
overall O +
survival O +
of O +
post O +
- O +
emergency O +
liver O +
transplantation O +
for O +
ALF O +
in O +
children O +
averages O +
65 O +
% O +
. O +

Blind O +
separation O +
of O +
auditory O +
event O +
- O +
related O +
brain O +
responses O +
into O +
independent O +
components O +
. O +

Averaged O +
event O +
- O +
related O +
potential O +
( O +
ERP O +
) O +
data O +
recorded O +
from O +
the O +
human O +
scalp O +
reveal O +
electroencephalographic O +
( O +
EEG O +
) O +
activity O +
that O +
is O +
reliably O +
time O +
- O +
locked O +
and O +
phase O +
- O +
locked O +
to O +
experimental O +
events O +
. O +

We O +
report O +
here O +
the O +
application O +
of O +
a O +
method O +
based O +
on O +
information O +
theory O +
that O +
decomposes O +
one O +
or O +
more O +
ERPs O +
recorded O +
at O +
multiple O +
scalp O +
sensors O +
into O +
a O +
sum O +
of O +
components O +
with O +
fixed O +
scalp O +
distributions O +
and O +
sparsely O +
activated O +
, O +
maximally O +
independent O +
time O +
courses O +
. O +

Independent O +
component O +
analysis O +
( O +
ICA O +
) O +
decomposes O +
ERP O +
data O +
into O +
a O +
number O +
of O +
components O +
equal O +
to O +
the O +
number O +
of O +
sensors O +
. O +

The O +
derived O +
components O +
have O +
distinct O +
but O +
not O +
necessarily O +
orthogonal O +
scalp O +
projections O +
. O +

Unlike O +
dipole O +
- O +
fitting O +
methods O +
, O +
the O +
algorithm O +
does O +
not O +
model O +
the O +
locations O +
of O +
their O +
generators O +
in O +
the O +
head O +
. O +

Unlike O +
methods O +
that O +
remove O +
second O +
- O +
order O +
correlations O +
, O +
such O +
as O +
principal O +
component O +
analysis O +
( O +
PCA O +
) O +
, O +
ICA O +
also O +
minimizes O +
higher O +
- O +
order O +
dependencies O +
. O +

Applied O +
to O +
detected O +
- O +
and O +
undetected O +
- O +
target O +
ERPs O +
from O +
an O +
auditory O +
vigilance O +
experiment O +
, O +
the O +
algorithm O +
derived O +
ten O +
components O +
that O +
decomposed O +
each O +
of O +
the O +
major O +
response O +
peaks O +
into O +
one O +
or O +
more O +
ICA O +
components O +
with O +
relatively O +
simple O +
scalp O +
distributions O +
. O +

Three O +
of O +
these O +
components O +
were O +
active O +
only O +
when O +
the O +
subject O +
detected O +
the O +
targets O +
, O +
three O +
other O +
components O +
only O +
when O +
the O +
target O +
went O +
undetected O +
, O +
and O +
one O +
in O +
both O +
cases O +
. O +

Three O +
additional O +
components O +
accounted O +
for O +
the O +
steady O +
- O +
state O +
brain O +
response O +
to O +
a O +
39 O +
- O +
Hz O +
background O +
click O +
train O +
. O +

Major O +
features O +
of O +
the O +
decomposition O +
proved O +
robust O +
across O +
sessions O +
and O +
changes O +
in O +
sensor O +
number O +
and O +
placement O +
. O +

This O +
method O +
of O +
ERP O +
analysis O +
can O +
be O +
used O +
to O +
compare O +
responses O +
from O +
multiple O +
stimuli O +
, O +
task O +
conditions O +
, O +
and O +
subject O +
states O +
. O +

CD56 O +
+ O +
putative O +
natural O +
killer O +
cell O +
lymphomas O +
: O +
production O +
of O +
cytolytic O +
effectors O +
and O +
related O +
proteins O +
mediating O +
tumor O +
cell O +
apoptosis O +
? O +

Apoptosis O +
is O +
a O +
regulated O +
form O +
of O +
cell O +
death O +
that O +
may O +
be O +
triggered O +
by O +
natural O +
killer O +
( O +
NK O +
) O +
or O +
cytotoxic O +
T O +
cells O +
, O +
which O +
effect O +
target O +
cell O +
lysis O +
by O +
cytolytic O +
effector O +
and O +
related O +
proteins O +
through O +
complex O +
intracellular O +
signals O +
. O +

This O +
study O +
was O +
aimed O +
to O +
investigate O +
whether O +
there O +
is O +
selective O +
expression O +
of O +
these O +
cytolytic O +
markers O +
in O +
the O +
putative O +
NK O +
- O +
cell O +
lymphomas O +
and O +
whether O +
there O +
is O +
correlation O +
with O +
zonal O +
tumor O +
cell O +
death O +
in O +
these O +
tumors O +
. O +

Expression O +
of O +
the O +
cytolytic O +
effectors O +
perforin O +
, O +
granzyme O +
B9 O +
, O +
and O +
the O +
granule O +
membrane O +
protein O +
TIA1 O +
were O +
examined O +
in O +
24 O +
putative O +
NK O +
- O +
cell O +
lymphomas O +
, O +
18 O +
postthymic O +
T O +
- O +
cell O +
lymphomas O +
( O +
one O +
case O +
CD8 O +
+ O +
CD56 O +
+ O +
and O +
three O +
anaplastic O +
large O +
cell O +
lymphomas O +
( O +
ALCL O +
) O +
, O +
three O +
T O +
- O +
lymphoblastic O +
lymphomas O +
, O +
and O +
20 O +
B O +
- O +
cell O +
lymphomas O +
. O +

Nineteen O +
( O +
79 O +
% O +
) O +
putative O +
NK O +
- O +
cell O +
lymphomas O +
expressed O +
perforin O +
, O +
and O +
all O +
24 O +
cases O +
expressed O +
granzyme O +
B9 O +
and O +
TIA1 O +
. O +

The O +
only O +
CD8 O +
+ O +
CD56 O +
+ O +
postthymic O +
T O +
- O +
cell O +
lymphoma O +
also O +
expressed O +
all O +
three O +
cytolytic O +
markers O +
, O +
two O +
CD8 O +
- O +
ALCL O +
expressed O +
TIA1 O +
; O +
other O +
postthymic O +
T O +
- O +
cell O +
, O +
T O +
- O +
lymphoblastic O +
, O +
and O +
B O +
- O +
cell O +
lymphomas O +
were O +
consistently O +
negative O +
. O +

There O +
was O +
strong O +
correlation O +
between O +
percentage O +
perforin O +
- O +
positive O +
cells O +
and O +
zonal O +
tumor O +
cell O +
death O +
. O +

Angioinvasion O +
, O +
in O +
contrast O +
, O +
was O +
present O +
only O +
in O +
a O +
proportion O +
( O +
37 O +
% O +
) O +
of O +
these O +
lymphomas O +
despite O +
the O +
frequent O +
presence O +
of O +
zonal O +
tumor O +
cell O +
death O +
( O +
71 O +
% O +
) O +
. O +

We O +
propose O +
that O +
cytolytic O +
effector O +
and O +
related O +
proteins O +
produced O +
by O +
putative O +
NK O +
and O +
some O +
CD8 O +
+ O +
CD56 O +
+ O +
postthymic O +
T O +
- O +
cell O +
lymphomas O +
, O +
probably O +
in O +
conjunction O +
with O +
other O +
mechanisms O +
, O +
may O +
effect O +
massive O +
tumor O +
cell O +
apoptosis O +
. O +

The O +
frequent O +
expression O +
of O +
cytolytic O +
effector O +
markers O +
in O +
the O +
CD2 O +
+ O +
surface O +
CD3 O +
- O +
CD56 O +
+ O +
putative O +
NK O +
- O +
cell O +
lymphomas O +
lends O +
further O +
support O +
to O +
their O +
probable O +
NK O +
cell O +
origin O +
. O +

Calretinin O +
. O +

A O +
selective O +
marker O +
of O +
normal O +
and O +
neoplastic O +
mesothelial O +
cells O +
in O +
serous O +
effusions O +
. O +

OBJECTIVE O +
: O +
To O +
document O +
that O +
a O +
polyclonal O +
antiserum O +
to O +
calretinin O +
, O +
a O +
29 O +
- O +
kd O +
calcium O +
- O +
binding O +
protein O +
, O +
consistently O +
decorates O +
normal O +
and O +
tumor O +
mesothelial O +
cells O +
in O +
cytologic O +
preparations O +
. O +

STUDY O +
DESIGN O +
: O +
Thirty O +
- O +
three O +
archival O +
cytologic O +
specimens O +
from O +
eight O +
patients O +
with O +
histologically O +
confirmed O +
malignant O +
mesothelioma O +
and O +
13 O +
from O +
patients O +
with O +
metastatic O +
serous O +
effusions O +
were O +
destained O +
and O +
then O +
immunostained O +
with O +
anticalretinin O +
antiserum O +
. O +

For O +
investigation O +
of O +
cell O +
suspensions O +
, O +
four O +
pleural O +
fluids O +
were O +
incubated O +
with O +
anticalretinin O +
antiserum O +
. O +

After O +
cytocentrifugation O +
the O +
specimens O +
were O +
stained O +
in O +
accordance O +
with O +
the O +
alkaline O +
phosphatase O +
anti O +
- O +
alkaline O +
phosphatase O +
( O +
APAAP O +
) O +
method O +
. O +

For O +
electron O +
microscopic O +
examination O +
the O +
cell O +
suspensions O +
were O +
then O +
incubated O +
with O +
gold O +
- O +
labeled O +
antirabbit O +
antibody O +
. O +

RESULTS O +
: O +
The O +
diagnostic O +
sensitivity O +
of O +
this O +
new O +
immunocytochemical O +
approach O +
reached O +
100 O +
% O +
for O +
the O +
eight O +
malignant O +
mesotheliomas O +
investigated O +
. O +

Only O +
3 O +
of O +
the O +
13 O +
adenocarcinomas O +
metastatic O +
to O +
the O +
serous O +
membranes O +
included O +
in O +
this O +
study O +
were O +
weakly O +
reactive O +
, O +
accounting O +
for O +
81 O +
% O +
specificity O +
. O +

Binding O +
of O +
anticalretinin O +
antiserum O +
to O +
living O +
mesothelial O +
cells O +
was O +
consistently O +
documented O +
in O +
all O +
four O +
cases O +
investigated O +
. O +

CONCLUSION O +
: O +
Calretinin O +
is O +
a O +
very O +
useful O +
marker O +
for O +
positive O +
identification O +
of O +
normal O +
and O +
tumor O +
mesothelial O +
cells O +
in O +
serous O +
effusions O +
. O +

[ O +
Extra O +
- O +
anatomic O +
bypass O +
from O +
the O +
ascending O +
aorta O +
to O +
the O +
supraceliac O +
abdominal O +
aorta O +
- O +
- O +
surgical O +
option O +
applied O +
to O +
reoperation O +
for O +
aortic O +
coarctation O +
or O +
interruption O +
] O +
. O +

The O +
optimal O +
approach O +
for O +
reoperation O +
following O +
repair O +
of O +
aortic O +
coarctation O +
( O +
CoA O +
) O +
or O +
interruption O +
( O +
IAA O +
) O +
remains O +
controversial O +
. O +

Four O +
patients O +
underwent O +
extra O +
- O +
anatomic O +
bypass O +
for O +
restenosis O +
after O +
repair O +
of O +
CoA O +
or O +
IAA O +
. O +

The O +
age O +
ranged O +
from O +
4 O +
to O +
12 O +
years O +
. O +

The O +
initial O +
repairs O +
for O +
two O +
CoA O +
, O +
one O +
type O +
A O +
- O +
IAA O +
, O +
and O +
one O +
type O +
B O +
- O +
IAA O +
consisted O +
of O +
two O +
grafting O +
, O +
one O +
subclavian O +
arterial O +
turning O +
- O +
down O +
aortoplasty O +
, O +
and O +
one O +
subclavian O +
flap O +
aortoplasty O +
. O +

All O +
of O +
them O +
underwent O +
during O +
infancy O +
. O +

Preoperative O +
right O +
arm O +
systolic O +
pressure O +
ranged O +
from O +
140 O +
to O +
190 O +
mmHg O +
ar O +
rest O +
. O +

Through O +
a O +
midline O +
sternotomy O +
and O +
an O +
upper O +
laparotmy O +
incision O +
, O +
an O +
extra O +
- O +
anatomic O +
bypass O +
from O +
the O +
ascending O +
aorta O +
to O +
the O +
supraceliac O +
abdominal O +
aorta O +
was O +
employed O +
using O +
a O +
12 O +
to O +
18 O +
mm O +
tube O +
graft O +
. O +

All O +
patients O +
survived O +
surgeries O +
, O +
and O +
their O +
hypertension O +
markedly O +
improved O +
. O +

Our O +
experience O +
confirms O +
safety O +
and O +
effectiveness O +
of O +
this O +
option O +
in O +
selected O +
young O +
patients O +
with O +
re O +
- O +
stenosis O +
of O +
following O +
repair O +
of O +
CoA O +
or O +
IAA O +
. O +

Effect O +
of O +
a O +
mutation O +
in O +
the O +
anticodon O +
of O +
human O +
mitochondrial O +
tRNAPro O +
on O +
its O +
post O +
- O +
transcriptional O +
modification O +
pattern O +
. O +

Although O +
the O +
gene O +
sequences O +
of O +
all O +
22 O +
tRNAs O +
encoded O +
in O +
the O +
human O +
mitochondrial O +
genome O +
are O +
known O +
, O +
little O +
information O +
exists O +
about O +
their O +
sequences O +
at O +
the O +
RNA O +
level O +
. O +

This O +
becomes O +
a O +
crucial O +
limitation O +
when O +
searching O +
for O +
a O +
molecular O +
understanding O +
of O +
the O +
growing O +
number O +
of O +
maternally O +
inherited O +
human O +
diseases O +
correlated O +
with O +
point O +
mutations O +
in O +
tRNA O +
genes O +
. O +

Here O +
we O +
describe O +
the O +
sequence O +
of O +
human O +
mt O +
- O +
tRNAPropurified O +
from O +
placenta O +
. O +

It O +
shows O +
absence O +
of O +
editing O +
events O +
in O +
this O +
tRNA O +
and O +
highlights O +
the O +
presence O +
of O +
eight O +
post O +
- O +
transcriptional O +
modifications O +
. O +

These O +
include O +
T54 O +
, O +
never O +
found O +
so O +
far O +
in O +
an O +
animal O +
mt O +
- O +
tRNA O +
, O +
and O +
m1G37 O +
, O +
a O +
modification O +
known O +
to O +
have O +
fundamental O +
functional O +
properties O +
in O +
a O +
number O +
of O +
canonical O +
tRNAs O +
. O +

Occurrence O +
of O +
m1G37 O +
was O +
further O +
investigated O +
in O +
an O +
analysis O +
of O +
the O +
substrate O +
properties O +
of O +
in O +
vitro O +
transcripts O +
of O +
human O +
mt O +
- O +
tRNAProtowards O +
pure O +
Escherichia O +
coli O +
methylguanosine O +
transferase O +
. O +

This O +
enzyme O +
properly O +
methylates O +
G37 O +
in O +
mt O +
- O +
tRNA O +
and O +
is O +
sensitive O +
to O +
the O +
presence O +
of O +
a O +
second O +
G O +
at O +
position O +
36 O +
, O +
neighboring O +
the O +
target O +
nucleotide O +
for O +
methylation O +
. O +

Since O +
mutation O +
of O +
nt O +
36 O +
was O +
shown O +
to O +
be O +
correlated O +
with O +
myopathy O +
, O +
the O +
potential O +
consequences O +
of O +
non O +
- O +
modification O +
or O +
under O +
- O +
modification O +
of O +
mt O +
- O +
tRNA O +
nucleotides O +
in O +
expression O +
of O +
the O +
particular O +
myopathy O +
and O +
of O +
mitochondrial O +
diseases O +
in O +
general O +
are O +
discussed O +
. O +

Prognostic O +
value O +
of O +
HLA O +
- O +
DR O +
expression O +
and O +
dendritic O +
cell O +
infiltration O +
in O +
gastric O +
cancer O +
. O +

We O +
attempted O +
to O +
correlate O +
the O +
expression O +
of O +
human O +
leukocyte O +
antigen O +
DR O +
( O +
HLA O +
- O +
DR O +
) O +
and O +
tumor O +
infiltration O +
by O +
S O +
- O +
100 O +
- O +
protein O +
- O +
positive O +
dendritic O +
cells O +
with O +
clinicopathologic O +
features O +
in O +
165 O +
patients O +
with O +
gastric O +
cancer O +
. O +

The O +
expression O +
of O +
HLA O +
- O +
DR O +
was O +
correlated O +
with O +
the O +
histologic O +
type O +
. O +

Infiltration O +
of O +
dendritic O +
cells O +
correlated O +
negatively O +
with O +
distant O +
lymph O +
node O +
metastases O +
, O +
clinical O +
stage O +
, O +
and O +
peritoneal O +
invasion O +
. O +

There O +
was O +
no O +
correlation O +
between O +
the O +
expression O +
of O +
HLA O +
- O +
DR O +
and O +
infiltration O +
by O +
dendritic O +
cells O +
. O +

In O +
patients O +
with O +
resectable O +
gastric O +
cancer O +
, O +
the O +
grade O +
of O +
infiltrating O +
dendritic O +
cells O +
may O +
be O +
a O +
suitable O +
predictor O +
of O +
prognosis O +
. O +

Integrin O +
alphavbeta3 O +
requirement O +
for O +
sustained O +
mitogen O +
- O +
activated O +
protein O +
kinase O +
activity O +
during O +
angiogenesis O +
. O +

Angiogenesis O +
depends O +
on O +
growth O +
factors O +
and O +
vascular O +
cell O +
adhesion O +
events O +
. O +

Integrins O +
and O +
growth O +
factors O +
are O +
capable O +
of O +
activating O +
the O +
ras O +
/ O +
MAP O +
kinase O +
pathway O +
in O +
vitro O +
, O +
yet O +
how O +
these O +
signals O +
influence O +
endothelial O +
cells O +
during O +
angiogenesis O +
is O +
unknown O +
. O +

Upon O +
initiation O +
of O +
angiogenesis O +
with O +
basic O +
fibroblast O +
growth O +
factor O +
( O +
bFGF O +
) O +
on O +
the O +
chick O +
chorioallantoic O +
membrane O +
( O +
CAM O +
) O +
, O +
endothelial O +
cell O +
mitogen O +
- O +
activated O +
protein O +
( O +
MAP O +
) O +
kinase O +
( O +
ERK O +
) O +
activity O +
was O +
detected O +
as O +
early O +
as O +
5 O +
min O +
yet O +
was O +
sustained O +
for O +
at O +
least O +
20 O +
h O +
. O +

The O +
initial O +
wave O +
of O +
ERK O +
activity O +
( O +
5 O +
- O +
120 O +
min O +
) O +
was O +
refractory O +
to O +
integrin O +
antagonists O +
, O +
whereas O +
the O +
sustained O +
activity O +
( O +
4 O +
- O +
20 O +
h O +
) O +
depended O +
on O +
integrin O +
alphavbeta3 O +
, O +
but O +
not O +
beta1 O +
integrins O +
. O +

Inhibition O +
of O +
MAP O +
kinase O +
kinase O +
( O +
MEK O +
) O +
during O +
this O +
sustained O +
alphavbeta3 O +
- O +
dependent O +
ERK O +
signal O +
blocked O +
the O +
formation O +
of O +
new O +
blood O +
vessels O +
while O +
not O +
influencing O +
preexisting O +
blood O +
vessels O +
on O +
the O +
CAM O +
. O +

Inhibition O +
of O +
MEK O +
also O +
blocked O +
growth O +
factor O +
induced O +
migration O +
but O +
not O +
adhesion O +
of O +
endothelial O +
cells O +
in O +
vitro O +
. O +

Therefore O +
, O +
angiogenesis O +
depends O +
on O +
sustained O +
ERK O +
activity O +
regulated O +
by O +
the O +
ligation O +
state O +
of O +
both O +
a O +
growth O +
factor O +
receptor O +
and O +
integrin O +
alphavbeta3 O +
. O +

Conservative O +
treatment O +
of O +
endometriosis O +
: O +
the O +
effects O +
of O +
limited O +
surgery O +
and O +
hormonal O +
pseudopregnancy O +
. O +

This O +
study O +
compares O +
the O +
effects O +
of O +
limited O +
surgery O +
or O +
hormonal O +
pseudopregnancy O +
, O +
or O +
a O +
combination O +
of O +
these O +
two O +
, O +
upon O +
fertility O +
and O +
the O +
need O +
for O +
subsequent O +
surgery O +
with O +
respect O +
to O +
the O +
extent O +
of O +
the O +
disease O +
at O +
the O +
time O +
of O +
initial O +
diagnosis O +
in O +
patients O +
with O +
endometriosis O +
externa O +
. O +

Of O +
the O +
61 O +
patients O +
who O +
desired O +
to O +
enhance O +
or O +
preserve O +
reproductive O +
capacity O +
, O +
20 O +
patients O +
became O +
pregnant O +
, O +
for O +
a O +
pregnancy O +
rate O +
of O +
33 O +
% O +
. O +

The O +
pregnancy O +
rate O +
in O +
all O +
categories O +
, O +
that O +
is O +
, O +
those O +
patients O +
treated O +
with O +
pseudopregnancy O +
, O +
conservative O +
surgery O +
, O +
and O +
combined O +
pseudopregnancy O +
and O +
surgery O +
, O +
was O +
found O +
to O +
be O +
in O +
direct O +
relationship O +
to O +
the O +
initial O +
extent O +
of O +
disease O +
. O +

In O +
such O +
patients O +
, O +
conservative O +
surgery O +
alone O +
seemed O +
to O +
give O +
the O +
best O +
results O +
in O +
the O +
achievement O +
of O +
pregnancy O +
. O +

There O +
seemed O +
to O +
be O +
little O +
difference O +
between O +
pseudopregnancy O +
alone O +
and O +
conservative O +
surgery O +
in O +
regard O +
to O +
the O +
need O +
for O +
subsequent O +
surgery O +
after O +
initial O +
therapy O +
, O +
although O +
there O +
seemed O +
to O +
be O +
a O +
significantly O +
greater O +
chance O +
for O +
the O +
need O +
for O +
subsequent O +
surgery O +
in O +
patients O +
receiving O +
a O +
combination O +
of O +
the O +
two O +
forms O +
of O +
therapy O +
. O +

The O +
need O +
for O +
subsequent O +
surgery O +
after O +
initial O +
therapy O +
in O +
80 O +
patients O +
increased O +
in O +
direct O +
relationship O +
to O +
the O +
initial O +
extent O +
of O +
disease O +
present O +
, O +
despite O +
the O +
form O +
of O +
therapy O +
used O +
. O +

Fifty O +
- O +
nine O +
other O +
patients O +
with O +
endometriosis O +
, O +
who O +
did O +
not O +
desire O +
to O +
preserve O +
fertility O +
and O +
presented O +
for O +
relief O +
of O +
other O +
symptoms O +
, O +
underwent O +
initial O +
" O +
radical O +
" O +
therapy O +
. O +

Forty O +
- O +
six O +
patients O +
underwent O +
complete O +
operation O +
, O +
including O +
removal O +
of O +
uterus O +
, O +
tubes O +
and O +
ovaries O +
, O +
and O +
none O +
required O +
subsequent O +
reoperation O +
. O +

Of O +
the O +
13 O +
remaining O +
patients O +
, O +
who O +
underwent O +
incomplete O +
surgical O +
removal O +
, O +
leaving O +
one O +
or O +
both O +
ovaries O +
in O +
situ O +
, O +
11 O +
required O +
subsequent O +
reoperation O +
for O +
recurrent O +
pelvic O +
endometriosis O +
. O +

Clozapine O +
- O +
induced O +
agranulocytosis O +
and O +
thrombopenia O +
in O +
a O +
patient O +
with O +
dopaminergic O +
psychosis O +
. O +

In O +
patients O +
with O +
Parkinson O +
' O +
disease O +
and O +
dopaminergic O +
psychosis O +
, O +
clozapine O +
treatment O +
is O +
recommended O +
as O +
the O +
drug O +
is O +
free O +
from O +
extrapyramidal O +
side O +
effects O +
and O +
does O +
not O +
worsen O +
motor O +
symptoms O +
of O +
the O +
underlying O +
disease O +
. O +

The O +
use O +
of O +
clozapine O +
, O +
however O +
, O +
is O +
limited O +
due O +
to O +
its O +
hematotoxic O +
side O +
effects O +
. O +

For O +
treatment O +
of O +
clozapine O +
- O +
induced O +
agranulocytosis O +
, O +
granulocyte O +
colony O +
- O +
stimulating O +
factors O +
( O +
G O +
- O +
CSF O +
) O +
are O +
recommended O +
. O +

We O +
report O +
the O +
case O +
of O +
a O +
72 O +
- O +
years O +
- O +
old O +
male O +
patient O +
with O +
clozapine O +
- O +
induced O +
agranulocytosis O +
and O +
thrombopenia O +
. O +

Neutropenia O +
was O +
successfully O +
treated O +
with O +
G O +
- O +
CSF O +
, O +
but O +
thrombopenia O +
persisted O +
and O +
resolved O +
spontaneously O +
after O +
14 O +
days O +
. O +

Bone O +
marrow O +
toxicity O +
of O +
clozapine O +
is O +
not O +
restricted O +
to O +
white O +
cell O +
maturation O +
, O +
but O +
may O +
also O +
impair O +
thrombocytopoesis O +
. O +

Basic O +
fibroblast O +
growth O +
factor O +
: O +
a O +
missing O +
link O +
between O +
collagen O +
VII O +
, O +
increased O +
collagenase O +
, O +
and O +
squamous O +
cell O +
carcinoma O +
in O +
recessive O +
dystrophic O +
epidermolysis O +
bullosa O +
. O +

BACKGROUND O +
: O +
Patients O +
with O +
recessive O +
dystrophic O +
epidermolysis O +
bullosa O +
( O +
RDEB O +
) O +
have O +
deficiencies O +
of O +
collagen O +
type O +
VII O +
and O +
have O +
elevated O +
levels O +
of O +
fibroblast O +
collagenase O +
, O +
and O +
a O +
greatly O +
increased O +
risk O +
of O +
cutaneous O +
squamous O +
cell O +
carcinoma O +
. O +

Patients O +
with O +
other O +
genetic O +
blistering O +
disorders O +
do O +
not O +
have O +
elevated O +
collagenase O +
or O +
an O +
increased O +
risk O +
of O +
squamous O +
cell O +
carcinoma O +
, O +
despite O +
chronic O +
wounding O +
. O +

The O +
connection O +
between O +
collagen O +
type O +
VII O +
deficiency O +
, O +
increased O +
collagenase O +
, O +
and O +
squamous O +
cell O +
carcinoma O +
is O +
not O +
understood O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
Urine O +
from O +
81 O +
patients O +
with O +
RDEB O +
( O +
39 O +
patients O +
) O +
, O +
junctional O +
epidermolysis O +
bullosa O +
( O +
JEB O +
; O +
12 O +
patients O +
) O +
, O +
and O +
epidermolysis O +
bullosa O +
simplex O +
( O +
EBS O +
; O +
30 O +
patients O +
) O +
, O +
as O +
well O +
as O +
unaffected O +
family O +
members O +
of O +
RDEB O +
patients O +
( O +
33 O +
patients O +
) O +
, O +
was O +
tested O +
for O +
the O +
presence O +
of O +
basic O +
fibroblast O +
growth O +
factor O +
( O +
bFGF O +
) O +
using O +
a O +
sensitive O +
radioimmunoassay O +
. O +

These O +
patients O +
included O +
many O +
who O +
were O +
enrolled O +
in O +
the O +
Epidermolysis O +
Bullosa O +
Registry O +
and O +
others O +
who O +
were O +
referred O +
by O +
their O +
physicians O +
. O +

RESULTS O +
: O +
Fifty O +
- O +
one O +
percent O +
of O +
patients O +
with O +
RDEB O +
had O +
elevated O +
levels O +
( O +
greater O +
than O +
5000 O +
pg O +
/ O +
g O +
) O +
of O +
urinary O +
bFGF O +
. O +

In O +
contrast O +
, O +
none O +
of O +
the O +
patients O +
with O +
JEB O +
had O +
elevated O +
levels O +
of O +
bFGF O +
. O +

Twenty O +
- O +
one O +
percent O +
of O +
clinically O +
unaffected O +
family O +
members O +
had O +
elevated O +
levels O +
of O +
bFGF O +
, O +
and O +
13 O +
% O +
of O +
patients O +
with O +
EBS O +
had O +
elevated O +
levels O +
of O +
bFGF O +
. O +

The O +
frequency O +
of O +
elevated O +
bFGF O +
values O +
among O +
all O +
groups O +
was O +
statistically O +
significant O +
( O +
p O +
= O +
0 O +
. O +
002 O +
) O +
, O +
and O +
the O +
levels O +
of O +
bFGF O +
in O +
RDEB O +
patients O +
were O +
significantly O +
elevated O +
compared O +
with O +
those O +
of O +
other O +
groups O +
( O +
p O +
less O +
than O +
0 O +
. O +
05 O +
) O +
. O +

CONCLUSIONS O +
: O +
We O +
have O +
found O +
that O +
patients O +
with O +
RDEB O +
have O +
elevated O +
levels O +
of O +
bFGF O +
, O +
which O +
may O +
contribute O +
to O +
increased O +
fibroblast O +
collagenase O +
and O +
the O +
development O +
of O +
squamous O +
cell O +
carcinoma O +
. O +

These O +
results O +
suggest O +
a O +
novel O +
treatment O +
for O +
RDEB O +
, O +
namely O +
, O +
angiogenesis O +
inhibitors O +
, O +
which O +
may O +
antagonize O +
the O +
effects O +
of O +
bFGF O +
in O +
this O +
disorder O +
. O +

There O +
are O +
currently O +
no O +
other O +
means O +
of O +
treatment O +
for O +
this O +
disorder O +
, O +
which O +
has O +
a O +
high O +
morbidity O +
and O +
mortality O +
rate O +
. O +

Multiple O +
phosphotyrosine O +
phosphatase O +
mRNAs O +
are O +
expressed O +
in O +
the O +
human O +
lung O +
fibroblast O +
cell O +
line O +
WI B-CellLine +
- I-CellLine +
38 I-CellLine +
. O +

Protein O +
tyrosine O +
phosphatases O +
are O +
important O +
components O +
of O +
signal O +
transduction O +
pathways O +
. O +

The O +
authors O +
have O +
used O +
reverse O +
transcription O +
/ O +
polymerase O +
chain O +
reactions O +
to O +
accomplish O +
a O +
comprehensive O +
examination O +
of O +
the O +
RNA O +
expression O +
for O +
58 O +
distinct O +
mammalian O +
protein O +
tyrosine O +
and O +
dual O +
specificity O +
phosphatase O +
( O +
PTPase O +
) O +
and O +
PTPase O +
- O +
like O +
genes O +
in O +
the O +
normal O +
human O +
diploid O +
fibroblast O +
cell O +
line O +
WI B-CellLine +
- I-CellLine +
38 I-CellLine +
. O +

Thirty O +
- O +
seven O +
of O +
these O +
PTPase O +
genes O +
express O +
easily O +
measurable O +
RNA O +
, O +
and O +
four O +
simultaneously O +
express O +
the O +
RNA O +
for O +
two O +
or O +
more O +
isoforms O +
. O +

Messages O +
for O +
an O +
additional O +
eight O +
PTPase O +
genes O +
are O +
detectable O +
at O +
low O +
levels O +
. O +

Only O +
14 O +
known O +
PTPase O +
genes O +
do O +
not O +
express O +
measurable O +
RNA O +
under O +
our O +
conditions O +
. O +

For O +
purposes O +
of O +
comparison O +
, O +
the O +
authors O +
also O +
assessed O +
the O +
PTPases O +
expressed O +
in O +
the O +
WI B-CellLine +
- I-CellLine +
38 I-CellLine +
cell O +
line O +
using O +
highly O +
degenerate O +
primers O +
to O +
conserved O +
motifs O +
found O +
in O +
the O +
classical O +
tyrosine O +
- O +
specific O +
PTPases O +
. O +

Only O +
eight O +
of O +
the O +
22 O +
classic O +
tyrosine O +
- O +
specific O +
PTPases O +
detected O +
using O +
the O +
specific O +
primers O +
were O +
detected O +
using O +
these O +
degenerate O +
primers O +
. O +

Our O +
panel O +
of O +
specific O +
PTPase O +
primers O +
should O +
be O +
very O +
useful O +
for O +
semiquantitatively O +
assessing O +
the O +
repertoire O +
of O +
PTPases O +
expressed O +
by O +
cells O +
. O +

Epstein O +
- O +
Barr O +
virus O +
- O +
associated O +
nonsmall O +
cell O +
lung O +
carcinoma O +
: O +
undifferentiated O +
" O +
lymphoepithelioma O +
- O +
like O +
" O +
carcinoma O +
as O +
a O +
distinct O +
entity O +
with O +
better O +
prognosis O +
. O +

BACKGROUND O +
: O +

Epstein O +
- O +
Barr O +
virus O +
( O +
EBV O +
) O +
infection O +
in O +
nonsmall O +
cell O +
lung O +
carcinoma O +
( O +
NSCLC O +
) O +
has O +
been O +
demonstrated O +
in O +
some O +
ethnic O +
groups O +
. O +

The O +
pathobiology O +
and O +
the O +
role O +
of O +
EBV O +
and O +
oncoprotein O +
expression O +
in O +
these O +
tumors O +
have O +
not O +
been O +
studied O +
extensively O +
. O +

In O +
this O +
study O +
, O +
the O +
authors O +
investigated O +
EBV O +
- O +
encoded O +
RNA O +
- O +
1 O +
( O +
EBER1 O +
) O +
transcripts O +
by O +
in O +
situ O +
hybridization O +
and O +
the O +
expression O +
of O +
latent O +
membrane O +
protein O +
- O +
1 O +
( O +
LMP O +
- O +
1 O +
) O +
and O +
bcl O +
- O +
2 O +
protein O +
by O +
immunohistochemistry O +
in O +
NSCLC O +
patients O +
from O +
Taiwan O +
, O +
where O +
nasopharyngeal O +
carcinoma O +
is O +
endemic O +
. O +

METHODS O +
: O +

A O +
total O +
of O +
127 O +
cases O +
of O +
NSCLC O +
( O +
43 O +
cases O +
of O +
squamous O +
cell O +
carcinoma O +
[ O +
SCC O +
] O +
, O +
67 O +
cases O +
of O +
adenocarcinoma O +
[ O +
AD O +
] O +
, O +
12 O +
cases O +
of O +
large O +
cell O +
carcinoma O +
[ O +
LCC O +
] O +
, O +
and O +
5 O +
cases O +
of O +
lymphoepithelioma O +
- O +
like O +
carcinoma O +
[ O +
LE O +
] O +
) O +
were O +
included O +
. O +

A O +
sensitive O +
polymerase O +
chain O +
reaction O +
- O +
derived O +
, O +
digoxigenin O +
- O +
labeled O +
DNA O +
probe O +
for O +
in O +
situ O +
detection O +
of O +
EBER1 O +
transcripts O +
was O +
performed O +
for O +
the O +
detection O +
of O +
EBV O +
. O +

Immunohistochemistry O +
using O +
the O +
avidin O +
- O +
biotin O +
- O +
immunoperoxidase O +
method O +
was O +
also O +
performed O +
to O +
evaluate O +
the O +
expression O +
of O +
bcl O +
- O +
2 O +
and O +
LMP O +
- O +
1 O +
. O +

RESULTS O +
: O +

EBER1 O +
was O +
detected O +
in O +
11 O +
of O +
the O +
127 O +
NSCLC O +
cases O +
( O +
8 O +
. O +
7 O +
% O +
; O +
6 O +
SCC O +
cases O +
and O +
5 O +
LE O +
cases O +
) O +
. O +

All O +
5 O +
LE O +
cases O +
were O +
EBV O +
- O +
positive O +
, O +
whereas O +
only O +
6 O +
of O +
the O +
43 O +
SCC O +
cases O +
( O +
14 O +
% O +
) O +
, O +
0 O +
of O +
67 O +
AD O +
cases O +
, O +
and O +
12 O +
LCC O +
cases O +
were O +
EBV O +
- O +
positive O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

All O +
five O +
LE O +
cases O +
showed O +
diffuse O +
, O +
strong O +
, O +
positive O +
staining O +
of O +
tumor O +
cells O +
; O +
five O +
of O +
the O +
six O +
SCC O +
cases O +
showed O +
diffuse O +
but O +
weak O +
staining O +
. O +

Among O +
the O +
nontumor O +
epithelial O +
cells O +
, O +
there O +
was O +
no O +
EBER1 O +
staining O +
of O +
any O +
of O +
the O +
11 O +
EBER1 O +
- O +
positive O +
cases O +
. O +

The O +
mean O +
age O +
of O +
the O +
LE O +
patients O +
was O +
10 O +
years O +
younger O +
than O +
that O +
of O +
the O +
patients O +
with O +
other O +
histological O +
types O +
. O +

All O +
5 O +
LE O +
patients O +
were O +
nonsmokers O +
, O +
whereas O +
3 O +
of O +
the O +
6 O +
patients O +
with O +
EBER1 O +
- O +
positive O +
SCC O +
( O +
50 O +
% O +
) O +
were O +
smokers O +
. O +

EBER1 O +
expression O +
did O +
not O +
correlate O +
with O +
the O +
2 O +
- O +
year O +
survival O +
rate O +
of O +
overall O +
cases O +
, O +
but O +
all O +
5 O +
LE O +
patients O +
were O +
alive O +
without O +
clinical O +
evidence O +
of O +
disease O +
at O +
last O +
follow O +
- O +
up O +
. O +

Gender O +
, O +
lymph O +
node O +
or O +
distant O +
metastasis O +
, O +
and O +
clinical O +
stage O +
were O +
not O +
found O +
to O +
have O +
any O +
correlation O +
with O +
EBER1 O +
expression O +
( O +
P O +
> O +
0 O +
. O +
05 O +
) O +
. O +

All O +
LE O +
cases O +
had O +
bcl O +
- O +
2 O +
oncoprotein O +
expression O +
( O +
100 O +
% O +
) O +
. O +

This O +
frequency O +
was O +
significantly O +
different O +
from O +
other O +
histologic O +
types O +
( O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

The O +
LMP O +
- O +
1 O +
detection O +
rate O +
was O +
low O +
and O +
demonstrated O +
no O +
correlation O +
with O +
bcl O +
- O +
2 O +
expression O +
. O +

CONCLUSIONS O +
: O +

In O +
this O +
study O +
, O +
the O +
authors O +
found O +
that O +
the O +
primary O +
LE O +
of O +
the O +
lung O +
is O +
associated O +
with O +
young O +
age O +
, O +
a O +
history O +
of O +
not O +
smoking O +
, O +
high O +
bcl O +
- O +
2 O +
immunoreactivity O +
, O +
and O +
better O +
survival O +
rate O +
. O +

These O +
characteristics O +
demonstrate O +
that O +
EBV O +
- O +
associated O +
LE O +
of O +
the O +
lung O +
is O +
a O +
unique O +
entity O +
. O +

The O +
findings O +
of O +
the O +
current O +
study O +
suggest O +
that O +
EBV O +
infection O +
may O +
play O +
a O +
different O +
role O +
in O +
the O +
tumorigenesis O +
of O +
primary O +
LE O +
of O +
the O +
lung O +
than O +
it O +
does O +
in O +
other O +
EBER1 O +
- O +
positive O +
NSCLCs O +
. O +

Prophylactic O +
thyroidectomy O +
in O +
MEN O +
IIA O +
: O +
does O +
the O +
calcitonin O +
level O +
correlate O +
with O +
tumor O +
spread O +
? O +

BACKGROUND O +
: O +
The O +
fate O +
of O +
patients O +
with O +
multiple O +
endocrine O +
neoplasia O +
of O +
type O +
II O +
A O +
( O +
MEN O +
II O +
A O +
) O +
is O +
determined O +
by O +
medullary O +
thyroid O +
carcinoma O +
, O +
which O +
occurs O +
in O +
all O +
cases O +
. O +

This O +
has O +
led O +
to O +
the O +
therapeutic O +
concept O +
of O +
prophylactic O +
thyroidectomy O +
in O +
affected O +
family O +
members O +
with O +
the O +
goal O +
of O +
removing O +
the O +
thyroid O +
before O +
the O +
manifestation O +
of O +
carcinoma O +
. O +

We O +
investigated O +
a O +
prophylactically O +
thyroidectomized O +
MEN O +
II O +
A O +
population O +
to O +
determine O +
whether O +
the O +
highly O +
specific O +
and O +
sensitive O +
tumor O +
marker O +
calcitonin O +
correlates O +
with O +
tumor O +
spread O +
. O +

PATIENTS O +
AND O +
METHODS O +
: O +
Fifteen O +
patients O +
with O +
MEN O +
II O +
A O +
( O +
aged O +
4 O +
- O +
24 O +
years O +
) O +
who O +
had O +
undergone O +
prophylactic O +
thyroidectomy O +
since O +
1990 O +
were O +
included O +
in O +
the O +
study O +
. O +

Baseline O +
and O +
pentagastrin O +
- O +
stimulated O +
calcitonin O +
levels O +
were O +
preoperatively O +
determined O +
in O +
all O +
cases O +
. O +

The O +
indication O +
for O +
surgery O +
was O +
established O +
on O +
the O +
basis O +
of O +
pathologic O +
calcitonin O +
levels O +
in O +
the O +
first O +
seven O +
patients O +
and O +
on O +
the O +
basis O +
of O +
detected O +
RET O +
proto O +
- O +
oncogene O +
mutation O +
in O +
the O +
other O +
eight O +
patients O +
. O +

Bilateral O +
central O +
lymphadenectomy O +
was O +
performed O +
in O +
all O +
patients O +
in O +
addition O +
to O +
thyroidectomy O +
. O +

RESULTS O +
: O +
Histology O +
demonstrated O +
C O +
- O +
cell O +
hyperplasia O +
in O +
five O +
patients O +
( O +
aged O +
4 O +
- O +
13 O +
years O +
) O +
, O +
unilateral O +
medullary O +
microcarcinoma O +
in O +
six O +
( O +
aged O +
9 O +
- O +
17 O +
years O +
) O +
and O +
a O +
bilateral O +
medullary O +
microcarcinoma O +
in O +
three O +
cases O +
( O +
aged O +
17 O +
- O +
24 O +
years O +
) O +
. O +

One O +
9 O +
- O +
year O +
- O +
old O +
boy O +
with O +
bilateral O +
microcarcinoma O +
already O +
had O +
a O +
lymph O +
node O +
metastasis O +
. O +

The O +
mean O +
baseline O +
calcitonin O +
level O +
correlated O +
with O +
the O +
histologic O +
findings O +
( O +
r O +
= O +
0 O +
. O +
71 O +
, O +
P O +
= O +
0 O +
. O +
003 O +
) O +
but O +
there O +
was O +
no O +
correlation O +
between O +
pentagastrin O +
- O +
stimulated O +
calcitonin O +
levels O +
and O +
histology O +
( O +
r O +
= O +
0 O +
. O +
21 O +
, O +
P O +
= O +
0 O +
. O +
47 O +
) O +
. O +

CONCLUSION O +
: O +
In O +
MEN O +
II O +
A O +
patients O +
undergoing O +
prophylactic O +
thyroidectomy O +
, O +
baseline O +
but O +
not O +
stimulated O +
calcitonin O +
levels O +
already O +
correlate O +
with O +
the O +
histologic O +
tumor O +
stage O +
at O +
the O +
stage O +
of O +
clinically O +
occult O +
C O +
- O +
cell O +
hyperplasia O +
or O +
medullary O +
microcarcinoma O +
. O +

However O +
, O +
biochemical O +
screening O +
can O -
not O +
reliably O +
discriminate O +
the O +
transition O +
from O +
C O +
- O +
cell O +
hyperplasia O +
to O +
invasive O +
microcarcinoma O +
. O +

Individuals O +
with O +
MEN O +
IIA O +
should O +
therefore O +
undergo O +
early O +
prophylactic O +
thyroidectomy O +
once O +
the O +
diagnosis O +
is O +
confirmed O +
by O +
molecular O +
genetic O +
testing O +
. O +

Induction O +
of O +
Ets O +
- O +
1 O +
in O +
endothelial O +
cells O +
during O +
reendothelialization O +
after O +
denuding O +
injury O +
. O +

Ets O +
- O +
1 O +
, O +
a O +
transcription O +
factor O +
, O +
is O +
induced O +
in O +
endothelial O +
cells O +
( O +
ECs O +
) O +
during O +
angiogenesis O +
. O +

Here O +
, O +
we O +
investigated O +
the O +
expression O +
of O +
Ets O +
- O +
1 O +
during O +
reendothelialization O +
. O +

When O +
a O +
confluent O +
monolayer O +
of O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
line O +
, O +
ECV304 B-CellLine +
, O +
was O +
denuded O +
, O +
ECV304 B-CellLine +
at O +
the O +
wound O +
edge O +
expressed O +
Ets O +
- O +
1 O +
. O +

An O +
immunohistochemical O +
analysis O +
revealed O +
that O +
Ets O +
- O +
1 O +
accumulated O +
in O +
migrating O +
cells O +
at O +
the O +
wound O +
edge O +
and O +
returned O +
to O +
basal O +
level O +
when O +
reendothelialization O +
was O +
accomplished O +
. O +

This O +
induction O +
of O +
Ets O +
- O +
1 O +
could O +
be O +
reproduced O +
in O +
in O +
vivo O +
denudation O +
of O +
rat O +
aortic O +
endothelium O +
by O +
a O +
balloon O +
catheter O +
. O +

The O +
induction O +
of O +
Ets O +
- O +
1 O +
in O +
ECs O +
after O +
denudation O +
was O +
regulated O +
transcriptionally O +
, O +
and O +
humeral O +
factors O +
released O +
from O +
injured O +
ECs O +
might O +
not O +
be O +
responsible O +
. O +

Mitogen O +
- O +
activated O +
protein O +
kinase O +
( O +
MAPK O +
) O +
activities O +
were O +
investigated O +
to O +
explore O +
the O +
mechanism O +
of O +
this O +
induction O +
. O +

Although O +
extracellular O +
signal O +
- O +
regulated O +
protein O +
kinase O +
1 O +
/ O +
2 O +
( O +
ERK1 O +
/ O +
2 O +
) O +
, O +
c O +
- O +
Jun O +
N O +
- O +
terminal O +
kinase O +
1 O +
( O +
JNK1 O +
) O +
, O +
and O +
p38 O +
were O +
activated O +
after O +
denudation O +
, O +
the O +
activation O +
of O +
ERK1 O +
and O +
p38 O +
was O +
more O +
rapid O +
and O +
prominent O +
. O +

PD98059 O +
, O +
a O +
specific O +
MAPK O +
/ O +
ERK O +
kinase O +
( O +
MEK O +
) O +
1 O +
inhibitor O +
, O +
did O +
not O +
affect O +
the O +
induction O +
of O +
ets O +
- O +
1 O +
mRNA O +
, O +
whereas O +
SB203580 O +
, O +
a O +
specific O +
p38 O +
inhibitor O +
, O +
almost O +
completely O +
abrogated O +
its O +
induction O +
. O +

These O +
results O +
indicate O +
that O +
Ets O +
- O +
1 O +
is O +
induced O +
in O +
ECs O +
after O +
denudation O +
through O +
activation O +
of O +
p38 O +
. O +

This O +
induction O +
of O +
Ets O +
- O +
1 O +
may O +
be O +
relevant O +
for O +
reendothelialization O +
by O +
regulating O +
the O +
expression O +
of O +
certain O +
genes O +
. O +

SV40 O +
Tag O +
transformation O +
of O +
the O +
normal O +
invasive O +
trophoblast O +
results O +
in O +
a O +
premalignant O +
phenotype O +
. O +

I O +
. O +

Mechanisms O +
responsible O +
for O +
hyperinvasiveness O +
and O +
resistance O +
to O +
anti O +
- O +
invasive O +
action O +
of O +
TGFbeta O +
. O +

Invasion O +
of O +
the O +
uterus O +
by O +
first O +
trimester O +
human O +
placental O +
extravillous O +
trophoblast O +
( O +
EVT O +
) O +
cells O +
depends O +
on O +
mechanisms O +
shared O +
by O +
malignant O +
cells O +
. O +

However O +
, O +
unlike O +
tumor O +
invasion O +
, O +
trophoblast O +
invasion O +
of O +
the O +
uterus O +
is O +
stringently O +
controlled O +
in O +
situ O +
by O +
local O +
molecules O +
such O +
as O +
transforming O +
growth O +
factor O +
( O +
TGF O +
) O +
beta O +
. O +

Since O +
EVT O +
cells O +
possess O +
active O +
invasion O +
- O +
associated O +
genes O +
but O +
are O +
nontumorigenic O +
, O +
our O +
objective O +
was O +
to O +
induce O +
premalignant O +
and O +
then O +
malignant O +
phenotype O +
into O +
a O +
normal O +
EVT B-CellLine +
cell O +
line O +
in O +
order O +
to O +
identify O +
the O +
molecular O +
basis O +
of O +
tumor O +
progression O +
. O +

Simian O +
virus O +
40 O +
large O +
T O +
antigen O +
( O +
SV40 O +
Tag O +
) O +
was O +
introduced O +
into O +
a O +
normal O +
human O +
first O +
trimester O +
invasive O +
EVT B-CellLine +
cell O +
line O +
, O +
HTR8 B-CellLine +
, O +
established O +
in O +
our O +
laboratory O +
. O +

Since O +
the O +
HTR8 B-CellLine +
line O +
has O +
a O +
limited O +
in O +
vitro O +
lifespan O +
of O +
12 O +
- O +
15 O +
passages O +
, O +
SV40 O +
Tag O +
- O +
transformed O +
cells O +
were O +
selected O +
on O +
the O +
basis O +
of O +
extended O +
lifespan O +
. O +

A O +
long O +
- O +
lived O +
line O +
, O +
RSVT B-CellLine +
- I-CellLine +
2 I-CellLine +
, O +
was O +
produced O +
and O +
an O +
immortalized O +
subclone O +
, O +
RSVT2 B-CellLine +
/ I-CellLine +
C I-CellLine +
, O +
was O +
further O +
derived O +
under O +
a O +
forced O +
crisis O +
regimen O +
. O +

We O +
examined O +
transformation O +
- O +
induced O +
alterations O +
in O +
proliferative O +
and O +
invasive O +
abilities O +
, O +
responses O +
to O +
the O +
invasion O +
and O +
proliferation O +
- O +
regulating O +
growth O +
factor O +
TGFbeta O +
and O +
changes O +
in O +
gene O +
expression O +
for O +
invasion O +
- O +
associated O +
enzymes O +
or O +
enzyme O +
inhibitors O +
. O +

RSVT B-CellLine +
- I-CellLine +
2 I-CellLine +
and O +
RSVT2 B-CellLine +
/ I-CellLine +
C I-CellLine +
cell O +
lines O +
were O +
hyperproliferative O +
and O +
hyperinvasive O +
when O +
compared O +
with O +
the O +
parental O +
HTR8 B-CellLine +
cell O +
line O +
. O +

They O +
were O +
also O +
variably O +
resistant O +
to O +
the O +
anti O +
- O +
proliferative O +
and O +
anti O +
- O +
invasive O +
signals O +
from O +
TGFbeta O +
. O +

Since O +
both O +
cell O +
lines O +
remained O +
non O +
- O +
tumorigenic O +
in O +
nude O +
mice O +
, O +
these O +
properties O +
indicate O +
that O +
they O +
attained O +
a O +
premalignant O +
phenotype O +
. O +

Both O +
cell O +
lines O +
showed O +
reduced O +
expression O +
of O +
tissue O +
inhibitor O +
of O +
metalloproteases O +
( O +
TIMP O +
) O +
- O +
1 O +
, O +
while O +
TIMP O +
- O +
2 O +
and O +
plasminogen O +
activator O +
inhibitor O +
( O +
PAI O +
) O +
- O +
I O +
expression O +
was O +
was O +
also O +
reduced O +
in O +
RSVT2 B-CellLine +
/ I-CellLine +
C I-CellLine +
cells O +
, O +
thus O +
contributing O +
to O +
their O +
hyperinvasiveness O +
. O +

Their O +
resistance O +
to O +
the O +
anti O +
- O +
invasive O +
action O +
of O +
TGFbeta O +
was O +
explained O +
by O +
the O +
failure O +
of O +
TGFbeta O +
to O +
upregulate O +
TIMPs O +
and O +
PAI O +
- O +
I O +
, O +
in O +
contrast O +
to O +
the O +
TGFbeta O +
- O +
induced O +
upregulation O +
noted O +
in O +
parental O +
HTR8 B-CellLine +
cells O +
. O +

Antisocial O +
patients O +
: O +
a O +
comparison O +
of O +
those O +
with O +
and O +
those O +
without O +
childhood O +
conduct O +
disorder O +
. O +

The O +
purpose O +
of O +
this O +
study O +
was O +
to O +
compare O +
persons O +
with O +
antisocial O +
personality O +
disorder O +
( O +
ASP O +
) O +
with O +
those O +
who O +
meet O +
the O +
adult O +
criteria O +
for O +
ASP O +
but O +
fail O +
to O +
meet O +
the O +
criteria O +
for O +
childhood O +
conduct O +
disorder O +
. O +

Sociodemographic O +
data O +
, O +
medical O +
history O +
, O +
and O +
psychiatric O +
symptoms O +
exhibited O +
during O +
a O +
recent O +
hospital O +
admission O +
were O +
compared O +
in O +
the O +
two O +
groups O +
by O +
chart O +
review O +
. O +

The O +
two O +
groups O +
were O +
virtually O +
indistinguishable O +
, O +
except O +
that O +
patients O +
without O +
childhood O +
conduct O +
disorder O +
were O +
less O +
likely O +
to O +
smoke O +
or O +
consume O +
alcohol O +
, O +
were O +
less O +
likely O +
to O +
have O +
spent O +
time O +
in O +
a O +
training O +
school O +
/ O +
boot O +
camp O +
as O +
a O +
child O +
or O +
adolescent O +
, O +
were O +
less O +
likely O +
to O +
have O +
been O +
admitted O +
for O +
a O +
recent O +
suicide O +
attempt O +
, O +
and O +
were O +
less O +
likely O +
to O +
have O +
conned O +
others O +
. O +

We O +
conclude O +
that O +
persons O +
meeting O +
the O +
adult O +
criteria O +
for O +
ASP O +
but O +
not O +
the O +
childhood O +
conduct O +
disorder O +
criteria O +
essentially O +
suffer O +
the O +
same O +
disorder O +
as O +
those O +
who O +
meet O +
full O +
ASP O +
criteria O +
but O +
are O +
less O +
severely O +
affected O +
. O +

Acylase O +
I O +
- O +
catalyzed O +
deacetylation O +
of O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
cysteine O +
and O +
S O +
- O +
alkyl O +
- O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
cysteines O +
. O +

The O +
aminoacylase O +
that O +
catalyzes O +
the O +
hydrolysis O +
of O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
cysteine O +
( O +
NAC O +
) O +
was O +
identified O +
as O +
acylase O +
I O +
after O +
purification O +
by O +
column O +
chromatography O +
and O +
electrophoretic O +
analysis O +
. O +

Rat O +
kidney O +
cytosol O +
was O +
fractionated O +
by O +
ammonium O +
sulfate O +
precipitation O +
, O +
and O +
the O +
proteins O +
were O +
separated O +
by O +
ion O +
- O +
exchange O +
column O +
chromatography O +
, O +
gel O +
- O +
filtration O +
column O +
chromatography O +
, O +
and O +
hydrophobic O +
interaction O +
column O +
chromatography O +
. O +

Acylase O +
activity O +
with O +
NAC O +
and O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
methionine O +
( O +
NAM O +
) O +
, O +
a O +
known O +
substrate O +
for O +
acylase O +
I O +
, O +
as O +
substrates O +
coeluted O +
during O +
all O +
chromatographic O +
steps O +
. O +

Sodium O +
dodecyl O +
sulfate O +
- O +
polyacrylamide O +
gel O +
electrophoresis O +
showed O +
that O +
the O +
protein O +
was O +
purified O +
to O +
near O +
homogeneity O +
and O +
had O +
a O +
subunit O +
Mr O +
of O +
43 O +
000 O +
, O +
which O +
is O +
identical O +
with O +
the O +
Mr O +
of O +
acylase O +
I O +
from O +
porcine O +
kidney O +
and O +
bovine O +
liver O +
. O +

n O +
- O +
Butylmalonic O +
acid O +
was O +
a O +
slow O +
- O +
binding O +
inhibitor O +
of O +
acylase O +
I O +
and O +
inhibited O +
the O +
deacetylation O +
of O +
NAC O +
with O +
a O +
Ki O +
of O +
192 O +
+ O +
/ O +
- O +
27 O +
microM O +
. O +

These O +
results O +
show O +
that O +
acylase O +
I O +
catalyzes O +
the O +
deacetylation O +
of O +
NAC O +
. O +

The O +
acylase O +
I O +
- O +
catalyzed O +
deacetylation O +
of O +
a O +
range O +
of O +
S O +
- O +
alkyl O +
- O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
cysteines O +
, O +
their O +
carbon O +
and O +
oxygen O +
analogues O +
, O +
and O +
the O +
selenium O +
analogue O +
of O +
NAM O +
was O +
also O +
studied O +
with O +
porcine O +
kidney O +
acylase O +
I O +
. O +

The O +
specific O +
activity O +
of O +
the O +
acylase O +
I O +
- O +
catalyzed O +
deacetylation O +
of O +
these O +
substrates O +
was O +
related O +
to O +
their O +
calculated O +
molar O +
volumes O +
and O +
log O +
P O +
values O +
. O +

The O +
S O +
- O +
alkyl O +
- O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
cysteines O +
with O +
short O +
( O +
C0 O +
- O +
C3 O +
) O +
and O +
unbranched O +
S O +
- O +
alkyl O +
substituents O +
were O +
good O +
acylase O +
I O +
substrates O +
, O +
whereas O +
the O +
S O +
- O +
alkyl O +
- O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
cysteines O +
with O +
long O +
( O +
> O +
C3 O +
) O +
and O +
branched O +
S O +
- O +
alkyl O +
substituents O +
were O +
poLr O +
acylase O +
I O +
substrates O +
. O +

The O +
carbon O +
and O +
oxygen O +
analogues O +
of O +
S O +
- O +
methyl O +
- O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
cysteine O +
and O +
the O +
carbon O +
analogue O +
of O +
S O +
- O +
ethyl O +
- O +
N O +
- O +
acetyl O +
- O +
L O +
- O +
cysteine O +
were O +
poor O +
acylase O +
I O +
substrates O +
, O +
whereas O +
the O +
selenium O +
analogue O +
of O +
NAM O +
was O +
a O +
good O +
acylase O +
I O +
substrate O +
. O +

Expression O +
of O +
two O +
type O +
II O +
- O +
like O +
tumor O +
hexokinase O +
RNA O +
transcripts O +
in O +
cancer O +
cell O +
lines O +
. O +

To O +
maintain O +
an O +
elevated O +
glycolytic O +
rate O +
, O +
cancerous O +
or O +
proliferating O +
cells O +
alter O +
the O +
expression O +
pattern O +
of O +
rate O +
limiting O +
glycolytic O +
enzymes O +
. O +

Since O +
glucose O +
phosphorylation O +
is O +
the O +
first O +
step O +
in O +
glycolysis O +
, O +
hexokinase O +
( O +
HK O +
) O +
, O +
the O +
first O +
rate O +
limiting O +
glycolytic O +
enzyme O +
, O +
can O +
play O +
a O +
key O +
regulatory O +
role O +
in O +
this O +
process O +
. O +

A O +
low O +
- O +
Km O +
, O +
mitochondrial O +
type O +
II O +
- O +
like O +
tumor O +
HK O +
is O +
described O +
as O +
the O +
predominant O +
form O +
in O +
hepatomas O +
. O +

However O +
, O +
recent O +
identification O +
of O +
a O +
high O +
- O +
Km O +
glucose O +
phosphorylating O +
activity O +
in O +
a O +
range O +
of O +
cancer O +
cells O +
prompted O +
us O +
to O +
characterize O +
glucose O +
phosphorylating O +
enzymes O +
of O +
cancer O +
cells O +
at O +
the O +
molecular O +
level O +
. O +

Highly O +
sensitive O +
reverse O +
- O +
transcription O +
polymerase O +
chain O +
reaction O +
identifies O +
an O +
induction O +
and O +
overexpression O +
of O +
a O +
type O +
II O +
- O +
like O +
tumor O +
HK O +
RNA O +
in O +
a O +
range O +
of O +
cancer O +
cell O +
lines O +
irrespective O +
of O +
tissue O +
origin O +
. O +

In O +
addition O +
, O +
we O +
report O +
here O +
the O +
identification O +
of O +
two O +
RNA O +
transcripts O +
of O +
type O +
II O +
- O +
like O +
tumor O +
HK O +
of O +
approximately O +
5 O +
. O +
5 O +
and O +
approximately O +
4 O +
. O +
0 O +
kb O +
in O +
these O +
cancer O +
cells O +
lines O +
, O +
including O +
muscle O +
- O +
derived O +
L6 B-CellLine +
myoblast O +
cells O +
. O +

Interestingly O +
, O +
under O +
normal O +
conditions O +
muscle O +
cells O +
express O +
only O +
a O +
approximately O +
5 O +
. O +
5 O +
- O +
kb O +
type O +
II O +
HK O +
RNA O +
transcript O +
. O +

A O +
significant O +
amount O +
of O +
type O +
I O +
HK O +
RNA O +
was O +
also O +
found O +
expressed O +
in O +
cancer O +
cell O +
lines O +
. O +

RNA O +
encoding O +
glucokinase O +
( O +
GK O +
) O +
, O +
the O +
high O +
- O +
Km O +
HK O +
isozyme O +
, O +
was O +
found O +
only O +
in O +
cancer O +
cells O +
originating O +
from O +
liver O +
and O +
pancreas O +
, O +
which O +
express O +
GK O +
under O +
normal O +
conditions O +
. O +

Homeobox O +
genes O +
in O +
hematopoiesis O +
and O +
leukemogenesis O +
. O +

Homeobox O +
genes O +
have O +
a O +
strikingly O +
conserved O +
61 O +
- O +
amino O +
acid O +
sequence O +
, O +
encoding O +
DNA O +
- O +
binding O +
domain O +
. O +

Some O +
homeobox O +
genes O +
, O +
located O +
in O +
four O +
clusters O +
are O +
designated O +
HOX O +
A O +
through O +
D O +
, O +
while O +
others O +
are O +
known O +
as O +
divergent O +
homeobox O +
genes O +
. O +

Many O +
researchers O +
have O +
demonstrated O +
that O +
hematopoietic O +
cells O +
express O +
many O +
homeobox O +
genes O +
. O +

Induced O +
over O +
- O +
and O +
under O +
- O +
expression O +
of O +
these O +
genes O +
has O +
been O +
used O +
to O +
demonstrate O +
their O +
affect O +
on O +
some O +
aspects O +
of O +
hematopoiesis O +
and O +
leukemogenesis O +
. O +

Recently O +
, O +
knock O +
- O +
out O +
mice O +
of O +
homeobox O +
genes O +
by O +
targeted O +
disruption O +
have O +
also O +
been O +
used O +
to O +
examine O +
their O +
hematological O +
effect O +
. O +

There O +
are O +
examples O +
of O +
the O +
aberrant O +
expression O +
of O +
a O +
homeobox O +
gene O +
causing O +
leukemias O +
in O +
humans O +
. O +

In O +
pre O +
- O +
B O +
acute O +
lymphoblastic O +
leukemia O +
( O +
ALL O +
) O +
with O +
t O +
( O +
1 O +
; O +
19 O +
) O +
translocation O +
, O +
a O +
fusion O +
protein O +
is O +
created O +
between O +
E2A O +
and O +
a O +
homeobox O +
gene O +
PBX O +
. O +

In O +
T O +
- O +
cell O +
ALL O +
with O +
t O +
( O +
10 O +
; O +
14 O +
) O +
translocation O +
, O +
the O +
HOX O +
11 O +
gene O +
is O +
deregulated O +
. O +

In O +
acute O +
myeloid O +
leukemia O +
( O +
AML O +
) O +
with O +
t O +
( O +
7 O +
; O +
11 O +
) O +
translocation O +
, O +
the O +
HOX O +
A9 O +
gene O +
is O +
rearranged O +
. O +

In O +
this O +
review O +
article O +
, O +
many O +
functions O +
of O +
homeobox O +
genes O +
both O +
at O +
the O +
early O +
stem O +
cell O +
level O +
as O +
well O +
as O +
at O +
the O +
later O +
stages O +
of O +
hematopoietic O +
differentiation O +
, O +
and O +
the O +
leukemogenic O +
effect O +
of O +
altered O +
homeobox O +
genes O +
are O +
discussed O +
. O +

The O +
myoadipose O +
flap O +
: O +
a O +
new O +
composite O +
. O +

A O +
prefabricated O +
composite O +
fat O +
flap O +
consisting O +
of O +
muscle O +
woven O +
into O +
an O +
anatomically O +
distinct O +
fat O +
pad O +
was O +
studied O +
in O +
a O +
rabbit O +
model O +
. O +

In O +
17 O +
rabbits O +
, O +
a O +
2 O +
- O +
cm O +
strip O +
of O +
latissimus O +
dorsi O +
was O +
woven O +
into O +
the O +
parascapular O +
fat O +
pad O +
on O +
one O +
side O +
, O +
with O +
the O +
contralateral O +
fat O +
pad O +
serving O +
as O +
a O +
control O +
. O +

At O +
3 O +
weeks O +
, O +
the O +
endogenous O +
blood O +
supply O +
of O +
both O +
the O +
control O +
and O +
the O +
experimental O +
fat O +
pads O +
was O +
isolated O +
and O +
ligated O +
, O +
and O +
the O +
composite O +
fat O +
/ O +
muscle O +
flap O +
was O +
transferred O +
to O +
the O +
chest O +
wall O +
. O +

At O +
6 O +
weeks O +
, O +
animals O +
were O +
killed O +
, O +
and O +
flaps O +
were O +
analyzed O +
for O +
length O +
, O +
width O +
, O +
and O +
weight O +
; O +
perfused O +
with O +
fluorescein O +
or O +
lead O +
oxide O +
; O +
and O +
examined O +
histologically O +
. O +

Significant O +
differences O +
were O +
found O +
between O +
the O +
control O +
and O +
experimental O +
fat O +
pads O +
with O +
regard O +
to O +
weight O +
and O +
length O +
. O +

Experimental O +
flaps O +
were O +
found O +
to O +
be O +
perfused O +
fully O +
with O +
fluorescein O +
and O +
lead O +
oxide O +
; O +
control O +
fat O +
pads O +
were O +
found O +
not O +
to O +
be O +
perfused O +
. O +

The O +
lead O +
oxide O +
group O +
revealed O +
extensive O +
growth O +
of O +
blood O +
vessels O +
from O +
the O +
latissimus O +
graft O +
into O +
the O +
experimental O +
fat O +
pad O +
. O +

No O +
vessels O +
were O +
visualized O +
in O +
the O +
controls O +
. O +

Finally O +
, O +
sections O +
of O +
the O +
control O +
and O +
experimental O +
flaps O +
were O +
analyzed O +
histologically O +
. O +

A O +
preponderance O +
of O +
viable O +
fat O +
, O +
with O +
evidence O +
of O +
neovascularization O +
, O +
was O +
found O +
in O +
experimental O +
flaps O +
, O +
compared O +
with O +
the O +
necrotic O +
fat O +
that O +
characterized O +
the O +
controls O +
. O +

We O +
conclude O +
that O +
prefabrication O +
of O +
a O +
fat O +
flap O +
is O +
possible O +
and O +
may O +
have O +
extensive O +
application O +
in O +
various O +
areas O +
of O +
plastic O +
surgery O +
. O +

Store O +
- O +
operated O +
calcium O +
entry O +
promotes O +
shape O +
change O +
in O +
pulmonary O +
endothelial O +
cells O +
expressing O +
Trp1 O +
. O +

Activation O +
of O +
Ca2 O +
+ O +
entry O +
is O +
known O +
to O +
produce O +
endothelial O +
cell O +
shape O +
change O +
, O +
leading O +
to O +
increased O +
permeability O +
, O +
leukocyte O +
migration O +
, O +
and O +
initiation O +
of O +
angiogenesis O +
in O +
conduit O +
- O +
vessel O +
endothelial O +
cells O +
. O +

The O +
mode O +
of O +
Ca2 O +
+ O +
entry O +
regulating O +
cell O +
shape O +
is O +
unknown O +
. O +

We O +
hypothesized O +
that O +
activation O +
of O +
store O +
- O +
operated O +
Ca2 O +
+ O +
channels O +
( O +
SOCs O +
) O +
is O +
sufficient O +
to O +
promote O +
cell O +
shape O +
change O +
necessary O +
for O +
these O +
processes O +
. O +

SOC O +
activation O +
in O +
rat O +
pulmonary O +
arterial O +
endothelial O +
cells O +
increased O +
free O +
cytosolic O +
Ca2 O +
+ O +
that O +
was O +
dependent O +
on O +
a O +
membrane O +
current O +
having O +
a O +
net O +
inward O +
component O +
of O +
5 O +
. O +
45 O +
+ O +
/ O +
- O +
0 O +
. O +
90 O +
pA O +
/ O +
pF O +
at O +
- O +
80 O +
mV O +
. O +

Changes O +
in O +
endothelial O +
cell O +
shape O +
accompanied O +
SOC O +
activation O +
and O +
were O +
dependent O +
on O +
Ca2 O +
+ O +
entry O +
- O +
induced O +
reconfiguration O +
of O +
peripheral O +
( O +
cortical O +
) O +
filamentous O +
actin O +
( O +
F O +
- O +
actin O +
) O +
. O +

Because O +
the O +
identity O +
of O +
pulmonary O +
endothelial O +
SOCs O +
is O +
unknown O +
, O +
but O +
mammalian O +
homologues O +
of O +
the O +
Drosophila O +
melanogaster O +
transient O +
receptor O +
potential O +
( O +
trp O +
) O +
gene O +
have O +
been O +
proposed O +
to O +
form O +
Ca2 O +
+ O +
entry O +
channels O +
in O +
nonexcitable O +
cells O +
, O +
we O +
performed O +
RT O +
- O +
PCR O +
using O +
Trp O +
oligonucleotide O +
primers O +
in O +
both O +
rat O +
and O +
human O +
pulmonary O +
arterial O +
endothelial O +
cells O +
. O +

Both O +
cell O +
types O +
were O +
found O +
to O +
express O +
Trp1 O +
, O +
but O +
neither O +
expressed O +
Trp3 O +
nor O +
Trp6 O +
. O +

Our O +
study O +
indicates O +
that O +
1 O +
) O +
Ca2 O +
+ O +
entry O +
in O +
pulmonary O +
endothelial O +
cells O +
through O +
SOCs O +
produces O +
cell O +
shape O +
change O +
that O +
is O +
dependent O +
on O +
site O +
- O +
specific O +
rearrangement O +
of O +
the O +
microfilamentous O +
cytoskeleton O +
and O +
2 O +
) O +
Trp1 O +
may O +
be O +
a O +
component O +
of O +
pulmonary O +
endothelial O +
SOCs O +
. O +

Brainstem O +
auditory O +
- O +
evoked O +
potential O +
evaluation O +
in O +
children O +
with O +
meningitis O +
. O +

Brainstem O +
auditory O +
- O +
evoked O +
potential O +
( O +
BAEP O +
) O +
was O +
performed O +
on O +
101 O +
children O +
with O +
meningitis O +
to O +
assess O +
the O +
incidence O +
of O +
hearing O +
impairment O +
. O +

Fifty O +
- O +
two O +
( O +
51 O +
. O +
5 O +
% O +
) O +
children O +
had O +
bacterial O +
meningitis O +
, O +
six O +
( O +
5 O +
. O +
9 O +
% O +
) O +
had O +
viral O +
meningitis O +
, O +
and O +
43 O +
( O +
42 O +
. O +
6 O +
% O +
) O +
had O +
aseptic O +
meningitis O +
. O +

Fifty O +
- O +
one O +
( O +
50 O +
. O +
5 O +
% O +
) O +
patients O +
were O +
assessed O +
before O +
discharge O +
and O +
50 O +
( O +
49 O +
. O +
5 O +
% O +
) O +
9 O +
days O +
to O +
17 O +
months O +
later O +
( O +
mean O +
= O +
4 O +
months O +
) O +
. O +

BAEP O +
impairment O +
was O +
found O +
in O +
28 O +
( O +
27 O +
. O +
7 O +
% O +
) O +
of O +
101 O +
patients O +
; O +
24 O +
had O +
sensorineural O +
and O +
four O +
had O +
conductive O +
type O +
of O +
hearing O +
loss O +
, O +
and O +
17 O +
( O +
60 O +
. O +
7 O +
% O +
) O +
had O +
unilateral O +
and O +
11 O +
( O +
39 O +
. O +
3 O +
% O +
) O +
had O +
bilateral O +
impairment O +
. O +

Hearing O +
threshold O +
was O +
elevated O +
in O +
22 O +
( O +
21 O +
. O +
8 O +
% O +
) O +
patients O +
, O +
and O +
the O +
other O +
six O +
had O +
increased O +
latency O +
and O +
interpeak O +
latencies O +
with O +
normal O +
threshold O +
. O +

Frequency O +
of O +
BAEP O +
impairment O +
or O +
hearing O +
loss O +
associated O +
with O +
bacterial O +
meningitis O +
was O +
34 O +
. O +
6 O +
% O +
and O +
30 O +
. O +
8 O +
% O +
, O +
respectively O +
; O +
frequency O +
associated O +
with O +
aseptic O +
meningitis O +
was O +
20 O +
. O +
9 O +
% O +
and O +
13 O +
. O +
9 O +
% O +
, O +
respectively O +
. O +

One O +
child O +
with O +
viral O +
meningitis O +
( O +
coxsackie O +
virus O +
) O +
had O +
mild O +
BAEP O +
impairment O +
. O +

Most O +
of O +
the O +
BAEP O +
impairment O +
in O +
the O +
bacterial O +
meningitis O +
group O +
was O +
associated O +
with O +
H O +
. O +
influenzae O +
. O +

Prospective O +
BAEP O +
study O +
was O +
performed O +
in O +
20 O +
patients O +
randomly O +
at O +
0 O +
. O +
3 O +
to O +
18 O +
months O +
to O +
assess O +
hearing O +
status O +
after O +
antibiotic O +
treatment O +
, O +
10 O +
with O +
normal O +
and O +
10 O +
with O +
abnormal O +
BAEP O +
. O +

All O +
the O +
initially O +
normal O +
BAEP O +
patients O +
remained O +
normal O +
. O +

Of O +
the O +
10 O +
patients O +
with O +
abnormal O +
BAEP O +
results O +
initially O +
, O +
four O +
returned O +
to O +
normal O +
, O +
two O +
improved O +
, O +
three O +
remained O +
unchanged O +
, O +
and O +
one O +
deteriorated O +
. O +

The O +
incidence O +
of O +
hearing O +
loss O +
after O +
bacterial O +
and O +
aseptic O +
meningitis O +
is O +
high O +
. O +

BAEP O +
is O +
useful O +
to O +
screen O +
for O +
possible O +
hearing O +
loss O +
in O +
children O +
with O +
meningitis O +
, O +
and O +
follow O +
- O +
up O +
BAEP O +
is O +
necessary O +
for O +
those O +
patients O +
with O +
initially O +
abnormal O +
BAEP O +
. O +

Hemispheric O +
control O +
of O +
motor O +
function O +
: O +
a O +
whole O +
brain O +
echo O +
planar O +
fMRI O +
study O +
. O +

The O +
aim O +
of O +
this O +
study O +
was O +
to O +
explore O +
whether O +
recruitment O +
of O +
the O +
ipsilateral O +
motor O +
cortex O +
during O +
non O +
- O +
dominant O +
motor O +
movement O +
reflects O +
left O +
hemispheric O +
control O +
of O +
motor O +
function O +
or O +
simply O +
the O +
greater O +
complexity O +
or O +
unfamiliarity O +
of O +
the O +
motor O +
task O +
. O +

BOLD O +
fMRI O +
was O +
performed O +
in O +
normal O +
right O +
- O +
handers O +
during O +
two O +
motor O +
tasks O +
: O +
( O +
1 O +
) O +
sequential O +
finger O +
movements O +
( O +
SM O +
task O +
) O +
with O +
the O +
right O +
or O +
left O +
hand O +
; O +
and O +
( O +
2 O +
) O +
random O +
finger O +
movements O +
( O +
RM O +
task O +
) O +
with O +
the O +
right O +
hand O +
. O +

In O +
all O +
subjects O +
, O +
activation O +
was O +
predominantly O +
in O +
the O +
contralateral O +
motor O +
areas O +
( O +
primary O +
sensorimotor O +
, O +
lateral O +
premotor O +
, O +
parietal O +
and O +
supplementary O +
motor O +
regions O +
) O +
and O +
ipsilateral O +
cerebellum O +
. O +

While O +
the O +
ipsilateral O +
motor O +
areas O +
were O +
also O +
activated O +
, O +
single O +
subject O +
analysis O +
revealed O +
these O +
areas O +
to O +
be O +
more O +
extensive O +
and O +
to O +
be O +
seen O +
in O +
more O +
subjects O +
during O +
the O +
non O +
- O +
dominant O +
hand O +
SM O +
task O +
and O +
dominant O +
hand O +
RM O +
task O +
than O +
during O +
the O +
more O +
familiar O +
dominant O +
hand O +
SM O +
task O +
. O +

Similarly O +
, O +
group O +
analysis O +
also O +
revealed O +
ipsilateral O +
activation O +
in O +
the O +
primary O +
sensorimotor O +
and O +
lateral O +
premotor O +
areas O +
, O +
but O +
only O +
during O +
the O +
non O +
- O +
dominant O +
SM O +
task O +
and O +
the O +
dominant O +
hand O +
RM O +
task O +
. O +

Non O +
- O +
dominant O +
hand O +
movements O +
, O +
perhaps O +
because O +
they O +
are O +
less O +
' O +
automatic O +
' O +
, O +
appear O +
to O +
require O +
more O +
cortical O +
activity O +
similar O +
to O +
complex O +
tasks O +
with O +
the O +
dominant O +
hand O +
, O +
and O +
result O +
in O +
greater O +
recruitment O +
of O +
ipsilateral O +
cortical O +
motor O +
areas O +
and O +
striatum O +
. O +

The O +
study O +
also O +
illustrates O +
how O +
potentially O +
meaningful O +
subtleties O +
seen O +
on O +
individual O +
maps O +
may O +
be O +
obscured O +
with O +
group O +
averaging O +
approaches O +
. O +

[ O +
The O +
assessment O +
of O +
flow O +
velocity O +
in O +
carotid O +
and O +
intracranial O +
arteries O +
in O +
three O +
different O +
age O +
groups O +
] O +
. O +

In O +
this O +
report O +
we O +
assess O +
the O +
systolic O +
maximal O +
flow O +
velocity O +
in O +
carotid O +
and O +
intracranial O +
arteries O +
in O +
191 O +
subjects O +
with O +
no O +
history O +
of O +
cerebral O +
vascular O +
disease O +
in O +
3 O +
age O +
groups O +
: O +
20 O +
- O +
40 O +
years O +
( O +
1 O +
group O +
) O +
, O +
41 O +
- O +
60 O +
years O +
( O +
2 O +
group O +
) O +
, O +
and O +
above O +
60 O +
years O +
( O +
3 O +
group O +
) O +
. O +

The O +
subjects O +
were O +
assessed O +
using O +
Sonomed O +
Transcranial O +
Doppler O +
Spectrograph O +
according O +
to O +
generally O +
accepted O +
principles O +
. O +

The O +
purpose O +
of O +
the O +
study O +
was O +
to O +
establish O +
the O +
mean O +
value O +
of O +
maximal O +
flow O +
velocity O +
in O +
each O +
particular O +
artery O +
in O +
three O +
age O +
groups O +
, O +
and O +
to O +
observe O +
the O +
changes O +
in O +
this O +
parameter O +
with O +
age O +
. O +

The O +
results O +
were O +
analyzed O +
using O +
statistical O +
methods O +
and O +
a O +
significant O +
decrease O +
in O +
blood O +
flow O +
, O +
Vmax O +
, O +
was O +
found O +
in O +
all O +
investigated O +
arteries O +
. O +

A O +
mean O +
decrease O +
of O +
8 O +
. O +
02 O +
% O +
in O +
flow O +
velocity O +
Vmax O +
was O +
found O +
, O +
when O +
comparing O +
groups O +
2 O +
and O +
1 O +
, O +
and O +
difference O +
15 O +
. O +
99 O +
% O +
comparing O +
3 O +
and O +
1 O +
. O +

Lack O +
of O +
developmental O +
and O +
reproductive O +
toxicity O +
of O +
2 O +
, O +
3 O +
, O +
3 O +
' O +
, O +
4 O +
, O +
4 O +
' O +
- O +
pentachlorobiphenyl O +
( O +
PCB O +
105 O +
) O +
in O +
ring O +
- O +
necked O +
pheasants O +
. O +

Mono O +
- O +
ortho O +
PCBs O +
are O +
global O +
contaminants O +
of O +
wildlife O +
with O +
the O +
potential O +
to O +
produce O +
toxicity O +
by O +
an O +
aryl O +
hydrocarbon O +
receptor O +
( O +
AhR O +
) O +
- O +
mediated O +
mechanism O +
. O +

To O +
determine O +
the O +
potency O +
of O +
2 O +
, O +
3 O +
, O +
3 O +
' O +
, O +
4 O +
, O +
4 O +
' O +
- O +
pentachlorobiphenyl O +
( O +
PCB O +
105 O +
) O +
for O +
producing O +
reproductive O +
and O +
developmental O +
toxicity O +
, O +
adult O +
ring O +
- O +
necked O +
pheasant O +
hens O +
( O +
Phasianus O +
colchicus O +
) O +
were O +
orally O +
dosed O +
with O +
0 O +
, O +
0 O +
. O +
06 O +
, O +
0 O +
. O +
6 O +
, O +
or O +
6 O +
mg O +
PCB O +
105 O +
/ O +
kg O +
hen O +
/ O +
week O +
for O +
10 O +
weeks O +
to O +
achieve O +
cumulative O +
doses O +
of O +
0 O +
, O +
0 O +
. O +
6 O +
, O +
6 O +
, O +
or O +
60 O +
mg O +
PCB O +
105 O +
/ O +
kg O +
hen O +
after O +
which O +
hens O +
were O +
bred O +
with O +
untreated O +
roosters O +
once O +
per O +
week O +
for O +
8 O +
weeks O +
. O +

Except O +
at O +
week O +
6 O +
of O +
the O +
egg O +
- O +
laying O +
period O +
when O +
cumulative O +
egg O +
production O +
in O +
the O +
6 O +
mg O +
PCB O +
105 O +
/ O +
kg O +
hen O +
group O +
was O +
greater O +
than O +
controls O +
, O +
fertilized O +
egg O +
production O +
was O +
not O +
significantly O +
different O +
between O +
treatment O +
groups O +
. O +

Embryo O +
mortality O +
and O +
chick O +
mortality O +
were O +
not O +
significantly O +
different O +
between O +
treatment O +
groups O +
. O +

Total O +
body O +
and O +
heart O +
weights O +
of O +
all O +
chicks O +
1 O +
day O +
posthatch O +
( O +
dph O +
) O +
were O +
not O +
different O +
between O +
groups O +
, O +
however O +
, O +
liver O +
weights O +
of O +
chicks O +
from O +
the O +
60 O +
mg O +
/ O +
kg O +
treatment O +
group O +
were O +
greater O +
than O +
controls O +
at O +
1 O +
dph O +
. O +

The O +
first O +
chick O +
to O +
hatch O +
from O +
each O +
hen O +
was O +
reared O +
to O +
21 O +
dph O +
and O +
among O +
these O +
birds O +
, O +
the O +
total O +
body O +
, O +
liver O +
, O +
and O +
heart O +
weights O +
were O +
not O +
different O +
between O +
groups O +
. O +

There O +
were O +
no O +
dose O +
- O +
related O +
malformations O +
of O +
the O +
beak O +
or O +
limbs O +
, O +
and O +
no O +
signs O +
of O +
subcutaneous O +
edema O +
, O +
ascites O +
, O +
or O +
pericardial O +
edema O +
in O +
chicks O +
at O +
1 O +
or O +
21 O +
dph O +
. O +

Hepatic O +
microsomal O +
monooxygenase O +
activities O +
[ O +
ethoxyresorufin O +
- O +
O O +
- O +
dealkylase O +
( O +
EROD O +
) O +
, O +
benzyloxyresorufin O +
- O +
O O +
- O +
dealkylase O +
( O +
BROD O +
) O +
, O +
and O +
methyloxyresorufin O +
- O +
O O +
- O +
dealkylase O +
( O +
MROD O +
) O +
] O +
were O +
significantly O +
elevated O +
in O +
chicks O +
at O +
1 O +
dph O +
from O +
hens O +
given O +
a O +
cumulative O +
PCB O +
105 O +
dose O +
of O +
6 O +
mg O +
/ O +
kg O +
and O +
in O +
chicks O +
at O +
21 O +
dph O +
from O +
hens O +
given O +
a O +
cumulative O +
PCB O +
dose O +
of O +
60 O +
mg O +
/ O +
kg O +
. O +

These O +
results O +
indicate O +
that O +
a O +
cumulative O +
PCB O +
105 O +
dose O +
up O +
to O +
60 O +
mg O +
/ O +
kg O +
hen O +
does O +
not O +
decrease O +
the O +
production O +
of O +
fertilized O +
eggs O +
or O +
increase O +
embryo O +
or O +
chick O +
mortality O +
in O +
ring O +
- O +
necked O +
pheasants O +
, O +
but O +
does O +
increase O +
chick O +
hepatic O +
monooxygenase O +
activity O +
. O +

Glucose O +
and O +
lactate O +
metabolism O +
in O +
C6 B-CellLine +
glioma O +
cells O +
: O +
evidence O +
for O +
the O +
preferential O +
utilization O +
of O +
lactate O +
for O +
cell O +
oxidative O +
metabolism O +
. O +

13C O +
and O +
1H O +
nuclear O +
magnetic O +
resonance O +
spectroscopy O +
( O +
NMR O +
) O +
was O +
used O +
to O +
investigate O +
the O +
metabolism O +
of O +
L O +
- O +
lactate O +
and O +
D O +
- O +
glucose O +
in O +
C6 B-CellLine +
glioma O +
cells O +
. O +

The O +
13C O +
enrichment O +
of O +
cell O +
metabolites O +
was O +
examined O +
after O +
a O +
4 O +
- O +
h O +
incubation O +
in O +
media O +
containing O +
5 O +
. O +
5 O +
mM O +
glucose O +
and O +
11 O +
mM O +
lactate O +
, O +
each O +
metabolite O +
being O +
alternatively O +
labelled O +
with O +
either O +
[ O +
1 O +
- O +
13C O +
] O +
D O +
- O +
glucose O +
or O +
[ O +
3 O +
- O +
13C O +
] O +
L O +
- O +
lactate O +
. O +

The O +
results O +
indicated O +
that O +
exogenous O +
lactate O +
was O +
the O +
major O +
substrate O +
for O +
oxidative O +
metabolism O +
. O +

They O +
were O +
consistent O +
with O +
the O +
concept O +
of O +
the O +
existence O +
of O +
2 O +
pools O +
of O +
both O +
lactate O +
and O +
pyruvate O +
, O +
of O +
which O +
1 O +
pool O +
was O +
closely O +
connected O +
with O +
exogenous O +
lactate O +
and O +
oxidative O +
metabolism O +
, O +
and O +
the O +
other O +
pool O +
was O +
closely O +
related O +
to O +
glycolysis O +
and O +
disconnected O +
from O +
oxidative O +
metabolism O +
. O +

The O +
molecular O +
basis O +
of O +
this O +
behaviour O +
could O +
be O +
related O +
to O +
different O +
locations O +
for O +
the O +
lactate O +
dehydrogenase O +
isoenzymes O +
, O +
as O +
suggested O +
by O +
their O +
immunohistochemical O +
labelling O +
. O +

Detection O +
of O +
total O +
assist O +
and O +
sucking O +
points O +
based O +
on O +
the O +
pulsatility O +
of O +
a O +
continuous O +
flow O +
artificial O +
heart O +
: O +
in O +
vivo O +
evaluation O +
. O +

Our O +
novel O +
control O +
strategy O +
for O +
a O +
continuous O +
flow O +
artificial O +
heart O +
by O +
detecting O +
the O +
total O +
assist O +
and O +
sucking O +
points O +
based O +
on O +
pump O +
pulsatility O +
was O +
evaluated O +
in O +
acute O +
animal O +
experiments O +
using O +
beagle O +
dogs O +
and O +
our O +
mixed O +
flow O +
pump O +
. O +

The O +
pump O +
was O +
installed O +
as O +
a O +
left O +
ventricular O +
( O +
LV O +
) O +
bypass O +
through O +
a O +
left O +
thoracotomy O +
. O +

To O +
change O +
LV O +
contractility O +
, O +
the O +
left O +
coronary O +
arteries O +
were O +
occluded O +
for O +
30 O +
min O +
, O +
followed O +
by O +
a O +
120 O +
min O +
reperfusion O +
. O +

To O +
change O +
LV O +
end O +
diastolic O +
pressure O +
( O +
LVEDP O +
) O +
, O +
dextran O +
solution O +
was O +
rapidly O +
infused O +
. O +

To O +
estimate O +
the O +
pump O +
pulsatility O +
without O +
any O +
specific O +
sensor O +
, O +
we O +
calculated O +
the O +
index O +
of O +
current O +
amplitude O +
( O +
ICA O +
) O +
, O +
which O +
was O +
obtained O +
from O +
the O +
amplitude O +
of O +
the O +
motor O +
current O +
waveform O +
divided O +
by O +
the O +
simultaneous O +
mean O +
value O +
. O +

To O +
investigate O +
the O +
basic O +
characteristics O +
of O +
the O +
ICA O +
, O +
the O +
pump O +
speed O +
was O +
changed O +
temporarily O +
from O +
2 O +
, O +
300 O +
rpm O +
to O +
5 O +
, O +
000 O +
rpm O +
. O +

In O +
92 O +
% O +
of O +
all O +
measurements O +
, O +
the O +
ICA O +
plotted O +
against O +
the O +
pump O +
speed O +
had O +
a O +
peak O +
point O +
( O +
t O +
- O +
point O +
) O +
that O +
corresponded O +
highly O +
with O +
the O +
turning O +
point O +
from O +
partial O +
to O +
total O +
assistance O +
. O +

The O +
ICA O +
also O +
had O +
a O +
trough O +
( O +
s O +
- O +
point O +
) O +
that O +
corresponded O +
with O +
the O +
beginning O +
of O +
severe O +
sucking O +
in O +
most O +
cases O +
. O +

Only O +
preload O +
significantly O +
influenced O +
pump O +
flow O +
rate O +
at O +
the O +
t O +
- O +
point O +
from O +
among O +
preload O +
( O +
LVEDP O +
) O +
, O +
afterload O +
( O +
SAoP O +
) O +
, O +
and O +
contractility O +
( O +
max O +
LV O +
dP O +
/ O +
dt O +
) O +
, O +
by O +
which O +
we O +
can O +
simulate O +
Starling O +
' O +
s O +
law O +
of O +
the O +
natural O +
heart O +
. O +

We O +
concluded O +
that O +
a O +
continuous O +
flow O +
artificial O +
heart O +
could O +
be O +
well O +
controlled O +
by O +
detecting O +
the O +
t O +
- O +
point O +
and O +
s O +
- O +
point O +
. O +

Tumors O +
of O +
the O +
retinal O +
pigment O +
epithelium O +
metastasize O +
to O +
inguinal O +
lymph O +
nodes O +
and O +
spleen O +
in O +
tyrosinase O +
- O +
related O +
protein O +
1 O +
/ O +
SV40 O +
T O +
antigen O +
transgenic O +
mice O +
. O +

The O +
pigment O +
epithelium O +
of O +
the O +
retina O +
( O +
RPE O +
) O +
is O +
derived O +
from O +
the O +
optic O +
cup O +
and O +
is O +
essential O +
for O +
function O +
and O +
development O +
of O +
the O +
eye O +
. O +

We O +
produced O +
a O +
transgenic O +
mouse O +
line O +
that O +
expresses O +
simian O +
virus O +
( O +
SV40 O +
) O +
transforming O +
sequences O +
under O +
control O +
of O +
the O +
1 O +
. O +
4 O +
kb O +
tyrosinase O +
- O +
related O +
protein O +
1 O +
( O +
TRP O +
- O +
1 O +
) O +
promoter O +
, O +
targeting O +
expression O +
of O +
T O +
antigen O +
( O +
Tag O +
) O +
to O +
the O +
RPE O +
. O +

In O +
transgenic O +
embryos O +
, O +
RPE O +
cells O +
proliferated O +
in O +
the O +
anterior O +
part O +
of O +
the O +
eye O +
and O +
near O +
the O +
optic O +
nerve O +
. O +

This O +
resulted O +
in O +
formation O +
of O +
tumors O +
, O +
which O +
were O +
pigmented O +
and O +
of O +
epithelial O +
origin O +
. O +

In O +
3 O +
months O +
- O +
old O +
mice O +
, O +
pigmented O +
cells O +
were O +
detected O +
in O +
spleen O +
and O +
inguinal O +
lymph O +
nodes O +
. O +

In O +
spleen O +
, O +
tyrosinase O +
, O +
TRP O +
- O +
1 O +
and O +
SV40 O +
Tag O +
were O +
expressed O +
and O +
tyrosinase O +
was O +
enzymatically O +
active O +
. O +

Pigmented O +
regions O +
were O +
positive O +
for O +
an O +
epithelial O +
marker O +
, O +
cytokeratin O +
. O +

Cell O +
lines O +
were O +
established O +
from O +
tumor O +
and O +
metastases O +
and O +
kept O +
in O +
culture O +
for O +
more O +
than O +
2 O +
months O +
. O +

These O +
were O +
pigmented O +
, O +
and O +
maintained O +
expression O +
of O +
tyrosinase O +
, O +
TRP O +
- O +
1 O +
, O +
cytokeratin O +
and O +
SV40 O +
Tag O +
. O +

This O +
demonstrates O +
that O +
RPE O +
tumor O +
cells O +
metastasize O +
to O +
lymph O +
node O +
and O +
spleen O +
. O +

In O +
conclusion O +
, O +
the O +
metastasis O +
from O +
TRP O +
- O +
1 O +
/ O +
Tag O +
RPE O +
tumors O +
towards O +
spleen O +
and O +
lymph O +
nodes O +
serves O +
as O +
potential O +
tool O +
to O +
investigate O +
biology O +
and O +
metastasis O +
of O +
tumors O +
derived O +
from O +
the O +
pigment O +
epithelium O +
. O +

Glucagon O +
induces O +
suppression O +
of O +
ATP O +
- O +
sensitive O +
K O +
+ O +
channel O +
activity O +
through O +
a O +
Ca2 O +
+ O +
/ O +
calmodulin O +
- O +
dependent O +
pathway O +
in O +
mouse O +
pancreatic O +
beta O +
- O +
cells O +
. O +

Glucagon O +
is O +
known O +
to O +
increase O +
intracellular O +
cAMP O +
levels O +
and O +
enhance O +
glucose O +
- O +
induced O +
electrical O +
activity O +
and O +
insulin O +
secretion O +
in O +
pancreatic O +
beta O +
- O +
cell O +
perfused O +
with O +
Krebs O +
- O +
Ringer O +
bicarbonate O +
solution O +
. O +

The O +
present O +
experiments O +
were O +
aimed O +
at O +
evaluation O +
of O +
the O +
hypothesis O +
that O +
changes O +
in O +
beta O +
- O +
cells O +
ATP O +
- O +
sensitive O +
K O +
+ O +
( O +
K O +
( O +
ATP O +
) O +
) O +
channel O +
activity O +
are O +
involved O +
in O +
the O +
glucagon O +
- O +
induced O +
enhancement O +
of O +
electrical O +
activity O +
. O +

Channel O +
activity O +
was O +
recorded O +
using O +
the O +
cell O +
- O +
attached O +
configuration O +
of O +
the O +
patch O +
- O +
clamp O +
technique O +
. O +

Addition O +
of O +
glucagon O +
( O +
2 O +
. O +
9 O +
x O +
10 O +
( O +
- O +
7 O +
) O +
m O +
) O +
in O +
the O +
presence O +
of O +
11 O +
. O +
1 O +
mm O +
glucose O +
caused O +
closure O +
of O +
K O +
( O +
ATP O +
) O +
channels O +
followed O +
by O +
an O +
increase O +
in O +
the O +
frequency O +
of O +
biphasic O +
current O +
transients O +
( O +
action O +
currents O +
) O +
due O +
to O +
action O +
potential O +
generation O +
in O +
the O +
cell O +
. O +

Three O +
calmodulin O +
- O +
antagonists O +
( O +
W O +
- O +
7 O +
, O +
chlorpromazine O +
, O +
and O +
trifluoperazine O +
) O +
restored O +
with O +
similar O +
efficacy O +
K O +
( O +
ATP O +
) O +
channel O +
activity O +
in O +
cells O +
being O +
exposed O +
to O +
glucagon O +
. O +

At O +
2 O +
. O +
8 O +
mm O +
glucose O +
, O +
glucagon O +
did O +
not O +
affect O +
K O +
( O +
ATP O +
) O +
channel O +
activity O +
until O +
Ca2 O +
+ O +
was O +
released O +
from O +
Nitr O +
- O +
5 O +
by O +
flash O +
photolysis O +
, O +
at O +
which O +
point O +
channel O +
activity O +
was O +
transiently O +
suppressed O +
. O +

Similar O +
effects O +
were O +
seen O +
when O +
db O +
- O +
cAMP O +
was O +
used O +
instead O +
of O +
glucagon O +
. O +

These O +
results O +
support O +
the O +
view O +
that O +
glucagon O +
and O +
other O +
cAMP O +
- O +
generating O +
agonists O +
enhance O +
glucose O +
- O +
induced O +
beta O +
- O +
cell O +
electrical O +
activity O +
through O +
a O +
Ca2 O +
+ O +
/ O +
calmodulin O +
dependent O +
- O +
closure O +
of O +
K O +
( O +
ATP O +
) O +
channels O +
. O +

Requirement O +
of O +
estrogen O +
receptor O +
expression O +
and O +
function O +
for O +
[ O +
12Val O +
] O +
K O +
- O +
Ras O +
- O +
mediated O +
NIH3T3 B-CellLine +
cell O +
transformation O +
. O +

We O +
investigated O +
the O +
biological O +
significance O +
of O +
estrogen O +
receptors O +
( O +
ERs O +
) O +
in O +
NIH3T3 B-CellLine +
cell O +
transformation O +
by O +
the O +
[ O +
12Val O +
] O +
K O +
- O +
Ras O +
mutant O +
. O +

This O +
mutant O +
enhanced O +
the O +
steady O +
- O +
level O +
and O +
transcriptional O +
activity O +
of O +
ER O +
. O +

Coexpression O +
of O +
the O +
progesterone O +
receptor O +
with O +
mutant O +
K O +
- O +
Ras O +
led O +
to O +
suppression O +
of O +
tumorigenicity O +
and O +
inhibition O +
of O +
the O +
activation O +
of O +
ER O +
. O +

The O +
antisense O +
oligomers O +
complementary O +
to O +
the O +
ER O +
suppressed O +
proliferation O +
and O +
transformed O +
phenotypes O +
of O +
K12V B-CellLine +
cells O +
. O +

These O +
observations O +
support O +
the O +
importance O +
of O +
ER O +
in O +
Ras O +
- O +
mediated O +
cell O +
transformation O +
. O +

Gene O +
therapy O +
for O +
gliomas O +
: O +
p53 O +
and O +
E2F O +
- O +
1 O +
proteins O +
and O +
the O +
target O +
of O +
apoptosis O +
. O +

Current O +
therapy O +
for O +
glioma O +
is O +
suboptimal O +
. O +

The O +
transfer O +
of O +
apoptosis O +
genes O +
to O +
tumors O +
constitutes O +
one O +
of O +
the O +
most O +
promising O +
strategies O +
for O +
cancer O +
gene O +
therapy O +
. O +

We O +
have O +
previously O +
shown O +
that O +
massive O +
apoptosis O +
occurs O +
when O +
wild O +
- O +
type O +
p53 O +
or O +
E2F O +
- O +
1 O +
expression O +
is O +
induced O +
in O +
glioma O +
. O +

However O +
, O +
the O +
mechanism O +
of O +
action O +
and O +
the O +
efficiency O +
in O +
inducing O +
apoptosis O +
of O +
these O +
two O +
proteins O +
are O +
not O +
similar O +
. O +

Adenovirus O +
- O +
mediated O +
p53 O +
gene O +
transfer O +
is O +
ineffective O +
in O +
causing O +
apoptosis O +
in O +
glioma O +
cells O +
that O +
retain O +
wild O +
- O +
type O +
p53 O +
genotype O +
or O +
overexpress O +
the O +
p21 O +
protein O +
. O +

The O +
p16 O +
/ O +
Rb O +
/ O +
E2F O +
pathway O +
is O +
the O +
most O +
frequent O +
target O +
of O +
genetic O +
alterations O +
in O +
gliomas O +
, O +
and O +
therefore O +
constitutes O +
a O +
suitable O +
target O +
for O +
gene O +
therapy O +
strategies O +
. O +

However O +
, O +
the O +
transfer O +
of O +
either O +
the O +
p16 O +
or O +
Rb O +
gene O +
to O +
glioma O +
cells O +
results O +
in O +
cytostatic O +
effect O +
. O +

The O +
E2F O +
- O +
1 O +
protein O +
is O +
able O +
to O +
induce O +
generalized O +
apoptosis O +
in O +
gliomas O +
independently O +
of O +
the O +
p53 O +
, O +
p16 O +
or O +
Rb O +
status O +
. O +

In O +
addition O +
, O +
p21 O +
- O +
or O +
p16 O +
- O +
mediated O +
growth O +
arrest O +
did O +
not O +
protect O +
glioma O +
cells O +
from O +
E2F O +
- O +
1 O +
- O +
mediated O +
apoptosis O +
. O +

The O +
apoptotic O +
molecule O +
bax O +
is O +
induced O +
in O +
p53 O +
- O +
mediated O +
apoptosis O +
, O +
but O +
bax O +
is O +
not O +
induced O +
in O +
E2F O +
- O +
1 O +
- O +
mediated O +
apoptosis O +
in O +
glioma O +
cells O +
. O +

Careful O +
selection O +
of O +
patients O +
may O +
be O +
necessary O +
before O +
designing O +
therapeutic O +
strategies O +
using O +
either O +
p53 O +
or O +
E2F O +
- O +
1 O +
as O +
a O +
therapeutic O +
tools O +
for O +
glioma O +
patients O +
. O +

Protective O +
function O +
of O +
von O +
Hippel O +
- O +
Lindau O +
protein O +
against O +
impaired O +
protein O +
processing O +
in O +
renal O +
carcinoma O +
cells O +
. O +

The O +
absence O +
of O +
functional O +
von O +
Hippel O +
- O +
Lindau O +
( O +
VHL O +
) O +
tumor O +
suppressor O +
gene O +
leads O +
to O +
the O +
development O +
of O +
neoplasias O +
characteristic O +
of O +
VHL O +
disease O +
, O +
including O +
renal O +
cell O +
carcinoma O +
( O +
RCC O +
) O +
. O +

Here O +
, O +
we O +
compared O +
the O +
sensitivity O +
of O +
RCC O +
cells O +
lacking O +
VHL O +
gene O +
function O +
with O +
that O +
of O +
RCC O +
cells O +
expressing O +
the O +
wild O +
- O +
type O +
VHL O +
gene O +
( O +
wtVHL O +
) O +
after O +
exposure O +
to O +
various O +
stresses O +
. O +

While O +
the O +
response O +
to O +
most O +
treatments O +
was O +
not O +
affected O +
by O +
the O +
VHL O +
gene O +
status O +
, O +
glucose O +
deprivation O +
was O +
found O +
to O +
be O +
much O +
more O +
cytotoxic O +
for O +
RCC O +
cells O +
lacking O +
VHL O +
gene O +
function O +
than O +
for O +
wtVHL O +
- O +
expressing O +
cells O +
. O +

The O +
heightened O +
sensitivity O +
of O +
VHL O +
- O +
deficient O +
cells O +
was O +
not O +
attributed O +
to O +
dissimilar O +
energy O +
requirements O +
or O +
to O +
differences O +
in O +
glucose O +
uptake O +
, O +
but O +
more O +
likely O +
reflects O +
a O +
lesser O +
ability O +
of O +
VHL O +
- O +
deficient O +
cells O +
to O +
handle O +
abnormally O +
processed O +
proteins O +
arising O +
from O +
impaired O +
glycosylation O +
. O +

In O +
support O +
of O +
this O +
hypothesis O +
, O +
other O +
treatments O +
which O +
act O +
through O +
different O +
mechanisms O +
to O +
interfere O +
with O +
protein O +
processing O +
( O +
i O +
. O +
e O +
. O +
, O +
tunicamycin O +
, O +
brefeldin O +
A O +
, O +
and O +
azetidine O +
) O +
were O +
also O +
found O +
to O +
be O +
much O +
more O +
toxic O +
for O +
VHL O +
- O +
deficient O +
cells O +
. O +

Furthermore O +
, O +
ubiquitination O +
of O +
cellular O +
proteins O +
was O +
elevated O +
in O +
VHL O +
- O +
deficient O +
cells O +
, O +
particularly O +
after O +
glucose O +
deprivation O +
, O +
supporting O +
a O +
role O +
for O +
the O +
VHL O +
gene O +
in O +
ubiquitin O +
- O +
mediated O +
proteolysis O +
. O +

Accordingly O +
, O +
the O +
rate O +
of O +
elimination O +
of O +
abnormal O +
proteins O +
was O +
lower O +
in O +
cells O +
lacking O +
a O +
functional O +
VHL O +
gene O +
than O +
in O +
wtVHL O +
- O +
expressing O +
cells O +
. O +

Thus O +
, O +
pVHL O +
appears O +
to O +
participate O +
in O +
the O +
elimination O +
of O +
misprocessed O +
proteins O +
, O +
such O +
as O +
those O +
arising O +
in O +
the O +
cell O +
due O +
to O +
the O +
unavailability O +
of O +
glucose O +
or O +
to O +
other O +
stresses O +
. O +

Effect O +
of O +
U O +
- O +
995 O +
, O +
a O +
potent O +
shark O +
cartilage O +
- O +
derived O +
angiogenesis O +
inhibitor O +
, O +
on O +
anti O +
- O +
angiogenesis O +
and O +
anti O +
- O +
tumor O +
activities O +
. O +

BACKGROUND O +
: O +
A O +
potent O +
angiogenesis O +
inhibitor O +
, O +
U O +
- O +
995 O +
, O +
has O +
been O +
purified O +
from O +
the O +
cartilage O +
of O +
the O +
blue O +
shark O +
( O +
Prionace O +
glauca O +
) O +
. O +

U O +
- O +
995 O +
is O +
composed O +
of O +
two O +
single O +
peptides O +
with O +
molecular O +
mass O +
of O +
10 O +
and O +
14 O +
kDa O +
, O +
respectively O +
. O +

MATERIALS O +
AND O +
METHODS O +
: O +
U O +
- O +
995 O +
was O +
designed O +
to O +
study O +
human O +
umbilical O +
vein O +
endothelial O +
cell O +
( O +
HUVEC O +
) O +
migration O +
and O +
proliferation O +
in O +
vitro O +
and O +
angiogenesis O +
induced O +
by O +
TNF O +
alpha O +
in O +
chicken O +
chorioallantoic O +
membrane O +
( O +
CAM O +
) O +
. O +

Furthermore O +
, O +
we O +
determined O +
the O +
ability O +
of O +
U O +
- O +
995 O +
to O +
inhibiting O +
tumor O +
cell O +
growth O +
and O +
metastasis O +
. O +

RESULTS O +
: O +
U O +
- O +
995 O +
( O +
15 O +
and O +
30 O +
micrograms O +
/ O +
ml O +
) O +
markedly O +
inhibited O +
HUVEC O +
migration O +
and O +
, O +
at O +
15 O +
- O +
50 O +
micrograms O +
/ O +
ml O +
produced O +
a O +
dose O +
- O +
dependent O +
decline O +
in O +
[ O +
3H O +
] O +
- O +
thymidine O +
incorporation O +
. O +

30 O +
and O +
50 O +
micrograms O +
/ O +
ml O +
of O +
U O +
- O +
995 O +
, O +
when O +
added O +
to O +
TNF O +
alpha O +
- O +
induced O +
angiogenesis O +
caused O +
discontinuous O +
and O +
disrupted O +
blood O +
vessels O +
. O +

Moreover O +
, O +
U O +
- O +
995 O +
( O +
30 O +
micrograms O +
/ O +
ml O +
) O +
markedly O +
prevented O +
collagenase O +
- O +
induced O +
collagenolysis O +
. O +

In O +
addition O +
, O +
when O +
200 O +
micrograms O +
U O +
- O +
995 O +
was O +
injected O +
i O +
. O +
p O +
. O +
into O +
mice O +
it O +
suppressed O +
sarcoma B-CellLine +
- I-CellLine +
180 I-CellLine +
cell O +
growth O +
and O +
B16 B-CellLine +
- I-CellLine +
F10 I-CellLine +
mouse O +
melanoma O +
cell O +
metastasis O +
in O +
vivo O +
. O +

CONCLUSIONS O +
: O +
These O +
results O +
suggest O +
that O +
the O +
anti O +
- O +
angiogenic O +
effects O +
of O +
U O +
- O +
995 O +
may O +
be O +
be O +
due O +
to O +
interference O +
with O +
the O +
proliferation O +
and O +
migration O +
of O +
HUVECs O +
as O +
well O +
as O +
inhibition O +
of O +
collagenolysis O +
, O +
thereby O +
leading O +
to O +
inhibition O +
of O +
both O +
angiogenesis O +
and O +
tumor O +
cell O +
growth O +
. O +

Potential O +
roles O +
for O +
focal O +
adhesion O +
kinase O +
in O +
development O +
. O +

Focal O +
adhesion O +
kinase O +
( O +
pp125FAK O +
or O +
FAK O +
) O +
is O +
a O +
protein O +
tyrosine O +
kinase O +
which O +
is O +
associated O +
with O +
intracellular O +
signalling O +
cascades O +
which O +
are O +
initiated O +
when O +
the O +
integrin O +
family O +
of O +
cell O +
adhesion O +
molecules O +
engage O +
extracellular O +
matrix O +
molecules O +
. O +

In O +
cultured O +
cells O +
, O +
this O +
molecule O +
is O +
physically O +
associated O +
with O +
focal O +
adhesions O +
, O +
which O +
are O +
well O +
- O +
defined O +
regions O +
of O +
intimate O +
cell O +
- O +
to O +
- O +
substratum O +
adhesion O +
. O +

In O +
this O +
location O +
, O +
it O +
interacts O +
with O +
other O +
proteins O +
of O +
the O +
focal O +
adhesion O +
to O +
activate O +
intracellular O +
signalling O +
events O +
associated O +
with O +
cell O +
adhesion O +
. O +

The O +
in O +
vitro O +
expression O +
of O +
FAK O +
and O +
its O +
level O +
of O +
phosphorylation O +
appear O +
to O +
be O +
related O +
to O +
several O +
physiological O +
phenomena O +
, O +
including O +
cell O +
spreading O +
, O +
cell O +
differentiation O +
, O +
cell O +
locomotion O +
and O +
cell O +
death O +
. O +

Because O +
these O +
phenomena O +
are O +
all O +
of O +
critical O +
importance O +
during O +
morphogenesis O +
, O +
and O +
because O +
FAK O +
is O +
expressed O +
in O +
embryonic O +
cells O +
, O +
evidence O +
has O +
been O +
accumulating O +
to O +
indicate O +
that O +
FAK O +
may O +
be O +
an O +
important O +
modulator O +
of O +
developmental O +
processes O +
. O +

In O +
this O +
review O +
, O +
this O +
evidence O +
is O +
surveyed O +
together O +
with O +
evidence O +
from O +
analogous O +
situations O +
, O +
such O +
as O +
tumour O +
cell O +
migration O +
and O +
invasiveness O +
. O +

Although O +
evidence O +
suggesting O +
a O +
role O +
for O +
FAK O +
in O +
morphogenesis O +
is O +
accumulating O +
, O +
current O +
uncertainties O +
regarding O +
its O +
cytoplasmic O +
location O +
and O +
its O +
molecular O +
interactions O +
in O +
vivo O +
make O +
it O +
difficult O +
to O +
reach O +
definitive O +
conclusions O +
regarding O +
the O +
significance O +
of O +
its O +
contributions O +
to O +
developmental O +
processes O +
. O +

Selective O +
inhibition O +
of O +
the O +
renal O +
dopamine O +
subtype O +
D1A O +
receptor O +
induces O +
antinatriuresis O +
in O +
conscious O +
rats O +
. O +

Both O +
dopamine O +
D1 O +
- O +
like O +
( O +
D1A O +
and O +
D1B O +
) O +
and O +
D2 O +
- O +
like O +
( O +
D2 O +
, O +
D3 O +
, O +
and O +
D4 O +
) O +
receptor O +
subfamilies O +
are O +
present O +
in O +
the O +
kidney O +
. O +

Blockade O +
of O +
the O +
intrarenal O +
D1 O +
- O +
like O +
receptor O +
family O +
is O +
associated O +
with O +
natriuresis O +
and O +
diuresis O +
. O +

Because O +
the O +
D1A O +
and O +
D1B O +
receptor O +
subtypes O +
are O +
not O +
distinguishable O +
by O +
currently O +
available O +
dopaminergic O +
agents O +
, O +
their O +
functional O +
role O +
remains O +
undefined O +
. O +

In O +
the O +
present O +
study O +
, O +
the O +
effect O +
of O +
selective O +
inhibition O +
of O +
the O +
renal O +
D1A O +
receptor O +
with O +
phosphorothioated O +
antisense O +
oligodeoxynucleotide O +
( O +
AS O +
- O +
ODN O +
) O +
was O +
investigated O +
in O +
conscious O +
uninephrectomized O +
rats O +
. O +

After O +
renal O +
interstitial O +
administration O +
of O +
Texas O +
red O +
- O +
labeled O +
D1A O +
receptor O +
AS O +
- O +
ODN O +
, O +
intense O +
fluorescent O +
signal O +
was O +
localized O +
in O +
the O +
renal O +
tubular O +
epithelium O +
and O +
vasculature O +
. O +

In O +
rats O +
on O +
normal O +
salt O +
intake O +
, O +
AS O +
- O +
ODN O +
injected O +
interstitially O +
into O +
the O +
kidney O +
reduced O +
daily O +
urinary O +
sodium O +
excretion O +
( O +
1 O +
. O +
4 O +
+ O +
/ O +
- O +
0 O +
. O +
04 O +
versus O +
0 O +
. O +
8 O +
+ O +
/ O +
- O +
0 O +
. O +
2 O +
mEq O +
/ O +
d O +
, O +
n O +
= O +
5 O +
, O +
P O +
< O +
0 O +
. O +
05 O +
) O +
and O +
urine O +
output O +
( O +
16 O +
. O +
9 O +
+ O +
/ O +
- O +
3 O +
. O +
8 O +
versus O +
12 O +
. O +
5 O +
+ O +
/ O +
- O +
3 O +
. O +
6 O +
mL O +
/ O +
d O +
, O +
n O +
= O +
5 O +
, O +
P O +
< O +
0 O +
. O +
05 O +
) O +
. O +

In O +
rats O +
on O +
high O +
sodium O +
intake O +
, O +
continuous O +
renal O +
interstitial O +
administration O +
of O +
D1A O +
receptor O +
AS O +
- O +
ODN O +
transiently O +
decreased O +
daily O +
urinary O +
sodium O +
excretion O +
( O +
5 O +
. O +
4 O +
+ O +
/ O +
- O +
0 O +
. O +
5 O +
versus O +
4 O +
. O +
2 O +
+ O +
/ O +
- O +
0 O +
. O +
3 O +
mEq O +
/ O +
d O +
, O +
n O +
= O +
7 O +
, O +
P O +
< O +
0 O +
. O +
01 O +
) O +
and O +
urine O +
output O +
( O +
27 O +
. O +
6 O +
+ O +
/ O +
- O +
4 O +
. O +
5 O +
versus O +
18 O +
. O +
1 O +
+ O +
/ O +
- O +
1 O +
. O +
8 O +
mL O +
/ O +
d O +
, O +
n O +
= O +
7 O +
, O +
P O +
< O +
0 O +
. O +
01 O +
) O +
. O +

Neither O +
vehicle O +
nor O +
sense O +
oligodeoxynucleotide O +
had O +
significant O +
effects O +
. O +

Systolic O +
blood O +
pressure O +
remained O +
unchanged O +
. O +

The O +
renal O +
D1A O +
receptor O +
protein O +
was O +
significantly O +
decreased O +
by O +
35 O +
% O +
and O +
46 O +
% O +
at O +
the O +
end O +
of O +
the O +
study O +
in O +
AS O +
- O +
ODN O +
- O +
treated O +
rats O +
on O +
normal O +
and O +
high O +
salt O +
intake O +
, O +
respectively O +
, O +
whereas O +
the O +
D1B O +
receptor O +
and O +
beta O +
- O +
actin O +
were O +
not O +
affected O +
. O +

These O +
results O +
provide O +
the O +
first O +
direct O +
evidence O +
that O +
the O +
renal O +
D1A O +
receptor O +
subtype O +
plays O +
an O +
important O +
role O +
in O +
the O +
control O +
of O +
sodium O +
excretion O +
. O +

